drTarget portfolio target-disease associations for psychiatric disorders DrTarget’s AI-Powered Indication Expansion for Psychiatric Disorders

DrTarget’s AI-Powered Insights for Psychiatric Disorders

DrTarget has identified target-disease associations for psychiatric disorders, leveraging data from PubChem, Open Targets and other public repositories. Our AI-driven analytics and machine learning models uncover novel targets and molecular pathways, enabling precision medicine approaches for conditions such as:

✔ Depression
✔ Schizophrenia
✔ Bipolar Disorder
✔ Anxiety Disorders
✔ Neurodevelopmental Conditions

By integrating virtual screening, drug repurposing strategies, and multi-omics validation, we provide deep insights into the molecular mechanisms of psychiatric diseases. Our approach also supports biomarker discovery and novel therapeutic development, bridging the gap between computational predictions and clinical applications.

Target-disease associations for psychiatric disorders.

Check best scored target-disease associations in table:

BioAssay Name	program	diseaseName	assayType	testedCompounds	activeCompounds	associationScore	numberOfEvidences
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	mental or behavioural disorder	targetBased	363803	2412	0.674689655936239	2309
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	mental or behavioural disorder	targetBased	108286	1415	0.551471869587019	1571
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	mental or behavioural disorder	targetBased	359518	300	0.710887433093737	2921
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	mental or behavioural disorder	targetBased	335652	1779	0.710887433093737	2921
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	mental or behavioural disorder	targetBased	357537	806	0.710887433093737	2921
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	mental or behavioural disorder	targetBased	339887	1178	0.710887433093737	2921
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	mental or behavioural disorder	targetBased	362274	1056	0.710887433093737	2921
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	mental or behavioural disorder	targetBased	336308	6862	0.710887433093737	2921
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	mental or behavioural disorder	targetBased	364051	9106	0.678096812690304	635
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	mental or behavioural disorder	targetBased	407539	2380	0.678096812690304	635
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	mental or behavioural disorder	targetBased	407539	2380	0.678096812690304	635
Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R	MC4R	mental or behavioural disorder	targetBased	356160	3470	0.520891499859175	39
TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R	MC4R	mental or behavioural disorder	targetBased	356160	1703	0.520891499859175	39
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	mental or behavioural disorder	targetBased	64908	366	0.636562574634408	918
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	mental or behavioural disorder	targetBased	61606	416	0.636562574634408	918
uHTS identification of small molecule modulators of NR3A	GRIN3A	mental or behavioural disorder	targetBased	339772	8480	0.569683743699563	262
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	post-traumatic stress disorder	targetBased	363803	2412	0.642088916127175	81
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	post-traumatic stress disorder	targetBased	335239	991	0.548657439227214	17
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	post-traumatic stress disorder	targetBased	335239	695	0.548657439227214	17
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	post-traumatic stress disorder	targetBased	359518	300	0.645823745379977	110
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	post-traumatic stress disorder	targetBased	335652	1779	0.645823745379977	110
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	post-traumatic stress disorder	targetBased	357537	806	0.645823745379977	110
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	post-traumatic stress disorder	targetBased	339887	1178	0.645823745379977	110
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	post-traumatic stress disorder	targetBased	362274	1056	0.645823745379977	110
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	post-traumatic stress disorder	targetBased	336308	6862	0.645823745379977	110
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	post-traumatic stress disorder	targetBased	339297	1446	0.627147038346792	44
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	post-traumatic stress disorder	targetBased	64908	366	0.607658019448827	59
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	post-traumatic stress disorder	targetBased	61606	416	0.607658019448827	59
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	cocaine dependence	targetBased	363803	2412	0.504413979083123	32
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	cocaine dependence	targetBased	359518	300	0.515032348421456	92
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	cocaine dependence	targetBased	335652	1779	0.515032348421456	92
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	cocaine dependence	targetBased	357537	806	0.515032348421456	92
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	cocaine dependence	targetBased	339887	1178	0.515032348421456	92
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	cocaine dependence	targetBased	362274	1056	0.515032348421456	92
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	cocaine dependence	targetBased	336308	6862	0.515032348421456	92
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	aggressive behavior	targetBased	363803	2412	0.65723170170587	63
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	aggressive behavior	targetBased	359518	300	0.65723170170587	63
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	aggressive behavior	targetBased	335652	1779	0.65723170170587	63
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	aggressive behavior	targetBased	357537	806	0.65723170170587	63
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	aggressive behavior	targetBased	339887	1178	0.65723170170587	63
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	aggressive behavior	targetBased	362274	1056	0.65723170170587	63
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	aggressive behavior	targetBased	336308	6862	0.65723170170587	63
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	nicotine dependence	targetBased	290355	265	0.560198005654315	29
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	nicotine dependence	targetBased	335239	991	0.565774937759867	57
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	nicotine dependence	targetBased	335239	695	0.565774937759867	57
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	nicotine dependence	targetBased	108286	1415	0.779304545775545	138
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	nicotine dependence	targetBased	339297	1446	0.55928325716652	8
qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding	MAPT	Pick disease	pathwayBased	267412	5703	0.813029001015443	2286
qHTS Assay for Tau Filament Binding	MAPT	Pick disease	targetBased	69668	1391	0.813029001015443	2286
qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization	MAPT	Pick disease	pathwayBased	271402	1048	0.813029001015443	2286
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	autism spectrum disorder	targetBased	363803	2412	0.589529636394361	105
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	autism spectrum disorder	targetBased	359518	300	0.701153255351398	112
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	autism spectrum disorder	targetBased	335652	1779	0.701153255351398	112
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	autism spectrum disorder	targetBased	357537	806	0.701153255351398	112
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	autism spectrum disorder	targetBased	339887	1178	0.701153255351398	112
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	autism spectrum disorder	targetBased	362274	1056	0.701153255351398	112
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	autism spectrum disorder	targetBased	336308	6862	0.701153255351398	112
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	autism spectrum disorder	targetBased	64908	366	0.568058344635926	30
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	autism spectrum disorder	targetBased	61606	416	0.568058344635926	30
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	autism spectrum disorder	targetBased	324747	1043	0.543942541384409	55
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	sleep apnea	targetBased	335239	991	0.591705290314346	14
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	sleep apnea	targetBased	335239	695	0.591705290314346	14
uHTS identification of small molecule modulators of NR3A	GRIN3A	autism spectrum disorder	targetBased	339772	8480	0.583045313028752	21
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	Asperger syndrome	targetBased	359518	300	0.506901236061246	11
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	Asperger syndrome	targetBased	335652	1779	0.506901236061246	11
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	Asperger syndrome	targetBased	357537	806	0.506901236061246	11
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	Asperger syndrome	targetBased	339887	1178	0.506901236061246	11
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	Asperger syndrome	targetBased	362274	1056	0.506901236061246	11
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	Asperger syndrome	targetBased	336308	6862	0.506901236061246	11
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	autism	targetBased	363803	2412	0.666809464893294	263
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	autism	targetBased	359518	300	0.675593943440856	261
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	autism	targetBased	335652	1779	0.675593943440856	261
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	autism	targetBased	357537	806	0.675593943440856	261
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	autism	targetBased	339887	1178	0.675593943440856	261
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	autism	targetBased	362274	1056	0.675593943440856	261
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	autism	targetBased	336308	6862	0.675593943440856	261
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	autism	targetBased	64908	366	0.654787051710058	59
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	autism	targetBased	61606	416	0.654787051710058	59
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	unipolar depression	targetBased	290355	265	0.626689907251647	26
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	unipolar depression	targetBased	363803	2412	0.673413511389257	303
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	unipolar depression	targetBased	335239	991	0.619197357878222	24
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	unipolar depression	targetBased	335239	695	0.619197357878222	24
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	unipolar depression	targetBased	86095	1114	0.502143011397617	12
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	unipolar depression	targetBased	108286	1415	0.67704520260216	473
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	unipolar depression	targetBased	359518	300	0.778810435779702	148
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	unipolar depression	targetBased	335652	1779	0.778810435779702	148
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	unipolar depression	targetBased	357537	806	0.778810435779702	148
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	unipolar depression	targetBased	339887	1178	0.778810435779702	148
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	unipolar depression	targetBased	362274	1056	0.778810435779702	148
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	unipolar depression	targetBased	336308	6862	0.778810435779702	148
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	unipolar depression	targetBased	364051	9106	0.652139811175138	47
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	unipolar depression	targetBased	407539	2380	0.652139811175138	47
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	unipolar depression	targetBased	407539	2380	0.652139811175138	47
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	unipolar depression	targetBased	64908	366	0.663206489836322	246
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	unipolar depression	targetBased	61606	416	0.663206489836322	246
Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS	D1_activators	unipolar depression	targetBased	361330	3713	0.594121772000262	11
Allosteric Modulators of D1 Receptors: Primary Screen	D1	unipolar depression	targetBased	57705	3413	0.594121772000262	11
Antagonist of Human D 1 Dopamine Receptor: qHTS	D1_inhibitors	unipolar depression	targetBased	355805	11440	0.594121772000262	11
uHTS identification of small molecule modulators of NR3A	GRIN3A	unipolar depression	targetBased	339772	8480	0.628732651518689	32
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	attention deficit hyperactivity disorder	targetBased	290355	265	0.553383944086691	12
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	attention deficit hyperactivity disorder	targetBased	363803	2412	0.639130063012709	60
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	attention deficit hyperactivity disorder	targetBased	335239	991	0.568194468638635	19
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	attention deficit hyperactivity disorder	targetBased	335239	695	0.568194468638635	19
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	attention deficit hyperactivity disorder	targetBased	108286	1415	0.709461505766322	1824
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	attention deficit hyperactivity disorder	targetBased	359518	300	0.721501946320093	203
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	attention deficit hyperactivity disorder	targetBased	335652	1779	0.721501946320093	203
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	attention deficit hyperactivity disorder	targetBased	357537	806	0.721501946320093	203
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	attention deficit hyperactivity disorder	targetBased	339887	1178	0.721501946320093	203
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	attention deficit hyperactivity disorder	targetBased	362274	1056	0.721501946320093	203
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	attention deficit hyperactivity disorder	targetBased	336308	6862	0.721501946320093	203
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	attention deficit hyperactivity disorder	targetBased	64908	366	0.551799572120731	32
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	attention deficit hyperactivity disorder	targetBased	61606	416	0.551799572120731	32
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	drug dependence	targetBased	290355	265	0.667078041570145	390
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	drug dependence	targetBased	363803	2412	0.574467276224984	70
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	drug dependence	targetBased	335239	991	0.676418660162289	657
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	drug dependence	targetBased	335239	695	0.676418660162289	657
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	drug dependence	targetBased	108286	1415	0.643739922579374	259
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	drug dependence	targetBased	359518	300	0.631827536503145	278
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	drug dependence	targetBased	335652	1779	0.631827536503145	278
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	drug dependence	targetBased	357537	806	0.631827536503145	278
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	drug dependence	targetBased	339887	1178	0.631827536503145	278
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	drug dependence	targetBased	362274	1056	0.631827536503145	278
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	drug dependence	targetBased	336308	6862	0.631827536503145	278
uHTS identification of small molecule modulators of NR3A	GRIN3A	drug dependence	targetBased	339772	8480	0.509507133272657	51
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	obstructive sleep apnea	targetBased	335239	991	0.542693545696731	18
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	obstructive sleep apnea	targetBased	335239	695	0.542693545696731	18
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	obstructive sleep apnea	targetBased	108286	1415	0.616870615441254	21
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	conduct disorder	targetBased	363803	2412	0.580921152944216	8
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	conduct disorder	targetBased	359518	300	0.595019512773013	24
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	conduct disorder	targetBased	335652	1779	0.595019512773013	24
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	conduct disorder	targetBased	357537	806	0.595019512773013	24
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	conduct disorder	targetBased	339887	1178	0.595019512773013	24
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	conduct disorder	targetBased	362274	1056	0.595019512773013	24
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	conduct disorder	targetBased	336308	6862	0.595019512773013	24
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	neurotic disorder	targetBased	359518	300	0.529577792747223	64
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	neurotic disorder	targetBased	335652	1779	0.529577792747223	64
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	neurotic disorder	targetBased	357537	806	0.529577792747223	64
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	neurotic disorder	targetBased	339887	1178	0.529577792747223	64
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	neurotic disorder	targetBased	362274	1056	0.529577792747223	64
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	neurotic disorder	targetBased	336308	6862	0.529577792747223	64
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	heroin dependence	targetBased	290355	265	0.631779587579708	51
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	heroin dependence	targetBased	335239	991	0.638960310809911	104
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	heroin dependence	targetBased	335239	695	0.638960310809911	104
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	obsessive-compulsive disorder	targetBased	363803	2412	0.614970694532657	62
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	obsessive-compulsive disorder	targetBased	108286	1415	0.52519332062715	39
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	obsessive-compulsive disorder	targetBased	359518	300	0.672861113899014	39
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	obsessive-compulsive disorder	targetBased	335652	1779	0.672861113899014	39
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	obsessive-compulsive disorder	targetBased	357537	806	0.672861113899014	39
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	obsessive-compulsive disorder	targetBased	339887	1178	0.672861113899014	39
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	obsessive-compulsive disorder	targetBased	362274	1056	0.672861113899014	39
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	obsessive-compulsive disorder	targetBased	336308	6862	0.672861113899014	39
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	panic disorder	targetBased	363803	2412	0.511722812322968	23
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	panic disorder	targetBased	359518	300	0.509506968390538	11
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	panic disorder	targetBased	335652	1779	0.509506968390538	11
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	panic disorder	targetBased	357537	806	0.509506968390538	11
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	panic disorder	targetBased	339887	1178	0.509506968390538	11
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	panic disorder	targetBased	362274	1056	0.509506968390538	11
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	panic disorder	targetBased	336308	6862	0.509506968390538	11
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	mood disorder	targetBased	363803	2412	0.59091958364141	767
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	mood disorder	targetBased	108286	1415	0.574924572650151	332
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	mood disorder	targetBased	359518	300	0.6712322106451	702
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	mood disorder	targetBased	335652	1779	0.6712322106451	702
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	mood disorder	targetBased	357537	806	0.6712322106451	702
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	mood disorder	targetBased	339887	1178	0.6712322106451	702
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	mood disorder	targetBased	362274	1056	0.6712322106451	702
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	mood disorder	targetBased	336308	6862	0.6712322106451	702
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	gambling behaviour	targetBased	290355	265	0.500222256227568	15
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	gambling behaviour	targetBased	335239	991	0.500222256227568	15
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	gambling behaviour	targetBased	335239	695	0.500222256227568	15
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	methamphetamine dependence	targetBased	363803	2412	0.598875408626687	20
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	methamphetamine dependence	targetBased	108286	1415	0.586268551754346	48
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	methamphetamine dependence	targetBased	359518	300	0.599218832228455	20
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	methamphetamine dependence	targetBased	335652	1779	0.599218832228455	20
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	methamphetamine dependence	targetBased	357537	806	0.599218832228455	20
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	methamphetamine dependence	targetBased	339887	1178	0.599218832228455	20
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	methamphetamine dependence	targetBased	362274	1056	0.599218832228455	20
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	methamphetamine dependence	targetBased	336308	6862	0.599218832228455	20
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	Tourette syndrome	targetBased	363803	2412	0.650624549944278	33
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	Tourette syndrome	targetBased	359518	300	0.710541683908988	86
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	Tourette syndrome	targetBased	335652	1779	0.710541683908988	86
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	Tourette syndrome	targetBased	357537	806	0.710541683908988	86
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	Tourette syndrome	targetBased	339887	1178	0.710541683908988	86
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	Tourette syndrome	targetBased	362274	1056	0.710541683908988	86
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	Tourette syndrome	targetBased	336308	6862	0.710541683908988	86
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	Tourette syndrome	targetBased	364051	9106	0.588857175513129	17
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	Tourette syndrome	targetBased	407539	2380	0.588857175513129	17
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	Tourette syndrome	targetBased	407539	2380	0.588857175513129	17
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	Tourette syndrome	targetBased	64908	366	0.60757010167286	18
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	Tourette syndrome	targetBased	61606	416	0.60757010167286	18
Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS	D1_activators	Tourette syndrome	targetBased	361330	3713	0.528076886310531	23
Allosteric Modulators of D1 Receptors: Primary Screen	D1	Tourette syndrome	targetBased	57705	3413	0.528076886310531	23
Antagonist of Human D 1 Dopamine Receptor: qHTS	D1_inhibitors	Tourette syndrome	targetBased	355805	11440	0.528076886310531	23
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	insomnia	targetBased	363803	2412	0.618331153675178	56
FRET-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1)	HCRTR1	insomnia	targetBased	326024	5748	0.648644519344265	89
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1)	HCRTR1	insomnia	targetBased	326024	1387	0.648644519344265	89
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	insomnia	targetBased	108286	1415	0.523021843492775	12
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	eating disorder	targetBased	363803	2412	0.565476040057905	31
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	eating disorder	targetBased	108286	1415	0.589793920351293	42
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	eating disorder	targetBased	359518	300	0.604372553853475	38
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	eating disorder	targetBased	335652	1779	0.604372553853475	38
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	eating disorder	targetBased	357537	806	0.604372553853475	38
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	eating disorder	targetBased	339887	1178	0.604372553853475	38
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	eating disorder	targetBased	362274	1056	0.604372553853475	38
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	eating disorder	targetBased	336308	6862	0.604372553853475	38
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	eating disorder	targetBased	364051	9106	0.531818103244732	10
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	eating disorder	targetBased	407539	2380	0.531818103244732	10
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	eating disorder	targetBased	407539	2380	0.531818103244732	10
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	opioid dependence	targetBased	290355	265	0.667574265772021	380
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	opioid dependence	targetBased	335239	991	0.67511318074411	666
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	opioid dependence	targetBased	335239	695	0.67511318074411	666
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	opioid dependence	targetBased	359518	300	0.586603345912258	54
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	opioid dependence	targetBased	335652	1779	0.586603345912258	54
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	opioid dependence	targetBased	357537	806	0.586603345912258	54
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	opioid dependence	targetBased	339887	1178	0.586603345912258	54
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	opioid dependence	targetBased	362274	1056	0.586603345912258	54
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	opioid dependence	targetBased	336308	6862	0.586603345912258	54
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	opioid dependence	targetBased	316642	617	0.577905333654408	10
uHTS identification of small molecule modulators of NR3A	GRIN3A	opioid dependence	targetBased	339772	8480	0.518667722386517	13
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	anxiety	targetBased	363803	2412	0.630433271106812	260
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	psychosis	targetBased	363803	2412	0.676238391345276	1279
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	psychosis	targetBased	359518	300	0.717504452857608	1775
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	psychosis	targetBased	335652	1779	0.717504452857608	1775
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	psychosis	targetBased	357537	806	0.717504452857608	1775
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	psychosis	targetBased	339887	1178	0.717504452857608	1775
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	psychosis	targetBased	362274	1056	0.717504452857608	1775
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	psychosis	targetBased	336308	6862	0.717504452857608	1775
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	psychosis	targetBased	364051	9106	0.690741306707689	392
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	psychosis	targetBased	407539	2380	0.690741306707689	392
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	psychosis	targetBased	407539	2380	0.690741306707689	392
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	psychosis	targetBased	64908	366	0.642439139861967	296
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	psychosis	targetBased	61606	416	0.642439139861967	296
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	anxiety	targetBased	359518	300	0.633822468610396	248
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	anxiety	targetBased	335652	1779	0.633822468610396	248
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	anxiety	targetBased	357537	806	0.633822468610396	248
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	anxiety	targetBased	339887	1178	0.633822468610396	248
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	anxiety	targetBased	362274	1056	0.633822468610396	248
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	anxiety	targetBased	336308	6862	0.633822468610396	248
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	anxiety	targetBased	64908	366	0.633991676701545	936
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	anxiety	targetBased	61606	416	0.633991676701545	936
uHTS identification of small molecule modulators of NR3A	GRIN3A	anxiety	targetBased	339772	8480	0.526319275317686	9
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	schizoaffective disorder	targetBased	363803	2412	0.664704658955117	297
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	schizoaffective disorder	targetBased	86095	1114	0.611730200008939	12
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	schizoaffective disorder	targetBased	108286	1415	0.578791172578599	8
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	schizoaffective disorder	targetBased	359518	300	0.665187702963058	315
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	schizoaffective disorder	targetBased	335652	1779	0.665187702963058	315
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	schizoaffective disorder	targetBased	357537	806	0.665187702963058	315
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	schizoaffective disorder	targetBased	339887	1178	0.665187702963058	315
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	schizoaffective disorder	targetBased	362274	1056	0.665187702963058	315
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	schizoaffective disorder	targetBased	336308	6862	0.665187702963058	315
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	schizoaffective disorder	targetBased	364051	9106	0.659694094276201	74
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	schizoaffective disorder	targetBased	407539	2380	0.659694094276201	74
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	schizoaffective disorder	targetBased	407539	2380	0.659694094276201	74
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	neonatal abstinence syndrome	targetBased	335239	991	0.639503808879902	57
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	neonatal abstinence syndrome	targetBased	335239	695	0.639503808879902	57
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	substance withdrawal syndrome	targetBased	290355	265	0.542268057325337	18
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	substance withdrawal syndrome	targetBased	335239	991	0.577358284792966	38
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	substance withdrawal syndrome	targetBased	335239	695	0.577358284792966	38
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	hypersomnia	targetBased	108286	1415	0.557795651831803	7
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	schizoaffective disorder	targetBased	64908	366	0.647495263851435	45
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	schizoaffective disorder	targetBased	61606	416	0.647495263851435	45
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	binge eating	targetBased	108286	1415	0.511646077243436	8
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	anxiety disorder	targetBased	363803	2412	0.565599835045342	93
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	anxiety disorder	targetBased	359518	300	0.624856199454065	112
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	anxiety disorder	targetBased	335652	1779	0.624856199454065	112
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	anxiety disorder	targetBased	357537	806	0.624856199454065	112
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	anxiety disorder	targetBased	339887	1178	0.624856199454065	112
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	anxiety disorder	targetBased	362274	1056	0.624856199454065	112
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	anxiety disorder	targetBased	336308	6862	0.624856199454065	112
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	anxiety disorder	targetBased	364051	9106	0.548807219432151	18
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	anxiety disorder	targetBased	407539	2380	0.548807219432151	18
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	anxiety disorder	targetBased	407539	2380	0.548807219432151	18
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	anxiety disorder	targetBased	64908	366	0.677507356279003	380
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	anxiety disorder	targetBased	61606	416	0.677507356279003	380
Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	drug use measurement	targetBased	329153	670	0.656828814690532	9
Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	drug use measurement	targetBased	329153	670	0.656828814690532	9
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor	TSHR	drug use measurement	targetBased	72026	352	0.656828814690532	9
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293	TSHR	drug use measurement	targetBased	72026	1794	0.656828814690532	9
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	cerebral amyloid angiopathy	pathwayBased	193714	1590	0.554715604164536	431
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	cerebral amyloid angiopathy	pathwayBased	193400	1987	0.554715604164536	431
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	cerebral amyloid angiopathy	targetBased	404343	257	0.554715604164536	431
TRFRET-based cell-based primary high throughput screening assay to identify inhibitors of cell surface Prion Protein (PRPC)	PRNP	cerebral amyloid angiopathy	targetBased	369953	1596	0.739822242551998	67
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	postpartum depression	targetBased	86095	1442	0.528912685748001	21
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	postpartum depression	targetBased	86095	1151	0.528912685748001	21
uHTS identification of small molecule modulators of NR3A	GRIN3A	postpartum depression	targetBased	339772	8480	0.603347240354886	12
FRET-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1)	HCRTR1	Sleep Disorder	targetBased	326024	5748	0.587025604857753	69
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1)	HCRTR1	Sleep Disorder	targetBased	326024	1387	0.587025604857753	69
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	Sleep Disorder	targetBased	108286	1415	0.670129565809086	83
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	delirium	targetBased	363803	2412	0.645294220123001	50
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	delirium	targetBased	335239	991	0.62243839148902	20
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	delirium	targetBased	335239	695	0.62243839148902	20
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	delirium	targetBased	359518	300	0.643827981382046	48
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	delirium	targetBased	335652	1779	0.643827981382046	48
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	delirium	targetBased	357537	806	0.643827981382046	48
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	delirium	targetBased	339887	1178	0.643827981382046	48
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	delirium	targetBased	362274	1056	0.643827981382046	48
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	delirium	targetBased	336308	6862	0.643827981382046	48
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	delirium	targetBased	364051	9106	0.636915792851204	35
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	delirium	targetBased	407539	2380	0.636915792851204	35
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	delirium	targetBased	407539	2380	0.636915792851204	35
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	delirium	targetBased	305610	3794	0.614214142126277	12
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	delirium	targetBased	339674	2841	0.614214142126277	12
uHTS identification of small molecule modulators of NR3A	GRIN3A	delirium	targetBased	339772	8480	0.602430510467206	12
Dyrk1 A HTS Measured in Biochemical System Using Plate Reader - 2124-01_Inhibitor_SinglePoint_HTS_Activity	DYRK1A_inhibitors	absent or delayed speech development	targetBased	310014	1321	0.559554695563483	14
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	dysthymic disorder	targetBased	108286	1415	0.594005318047291	9
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	bipolar I disorder	targetBased	363803	2412	0.662096838691452	110
Luminescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha	GSK3A	bipolar I disorder	targetBased	315412	318	0.636160747136378	23
qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium	IMPA1	bipolar I disorder	targetBased	205582	727	0.636160747136378	23
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	bipolar I disorder	targetBased	359518	300	0.663161506636499	119
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	bipolar I disorder	targetBased	335652	1779	0.663161506636499	119
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	bipolar I disorder	targetBased	357537	806	0.663161506636499	119
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	bipolar I disorder	targetBased	339887	1178	0.663161506636499	119
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	bipolar I disorder	targetBased	362274	1056	0.663161506636499	119
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	bipolar I disorder	targetBased	336308	6862	0.663161506636499	119
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	bipolar I disorder	targetBased	364051	9106	0.640639481752904	29
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	bipolar I disorder	targetBased	407539	2380	0.640639481752904	29
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	bipolar I disorder	targetBased	407539	2380	0.640639481752904	29
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	bipolar I disorder	targetBased	64908	366	0.633262908369513	30
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	bipolar I disorder	targetBased	61606	416	0.633262908369513	30
uHTS identification of small molecule modulators of NR3A	GRIN3A	bipolar I disorder	targetBased	339772	8480	0.526319275317686	9
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	bipolar II disorder	targetBased	363803	2412	0.579805448943178	8
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	bipolar II disorder	targetBased	359518	300	0.579839258155331	11
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	bipolar II disorder	targetBased	335652	1779	0.579839258155331	11
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	bipolar II disorder	targetBased	357537	806	0.579839258155331	11
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	bipolar II disorder	targetBased	339887	1178	0.579839258155331	11
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	bipolar II disorder	targetBased	362274	1056	0.579839258155331	11
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	bipolar II disorder	targetBased	336308	6862	0.579839258155331	11
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	opioid use disorder	targetBased	290355	265	0.659567124251188	153
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	opioid use disorder	targetBased	335239	991	0.746624149297985	278
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	opioid use disorder	targetBased	335239	695	0.746624149297985	278
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	treatment resistant depression	targetBased	363803	2412	0.605959064966353	29
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	treatment resistant depression	targetBased	359518	300	0.600532105955236	12
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	treatment resistant depression	targetBased	335652	1779	0.600532105955236	12
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	treatment resistant depression	targetBased	357537	806	0.600532105955236	12
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	treatment resistant depression	targetBased	339887	1178	0.600532105955236	12
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	treatment resistant depression	targetBased	362274	1056	0.600532105955236	12
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	treatment resistant depression	targetBased	336308	6862	0.600532105955236	12
uHTS identification of small molecule modulators of NR3A	GRIN3A	treatment resistant depression	targetBased	339772	8480	0.624163682944734	29
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	overdose	targetBased	335239	991	0.578681292639103	12
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	overdose	targetBased	335239	695	0.578681292639103	12
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	pain agnosia	targetBased	335239	991	0.60508047996565	11
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	pain agnosia	targetBased	335239	695	0.60508047996565	11
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	generalized anxiety disorder	targetBased	64908	366	0.595808212813299	59
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	generalized anxiety disorder	targetBased	61606	416	0.595808212813299	59
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	social anxiety disorder	targetBased	363803	2412	0.592744921862423	17
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	social anxiety disorder	targetBased	359518	300	0.609866499579936	29
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	social anxiety disorder	targetBased	335652	1779	0.609866499579936	29
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	social anxiety disorder	targetBased	357537	806	0.609866499579936	29
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	social anxiety disorder	targetBased	339887	1178	0.609866499579936	29
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	social anxiety disorder	targetBased	362274	1056	0.609866499579936	29
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	social anxiety disorder	targetBased	336308	6862	0.609866499579936	29
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	Agitation	targetBased	363803	2412	0.660174078598244	98
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	Agitation	targetBased	335239	991	0.619285523949174	12
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	Agitation	targetBased	335239	695	0.619285523949174	12
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	Agitation	targetBased	359518	300	0.660145911506038	99
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	Agitation	targetBased	335652	1779	0.660145911506038	99
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	Agitation	targetBased	357537	806	0.660145911506038	99
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	Agitation	targetBased	339887	1178	0.660145911506038	99
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	Agitation	targetBased	362274	1056	0.660145911506038	99
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	Agitation	targetBased	336308	6862	0.660145911506038	99
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	Agitation	targetBased	364051	9106	0.655849552139749	60
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	Agitation	targetBased	407539	2380	0.655849552139749	60
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	Agitation	targetBased	407539	2380	0.655849552139749	60
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	Agitation	targetBased	305610	3794	0.60466648961276	9
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	Agitation	targetBased	339674	2841	0.60466648961276	9
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	Agitation	targetBased	64908	366	0.630698487380588	17
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	Agitation	targetBased	61606	416	0.630698487380588	17
uHTS identification of small molecule modulators of NR3A	GRIN3A	Agitation	targetBased	339772	8480	0.560128487470336	8
Primary screen for KDM5B Histone Demethylases FDH-coupled qHTS	KDM5B	Autism	targetBased	217819	5697	0.609806441526676	12
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	Dementia	targetBased	363803	2412	0.630487519911276	45
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	Dementia	pathwayBased	193714	1590	0.5081212394352	31
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	Dementia	pathwayBased	193400	1987	0.5081212394352	31
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	Dementia	targetBased	404343	257	0.5081212394352	31
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	Dementia	targetBased	108286	1415	0.55756748337005	12
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	Dementia	targetBased	359518	300	0.632086682659489	54
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	Dementia	targetBased	335652	1779	0.632086682659489	54
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	Dementia	targetBased	357537	806	0.632086682659489	54
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	Dementia	targetBased	339887	1178	0.632086682659489	54
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	Dementia	targetBased	362274	1056	0.632086682659489	54
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	Dementia	targetBased	336308	6862	0.632086682659489	54
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	Dementia	targetBased	364051	9106	0.591865722627954	15
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	Dementia	targetBased	407539	2380	0.591865722627954	15
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	Dementia	targetBased	407539	2380	0.591865722627954	15
TRFRET-based cell-based primary high throughput screening assay to identify inhibitors of cell surface Prion Protein (PRPC)	PRNP	Dementia	targetBased	369953	1596	0.510298457303692	16
uHTS identification of small molecule modulators of NR3A	GRIN3A	Dementia	targetBased	339772	8480	0.645650315796052	30
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	Hallucinations	targetBased	363803	2412	0.51738963111677	18
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	Atypical behavior	pathwayBased	70898	707	0.666103237753127	22
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	Atypical behavior	pathwayBased	131324	544	0.666103237753127	22
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	Specific learning disability	pathwayBased	70898	707	0.563878136093242	11
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	Specific learning disability	pathwayBased	131324	544	0.563878136093242	11
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	Anorexia	targetBased	359518	300	0.539970044931212	18
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	Anorexia	targetBased	335652	1779	0.539970044931212	18
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	Anorexia	targetBased	357537	806	0.539970044931212	18
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	Anorexia	targetBased	339887	1178	0.539970044931212	18
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	Anorexia	targetBased	362274	1056	0.539970044931212	18
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	Anorexia	targetBased	336308	6862	0.539970044931212	18
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	Borderline personality disorder	targetBased	363803	2412	0.556262633365197	27
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	Borderline personality disorder	targetBased	359518	300	0.559271258805975	23
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	Borderline personality disorder	targetBased	335652	1779	0.559271258805975	23
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	Borderline personality disorder	targetBased	357537	806	0.559271258805975	23
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	Borderline personality disorder	targetBased	339887	1178	0.559271258805975	23
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	Borderline personality disorder	targetBased	362274	1056	0.559271258805975	23
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	Borderline personality disorder	targetBased	336308	6862	0.559271258805975	23
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	dementia	pathwayBased	193714	1590	0.583153557937084	700
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	dementia	pathwayBased	193400	1987	0.583153557937084	700
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	dementia	targetBased	404343	257	0.583153557937084	700
TRFRET-based cell-based primary high throughput screening assay to identify inhibitors of cell surface Prion Protein (PRPC)	PRNP	dementia	targetBased	369953	1596	0.521539092706237	119
qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding	MAPT	dementia	pathwayBased	267412	5703	0.55546276458891	1658
qHTS Assay for Tau Filament Binding	MAPT	dementia	targetBased	69668	1391	0.55546276458891	1658
qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization	MAPT	dementia	pathwayBased	271402	1048	0.55546276458891	1658
Development of Small Molecule Probes of the Histone Methyltransferase, NSD2 Measured in Biochemical System Using Plate Reader - 7053-01_Inhibitor_SinglePoint_HTS_Activity_Set2	NSD2	syndromic intellectual disability	targetBased	309684	1662	0.546843946436569	7
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	major depressive disorder	targetBased	290355	265	0.596086455816202	42
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	major depressive disorder	targetBased	363803	2412	0.693202281364196	303
Luminescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha	GSK3A	major depressive disorder	targetBased	315412	318	0.583510030116279	12
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	major depressive disorder	targetBased	335239	991	0.592300374829612	44
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	major depressive disorder	targetBased	335239	695	0.592300374829612	44
qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium	IMPA1	major depressive disorder	targetBased	205582	727	0.583510030116279	12
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	major depressive disorder	targetBased	108286	1415	0.684232928654062	180
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	major depressive disorder	targetBased	359518	300	0.77144510239322	225
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	major depressive disorder	targetBased	335652	1779	0.77144510239322	225
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	major depressive disorder	targetBased	357537	806	0.77144510239322	225
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	major depressive disorder	targetBased	339887	1178	0.77144510239322	225
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	major depressive disorder	targetBased	362274	1056	0.77144510239322	225
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	major depressive disorder	targetBased	336308	6862	0.77144510239322	225
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	major depressive disorder	targetBased	364051	9106	0.644790053219678	33
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	major depressive disorder	targetBased	407539	2380	0.644790053219678	33
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	major depressive disorder	targetBased	407539	2380	0.644790053219678	33
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	major depressive disorder	targetBased	64908	366	0.695750938597305	389
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	major depressive disorder	targetBased	61606	416	0.695750938597305	389
uHTS identification of small molecule modulators of NR3A	GRIN3A	major depressive disorder	targetBased	339772	8480	0.654704899119961	125
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	alcohol abuse	targetBased	363803	2412	0.521574715878931	11
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	alcohol abuse	targetBased	359518	300	0.52882174426934	68
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	alcohol abuse	targetBased	335652	1779	0.52882174426934	68
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	alcohol abuse	targetBased	357537	806	0.52882174426934	68
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	alcohol abuse	targetBased	339887	1178	0.52882174426934	68
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	alcohol abuse	targetBased	362274	1056	0.52882174426934	68
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	alcohol abuse	targetBased	336308	6862	0.52882174426934	68
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	depressive disorder	targetBased	290355	265	0.610437333238209	44
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	depressive disorder	targetBased	86095	1442	0.568729888416492	32
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	depressive disorder	targetBased	86095	1151	0.568729888416492	32
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	depressive disorder	targetBased	363803	2412	0.671961291843088	359
Luminescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha	GSK3A	depressive disorder	targetBased	315412	318	0.641528774775255	33
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	depressive disorder	targetBased	335239	991	0.619661194229996	48
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	depressive disorder	targetBased	335239	695	0.619661194229996	48
qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium	IMPA1	depressive disorder	targetBased	205582	727	0.641258301078033	33
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	depressive disorder	targetBased	86095	1114	0.553635020531971	10
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	depressive disorder	targetBased	108286	1415	0.667053686218244	313
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	depressive disorder	targetBased	359518	300	0.702767776105905	257
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	depressive disorder	targetBased	335652	1779	0.702767776105905	257
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	depressive disorder	targetBased	357537	806	0.702767776105905	257
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	depressive disorder	targetBased	339887	1178	0.702767776105905	257
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	depressive disorder	targetBased	362274	1056	0.702767776105905	257
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	depressive disorder	targetBased	336308	6862	0.702767776105905	257
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	depressive disorder	targetBased	276265	806	0.598348996827665	10
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	depressive disorder	targetBased	364051	9106	0.660408365269154	68
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	depressive disorder	targetBased	407539	2380	0.660408365269154	68
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	depressive disorder	targetBased	407539	2380	0.660408365269154	68
Counterscreen for agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A)	HTR5A	depressive disorder	targetBased	335239	2035	0.505733262637839	22
Counterscreen for inverse agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify inverse agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A)	HTR5A	depressive disorder	targetBased	335239	279	0.505733262637839	22
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	depressive disorder	targetBased	64908	366	0.663494633120395	264
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	depressive disorder	targetBased	61606	416	0.663494633120395	264
uHTS identification of small molecule modulators of NR3A	GRIN3A	depressive disorder	targetBased	339772	8480	0.659245989128873	186
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	tic disorder	targetBased	363803	2412	0.558316127425329	18
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	tic disorder	targetBased	359518	300	0.580042296367147	42
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	tic disorder	targetBased	335652	1779	0.580042296367147	42
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	tic disorder	targetBased	357537	806	0.580042296367147	42
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	tic disorder	targetBased	339887	1178	0.580042296367147	42
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	tic disorder	targetBased	362274	1056	0.580042296367147	42
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	tic disorder	targetBased	336308	6862	0.580042296367147	42
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	tic disorder	targetBased	64908	366	0.546400426458304	13
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	tic disorder	targetBased	61606	416	0.546400426458304	13
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	depressive disorder	targetBased	359207	1189	0.518981413439618	11
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	depressive disorder	targetBased	63676	1938	0.518981413439618	11
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	depressive disorder	targetBased	359207	316	0.518981413439618	11
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	depressive disorder	targetBased	63656	2179	0.518981413439618	11
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	depressive disorder	targetBased	359207	4555	0.518981413439618	11
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	substance abuse	targetBased	363803	2412	0.57215424526313	13
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	substance abuse	targetBased	108286	1415	0.526861384355099	57
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	substance abuse	targetBased	359518	300	0.577999965458365	102
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	substance abuse	targetBased	335652	1779	0.577999965458365	102
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	substance abuse	targetBased	357537	806	0.577999965458365	102
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	substance abuse	targetBased	339887	1178	0.577999965458365	102
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	substance abuse	targetBased	362274	1056	0.577999965458365	102
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	substance abuse	targetBased	336308	6862	0.577999965458365	102
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	substance dependence	targetBased	363803	2412	0.562245621886424	59
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	substance dependence	targetBased	108286	1415	0.606253414937565	201
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	substance dependence	targetBased	359518	300	0.593933381960675	250
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	substance dependence	targetBased	335652	1779	0.593933381960675	250
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	substance dependence	targetBased	357537	806	0.593933381960675	250
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	substance dependence	targetBased	339887	1178	0.593933381960675	250
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	substance dependence	targetBased	362274	1056	0.593933381960675	250
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	substance dependence	targetBased	336308	6862	0.593933381960675	250
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	schizophrenia	targetBased	290355	265	0.528898327260153	32
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	schizophrenia	targetBased	363803	2412	0.684251885809616	2878
Luminescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha	GSK3A	schizophrenia	targetBased	315412	318	0.510856626964792	17
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	schizophrenia	targetBased	335239	991	0.537788597367771	37
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	schizophrenia	targetBased	335239	695	0.537788597367771	37
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	schizophrenia	targetBased	86095	1114	0.743395452086089	48
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	schizophrenia	targetBased	108286	1415	0.681178593375036	351
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	schizophrenia	targetBased	359518	300	0.803689936994135	4030
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	schizophrenia	targetBased	335652	1779	0.803689936994135	4030
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	schizophrenia	targetBased	357537	806	0.803689936994135	4030
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	schizophrenia	targetBased	339887	1178	0.803689936994135	4030
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	schizophrenia	targetBased	362274	1056	0.803689936994135	4030
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	schizophrenia	targetBased	336308	6862	0.803689936994135	4030
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	schizophrenia	targetBased	364051	9106	0.773518981697282	911
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	schizophrenia	targetBased	407539	2380	0.773518981697282	911
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	schizophrenia	targetBased	407539	2380	0.773518981697282	911
Counterscreen for agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A)	HTR5A	schizophrenia	targetBased	335239	2035	0.65253676906973	96
Counterscreen for inverse agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify inverse agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A)	HTR5A	schizophrenia	targetBased	335239	279	0.65253676906973	96
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	bipolar disorder	targetBased	363803	2412	0.673380276889437	1227
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	schizophrenia	targetBased	359207	1189	0.58146298491719	81
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	schizophrenia	targetBased	63676	1938	0.58146298491719	81
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	schizophrenia	targetBased	359207	316	0.58146298491719	81
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	schizophrenia	targetBased	63656	2179	0.58146298491719	81
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	schizophrenia	targetBased	359207	4555	0.58146298491719	81
Primary Cell Based High Throughput Screening Assay for Agonists of the 5-Hydroxytryptamine Receptor Subtype 1E (5HT1E)	HTR1E	schizophrenia	targetBased	64908	446	0.646240142990496	35
Primary Cell Based High Throughput Screening Assay for Antagonists of the 5-Hydroxytryptamine Receptor Subtype 1E (5HT1E)	HTR1E	schizophrenia	targetBased	64908	641	0.646240142990496	35
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	schizophrenia	targetBased	64908	366	0.683528594348945	696
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	schizophrenia	targetBased	61606	416	0.683528594348945	696
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	schizophrenia	targetBased	324747	1043	0.576028462802304	99
Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS	D1_activators	schizophrenia	targetBased	361330	3713	0.556751417718264	233
Allosteric Modulators of D1 Receptors: Primary Screen	D1	schizophrenia	targetBased	57705	3413	0.556751417718264	233
Antagonist of Human D 1 Dopamine Receptor: qHTS	D1_inhibitors	schizophrenia	targetBased	355805	11440	0.556751417718264	233
uHTS identification of small molecule modulators of NR3A	GRIN3A	schizophrenia	targetBased	339772	8480	0.629740114179662	65
Luminescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha	GSK3A	bipolar disorder	targetBased	315412	318	0.664011412408151	167
qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium	IMPA1	bipolar disorder	targetBased	205582	727	0.666223962413413	179
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	bipolar disorder	targetBased	108286	1415	0.62804776439785	139
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	bipolar disorder	targetBased	359518	300	0.784698432000525	1317
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	bipolar disorder	targetBased	335652	1779	0.784698432000525	1317
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	bipolar disorder	targetBased	357537	806	0.784698432000525	1317
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	bipolar disorder	targetBased	339887	1178	0.784698432000525	1317
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	bipolar disorder	targetBased	362274	1056	0.784698432000525	1317
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	bipolar disorder	targetBased	336308	6862	0.784698432000525	1317
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	bipolar disorder	targetBased	364051	9106	0.669375228835304	280
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	bipolar disorder	targetBased	407539	2380	0.669375228835304	280
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	bipolar disorder	targetBased	407539	2380	0.669375228835304	280
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	bipolar disorder	targetBased	64908	366	0.664540949556231	143
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	bipolar disorder	targetBased	61606	416	0.664540949556231	143
uHTS identification of small molecule modulators of NR3A	GRIN3A	bipolar disorder	targetBased	339772	8480	0.636690276883609	44
Luminescence cell-based high throughput primary assay to identify inhibitors of TEAD-YAP interaction.	YAP1	uveal coloboma-cleft lip and palate-intellectual disability	targetBased	639428	9218	0.738514274092363	21
TRFRET-based cell-based primary high throughput screening assay to identify inhibitors of cell surface Prion Protein (PRPC)	PRNP	inherited Creutzfeldt-Jakob disease	targetBased	369953	1596	0.837038041259018	132
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	alcohol dependence	targetBased	290355	265	0.670607044489001	198
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	alcohol dependence	targetBased	363803	2412	0.586130803291848	66
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	alcohol dependence	targetBased	335239	991	0.673240401913081	285
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	alcohol dependence	targetBased	335239	695	0.673240401913081	285
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	alcohol dependence	targetBased	359518	300	0.664778854425383	200
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	alcohol dependence	targetBased	335652	1779	0.664778854425383	200
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	alcohol dependence	targetBased	357537	806	0.664778854425383	200
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	alcohol dependence	targetBased	339887	1178	0.664778854425383	200
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	alcohol dependence	targetBased	362274	1056	0.664778854425383	200
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	alcohol dependence	targetBased	336308	6862	0.664778854425383	200
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	alcohol dependence	targetBased	324747	1043	0.539074368589372	32
uHTS identification of small molecule modulators of NR3A	GRIN3A	alcohol dependence	targetBased	339772	8480	0.648735442562118	57
TRFRET-based cell-based primary high throughput screening assay to identify inhibitors of cell surface Prion Protein (PRPC)	PRNP	Gerstmann-Straussler-Scheinker syndrome	targetBased	369953	1596	0.893488295726227	213
Development of Small Molecule Probes of the Histone Methyltransferase, NSD2 Measured in Biochemical System Using Plate Reader - 7053-01_Inhibitor_SinglePoint_HTS_Activity_Set2	NSD2	Wolf-Hirschhorn syndrome	targetBased	309684	1662	0.580036883778645	149
Glucocerebrosidase	GBA1	Gaucher disease type I	targetBased	48118	549	0.878031247240919	443
Glucocerebrosidase	GBA1	Gaucher disease type II	targetBased	48118	549	0.855638338257464	192
Primary qHTS for Inhibitors of ATXN expression	ATXN2_repressors	spinocerebellar ataxia type 2	targetBased	358434	2554	0.731331827352406	473
TRFRET-based cell-based primary high throughput screening assay to identify inhibitors of cell surface Prion Protein (PRPC)	PRNP	fatal familial insomnia	targetBased	369953	1596	0.7364832327914	188
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the HTRA serine peptidase 1 (HTRA1)	HTRA1	CARASIL syndrome	targetBased	343467	1710	0.784936074971295	51
qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding	MAPT	semantic dementia	pathwayBased	267412	5703	0.847634887281404	330
qHTS Assay for Tau Filament Binding	MAPT	semantic dementia	targetBased	69668	1391	0.847634887281404	330
qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization	MAPT	semantic dementia	pathwayBased	271402	1048	0.847634887281404	330
Luminescence-based cell-based primary high throughput screening assay to identify activators of the function of SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 (SMARCA2, BRM)	SMARCA2	intellectual disability-sparse hair-brachydactyly syndrome	targetBased	368927	3838	0.903276780005793	93
TRFRET-based cell-based primary high throughput screening assay to identify inhibitors of cell surface Prion Protein (PRPC)	PRNP	Huntington disease-like 1	targetBased	369953	1596	0.843396184087878	176
qHTS of TDP-43 Inhibitors: NCGC Sytravon Library Screen	TARDBP	GRN-related frontotemporal lobar degeneration with Tdp43 inclusions	pathwayBased	45163	203	0.605944606681798	205
qHTS of TDP-43 Inhibitors	TARDBP	GRN-related frontotemporal lobar degeneration with Tdp43 inclusions	pathwayBased	403703	7150	0.605944606681798	205
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	cerebral amyloid angiopathy, APP-related	pathwayBased	193714	1590	0.826810281381391	53
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	cerebral amyloid angiopathy, APP-related	pathwayBased	193400	1987	0.826810281381391	53
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	cerebral amyloid angiopathy, APP-related	targetBased	404343	257	0.826810281381391	53
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	autosomal dominant cerebellar ataxia, deafness and narcolepsy	targetBased	359244	2975	0.8534316413014	93
qHTS Assay for Identification of Novel General Anesthetics	FTL	neuroferritinopathy	targetBased	341499	255	0.835274341530147	296
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	Birk-Barel syndrome	targetBased	305610	3794	0.771166979421912	51
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	severe intellectual disability-progressive spastic diplegia syndrome	targetBased	193542	587	0.869266163504584	149
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	ABeta amyloidosis, dutch type	pathwayBased	193714	1590	0.500813042182858	9
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	ABeta amyloidosis, dutch type	pathwayBased	193400	1987	0.500813042182858	9
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	ABeta amyloidosis, dutch type	targetBased	404343	257	0.500813042182858	9
Dyrk1 A HTS Measured in Biochemical System Using Plate Reader - 2124-01_Inhibitor_SinglePoint_HTS_Activity	DYRK1A_inhibitors	DYRK1A-related intellectual disability syndrome	targetBased	310014	1321	0.808262884097842	1089
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	early-onset autosomal dominant Alzheimer disease	pathwayBased	193714	1590	0.602429390128475	128
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	early-onset autosomal dominant Alzheimer disease	pathwayBased	193400	1987	0.602429390128475	128
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	early-onset autosomal dominant Alzheimer disease	targetBased	404343	257	0.602429390128475	128
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the HTRA serine peptidase 1 (HTRA1)	HTRA1	cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 2	targetBased	343467	1710	0.83274242648193	85
Epi Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of human tyrosyl-DNA phosphodiesterase 2 (TDP2)	TDP2	spinocerebellar ataxia, autosomal recessive 23	targetBased	369953	1241	0.719126736741118	27
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	narcolepsy-cataplexy syndrome	targetBased	108286	1415	0.649086161600151	35
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	ABeta amyloidosis, Iowa type	pathwayBased	193714	1590	0.501814132954698	6
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	ABeta amyloidosis, Iowa type	pathwayBased	193400	1987	0.501814132954698	6
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	ABeta amyloidosis, Iowa type	targetBased	404343	257	0.501814132954698	6
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	West syndrome	targetBased	305609	3405	0.542134231909906	11
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	West syndrome	targetBased	305600	1644	0.542134231909906	11
qHTS Assay for Inhibitors of the CtBP/E1A Interaction	RBBP8	Seckel syndrome	targetBased	335214	1652	0.563779003089398	24
Primary screen for KDM5B Histone Demethylases FDH-coupled qHTS	KDM5B	autosomal recessive non-syndromic intellectual disability	targetBased	217819	5697	0.537940614194576	28
Primary screen for KDM5B Histone Demethylases FDH-coupled qHTS	KDM5B	intellectual disability, autosomal recessive 65	targetBased	217819	5697	0.777855262897303	78
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	alcohol-related disorders	targetBased	290355	265	0.507369097179461	79
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	alcohol-related disorders	targetBased	335239	991	0.508266406705186	113
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	alcohol-related disorders	targetBased	335239	695	0.508266406705186	113
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	narcolepsy	targetBased	108286	1415	0.511411229293004	40
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	enuresis	targetBased	324747	813	0.643223221917796	27
qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding	MAPT	Classical progressive supranuclear palsy	pathwayBased	267412	5703	0.724714707725161	50
qHTS Assay for Tau Filament Binding	MAPT	Classical progressive supranuclear palsy	targetBased	69668	1391	0.724714707725161	50
qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization	MAPT	Classical progressive supranuclear palsy	pathwayBased	271402	1048	0.724714707725161	50
qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding	MAPT	Progressive supranuclear palsy - parkinsonism	pathwayBased	267412	5703	0.673064875545468	26
qHTS Assay for Tau Filament Binding	MAPT	Progressive supranuclear palsy - parkinsonism	targetBased	69668	1391	0.673064875545468	26
qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization	MAPT	Progressive supranuclear palsy - parkinsonism	pathwayBased	271402	1048	0.673064875545468	26
qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)	HSD17B10	HSD10 disease	targetBased	72072	2464	0.865073065613424	59
qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4	HSD17B10	HSD10 disease	targetBased	73912	5649	0.865073065613424	59
qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding	MAPT	Atypical progressive supranuclear palsy	pathwayBased	267412	5703	0.689294807696597	33
qHTS Assay for Tau Filament Binding	MAPT	Atypical progressive supranuclear palsy	targetBased	69668	1391	0.689294807696597	33
qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization	MAPT	Atypical progressive supranuclear palsy	pathwayBased	271402	1048	0.689294807696597	33

Some of these associations have also gone through clinical trials, as those in the graph below.

Find clinical trials details in table. Use scroll bar or search funtion to select specific drugs, molecular targets or diseases.

BioAssay Name	program	gene	protName	diseaseName	molname	assayMode	clinicalPhase	clinicalStatus	studyStartDate	url	score	variantEffect	directionOnTrait	studyStopReason
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	major depressive disorder	AMPHETAMINE	targetBased	4	Completed	01/12/2010	https://clinicaltrials.gov/study/NCT02058693	1		protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	narcolepsy-cataplexy syndrome	AMPHETAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ffd56d70-d884-43be-a994-6e70a10e823e	1		protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	narcolepsy-cataplexy syndrome	AMPHETAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bb12811f-4cce-4010-aa48-d17c46ca1d3a	1		protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	narcolepsy-cataplexy syndrome	AMPHETAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f469fb38-0380-4621-9db3-a4f429126156	1		protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	eating disorder	AMPHETAMINE	targetBased	4	Completed	01/05/2011	https://clinicaltrials.gov/study/NCT02020408	1		protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	AMPHETAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c1179269-00b5-48ea-972d-31e614e99b7e	1		protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	AMPHETAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ffd56d70-d884-43be-a994-6e70a10e823e	1		protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	AMPHETAMINE	targetBased	4	Recruiting	01/07/2018	https://clinicaltrials.gov/study/NCT03153488	1		protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	AMPHETAMINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N06BA01	1		protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	AMPHETAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f469fb38-0380-4621-9db3-a4f429126156	1		protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	AMPHETAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=eb1cc8d0-4231-41ea-8535-4fd872129713	1		protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	AMPHETAMINE	targetBased	4	Completed	07/05/2018	https://clinicaltrials.gov/study/NCT03610464	1		protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	bipolar disorder	VERAPAMIL	targetBased	3	Completed	01/11/1994	https://clinicaltrials.gov/study/NCT00518947	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	circadian rhythm sleep disorder	DILTIAZEM	targetBased	4	Completed	01/06/2009	https://clinicaltrials.gov/study/NCT01914926	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	anxiety disorder	TRIFLUOPERAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=09dc7f6a-cc69-4de8-8e13-b837ce144b4a	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	mental or behavioural disorder	TRIFLUOPERAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=09dc7f6a-cc69-4de8-8e13-b837ce144b4a	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	mental or behavioural disorder	TRIFLUOPERAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=09dc7f6a-cc69-4de8-8e13-b837ce144b4a	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	mental or behavioural disorder	TRIFLUOPERAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=09dc7f6a-cc69-4de8-8e13-b837ce144b4a	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	TRIFLUOPERAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=09dc7f6a-cc69-4de8-8e13-b837ce144b4a	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	mental or behavioural disorder	TRIFLUOPERAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=09dc7f6a-cc69-4de8-8e13-b837ce144b4a	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	psychosis	TRIFLUOPERAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AB06	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	psychosis	TRIFLUOPERAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AB06	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	psychosis	TRIFLUOPERAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AB06	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	TRIFLUOPERAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=09dc7f6a-cc69-4de8-8e13-b837ce144b4a	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	TRIFLUOPERAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=09dc7f6a-cc69-4de8-8e13-b837ce144b4a	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	mental or behavioural disorder	TRIFLUOPERAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=09dc7f6a-cc69-4de8-8e13-b837ce144b4a	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	mental or behavioural disorder	TRIFLUOPERAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=09dc7f6a-cc69-4de8-8e13-b837ce144b4a	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	TRIFLUOPERAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=09dc7f6a-cc69-4de8-8e13-b837ce144b4a	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	TRIFLUOPERAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=09dc7f6a-cc69-4de8-8e13-b837ce144b4a	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	psychosis	TRIFLUOPERAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AB06	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	schizophrenia	TRIFLUOPERAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=09dc7f6a-cc69-4de8-8e13-b837ce144b4a	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	schizophrenia	TRIFLUOPERAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=09dc7f6a-cc69-4de8-8e13-b837ce144b4a	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	schizophrenia	TRIFLUOPERAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=09dc7f6a-cc69-4de8-8e13-b837ce144b4a	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	psychosis	TRIFLUOPERAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AB06	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	psychosis	TRIFLUOPERAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AB06	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	psychosis	TRIFLUOPERAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AB06	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	psychosis	TRIFLUOPERAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AB06	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	TRIFLUOPERAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AB06	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	TRIFLUOPERAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AB06	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	anxiety disorder	TRIFLUOPERAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=09dc7f6a-cc69-4de8-8e13-b837ce144b4a	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	anxiety disorder	TRIFLUOPERAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=09dc7f6a-cc69-4de8-8e13-b837ce144b4a	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	anxiety disorder	TRIFLUOPERAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=09dc7f6a-cc69-4de8-8e13-b837ce144b4a	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	TRIFLUOPERAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=09dc7f6a-cc69-4de8-8e13-b837ce144b4a	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	TRIFLUOPERAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=09dc7f6a-cc69-4de8-8e13-b837ce144b4a	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	TRIFLUOPERAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=09dc7f6a-cc69-4de8-8e13-b837ce144b4a	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	TRIFLUOPERAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=09dc7f6a-cc69-4de8-8e13-b837ce144b4a	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	TRIFLUOPERAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=09dc7f6a-cc69-4de8-8e13-b837ce144b4a	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	TRIFLUOPERAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=09dc7f6a-cc69-4de8-8e13-b837ce144b4a	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	anxiety disorder	TRIFLUOPERAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=09dc7f6a-cc69-4de8-8e13-b837ce144b4a	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	anxiety disorder	TRIFLUOPERAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=09dc7f6a-cc69-4de8-8e13-b837ce144b4a	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	anxiety disorder	TRIFLUOPERAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=09dc7f6a-cc69-4de8-8e13-b837ce144b4a	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	anxiety disorder	TRIFLUOPERAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=09dc7f6a-cc69-4de8-8e13-b837ce144b4a	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	anxiety disorder	TRIFLUOPERAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=09dc7f6a-cc69-4de8-8e13-b837ce144b4a	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	anxiety disorder	TRIFLUOPERAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=09dc7f6a-cc69-4de8-8e13-b837ce144b4a	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	depressive disorder	SULPIRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	depressive disorder	SULPIRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	depressive disorder	SULPIRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	depressive disorder	SULPIRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	depressive disorder	SULPIRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	depressive disorder	SULPIRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	anxiety	SULPIRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	anxiety	SULPIRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	anxiety	SULPIRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	anxiety	SULPIRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	anxiety	SULPIRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	anxiety	SULPIRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizoaffective disorder	SULPIRIDE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizoaffective disorder	SULPIRIDE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizoaffective disorder	SULPIRIDE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizoaffective disorder	SULPIRIDE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizoaffective disorder	SULPIRIDE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizoaffective disorder	SULPIRIDE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	psychosis	SULPIRIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AL01	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	psychosis	SULPIRIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AL01	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	psychosis	SULPIRIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AL01	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	psychosis	SULPIRIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AL01	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	SULPIRIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AL01	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	SULPIRIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AL01	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Dementia	SULPIRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Dementia	SULPIRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Dementia	SULPIRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Dementia	SULPIRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Dementia	SULPIRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Dementia	SULPIRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	SULPIRIDE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	SULPIRIDE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	SULPIRIDE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	SULPIRIDE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	SULPIRIDE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	SULPIRIDE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	SULPIRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	social anxiety disorder	PROPRANOLOL	targetBased	4	Terminated	01/06/2016	https://clinicaltrials.gov/study/NCT02790736	1	LoF	protect	COVID-19 restrictions
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	social anxiety disorder	PROPRANOLOL	targetBased	4	Not yet recruiting	01/10/2016	https://clinicaltrials.gov/study/NCT02924610	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	anxiety	PROPRANOLOL	targetBased	4	Completed	16/06/2014	https://clinicaltrials.gov/study/NCT02153944	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	post-traumatic stress disorder	PROPRANOLOL	targetBased	4	Terminated	01/04/2008	https://clinicaltrials.gov/study/NCT00645450	1	LoF	protect	Difficulty recruiting subjects and loss of study physician for new job
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	post-traumatic stress disorder	PROPRANOLOL	targetBased	4	Terminated	01/12/2003	https://clinicaltrials.gov/study/NCT00648375	1	LoF	protect	inadequate recruitment
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	post-traumatic stress disorder	PROPRANOLOL	targetBased	4	Completed	01/05/2007	https://clinicaltrials.gov/study/NCT00709735	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	post-traumatic stress disorder	PROPRANOLOL	targetBased	4	Completed	01/09/2004	https://clinicaltrials.gov/study/NCT00158262	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	post-traumatic stress disorder	PROPRANOLOL	targetBased	3	Recruiting	01/02/2023	https://clinicaltrials.gov/study/NCT04985344	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	post-traumatic stress disorder	PROPRANOLOL	targetBased	3	Completed	27/05/2016	https://clinicaltrials.gov/study/NCT02789982	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	post-traumatic stress disorder	PROPRANOLOL	targetBased	3	Terminated	01/09/2010	https://clinicaltrials.gov/study/NCT01239173	0.7	LoF	protect	Study stopped by promoter for lack of inclusion
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	post-traumatic stress disorder	PROPRANOLOL	targetBased	4	Recruiting	15/06/2023	https://clinicaltrials.gov/study/NCT05853627	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	obsessive-compulsive disorder	PROPRANOLOL	targetBased	4	Withdrawn	01/06/2016	https://clinicaltrials.gov/study/NCT02790710	1	LoF	protect	Study has been withdrawn due to reconsideration of study design.
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	nicotine dependence	PROPRANOLOL	targetBased	4	Not yet recruiting	01/06/2024	https://clinicaltrials.gov/study/NCT05587361	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	nicotine dependence	PROPRANOLOL	targetBased	4	Completed	16/01/2018	https://clinicaltrials.gov/study/NCT03309943	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	CLOZAPINE	targetBased	4	Recruiting	01/08/2016	https://clinicaltrials.gov/study/NCT02639702	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	CLOZAPINE	targetBased	4	Completed	01/08/1998	https://clinicaltrials.gov/study/NCT00169065	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	CLOZAPINE	targetBased	4	Terminated	01/12/1994	https://clinicaltrials.gov/study/NCT00169039	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	CLOZAPINE	targetBased	4	Completed	01/11/2006	https://clinicaltrials.gov/study/NCT00501618	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	CLOZAPINE	targetBased	4	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT01663077	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	CLOZAPINE	targetBased	4	Recruiting	16/08/2023	https://clinicaltrials.gov/study/NCT05741502	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	CLOZAPINE	targetBased	4	Completed	01/09/2015	https://clinicaltrials.gov/study/NCT02625103	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	bipolar disorder	CLOZAPINE	targetBased	4	Unknown status	01/10/2015	https://clinicaltrials.gov/study/NCT02562287	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	bipolar disorder	CLOZAPINE	targetBased	4	Unknown status	01/10/2015	https://clinicaltrials.gov/study/NCT02562287	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar disorder	CLOZAPINE	targetBased	4	Unknown status	01/10/2015	https://clinicaltrials.gov/study/NCT02562287	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar disorder	CLOZAPINE	targetBased	4	Unknown status	01/10/2015	https://clinicaltrials.gov/study/NCT02562287	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar disorder	CLOZAPINE	targetBased	4	Unknown status	01/10/2015	https://clinicaltrials.gov/study/NCT02562287	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar disorder	CLOZAPINE	targetBased	4	Unknown status	01/10/2015	https://clinicaltrials.gov/study/NCT02562287	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar disorder	CLOZAPINE	targetBased	3	Completed	01/05/2002	https://clinicaltrials.gov/study/NCT00036582	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	mental or behavioural disorder	CLOZAPINE	targetBased	4	Completed	01/06/1997	https://clinicaltrials.gov/study/NCT00001656	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	mental or behavioural disorder	CLOZAPINE	targetBased	4	Withdrawn	01/01/2015	https://clinicaltrials.gov/study/NCT02286206	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Dementia	CLOZAPINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	depressive disorder	CLOZAPINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	depressive disorder	CLOZAPINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	depressive disorder	CLOZAPINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	depressive disorder	CLOZAPINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	depressive disorder	CLOZAPINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	depressive disorder	CLOZAPINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	treatment refractory schizophrenia	CLOZAPINE	targetBased	4	Completed	01/02/2019	https://clinicaltrials.gov/study/NCT03807882	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	anxiety	CLOZAPINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	anxiety	CLOZAPINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	anxiety	CLOZAPINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	anxiety	CLOZAPINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	anxiety	CLOZAPINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	anxiety	CLOZAPINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	panic disorder	CLOZAPINE	targetBased	4	Completed	01/02/2002	https://clinicaltrials.gov/study/NCT00031317	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizoaffective disorder	CLOZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=693cb9d4-39db-4ecf-9eae-b01f06f8d5d1	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizoaffective disorder	CLOZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b7b7541a-1fe4-4b11-b6b7-68fb5510faa4	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizoaffective disorder	CLOZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b7b7541a-1fe4-4b11-b6b7-68fb5510faa4	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizoaffective disorder	CLOZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b7b7541a-1fe4-4b11-b6b7-68fb5510faa4	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizoaffective disorder	CLOZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b7b7541a-1fe4-4b11-b6b7-68fb5510faa4	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizoaffective disorder	CLOZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b7b7541a-1fe4-4b11-b6b7-68fb5510faa4	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizoaffective disorder	CLOZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b7b7541a-1fe4-4b11-b6b7-68fb5510faa4	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	panic disorder	CLOZAPINE	targetBased	4	Completed	01/02/2002	https://clinicaltrials.gov/study/NCT00031317	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	panic disorder	CLOZAPINE	targetBased	4	Completed	01/02/2002	https://clinicaltrials.gov/study/NCT00031317	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	panic disorder	CLOZAPINE	targetBased	4	Completed	01/02/2002	https://clinicaltrials.gov/study/NCT00031317	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	panic disorder	CLOZAPINE	targetBased	4	Completed	01/02/2002	https://clinicaltrials.gov/study/NCT00031317	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	panic disorder	CLOZAPINE	targetBased	4	Completed	01/02/2002	https://clinicaltrials.gov/study/NCT00031317	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	panic disorder	CLOZAPINE	targetBased	4	Completed	01/02/2002	https://clinicaltrials.gov/study/NCT00031317	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	CLOZAPINE	targetBased	4	Unknown status	01/10/2015	https://clinicaltrials.gov/study/NCT02562287	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	CLOZAPINE	targetBased	3	Completed	01/05/2002	https://clinicaltrials.gov/study/NCT00036582	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	CLOZAPINE	targetBased	4	Completed	01/06/1997	https://clinicaltrials.gov/study/NCT00001656	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	CLOZAPINE	targetBased	4	Withdrawn	01/01/2015	https://clinicaltrials.gov/study/NCT02286206	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	CLOZAPINE	targetBased	4	Withdrawn	01/01/2015	https://clinicaltrials.gov/study/NCT02286206	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	mental or behavioural disorder	CLOZAPINE	targetBased	4	Withdrawn	01/01/2015	https://clinicaltrials.gov/study/NCT02286206	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	mental or behavioural disorder	CLOZAPINE	targetBased	4	Withdrawn	01/01/2015	https://clinicaltrials.gov/study/NCT02286206	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	CLOZAPINE	targetBased	4	Withdrawn	01/01/2015	https://clinicaltrials.gov/study/NCT02286206	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	CLOZAPINE	targetBased	4	Withdrawn	01/01/2015	https://clinicaltrials.gov/study/NCT02286206	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	treatment refractory schizophrenia	CLOZAPINE	targetBased	4	Completed	01/02/2019	https://clinicaltrials.gov/study/NCT03807882	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	treatment refractory schizophrenia	CLOZAPINE	targetBased	4	Completed	01/02/2019	https://clinicaltrials.gov/study/NCT03807882	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	treatment refractory schizophrenia	CLOZAPINE	targetBased	4	Completed	01/02/2019	https://clinicaltrials.gov/study/NCT03807882	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	treatment refractory schizophrenia	CLOZAPINE	targetBased	4	Completed	01/02/2019	https://clinicaltrials.gov/study/NCT03807882	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	treatment refractory schizophrenia	CLOZAPINE	targetBased	4	Completed	01/02/2019	https://clinicaltrials.gov/study/NCT03807882	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	treatment refractory schizophrenia	CLOZAPINE	targetBased	4	Completed	01/02/2019	https://clinicaltrials.gov/study/NCT03807882	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	psychosis	CLOZAPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AH02	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizoaffective disorder	CLOZAPINE	targetBased	4	Completed	01/11/2006	https://clinicaltrials.gov/study/NCT00501618	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizoaffective disorder	CLOZAPINE	targetBased	4	Completed	01/03/2009	https://clinicaltrials.gov/study/NCT00981526	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizoaffective disorder	CLOZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=47c4897c-ee95-4eaf-adbc-84130d021d2d	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizoaffective disorder	CLOZAPINE	targetBased	4	Completed	01/05/2011	https://clinicaltrials.gov/study/NCT01248195	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizoaffective disorder	CLOZAPINE	targetBased	4	Completed	01/05/1999	https://clinicaltrials.gov/study/NCT02640300	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizoaffective disorder	CLOZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=883b5d43-0339-7dc1-f775-93791fb9b978	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizoaffective disorder	CLOZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=90876802-0e3a-44c9-9ff7-1754dfbe736a	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	depressive disorder	CLOZAPINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	psychosis	CLOZAPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AH02	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	psychosis	CLOZAPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AH02	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	psychosis	CLOZAPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AH02	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	psychosis	CLOZAPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AH02	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	CLOZAPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AH02	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	CLOZAPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AH02	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	anxiety	CLOZAPINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Dementia	CLOZAPINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Dementia	CLOZAPINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Dementia	CLOZAPINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Dementia	CLOZAPINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Dementia	CLOZAPINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Dementia	CLOZAPINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	CLOZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=883b5d43-0339-7dc1-f775-93791fb9b978	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	CLOZAPINE	targetBased	4	Recruiting	28/02/2021	https://clinicaltrials.gov/study/NCT05316883	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	CLOZAPINE	targetBased	4	Recruiting	28/02/2021	https://clinicaltrials.gov/study/NCT05316883	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	CLOZAPINE	targetBased	4	Recruiting	28/02/2021	https://clinicaltrials.gov/study/NCT05316883	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	CLOZAPINE	targetBased	4	Recruiting	28/02/2021	https://clinicaltrials.gov/study/NCT05316883	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	CLOZAPINE	targetBased	4	Recruiting	28/02/2021	https://clinicaltrials.gov/study/NCT05316883	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	CLOZAPINE	targetBased	4	Recruiting	28/02/2021	https://clinicaltrials.gov/study/NCT05316883	1	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	cannabis dependence	BUSPIRONE	targetBased	4	Completed	01/09/2009	https://clinicaltrials.gov/study/NCT00875836	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	cannabis dependence	BUSPIRONE	targetBased	4	Completed	01/09/2009	https://clinicaltrials.gov/study/NCT00875836	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	autism spectrum disorder	BUSPIRONE	targetBased	4	Completed	31/10/2018	https://clinicaltrials.gov/study/NCT03538431	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	autism spectrum disorder	BUSPIRONE	targetBased	4	Completed	31/10/2018	https://clinicaltrials.gov/study/NCT03538431	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	depressive disorder	BUSPIRONE	targetBased	4	Unknown status	01/08/2014	https://clinicaltrials.gov/study/NCT02273154	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	depressive disorder	BUSPIRONE	targetBased	4	Unknown status	01/08/2014	https://clinicaltrials.gov/study/NCT02273154	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	depressive disorder	BUSPIRONE	targetBased	4	Completed	01/07/2001	https://clinicaltrials.gov/study/NCT00021528	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	depressive disorder	BUSPIRONE	targetBased	4	Completed	01/07/2001	https://clinicaltrials.gov/study/NCT00021528	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	depressive disorder	BUSPIRONE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	depressive disorder	BUSPIRONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=19a92a99-f73a-42f5-b048-28ba0b4df9e6	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	depressive disorder	BUSPIRONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=19a92a99-f73a-42f5-b048-28ba0b4df9e6	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	heroin dependence	BUSPIRONE	targetBased	4	Completed	01/01/2002	https://clinicaltrials.gov/study/NCT00326235	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	heroin dependence	BUSPIRONE	targetBased	4	Completed	01/01/2002	https://clinicaltrials.gov/study/NCT00326235	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	anxiety disorder	BUSPIRONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0568f0c0-2f05-374d-11bf-c74796629535	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	anxiety disorder	BUSPIRONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bbf2015c-0093-4e53-b25e-33f5d2987a7a	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	anxiety disorder	BUSPIRONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bbf2015c-0093-4e53-b25e-33f5d2987a7a	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	anxiety disorder	BUSPIRONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f61184d1-e34a-4a84-9432-a7bacf09e818	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	anxiety disorder	BUSPIRONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f61184d1-e34a-4a84-9432-a7bacf09e818	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	anxiety disorder	BUSPIRONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ed60a885-6b02-48c8-979f-27d371e91d6e	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	anxiety disorder	BUSPIRONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ed60a885-6b02-48c8-979f-27d371e91d6e	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	schizoaffective disorder	BUSPIRONE	targetBased	3	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT00178971	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	schizoaffective disorder	BUSPIRONE	targetBased	3	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT00178971	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	schizophrenia	BUSPIRONE	targetBased	3	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT00178971	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	schizophrenia	BUSPIRONE	targetBased	3	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT00178971	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	schizophrenia	BUSPIRONE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	schizophrenia	BUSPIRONE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	anxiety	BUSPIRONE	targetBased	4	Withdrawn	01/03/2012	https://clinicaltrials.gov/study/NCT01546896	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	anxiety	BUSPIRONE	targetBased	4	Withdrawn	01/03/2012	https://clinicaltrials.gov/study/NCT01546896	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	anxiety	BUSPIRONE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05BE01	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	anxiety	BUSPIRONE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05BE01	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	anxiety	BUSPIRONE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	anxiety	BUSPIRONE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	generalized anxiety disorder	BUSPIRONE	targetBased	3	Recruiting	24/07/2023	https://clinicaltrials.gov/study/NCT06243614	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	generalized anxiety disorder	BUSPIRONE	targetBased	3	Recruiting	24/07/2023	https://clinicaltrials.gov/study/NCT06243614	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	generalized anxiety disorder	BUSPIRONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=19a92a99-f73a-42f5-b048-28ba0b4df9e6	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	generalized anxiety disorder	BUSPIRONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=19a92a99-f73a-42f5-b048-28ba0b4df9e6	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Dementia	BUSPIRONE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Dementia	BUSPIRONE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	MOLINDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1275e92f-9573-4d0c-8e77-1c9ac47696d2	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	MOLINDONE	targetBased	4	Completed	01/02/2002	https://clinicaltrials.gov/study/NCT00053703	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	psychosis	MOLINDONE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AE02	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	psychosis	MOLINDONE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AE02	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	psychosis	MOLINDONE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AE02	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	psychosis	MOLINDONE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AE02	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	psychosis	MOLINDONE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AE02	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	MOLINDONE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AE02	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	MOLINDONE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AE02	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	attention deficit hyperactivity disorder	MOLINDONE	targetBased	3	Terminated	01/04/2016	https://clinicaltrials.gov/study/NCT02691182	0.35	LoF	protect	The program was shut down due to a lack of efficacy.
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	attention deficit hyperactivity disorder	MOLINDONE	targetBased	3	Completed	25/01/2016	https://clinicaltrials.gov/study/NCT02618408	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	attention deficit hyperactivity disorder	MOLINDONE	targetBased	3	Completed	16/02/2016	https://clinicaltrials.gov/study/NCT02618434	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	attention deficit hyperactivity disorder	MOLINDONE	targetBased	3	Terminated	31/07/2018	https://clinicaltrials.gov/study/NCT03597503	0.7	LoF	protect	Business decision, not related to safety
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	MOLINDONE	targetBased	4	Completed	01/02/2002	https://clinicaltrials.gov/study/NCT00053703	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	MOLINDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1275e92f-9573-4d0c-8e77-1c9ac47696d2	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	MOLINDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1275e92f-9573-4d0c-8e77-1c9ac47696d2	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	MOLINDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1275e92f-9573-4d0c-8e77-1c9ac47696d2	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	MOLINDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1275e92f-9573-4d0c-8e77-1c9ac47696d2	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	MOLINDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1275e92f-9573-4d0c-8e77-1c9ac47696d2	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	MOLINDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1275e92f-9573-4d0c-8e77-1c9ac47696d2	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	attention deficit hyperactivity disorder	MOLINDONE	targetBased	3	Completed	16/02/2016	https://clinicaltrials.gov/study/NCT02618434	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	attention deficit hyperactivity disorder	MOLINDONE	targetBased	3	Completed	16/02/2016	https://clinicaltrials.gov/study/NCT02618434	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	attention deficit hyperactivity disorder	MOLINDONE	targetBased	3	Completed	16/02/2016	https://clinicaltrials.gov/study/NCT02618434	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	attention deficit hyperactivity disorder	MOLINDONE	targetBased	3	Completed	16/02/2016	https://clinicaltrials.gov/study/NCT02618434	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	attention deficit hyperactivity disorder	MOLINDONE	targetBased	3	Completed	25/01/2016	https://clinicaltrials.gov/study/NCT02618408	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	attention deficit hyperactivity disorder	MOLINDONE	targetBased	3	Completed	25/01/2016	https://clinicaltrials.gov/study/NCT02618408	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	attention deficit hyperactivity disorder	MOLINDONE	targetBased	3	Completed	25/01/2016	https://clinicaltrials.gov/study/NCT02618408	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	attention deficit hyperactivity disorder	MOLINDONE	targetBased	3	Completed	25/01/2016	https://clinicaltrials.gov/study/NCT02618408	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	attention deficit hyperactivity disorder	MOLINDONE	targetBased	3	Completed	25/01/2016	https://clinicaltrials.gov/study/NCT02618408	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	attention deficit hyperactivity disorder	MOLINDONE	targetBased	3	Completed	25/01/2016	https://clinicaltrials.gov/study/NCT02618408	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	delirium	HALOPERIDOL	targetBased	4	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02343575	1	LoF	protect	We did not recruit the research assistant and terminated the study
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	delirium	HALOPERIDOL	targetBased	4	Completed	01/07/2013	https://clinicaltrials.gov/study/NCT02433041	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	delirium	HALOPERIDOL	targetBased	4	Completed	01/06/2013	https://clinicaltrials.gov/study/NCT01785290	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	delirium	HALOPERIDOL	targetBased	4	Active, not recruiting	13/06/2018	https://clinicaltrials.gov/study/NCT03392376	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	delirium	HALOPERIDOL	targetBased	4	Completed	01/11/2011	https://clinicaltrials.gov/study/NCT03489551	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	delirium	HALOPERIDOL	targetBased	4	Unknown status	23/06/2017	https://clinicaltrials.gov/study/NCT03199950	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	delirium	HALOPERIDOL	targetBased	4	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01530308	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	bipolar disorder	HALOPERIDOL	targetBased	3	Completed	01/12/2004	https://clinicaltrials.gov/study/NCT00097266	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	bipolar disorder	HALOPERIDOL	targetBased	3	Completed	01/12/2004	https://clinicaltrials.gov/study/NCT00097266	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	bipolar disorder	HALOPERIDOL	targetBased	3	Completed	01/12/2004	https://clinicaltrials.gov/study/NCT00097266	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	bipolar disorder	HALOPERIDOL	targetBased	3	Completed	01/07/2005	https://clinicaltrials.gov/study/NCT00129220	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	bipolar disorder	HALOPERIDOL	targetBased	3	Completed	01/07/2005	https://clinicaltrials.gov/study/NCT00129220	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	bipolar disorder	HALOPERIDOL	targetBased	3	Completed	01/07/2005	https://clinicaltrials.gov/study/NCT00129220	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	bipolar disorder	HALOPERIDOL	targetBased	4	Terminated	01/10/2004	https://clinicaltrials.gov/study/NCT00767715	1	LoF	protect	Trial discontinued due to low enrollment
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	bipolar disorder	HALOPERIDOL	targetBased	4	Terminated	01/10/2004	https://clinicaltrials.gov/study/NCT00767715	1	LoF	protect	Trial discontinued due to low enrollment
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	bipolar disorder	HALOPERIDOL	targetBased	4	Terminated	01/10/2004	https://clinicaltrials.gov/study/NCT00767715	1	LoF	protect	Trial discontinued due to low enrollment
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	conduct disorder	HALOPERIDOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0027b8a3-73bf-4005-a7e3-b035f451a861	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	conduct disorder	HALOPERIDOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0027b8a3-73bf-4005-a7e3-b035f451a861	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	conduct disorder	HALOPERIDOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0027b8a3-73bf-4005-a7e3-b035f451a861	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	conduct disorder	HALOPERIDOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0027b8a3-73bf-4005-a7e3-b035f451a861	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	conduct disorder	HALOPERIDOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0027b8a3-73bf-4005-a7e3-b035f451a861	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	conduct disorder	HALOPERIDOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0027b8a3-73bf-4005-a7e3-b035f451a861	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	post-operative delirium	HALOPERIDOL	targetBased	3	Completed	01/11/2005	https://clinicaltrials.gov/study/NCT00250237	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	post-operative delirium	HALOPERIDOL	targetBased	3	Completed	01/11/2005	https://clinicaltrials.gov/study/NCT00250237	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	post-operative delirium	HALOPERIDOL	targetBased	3	Completed	01/11/2005	https://clinicaltrials.gov/study/NCT00250237	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	post-operative delirium	HALOPERIDOL	targetBased	3	Completed	01/11/2005	https://clinicaltrials.gov/study/NCT00250237	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	post-operative delirium	HALOPERIDOL	targetBased	3	Completed	01/11/2005	https://clinicaltrials.gov/study/NCT00250237	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	post-operative delirium	HALOPERIDOL	targetBased	3	Completed	01/11/2005	https://clinicaltrials.gov/study/NCT00250237	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	mental or behavioural disorder	HALOPERIDOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0027b8a3-73bf-4005-a7e3-b035f451a861	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	mental or behavioural disorder	HALOPERIDOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0027b8a3-73bf-4005-a7e3-b035f451a861	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	mental or behavioural disorder	HALOPERIDOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0027b8a3-73bf-4005-a7e3-b035f451a861	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	delirium	HALOPERIDOL	targetBased	4	Completed	01/06/2013	https://clinicaltrials.gov/study/NCT01785290	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	delirium	HALOPERIDOL	targetBased	4	Completed	01/11/2011	https://clinicaltrials.gov/study/NCT03489551	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	delirium	HALOPERIDOL	targetBased	4	Completed	01/11/2011	https://clinicaltrials.gov/study/NCT03489551	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	delirium	HALOPERIDOL	targetBased	4	Completed	01/11/2011	https://clinicaltrials.gov/study/NCT03489551	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	delirium	HALOPERIDOL	targetBased	4	Completed	01/11/2011	https://clinicaltrials.gov/study/NCT03489551	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	delirium	HALOPERIDOL	targetBased	4	Completed	01/11/2011	https://clinicaltrials.gov/study/NCT03489551	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	delirium	HALOPERIDOL	targetBased	4	Completed	01/11/2011	https://clinicaltrials.gov/study/NCT03489551	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	HALOPERIDOL	targetBased	4	Unknown status	01/08/2008	https://clinicaltrials.gov/study/NCT00838032	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	HALOPERIDOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7d1a9689-23c8-44ef-a474-8c607e13d794	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	HALOPERIDOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=12053bcb-dc5a-49a6-8e92-6804c07b0355	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	HALOPERIDOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7b01bd62-d0fa-4229-9a09-f90893dd6dbd	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	HALOPERIDOL	targetBased	4	Terminated	01/01/2003	https://clinicaltrials.gov/study/NCT00419653	1	LoF	protect	Recruitment issues
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	HALOPERIDOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27cfe684-7d11-4f37-9c8b-b2bdd6b5348e	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	HALOPERIDOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e2eed126-cb82-42b1-9b48-9cbeb6873b50	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	bipolar disorder	HALOPERIDOL	targetBased	4	Terminated	01/10/2004	https://clinicaltrials.gov/study/NCT00767715	1	LoF	protect	Trial discontinued due to low enrollment
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	bipolar disorder	HALOPERIDOL	targetBased	4	Terminated	01/10/2004	https://clinicaltrials.gov/study/NCT00767715	1	LoF	protect	Trial discontinued due to low enrollment
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar disorder	HALOPERIDOL	targetBased	4	Terminated	01/10/2004	https://clinicaltrials.gov/study/NCT00767715	1	LoF	protect	Trial discontinued due to low enrollment
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar disorder	HALOPERIDOL	targetBased	4	Terminated	01/10/2004	https://clinicaltrials.gov/study/NCT00767715	1	LoF	protect	Trial discontinued due to low enrollment
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar disorder	HALOPERIDOL	targetBased	4	Terminated	01/10/2004	https://clinicaltrials.gov/study/NCT00767715	1	LoF	protect	Trial discontinued due to low enrollment
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar disorder	HALOPERIDOL	targetBased	4	Terminated	01/10/2004	https://clinicaltrials.gov/study/NCT00767715	1	LoF	protect	Trial discontinued due to low enrollment
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar disorder	HALOPERIDOL	targetBased	3	Completed	01/07/2005	https://clinicaltrials.gov/study/NCT00129220	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	post-operative delirium	HALOPERIDOL	targetBased	3	Completed	01/11/2005	https://clinicaltrials.gov/study/NCT00250237	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	post-operative delirium	HALOPERIDOL	targetBased	3	Completed	01/11/2005	https://clinicaltrials.gov/study/NCT00250237	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	post-operative delirium	HALOPERIDOL	targetBased	3	Completed	01/11/2005	https://clinicaltrials.gov/study/NCT00250237	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Tourette syndrome	HALOPERIDOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0027b8a3-73bf-4005-a7e3-b035f451a861	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Tourette syndrome	HALOPERIDOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e69578b5-3e98-4fc6-a5ad-61e8ec4cb8c1	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Tourette syndrome	HALOPERIDOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e69578b5-3e98-4fc6-a5ad-61e8ec4cb8c1	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Tourette syndrome	HALOPERIDOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e69578b5-3e98-4fc6-a5ad-61e8ec4cb8c1	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Tourette syndrome	HALOPERIDOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e69578b5-3e98-4fc6-a5ad-61e8ec4cb8c1	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Tourette syndrome	HALOPERIDOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e69578b5-3e98-4fc6-a5ad-61e8ec4cb8c1	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Tourette syndrome	HALOPERIDOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e69578b5-3e98-4fc6-a5ad-61e8ec4cb8c1	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Dementia	HALOPERIDOL	targetBased	4	Completed	01/09/2006	https://clinicaltrials.gov/study/NCT00433121	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Dementia	HALOPERIDOL	targetBased	4	Completed	01/09/2006	https://clinicaltrials.gov/study/NCT00433121	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Dementia	HALOPERIDOL	targetBased	4	Completed	01/09/2006	https://clinicaltrials.gov/study/NCT00433121	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Dementia	HALOPERIDOL	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Dementia	HALOPERIDOL	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Dementia	HALOPERIDOL	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	delirium	HALOPERIDOL	targetBased	4	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01530308	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	delirium	HALOPERIDOL	targetBased	4	Active, not recruiting	13/06/2018	https://clinicaltrials.gov/study/NCT03392376	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	delirium	HALOPERIDOL	targetBased	4	Active, not recruiting	13/06/2018	https://clinicaltrials.gov/study/NCT03392376	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	delirium	HALOPERIDOL	targetBased	4	Active, not recruiting	13/06/2018	https://clinicaltrials.gov/study/NCT03392376	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	delirium	HALOPERIDOL	targetBased	4	Completed	01/11/2011	https://clinicaltrials.gov/study/NCT03489551	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	delirium	HALOPERIDOL	targetBased	4	Completed	01/11/2011	https://clinicaltrials.gov/study/NCT03489551	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	delirium	HALOPERIDOL	targetBased	4	Completed	01/11/2011	https://clinicaltrials.gov/study/NCT03489551	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	mental or behavioural disorder	HALOPERIDOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0027b8a3-73bf-4005-a7e3-b035f451a861	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	conduct disorder	HALOPERIDOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0027b8a3-73bf-4005-a7e3-b035f451a861	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	cannabis dependence	HALOPERIDOL	targetBased	4	Completed	21/05/2017	https://clinicaltrials.gov/study/NCT03056482	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	cannabis dependence	HALOPERIDOL	targetBased	4	Completed	21/05/2017	https://clinicaltrials.gov/study/NCT03056482	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	cannabis dependence	HALOPERIDOL	targetBased	4	Completed	21/05/2017	https://clinicaltrials.gov/study/NCT03056482	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	cannabis dependence	HALOPERIDOL	targetBased	4	Completed	21/05/2017	https://clinicaltrials.gov/study/NCT03056482	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	cannabis dependence	HALOPERIDOL	targetBased	4	Completed	21/05/2017	https://clinicaltrials.gov/study/NCT03056482	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	cannabis dependence	HALOPERIDOL	targetBased	4	Completed	21/05/2017	https://clinicaltrials.gov/study/NCT03056482	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Dementia	HALOPERIDOL	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Dementia	HALOPERIDOL	targetBased	4	Completed	01/09/2006	https://clinicaltrials.gov/study/NCT00433121	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Tourette syndrome	HALOPERIDOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e69578b5-3e98-4fc6-a5ad-61e8ec4cb8c1	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Tourette syndrome	HALOPERIDOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0027b8a3-73bf-4005-a7e3-b035f451a861	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	psychosis	HALOPERIDOL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AD01	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	psychosis	HALOPERIDOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0027b8a3-73bf-4005-a7e3-b035f451a861	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	psychosis	HALOPERIDOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0027b8a3-73bf-4005-a7e3-b035f451a861	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	psychosis	HALOPERIDOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0027b8a3-73bf-4005-a7e3-b035f451a861	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	psychosis	HALOPERIDOL	targetBased	4	Completed	01/08/2010	https://clinicaltrials.gov/study/NCT01161277	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	psychosis	HALOPERIDOL	targetBased	4	Completed	01/08/2010	https://clinicaltrials.gov/study/NCT01161277	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	psychosis	HALOPERIDOL	targetBased	4	Completed	01/08/2010	https://clinicaltrials.gov/study/NCT01161277	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	depressive disorder	HALOPERIDOL	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	depressive disorder	HALOPERIDOL	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	depressive disorder	HALOPERIDOL	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	depressive disorder	HALOPERIDOL	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	depressive disorder	HALOPERIDOL	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	depressive disorder	HALOPERIDOL	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	anxiety	HALOPERIDOL	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	anxiety	HALOPERIDOL	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	anxiety	HALOPERIDOL	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	anxiety	HALOPERIDOL	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	anxiety	HALOPERIDOL	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	anxiety	HALOPERIDOL	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Agitation	HALOPERIDOL	targetBased	4	Terminated	01/09/2017	https://clinicaltrials.gov/study/NCT03246620	1	LoF	protect	The study was terminated prematurely due to difficulties in patient recruitment and associated potential for selection bias.
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Agitation	HALOPERIDOL	targetBased	4	Completed	01/07/2016	https://clinicaltrials.gov/study/NCT02909465	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Agitation	HALOPERIDOL	targetBased	4	Completed	01/07/2016	https://clinicaltrials.gov/study/NCT02909465	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Agitation	HALOPERIDOL	targetBased	4	Completed	01/07/2016	https://clinicaltrials.gov/study/NCT02909465	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Agitation	HALOPERIDOL	targetBased	4	Completed	01/07/2016	https://clinicaltrials.gov/study/NCT02909465	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Agitation	HALOPERIDOL	targetBased	4	Completed	01/07/2016	https://clinicaltrials.gov/study/NCT02909465	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Agitation	HALOPERIDOL	targetBased	4	Completed	01/07/2016	https://clinicaltrials.gov/study/NCT02909465	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	cannabis dependence	HALOPERIDOL	targetBased	4	Completed	21/05/2017	https://clinicaltrials.gov/study/NCT03056482	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizoaffective disorder	HALOPERIDOL	targetBased	4	Completed	01/05/1996	https://clinicaltrials.gov/study/NCT00253110	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizoaffective disorder	HALOPERIDOL	targetBased	4	Completed	01/02/2013	https://clinicaltrials.gov/study/NCT02199743	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizoaffective disorder	HALOPERIDOL	targetBased	4	Completed	01/02/2013	https://clinicaltrials.gov/study/NCT02199743	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizoaffective disorder	HALOPERIDOL	targetBased	4	Completed	01/02/2013	https://clinicaltrials.gov/study/NCT02199743	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizoaffective disorder	HALOPERIDOL	targetBased	4	Completed	01/02/2013	https://clinicaltrials.gov/study/NCT02199743	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizoaffective disorder	HALOPERIDOL	targetBased	4	Completed	01/02/2013	https://clinicaltrials.gov/study/NCT02199743	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizoaffective disorder	HALOPERIDOL	targetBased	4	Completed	01/02/2013	https://clinicaltrials.gov/study/NCT02199743	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	HALOPERIDOL	targetBased	4	Terminated	01/10/2004	https://clinicaltrials.gov/study/NCT00767715	1	LoF	protect	Trial discontinued due to low enrollment
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	HALOPERIDOL	targetBased	3	Completed	01/12/2004	https://clinicaltrials.gov/study/NCT00097266	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	HALOPERIDOL	targetBased	3	Completed	01/07/2005	https://clinicaltrials.gov/study/NCT00129220	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	HALOPERIDOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0027b8a3-73bf-4005-a7e3-b035f451a861	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	HALOPERIDOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0027b8a3-73bf-4005-a7e3-b035f451a861	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	mental or behavioural disorder	HALOPERIDOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0027b8a3-73bf-4005-a7e3-b035f451a861	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	mental or behavioural disorder	HALOPERIDOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0027b8a3-73bf-4005-a7e3-b035f451a861	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	HALOPERIDOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0027b8a3-73bf-4005-a7e3-b035f451a861	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	HALOPERIDOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0027b8a3-73bf-4005-a7e3-b035f451a861	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	cannabis dependence	HALOPERIDOL	targetBased	4	Completed	21/05/2017	https://clinicaltrials.gov/study/NCT03056482	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	cannabis dependence	HALOPERIDOL	targetBased	4	Completed	21/05/2017	https://clinicaltrials.gov/study/NCT03056482	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	cannabis dependence	HALOPERIDOL	targetBased	4	Completed	21/05/2017	https://clinicaltrials.gov/study/NCT03056482	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	psychosis	HALOPERIDOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0027b8a3-73bf-4005-a7e3-b035f451a861	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	psychosis	HALOPERIDOL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AD01	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	psychosis	HALOPERIDOL	targetBased	4	Completed	01/08/2010	https://clinicaltrials.gov/study/NCT01161277	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizoaffective disorder	HALOPERIDOL	targetBased	4	Completed	01/03/1998	https://clinicaltrials.gov/study/NCT00007774	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizoaffective disorder	HALOPERIDOL	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizoaffective disorder	HALOPERIDOL	targetBased	3	Completed	01/07/2006	https://clinicaltrials.gov/study/NCT00797277	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizoaffective disorder	HALOPERIDOL	targetBased	4	Completed	01/05/1996	https://clinicaltrials.gov/study/NCT00253110	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizoaffective disorder	HALOPERIDOL	targetBased	4	Completed	01/02/2013	https://clinicaltrials.gov/study/NCT02199743	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Agitation	HALOPERIDOL	targetBased	4	Withdrawn	01/04/2014	https://clinicaltrials.gov/study/NCT02103881	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Agitation	HALOPERIDOL	targetBased	4	Terminated	30/09/2017	https://clinicaltrials.gov/study/NCT03110900	1	LoF	protect	Sponsor Withdrawal
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Agitation	HALOPERIDOL	targetBased	4	Terminated	30/09/2017	https://clinicaltrials.gov/study/NCT03110900	1	LoF	protect	Sponsor Withdrawal
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Agitation	HALOPERIDOL	targetBased	4	Terminated	30/09/2017	https://clinicaltrials.gov/study/NCT03110900	1	LoF	protect	Sponsor Withdrawal
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Agitation	HALOPERIDOL	targetBased	4	Completed	01/07/2016	https://clinicaltrials.gov/study/NCT02909465	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Agitation	HALOPERIDOL	targetBased	4	Completed	01/07/2016	https://clinicaltrials.gov/study/NCT02909465	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Agitation	HALOPERIDOL	targetBased	4	Completed	01/07/2016	https://clinicaltrials.gov/study/NCT02909465	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	schizophrenia	HALOPERIDOL	targetBased	4	Completed	01/08/2010	https://clinicaltrials.gov/study/NCT01161277	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	schizophrenia	HALOPERIDOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=153e747c-861d-44c4-aef6-6c49f53ca34a	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	schizophrenia	HALOPERIDOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=153e747c-861d-44c4-aef6-6c49f53ca34a	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	schizophrenia	HALOPERIDOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=153e747c-861d-44c4-aef6-6c49f53ca34a	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	schizophrenia	HALOPERIDOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c9d0d515-adb7-4f93-8363-0f11771321c9	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	schizophrenia	HALOPERIDOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c9d0d515-adb7-4f93-8363-0f11771321c9	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	schizophrenia	HALOPERIDOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c9d0d515-adb7-4f93-8363-0f11771321c9	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	depressive disorder	HALOPERIDOL	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	depressive disorder	HALOPERIDOL	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	depressive disorder	HALOPERIDOL	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	depressive disorder	HALOPERIDOL	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	HALOPERIDOL	targetBased	4	Completed	01/08/2010	https://clinicaltrials.gov/study/NCT01161277	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	psychosis	HALOPERIDOL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AD01	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	psychosis	HALOPERIDOL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AD01	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	psychosis	HALOPERIDOL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AD01	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	psychosis	HALOPERIDOL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AD01	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	HALOPERIDOL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AD01	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	HALOPERIDOL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AD01	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	anxiety	HALOPERIDOL	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Tourette syndrome	HALOPERIDOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e69578b5-3e98-4fc6-a5ad-61e8ec4cb8c1	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Tourette syndrome	HALOPERIDOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e69578b5-3e98-4fc6-a5ad-61e8ec4cb8c1	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Tourette syndrome	HALOPERIDOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e69578b5-3e98-4fc6-a5ad-61e8ec4cb8c1	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Tourette syndrome	HALOPERIDOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0027b8a3-73bf-4005-a7e3-b035f451a861	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Tourette syndrome	HALOPERIDOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0027b8a3-73bf-4005-a7e3-b035f451a861	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Tourette syndrome	HALOPERIDOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0027b8a3-73bf-4005-a7e3-b035f451a861	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Dementia	HALOPERIDOL	targetBased	4	Completed	01/09/2006	https://clinicaltrials.gov/study/NCT00433121	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Dementia	HALOPERIDOL	targetBased	4	Completed	01/09/2006	https://clinicaltrials.gov/study/NCT00433121	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Dementia	HALOPERIDOL	targetBased	4	Completed	01/09/2006	https://clinicaltrials.gov/study/NCT00433121	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Dementia	HALOPERIDOL	targetBased	4	Completed	01/09/2006	https://clinicaltrials.gov/study/NCT00433121	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Dementia	HALOPERIDOL	targetBased	4	Completed	01/09/2006	https://clinicaltrials.gov/study/NCT00433121	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Dementia	HALOPERIDOL	targetBased	4	Completed	01/09/2006	https://clinicaltrials.gov/study/NCT00433121	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Dementia	HALOPERIDOL	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	post-operative delirium	HALOPERIDOL	targetBased	3	Completed	01/11/2005	https://clinicaltrials.gov/study/NCT00250237	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Agitation	HALOPERIDOL	targetBased	3	Not yet recruiting	28/03/2023	https://clinicaltrials.gov/study/NCT05803642	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Agitation	HALOPERIDOL	targetBased	3	Completed	01/07/2006	https://clinicaltrials.gov/study/NCT00797277	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Agitation	HALOPERIDOL	targetBased	4	Completed	01/07/2016	https://clinicaltrials.gov/study/NCT02909465	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Agitation	HALOPERIDOL	targetBased	4	Terminated	01/09/2017	https://clinicaltrials.gov/study/NCT03246620	1	LoF	protect	The study was terminated prematurely due to difficulties in patient recruitment and associated potential for selection bias.
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Agitation	HALOPERIDOL	targetBased	4	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00457366	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Agitation	HALOPERIDOL	targetBased	4	Terminated	30/09/2017	https://clinicaltrials.gov/study/NCT03110900	1	LoF	protect	Sponsor Withdrawal
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Agitation	HALOPERIDOL	targetBased	4	Withdrawn	01/04/2014	https://clinicaltrials.gov/study/NCT02103881	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Agitation	HALOPERIDOL	targetBased	3	Completed	01/12/2012	https://clinicaltrials.gov/study/NCT01750541	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	HALOPERIDOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e69578b5-3e98-4fc6-a5ad-61e8ec4cb8c1	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	HALOPERIDOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c72c2366-7b40-4cd9-845d-4b3983e6141a	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	HALOPERIDOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c72c2366-7b40-4cd9-845d-4b3983e6141a	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	HALOPERIDOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c72c2366-7b40-4cd9-845d-4b3983e6141a	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	HALOPERIDOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c72c2366-7b40-4cd9-845d-4b3983e6141a	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	HALOPERIDOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c72c2366-7b40-4cd9-845d-4b3983e6141a	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	HALOPERIDOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c72c2366-7b40-4cd9-845d-4b3983e6141a	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	conduct disorder	HALOPERIDOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0027b8a3-73bf-4005-a7e3-b035f451a861	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	conduct disorder	HALOPERIDOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0027b8a3-73bf-4005-a7e3-b035f451a861	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	conduct disorder	HALOPERIDOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0027b8a3-73bf-4005-a7e3-b035f451a861	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	anxiety	HALOPERIDOL	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	anxiety	HALOPERIDOL	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	anxiety	HALOPERIDOL	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	schizoaffective disorder	HALOPERIDOL	targetBased	4	Completed	01/05/1996	https://clinicaltrials.gov/study/NCT00253110	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	schizoaffective disorder	HALOPERIDOL	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	schizoaffective disorder	HALOPERIDOL	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	schizoaffective disorder	HALOPERIDOL	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	schizoaffective disorder	HALOPERIDOL	targetBased	4	Completed	01/03/1998	https://clinicaltrials.gov/study/NCT00007774	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	schizoaffective disorder	HALOPERIDOL	targetBased	4	Completed	01/03/1998	https://clinicaltrials.gov/study/NCT00007774	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	schizoaffective disorder	HALOPERIDOL	targetBased	4	Completed	01/03/1998	https://clinicaltrials.gov/study/NCT00007774	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	THIORIDAZINE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	THIORIDAZINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Dementia	THIORIDAZINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Dementia	THIORIDAZINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Dementia	THIORIDAZINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Dementia	THIORIDAZINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	psychosis	THIORIDAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AC02	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	psychosis	THIORIDAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AC02	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	psychosis	THIORIDAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AC02	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	depressive disorder	THIORIDAZINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	depressive disorder	THIORIDAZINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	depressive disorder	THIORIDAZINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	depressive disorder	THIORIDAZINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	depressive disorder	THIORIDAZINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	depressive disorder	THIORIDAZINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	anxiety	THIORIDAZINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	anxiety	THIORIDAZINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	anxiety	THIORIDAZINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	anxiety	THIORIDAZINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	anxiety	THIORIDAZINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	anxiety	THIORIDAZINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizoaffective disorder	THIORIDAZINE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizoaffective disorder	THIORIDAZINE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizoaffective disorder	THIORIDAZINE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizoaffective disorder	THIORIDAZINE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizoaffective disorder	THIORIDAZINE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizoaffective disorder	THIORIDAZINE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	psychosis	THIORIDAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AC02	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizoaffective disorder	THIORIDAZINE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	schizophrenia	THIORIDAZINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	schizophrenia	THIORIDAZINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	schizophrenia	THIORIDAZINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	schizophrenia	THIORIDAZINE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	schizophrenia	THIORIDAZINE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	schizophrenia	THIORIDAZINE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	depressive disorder	THIORIDAZINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	depressive disorder	THIORIDAZINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	depressive disorder	THIORIDAZINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	depressive disorder	THIORIDAZINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	psychosis	THIORIDAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AC02	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	psychosis	THIORIDAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AC02	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	psychosis	THIORIDAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AC02	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	psychosis	THIORIDAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AC02	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	THIORIDAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AC02	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	THIORIDAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AC02	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	anxiety	THIORIDAZINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Dementia	THIORIDAZINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Dementia	THIORIDAZINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Dementia	THIORIDAZINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Dementia	THIORIDAZINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Dementia	THIORIDAZINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Dementia	THIORIDAZINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	THIORIDAZINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	THIORIDAZINE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	THIORIDAZINE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	THIORIDAZINE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	THIORIDAZINE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	THIORIDAZINE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	THIORIDAZINE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	anxiety	THIORIDAZINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	anxiety	THIORIDAZINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	anxiety	THIORIDAZINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	schizoaffective disorder	THIORIDAZINE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	schizoaffective disorder	THIORIDAZINE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	schizoaffective disorder	THIORIDAZINE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain agnosia	MORPHINE	targetBased	4	Not yet recruiting	06/06/2024	https://clinicaltrials.gov/study/NCT06458400	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain agnosia	MORPHINE	targetBased	4	Not yet recruiting	06/06/2024	https://clinicaltrials.gov/study/NCT06458400	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	MORPHINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=533034fd-c8e7-495b-8874-0db41bd1e65a	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	MORPHINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=533034fd-c8e7-495b-8874-0db41bd1e65a	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	MORPHINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=83497476-dea9-57ec-e053-2991aa0a08c1	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	MORPHINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=83497476-dea9-57ec-e053-2991aa0a08c1	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	delirium	MORPHINE	targetBased	4	Completed	01/03/2013	https://clinicaltrials.gov/study/NCT03078946	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	delirium	MORPHINE	targetBased	4	Completed	01/03/2013	https://clinicaltrials.gov/study/NCT03078946	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	obstructive sleep apnea	MORPHINE	targetBased	3	Terminated	20/05/2016	https://clinicaltrials.gov/study/NCT03127800	0.7	GoF	protect	Difficulties with recruitment
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	obstructive sleep apnea	MORPHINE	targetBased	3	Terminated	20/05/2016	https://clinicaltrials.gov/study/NCT03127800	0.7	GoF	protect	Difficulties with recruitment
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	obstructive sleep apnea	MORPHINE	targetBased	3	Unknown status	01/05/2012	https://clinicaltrials.gov/study/NCT01680939	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	obstructive sleep apnea	MORPHINE	targetBased	3	Unknown status	01/05/2012	https://clinicaltrials.gov/study/NCT01680939	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	MORPHINE	targetBased	4	Terminated	14/09/2016	https://clinicaltrials.gov/study/NCT02741076	1	GoF	protect	Inability to recruit sufficient no. of subjects over an acceptable time period
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	MORPHINE	targetBased	4	Terminated	14/09/2016	https://clinicaltrials.gov/study/NCT02741076	1	GoF	protect	Inability to recruit sufficient no. of subjects over an acceptable time period
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	MORPHINE	targetBased	4	Recruiting	13/12/2022	https://clinicaltrials.gov/study/NCT05639712	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	MORPHINE	targetBased	4	Recruiting	13/12/2022	https://clinicaltrials.gov/study/NCT05639712	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	MORPHINE	targetBased	3	Terminated	06/12/2019	https://clinicaltrials.gov/study/NCT03948464	0.7	GoF	protect	Study unable to proceed per protocol due to COVID-19 precautions
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	MORPHINE	targetBased	3	Terminated	06/12/2019	https://clinicaltrials.gov/study/NCT03948464	0.7	GoF	protect	Study unable to proceed per protocol due to COVID-19 precautions
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	MORPHINE	targetBased	3	Active, not recruiting	08/09/2020	https://clinicaltrials.gov/study/NCT04214834	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	MORPHINE	targetBased	3	Active, not recruiting	08/09/2020	https://clinicaltrials.gov/study/NCT04214834	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	postpartum depression	MORPHINE	targetBased	4	Completed	19/10/2019	https://clinicaltrials.gov/study/NCT04017442	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	postpartum depression	MORPHINE	targetBased	4	Completed	19/10/2019	https://clinicaltrials.gov/study/NCT04017442	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	overdose	MORPHINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=533034fd-c8e7-495b-8874-0db41bd1e65a	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	overdose	MORPHINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=533034fd-c8e7-495b-8874-0db41bd1e65a	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	neonatal abstinence syndrome	MORPHINE	targetBased	4	Completed	01/09/2011	https://clinicaltrials.gov/study/NCT01734551	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	neonatal abstinence syndrome	MORPHINE	targetBased	4	Completed	01/10/2016	https://clinicaltrials.gov/study/NCT02851303	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	neonatal abstinence syndrome	MORPHINE	targetBased	4	Completed	01/10/2016	https://clinicaltrials.gov/study/NCT02851303	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	neonatal abstinence syndrome	MORPHINE	targetBased	4	Recruiting	21/02/2018	https://clinicaltrials.gov/study/NCT03092011	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	neonatal abstinence syndrome	MORPHINE	targetBased	4	Recruiting	21/02/2018	https://clinicaltrials.gov/study/NCT03092011	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	neonatal abstinence syndrome	MORPHINE	targetBased	4	Completed	01/01/2011	https://clinicaltrials.gov/study/NCT01804075	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	neonatal abstinence syndrome	MORPHINE	targetBased	4	Completed	01/01/2011	https://clinicaltrials.gov/study/NCT01804075	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid use disorder	MORPHINE	targetBased	4	Recruiting	29/01/2024	https://clinicaltrials.gov/study/NCT05905367	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid use disorder	MORPHINE	targetBased	4	Recruiting	29/01/2024	https://clinicaltrials.gov/study/NCT05905367	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	sleep apnea	MORPHINE	targetBased	4	Completed	01/11/2015	https://clinicaltrials.gov/study/NCT02566226	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	sleep apnea	MORPHINE	targetBased	4	Completed	01/11/2015	https://clinicaltrials.gov/study/NCT02566226	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	CODEINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=73828e5b-6a29-21d9-e053-2991aa0acac4	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	CODEINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1cab3106-1064-4b42-892b-39f405d9e02f	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	CODEINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1cab3106-1064-4b42-892b-39f405d9e02f	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	CODEINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=df9801fc-03fe-41da-a6b3-0f76788217c9	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	CODEINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=df9801fc-03fe-41da-a6b3-0f76788217c9	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	CODEINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=160cd55a-a8ed-43f2-baf7-046d3c3b317f	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	CODEINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=160cd55a-a8ed-43f2-baf7-046d3c3b317f	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	drug dependence	CODEINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=44aeca03-3ac2-4d5b-91c2-9d0442086468	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	drug dependence	CODEINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=df9801fc-03fe-41da-a6b3-0f76788217c9	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	drug dependence	CODEINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=73828e5b-6a29-21d9-e053-2991aa0acac4	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	drug dependence	CODEINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1cab3106-1064-4b42-892b-39f405d9e02f	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	drug dependence	CODEINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=160cd55a-a8ed-43f2-baf7-046d3c3b317f	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	drug dependence	CODEINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=48a7e42b-934f-4ec6-e054-00144ff88e88	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	drug dependence	CODEINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=010905f9-3bcb-4b50-9fe8-a3ad0010f14c	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	conduct disorder	CHLORPROMAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9575c766-3758-6f33-e053-2995a90ae6b1	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	conduct disorder	CHLORPROMAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9575c766-3758-6f33-e053-2995a90ae6b1	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	conduct disorder	CHLORPROMAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9575c766-3758-6f33-e053-2995a90ae6b1	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	conduct disorder	CHLORPROMAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9575c766-3758-6f33-e053-2995a90ae6b1	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	conduct disorder	CHLORPROMAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9575c766-3758-6f33-e053-2995a90ae6b1	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	conduct disorder	CHLORPROMAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9575c766-3758-6f33-e053-2995a90ae6b1	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	neonatal abstinence syndrome	CHLORPROMAZINE	targetBased	3	Completed	01/06/2001	https://clinicaltrials.gov/study/NCT02810782	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	mental or behavioural disorder	CHLORPROMAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9575c766-3758-6f33-e053-2995a90ae6b1	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	mental or behavioural disorder	CHLORPROMAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9575c766-3758-6f33-e053-2995a90ae6b1	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	mental or behavioural disorder	CHLORPROMAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9575c766-3758-6f33-e053-2995a90ae6b1	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	CHLORPROMAZINE	targetBased	4	Completed	01/02/2005	https://clinicaltrials.gov/study/NCT00654576	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	CHLORPROMAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9575c766-3758-6f33-e053-2995a90ae6b1	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	CHLORPROMAZINE	targetBased	4	Terminated	01/12/1994	https://clinicaltrials.gov/study/NCT00169039	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	CHLORPROMAZINE	targetBased	3	Completed	01/04/2009	https://clinicaltrials.gov/study/NCT00882518	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	mental or behavioural disorder	CHLORPROMAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9575c766-3758-6f33-e053-2995a90ae6b1	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	conduct disorder	CHLORPROMAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9575c766-3758-6f33-e053-2995a90ae6b1	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	psychosis	CHLORPROMAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AA01	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	psychosis	CHLORPROMAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AA01	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	psychosis	CHLORPROMAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AA01	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	CHLORPROMAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9575c766-3758-6f33-e053-2995a90ae6b1	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	CHLORPROMAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9575c766-3758-6f33-e053-2995a90ae6b1	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	mental or behavioural disorder	CHLORPROMAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9575c766-3758-6f33-e053-2995a90ae6b1	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	mental or behavioural disorder	CHLORPROMAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9575c766-3758-6f33-e053-2995a90ae6b1	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	CHLORPROMAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9575c766-3758-6f33-e053-2995a90ae6b1	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	CHLORPROMAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9575c766-3758-6f33-e053-2995a90ae6b1	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	psychosis	CHLORPROMAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AA01	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	schizophrenia	CHLORPROMAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9575c766-3758-6f33-e053-2995a90ae6b1	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	schizophrenia	CHLORPROMAZINE	targetBased	4	Completed	01/02/2005	https://clinicaltrials.gov/study/NCT00654576	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	schizophrenia	CHLORPROMAZINE	targetBased	4	Completed	01/02/2005	https://clinicaltrials.gov/study/NCT00654576	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	schizophrenia	CHLORPROMAZINE	targetBased	4	Completed	01/02/2005	https://clinicaltrials.gov/study/NCT00654576	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	schizophrenia	CHLORPROMAZINE	targetBased	4	Terminated	01/12/1994	https://clinicaltrials.gov/study/NCT00169039	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	schizophrenia	CHLORPROMAZINE	targetBased	4	Terminated	01/12/1994	https://clinicaltrials.gov/study/NCT00169039	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	schizophrenia	CHLORPROMAZINE	targetBased	4	Terminated	01/12/1994	https://clinicaltrials.gov/study/NCT00169039	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	psychosis	CHLORPROMAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AA01	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	psychosis	CHLORPROMAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AA01	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	psychosis	CHLORPROMAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AA01	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	psychosis	CHLORPROMAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AA01	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	CHLORPROMAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AA01	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	CHLORPROMAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AA01	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	neonatal abstinence syndrome	CHLORPROMAZINE	targetBased	3	Completed	01/06/2001	https://clinicaltrials.gov/study/NCT02810782	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	neonatal abstinence syndrome	CHLORPROMAZINE	targetBased	3	Completed	01/06/2001	https://clinicaltrials.gov/study/NCT02810782	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	neonatal abstinence syndrome	CHLORPROMAZINE	targetBased	3	Completed	01/06/2001	https://clinicaltrials.gov/study/NCT02810782	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	neonatal abstinence syndrome	CHLORPROMAZINE	targetBased	3	Completed	01/06/2001	https://clinicaltrials.gov/study/NCT02810782	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	neonatal abstinence syndrome	CHLORPROMAZINE	targetBased	3	Completed	01/06/2001	https://clinicaltrials.gov/study/NCT02810782	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	neonatal abstinence syndrome	CHLORPROMAZINE	targetBased	3	Completed	01/06/2001	https://clinicaltrials.gov/study/NCT02810782	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	neonatal abstinence syndrome	CHLORPROMAZINE	targetBased	3	Completed	01/06/2001	https://clinicaltrials.gov/study/NCT02810782	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	neonatal abstinence syndrome	CHLORPROMAZINE	targetBased	3	Completed	01/06/2001	https://clinicaltrials.gov/study/NCT02810782	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	neonatal abstinence syndrome	CHLORPROMAZINE	targetBased	3	Completed	01/06/2001	https://clinicaltrials.gov/study/NCT02810782	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	CHLORPROMAZINE	targetBased	4	Completed	01/02/2005	https://clinicaltrials.gov/study/NCT00654576	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	CHLORPROMAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9575c766-3758-6f33-e053-2995a90ae6b1	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	CHLORPROMAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9575c766-3758-6f33-e053-2995a90ae6b1	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	CHLORPROMAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9575c766-3758-6f33-e053-2995a90ae6b1	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	CHLORPROMAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9575c766-3758-6f33-e053-2995a90ae6b1	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	CHLORPROMAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9575c766-3758-6f33-e053-2995a90ae6b1	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	CHLORPROMAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9575c766-3758-6f33-e053-2995a90ae6b1	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	conduct disorder	CHLORPROMAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9575c766-3758-6f33-e053-2995a90ae6b1	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	conduct disorder	CHLORPROMAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9575c766-3758-6f33-e053-2995a90ae6b1	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	conduct disorder	CHLORPROMAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9575c766-3758-6f33-e053-2995a90ae6b1	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	opioid dependence	NALOXONE	targetBased	4	Completed	01/07/2011	https://clinicaltrials.gov/study/NCT01374763	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	opioid dependence	NALOXONE	targetBased	4	Completed	01/07/2007	https://clinicaltrials.gov/study/NCT00684073	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	opioid dependence	NALOXONE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/nyxoid	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	opioid dependence	NALOXONE	targetBased	4	Completed	01/10/2010	https://clinicaltrials.gov/study/NCT01191645	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	opioid dependence	NALOXONE	targetBased	4	Completed	01/11/2013	https://clinicaltrials.gov/study/NCT02038790	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	opioid dependence	NALOXONE	targetBased	4	Completed	01/03/2008	https://clinicaltrials.gov/study/NCT00605033	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	opioid dependence	NALOXONE	targetBased	4	Withdrawn	01/11/2009	https://clinicaltrials.gov/study/NCT01015066	1	LoF	protect	Study personnel left institution, anticipated funding did not occur
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	heroin dependence	NALOXONE	targetBased	3	Completed	01/02/2001	https://clinicaltrials.gov/study/NCT00032955	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	heroin dependence	NALOXONE	targetBased	3	Completed	01/02/2001	https://clinicaltrials.gov/study/NCT00032955	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	heroin dependence	NALOXONE	targetBased	3	Terminated	01/11/2018	https://clinicaltrials.gov/study/NCT03711318	0.7	LoF	protect	continuing study was no longer feasible
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	heroin dependence	NALOXONE	targetBased	3	Terminated	01/11/2018	https://clinicaltrials.gov/study/NCT03711318	0.7	LoF	protect	continuing study was no longer feasible
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	heroin dependence	NALOXONE	targetBased	3	Completed	01/04/1996	https://clinicaltrials.gov/study/NCT00015171	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	heroin dependence	NALOXONE	targetBased	3	Completed	01/04/1996	https://clinicaltrials.gov/study/NCT00015171	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	heroin dependence	NALOXONE	targetBased	3	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT00032968	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	heroin dependence	NALOXONE	targetBased	3	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT00032968	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	NALOXONE	targetBased	4	Completed	01/08/1999	https://clinicaltrials.gov/study/NCT00015340	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	NALOXONE	targetBased	4	Completed	01/08/1999	https://clinicaltrials.gov/study/NCT00015340	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	NALOXONE	targetBased	3	Completed	15/05/2018	https://clinicaltrials.gov/study/NCT03518021	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	NALOXONE	targetBased	3	Completed	15/05/2018	https://clinicaltrials.gov/study/NCT03518021	0.7	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	opioid use disorder	NALOXONE	targetBased	4	Completed	15/07/2019	https://clinicaltrials.gov/study/NCT03908437	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	opioid use disorder	NALOXONE	targetBased	4	Withdrawn	30/11/2018	https://clinicaltrials.gov/study/NCT03740243	1	LoF	protect	No enrollment
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	opioid use disorder	NALOXONE	targetBased	4	Recruiting	03/11/2020	https://clinicaltrials.gov/study/NCT04375033	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	opioid use disorder	NALOXONE	targetBased	4	Recruiting	01/12/2023	https://clinicaltrials.gov/study/NCT05944952	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	opioid use disorder	NALOXONE	targetBased	4	Not yet recruiting	01/01/2020	https://clinicaltrials.gov/study/NCT04091009	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	opioid use disorder	NALOXONE	targetBased	3	Recruiting	09/01/2024	https://clinicaltrials.gov/study/NCT06089707	0.7	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	opioid use disorder	NALOXONE	targetBased	4	Completed	01/11/2020	https://clinicaltrials.gov/study/NCT04283500	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	drug dependence	NALOXONE	targetBased	3	Completed	15/05/2018	https://clinicaltrials.gov/study/NCT03518021	0.7	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	drug dependence	NALOXONE	targetBased	4	Completed	01/08/1999	https://clinicaltrials.gov/study/NCT00015340	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	heroin dependence	NALOXONE	targetBased	3	Completed	01/04/1996	https://clinicaltrials.gov/study/NCT00015171	0.7	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	heroin dependence	NALOXONE	targetBased	3	Completed	01/02/2001	https://clinicaltrials.gov/study/NCT00032955	0.7	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	heroin dependence	NALOXONE	targetBased	3	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT00032968	0.7	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	heroin dependence	NALOXONE	targetBased	3	Terminated	01/11/2018	https://clinicaltrials.gov/study/NCT03711318	0.7	LoF	protect	continuing study was no longer feasible
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	overdose	NALOXONE	targetBased	4	Not yet recruiting	01/08/2024	https://clinicaltrials.gov/study/NCT05876572	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	morphine dependence	NALOXONE	targetBased	3	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT00032968	0.7	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	morphine dependence	NALOXONE	targetBased	3	Completed	01/02/2001	https://clinicaltrials.gov/study/NCT00032955	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	unipolar depression	NALOXONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=236349ef-2cb5-47ca-a3a5-99534c3a4996	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	unipolar depression	NALOXONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=236349ef-2cb5-47ca-a3a5-99534c3a4996	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	unipolar depression	NALOXONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=784a0e98-c2d6-f845-e053-2991aa0ac4b4	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	unipolar depression	NALOXONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=784a0e98-c2d6-f845-e053-2991aa0ac4b4	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	unipolar depression	NALOXONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9be31bdf-e220-2978-e053-2a95a90a03c6	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	unipolar depression	NALOXONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9be31bdf-e220-2978-e053-2a95a90a03c6	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	substance withdrawal syndrome	NALOXONE	targetBased	3	Completed	01/02/2001	https://clinicaltrials.gov/study/NCT00032955	0.7	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	substance withdrawal syndrome	NALOXONE	targetBased	3	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT00032968	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	NALOXONE	targetBased	4	Withdrawn	01/06/2023	https://clinicaltrials.gov/study/NCT05808881	1	LoF	protect	Due to changes in research objectives and methodological approach.
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	NALOXONE	targetBased	4	Completed	01/10/2010	https://clinicaltrials.gov/study/NCT01191645	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	NALOXONE	targetBased	4	Completed	01/10/2010	https://clinicaltrials.gov/study/NCT01191645	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	NALOXONE	targetBased	4	Completed	01/08/1999	https://clinicaltrials.gov/study/NCT00015340	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	NALOXONE	targetBased	4	Completed	01/08/1999	https://clinicaltrials.gov/study/NCT00015340	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	NALOXONE	targetBased	4	Completed	01/03/2008	https://clinicaltrials.gov/study/NCT00605033	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	NALOXONE	targetBased	4	Completed	01/03/2008	https://clinicaltrials.gov/study/NCT00605033	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	overdose	NALOXONE	targetBased	4	Not yet recruiting	01/08/2024	https://clinicaltrials.gov/study/NCT05876572	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	overdose	NALOXONE	targetBased	4	Not yet recruiting	01/08/2024	https://clinicaltrials.gov/study/NCT05876572	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid use disorder	NALOXONE	targetBased	4	Completed	01/11/2020	https://clinicaltrials.gov/study/NCT04283500	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid use disorder	NALOXONE	targetBased	4	Completed	15/07/2019	https://clinicaltrials.gov/study/NCT03908437	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid use disorder	NALOXONE	targetBased	4	Completed	15/07/2019	https://clinicaltrials.gov/study/NCT03908437	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid use disorder	NALOXONE	targetBased	4	Withdrawn	30/11/2018	https://clinicaltrials.gov/study/NCT03740243	1	LoF	protect	No enrollment
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid use disorder	NALOXONE	targetBased	4	Withdrawn	30/11/2018	https://clinicaltrials.gov/study/NCT03740243	1	LoF	protect	No enrollment
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid use disorder	NALOXONE	targetBased	4	Not yet recruiting	01/01/2020	https://clinicaltrials.gov/study/NCT04091009	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid use disorder	NALOXONE	targetBased	4	Not yet recruiting	01/01/2020	https://clinicaltrials.gov/study/NCT04091009	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	substance withdrawal syndrome	NALOXONE	targetBased	3	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT00032968	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	substance withdrawal syndrome	NALOXONE	targetBased	3	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT00032968	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	substance withdrawal syndrome	NALOXONE	targetBased	3	Completed	01/02/2001	https://clinicaltrials.gov/study/NCT00032955	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	substance withdrawal syndrome	NALOXONE	targetBased	3	Completed	01/02/2001	https://clinicaltrials.gov/study/NCT00032955	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	morphine dependence	NALOXONE	targetBased	3	Completed	01/02/2001	https://clinicaltrials.gov/study/NCT00032955	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	morphine dependence	NALOXONE	targetBased	3	Completed	01/02/2001	https://clinicaltrials.gov/study/NCT00032955	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	morphine dependence	NALOXONE	targetBased	3	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT00032968	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	morphine dependence	NALOXONE	targetBased	3	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT00032968	0.7	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	unipolar depression	NALOXONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=784a0e98-c2d6-f845-e053-2991aa0ac4b4	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	unipolar depression	NALOXONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=236349ef-2cb5-47ca-a3a5-99534c3a4996	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	unipolar depression	NALOXONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9be31bdf-e220-2978-e053-2a95a90a03c6	1	LoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	schizophrenia	RALOXIFENE	targetBased	4	Completed	17/07/2018	https://clinicaltrials.gov/study/NCT03418831	1		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	schizophrenia	RALOXIFENE	targetBased	4	Completed	01/08/2006	https://clinicaltrials.gov/study/NCT00361543	1		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	schizophrenia	RALOXIFENE	targetBased	3	Completed	01/07/2011	https://clinicaltrials.gov/study/NCT01573637	0.7		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	schizophrenia	RALOXIFENE	targetBased	3	Unknown status	01/03/2011	https://clinicaltrials.gov/study/NCT01280305	0.7		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	schizophrenia	RALOXIFENE	targetBased	4	Completed	01/04/2011	https://clinicaltrials.gov/study/NCT02354001	1		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	schizophrenia	RALOXIFENE	targetBased	4	Completed	01/01/2012	https://clinicaltrials.gov/study/NCT01481883	1		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	schizophrenia	RALOXIFENE	targetBased	4	Completed	01/06/2004	https://clinicaltrials.gov/study/NCT01041092	1		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	depressive disorder	RALOXIFENE	targetBased	4	Completed	01/02/2002	https://clinicaltrials.gov/study/NCT00030147	1		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	depressive disorder	RALOXIFENE	targetBased	4	Unknown status	01/01/2017	https://clinicaltrials.gov/study/NCT03006003	1		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	schizoaffective disorder	RALOXIFENE	targetBased	4	Completed	01/08/2006	https://clinicaltrials.gov/study/NCT00361543	1		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	schizoaffective disorder	RALOXIFENE	targetBased	4	Completed	01/04/2011	https://clinicaltrials.gov/study/NCT02354001	1		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	schizoaffective disorder	RALOXIFENE	targetBased	3	Unknown status	01/03/2011	https://clinicaltrials.gov/study/NCT01280305	0.7		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	schizoaffective disorder	RALOXIFENE	targetBased	4	Completed	01/01/2012	https://clinicaltrials.gov/study/NCT01481883	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	bipolar disorder	TAMOXIFEN	targetBased	3	Completed	01/04/2003	https://clinicaltrials.gov/study/NCT00411203	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	bipolar disorder	TAMOXIFEN	targetBased	3	Completed	01/04/2003	https://clinicaltrials.gov/study/NCT00411203	0.7		protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	drug dependence	BROMOCRIPTINE	targetBased	4	Withdrawn	01/07/2013	https://clinicaltrials.gov/study/NCT02929485	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	drug dependence	BROMOCRIPTINE	targetBased	4	Withdrawn	01/07/2013	https://clinicaltrials.gov/study/NCT02929485	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	drug dependence	BROMOCRIPTINE	targetBased	4	Withdrawn	01/07/2013	https://clinicaltrials.gov/study/NCT02929485	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	drug dependence	BROMOCRIPTINE	targetBased	4	Withdrawn	01/07/2013	https://clinicaltrials.gov/study/NCT02929485	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	drug dependence	BROMOCRIPTINE	targetBased	4	Withdrawn	01/07/2013	https://clinicaltrials.gov/study/NCT02929485	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	drug dependence	BROMOCRIPTINE	targetBased	4	Withdrawn	01/07/2013	https://clinicaltrials.gov/study/NCT02929485	1	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	drug dependence	BROMOCRIPTINE	targetBased	4	Withdrawn	01/07/2013	https://clinicaltrials.gov/study/NCT02929485	1	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	drug dependence	BROMOCRIPTINE	targetBased	4	Withdrawn	01/07/2013	https://clinicaltrials.gov/study/NCT02929485	1	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	drug dependence	BROMOCRIPTINE	targetBased	4	Withdrawn	01/07/2013	https://clinicaltrials.gov/study/NCT02929485	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	delirium	RISPERIDONE	targetBased	4	Terminated	01/01/2008	https://clinicaltrials.gov/study/NCT00622011	1	LoF	protect	inadequate participant
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	major depressive disorder	RISPERIDONE	targetBased	3	Completed	01/10/2004	https://clinicaltrials.gov/study/NCT00095134	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	major depressive disorder	RISPERIDONE	targetBased	3	Completed	01/10/2002	https://clinicaltrials.gov/study/NCT00044681	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	conduct disorder	RISPERIDONE	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00266552	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	conduct disorder	RISPERIDONE	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00266552	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	conduct disorder	RISPERIDONE	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00266552	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	conduct disorder	RISPERIDONE	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00266552	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	conduct disorder	RISPERIDONE	targetBased	3	Completed	01/09/1997	https://clinicaltrials.gov/study/NCT00250354	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	conduct disorder	RISPERIDONE	targetBased	3	Completed	01/09/1997	https://clinicaltrials.gov/study/NCT00250354	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	conduct disorder	RISPERIDONE	targetBased	3	Completed	01/09/1997	https://clinicaltrials.gov/study/NCT00250354	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	conduct disorder	RISPERIDONE	targetBased	3	Completed	01/09/1997	https://clinicaltrials.gov/study/NCT00250354	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	conduct disorder	RISPERIDONE	targetBased	3	Completed	01/09/1997	https://clinicaltrials.gov/study/NCT00250354	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	conduct disorder	RISPERIDONE	targetBased	3	Completed	01/09/1997	https://clinicaltrials.gov/study/NCT00250354	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	post-traumatic stress disorder	RISPERIDONE	targetBased	4	Completed	01/07/2001	https://clinicaltrials.gov/study/NCT00208182	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	aggressive behavior	RISPERIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1522f0b9-2bbc-4785-bada-fa6ae7986bb4	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	aggressive behavior	RISPERIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a6347895-5f16-43b4-92a0-b9904ac81937	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	aggressive behavior	RISPERIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a6347895-5f16-43b4-92a0-b9904ac81937	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	aggressive behavior	RISPERIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a6347895-5f16-43b4-92a0-b9904ac81937	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	aggressive behavior	RISPERIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a6347895-5f16-43b4-92a0-b9904ac81937	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	aggressive behavior	RISPERIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a6347895-5f16-43b4-92a0-b9904ac81937	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	aggressive behavior	RISPERIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a6347895-5f16-43b4-92a0-b9904ac81937	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Oppositional defiant disorder	RISPERIDONE	targetBased	3	Completed	01/09/1997	https://clinicaltrials.gov/study/NCT00250354	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Oppositional defiant disorder	RISPERIDONE	targetBased	3	Completed	01/12/2001	https://clinicaltrials.gov/study/NCT00236444	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Oppositional defiant disorder	RISPERIDONE	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00266552	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Oppositional defiant disorder	RISPERIDONE	targetBased	3	Completed	01/01/2002	https://clinicaltrials.gov/study/NCT00236470	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Rett syndrome	RISPERIDONE	targetBased	3	Completed	01/08/1999	https://clinicaltrials.gov/study/NCT00261508	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	delirium	RISPERIDONE	targetBased	4	Terminated	01/01/2008	https://clinicaltrials.gov/study/NCT00622011	1	LoF	protect	inadequate participant
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	delirium	RISPERIDONE	targetBased	4	Terminated	01/01/2008	https://clinicaltrials.gov/study/NCT00622011	1	LoF	protect	inadequate participant
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	delirium	RISPERIDONE	targetBased	4	Terminated	01/01/2008	https://clinicaltrials.gov/study/NCT00622011	1	LoF	protect	inadequate participant
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	delirium	RISPERIDONE	targetBased	4	Terminated	01/01/2008	https://clinicaltrials.gov/study/NCT00622011	1	LoF	protect	inadequate participant
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	delirium	RISPERIDONE	targetBased	4	Terminated	01/01/2008	https://clinicaltrials.gov/study/NCT00622011	1	LoF	protect	inadequate participant
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	delirium	RISPERIDONE	targetBased	4	Terminated	01/01/2008	https://clinicaltrials.gov/study/NCT00622011	1	LoF	protect	inadequate participant
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Asperger syndrome	RISPERIDONE	targetBased	4	Completed	01/11/2001	https://clinicaltrials.gov/study/NCT00352196	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Asperger syndrome	RISPERIDONE	targetBased	4	Completed	01/11/2001	https://clinicaltrials.gov/study/NCT00352196	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Asperger syndrome	RISPERIDONE	targetBased	4	Completed	01/11/2001	https://clinicaltrials.gov/study/NCT00352196	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Asperger syndrome	RISPERIDONE	targetBased	4	Completed	01/11/2001	https://clinicaltrials.gov/study/NCT00352196	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Asperger syndrome	RISPERIDONE	targetBased	4	Completed	01/11/2001	https://clinicaltrials.gov/study/NCT00352196	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Asperger syndrome	RISPERIDONE	targetBased	4	Completed	01/11/2001	https://clinicaltrials.gov/study/NCT00352196	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Asperger syndrome	RISPERIDONE	targetBased	3	Completed	01/08/1999	https://clinicaltrials.gov/study/NCT00261508	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Borderline personality disorder	RISPERIDONE	targetBased	4	Completed	01/07/2003	https://clinicaltrials.gov/study/NCT00204347	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	RISPERIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ea914046-6cc2-4c7b-b12b-76c31bb18def	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	RISPERIDONE	targetBased	4	Completed	01/09/1999	https://clinicaltrials.gov/study/NCT00308360	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	RISPERIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5b597f75-e579-438d-b162-c906c3b01088	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	RISPERIDONE	targetBased	4	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00130923	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	RISPERIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2e5c6b7f-1d57-4114-9067-79dca009c4cc	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	RISPERIDONE	targetBased	4	Unknown status	01/07/2009	https://clinicaltrials.gov/study/NCT00937261	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	RISPERIDONE	targetBased	4	Terminated	01/08/2007	https://clinicaltrials.gov/study/NCT00498004	1	LoF	protect	difficult to recruit subject
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar disorder	RISPERIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5958bb43-6967-4f15-9bd1-7f06340527ff	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	bipolar disorder	RISPERIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d072638f-70d6-4ce9-a0d4-16db4b31d824	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	bipolar disorder	RISPERIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d072638f-70d6-4ce9-a0d4-16db4b31d824	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar disorder	RISPERIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d072638f-70d6-4ce9-a0d4-16db4b31d824	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar disorder	RISPERIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d072638f-70d6-4ce9-a0d4-16db4b31d824	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar disorder	RISPERIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d072638f-70d6-4ce9-a0d4-16db4b31d824	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar disorder	RISPERIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d072638f-70d6-4ce9-a0d4-16db4b31d824	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	methamphetamine dependence	RISPERIDONE	targetBased	4	Completed	01/02/2013	https://clinicaltrials.gov/study/NCT01822730	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	methamphetamine dependence	RISPERIDONE	targetBased	4	Terminated	01/07/2012	https://clinicaltrials.gov/study/NCT01813643	0.5	LoF	protect	Effects of aripiprazole was not obvious and showed adverse reaction obviously
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	mental or behavioural disorder	RISPERIDONE	targetBased	3	Completed	01/11/1999	https://clinicaltrials.gov/study/NCT00253136	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	mental or behavioural disorder	RISPERIDONE	targetBased	3	Completed	01/01/2000	https://clinicaltrials.gov/study/NCT00249223	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	mental or behavioural disorder	RISPERIDONE	targetBased	3	Completed	01/11/2000	https://clinicaltrials.gov/study/NCT00236457	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	mental or behavioural disorder	RISPERIDONE	targetBased	3	Completed	01/12/2000	https://clinicaltrials.gov/study/NCT00034762	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	mental or behavioural disorder	RISPERIDONE	targetBased	4	Completed	01/03/2006	https://clinicaltrials.gov/study/NCT00369239	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	mental or behavioural disorder	RISPERIDONE	targetBased	4	Completed	01/02/2003	https://clinicaltrials.gov/study/NCT00932529	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	mental or behavioural disorder	RISPERIDONE	targetBased	4	Completed	01/10/2003	https://clinicaltrials.gov/study/NCT00108368	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	mental or behavioural disorder	RISPERIDONE	targetBased	4	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT00806234	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	conduct disorder	RISPERIDONE	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00266552	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	conduct disorder	RISPERIDONE	targetBased	3	Completed	01/09/1997	https://clinicaltrials.gov/study/NCT00250354	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	vascular dementia	RISPERIDONE	targetBased	3	Completed	01/03/1998	https://clinicaltrials.gov/study/NCT00249158	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	vascular dementia	RISPERIDONE	targetBased	3	Completed	01/03/1998	https://clinicaltrials.gov/study/NCT00249158	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	vascular dementia	RISPERIDONE	targetBased	3	Completed	01/03/1998	https://clinicaltrials.gov/study/NCT00249158	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	vascular dementia	RISPERIDONE	targetBased	3	Completed	01/03/1998	https://clinicaltrials.gov/study/NCT00249158	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	vascular dementia	RISPERIDONE	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00253123	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	vascular dementia	RISPERIDONE	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00253123	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	vascular dementia	RISPERIDONE	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00253123	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	vascular dementia	RISPERIDONE	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00253123	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	vascular dementia	RISPERIDONE	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00253123	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	vascular dementia	RISPERIDONE	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00253123	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	treatment resistant depression	RISPERIDONE	targetBased	4	Withdrawn	01/05/2004	https://clinicaltrials.gov/study/NCT00178854	1	LoF	protect	failed recruitment efforts
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Dementia	RISPERIDONE	targetBased	3	Terminated	01/03/2002	https://clinicaltrials.gov/study/NCT00287742	0.7	LoF	protect	A decision was made to discontinue the study due to a change in the strategic direction of the company.
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Dementia	RISPERIDONE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Dementia	RISPERIDONE	targetBased	3	Completed	01/12/2000	https://clinicaltrials.gov/study/NCT00034762	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Dementia	RISPERIDONE	targetBased	4	Completed	01/09/2006	https://clinicaltrials.gov/study/NCT00433121	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Dementia	RISPERIDONE	targetBased	3	Completed	01/03/1998	https://clinicaltrials.gov/study/NCT00249158	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Dementia	RISPERIDONE	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00253123	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Dementia	RISPERIDONE	targetBased	3	Completed	01/04/1995	https://clinicaltrials.gov/study/NCT00249145	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Dementia	RISPERIDONE	targetBased	4	Completed	01/08/2008	https://clinicaltrials.gov/study/NCT00594269	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	major depressive disorder	RISPERIDONE	targetBased	3	Completed	01/10/2004	https://clinicaltrials.gov/study/NCT00095134	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	major depressive disorder	RISPERIDONE	targetBased	3	Completed	01/10/2004	https://clinicaltrials.gov/study/NCT00095134	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	major depressive disorder	RISPERIDONE	targetBased	3	Completed	01/10/2004	https://clinicaltrials.gov/study/NCT00095134	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	major depressive disorder	RISPERIDONE	targetBased	3	Completed	01/10/2004	https://clinicaltrials.gov/study/NCT00095134	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	major depressive disorder	RISPERIDONE	targetBased	3	Completed	01/10/2002	https://clinicaltrials.gov/study/NCT00044681	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	major depressive disorder	RISPERIDONE	targetBased	3	Completed	01/10/2002	https://clinicaltrials.gov/study/NCT00044681	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	major depressive disorder	RISPERIDONE	targetBased	3	Completed	01/10/2002	https://clinicaltrials.gov/study/NCT00044681	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	major depressive disorder	RISPERIDONE	targetBased	3	Completed	01/10/2002	https://clinicaltrials.gov/study/NCT00044681	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	major depressive disorder	RISPERIDONE	targetBased	3	Completed	01/10/2002	https://clinicaltrials.gov/study/NCT00044681	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	major depressive disorder	RISPERIDONE	targetBased	3	Completed	01/10/2002	https://clinicaltrials.gov/study/NCT00044681	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Asperger syndrome	RISPERIDONE	targetBased	4	Completed	01/11/2001	https://clinicaltrials.gov/study/NCT00352196	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Asperger syndrome	RISPERIDONE	targetBased	3	Completed	01/08/1999	https://clinicaltrials.gov/study/NCT00261508	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Rett syndrome	RISPERIDONE	targetBased	3	Completed	01/08/1999	https://clinicaltrials.gov/study/NCT00261508	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Rett syndrome	RISPERIDONE	targetBased	3	Completed	01/08/1999	https://clinicaltrials.gov/study/NCT00261508	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Rett syndrome	RISPERIDONE	targetBased	3	Completed	01/08/1999	https://clinicaltrials.gov/study/NCT00261508	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Rett syndrome	RISPERIDONE	targetBased	3	Completed	01/08/1999	https://clinicaltrials.gov/study/NCT00261508	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Rett syndrome	RISPERIDONE	targetBased	3	Completed	01/08/1999	https://clinicaltrials.gov/study/NCT00261508	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Rett syndrome	RISPERIDONE	targetBased	3	Completed	01/08/1999	https://clinicaltrials.gov/study/NCT00261508	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	post-traumatic stress disorder	RISPERIDONE	targetBased	4	Completed	01/07/2001	https://clinicaltrials.gov/study/NCT00208182	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	post-traumatic stress disorder	RISPERIDONE	targetBased	4	Completed	01/07/2001	https://clinicaltrials.gov/study/NCT00208182	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	post-traumatic stress disorder	RISPERIDONE	targetBased	4	Completed	01/07/2001	https://clinicaltrials.gov/study/NCT00208182	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	post-traumatic stress disorder	RISPERIDONE	targetBased	4	Completed	01/07/2001	https://clinicaltrials.gov/study/NCT00208182	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	post-traumatic stress disorder	RISPERIDONE	targetBased	4	Completed	01/07/2001	https://clinicaltrials.gov/study/NCT00208182	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	post-traumatic stress disorder	RISPERIDONE	targetBased	4	Completed	01/07/2001	https://clinicaltrials.gov/study/NCT00208182	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	depressive disorder	RISPERIDONE	targetBased	4	Terminated	01/03/2005	https://clinicaltrials.gov/study/NCT00203723	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	depressive disorder	RISPERIDONE	targetBased	4	Unknown status	01/06/2017	https://clinicaltrials.gov/study/NCT03148509	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	depressive disorder	RISPERIDONE	targetBased	4	Unknown status	01/06/2017	https://clinicaltrials.gov/study/NCT03148509	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	depressive disorder	RISPERIDONE	targetBased	4	Unknown status	01/06/2017	https://clinicaltrials.gov/study/NCT03148509	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	depressive disorder	RISPERIDONE	targetBased	4	Unknown status	01/06/2017	https://clinicaltrials.gov/study/NCT03148509	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	depressive disorder	RISPERIDONE	targetBased	4	Unknown status	01/06/2017	https://clinicaltrials.gov/study/NCT03148509	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	depressive disorder	RISPERIDONE	targetBased	4	Unknown status	01/06/2017	https://clinicaltrials.gov/study/NCT03148509	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	alcohol abuse	RISPERIDONE	targetBased	4	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00130923	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	anxiety	RISPERIDONE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	anxiety	RISPERIDONE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	anxiety	RISPERIDONE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	anxiety	RISPERIDONE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	anxiety	RISPERIDONE	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00086112	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	anxiety	RISPERIDONE	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00086112	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	anxiety	RISPERIDONE	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00086112	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	anxiety	RISPERIDONE	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00086112	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	anxiety	RISPERIDONE	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00086112	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	anxiety	RISPERIDONE	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00086112	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Agitation	RISPERIDONE	targetBased	4	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT00790075	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Agitation	RISPERIDONE	targetBased	4	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT00790075	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Agitation	RISPERIDONE	targetBased	4	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT00790075	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Agitation	RISPERIDONE	targetBased	4	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT00790075	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Agitation	RISPERIDONE	targetBased	4	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT00790075	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Agitation	RISPERIDONE	targetBased	4	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT00790075	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizoaffective disorder	RISPERIDONE	targetBased	4	Completed	01/07/2006	https://clinicaltrials.gov/study/NCT00325689	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizoaffective disorder	RISPERIDONE	targetBased	4	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00337662	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizoaffective disorder	RISPERIDONE	targetBased	4	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00337662	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizoaffective disorder	RISPERIDONE	targetBased	4	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00337662	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizoaffective disorder	RISPERIDONE	targetBased	4	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00337662	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizoaffective disorder	RISPERIDONE	targetBased	4	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00337662	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizoaffective disorder	RISPERIDONE	targetBased	4	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00337662	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	aggressive behavior	RISPERIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b6b3577f-7ebb-401f-b7e0-b707b35e09ed	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	aggressive behavior	RISPERIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=246866c2-31f0-4770-8fa4-22e5b3556347	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	aggressive behavior	RISPERIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=275e99fc-7977-4d72-9294-1d1348188798	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	aggressive behavior	RISPERIDONE	targetBased	4	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT00297739	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	aggressive behavior	RISPERIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b6a3d727-030c-407a-9bbf-34da8ce54fa6	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	aggressive behavior	RISPERIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=23993d21-80bf-41c4-b57d-88a620173b6b	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	aggressive behavior	RISPERIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1522f0b9-2bbc-4785-bada-fa6ae7986bb4	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar I disorder	RISPERIDONE	targetBased	3	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00177164	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar I disorder	RISPERIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5e1eba05-036a-440f-85e3-a24b7ff3eb55	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar I disorder	RISPERIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=51b65970-02e6-4558-a4b3-38e56e0c073c	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar I disorder	RISPERIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bb34ee82-d2c2-43b8-ba21-2825c0954691	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar I disorder	RISPERIDONE	targetBased	3	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT01977300	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar I disorder	RISPERIDONE	targetBased	3	Terminated	01/04/2009	https://clinicaltrials.gov/study/NCT00857818	0.7	LoF	protect	Slow Accrual
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar I disorder	RISPERIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=89595dbd-2722-41f2-88ae-8c43769702bf	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar I disorder	RISPERIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=daf11e04-d69c-4aaa-80e6-a4bac692736c	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	RISPERIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e5ec2af6-7777-4dc2-9cea-eefc2629d5ad	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	RISPERIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=82effea8-5782-4aa5-969e-b635423ae3c6	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	RISPERIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e344c976-fc8b-42b4-933c-2d63488182f0	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	RISPERIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5e1eba05-036a-440f-85e3-a24b7ff3eb55	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	RISPERIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f06a91eb-5aa0-4722-8644-c56bbd975f02	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	RISPERIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dd1c68bd-abba-45b3-9c3c-586d77c18853	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	RISPERIDONE	targetBased	4	Completed	01/06/2001	https://clinicaltrials.gov/study/NCT00182013	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	RISPERIDONE	targetBased	4	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT00806234	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	RISPERIDONE	targetBased	4	Completed	01/02/2003	https://clinicaltrials.gov/study/NCT00932529	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	RISPERIDONE	targetBased	4	Completed	01/02/2003	https://clinicaltrials.gov/study/NCT00932529	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	mental or behavioural disorder	RISPERIDONE	targetBased	4	Completed	01/02/2003	https://clinicaltrials.gov/study/NCT00932529	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	mental or behavioural disorder	RISPERIDONE	targetBased	4	Completed	01/02/2003	https://clinicaltrials.gov/study/NCT00932529	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	RISPERIDONE	targetBased	4	Completed	01/02/2003	https://clinicaltrials.gov/study/NCT00932529	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	RISPERIDONE	targetBased	4	Completed	01/02/2003	https://clinicaltrials.gov/study/NCT00932529	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	substance dependence	RISPERIDONE	targetBased	4	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00208143	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	substance dependence	RISPERIDONE	targetBased	4	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00208143	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	substance dependence	RISPERIDONE	targetBased	4	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00208143	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	substance dependence	RISPERIDONE	targetBased	4	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00208143	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	substance dependence	RISPERIDONE	targetBased	4	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00208143	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	substance dependence	RISPERIDONE	targetBased	4	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00208143	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	autism spectrum disorder	RISPERIDONE	targetBased	4	Recruiting	01/12/2021	https://clinicaltrials.gov/study/NCT05146245	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Williams syndrome	RISPERIDONE	targetBased	4	Recruiting	01/05/2001	https://clinicaltrials.gov/study/NCT00768820	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Williams syndrome	RISPERIDONE	targetBased	4	Recruiting	01/05/2001	https://clinicaltrials.gov/study/NCT00768820	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Williams syndrome	RISPERIDONE	targetBased	4	Recruiting	01/05/2001	https://clinicaltrials.gov/study/NCT00768820	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Williams syndrome	RISPERIDONE	targetBased	4	Recruiting	01/05/2001	https://clinicaltrials.gov/study/NCT00768820	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Williams syndrome	RISPERIDONE	targetBased	4	Recruiting	01/05/2001	https://clinicaltrials.gov/study/NCT00768820	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Williams syndrome	RISPERIDONE	targetBased	4	Recruiting	01/05/2001	https://clinicaltrials.gov/study/NCT00768820	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Oppositional defiant disorder	RISPERIDONE	targetBased	3	Completed	01/01/2002	https://clinicaltrials.gov/study/NCT00236470	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Oppositional defiant disorder	RISPERIDONE	targetBased	3	Completed	01/01/2002	https://clinicaltrials.gov/study/NCT00236470	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Oppositional defiant disorder	RISPERIDONE	targetBased	3	Completed	01/01/2002	https://clinicaltrials.gov/study/NCT00236470	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Oppositional defiant disorder	RISPERIDONE	targetBased	3	Completed	01/01/2002	https://clinicaltrials.gov/study/NCT00236470	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Oppositional defiant disorder	RISPERIDONE	targetBased	3	Completed	01/12/2001	https://clinicaltrials.gov/study/NCT00236444	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Oppositional defiant disorder	RISPERIDONE	targetBased	3	Completed	01/12/2001	https://clinicaltrials.gov/study/NCT00236444	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Oppositional defiant disorder	RISPERIDONE	targetBased	3	Completed	01/12/2001	https://clinicaltrials.gov/study/NCT00236444	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Oppositional defiant disorder	RISPERIDONE	targetBased	3	Completed	01/12/2001	https://clinicaltrials.gov/study/NCT00236444	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Oppositional defiant disorder	RISPERIDONE	targetBased	3	Completed	01/12/2001	https://clinicaltrials.gov/study/NCT00236444	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Oppositional defiant disorder	RISPERIDONE	targetBased	3	Completed	01/12/2001	https://clinicaltrials.gov/study/NCT00236444	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	psychosis	RISPERIDONE	targetBased	4	Terminated	11/05/2023	https://clinicaltrials.gov/study/NCT05890768	1	LoF	protect	PI was unable to meet 1 year recruitment goal
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	psychosis	RISPERIDONE	targetBased	4	Terminated	01/07/2013	https://clinicaltrials.gov/study/NCT01844700	0.5	LoF	protect	very slow recruitment, no sufficient results
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	psychosis	RISPERIDONE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AX08	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	substance abuse	RISPERIDONE	targetBased	4	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00208143	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	substance abuse	RISPERIDONE	targetBased	4	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00208143	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	substance abuse	RISPERIDONE	targetBased	4	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00208143	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	substance abuse	RISPERIDONE	targetBased	4	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00208143	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	substance abuse	RISPERIDONE	targetBased	4	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00208143	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	substance abuse	RISPERIDONE	targetBased	4	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00208143	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	vascular dementia	RISPERIDONE	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00253123	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	vascular dementia	RISPERIDONE	targetBased	3	Completed	01/03/1998	https://clinicaltrials.gov/study/NCT00249158	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	vascular dementia	RISPERIDONE	targetBased	3	Completed	01/04/1995	https://clinicaltrials.gov/study/NCT00249145	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizoaffective disorder	RISPERIDONE	targetBased	4	Completed	01/05/1996	https://clinicaltrials.gov/study/NCT00253110	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizoaffective disorder	RISPERIDONE	targetBased	4	Completed	01/03/2006	https://clinicaltrials.gov/study/NCT00369239	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizoaffective disorder	RISPERIDONE	targetBased	4	Completed	01/01/2007	https://clinicaltrials.gov/study/NCT00423878	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizoaffective disorder	RISPERIDONE	targetBased	4	Completed	01/10/2003	https://clinicaltrials.gov/study/NCT00190749	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizoaffective disorder	RISPERIDONE	targetBased	4	Completed	01/04/2004	https://clinicaltrials.gov/study/NCT00215579	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizoaffective disorder	RISPERIDONE	targetBased	4	Terminated	01/04/2013	https://clinicaltrials.gov/study/NCT01913327	1	LoF	protect	Insufficient Funds and Inadequate Subject Recruitment
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizoaffective disorder	RISPERIDONE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	substance dependence	RISPERIDONE	targetBased	4	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00208143	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	depressive disorder	RISPERIDONE	targetBased	4	Unknown status	01/06/2017	https://clinicaltrials.gov/study/NCT03148509	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	depressive disorder	RISPERIDONE	targetBased	3	Unknown status	01/02/2003	https://clinicaltrials.gov/study/NCT00174577	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	depressive disorder	RISPERIDONE	targetBased	4	Terminated	01/03/2005	https://clinicaltrials.gov/study/NCT00203723	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	depressive disorder	RISPERIDONE	targetBased	4	Terminated	01/07/2009	https://clinicaltrials.gov/study/NCT01305707	1	LoF	protect	Difficulties in recruiting
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	depressive disorder	RISPERIDONE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	depressive disorder	RISPERIDONE	targetBased	3	Completed	01/10/2002	https://clinicaltrials.gov/study/NCT00044681	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	depressive disorder	RISPERIDONE	targetBased	3	Completed	01/02/2008	https://clinicaltrials.gov/study/NCT00640562	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	depressive disorder	RISPERIDONE	targetBased	3	Terminated	01/09/2001	https://clinicaltrials.gov/study/NCT00174590	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	depressive disorder	RISPERIDONE	targetBased	3	Completed	01/06/2004	https://clinicaltrials.gov/study/NCT00167154	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	RISPERIDONE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AX08	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	psychosis	RISPERIDONE	targetBased	4	Terminated	11/05/2023	https://clinicaltrials.gov/study/NCT05890768	1	LoF	protect	PI was unable to meet 1 year recruitment goal
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	psychosis	RISPERIDONE	targetBased	4	Terminated	11/05/2023	https://clinicaltrials.gov/study/NCT05890768	1	LoF	protect	PI was unable to meet 1 year recruitment goal
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	psychosis	RISPERIDONE	targetBased	4	Terminated	11/05/2023	https://clinicaltrials.gov/study/NCT05890768	1	LoF	protect	PI was unable to meet 1 year recruitment goal
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	psychosis	RISPERIDONE	targetBased	4	Terminated	11/05/2023	https://clinicaltrials.gov/study/NCT05890768	1	LoF	protect	PI was unable to meet 1 year recruitment goal
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	RISPERIDONE	targetBased	4	Terminated	11/05/2023	https://clinicaltrials.gov/study/NCT05890768	1	LoF	protect	PI was unable to meet 1 year recruitment goal
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	RISPERIDONE	targetBased	4	Terminated	11/05/2023	https://clinicaltrials.gov/study/NCT05890768	1	LoF	protect	PI was unable to meet 1 year recruitment goal
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	anxiety	RISPERIDONE	targetBased	3	Completed	01/02/2004	https://clinicaltrials.gov/study/NCT00277654	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	anxiety	RISPERIDONE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	anxiety	RISPERIDONE	targetBased	3	Terminated	01/09/2017	https://clinicaltrials.gov/study/NCT03227562	0.7	LoF	protect	not enough patient
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	anxiety	RISPERIDONE	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00086112	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	substance abuse	RISPERIDONE	targetBased	4	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00208143	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	attention deficit hyperactivity disorder	RISPERIDONE	targetBased	4	Completed	01/08/2008	https://clinicaltrials.gov/study/NCT00796302	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	attention deficit hyperactivity disorder	RISPERIDONE	targetBased	4	Unknown status	01/11/2008	https://clinicaltrials.gov/study/NCT00794625	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	autism	RISPERIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f11dae15-b057-4258-9229-3819d0c980fe	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	autism	RISPERIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1097d343-413d-49fc-8bc9-34a1fdc0b643	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	autism	RISPERIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1cd2c55a-f30a-4a3f-92d8-baa3886b3a8b	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	autism	RISPERIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0dc12b44-73f8-416c-88bb-0b11b3e35458	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	autism	RISPERIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b939e746-6b5f-ae82-c5f4-79cfdf6253ea	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	autism	RISPERIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7073b706-1946-4ff2-8788-fb9452a59cae	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	autism	RISPERIDONE	targetBased	4	Completed	01/07/2011	https://clinicaltrials.gov/study/NCT01333072	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	methamphetamine dependence	RISPERIDONE	targetBased	4	Terminated	01/07/2012	https://clinicaltrials.gov/study/NCT01813643	0.5	LoF	protect	Effects of aripiprazole was not obvious and showed adverse reaction obviously
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	methamphetamine dependence	RISPERIDONE	targetBased	4	Terminated	01/07/2012	https://clinicaltrials.gov/study/NCT01813643	0.5	LoF	protect	Effects of aripiprazole was not obvious and showed adverse reaction obviously
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	methamphetamine dependence	RISPERIDONE	targetBased	4	Completed	01/02/2013	https://clinicaltrials.gov/study/NCT01822730	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	methamphetamine dependence	RISPERIDONE	targetBased	4	Completed	01/02/2013	https://clinicaltrials.gov/study/NCT01822730	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	methamphetamine dependence	RISPERIDONE	targetBased	4	Completed	01/02/2013	https://clinicaltrials.gov/study/NCT01822730	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	methamphetamine dependence	RISPERIDONE	targetBased	4	Completed	01/02/2013	https://clinicaltrials.gov/study/NCT01822730	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	methamphetamine dependence	RISPERIDONE	targetBased	4	Completed	01/02/2013	https://clinicaltrials.gov/study/NCT01822730	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	methamphetamine dependence	RISPERIDONE	targetBased	4	Completed	01/02/2013	https://clinicaltrials.gov/study/NCT01822730	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Williams syndrome	RISPERIDONE	targetBased	4	Recruiting	01/05/2001	https://clinicaltrials.gov/study/NCT00768820	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Dementia	RISPERIDONE	targetBased	4	Completed	01/09/2006	https://clinicaltrials.gov/study/NCT00433121	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Dementia	RISPERIDONE	targetBased	4	Completed	01/08/2008	https://clinicaltrials.gov/study/NCT00594269	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Dementia	RISPERIDONE	targetBased	4	Completed	01/08/2008	https://clinicaltrials.gov/study/NCT00594269	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Dementia	RISPERIDONE	targetBased	4	Completed	01/08/2008	https://clinicaltrials.gov/study/NCT00594269	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Dementia	RISPERIDONE	targetBased	4	Completed	01/08/2008	https://clinicaltrials.gov/study/NCT00594269	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Dementia	RISPERIDONE	targetBased	4	Completed	01/08/2008	https://clinicaltrials.gov/study/NCT00594269	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Dementia	RISPERIDONE	targetBased	4	Completed	01/08/2008	https://clinicaltrials.gov/study/NCT00594269	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	autism spectrum disorder	RISPERIDONE	targetBased	4	Recruiting	01/12/2021	https://clinicaltrials.gov/study/NCT05146245	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	autism spectrum disorder	RISPERIDONE	targetBased	4	Recruiting	01/12/2021	https://clinicaltrials.gov/study/NCT05146245	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	autism spectrum disorder	RISPERIDONE	targetBased	4	Recruiting	01/12/2021	https://clinicaltrials.gov/study/NCT05146245	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	autism spectrum disorder	RISPERIDONE	targetBased	4	Recruiting	01/12/2021	https://clinicaltrials.gov/study/NCT05146245	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	autism spectrum disorder	RISPERIDONE	targetBased	4	Recruiting	01/12/2021	https://clinicaltrials.gov/study/NCT05146245	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	autism spectrum disorder	RISPERIDONE	targetBased	4	Recruiting	01/12/2021	https://clinicaltrials.gov/study/NCT05146245	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar I disorder	RISPERIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bb34ee82-d2c2-43b8-ba21-2825c0954691	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	bipolar I disorder	RISPERIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=89595dbd-2722-41f2-88ae-8c43769702bf	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	bipolar I disorder	RISPERIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=89595dbd-2722-41f2-88ae-8c43769702bf	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar I disorder	RISPERIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=89595dbd-2722-41f2-88ae-8c43769702bf	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar I disorder	RISPERIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=89595dbd-2722-41f2-88ae-8c43769702bf	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar I disorder	RISPERIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=89595dbd-2722-41f2-88ae-8c43769702bf	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar I disorder	RISPERIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=89595dbd-2722-41f2-88ae-8c43769702bf	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	alcohol abuse	RISPERIDONE	targetBased	4	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00130923	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	alcohol abuse	RISPERIDONE	targetBased	4	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00130923	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	alcohol abuse	RISPERIDONE	targetBased	4	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00130923	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	alcohol abuse	RISPERIDONE	targetBased	4	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00130923	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	alcohol abuse	RISPERIDONE	targetBased	4	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00130923	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	alcohol abuse	RISPERIDONE	targetBased	4	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00130923	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Agitation	RISPERIDONE	targetBased	4	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT00790075	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	RISPERIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1ecf6682-7ad4-4320-ab19-f17dfc5241f8	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	RISPERIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5f0bdf9d-fa78-45e8-913a-81beff57cf34	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	RISPERIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5f0bdf9d-fa78-45e8-913a-81beff57cf34	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	RISPERIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5f0bdf9d-fa78-45e8-913a-81beff57cf34	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	RISPERIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5f0bdf9d-fa78-45e8-913a-81beff57cf34	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	RISPERIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5f0bdf9d-fa78-45e8-913a-81beff57cf34	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	RISPERIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5f0bdf9d-fa78-45e8-913a-81beff57cf34	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	attention deficit hyperactivity disorder	RISPERIDONE	targetBased	4	Completed	01/08/2008	https://clinicaltrials.gov/study/NCT00796302	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	attention deficit hyperactivity disorder	RISPERIDONE	targetBased	4	Unknown status	01/11/2008	https://clinicaltrials.gov/study/NCT00794625	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	attention deficit hyperactivity disorder	RISPERIDONE	targetBased	4	Unknown status	01/11/2008	https://clinicaltrials.gov/study/NCT00794625	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	attention deficit hyperactivity disorder	RISPERIDONE	targetBased	4	Unknown status	01/11/2008	https://clinicaltrials.gov/study/NCT00794625	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	attention deficit hyperactivity disorder	RISPERIDONE	targetBased	4	Unknown status	01/11/2008	https://clinicaltrials.gov/study/NCT00794625	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	attention deficit hyperactivity disorder	RISPERIDONE	targetBased	4	Unknown status	01/11/2008	https://clinicaltrials.gov/study/NCT00794625	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	attention deficit hyperactivity disorder	RISPERIDONE	targetBased	4	Unknown status	01/11/2008	https://clinicaltrials.gov/study/NCT00794625	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	autism	RISPERIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cd742c16-c003-4c4c-8fa0-a3b4d0158383	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	autism	RISPERIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7a3c4f98-753f-4930-8b97-24d2d40ecfa7	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	autism	RISPERIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7a3c4f98-753f-4930-8b97-24d2d40ecfa7	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	autism	RISPERIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7a3c4f98-753f-4930-8b97-24d2d40ecfa7	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	autism	RISPERIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7a3c4f98-753f-4930-8b97-24d2d40ecfa7	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	autism	RISPERIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7a3c4f98-753f-4930-8b97-24d2d40ecfa7	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	autism	RISPERIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7a3c4f98-753f-4930-8b97-24d2d40ecfa7	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	treatment resistant depression	RISPERIDONE	targetBased	4	Withdrawn	01/05/2004	https://clinicaltrials.gov/study/NCT00178854	1	LoF	protect	failed recruitment efforts
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	treatment resistant depression	RISPERIDONE	targetBased	4	Withdrawn	01/05/2004	https://clinicaltrials.gov/study/NCT00178854	1	LoF	protect	failed recruitment efforts
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	treatment resistant depression	RISPERIDONE	targetBased	4	Withdrawn	01/05/2004	https://clinicaltrials.gov/study/NCT00178854	1	LoF	protect	failed recruitment efforts
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	treatment resistant depression	RISPERIDONE	targetBased	4	Withdrawn	01/05/2004	https://clinicaltrials.gov/study/NCT00178854	1	LoF	protect	failed recruitment efforts
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	treatment resistant depression	RISPERIDONE	targetBased	4	Withdrawn	01/05/2004	https://clinicaltrials.gov/study/NCT00178854	1	LoF	protect	failed recruitment efforts
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	treatment resistant depression	RISPERIDONE	targetBased	4	Withdrawn	01/05/2004	https://clinicaltrials.gov/study/NCT00178854	1	LoF	protect	failed recruitment efforts
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Borderline personality disorder	RISPERIDONE	targetBased	4	Completed	01/07/2003	https://clinicaltrials.gov/study/NCT00204347	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Borderline personality disorder	RISPERIDONE	targetBased	4	Completed	01/07/2003	https://clinicaltrials.gov/study/NCT00204347	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Borderline personality disorder	RISPERIDONE	targetBased	4	Completed	01/07/2003	https://clinicaltrials.gov/study/NCT00204347	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Borderline personality disorder	RISPERIDONE	targetBased	4	Completed	01/07/2003	https://clinicaltrials.gov/study/NCT00204347	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Borderline personality disorder	RISPERIDONE	targetBased	4	Completed	01/07/2003	https://clinicaltrials.gov/study/NCT00204347	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Borderline personality disorder	RISPERIDONE	targetBased	4	Completed	01/07/2003	https://clinicaltrials.gov/study/NCT00204347	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	opioid dependence	METOCLOPRAMIDE	targetBased	4	Completed	01/01/2014	https://clinicaltrials.gov/study/NCT03017430	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	opioid dependence	METOCLOPRAMIDE	targetBased	4	Completed	01/10/2010	https://clinicaltrials.gov/study/NCT01191645	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	opioid dependence	METOCLOPRAMIDE	targetBased	4	Completed	01/10/2010	https://clinicaltrials.gov/study/NCT01191645	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	opioid dependence	METOCLOPRAMIDE	targetBased	4	Completed	01/10/2010	https://clinicaltrials.gov/study/NCT01191645	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	opioid dependence	METOCLOPRAMIDE	targetBased	4	Completed	01/10/2010	https://clinicaltrials.gov/study/NCT01191645	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	opioid dependence	METOCLOPRAMIDE	targetBased	4	Completed	01/10/2010	https://clinicaltrials.gov/study/NCT01191645	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	opioid dependence	METOCLOPRAMIDE	targetBased	4	Completed	01/10/2010	https://clinicaltrials.gov/study/NCT01191645	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Anorexia	METOCLOPRAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=80fb18a3-824a-4360-947e-63f0a167245b	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Anorexia	METOCLOPRAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=80fb18a3-824a-4360-947e-63f0a167245b	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Anorexia	METOCLOPRAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=80fb18a3-824a-4360-947e-63f0a167245b	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Anorexia	METOCLOPRAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=80fb18a3-824a-4360-947e-63f0a167245b	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Anorexia	METOCLOPRAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=80fb18a3-824a-4360-947e-63f0a167245b	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Anorexia	METOCLOPRAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=80fb18a3-824a-4360-947e-63f0a167245b	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	depressive disorder	PINDOLOL	targetBased	4	Withdrawn	01/01/2004	https://clinicaltrials.gov/study/NCT00221494	1	GoF	protect	PI move
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	narcolepsy-cataplexy syndrome	AMPHETAMINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bb12811f-4cce-4010-aa48-d17c46ca1d3a	1		protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	narcolepsy-cataplexy syndrome	AMPHETAMINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ffd56d70-d884-43be-a994-6e70a10e823e	1		protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	narcolepsy-cataplexy syndrome	AMPHETAMINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f469fb38-0380-4621-9db3-a4f429126156	1		protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	AMPHETAMINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ffd56d70-d884-43be-a994-6e70a10e823e	1		protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	AMPHETAMINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1e25f905-6c0b-4b19-a3b6-b2a386afa1c3	1		protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	AMPHETAMINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f469fb38-0380-4621-9db3-a4f429126156	1		protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	AMPHETAMINE SULFATE	targetBased	3	Completed	13/09/2018	https://clinicaltrials.gov/study/NCT03659929	0.7		protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	AMPHETAMINE SULFATE	targetBased	3	Completed	27/01/2005	https://clinicaltrials.gov/study/NCT00150579	0.7		protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	AMPHETAMINE SULFATE	targetBased	3	Completed	10/03/2005	https://clinicaltrials.gov/study/NCT00152035	0.7		protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Anorexia	DOCETAXEL	targetBased	3	Completed	01/10/2002	https://clinicaltrials.gov/study/NCT00040885	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	SERTINDOLE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	SERTINDOLE	targetBased	4	Unknown status	01/10/2008	https://clinicaltrials.gov/study/NCT00480844	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	SERTINDOLE	targetBased	3	Completed	01/10/2006	https://clinicaltrials.gov/study/NCT00759421	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	SERTINDOLE	targetBased	3	Completed	01/03/2007	https://clinicaltrials.gov/study/NCT00759460	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	SERTINDOLE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	SERTINDOLE	targetBased	3	Completed	01/07/2002	https://clinicaltrials.gov/study/NCT00856583	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	SERTINDOLE	targetBased	4	Terminated	01/07/2008	https://clinicaltrials.gov/study/NCT02021201	1	LoF	protect	No suitable patients could be recruited in the available time period
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	SERTINDOLE	targetBased	4	Completed	01/11/2007	https://clinicaltrials.gov/study/NCT00763438	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Dementia	SERTINDOLE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	depressive disorder	SERTINDOLE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	depressive disorder	SERTINDOLE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	depressive disorder	SERTINDOLE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	depressive disorder	SERTINDOLE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	depressive disorder	SERTINDOLE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	depressive disorder	SERTINDOLE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	anxiety	SERTINDOLE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	anxiety	SERTINDOLE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	anxiety	SERTINDOLE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	anxiety	SERTINDOLE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	anxiety	SERTINDOLE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	anxiety	SERTINDOLE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizoaffective disorder	SERTINDOLE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizoaffective disorder	SERTINDOLE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizoaffective disorder	SERTINDOLE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizoaffective disorder	SERTINDOLE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizoaffective disorder	SERTINDOLE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizoaffective disorder	SERTINDOLE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	psychosis	SERTINDOLE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AE03	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizoaffective disorder	SERTINDOLE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	depressive disorder	SERTINDOLE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	psychosis	SERTINDOLE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AE03	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	psychosis	SERTINDOLE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AE03	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	psychosis	SERTINDOLE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AE03	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	psychosis	SERTINDOLE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AE03	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	SERTINDOLE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AE03	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	SERTINDOLE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AE03	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	anxiety	SERTINDOLE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Dementia	SERTINDOLE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Dementia	SERTINDOLE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Dementia	SERTINDOLE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Dementia	SERTINDOLE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Dementia	SERTINDOLE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Dementia	SERTINDOLE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	SERTINDOLE	targetBased	4	Terminated	01/07/2008	https://clinicaltrials.gov/study/NCT02021201	1	LoF	protect	No suitable patients could be recruited in the available time period
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	SERTINDOLE	targetBased	4	Completed	01/11/2007	https://clinicaltrials.gov/study/NCT00763438	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	SERTINDOLE	targetBased	4	Completed	01/11/2007	https://clinicaltrials.gov/study/NCT00763438	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	SERTINDOLE	targetBased	4	Completed	01/11/2007	https://clinicaltrials.gov/study/NCT00763438	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	SERTINDOLE	targetBased	4	Completed	01/11/2007	https://clinicaltrials.gov/study/NCT00763438	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	SERTINDOLE	targetBased	4	Completed	01/11/2007	https://clinicaltrials.gov/study/NCT00763438	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	SERTINDOLE	targetBased	4	Completed	01/11/2007	https://clinicaltrials.gov/study/NCT00763438	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	cocaine dependence	PERGOLIDE	targetBased	3	Completed	01/02/1996	https://clinicaltrials.gov/study/NCT00000248	0.7	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	cocaine dependence	PERGOLIDE	targetBased	3	Completed	01/02/1996	https://clinicaltrials.gov/study/NCT00000248	0.7	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	cocaine dependence	PERGOLIDE	targetBased	3	Completed	01/02/1996	https://clinicaltrials.gov/study/NCT00000248	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	cocaine dependence	PERGOLIDE	targetBased	3	Completed	01/02/1996	https://clinicaltrials.gov/study/NCT00000248	0.7	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	cocaine dependence	PERGOLIDE	targetBased	3	Completed	01/02/1996	https://clinicaltrials.gov/study/NCT00000248	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	cocaine dependence	PERGOLIDE	targetBased	3	Completed	01/02/1996	https://clinicaltrials.gov/study/NCT00000248	0.7	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	cocaine dependence	PERGOLIDE	targetBased	3	Completed	01/02/1996	https://clinicaltrials.gov/study/NCT00000248	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	cocaine dependence	PERGOLIDE	targetBased	3	Completed	01/02/1996	https://clinicaltrials.gov/study/NCT00000248	0.7	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	cocaine dependence	PERGOLIDE	targetBased	3	Completed	01/02/1996	https://clinicaltrials.gov/study/NCT00000248	0.7	GoF	protect
Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS	D1_activators	DRD1	Dopaminereceptor1	cocaine dependence	PERGOLIDE	targetBased	3	Completed	01/02/1996	https://clinicaltrials.gov/study/NCT00000248	0.7	GoF	protect
Allosteric Modulators of D1 Receptors: Primary Screen	D1	DRD1	Dopamine receptor D1	cocaine dependence	PERGOLIDE	targetBased	3	Completed	01/02/1996	https://clinicaltrials.gov/study/NCT00000248	0.7	GoF	protect
Antagonist of Human D 1 Dopamine Receptor: qHTS	D1_inhibitors	DRD1	Dopaminereceptor1	cocaine dependence	PERGOLIDE	targetBased	3	Completed	01/02/1996	https://clinicaltrials.gov/study/NCT00000248	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	major depressive disorder	ILOPERIDONE	targetBased	4	Completed	01/04/2012	https://clinicaltrials.gov/study/NCT01464229	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	ILOPERIDONE	targetBased	3	Unknown status	01/11/2013	https://clinicaltrials.gov/study/NCT02453893	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	ILOPERIDONE	targetBased	3	Completed	01/02/2011	https://clinicaltrials.gov/study/NCT01291511	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	ILOPERIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=43452bf8-76e7-47a9-a5d8-41fe84d061f0	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	ILOPERIDONE	targetBased	3	Completed	01/11/2005	https://clinicaltrials.gov/study/NCT00254202	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	ILOPERIDONE	targetBased	4	Completed	01/08/2010	https://clinicaltrials.gov/study/NCT01207414	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	ILOPERIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6f17cc91-86b3-42e3-9bf2-935dd360c3eb	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	ILOPERIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=33f60b40-3fca-11de-8f56-0002a5d5c51b	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	ILOPERIDONE	targetBased	4	Terminated	01/04/2012	https://clinicaltrials.gov/study/NCT01929889	1	LoF	protect	Low recruitment
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	bipolar disorder	ILOPERIDONE	targetBased	4	Completed	01/04/2012	https://clinicaltrials.gov/study/NCT02413918	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	bipolar disorder	ILOPERIDONE	targetBased	4	Completed	01/04/2012	https://clinicaltrials.gov/study/NCT02413918	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar disorder	ILOPERIDONE	targetBased	4	Completed	01/04/2012	https://clinicaltrials.gov/study/NCT02413918	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar disorder	ILOPERIDONE	targetBased	4	Completed	01/04/2012	https://clinicaltrials.gov/study/NCT02413918	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar disorder	ILOPERIDONE	targetBased	4	Completed	01/04/2012	https://clinicaltrials.gov/study/NCT02413918	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar disorder	ILOPERIDONE	targetBased	4	Completed	01/04/2012	https://clinicaltrials.gov/study/NCT02413918	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	mental or behavioural disorder	ILOPERIDONE	targetBased	4	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT00806234	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	major depressive disorder	ILOPERIDONE	targetBased	4	Completed	01/04/2012	https://clinicaltrials.gov/study/NCT01464229	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	major depressive disorder	ILOPERIDONE	targetBased	4	Completed	01/04/2012	https://clinicaltrials.gov/study/NCT01464229	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	major depressive disorder	ILOPERIDONE	targetBased	4	Completed	01/04/2012	https://clinicaltrials.gov/study/NCT01464229	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	major depressive disorder	ILOPERIDONE	targetBased	4	Completed	01/04/2012	https://clinicaltrials.gov/study/NCT01464229	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	major depressive disorder	ILOPERIDONE	targetBased	4	Completed	01/04/2012	https://clinicaltrials.gov/study/NCT01464229	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	major depressive disorder	ILOPERIDONE	targetBased	4	Completed	01/04/2012	https://clinicaltrials.gov/study/NCT01464229	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizoaffective disorder	ILOPERIDONE	targetBased	4	Terminated	01/04/2012	https://clinicaltrials.gov/study/NCT01929889	1	LoF	protect	Low recruitment
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizoaffective disorder	ILOPERIDONE	targetBased	4	Terminated	01/04/2012	https://clinicaltrials.gov/study/NCT01929889	1	LoF	protect	Low recruitment
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizoaffective disorder	ILOPERIDONE	targetBased	4	Terminated	01/04/2012	https://clinicaltrials.gov/study/NCT01929889	1	LoF	protect	Low recruitment
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizoaffective disorder	ILOPERIDONE	targetBased	4	Terminated	01/04/2012	https://clinicaltrials.gov/study/NCT01929889	1	LoF	protect	Low recruitment
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizoaffective disorder	ILOPERIDONE	targetBased	4	Terminated	01/04/2012	https://clinicaltrials.gov/study/NCT01929889	1	LoF	protect	Low recruitment
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizoaffective disorder	ILOPERIDONE	targetBased	4	Terminated	01/04/2012	https://clinicaltrials.gov/study/NCT01929889	1	LoF	protect	Low recruitment
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar I disorder	ILOPERIDONE	targetBased	3	Completed	22/03/2021	https://clinicaltrials.gov/study/NCT04819776	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	ILOPERIDONE	targetBased	4	Completed	01/04/2012	https://clinicaltrials.gov/study/NCT02413918	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	ILOPERIDONE	targetBased	4	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT00806234	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	ILOPERIDONE	targetBased	4	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT00806234	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	mental or behavioural disorder	ILOPERIDONE	targetBased	4	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT00806234	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	mental or behavioural disorder	ILOPERIDONE	targetBased	4	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT00806234	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	ILOPERIDONE	targetBased	4	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT00806234	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	ILOPERIDONE	targetBased	4	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT00806234	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	psychosis	ILOPERIDONE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AX14	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizoaffective disorder	ILOPERIDONE	targetBased	4	Terminated	01/04/2012	https://clinicaltrials.gov/study/NCT01929889	1	LoF	protect	Low recruitment
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	psychosis	ILOPERIDONE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AX14	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	psychosis	ILOPERIDONE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AX14	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	psychosis	ILOPERIDONE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AX14	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	psychosis	ILOPERIDONE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AX14	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	ILOPERIDONE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AX14	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	ILOPERIDONE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AX14	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	bipolar I disorder	ILOPERIDONE	targetBased	3	Completed	22/03/2021	https://clinicaltrials.gov/study/NCT04819776	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	bipolar I disorder	ILOPERIDONE	targetBased	3	Completed	22/03/2021	https://clinicaltrials.gov/study/NCT04819776	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar I disorder	ILOPERIDONE	targetBased	3	Completed	22/03/2021	https://clinicaltrials.gov/study/NCT04819776	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar I disorder	ILOPERIDONE	targetBased	3	Completed	22/03/2021	https://clinicaltrials.gov/study/NCT04819776	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar I disorder	ILOPERIDONE	targetBased	3	Completed	22/03/2021	https://clinicaltrials.gov/study/NCT04819776	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar I disorder	ILOPERIDONE	targetBased	3	Completed	22/03/2021	https://clinicaltrials.gov/study/NCT04819776	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	ILOPERIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6f17cc91-86b3-42e3-9bf2-935dd360c3eb	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	ILOPERIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=43452bf8-76e7-47a9-a5d8-41fe84d061f0	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	ILOPERIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=43452bf8-76e7-47a9-a5d8-41fe84d061f0	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	ILOPERIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=43452bf8-76e7-47a9-a5d8-41fe84d061f0	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	ILOPERIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=43452bf8-76e7-47a9-a5d8-41fe84d061f0	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	ILOPERIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=43452bf8-76e7-47a9-a5d8-41fe84d061f0	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	ILOPERIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=43452bf8-76e7-47a9-a5d8-41fe84d061f0	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	unipolar depression	NOMIFENSINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N06AX04	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	PROMAZINE	targetBased	4	Completed	01/02/2005	https://clinicaltrials.gov/study/NCT00654576	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	psychosis	PROMAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AA03	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	psychosis	PROMAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AA03	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	psychosis	PROMAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AA03	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	psychosis	PROMAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AA03	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	schizophrenia	PROMAZINE	targetBased	4	Completed	01/02/2005	https://clinicaltrials.gov/study/NCT00654576	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	schizophrenia	PROMAZINE	targetBased	4	Completed	01/02/2005	https://clinicaltrials.gov/study/NCT00654576	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	schizophrenia	PROMAZINE	targetBased	4	Completed	01/02/2005	https://clinicaltrials.gov/study/NCT00654576	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	psychosis	PROMAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AA03	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	psychosis	PROMAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AA03	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	psychosis	PROMAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AA03	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	psychosis	PROMAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AA03	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	PROMAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AA03	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	PROMAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AA03	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	PROMAZINE	targetBased	4	Completed	01/02/2005	https://clinicaltrials.gov/study/NCT00654576	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	PROMAZINE	targetBased	4	Completed	01/02/2005	https://clinicaltrials.gov/study/NCT00654576	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	PROMAZINE	targetBased	4	Completed	01/02/2005	https://clinicaltrials.gov/study/NCT00654576	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	PROMAZINE	targetBased	4	Completed	01/02/2005	https://clinicaltrials.gov/study/NCT00654576	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	PROMAZINE	targetBased	4	Completed	01/02/2005	https://clinicaltrials.gov/study/NCT00654576	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	PROMAZINE	targetBased	4	Completed	01/02/2005	https://clinicaltrials.gov/study/NCT00654576	1	LoF	protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	opioid dependence	ACETAMINOPHEN	targetBased	4	Completed	01/08/2019	https://clinicaltrials.gov/study/NCT04015908	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	opioid dependence	ACETAMINOPHEN	targetBased	4	Terminated	17/05/2021	https://clinicaltrials.gov/study/NCT04766996	1		protect	Loss of surgery team member deemed the study procedures impossible to achieve, and no replacement could be found in a timely manner to complete trial as initially planned.
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	opioid dependence	ACETAMINOPHEN	targetBased	4	Terminated	01/11/2019	https://clinicaltrials.gov/study/NCT03732469	1		protect	Significant change in our clinic structure prevented continued recruitment of patients to the study
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	opioid dependence	ACETAMINOPHEN	targetBased	4	Completed	30/01/2018	https://clinicaltrials.gov/study/NCT03457116	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	mental or behavioural disorder	ACETAMINOPHEN	targetBased	4	Unknown status	20/11/2018	https://clinicaltrials.gov/study/NCT03830398	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	alcohol dependence	ACETAMINOPHEN	targetBased	4	Completed	01/11/2004	https://clinicaltrials.gov/study/NCT00427206	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	alcohol dependence	ACETAMINOPHEN	targetBased	4	Completed	01/01/2002	https://clinicaltrials.gov/study/NCT00402571	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	delirium	ACETAMINOPHEN	targetBased	4	Completed	01/10/2015	https://clinicaltrials.gov/study/NCT02546765	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	delirium	ACETAMINOPHEN	targetBased	3	Recruiting	06/06/2023	https://clinicaltrials.gov/study/NCT05246644	0.7		protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	depressive disorder	PERPHENAZINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	depressive disorder	PERPHENAZINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	depressive disorder	PERPHENAZINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	depressive disorder	PERPHENAZINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	depressive disorder	PERPHENAZINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	depressive disorder	PERPHENAZINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	anxiety	PERPHENAZINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	anxiety	PERPHENAZINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	anxiety	PERPHENAZINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	anxiety	PERPHENAZINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	anxiety	PERPHENAZINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	anxiety	PERPHENAZINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Agitation	PERPHENAZINE	targetBased	3	Completed	01/09/1995	https://clinicaltrials.gov/study/NCT00009204	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Agitation	PERPHENAZINE	targetBased	3	Completed	01/09/1995	https://clinicaltrials.gov/study/NCT00009204	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Agitation	PERPHENAZINE	targetBased	3	Completed	01/09/1995	https://clinicaltrials.gov/study/NCT00009204	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Agitation	PERPHENAZINE	targetBased	3	Completed	01/09/1995	https://clinicaltrials.gov/study/NCT00009204	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Agitation	PERPHENAZINE	targetBased	3	Completed	01/09/1995	https://clinicaltrials.gov/study/NCT00009204	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Agitation	PERPHENAZINE	targetBased	3	Completed	01/09/1995	https://clinicaltrials.gov/study/NCT00009204	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizoaffective disorder	PERPHENAZINE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizoaffective disorder	PERPHENAZINE	targetBased	4	Completed	01/02/2013	https://clinicaltrials.gov/study/NCT02199743	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizoaffective disorder	PERPHENAZINE	targetBased	4	Completed	01/02/2013	https://clinicaltrials.gov/study/NCT02199743	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizoaffective disorder	PERPHENAZINE	targetBased	4	Completed	01/02/2013	https://clinicaltrials.gov/study/NCT02199743	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizoaffective disorder	PERPHENAZINE	targetBased	4	Completed	01/02/2013	https://clinicaltrials.gov/study/NCT02199743	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizoaffective disorder	PERPHENAZINE	targetBased	4	Completed	01/02/2013	https://clinicaltrials.gov/study/NCT02199743	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizoaffective disorder	PERPHENAZINE	targetBased	4	Completed	01/02/2013	https://clinicaltrials.gov/study/NCT02199743	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	PERPHENAZINE	targetBased	4	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT00806234	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	PERPHENAZINE	targetBased	4	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT00806234	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	mental or behavioural disorder	PERPHENAZINE	targetBased	4	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT00806234	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	mental or behavioural disorder	PERPHENAZINE	targetBased	4	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT00806234	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	PERPHENAZINE	targetBased	4	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT00806234	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	PERPHENAZINE	targetBased	4	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT00806234	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	psychosis	PERPHENAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AB03	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	psychosis	PERPHENAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AB03	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	psychosis	PERPHENAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AB03	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	psychosis	PERPHENAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AB03	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	PERPHENAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AB03	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	PERPHENAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AB03	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Dementia	PERPHENAZINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Dementia	PERPHENAZINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Dementia	PERPHENAZINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Dementia	PERPHENAZINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Dementia	PERPHENAZINE	targetBased	3	Completed	01/09/1995	https://clinicaltrials.gov/study/NCT00009204	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Dementia	PERPHENAZINE	targetBased	3	Completed	01/09/1995	https://clinicaltrials.gov/study/NCT00009204	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Dementia	PERPHENAZINE	targetBased	3	Completed	01/09/1995	https://clinicaltrials.gov/study/NCT00009204	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Dementia	PERPHENAZINE	targetBased	3	Completed	01/09/1995	https://clinicaltrials.gov/study/NCT00009204	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Dementia	PERPHENAZINE	targetBased	3	Completed	01/09/1995	https://clinicaltrials.gov/study/NCT00009204	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Dementia	PERPHENAZINE	targetBased	3	Completed	01/09/1995	https://clinicaltrials.gov/study/NCT00009204	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	PERPHENAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=20e508cb-20ae-48dc-838a-abe61eb7c0ee	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	PERPHENAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0ebf4c11-1810-42f6-a8e3-071616e33d5d	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	PERPHENAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0ebf4c11-1810-42f6-a8e3-071616e33d5d	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	PERPHENAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0ebf4c11-1810-42f6-a8e3-071616e33d5d	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	PERPHENAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0ebf4c11-1810-42f6-a8e3-071616e33d5d	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	PERPHENAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0ebf4c11-1810-42f6-a8e3-071616e33d5d	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	PERPHENAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0ebf4c11-1810-42f6-a8e3-071616e33d5d	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	psychosis	TRIFLUPROMAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AA05	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	psychosis	TRIFLUPROMAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AA05	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	psychosis	TRIFLUPROMAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AA05	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	psychosis	TRIFLUPROMAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AA05	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	TRIFLUPROMAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AA05	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	TRIFLUPROMAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AA05	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	bipolar disorder	ROPINIROLE	targetBased	4	Unknown status	01/04/2003	https://clinicaltrials.gov/study/NCT00335205	1	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	bipolar disorder	ROPINIROLE	targetBased	4	Unknown status	01/04/2003	https://clinicaltrials.gov/study/NCT00335205	1	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	bipolar disorder	ROPINIROLE	targetBased	4	Unknown status	01/04/2003	https://clinicaltrials.gov/study/NCT00335205	1	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	bipolar disorder	ROPINIROLE	targetBased	4	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00314821	1	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	bipolar disorder	ROPINIROLE	targetBased	4	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00314821	1	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	bipolar disorder	ROPINIROLE	targetBased	4	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00314821	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar disorder	ROPINIROLE	targetBased	4	Unknown status	01/04/2003	https://clinicaltrials.gov/study/NCT00335205	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	bipolar disorder	ROPINIROLE	targetBased	4	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00314821	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	bipolar disorder	ROPINIROLE	targetBased	4	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00314821	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar disorder	ROPINIROLE	targetBased	4	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00314821	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar disorder	ROPINIROLE	targetBased	4	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00314821	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar disorder	ROPINIROLE	targetBased	4	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00314821	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar disorder	ROPINIROLE	targetBased	4	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00314821	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	major depressive disorder	ROPINIROLE	targetBased	4	Unknown status	01/04/2003	https://clinicaltrials.gov/study/NCT00335205	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	major depressive disorder	ROPINIROLE	targetBased	4	Unknown status	01/04/2003	https://clinicaltrials.gov/study/NCT00335205	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	major depressive disorder	ROPINIROLE	targetBased	4	Unknown status	01/04/2003	https://clinicaltrials.gov/study/NCT00335205	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	major depressive disorder	ROPINIROLE	targetBased	4	Unknown status	01/04/2003	https://clinicaltrials.gov/study/NCT00335205	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	major depressive disorder	ROPINIROLE	targetBased	4	Unknown status	01/04/2003	https://clinicaltrials.gov/study/NCT00335205	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	major depressive disorder	ROPINIROLE	targetBased	4	Unknown status	01/04/2003	https://clinicaltrials.gov/study/NCT00335205	1	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	major depressive disorder	ROPINIROLE	targetBased	4	Unknown status	01/04/2003	https://clinicaltrials.gov/study/NCT00335205	1	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	major depressive disorder	ROPINIROLE	targetBased	4	Unknown status	01/04/2003	https://clinicaltrials.gov/study/NCT00335205	1	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	major depressive disorder	ROPINIROLE	targetBased	4	Unknown status	01/04/2003	https://clinicaltrials.gov/study/NCT00335205	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	delirium	FENTANYL	targetBased	4	Withdrawn	01/08/2017	https://clinicaltrials.gov/study/NCT02119806	1	GoF	protect	Study was never initiated.
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	delirium	FENTANYL	targetBased	4	Unknown status	01/02/2014	https://clinicaltrials.gov/study/NCT02080169	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	delirium	FENTANYL	targetBased	4	Unknown status	01/02/2014	https://clinicaltrials.gov/study/NCT02080169	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	delirium	FENTANYL	targetBased	4	Unknown status	01/12/2015	https://clinicaltrials.gov/study/NCT02528513	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	delirium	FENTANYL	targetBased	4	Unknown status	01/12/2015	https://clinicaltrials.gov/study/NCT02528513	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	delirium	FENTANYL	targetBased	4	Unknown status	01/07/2014	https://clinicaltrials.gov/study/NCT02078583	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	delirium	FENTANYL	targetBased	4	Unknown status	01/07/2014	https://clinicaltrials.gov/study/NCT02078583	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	obstructive sleep apnea	FENTANYL	targetBased	3	Completed	01/03/2007	https://clinicaltrials.gov/study/NCT00468052	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	obstructive sleep apnea	FENTANYL	targetBased	3	Completed	01/03/2007	https://clinicaltrials.gov/study/NCT00468052	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	FENTANYL	targetBased	4	Terminated	01/11/2019	https://clinicaltrials.gov/study/NCT03732469	1	GoF	protect	Significant change in our clinic structure prevented continued recruitment of patients to the study
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	FENTANYL	targetBased	4	Completed	16/01/2019	https://clinicaltrials.gov/study/NCT03809949	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	FENTANYL	targetBased	4	Completed	16/01/2019	https://clinicaltrials.gov/study/NCT03809949	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	FENTANYL	targetBased	4	Recruiting	13/12/2022	https://clinicaltrials.gov/study/NCT05639712	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	FENTANYL	targetBased	4	Recruiting	13/12/2022	https://clinicaltrials.gov/study/NCT05639712	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	FENTANYL	targetBased	4	Recruiting	07/06/2023	https://clinicaltrials.gov/study/NCT05980546	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	FENTANYL	targetBased	4	Recruiting	07/06/2023	https://clinicaltrials.gov/study/NCT05980546	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	depressive disorder	FENTANYL	targetBased	4	Unknown status	01/12/2018	https://clinicaltrials.gov/study/NCT03666494	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	depressive disorder	FENTANYL	targetBased	4	Unknown status	01/12/2018	https://clinicaltrials.gov/study/NCT03666494	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid use disorder	FENTANYL	targetBased	4	Recruiting	29/01/2024	https://clinicaltrials.gov/study/NCT05905367	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid use disorder	FENTANYL	targetBased	4	Recruiting	29/01/2024	https://clinicaltrials.gov/study/NCT05905367	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	schizophrenia	ROSIGLITAZONE	targetBased	4	Completed	01/09/2003	https://clinicaltrials.gov/study/NCT00337350	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	schizophrenia	ROSIGLITAZONE	targetBased	4	Completed	01/09/2003	https://clinicaltrials.gov/study/NCT00337350	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	schizophrenia	ROSIGLITAZONE	targetBased	4	Completed	01/09/2003	https://clinicaltrials.gov/study/NCT00337350	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	schizophrenia	ROSIGLITAZONE	targetBased	4	Completed	01/09/2003	https://clinicaltrials.gov/study/NCT00337350	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	schizophrenia	ROSIGLITAZONE	targetBased	4	Completed	01/09/2003	https://clinicaltrials.gov/study/NCT00337350	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	schizophrenia	ROSIGLITAZONE	targetBased	4	Completed	01/09/2003	https://clinicaltrials.gov/study/NCT00337350	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	alcohol-related disorders	NALTREXONE	targetBased	4	Completed	01/04/2003	https://clinicaltrials.gov/study/NCT00145847	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	major depressive disorder	NALTREXONE	targetBased	4	Completed	01/07/2017	https://clinicaltrials.gov/study/NCT04322526	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	major depressive disorder	NALTREXONE	targetBased	4	Recruiting	19/10/2020	https://clinicaltrials.gov/study/NCT04276259	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	cocaine dependence	NALTREXONE	targetBased	3	Completed	01/01/1998	https://clinicaltrials.gov/study/NCT00167232	0.7	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	cocaine dependence	NALTREXONE	targetBased	3	Completed	01/04/1998	https://clinicaltrials.gov/study/NCT00218660	0.7	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Euphoria	NALTREXONE	targetBased	4	Completed	01/09/2012	https://clinicaltrials.gov/study/NCT01673594	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	methamphetamine dependence	NALTREXONE	targetBased	3	Not yet recruiting	01/05/2024	https://clinicaltrials.gov/study/NCT06233799	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	methamphetamine dependence	NALTREXONE	targetBased	3	Not yet recruiting	01/05/2024	https://clinicaltrials.gov/study/NCT06233799	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	methamphetamine dependence	NALTREXONE	targetBased	3	Completed	05/05/2017	https://clinicaltrials.gov/study/NCT03078075	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	methamphetamine dependence	NALTREXONE	targetBased	3	Completed	05/05/2017	https://clinicaltrials.gov/study/NCT03078075	0.7	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	opioid dependence	NALTREXONE	targetBased	4	Withdrawn	01/11/2009	https://clinicaltrials.gov/study/NCT01015066	1	LoF	protect	Study personnel left institution, anticipated funding did not occur
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	opioid dependence	NALTREXONE	targetBased	4	Completed	21/09/2017	https://clinicaltrials.gov/study/NCT02978417	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	opioid dependence	NALTREXONE	targetBased	4	Completed	01/10/2011	https://clinicaltrials.gov/study/NCT02324725	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	opioid dependence	NALTREXONE	targetBased	4	Completed	01/01/2011	https://clinicaltrials.gov/study/NCT01453374	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	opioid dependence	NALTREXONE	targetBased	3	Completed	01/05/2010	https://clinicaltrials.gov/study/NCT01180647	0.7	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	opioid dependence	NALTREXONE	targetBased	4	Completed	01/01/2013	https://clinicaltrials.gov/study/NCT01471145	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	opioid dependence	NALTREXONE	targetBased	3	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT01717963	0.7	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	opioid dependence	NALTREXONE	targetBased	3	Terminated	01/08/2004	https://clinicaltrials.gov/study/NCT00156936	0.7	LoF	protect	Business decision
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	sleep apnea	NALTREXONE	targetBased	4	Completed	08/08/2021	https://clinicaltrials.gov/study/NCT05037032	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Self-injurious behavior	NALTREXONE	targetBased	3	Unknown status	01/07/1997	https://clinicaltrials.gov/study/NCT00065936	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Self-injurious behavior	NALTREXONE	targetBased	3	Unknown status	01/07/1997	https://clinicaltrials.gov/study/NCT00065936	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Self-injurious behavior	NALTREXONE	targetBased	4	Withdrawn	22/02/2014	https://clinicaltrials.gov/study/NCT02726035	1	LoF	protect	PI deceased
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Self-injurious behavior	NALTREXONE	targetBased	4	Withdrawn	22/02/2014	https://clinicaltrials.gov/study/NCT02726035	1	LoF	protect	PI deceased
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	eating disorder	NALTREXONE	targetBased	4	Completed	01/10/1995	https://clinicaltrials.gov/study/NCT00000448	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	eating disorder	NALTREXONE	targetBased	4	Completed	01/10/1995	https://clinicaltrials.gov/study/NCT00000448	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	eating disorder	NALTREXONE	targetBased	4	Completed	01/10/1995	https://clinicaltrials.gov/study/NCT00000448	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	methamphetamine dependence	NALTREXONE	targetBased	3	Completed	05/05/2017	https://clinicaltrials.gov/study/NCT03078075	0.7	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	methamphetamine dependence	NALTREXONE	targetBased	3	Not yet recruiting	01/05/2024	https://clinicaltrials.gov/study/NCT06233799	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	heroin dependence	NALTREXONE	targetBased	3	Completed	01/09/2007	https://clinicaltrials.gov/study/NCT00577408	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	heroin dependence	NALTREXONE	targetBased	4	Completed	01/01/2013	https://clinicaltrials.gov/study/NCT01471145	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	heroin dependence	NALTREXONE	targetBased	4	Completed	01/01/2013	https://clinicaltrials.gov/study/NCT01471145	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	heroin dependence	NALTREXONE	targetBased	4	Completed	01/10/2011	https://clinicaltrials.gov/study/NCT02324725	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	heroin dependence	NALTREXONE	targetBased	4	Completed	01/10/2011	https://clinicaltrials.gov/study/NCT02324725	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	heroin dependence	NALTREXONE	targetBased	4	Completed	27/06/2014	https://clinicaltrials.gov/study/NCT01999946	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	heroin dependence	NALTREXONE	targetBased	4	Completed	27/06/2014	https://clinicaltrials.gov/study/NCT01999946	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	NALTREXONE	targetBased	3	Completed	01/05/2010	https://clinicaltrials.gov/study/NCT01100853	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	NALTREXONE	targetBased	3	Completed	01/05/2010	https://clinicaltrials.gov/study/NCT01100853	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	NALTREXONE	targetBased	4	Completed	01/03/2012	https://clinicaltrials.gov/study/NCT01563718	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	NALTREXONE	targetBased	4	Completed	01/03/2012	https://clinicaltrials.gov/study/NCT01563718	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	NALTREXONE	targetBased	4	Completed	01/06/2013	https://clinicaltrials.gov/study/NCT01843023	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	NALTREXONE	targetBased	4	Completed	01/06/2013	https://clinicaltrials.gov/study/NCT01843023	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	alcohol abuse	NALTREXONE	targetBased	3	Unknown status	01/02/2007	https://clinicaltrials.gov/study/NCT01115894	0.7	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	alcohol abuse	NALTREXONE	targetBased	4	Completed	01/04/2003	https://clinicaltrials.gov/study/NCT00145847	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	post-traumatic stress disorder	NALTREXONE	targetBased	4	Completed	01/12/2000	https://clinicaltrials.gov/study/NCT00006489	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	post-traumatic stress disorder	NALTREXONE	targetBased	4	Completed	01/12/2000	https://clinicaltrials.gov/study/NCT00006489	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	post-traumatic stress disorder	NALTREXONE	targetBased	3	Completed	01/10/2001	https://clinicaltrials.gov/study/NCT00338962	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	post-traumatic stress disorder	NALTREXONE	targetBased	3	Completed	01/10/2001	https://clinicaltrials.gov/study/NCT00338962	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	gambling behaviour	NALTREXONE	targetBased	4	Completed	01/01/2011	https://clinicaltrials.gov/study/NCT01528007	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	gambling behaviour	NALTREXONE	targetBased	4	Completed	01/01/2011	https://clinicaltrials.gov/study/NCT01528007	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	gambling behaviour	NALTREXONE	targetBased	3	Completed	01/12/2002	https://clinicaltrials.gov/study/NCT00053677	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	gambling behaviour	NALTREXONE	targetBased	3	Completed	01/12/2002	https://clinicaltrials.gov/study/NCT00053677	0.7	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	post-traumatic stress disorder	NALTREXONE	targetBased	4	Completed	01/12/2000	https://clinicaltrials.gov/study/NCT00006489	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	post-traumatic stress disorder	NALTREXONE	targetBased	3	Completed	01/10/2001	https://clinicaltrials.gov/study/NCT00338962	0.7	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	opioid use disorder	NALTREXONE	targetBased	4	Completed	29/01/2014	https://clinicaltrials.gov/study/NCT02032433	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	opioid use disorder	NALTREXONE	targetBased	3	Completed	01/08/2017	https://clinicaltrials.gov/study/NCT03232346	0.7	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	opioid use disorder	NALTREXONE	targetBased	3	Completed	01/06/2014	https://clinicaltrials.gov/study/NCT01908062	0.7	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	opioid use disorder	NALTREXONE	targetBased	3	Completed	01/04/2016	https://clinicaltrials.gov/study/NCT02696434	0.7	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	opioid use disorder	NALTREXONE	targetBased	4	Completed	01/08/2018	https://clinicaltrials.gov/study/NCT03647774	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	major depressive disorder	NALTREXONE	targetBased	4	Recruiting	19/10/2020	https://clinicaltrials.gov/study/NCT04276259	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	major depressive disorder	NALTREXONE	targetBased	4	Recruiting	19/10/2020	https://clinicaltrials.gov/study/NCT04276259	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	major depressive disorder	NALTREXONE	targetBased	4	Completed	01/07/2017	https://clinicaltrials.gov/study/NCT04322526	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	major depressive disorder	NALTREXONE	targetBased	4	Completed	01/07/2017	https://clinicaltrials.gov/study/NCT04322526	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	drug dependence	NALTREXONE	targetBased	4	Completed	01/03/2012	https://clinicaltrials.gov/study/NCT01563718	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	drug dependence	NALTREXONE	targetBased	4	Completed	01/06/2013	https://clinicaltrials.gov/study/NCT01843023	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	drug dependence	NALTREXONE	targetBased	3	Completed	01/05/2010	https://clinicaltrials.gov/study/NCT01100853	0.7	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Self-injurious behavior	NALTREXONE	targetBased	3	Unknown status	01/07/1997	https://clinicaltrials.gov/study/NCT00065936	0.7	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Self-injurious behavior	NALTREXONE	targetBased	4	Withdrawn	22/02/2014	https://clinicaltrials.gov/study/NCT02726035	1	LoF	protect	PI deceased
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	heroin dependence	NALTREXONE	targetBased	3	Completed	01/09/2007	https://clinicaltrials.gov/study/NCT00577408	0.7	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	heroin dependence	NALTREXONE	targetBased	4	Completed	27/06/2014	https://clinicaltrials.gov/study/NCT01999946	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	heroin dependence	NALTREXONE	targetBased	4	Completed	01/01/2013	https://clinicaltrials.gov/study/NCT01471145	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	heroin dependence	NALTREXONE	targetBased	4	Completed	01/10/2011	https://clinicaltrials.gov/study/NCT02324725	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	depressive disorder	NALTREXONE	targetBased	4	Completed	01/01/2018	https://clinicaltrials.gov/study/NCT03386448	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	depressive disorder	NALTREXONE	targetBased	4	Recruiting	19/10/2020	https://clinicaltrials.gov/study/NCT04276259	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	depressive disorder	NALTREXONE	targetBased	3	Completed	01/10/2001	https://clinicaltrials.gov/study/NCT00338962	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	nicotine dependence	NALTREXONE	targetBased	4	Completed	26/09/1997	https://clinicaltrials.gov/study/NCT00000437	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	nicotine dependence	NALTREXONE	targetBased	4	Completed	26/09/1997	https://clinicaltrials.gov/study/NCT00000437	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	nicotine dependence	NALTREXONE	targetBased	3	Completed	01/11/2000	https://clinicaltrials.gov/study/NCT00218153	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	nicotine dependence	NALTREXONE	targetBased	3	Completed	01/11/2000	https://clinicaltrials.gov/study/NCT00218153	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	nicotine dependence	NALTREXONE	targetBased	4	Completed	01/09/1998	https://clinicaltrials.gov/study/NCT00000447	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	nicotine dependence	NALTREXONE	targetBased	4	Completed	01/09/1998	https://clinicaltrials.gov/study/NCT00000447	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	gambling behaviour	NALTREXONE	targetBased	3	Completed	01/12/2002	https://clinicaltrials.gov/study/NCT00053677	0.7	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	gambling behaviour	NALTREXONE	targetBased	4	Completed	01/01/2011	https://clinicaltrials.gov/study/NCT01528007	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	attention deficit hyperactivity disorder	NALTREXONE	targetBased	4	Terminated	01/11/2012	https://clinicaltrials.gov/study/NCT01721330	1	LoF	protect	Competing studies
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	attention deficit hyperactivity disorder	NALTREXONE	targetBased	4	Completed	01/11/2013	https://clinicaltrials.gov/study/NCT01873729	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	attention deficit hyperactivity disorder	NALTREXONE	targetBased	4	Completed	01/10/2013	https://clinicaltrials.gov/study/NCT01993108	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	NALTREXONE	targetBased	4	Completed	01/01/2013	https://clinicaltrials.gov/study/NCT01471145	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	NALTREXONE	targetBased	4	Completed	01/10/2011	https://clinicaltrials.gov/study/NCT02324725	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	NALTREXONE	targetBased	4	Completed	01/10/2011	https://clinicaltrials.gov/study/NCT02324725	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	NALTREXONE	targetBased	4	Completed	01/01/2011	https://clinicaltrials.gov/study/NCT01453374	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	NALTREXONE	targetBased	4	Completed	01/01/2011	https://clinicaltrials.gov/study/NCT01453374	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	NALTREXONE	targetBased	4	Completed	21/09/2017	https://clinicaltrials.gov/study/NCT02978417	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	NALTREXONE	targetBased	4	Completed	21/09/2017	https://clinicaltrials.gov/study/NCT02978417	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	alcohol-related disorders	NALTREXONE	targetBased	4	Completed	01/04/2003	https://clinicaltrials.gov/study/NCT00145847	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	alcohol-related disorders	NALTREXONE	targetBased	4	Completed	01/04/2003	https://clinicaltrials.gov/study/NCT00145847	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	alcohol abuse	NALTREXONE	targetBased	4	Completed	01/04/2003	https://clinicaltrials.gov/study/NCT00145847	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	alcohol abuse	NALTREXONE	targetBased	4	Completed	01/04/2003	https://clinicaltrials.gov/study/NCT00145847	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	alcohol abuse	NALTREXONE	targetBased	3	Unknown status	01/02/2007	https://clinicaltrials.gov/study/NCT01115894	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	alcohol abuse	NALTREXONE	targetBased	3	Unknown status	01/02/2007	https://clinicaltrials.gov/study/NCT01115894	0.7	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Borderline personality disorder	NALTREXONE	targetBased	3	Terminated	01/10/2005	https://clinicaltrials.gov/study/NCT00124839	0.7	LoF	protect	Difficulties in recruiting enough subjects
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	depressive disorder	NALTREXONE	targetBased	3	Completed	01/10/2001	https://clinicaltrials.gov/study/NCT00338962	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	depressive disorder	NALTREXONE	targetBased	3	Completed	01/10/2001	https://clinicaltrials.gov/study/NCT00338962	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	depressive disorder	NALTREXONE	targetBased	4	Recruiting	19/10/2020	https://clinicaltrials.gov/study/NCT04276259	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	depressive disorder	NALTREXONE	targetBased	4	Recruiting	19/10/2020	https://clinicaltrials.gov/study/NCT04276259	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	depressive disorder	NALTREXONE	targetBased	4	Completed	01/01/2018	https://clinicaltrials.gov/study/NCT03386448	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	depressive disorder	NALTREXONE	targetBased	4	Completed	01/01/2018	https://clinicaltrials.gov/study/NCT03386448	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	alcohol dependence	NALTREXONE	targetBased	4	Unknown status	01/03/2003	https://clinicaltrials.gov/study/NCT00120601	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	alcohol dependence	NALTREXONE	targetBased	4	Completed		https://clinicaltrials.gov/study/NCT00000445	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	alcohol dependence	NALTREXONE	targetBased	4	Completed		https://clinicaltrials.gov/study/NCT00000445	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	alcohol dependence	NALTREXONE	targetBased	4	Terminated	01/08/2012	https://clinicaltrials.gov/study/NCT01638377	1	LoF	protect	Recruitment proved to be extremely difficult.
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	alcohol dependence	NALTREXONE	targetBased	4	Terminated	01/08/2012	https://clinicaltrials.gov/study/NCT01638377	1	LoF	protect	Recruitment proved to be extremely difficult.
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	alcohol dependence	NALTREXONE	targetBased	4	Completed	01/07/2006	https://clinicaltrials.gov/study/NCT00453804	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	alcohol dependence	NALTREXONE	targetBased	4	Completed	01/07/2006	https://clinicaltrials.gov/study/NCT00453804	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Borderline personality disorder	NALTREXONE	targetBased	3	Terminated	01/10/2005	https://clinicaltrials.gov/study/NCT00124839	0.7	LoF	protect	Difficulties in recruiting enough subjects
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Borderline personality disorder	NALTREXONE	targetBased	3	Terminated	01/10/2005	https://clinicaltrials.gov/study/NCT00124839	0.7	LoF	protect	Difficulties in recruiting enough subjects
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	alcohol dependence	NALTREXONE	targetBased	4	Completed	01/06/2009	https://clinicaltrials.gov/study/NCT00920829	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	alcohol dependence	NALTREXONE	targetBased	4	Completed		https://clinicaltrials.gov/study/NCT00000449	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	alcohol dependence	NALTREXONE	targetBased	4	Withdrawn	01/03/2022	https://clinicaltrials.gov/study/NCT05087771	1	LoF	protect	no longer randomized, drug being offered to all patients
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	alcohol dependence	NALTREXONE	targetBased	4	Completed	01/12/2000	https://clinicaltrials.gov/study/NCT00006489	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	alcohol dependence	NALTREXONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cd11c435-b0f0-4bb9-ae78-60f101f3703f	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	alcohol dependence	NALTREXONE	targetBased	4	Completed		https://clinicaltrials.gov/study/NCT00000455	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	alcohol dependence	NALTREXONE	targetBased	4	Completed	01/09/2000	https://clinicaltrials.gov/study/NCT00006449	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid use disorder	NALTREXONE	targetBased	4	Completed	29/01/2014	https://clinicaltrials.gov/study/NCT02032433	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid use disorder	NALTREXONE	targetBased	4	Completed	29/01/2014	https://clinicaltrials.gov/study/NCT02032433	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid use disorder	NALTREXONE	targetBased	3	Completed	01/08/2017	https://clinicaltrials.gov/study/NCT03232346	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid use disorder	NALTREXONE	targetBased	3	Completed	01/08/2017	https://clinicaltrials.gov/study/NCT03232346	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid use disorder	NALTREXONE	targetBased	3	Completed	01/04/2016	https://clinicaltrials.gov/study/NCT02696434	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid use disorder	NALTREXONE	targetBased	3	Completed	01/04/2016	https://clinicaltrials.gov/study/NCT02696434	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid use disorder	NALTREXONE	targetBased	4	Completed	01/08/2018	https://clinicaltrials.gov/study/NCT03647774	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid use disorder	NALTREXONE	targetBased	4	Completed	01/08/2018	https://clinicaltrials.gov/study/NCT03647774	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	attention deficit hyperactivity disorder	NALTREXONE	targetBased	4	Completed	01/11/2013	https://clinicaltrials.gov/study/NCT01873729	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	attention deficit hyperactivity disorder	NALTREXONE	targetBased	4	Completed	01/11/2013	https://clinicaltrials.gov/study/NCT01873729	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	attention deficit hyperactivity disorder	NALTREXONE	targetBased	4	Terminated	01/11/2012	https://clinicaltrials.gov/study/NCT01721330	1	LoF	protect	Competing studies
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	attention deficit hyperactivity disorder	NALTREXONE	targetBased	4	Terminated	01/11/2012	https://clinicaltrials.gov/study/NCT01721330	1	LoF	protect	Competing studies
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	attention deficit hyperactivity disorder	NALTREXONE	targetBased	4	Completed	01/10/2013	https://clinicaltrials.gov/study/NCT01993108	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	attention deficit hyperactivity disorder	NALTREXONE	targetBased	4	Completed	01/10/2013	https://clinicaltrials.gov/study/NCT01993108	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cocaine dependence	NALTREXONE	targetBased	3	Completed	01/01/1998	https://clinicaltrials.gov/study/NCT00167232	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cocaine dependence	NALTREXONE	targetBased	3	Completed	01/01/1998	https://clinicaltrials.gov/study/NCT00167232	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cocaine dependence	NALTREXONE	targetBased	3	Completed	01/04/1998	https://clinicaltrials.gov/study/NCT00218660	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cocaine dependence	NALTREXONE	targetBased	3	Completed	01/04/1998	https://clinicaltrials.gov/study/NCT00218660	0.7	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	nicotine dependence	NALTREXONE	targetBased	3	Completed	01/11/2000	https://clinicaltrials.gov/study/NCT00218153	0.7	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	nicotine dependence	NALTREXONE	targetBased	4	Completed	01/09/1998	https://clinicaltrials.gov/study/NCT00000447	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	nicotine dependence	NALTREXONE	targetBased	4	Completed	26/09/1997	https://clinicaltrials.gov/study/NCT00000437	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	sleep apnea	NALTREXONE	targetBased	4	Completed	08/08/2021	https://clinicaltrials.gov/study/NCT05037032	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	sleep apnea	NALTREXONE	targetBased	4	Completed	08/08/2021	https://clinicaltrials.gov/study/NCT05037032	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Euphoria	NALTREXONE	targetBased	4	Completed	01/09/2012	https://clinicaltrials.gov/study/NCT01673594	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Euphoria	NALTREXONE	targetBased	4	Completed	01/09/2012	https://clinicaltrials.gov/study/NCT01673594	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	MEPERIDINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fae5cc34-5917-4445-9516-25f97ffca8db	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	MEPERIDINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fae5cc34-5917-4445-9516-25f97ffca8db	1	GoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	depressive disorder	DEXTROAMPHETAMINE	targetBased	4	Terminated	01/09/2001	https://clinicaltrials.gov/study/NCT00296686	1		protect	Study is no longer funded.
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	narcolepsy-cataplexy syndrome	DEXTROAMPHETAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d6394df5-f2c9-47eb-b57e-f3e9cfd94f84	1		protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	narcolepsy-cataplexy syndrome	DEXTROAMPHETAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ffd56d70-d884-43be-a994-6e70a10e823e	1		protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	drug dependence	DEXTROAMPHETAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=35744538-1704-4ee0-954d-52710cf3456d	1		protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	DEXTROAMPHETAMINE	targetBased	4	Completed	05/08/2003	https://clinicaltrials.gov/study/NCT00506727	1		protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	DEXTROAMPHETAMINE	targetBased	4	Completed	01/08/2007	https://clinicaltrials.gov/study/NCT00468143	1		protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	DEXTROAMPHETAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=141a7970-3f06-44ea-9ab7-aeece2c085fc	1		protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	DEXTROAMPHETAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ffd56d70-d884-43be-a994-6e70a10e823e	1		protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	DEXTROAMPHETAMINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N06BA02	1		protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	DEXTROAMPHETAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d6394df5-f2c9-47eb-b57e-f3e9cfd94f84	1		protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	DEXTROAMPHETAMINE	targetBased	4	Completed	01/01/2006	https://clinicaltrials.gov/study/NCT01220440	1		protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Sleep Disorder	TRAZODONE	targetBased	3	Completed	01/04/2008	https://clinicaltrials.gov/study/NCT01468038	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	delirium	TRAZODONE	targetBased	4	Not yet recruiting	01/03/2025	https://clinicaltrials.gov/study/NCT05085808	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	major depressive disorder	TRAZODONE	targetBased	3	Completed	01/12/2012	https://clinicaltrials.gov/study/NCT02086929	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	major depressive disorder	TRAZODONE	targetBased	4	Unknown status	01/06/2012	https://clinicaltrials.gov/study/NCT01764867	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	major depressive disorder	TRAZODONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=17b3356e-458d-47f6-89a5-80828ab48d4c	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	major depressive disorder	TRAZODONE	targetBased	3	Completed	01/06/2007	https://clinicaltrials.gov/study/NCT00775203	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	major depressive disorder	TRAZODONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10a30879-f6e2-4030-95b8-0979c18c418a	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	major depressive disorder	TRAZODONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=66da652a-72b4-c17f-e053-2a91aa0a8d69	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	unipolar depression	TRAZODONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=49196e9e-aeef-4663-8be9-6b523ae7fb7a	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	unipolar depression	TRAZODONE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N06AX05	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	TRAZODONE	targetBased	4	Completed	01/11/2000	https://clinicaltrials.gov/study/NCT00659919	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	TRAZODONE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Dementia	TRAZODONE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	insomnia	TRAZODONE	targetBased	4	Active, not recruiting	25/02/2022	https://clinicaltrials.gov/study/NCT04468776	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	insomnia	TRAZODONE	targetBased	4	Active, not recruiting	01/06/2011	https://clinicaltrials.gov/study/NCT01651442	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	insomnia	TRAZODONE	targetBased	3	Recruiting	25/02/2021	https://clinicaltrials.gov/study/NCT03668041	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	depressive disorder	TRAZODONE	targetBased	4	Terminated	01/07/2009	https://clinicaltrials.gov/study/NCT01305707	1	LoF	protect	Difficulties in recruiting
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	depressive disorder	TRAZODONE	targetBased	3	Withdrawn	01/12/2019	https://clinicaltrials.gov/study/NCT03852160	0.7	LoF	protect	New design was developed to better fit company strategy, a new study has replaced 5413541TRD3011 study
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	depressive disorder	TRAZODONE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	anxiety	TRAZODONE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	major depressive disorder	NEFAZODONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0bd4c34a-4f43-4c84-8b98-1d074cba97d5	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	unipolar depression	NEFAZODONE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N06AX06	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	unipolar depression	NEFAZODONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0bd4c34a-4f43-4c84-8b98-1d074cba97d5	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	cocaine dependence	NEFAZODONE	targetBased	3	Completed	01/01/1999	https://clinicaltrials.gov/study/NCT00000293	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	anxiety	NEFAZODONE	targetBased	4	Completed		https://clinicaltrials.gov/study/NCT00231348	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	schizophrenia	XANOMELINE	targetBased	3	Completed	16/12/2020	https://clinicaltrials.gov/study/NCT04659161	0.7	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	schizophrenia	XANOMELINE	targetBased	3	Completed	01/02/2021	https://clinicaltrials.gov/study/NCT04659174	0.7	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	schizophrenia	XANOMELINE	targetBased	3	Completed	01/02/2021	https://clinicaltrials.gov/study/NCT04659174	0.7	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	schizophrenia	XANOMELINE	targetBased	3	Completed	01/02/2021	https://clinicaltrials.gov/study/NCT04659174	0.7	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	schizophrenia	XANOMELINE	targetBased	3	Terminated	08/11/2022	https://clinicaltrials.gov/study/NCT05643170	0.7	GoF	protect	Company's business decision.
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	schizophrenia	XANOMELINE	targetBased	3	Terminated	08/11/2022	https://clinicaltrials.gov/study/NCT05643170	0.7	GoF	protect	Company's business decision.
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	schizophrenia	XANOMELINE	targetBased	3	Terminated	08/11/2022	https://clinicaltrials.gov/study/NCT05643170	0.7	GoF	protect	Company's business decision.
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	schizophrenia	XANOMELINE	targetBased	3	Active, not recruiting	02/06/2021	https://clinicaltrials.gov/study/NCT04820309	0.7	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	schizophrenia	XANOMELINE	targetBased	3	Active, not recruiting	02/06/2021	https://clinicaltrials.gov/study/NCT04820309	0.7	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	schizophrenia	XANOMELINE	targetBased	3	Active, not recruiting	02/06/2021	https://clinicaltrials.gov/study/NCT04820309	0.7	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	schizophrenia	XANOMELINE	targetBased	3	Completed	16/12/2020	https://clinicaltrials.gov/study/NCT04659161	0.7	GoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	schizophrenia	XANOMELINE	targetBased	3	Completed	16/12/2020	https://clinicaltrials.gov/study/NCT04659161	0.7	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	schizophrenia	XANOMELINE	targetBased	3	Completed	16/12/2020	https://clinicaltrials.gov/study/NCT04659161	0.7	GoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	schizophrenia	XANOMELINE	targetBased	3	Completed	16/12/2020	https://clinicaltrials.gov/study/NCT04659161	0.7	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	schizophrenia	XANOMELINE	targetBased	3	Completed	16/12/2020	https://clinicaltrials.gov/study/NCT04659161	0.7	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	schizophrenia	XANOMELINE	targetBased	3	Completed	06/04/2021	https://clinicaltrials.gov/study/NCT04738123	0.7	GoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	schizophrenia	XANOMELINE	targetBased	3	Completed	06/04/2021	https://clinicaltrials.gov/study/NCT04738123	0.7	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	schizophrenia	XANOMELINE	targetBased	3	Completed	06/04/2021	https://clinicaltrials.gov/study/NCT04738123	0.7	GoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	schizophrenia	XANOMELINE	targetBased	3	Completed	06/04/2021	https://clinicaltrials.gov/study/NCT04738123	0.7	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	schizophrenia	XANOMELINE	targetBased	3	Completed	06/04/2021	https://clinicaltrials.gov/study/NCT04738123	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Agitation	ALFENTANIL	targetBased	4	Completed	01/02/2012	https://clinicaltrials.gov/study/NCT02022488	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Agitation	ALFENTANIL	targetBased	4	Completed	01/02/2012	https://clinicaltrials.gov/study/NCT02022488	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	unipolar depression	TRIMIPRAMINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N06AA06	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	TRIMIPRAMINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Dementia	TRIMIPRAMINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	depressive disorder	TRIMIPRAMINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	depressive disorder	TRIMIPRAMINE	targetBased	4	Unknown status	01/09/2011	https://clinicaltrials.gov/study/NCT02237937	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	depressive disorder	TRIMIPRAMINE	targetBased	4	Unknown status	01/09/2011	https://clinicaltrials.gov/study/NCT02237937	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	depressive disorder	TRIMIPRAMINE	targetBased	4	Unknown status	01/09/2011	https://clinicaltrials.gov/study/NCT02237937	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	depressive disorder	TRIMIPRAMINE	targetBased	4	Unknown status	01/09/2011	https://clinicaltrials.gov/study/NCT02237937	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	depressive disorder	TRIMIPRAMINE	targetBased	4	Unknown status	01/09/2011	https://clinicaltrials.gov/study/NCT02237937	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	depressive disorder	TRIMIPRAMINE	targetBased	4	Unknown status	01/09/2011	https://clinicaltrials.gov/study/NCT02237937	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	unipolar depression	TRIMIPRAMINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N06AA06	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	unipolar depression	TRIMIPRAMINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N06AA06	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	unipolar depression	TRIMIPRAMINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N06AA06	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	unipolar depression	TRIMIPRAMINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N06AA06	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	unipolar depression	TRIMIPRAMINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N06AA06	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	unipolar depression	TRIMIPRAMINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N06AA06	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	anxiety	TRIMIPRAMINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	anxiety	TRIMIPRAMINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	anxiety	TRIMIPRAMINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	anxiety	TRIMIPRAMINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	anxiety	TRIMIPRAMINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	anxiety	TRIMIPRAMINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	depressive disorder	TRIMIPRAMINE	targetBased	4	Unknown status	01/09/2011	https://clinicaltrials.gov/study/NCT02237937	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	depressive disorder	TRIMIPRAMINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	anxiety	TRIMIPRAMINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Dementia	TRIMIPRAMINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Dementia	TRIMIPRAMINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Dementia	TRIMIPRAMINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Dementia	TRIMIPRAMINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Dementia	TRIMIPRAMINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Dementia	TRIMIPRAMINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	TRIMIPRAMINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	TRIMIPRAMINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	TRIMIPRAMINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	TRIMIPRAMINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	TRIMIPRAMINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	TRIMIPRAMINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	heroin dependence	METHADONE	targetBased	3	Completed	01/09/2003	https://clinicaltrials.gov/study/NCT00378079	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	heroin dependence	METHADONE	targetBased	3	Completed	01/09/2003	https://clinicaltrials.gov/study/NCT00378079	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	heroin dependence	METHADONE	targetBased	4	Completed	01/08/2005	https://clinicaltrials.gov/study/NCT00310934	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	heroin dependence	METHADONE	targetBased	4	Completed	01/08/2005	https://clinicaltrials.gov/study/NCT00310934	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	METHADONE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N07BC02	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	METHADONE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N07BC02	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	METHADONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4a44bde6-c348-4316-b0e0-c24b407cb823	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	METHADONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4a44bde6-c348-4316-b0e0-c24b407cb823	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	METHADONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4c796a39-d87f-4358-9d4b-26e27464b642	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	METHADONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4c796a39-d87f-4358-9d4b-26e27464b642	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	METHADONE	targetBased	4	Completed	01/04/2009	https://clinicaltrials.gov/study/NCT00879996	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	METHADONE	targetBased	4	Unknown status	01/06/2009	https://clinicaltrials.gov/study/NCT01047956	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	METHADONE	targetBased	4	Unknown status	01/06/2009	https://clinicaltrials.gov/study/NCT01047956	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	METHADONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=06cc3fba-68f9-4188-a239-fbd37a9f563a	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	METHADONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=06cc3fba-68f9-4188-a239-fbd37a9f563a	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	METHADONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4c796a39-d87f-4358-9d4b-26e27464b642	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	METHADONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4c796a39-d87f-4358-9d4b-26e27464b642	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	neonatal abstinence syndrome	METHADONE	targetBased	4	Completed	01/10/2016	https://clinicaltrials.gov/study/NCT02851303	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	neonatal abstinence syndrome	METHADONE	targetBased	4	Completed	01/10/2016	https://clinicaltrials.gov/study/NCT02851303	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	neonatal abstinence syndrome	METHADONE	targetBased	4	Completed	01/01/2007	https://clinicaltrials.gov/study/NCT01723722	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	neonatal abstinence syndrome	METHADONE	targetBased	4	Completed	01/01/2007	https://clinicaltrials.gov/study/NCT01723722	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	neonatal abstinence syndrome	METHADONE	targetBased	4	Completed	01/01/2011	https://clinicaltrials.gov/study/NCT01804075	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	neonatal abstinence syndrome	METHADONE	targetBased	4	Completed	01/01/2011	https://clinicaltrials.gov/study/NCT01804075	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid use disorder	METHADONE	targetBased	4	Completed	02/10/2017	https://clinicaltrials.gov/study/NCT03033732	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid use disorder	METHADONE	targetBased	4	Completed	02/10/2017	https://clinicaltrials.gov/study/NCT03033732	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid use disorder	METHADONE	targetBased	4	Recruiting	04/06/2024	https://clinicaltrials.gov/study/NCT06323824	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid use disorder	METHADONE	targetBased	4	Recruiting	04/06/2024	https://clinicaltrials.gov/study/NCT06323824	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid use disorder	METHADONE	targetBased	4	Recruiting	29/01/2024	https://clinicaltrials.gov/study/NCT05905367	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid use disorder	METHADONE	targetBased	4	Recruiting	29/01/2024	https://clinicaltrials.gov/study/NCT05905367	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cocaine dependence	METHADONE	targetBased	3	Completed	01/02/1995	https://clinicaltrials.gov/study/NCT00000311	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cocaine dependence	METHADONE	targetBased	3	Completed	01/02/1995	https://clinicaltrials.gov/study/NCT00000311	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	major depressive disorder	MIRTAZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=40c95daa-bbd5-48d9-97e4-c87f2c1f0fa5	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	major depressive disorder	MIRTAZAPINE	targetBased	4	Completed	01/06/2011	https://clinicaltrials.gov/study/NCT02191124	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	major depressive disorder	MIRTAZAPINE	targetBased	4	Completed	01/06/2012	https://clinicaltrials.gov/study/NCT01601002	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	major depressive disorder	MIRTAZAPINE	targetBased	4	Unknown status	01/05/2015	https://clinicaltrials.gov/study/NCT02711215	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	major depressive disorder	MIRTAZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8feda54f-a3fa-4108-bfc4-c15b0eab4396	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	major depressive disorder	MIRTAZAPINE	targetBased	4	Unknown status	01/06/2012	https://clinicaltrials.gov/study/NCT01764867	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	major depressive disorder	MIRTAZAPINE	targetBased	4	Terminated	01/05/2009	https://clinicaltrials.gov/study/NCT00926835	1	LoF	protect	due to patient recruitment difficulties
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	post-traumatic stress disorder	MIRTAZAPINE	targetBased	4	Completed	01/10/2006	https://clinicaltrials.gov/study/NCT00449189	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	post-traumatic stress disorder	MIRTAZAPINE	targetBased	4	Completed	01/07/2010	https://clinicaltrials.gov/study/NCT01178671	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	unipolar depression	MIRTAZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5990a1f2-a5c9-4f40-ab5f-a32c1bd218b9	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	unipolar depression	MIRTAZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b8df747e-dfce-4411-b892-086532ffabfb	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	unipolar depression	MIRTAZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a4c012f0-50b6-42fb-9f06-a14632f23f2e	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	unipolar depression	MIRTAZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=34c0b734-98ca-4aec-965f-e55edd3317f3	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	unipolar depression	MIRTAZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=18fbbcbb-73bd-4d22-8f4e-9a2777f0daf8	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	unipolar depression	MIRTAZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de019322-8145-4aba-95e1-d238df4df475	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	unipolar depression	MIRTAZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=711aa80b-8fc6-49e6-9494-3db31d9b53a4	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	MIRTAZAPINE	targetBased	4	Completed	01/11/2010	https://clinicaltrials.gov/study/NCT01263080	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	MIRTAZAPINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	major depressive episode	MIRTAZAPINE	targetBased	4	Completed	01/12/2010	https://clinicaltrials.gov/study/NCT01109693	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Dementia	MIRTAZAPINE	targetBased	3	Completed	01/01/2017	https://clinicaltrials.gov/study/NCT03031184	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Dementia	MIRTAZAPINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	MIRTAZAPINE	targetBased	4	Completed	01/07/2001	https://clinicaltrials.gov/study/NCT00177567	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	autism spectrum disorder	MIRTAZAPINE	targetBased	3	Completed	01/08/2010	https://clinicaltrials.gov/study/NCT01302964	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	heroin dependence	MIRTAZAPINE	targetBased	3	Unknown status	01/05/2013	https://clinicaltrials.gov/study/NCT02541526	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	insomnia	MIRTAZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8feda54f-a3fa-4108-bfc4-c15b0eab4396	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	depressive disorder	MIRTAZAPINE	targetBased	4	Completed	01/07/2001	https://clinicaltrials.gov/study/NCT00021528	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	depressive disorder	MIRTAZAPINE	targetBased	4	Not yet recruiting	01/06/2017	https://clinicaltrials.gov/study/NCT03148522	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	depressive disorder	MIRTAZAPINE	targetBased	4	Completed	14/11/2012	https://clinicaltrials.gov/study/NCT01458626	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	depressive disorder	MIRTAZAPINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	depressive disorder	MIRTAZAPINE	targetBased	4	Terminated	01/07/2009	https://clinicaltrials.gov/study/NCT01305707	1	LoF	protect	Difficulties in recruiting
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	depressive disorder	MIRTAZAPINE	targetBased	4	Unknown status	01/08/2017	https://clinicaltrials.gov/study/NCT03219008	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	depressive disorder	MIRTAZAPINE	targetBased	4	Terminated	01/08/2011	https://clinicaltrials.gov/study/NCT01465919	1	LoF	protect	Due to the recent change in standard of care for hepatitis C.
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	anxiety	MIRTAZAPINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Agitation	MIRTAZAPINE	targetBased	4	Completed	15/06/2021	https://clinicaltrials.gov/study/NCT04908605	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	psychosis	REMOXIPRIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AL04	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	psychosis	REMOXIPRIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AL04	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	psychosis	REMOXIPRIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AL04	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	psychosis	REMOXIPRIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AL04	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	REMOXIPRIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AL04	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	REMOXIPRIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AL04	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain agnosia	OXYCODONE	targetBased	4	Not yet recruiting	01/06/2024	https://clinicaltrials.gov/study/NCT06444997	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain agnosia	OXYCODONE	targetBased	4	Not yet recruiting	01/06/2024	https://clinicaltrials.gov/study/NCT06444997	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	OXYCODONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8a9529a3-8922-6b50-e053-2995a90a4b08	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	OXYCODONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3848642e-cc9e-4150-8199-281b294c18bc	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	OXYCODONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3848642e-cc9e-4150-8199-281b294c18bc	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	OXYCODONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=504aa63a-4772-2e03-e054-00144ff88e88	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	OXYCODONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=504aa63a-4772-2e03-e054-00144ff88e88	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	OXYCODONE	targetBased	4	Completed	01/02/2014	https://clinicaltrials.gov/study/NCT02101840	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	OXYCODONE	targetBased	4	Completed	01/02/2014	https://clinicaltrials.gov/study/NCT02101840	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	OXYCODONE	targetBased	4	Completed	01/08/2019	https://clinicaltrials.gov/study/NCT04015908	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	OXYCODONE	targetBased	4	Terminated	14/09/2016	https://clinicaltrials.gov/study/NCT02741076	1	GoF	protect	Inability to recruit sufficient no. of subjects over an acceptable time period
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	OXYCODONE	targetBased	4	Terminated	14/09/2016	https://clinicaltrials.gov/study/NCT02741076	1	GoF	protect	Inability to recruit sufficient no. of subjects over an acceptable time period
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	OXYCODONE	targetBased	4	Completed	01/07/2011	https://clinicaltrials.gov/study/NCT01374763	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	OXYCODONE	targetBased	4	Completed	01/07/2011	https://clinicaltrials.gov/study/NCT01374763	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	OXYCODONE	targetBased	4	Completed	20/05/2020	https://clinicaltrials.gov/study/NCT04396587	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	OXYCODONE	targetBased	4	Completed	20/05/2020	https://clinicaltrials.gov/study/NCT04396587	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	sleep apnea	OXYCODONE	targetBased	4	Completed	01/03/2018	https://clinicaltrials.gov/study/NCT03454217	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	sleep apnea	OXYCODONE	targetBased	4	Completed	01/03/2018	https://clinicaltrials.gov/study/NCT03454217	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	postpartum depression	ESTRADIOL	targetBased	4	Terminated	01/08/2008	https://clinicaltrials.gov/study/NCT00744328	1	GoF	protect	Recruitment Issues
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	postpartum depression	ESTRADIOL	targetBased	4	Terminated	01/08/2008	https://clinicaltrials.gov/study/NCT00744328	1	GoF	protect	Recruitment Issues
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	dysphoria	ESTRADIOL	targetBased	4	Unknown status	06/02/2017	https://clinicaltrials.gov/study/NCT02715232	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	dysphoria	ESTRADIOL	targetBased	4	Unknown status	06/02/2017	https://clinicaltrials.gov/study/NCT02715232	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	dysphoria	ESTRADIOL	targetBased	4	Terminated	29/12/2022	https://clinicaltrials.gov/study/NCT05428215	1	GoF	protect	Inability to adequately recruit participants, need for additional study participants based on preliminary data collection
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	dysphoria	ESTRADIOL	targetBased	4	Terminated	29/12/2022	https://clinicaltrials.gov/study/NCT05428215	1	GoF	protect	Inability to adequately recruit participants, need for additional study participants based on preliminary data collection
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	post-traumatic stress disorder	ESTRADIOL	targetBased	3	Recruiting	24/06/2020	https://clinicaltrials.gov/study/NCT04192266	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	post-traumatic stress disorder	ESTRADIOL	targetBased	3	Recruiting	24/06/2020	https://clinicaltrials.gov/study/NCT04192266	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	post-traumatic stress disorder	ESTRADIOL	targetBased	4	Recruiting	29/11/2017	https://clinicaltrials.gov/study/NCT03371654	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	post-traumatic stress disorder	ESTRADIOL	targetBased	4	Recruiting	29/11/2017	https://clinicaltrials.gov/study/NCT03371654	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	depressive disorder	ESTRADIOL	targetBased	4	Completed	01/10/2015	https://clinicaltrials.gov/study/NCT02255175	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	depressive disorder	ESTRADIOL	targetBased	4	Completed	01/10/2015	https://clinicaltrials.gov/study/NCT02255175	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	depressive disorder	ESTRADIOL	targetBased	4	Completed	01/02/2002	https://clinicaltrials.gov/study/NCT00030147	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	depressive disorder	ESTRADIOL	targetBased	4	Completed	01/02/2002	https://clinicaltrials.gov/study/NCT00030147	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Agitation	SUFENTANIL	targetBased	4	Not yet recruiting	15/11/2022	https://clinicaltrials.gov/study/NCT05624424	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Agitation	SUFENTANIL	targetBased	4	Not yet recruiting	15/11/2022	https://clinicaltrials.gov/study/NCT05624424	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	SUFENTANIL	targetBased	4	Completed	20/05/2020	https://clinicaltrials.gov/study/NCT04396587	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	SUFENTANIL	targetBased	4	Completed	20/05/2020	https://clinicaltrials.gov/study/NCT04396587	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	postpartum depression	SUFENTANIL	targetBased	4	Recruiting	01/05/2023	https://clinicaltrials.gov/study/NCT05826327	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	postpartum depression	SUFENTANIL	targetBased	4	Recruiting	01/05/2023	https://clinicaltrials.gov/study/NCT05826327	1	GoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		drug dependence	AMANTADINE	targetBased	4	Completed	01/03/1997	https://clinicaltrials.gov/study/NCT00015236	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Dementia	AMANTADINE	targetBased	4	Withdrawn	01/09/2005	https://clinicaltrials.gov/study/NCT00127114	1	LoF	protect	No funding and exclusion criteria were to stringent.
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		schizophrenia	AMANTADINE	targetBased	3	Unknown status	01/05/2010	https://clinicaltrials.gov/study/NCT00999505	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		schizophrenia	AMANTADINE	targetBased	3	Completed	01/11/2006	https://clinicaltrials.gov/study/NCT00401973	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		treatment resistant depression	AMANTADINE	targetBased	4	Recruiting	07/08/2021	https://clinicaltrials.gov/study/NCT04936126	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		schizoaffective disorder	AMANTADINE	targetBased	3	Completed	01/11/2006	https://clinicaltrials.gov/study/NCT00401973	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		cocaine dependence	AMANTADINE	targetBased	4	Completed	01/03/1997	https://clinicaltrials.gov/study/NCT00015236	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	post-traumatic stress disorder	CYCLOBENZAPRINE	targetBased	3	Terminated	27/03/2017	https://clinicaltrials.gov/study/NCT03062540	0.35	LoF	protect	Stopped early due to inadequate separation on primary efficacy endpoint at Week 12 according to Interim Analysis conducted on the first 274 (50%) patients.
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	post-traumatic stress disorder	CYCLOBENZAPRINE	targetBased	3	Completed	19/04/2018	https://clinicaltrials.gov/study/NCT03508700	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	post-traumatic stress disorder	CYCLOBENZAPRINE	targetBased	3	Terminated	07/03/2019	https://clinicaltrials.gov/study/NCT03841773	0.7	LoF	protect	Interim Analysis results
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	post-traumatic stress disorder	CYCLOBENZAPRINE	targetBased	3	Terminated	20/06/2017	https://clinicaltrials.gov/study/NCT03110575	0.35	LoF	protect	Stopped early due to inadequate separation on primary efficacy endpoint in the lead-in HONOR study, TNX-CY-P301
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	postpartum depression	ETHINYL ESTRADIOL	targetBased	4	Unknown status	01/07/2014	https://clinicaltrials.gov/study/NCT02210702	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	postpartum depression	ETHINYL ESTRADIOL	targetBased	4	Unknown status	01/07/2014	https://clinicaltrials.gov/study/NCT02210702	1	GoF	protect
Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS	D1_activators	DRD1	Dopaminereceptor1	unipolar depression	MINAPRINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N06AX07	1	GoF	protect
Allosteric Modulators of D1 Receptors: Primary Screen	D1	DRD1	Dopamine receptor D1	unipolar depression	MINAPRINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N06AX07	1	GoF	protect
Antagonist of Human D 1 Dopamine Receptor: qHTS	D1_inhibitors	DRD1	Dopaminereceptor1	unipolar depression	MINAPRINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N06AX07	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	unipolar depression	MINAPRINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N06AX07	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	unipolar depression	MINAPRINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N06AX07	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	unipolar depression	MINAPRINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N06AX07	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	unipolar depression	MINAPRINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N06AX07	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	unipolar depression	MINAPRINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N06AX07	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	unipolar depression	MINAPRINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N06AX07	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	unipolar depression	MINAPRINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N06AX07	1	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	unipolar depression	MINAPRINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N06AX07	1	GoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	unipolar depression	MINAPRINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N06AX07	1	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	unipolar depression	MINAPRINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N06AX07	1	GoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	unipolar depression	MINAPRINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N06AX07	1	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	unipolar depression	MINAPRINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N06AX07	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	ZIPRASIDONE	targetBased	4	Unknown status	01/02/2014	https://clinicaltrials.gov/study/NCT02040883	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	ZIPRASIDONE	targetBased	4	Unknown status	01/10/2016	https://clinicaltrials.gov/study/NCT02935998	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	ZIPRASIDONE	targetBased	4	Completed	01/12/2003	https://clinicaltrials.gov/study/NCT00199940	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	ZIPRASIDONE	targetBased	4	Completed	01/03/2004	https://clinicaltrials.gov/study/NCT00148564	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	ZIPRASIDONE	targetBased	4	Completed	01/04/2004	https://clinicaltrials.gov/study/NCT00634348	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	ZIPRASIDONE	targetBased	4	Not yet recruiting	01/05/2021	https://clinicaltrials.gov/study/NCT04446234	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	ZIPRASIDONE	targetBased	4	Completed	01/09/2001	https://clinicaltrials.gov/study/NCT00515723	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar disorder	ZIPRASIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b4001db4-1ccb-42f3-af4a-7276c51f4ad5	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	bipolar disorder	ZIPRASIDONE	targetBased	4	Unknown status	01/09/2013	https://clinicaltrials.gov/study/NCT01893229	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	bipolar disorder	ZIPRASIDONE	targetBased	4	Unknown status	01/09/2013	https://clinicaltrials.gov/study/NCT01893229	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar disorder	ZIPRASIDONE	targetBased	4	Unknown status	01/09/2013	https://clinicaltrials.gov/study/NCT01893229	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar disorder	ZIPRASIDONE	targetBased	4	Unknown status	01/09/2013	https://clinicaltrials.gov/study/NCT01893229	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar disorder	ZIPRASIDONE	targetBased	4	Unknown status	01/09/2013	https://clinicaltrials.gov/study/NCT01893229	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar disorder	ZIPRASIDONE	targetBased	4	Unknown status	01/09/2013	https://clinicaltrials.gov/study/NCT01893229	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	mental or behavioural disorder	ZIPRASIDONE	targetBased	4	Completed	01/10/2008	https://clinicaltrials.gov/study/NCT02526030	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	mental or behavioural disorder	ZIPRASIDONE	targetBased	4	Completed	01/02/2003	https://clinicaltrials.gov/study/NCT00932529	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	mental or behavioural disorder	ZIPRASIDONE	targetBased	4	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT00806234	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	mental or behavioural disorder	ZIPRASIDONE	targetBased	4	Completed	01/10/2005	https://clinicaltrials.gov/study/NCT02305823	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Dementia	ZIPRASIDONE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	depressive disorder	ZIPRASIDONE	targetBased	4	Completed	01/02/2010	https://clinicaltrials.gov/study/NCT01168674	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	depressive disorder	ZIPRASIDONE	targetBased	4	Completed	01/09/2001	https://clinicaltrials.gov/study/NCT00034801	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	depressive disorder	ZIPRASIDONE	targetBased	4	Completed	01/09/2001	https://clinicaltrials.gov/study/NCT00034801	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	depressive disorder	ZIPRASIDONE	targetBased	4	Completed	01/09/2001	https://clinicaltrials.gov/study/NCT00034801	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	depressive disorder	ZIPRASIDONE	targetBased	4	Completed	01/09/2001	https://clinicaltrials.gov/study/NCT00034801	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	depressive disorder	ZIPRASIDONE	targetBased	4	Completed	01/09/2001	https://clinicaltrials.gov/study/NCT00034801	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	depressive disorder	ZIPRASIDONE	targetBased	4	Completed	01/09/2001	https://clinicaltrials.gov/study/NCT00034801	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	anxiety	ZIPRASIDONE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	anxiety	ZIPRASIDONE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	anxiety	ZIPRASIDONE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	anxiety	ZIPRASIDONE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	anxiety	ZIPRASIDONE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	anxiety	ZIPRASIDONE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Agitation	ZIPRASIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=61e3fa7b-61c2-4d5d-a6b3-2618c15a6bd9	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Agitation	ZIPRASIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=819997d8-e091-4081-85e1-bf50d39837ee	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Agitation	ZIPRASIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=819997d8-e091-4081-85e1-bf50d39837ee	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Agitation	ZIPRASIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=819997d8-e091-4081-85e1-bf50d39837ee	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Agitation	ZIPRASIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=819997d8-e091-4081-85e1-bf50d39837ee	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Agitation	ZIPRASIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=819997d8-e091-4081-85e1-bf50d39837ee	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Agitation	ZIPRASIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=819997d8-e091-4081-85e1-bf50d39837ee	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizoaffective disorder	ZIPRASIDONE	targetBased	4	Completed	01/09/2001	https://clinicaltrials.gov/study/NCT00034801	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizoaffective disorder	ZIPRASIDONE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizoaffective disorder	ZIPRASIDONE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizoaffective disorder	ZIPRASIDONE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizoaffective disorder	ZIPRASIDONE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizoaffective disorder	ZIPRASIDONE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizoaffective disorder	ZIPRASIDONE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar I disorder	ZIPRASIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=819997d8-e091-4081-85e1-bf50d39837ee	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar I disorder	ZIPRASIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=61e3fa7b-61c2-4d5d-a6b3-2618c15a6bd9	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	ZIPRASIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b4001db4-1ccb-42f3-af4a-7276c51f4ad5	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	ZIPRASIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=315e24c2-2f8c-47d9-b1b1-ce006646098a	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	ZIPRASIDONE	targetBased	4	Completed	01/02/2007	https://clinicaltrials.gov/study/NCT00622739	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	ZIPRASIDONE	targetBased	4	Unknown status	01/09/2013	https://clinicaltrials.gov/study/NCT01893229	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	ZIPRASIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=67696348-8039-4bd2-bbae-d4229c92a4d0	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	ZIPRASIDONE	targetBased	4	Completed	01/08/2002	https://clinicaltrials.gov/study/NCT00048802	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	ZIPRASIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8326928a-2cb6-4f7f-9712-03a425a14c37	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	ZIPRASIDONE	targetBased	4	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT00806234	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	ZIPRASIDONE	targetBased	4	Completed	01/02/2003	https://clinicaltrials.gov/study/NCT00932529	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	ZIPRASIDONE	targetBased	4	Completed	01/02/2003	https://clinicaltrials.gov/study/NCT00932529	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	mental or behavioural disorder	ZIPRASIDONE	targetBased	4	Completed	01/02/2003	https://clinicaltrials.gov/study/NCT00932529	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	mental or behavioural disorder	ZIPRASIDONE	targetBased	4	Completed	01/02/2003	https://clinicaltrials.gov/study/NCT00932529	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	ZIPRASIDONE	targetBased	4	Completed	01/02/2003	https://clinicaltrials.gov/study/NCT00932529	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	ZIPRASIDONE	targetBased	4	Completed	01/02/2003	https://clinicaltrials.gov/study/NCT00932529	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	psychosis	ZIPRASIDONE	targetBased	4	Terminated	01/07/2013	https://clinicaltrials.gov/study/NCT01844700	0.5	LoF	protect	very slow recruitment, no sufficient results
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	psychosis	ZIPRASIDONE	targetBased	4	Completed		https://clinicaltrials.gov/study/NCT01157559	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	psychosis	ZIPRASIDONE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AE04	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizoaffective disorder	ZIPRASIDONE	targetBased	4	Completed	01/11/2006	https://clinicaltrials.gov/study/NCT00406315	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizoaffective disorder	ZIPRASIDONE	targetBased	4	Completed	01/09/2001	https://clinicaltrials.gov/study/NCT00034801	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizoaffective disorder	ZIPRASIDONE	targetBased	4	Completed	01/05/2005	https://clinicaltrials.gov/study/NCT00458211	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizoaffective disorder	ZIPRASIDONE	targetBased	4	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00330863	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizoaffective disorder	ZIPRASIDONE	targetBased	4	Completed	01/09/2001	https://clinicaltrials.gov/study/NCT00515723	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizoaffective disorder	ZIPRASIDONE	targetBased	4	Completed	01/12/2003	https://clinicaltrials.gov/study/NCT00649064	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizoaffective disorder	ZIPRASIDONE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	depressive disorder	ZIPRASIDONE	targetBased	3	Completed	01/03/2008	https://clinicaltrials.gov/study/NCT00657592	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	depressive disorder	ZIPRASIDONE	targetBased	4	Completed	01/02/2010	https://clinicaltrials.gov/study/NCT01168674	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	depressive disorder	ZIPRASIDONE	targetBased	4	Completed	01/09/2001	https://clinicaltrials.gov/study/NCT00034801	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	depressive disorder	ZIPRASIDONE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	ZIPRASIDONE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AE04	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	psychosis	ZIPRASIDONE	targetBased	4	Completed		https://clinicaltrials.gov/study/NCT01157559	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	psychosis	ZIPRASIDONE	targetBased	4	Completed		https://clinicaltrials.gov/study/NCT01157559	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	psychosis	ZIPRASIDONE	targetBased	4	Completed		https://clinicaltrials.gov/study/NCT01157559	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	psychosis	ZIPRASIDONE	targetBased	4	Completed		https://clinicaltrials.gov/study/NCT01157559	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	ZIPRASIDONE	targetBased	4	Completed		https://clinicaltrials.gov/study/NCT01157559	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	ZIPRASIDONE	targetBased	4	Completed		https://clinicaltrials.gov/study/NCT01157559	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	anxiety	ZIPRASIDONE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	mood disorder	ZIPRASIDONE	targetBased	4	Completed	01/12/2003	https://clinicaltrials.gov/study/NCT00199940	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Dementia	ZIPRASIDONE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Dementia	ZIPRASIDONE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Dementia	ZIPRASIDONE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Dementia	ZIPRASIDONE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Dementia	ZIPRASIDONE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Dementia	ZIPRASIDONE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	mood disorder	ZIPRASIDONE	targetBased	4	Completed	01/12/2003	https://clinicaltrials.gov/study/NCT00199940	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	mood disorder	ZIPRASIDONE	targetBased	4	Completed	01/12/2003	https://clinicaltrials.gov/study/NCT00199940	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	mood disorder	ZIPRASIDONE	targetBased	4	Completed	01/12/2003	https://clinicaltrials.gov/study/NCT00199940	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	mood disorder	ZIPRASIDONE	targetBased	4	Completed	01/12/2003	https://clinicaltrials.gov/study/NCT00199940	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	mood disorder	ZIPRASIDONE	targetBased	4	Completed	01/12/2003	https://clinicaltrials.gov/study/NCT00199940	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	mood disorder	ZIPRASIDONE	targetBased	4	Completed	01/12/2003	https://clinicaltrials.gov/study/NCT00199940	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar I disorder	ZIPRASIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=819997d8-e091-4081-85e1-bf50d39837ee	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	bipolar I disorder	ZIPRASIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=61e3fa7b-61c2-4d5d-a6b3-2618c15a6bd9	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	bipolar I disorder	ZIPRASIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=61e3fa7b-61c2-4d5d-a6b3-2618c15a6bd9	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar I disorder	ZIPRASIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=61e3fa7b-61c2-4d5d-a6b3-2618c15a6bd9	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar I disorder	ZIPRASIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=61e3fa7b-61c2-4d5d-a6b3-2618c15a6bd9	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar I disorder	ZIPRASIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=61e3fa7b-61c2-4d5d-a6b3-2618c15a6bd9	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar I disorder	ZIPRASIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=61e3fa7b-61c2-4d5d-a6b3-2618c15a6bd9	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Agitation	ZIPRASIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=819997d8-e091-4081-85e1-bf50d39837ee	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Agitation	ZIPRASIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=61e3fa7b-61c2-4d5d-a6b3-2618c15a6bd9	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	ZIPRASIDONE	targetBased	4	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00330863	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	ZIPRASIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4890cf77-8da3-46ae-b6f6-abea7aae6b4d	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	ZIPRASIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4890cf77-8da3-46ae-b6f6-abea7aae6b4d	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	ZIPRASIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4890cf77-8da3-46ae-b6f6-abea7aae6b4d	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	ZIPRASIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4890cf77-8da3-46ae-b6f6-abea7aae6b4d	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	ZIPRASIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4890cf77-8da3-46ae-b6f6-abea7aae6b4d	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	ZIPRASIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4890cf77-8da3-46ae-b6f6-abea7aae6b4d	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	bipolar disorder	OLANZAPINE	targetBased	4	Terminated	01/10/2004	https://clinicaltrials.gov/study/NCT00767715	1	LoF	protect	Trial discontinued due to low enrollment
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	bipolar disorder	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fad5c029-4531-4913-ab7b-0c68a625447f	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	bipolar disorder	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fad5c029-4531-4913-ab7b-0c68a625447f	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	bipolar disorder	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fad5c029-4531-4913-ab7b-0c68a625447f	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	bipolar disorder	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=40506b0c-1444-4e02-8e80-63f92af8a7b9	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	bipolar disorder	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=40506b0c-1444-4e02-8e80-63f92af8a7b9	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	bipolar disorder	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=40506b0c-1444-4e02-8e80-63f92af8a7b9	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	eating disorder	OLANZAPINE	targetBased	4	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00685334	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	eating disorder	OLANZAPINE	targetBased	4	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00685334	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	eating disorder	OLANZAPINE	targetBased	4	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00685334	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	eating disorder	OLANZAPINE	targetBased	3	Terminated	01/08/2010	https://clinicaltrials.gov/study/NCT01184443	0.7	LoF	protect	Poor recruitment
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	eating disorder	OLANZAPINE	targetBased	3	Terminated	01/08/2010	https://clinicaltrials.gov/study/NCT01184443	0.7	LoF	protect	Poor recruitment
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	eating disorder	OLANZAPINE	targetBased	3	Terminated	01/08/2010	https://clinicaltrials.gov/study/NCT01184443	0.7	LoF	protect	Poor recruitment
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	major depressive disorder	OLANZAPINE	targetBased	3	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT00056472	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	major depressive disorder	OLANZAPINE	targetBased	3	Completed	01/04/2002	https://clinicaltrials.gov/study/NCT00035321	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	treatment resistant depression	OLANZAPINE	targetBased	3	Completed	01/08/2009	https://clinicaltrials.gov/study/NCT00958568	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	treatment resistant depression	OLANZAPINE	targetBased	3	Completed	01/08/2009	https://clinicaltrials.gov/study/NCT00958568	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	treatment resistant depression	OLANZAPINE	targetBased	3	Completed	01/08/2009	https://clinicaltrials.gov/study/NCT00958568	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	treatment resistant depression	OLANZAPINE	targetBased	3	Terminated	01/09/2012	https://clinicaltrials.gov/study/NCT01687478	0.35	LoF	protect	Interim assessment: Lack of efficacy
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	treatment resistant depression	OLANZAPINE	targetBased	3	Terminated	01/09/2012	https://clinicaltrials.gov/study/NCT01687478	0.35	LoF	protect	Interim assessment: Lack of efficacy
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	treatment resistant depression	OLANZAPINE	targetBased	3	Terminated	01/09/2012	https://clinicaltrials.gov/study/NCT01687478	0.35	LoF	protect	Interim assessment: Lack of efficacy
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	mental or behavioural disorder	OLANZAPINE	targetBased	4	Completed	01/10/2003	https://clinicaltrials.gov/study/NCT00108368	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	mental or behavioural disorder	OLANZAPINE	targetBased	4	Completed	01/06/1997	https://clinicaltrials.gov/study/NCT00001656	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	mental or behavioural disorder	OLANZAPINE	targetBased	4	Completed	01/06/1997	https://clinicaltrials.gov/study/NCT00001656	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	mental or behavioural disorder	OLANZAPINE	targetBased	4	Completed	01/06/1997	https://clinicaltrials.gov/study/NCT00001656	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	mental or behavioural disorder	OLANZAPINE	targetBased	4	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT00806234	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	mental or behavioural disorder	OLANZAPINE	targetBased	4	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT00806234	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	mental or behavioural disorder	OLANZAPINE	targetBased	4	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT00806234	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	unipolar depression	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6b28c424-0b7e-4b75-b090-f116b113554e	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	unipolar depression	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=acd8f466-e5f5-4e15-a4fb-14ab8199cda2	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	unipolar depression	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7881c39e-0624-4c14-a6c3-7a9dc81c198c	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	unipolar depression	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f40ac986-c161-49ae-8650-8ae4c59ce5be	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	unipolar depression	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=66ef201f-85eb-44f0-9ef0-1b618c6e0bff	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	unipolar depression	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a3c9ea17-3793-494a-8b32-44e48f9f4503	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	unipolar depression	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=624d55e0-6cee-4366-9490-3b291c777c78	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	obsessive-compulsive disorder	OLANZAPINE	targetBased	4	Completed	01/09/1992	https://clinicaltrials.gov/study/NCT00000373	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Borderline personality disorder	OLANZAPINE	targetBased	3	Completed	01/02/2004	https://clinicaltrials.gov/study/NCT00088036	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Borderline personality disorder	OLANZAPINE	targetBased	3	Completed	01/03/2004	https://clinicaltrials.gov/study/NCT00091650	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4ff92ebf-6e0d-458e-a000-ec30df7664d7	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=842b438f-86c7-44f2-a614-06915757a4dd	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	obsessive-compulsive disorder	OLANZAPINE	targetBased	4	Completed	01/09/1992	https://clinicaltrials.gov/study/NCT00000373	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	obsessive-compulsive disorder	OLANZAPINE	targetBased	4	Completed	01/09/1992	https://clinicaltrials.gov/study/NCT00000373	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	obsessive-compulsive disorder	OLANZAPINE	targetBased	4	Completed	01/09/1992	https://clinicaltrials.gov/study/NCT00000373	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	obsessive-compulsive disorder	OLANZAPINE	targetBased	4	Completed	01/09/1992	https://clinicaltrials.gov/study/NCT00000373	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	obsessive-compulsive disorder	OLANZAPINE	targetBased	4	Completed	01/09/1992	https://clinicaltrials.gov/study/NCT00000373	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	obsessive-compulsive disorder	OLANZAPINE	targetBased	4	Completed	01/09/1992	https://clinicaltrials.gov/study/NCT00000373	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a1dfb4e7-4143-4422-b7a7-292e4fd75044	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5f3a9abd-aaca-48b9-8cc9-79bb21179ff5	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	OLANZAPINE	targetBased	4	Terminated	01/07/2012	https://clinicaltrials.gov/study/NCT01592201	1	LoF	protect	This study was early terminated due to insufficient enrollment required for hypothesis testing.
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f6ec3e3e-24c3-4360-b712-ca6017af1347	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	OLANZAPINE	targetBased	4	Completed	01/10/2011	https://clinicaltrials.gov/study/NCT01446328	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar disorder	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=636665be-9d7e-443a-8134-e8cc47e6ba24	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	bipolar disorder	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c8c2fb7b-210d-4e44-9c86-bb999deec2fe	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	bipolar disorder	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c8c2fb7b-210d-4e44-9c86-bb999deec2fe	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar disorder	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c8c2fb7b-210d-4e44-9c86-bb999deec2fe	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar disorder	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c8c2fb7b-210d-4e44-9c86-bb999deec2fe	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar disorder	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c8c2fb7b-210d-4e44-9c86-bb999deec2fe	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar disorder	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c8c2fb7b-210d-4e44-9c86-bb999deec2fe	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	gambling behaviour	OLANZAPINE	targetBased	3	Completed	01/02/2007	https://clinicaltrials.gov/study/NCT00438776	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	gambling behaviour	OLANZAPINE	targetBased	3	Completed	01/02/2007	https://clinicaltrials.gov/study/NCT00438776	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	gambling behaviour	OLANZAPINE	targetBased	3	Completed	01/02/2007	https://clinicaltrials.gov/study/NCT00438776	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	alcohol dependence	OLANZAPINE	targetBased	3	Completed	01/09/2002	https://clinicaltrials.gov/study/NCT00746785	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	gambling behaviour	OLANZAPINE	targetBased	3	Completed	01/02/2007	https://clinicaltrials.gov/study/NCT00438776	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	gambling behaviour	OLANZAPINE	targetBased	3	Completed	01/02/2007	https://clinicaltrials.gov/study/NCT00438776	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	gambling behaviour	OLANZAPINE	targetBased	3	Completed	01/02/2007	https://clinicaltrials.gov/study/NCT00438776	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	gambling behaviour	OLANZAPINE	targetBased	3	Completed	01/02/2007	https://clinicaltrials.gov/study/NCT00438776	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	gambling behaviour	OLANZAPINE	targetBased	3	Completed	01/02/2007	https://clinicaltrials.gov/study/NCT00438776	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	gambling behaviour	OLANZAPINE	targetBased	3	Completed	01/02/2007	https://clinicaltrials.gov/study/NCT00438776	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	alcohol dependence	OLANZAPINE	targetBased	3	Completed	01/09/2002	https://clinicaltrials.gov/study/NCT00746785	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	alcohol dependence	OLANZAPINE	targetBased	3	Completed	01/09/2002	https://clinicaltrials.gov/study/NCT00746785	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	alcohol dependence	OLANZAPINE	targetBased	3	Completed	01/09/2002	https://clinicaltrials.gov/study/NCT00746785	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Dementia	OLANZAPINE	targetBased	4	Completed	01/09/2006	https://clinicaltrials.gov/study/NCT00433121	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Dementia	OLANZAPINE	targetBased	4	Completed	01/09/2006	https://clinicaltrials.gov/study/NCT00433121	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Dementia	OLANZAPINE	targetBased	4	Completed	01/09/2006	https://clinicaltrials.gov/study/NCT00433121	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Dementia	OLANZAPINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Dementia	OLANZAPINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Dementia	OLANZAPINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	mental or behavioural disorder	OLANZAPINE	targetBased	4	Completed	01/02/2003	https://clinicaltrials.gov/study/NCT00932529	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	mental or behavioural disorder	OLANZAPINE	targetBased	4	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT00806234	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	mental or behavioural disorder	OLANZAPINE	targetBased	4	Completed	01/10/2003	https://clinicaltrials.gov/study/NCT00108368	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	mental or behavioural disorder	OLANZAPINE	targetBased	4	Completed	01/06/1997	https://clinicaltrials.gov/study/NCT00001656	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	treatment resistant depression	OLANZAPINE	targetBased	3	Completed	01/08/2009	https://clinicaltrials.gov/study/NCT00958568	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	treatment resistant depression	OLANZAPINE	targetBased	3	Terminated	01/09/2012	https://clinicaltrials.gov/study/NCT01687478	0.35	LoF	protect	Interim assessment: Lack of efficacy
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Dementia	OLANZAPINE	targetBased	4	Completed	01/09/2006	https://clinicaltrials.gov/study/NCT00433121	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Dementia	OLANZAPINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	major depressive disorder	OLANZAPINE	targetBased	3	Completed	01/04/2002	https://clinicaltrials.gov/study/NCT00035321	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	major depressive disorder	OLANZAPINE	targetBased	3	Completed	01/04/2002	https://clinicaltrials.gov/study/NCT00035321	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	major depressive disorder	OLANZAPINE	targetBased	3	Completed	01/04/2002	https://clinicaltrials.gov/study/NCT00035321	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	major depressive disorder	OLANZAPINE	targetBased	3	Completed	01/04/2002	https://clinicaltrials.gov/study/NCT00035321	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	major depressive disorder	OLANZAPINE	targetBased	3	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT00056472	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	major depressive disorder	OLANZAPINE	targetBased	3	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT00056472	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	major depressive disorder	OLANZAPINE	targetBased	3	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT00056472	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	major depressive disorder	OLANZAPINE	targetBased	3	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT00056472	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	major depressive disorder	OLANZAPINE	targetBased	3	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT00056472	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	major depressive disorder	OLANZAPINE	targetBased	3	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT00056472	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Anorexia	OLANZAPINE	targetBased	3	Recruiting	25/12/2021	https://clinicaltrials.gov/study/NCT05243251	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	psychosis	OLANZAPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AH03	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	psychosis	OLANZAPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AH03	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	psychosis	OLANZAPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AH03	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	major depressive disorder	OLANZAPINE	targetBased	3	Completed	01/04/2002	https://clinicaltrials.gov/study/NCT00035321	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	major depressive disorder	OLANZAPINE	targetBased	3	Completed	01/04/2002	https://clinicaltrials.gov/study/NCT00035321	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	major depressive disorder	OLANZAPINE	targetBased	3	Completed	01/04/2002	https://clinicaltrials.gov/study/NCT00035321	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	major depressive disorder	OLANZAPINE	targetBased	3	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT00056472	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	major depressive disorder	OLANZAPINE	targetBased	3	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT00056472	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	major depressive disorder	OLANZAPINE	targetBased	3	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT00056472	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Anorexia	OLANZAPINE	targetBased	3	Recruiting	25/12/2021	https://clinicaltrials.gov/study/NCT05243251	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Anorexia	OLANZAPINE	targetBased	3	Recruiting	25/12/2021	https://clinicaltrials.gov/study/NCT05243251	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Anorexia	OLANZAPINE	targetBased	3	Recruiting	25/12/2021	https://clinicaltrials.gov/study/NCT05243251	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Anorexia	OLANZAPINE	targetBased	3	Recruiting	25/12/2021	https://clinicaltrials.gov/study/NCT05243251	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Anorexia	OLANZAPINE	targetBased	3	Recruiting	25/12/2021	https://clinicaltrials.gov/study/NCT05243251	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Anorexia	OLANZAPINE	targetBased	3	Recruiting	25/12/2021	https://clinicaltrials.gov/study/NCT05243251	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	depressive disorder	OLANZAPINE	targetBased	4	Terminated	01/07/2009	https://clinicaltrials.gov/study/NCT01305707	1	LoF	protect	Difficulties in recruiting
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	depressive disorder	OLANZAPINE	targetBased	4	Recruiting	04/05/2021	https://clinicaltrials.gov/study/NCT04876521	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	depressive disorder	OLANZAPINE	targetBased	4	Recruiting	04/05/2021	https://clinicaltrials.gov/study/NCT04876521	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	depressive disorder	OLANZAPINE	targetBased	4	Recruiting	04/05/2021	https://clinicaltrials.gov/study/NCT04876521	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	depressive disorder	OLANZAPINE	targetBased	4	Recruiting	04/05/2021	https://clinicaltrials.gov/study/NCT04876521	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	depressive disorder	OLANZAPINE	targetBased	4	Recruiting	04/05/2021	https://clinicaltrials.gov/study/NCT04876521	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	depressive disorder	OLANZAPINE	targetBased	4	Recruiting	04/05/2021	https://clinicaltrials.gov/study/NCT04876521	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	eating disorder	OLANZAPINE	targetBased	4	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00685334	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	eating disorder	OLANZAPINE	targetBased	3	Terminated	01/08/2010	https://clinicaltrials.gov/study/NCT01184443	0.7	LoF	protect	Poor recruitment
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	unipolar depression	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a3c9ea17-3793-494a-8b32-44e48f9f4503	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	unipolar depression	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=30a963ab-b2ee-4949-8c3c-00d0f308dd61	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	unipolar depression	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=30a963ab-b2ee-4949-8c3c-00d0f308dd61	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	unipolar depression	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=30a963ab-b2ee-4949-8c3c-00d0f308dd61	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	unipolar depression	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=30a963ab-b2ee-4949-8c3c-00d0f308dd61	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	unipolar depression	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=30a963ab-b2ee-4949-8c3c-00d0f308dd61	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	unipolar depression	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=30a963ab-b2ee-4949-8c3c-00d0f308dd61	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	obsessive-compulsive disorder	OLANZAPINE	targetBased	4	Completed	01/09/1992	https://clinicaltrials.gov/study/NCT00000373	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	obsessive-compulsive disorder	OLANZAPINE	targetBased	4	Completed	01/09/1992	https://clinicaltrials.gov/study/NCT00000373	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	obsessive-compulsive disorder	OLANZAPINE	targetBased	4	Completed	01/09/1992	https://clinicaltrials.gov/study/NCT00000373	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	anxiety	OLANZAPINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	anxiety	OLANZAPINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	anxiety	OLANZAPINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	anxiety	OLANZAPINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	anxiety	OLANZAPINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	anxiety	OLANZAPINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Borderline personality disorder	OLANZAPINE	targetBased	3	Completed	01/02/2004	https://clinicaltrials.gov/study/NCT00088036	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Borderline personality disorder	OLANZAPINE	targetBased	3	Completed	01/02/2004	https://clinicaltrials.gov/study/NCT00088036	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Borderline personality disorder	OLANZAPINE	targetBased	3	Completed	01/02/2004	https://clinicaltrials.gov/study/NCT00088036	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Borderline personality disorder	OLANZAPINE	targetBased	3	Completed	01/03/2004	https://clinicaltrials.gov/study/NCT00091650	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Borderline personality disorder	OLANZAPINE	targetBased	3	Completed	01/03/2004	https://clinicaltrials.gov/study/NCT00091650	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Borderline personality disorder	OLANZAPINE	targetBased	3	Completed	01/03/2004	https://clinicaltrials.gov/study/NCT00091650	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Agitation	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f40ac986-c161-49ae-8650-8ae4c59ce5be	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Agitation	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=acd8f466-e5f5-4e15-a4fb-14ab8199cda2	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Agitation	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=acd8f466-e5f5-4e15-a4fb-14ab8199cda2	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Agitation	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=acd8f466-e5f5-4e15-a4fb-14ab8199cda2	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Agitation	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=acd8f466-e5f5-4e15-a4fb-14ab8199cda2	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Agitation	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=acd8f466-e5f5-4e15-a4fb-14ab8199cda2	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Agitation	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=acd8f466-e5f5-4e15-a4fb-14ab8199cda2	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizoaffective disorder	OLANZAPINE	targetBased	4	Completed	01/07/2004	https://clinicaltrials.gov/study/NCT00090012	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizoaffective disorder	OLANZAPINE	targetBased	4	Completed	01/03/2006	https://clinicaltrials.gov/study/NCT00303602	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizoaffective disorder	OLANZAPINE	targetBased	4	Completed	01/03/2006	https://clinicaltrials.gov/study/NCT00303602	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizoaffective disorder	OLANZAPINE	targetBased	4	Completed	01/03/2006	https://clinicaltrials.gov/study/NCT00303602	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizoaffective disorder	OLANZAPINE	targetBased	4	Completed	01/03/2006	https://clinicaltrials.gov/study/NCT00303602	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizoaffective disorder	OLANZAPINE	targetBased	4	Completed	01/03/2006	https://clinicaltrials.gov/study/NCT00303602	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizoaffective disorder	OLANZAPINE	targetBased	4	Completed	01/03/2006	https://clinicaltrials.gov/study/NCT00303602	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	eating disorder	OLANZAPINE	targetBased	3	Terminated	01/08/2010	https://clinicaltrials.gov/study/NCT01184443	0.7	LoF	protect	Poor recruitment
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	eating disorder	OLANZAPINE	targetBased	4	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00685334	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	eating disorder	OLANZAPINE	targetBased	4	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00685334	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	eating disorder	OLANZAPINE	targetBased	4	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00685334	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	eating disorder	OLANZAPINE	targetBased	4	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00685334	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	eating disorder	OLANZAPINE	targetBased	4	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00685334	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	eating disorder	OLANZAPINE	targetBased	4	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00685334	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar I disorder	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d976599a-0ee0-4fa4-afe6-bdfbca570afe	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar I disorder	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=96ddc4f5-43be-5d42-e053-2a95a90a5d12	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar I disorder	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e9ac2bd3-dbff-4b1a-952f-da3909c6e4ee	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar I disorder	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e8626e68-088d-47ff-bf06-489a778815aa	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar I disorder	OLANZAPINE	targetBased	4	Completed	01/12/2006	https://clinicaltrials.gov/study/NCT00402324	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar I disorder	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6b28c424-0b7e-4b75-b090-f116b113554e	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar I disorder	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=66ef201f-85eb-44f0-9ef0-1b618c6e0bff	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2f6ceda3-3edc-4427-98a6-23e3c930c44d	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=97ae6a74-8904-4d74-99af-2b679c89f516	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ad42af27-3801-4c29-9e4c-6752cb5f735c	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3c28cf18-01a3-468a-ab3e-8aa82f918251	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=80a810aa-d34c-48ca-a9c9-9a79e01afcee	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=250ed608-092c-4e19-884f-a15bdea065d7	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=15c99a41-322d-4ac6-b514-bd381be8aa7b	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	OLANZAPINE	targetBased	4	Completed	01/06/1997	https://clinicaltrials.gov/study/NCT00001656	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	OLANZAPINE	targetBased	4	Completed	01/10/2003	https://clinicaltrials.gov/study/NCT00108368	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	OLANZAPINE	targetBased	4	Completed	01/10/2003	https://clinicaltrials.gov/study/NCT00108368	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	mental or behavioural disorder	OLANZAPINE	targetBased	4	Completed	01/10/2003	https://clinicaltrials.gov/study/NCT00108368	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	mental or behavioural disorder	OLANZAPINE	targetBased	4	Completed	01/10/2003	https://clinicaltrials.gov/study/NCT00108368	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	OLANZAPINE	targetBased	4	Completed	01/10/2003	https://clinicaltrials.gov/study/NCT00108368	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	OLANZAPINE	targetBased	4	Completed	01/10/2003	https://clinicaltrials.gov/study/NCT00108368	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	psychosis	OLANZAPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AH03	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizoaffective disorder	OLANZAPINE	targetBased	4	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00337662	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizoaffective disorder	OLANZAPINE	targetBased	4	Withdrawn	01/04/2008	https://clinicaltrials.gov/study/NCT00672464	1	LoF	protect	lack of funding
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizoaffective disorder	OLANZAPINE	targetBased	4	Completed	01/06/2012	https://clinicaltrials.gov/study/NCT01609153	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizoaffective disorder	OLANZAPINE	targetBased	4	Completed	01/03/2012	https://clinicaltrials.gov/study/NCT02137993	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizoaffective disorder	OLANZAPINE	targetBased	4	Completed	01/03/2006	https://clinicaltrials.gov/study/NCT00303602	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizoaffective disorder	OLANZAPINE	targetBased	4	Completed	01/03/2009	https://clinicaltrials.gov/study/NCT00981526	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizoaffective disorder	OLANZAPINE	targetBased	4	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00330863	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Agitation	OLANZAPINE	targetBased	4	Terminated	01/09/2017	https://clinicaltrials.gov/study/NCT03246620	1	LoF	protect	The study was terminated prematurely due to difficulties in patient recruitment and associated potential for selection bias.
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Agitation	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=15c99a41-322d-4ac6-b514-bd381be8aa7b	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Agitation	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=15c99a41-322d-4ac6-b514-bd381be8aa7b	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Agitation	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=15c99a41-322d-4ac6-b514-bd381be8aa7b	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Agitation	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7c6ff491-c30c-4ada-85a0-cbee98f2fe32	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Agitation	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7c6ff491-c30c-4ada-85a0-cbee98f2fe32	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Agitation	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7c6ff491-c30c-4ada-85a0-cbee98f2fe32	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	schizophrenia	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c7d0d5fb-2810-410b-b718-27ae019c8169	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	schizophrenia	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=16c999a9-399c-4407-883e-8e66b0239ed2	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	schizophrenia	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=16c999a9-399c-4407-883e-8e66b0239ed2	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	schizophrenia	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=16c999a9-399c-4407-883e-8e66b0239ed2	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	schizophrenia	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fcb7d340-a167-41f2-b85d-916c542067da	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	schizophrenia	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fcb7d340-a167-41f2-b85d-916c542067da	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	schizophrenia	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fcb7d340-a167-41f2-b85d-916c542067da	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	depressive disorder	OLANZAPINE	targetBased	4	Completed	01/10/2007	https://clinicaltrials.gov/study/NCT00520507	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	depressive disorder	OLANZAPINE	targetBased	4	Completed	01/10/2011	https://clinicaltrials.gov/study/NCT01427608	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	depressive disorder	OLANZAPINE	targetBased	4	Completed	01/10/2011	https://clinicaltrials.gov/study/NCT01427608	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	depressive disorder	OLANZAPINE	targetBased	4	Completed	01/10/2011	https://clinicaltrials.gov/study/NCT01427608	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	depressive disorder	OLANZAPINE	targetBased	4	Completed	01/09/2001	https://clinicaltrials.gov/study/NCT00034801	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	depressive disorder	OLANZAPINE	targetBased	4	Completed	01/09/2001	https://clinicaltrials.gov/study/NCT00034801	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	depressive disorder	OLANZAPINE	targetBased	4	Completed	01/09/2001	https://clinicaltrials.gov/study/NCT00034801	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	depressive disorder	OLANZAPINE	targetBased	4	Completed	01/10/2007	https://clinicaltrials.gov/study/NCT00520507	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	depressive disorder	OLANZAPINE	targetBased	3	Withdrawn	01/06/2005	https://clinicaltrials.gov/study/NCT00273624	0.7	LoF	protect	Study withdrawn before inclusion of first participant for administrative reasons
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	depressive disorder	OLANZAPINE	targetBased	4	Recruiting	04/05/2021	https://clinicaltrials.gov/study/NCT04876521	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	depressive disorder	OLANZAPINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	depressive disorder	OLANZAPINE	targetBased	4	Completed	01/10/2011	https://clinicaltrials.gov/study/NCT01427608	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	depressive disorder	OLANZAPINE	targetBased	4	Completed	01/09/2001	https://clinicaltrials.gov/study/NCT00034801	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	depressive disorder	OLANZAPINE	targetBased	4	Terminated	01/07/2009	https://clinicaltrials.gov/study/NCT01305707	1	LoF	protect	Difficulties in recruiting
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	psychosis	OLANZAPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AH03	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	psychosis	OLANZAPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AH03	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	psychosis	OLANZAPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AH03	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	psychosis	OLANZAPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AH03	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	OLANZAPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AH03	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	OLANZAPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AH03	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	anxiety	OLANZAPINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	bipolar I disorder	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e9ac2bd3-dbff-4b1a-952f-da3909c6e4ee	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	bipolar I disorder	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e8626e68-088d-47ff-bf06-489a778815aa	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	bipolar I disorder	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e8626e68-088d-47ff-bf06-489a778815aa	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	bipolar I disorder	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e8626e68-088d-47ff-bf06-489a778815aa	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	bipolar I disorder	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6b28c424-0b7e-4b75-b090-f116b113554e	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	bipolar I disorder	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6b28c424-0b7e-4b75-b090-f116b113554e	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	bipolar I disorder	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6b28c424-0b7e-4b75-b090-f116b113554e	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	unipolar depression	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=15c99a41-322d-4ac6-b514-bd381be8aa7b	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	unipolar depression	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0e986037-41c9-431e-b007-0e7764523fdd	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	unipolar depression	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0e986037-41c9-431e-b007-0e7764523fdd	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	unipolar depression	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0e986037-41c9-431e-b007-0e7764523fdd	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	unipolar depression	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=250ed608-092c-4e19-884f-a15bdea065d7	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	unipolar depression	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=250ed608-092c-4e19-884f-a15bdea065d7	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	unipolar depression	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=250ed608-092c-4e19-884f-a15bdea065d7	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Anorexia	OLANZAPINE	targetBased	3	Recruiting	25/12/2021	https://clinicaltrials.gov/study/NCT05243251	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Anorexia	OLANZAPINE	targetBased	3	Recruiting	25/12/2021	https://clinicaltrials.gov/study/NCT05243251	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Anorexia	OLANZAPINE	targetBased	3	Recruiting	25/12/2021	https://clinicaltrials.gov/study/NCT05243251	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Dementia	OLANZAPINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Dementia	OLANZAPINE	targetBased	4	Completed	01/09/2006	https://clinicaltrials.gov/study/NCT00433121	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Dementia	OLANZAPINE	targetBased	4	Completed	01/09/2006	https://clinicaltrials.gov/study/NCT00433121	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Dementia	OLANZAPINE	targetBased	4	Completed	01/09/2006	https://clinicaltrials.gov/study/NCT00433121	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Dementia	OLANZAPINE	targetBased	4	Completed	01/09/2006	https://clinicaltrials.gov/study/NCT00433121	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Dementia	OLANZAPINE	targetBased	4	Completed	01/09/2006	https://clinicaltrials.gov/study/NCT00433121	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Dementia	OLANZAPINE	targetBased	4	Completed	01/09/2006	https://clinicaltrials.gov/study/NCT00433121	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	gambling behaviour	OLANZAPINE	targetBased	3	Completed	01/02/2007	https://clinicaltrials.gov/study/NCT00438776	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar I disorder	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d976599a-0ee0-4fa4-afe6-bdfbca570afe	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	bipolar I disorder	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e9ac2bd3-dbff-4b1a-952f-da3909c6e4ee	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	bipolar I disorder	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e9ac2bd3-dbff-4b1a-952f-da3909c6e4ee	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar I disorder	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e9ac2bd3-dbff-4b1a-952f-da3909c6e4ee	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar I disorder	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e9ac2bd3-dbff-4b1a-952f-da3909c6e4ee	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar I disorder	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e9ac2bd3-dbff-4b1a-952f-da3909c6e4ee	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar I disorder	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e9ac2bd3-dbff-4b1a-952f-da3909c6e4ee	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	alcohol dependence	OLANZAPINE	targetBased	3	Completed	01/09/2002	https://clinicaltrials.gov/study/NCT00746785	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	alcohol dependence	OLANZAPINE	targetBased	3	Completed	01/09/2002	https://clinicaltrials.gov/study/NCT00746785	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	alcohol dependence	OLANZAPINE	targetBased	3	Completed	01/09/2002	https://clinicaltrials.gov/study/NCT00746785	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	alcohol dependence	OLANZAPINE	targetBased	3	Completed	01/09/2002	https://clinicaltrials.gov/study/NCT00746785	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	alcohol dependence	OLANZAPINE	targetBased	3	Completed	01/09/2002	https://clinicaltrials.gov/study/NCT00746785	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	alcohol dependence	OLANZAPINE	targetBased	3	Completed	01/09/2002	https://clinicaltrials.gov/study/NCT00746785	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Agitation	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d5051fbc-846b-4946-82df-341fb1216341	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Agitation	OLANZAPINE	targetBased	4	Terminated	01/09/2017	https://clinicaltrials.gov/study/NCT03246620	1	LoF	protect	The study was terminated prematurely due to difficulties in patient recruitment and associated potential for selection bias.
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Agitation	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=624d55e0-6cee-4366-9490-3b291c777c78	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Agitation	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=71c6577c-ffea-4934-bc10-2d35942f8a16	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Agitation	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=488fa7d5-9207-4efc-9918-6fc206155e7d	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Agitation	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1e9666ef-4271-4834-8496-ccb3125d83db	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Agitation	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=591f9bb1-f119-4739-87b0-de29c9446727	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aff02cff-d079-bc82-6182-a24c4c6e09a6	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a3c9ea17-3793-494a-8b32-44e48f9f4503	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a3c9ea17-3793-494a-8b32-44e48f9f4503	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a3c9ea17-3793-494a-8b32-44e48f9f4503	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a3c9ea17-3793-494a-8b32-44e48f9f4503	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a3c9ea17-3793-494a-8b32-44e48f9f4503	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	OLANZAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a3c9ea17-3793-494a-8b32-44e48f9f4503	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	anxiety	OLANZAPINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	anxiety	OLANZAPINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	anxiety	OLANZAPINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	treatment resistant depression	OLANZAPINE	targetBased	3	Terminated	01/09/2012	https://clinicaltrials.gov/study/NCT01687478	0.35	LoF	protect	Interim assessment: Lack of efficacy
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	treatment resistant depression	OLANZAPINE	targetBased	3	Terminated	01/09/2012	https://clinicaltrials.gov/study/NCT01687478	0.35	LoF	protect	Interim assessment: Lack of efficacy
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	treatment resistant depression	OLANZAPINE	targetBased	3	Terminated	01/09/2012	https://clinicaltrials.gov/study/NCT01687478	0.35	LoF	protect	Interim assessment: Lack of efficacy
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	treatment resistant depression	OLANZAPINE	targetBased	3	Terminated	01/09/2012	https://clinicaltrials.gov/study/NCT01687478	0.35	LoF	protect	Interim assessment: Lack of efficacy
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	treatment resistant depression	OLANZAPINE	targetBased	3	Terminated	01/09/2012	https://clinicaltrials.gov/study/NCT01687478	0.35	LoF	protect	Interim assessment: Lack of efficacy
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	treatment resistant depression	OLANZAPINE	targetBased	3	Terminated	01/09/2012	https://clinicaltrials.gov/study/NCT01687478	0.35	LoF	protect	Interim assessment: Lack of efficacy
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	treatment resistant depression	OLANZAPINE	targetBased	3	Completed	01/08/2009	https://clinicaltrials.gov/study/NCT00958568	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	treatment resistant depression	OLANZAPINE	targetBased	3	Completed	01/08/2009	https://clinicaltrials.gov/study/NCT00958568	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	treatment resistant depression	OLANZAPINE	targetBased	3	Completed	01/08/2009	https://clinicaltrials.gov/study/NCT00958568	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	treatment resistant depression	OLANZAPINE	targetBased	3	Completed	01/08/2009	https://clinicaltrials.gov/study/NCT00958568	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	treatment resistant depression	OLANZAPINE	targetBased	3	Completed	01/08/2009	https://clinicaltrials.gov/study/NCT00958568	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	treatment resistant depression	OLANZAPINE	targetBased	3	Completed	01/08/2009	https://clinicaltrials.gov/study/NCT00958568	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Borderline personality disorder	OLANZAPINE	targetBased	3	Completed	01/02/2004	https://clinicaltrials.gov/study/NCT00088036	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Borderline personality disorder	OLANZAPINE	targetBased	3	Completed	01/02/2004	https://clinicaltrials.gov/study/NCT00088036	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Borderline personality disorder	OLANZAPINE	targetBased	3	Completed	01/02/2004	https://clinicaltrials.gov/study/NCT00088036	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Borderline personality disorder	OLANZAPINE	targetBased	3	Completed	01/02/2004	https://clinicaltrials.gov/study/NCT00088036	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Borderline personality disorder	OLANZAPINE	targetBased	3	Completed	01/03/2004	https://clinicaltrials.gov/study/NCT00091650	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Borderline personality disorder	OLANZAPINE	targetBased	3	Completed	01/03/2004	https://clinicaltrials.gov/study/NCT00091650	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Borderline personality disorder	OLANZAPINE	targetBased	3	Completed	01/03/2004	https://clinicaltrials.gov/study/NCT00091650	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Borderline personality disorder	OLANZAPINE	targetBased	3	Completed	01/03/2004	https://clinicaltrials.gov/study/NCT00091650	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Borderline personality disorder	OLANZAPINE	targetBased	3	Completed	01/03/2004	https://clinicaltrials.gov/study/NCT00091650	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Borderline personality disorder	OLANZAPINE	targetBased	3	Completed	01/03/2004	https://clinicaltrials.gov/study/NCT00091650	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	schizoaffective disorder	OLANZAPINE	targetBased	4	Completed	01/09/2003	https://clinicaltrials.gov/study/NCT00100776	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	schizoaffective disorder	OLANZAPINE	targetBased	4	Completed	01/06/2009	https://clinicaltrials.gov/study/NCT00918021	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	schizoaffective disorder	OLANZAPINE	targetBased	4	Completed	01/06/2009	https://clinicaltrials.gov/study/NCT00918021	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	schizoaffective disorder	OLANZAPINE	targetBased	4	Completed	01/06/2009	https://clinicaltrials.gov/study/NCT00918021	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	schizoaffective disorder	OLANZAPINE	targetBased	4	Completed	01/10/2004	https://clinicaltrials.gov/study/NCT00246259	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	schizoaffective disorder	OLANZAPINE	targetBased	4	Completed	01/10/2004	https://clinicaltrials.gov/study/NCT00246259	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	schizoaffective disorder	OLANZAPINE	targetBased	4	Completed	01/10/2004	https://clinicaltrials.gov/study/NCT00246259	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	delirium	QUETIAPINE	targetBased	3	Unknown status	01/03/2015	https://clinicaltrials.gov/study/NCT02297763	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	delirium	QUETIAPINE	targetBased	3	Terminated	01/06/2009	https://clinicaltrials.gov/study/NCT00954603	0.7	LoF	protect	few delirious patients were enrolled.
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	delirium	QUETIAPINE	targetBased	3	Terminated	13/02/2019	https://clinicaltrials.gov/study/NCT03739476	0.7	LoF	protect	Due to the crisis SARS-COV-2 pandemic: recruitment of patients for the trial is stopped, healthcare pressure generated, suspend the non-essential scheduled surgical activity and on June 30, 2020 medication expired, funding has been exhausted.
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	delirium	QUETIAPINE	targetBased	4	Not yet recruiting	01/03/2025	https://clinicaltrials.gov/study/NCT05085808	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	delirium	QUETIAPINE	targetBased	3	Completed	01/02/2013	https://clinicaltrials.gov/study/NCT01811459	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	generalized anxiety disorder	QUETIAPINE	targetBased	3	Completed	01/04/2006	https://clinicaltrials.gov/study/NCT00329446	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	generalized anxiety disorder	QUETIAPINE	targetBased	3	Completed	01/04/2006	https://clinicaltrials.gov/study/NCT00329264	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	generalized anxiety disorder	QUETIAPINE	targetBased	3	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00322595	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	major depressive disorder	QUETIAPINE	targetBased	4	Completed	01/12/2008	https://clinicaltrials.gov/study/NCT02132286	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	major depressive disorder	QUETIAPINE	targetBased	4	Completed	01/05/2009	https://clinicaltrials.gov/study/NCT00892463	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	major depressive disorder	QUETIAPINE	targetBased	4	Terminated	01/09/2008	https://clinicaltrials.gov/study/NCT00955474	1	LoF	protect	AstraZeneca halted funding; patent expired for Seroquel (Quetiapine) in 2012
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	major depressive disorder	QUETIAPINE	targetBased	4	Unknown status	01/05/2011	https://clinicaltrials.gov/study/NCT01357967	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	major depressive disorder	QUETIAPINE	targetBased	4	Completed	01/04/2006	https://clinicaltrials.gov/study/NCT03207438	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	major depressive disorder	QUETIAPINE	targetBased	3	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00351169	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	major depressive disorder	QUETIAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03517f29-f270-4350-a57a-fbe1967b0096	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	post-traumatic stress disorder	QUETIAPINE	targetBased	4	Completed	01/01/2006	https://clinicaltrials.gov/study/NCT00292370	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	post-traumatic stress disorder	QUETIAPINE	targetBased	3	Completed	01/12/2004	https://clinicaltrials.gov/study/NCT00306540	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	post-traumatic stress disorder	QUETIAPINE	targetBased	4	Completed	01/08/2003	https://clinicaltrials.gov/study/NCT00237393	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	unipolar depression	QUETIAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=51927f2e-3d56-4644-a6a8-40e0b9a5b579	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	unipolar depression	QUETIAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7e37e999-f225-4d0a-b16d-37ac14ff29da	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	unipolar depression	QUETIAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2a74e8a0-b2fd-4d7f-8bf8-72148b1d3ae7	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	unipolar depression	QUETIAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=473a3ac4-67f4-4782-baa9-7f9bdd8761f4	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	unipolar depression	QUETIAPINE	targetBased	3	Completed	01/09/2007	https://clinicaltrials.gov/study/NCT00517387	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	neurotic disorder	QUETIAPINE	targetBased	3	Completed	01/08/2007	https://clinicaltrials.gov/study/NCT00534599	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	neurotic disorder	QUETIAPINE	targetBased	3	Completed	01/08/2007	https://clinicaltrials.gov/study/NCT00534599	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	neurotic disorder	QUETIAPINE	targetBased	3	Completed	01/08/2007	https://clinicaltrials.gov/study/NCT00534599	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	neurotic disorder	QUETIAPINE	targetBased	3	Completed	01/08/2007	https://clinicaltrials.gov/study/NCT00534599	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	neurotic disorder	QUETIAPINE	targetBased	3	Completed	01/08/2007	https://clinicaltrials.gov/study/NCT00534599	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	neurotic disorder	QUETIAPINE	targetBased	3	Completed	01/08/2007	https://clinicaltrials.gov/study/NCT00534599	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	delirium	QUETIAPINE	targetBased	3	Terminated	01/06/2009	https://clinicaltrials.gov/study/NCT00954603	0.7	LoF	protect	few delirious patients were enrolled.
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	delirium	QUETIAPINE	targetBased	4	Not yet recruiting	01/03/2025	https://clinicaltrials.gov/study/NCT05085808	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	delirium	QUETIAPINE	targetBased	4	Not yet recruiting	01/03/2025	https://clinicaltrials.gov/study/NCT05085808	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	delirium	QUETIAPINE	targetBased	4	Not yet recruiting	01/03/2025	https://clinicaltrials.gov/study/NCT05085808	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	delirium	QUETIAPINE	targetBased	4	Not yet recruiting	01/03/2025	https://clinicaltrials.gov/study/NCT05085808	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	delirium	QUETIAPINE	targetBased	4	Not yet recruiting	01/03/2025	https://clinicaltrials.gov/study/NCT05085808	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	delirium	QUETIAPINE	targetBased	4	Not yet recruiting	01/03/2025	https://clinicaltrials.gov/study/NCT05085808	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	obsessive-compulsive disorder	QUETIAPINE	targetBased	4	Completed	01/05/2007	https://clinicaltrials.gov/study/NCT00466609	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	obsessive-compulsive disorder	QUETIAPINE	targetBased	4	Completed	01/01/2006	https://clinicaltrials.gov/study/NCT00564564	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	obsessive-compulsive disorder	QUETIAPINE	targetBased	3	Completed	01/04/2002	https://clinicaltrials.gov/study/NCT00254735	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Borderline personality disorder	QUETIAPINE	targetBased	3	Completed	01/06/2008	https://clinicaltrials.gov/study/NCT00880919	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Borderline personality disorder	QUETIAPINE	targetBased	3	Completed	01/05/2005	https://clinicaltrials.gov/study/NCT00122070	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	QUETIAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=577a9332-e340-451f-ac45-350333562fd7	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	obsessive-compulsive disorder	QUETIAPINE	targetBased	4	Completed	01/05/2007	https://clinicaltrials.gov/study/NCT00466609	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	obsessive-compulsive disorder	QUETIAPINE	targetBased	4	Completed	01/01/2006	https://clinicaltrials.gov/study/NCT00564564	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	obsessive-compulsive disorder	QUETIAPINE	targetBased	4	Completed	01/01/2006	https://clinicaltrials.gov/study/NCT00564564	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	obsessive-compulsive disorder	QUETIAPINE	targetBased	4	Completed	01/01/2006	https://clinicaltrials.gov/study/NCT00564564	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	obsessive-compulsive disorder	QUETIAPINE	targetBased	4	Completed	01/01/2006	https://clinicaltrials.gov/study/NCT00564564	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	obsessive-compulsive disorder	QUETIAPINE	targetBased	4	Completed	01/01/2006	https://clinicaltrials.gov/study/NCT00564564	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	obsessive-compulsive disorder	QUETIAPINE	targetBased	4	Completed	01/01/2006	https://clinicaltrials.gov/study/NCT00564564	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	QUETIAPINE	targetBased	4	Completed	01/03/2004	https://clinicaltrials.gov/study/NCT00156715	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	QUETIAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7e37e999-f225-4d0a-b16d-37ac14ff29da	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	QUETIAPINE	targetBased	4	Unknown status	01/10/2009	https://clinicaltrials.gov/study/NCT00986167	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	QUETIAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=daec35ae-a9e7-494a-90a6-c8aff1c65c71	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	QUETIAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b007bac6-a207-481c-8aba-03ade1dd6a88	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	QUETIAPINE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar disorder	QUETIAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3ea59594-8a2b-4b64-9aa8-1d53d9027bb0	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	bipolar disorder	QUETIAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aaf50e8a-3c8e-4b19-b539-0384a9b1a707	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	bipolar disorder	QUETIAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aaf50e8a-3c8e-4b19-b539-0384a9b1a707	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar disorder	QUETIAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aaf50e8a-3c8e-4b19-b539-0384a9b1a707	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar disorder	QUETIAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aaf50e8a-3c8e-4b19-b539-0384a9b1a707	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar disorder	QUETIAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aaf50e8a-3c8e-4b19-b539-0384a9b1a707	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar disorder	QUETIAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aaf50e8a-3c8e-4b19-b539-0384a9b1a707	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	alcohol dependence	QUETIAPINE	targetBased	3	Completed	01/03/2003	https://clinicaltrials.gov/study/NCT00124059	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	alcohol dependence	QUETIAPINE	targetBased	3	Completed	01/01/2006	https://clinicaltrials.gov/study/NCT00114686	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar II disorder	QUETIAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03517f29-f270-4350-a57a-fbe1967b0096	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar II disorder	QUETIAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45c4c3a4-3acc-413e-9746-4816d513fac6	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	drug dependence	QUETIAPINE	targetBased	4	Completed	01/10/2003	https://clinicaltrials.gov/study/NCT00232336	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	drug dependence	QUETIAPINE	targetBased	4	Completed		https://clinicaltrials.gov/study/NCT00295412	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	drug dependence	QUETIAPINE	targetBased	4	Completed		https://clinicaltrials.gov/study/NCT00295412	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	drug dependence	QUETIAPINE	targetBased	4	Completed		https://clinicaltrials.gov/study/NCT00295412	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	drug dependence	QUETIAPINE	targetBased	4	Completed		https://clinicaltrials.gov/study/NCT00295412	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	drug dependence	QUETIAPINE	targetBased	4	Completed		https://clinicaltrials.gov/study/NCT00295412	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	drug dependence	QUETIAPINE	targetBased	4	Completed		https://clinicaltrials.gov/study/NCT00295412	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	drug dependence	QUETIAPINE	targetBased	4	Completed	01/10/2003	https://clinicaltrials.gov/study/NCT00232336	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	drug dependence	QUETIAPINE	targetBased	4	Completed		https://clinicaltrials.gov/study/NCT00295412	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	mental or behavioural disorder	QUETIAPINE	targetBased	4	Completed	01/02/2003	https://clinicaltrials.gov/study/NCT00932529	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	mental or behavioural disorder	QUETIAPINE	targetBased	4	Completed	01/10/2005	https://clinicaltrials.gov/study/NCT02305823	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	mental or behavioural disorder	QUETIAPINE	targetBased	4	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT00806234	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	mental or behavioural disorder	QUETIAPINE	targetBased	4	Completed	01/10/2008	https://clinicaltrials.gov/study/NCT02526030	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	mental or behavioural disorder	QUETIAPINE	targetBased	3	Completed	01/10/2004	https://clinicaltrials.gov/study/NCT00254813	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	treatment resistant depression	QUETIAPINE	targetBased	4	Recruiting	07/08/2021	https://clinicaltrials.gov/study/NCT04936126	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	treatment resistant depression	QUETIAPINE	targetBased	3	Completed	01/11/2008	https://clinicaltrials.gov/study/NCT00789854	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Dementia	QUETIAPINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Dementia	QUETIAPINE	targetBased	3	Terminated	01/05/2006	https://clinicaltrials.gov/study/NCT00315900	0.7	LoF	protect	Investigator closed study and left VAMC.
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	major depressive disorder	QUETIAPINE	targetBased	4	Completed	01/04/2006	https://clinicaltrials.gov/study/NCT03207438	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	major depressive disorder	QUETIAPINE	targetBased	4	Completed	01/12/2008	https://clinicaltrials.gov/study/NCT02132286	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	major depressive disorder	QUETIAPINE	targetBased	4	Completed	01/12/2008	https://clinicaltrials.gov/study/NCT02132286	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	major depressive disorder	QUETIAPINE	targetBased	4	Completed	01/12/2008	https://clinicaltrials.gov/study/NCT02132286	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	major depressive disorder	QUETIAPINE	targetBased	4	Completed	01/12/2008	https://clinicaltrials.gov/study/NCT02132286	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	major depressive disorder	QUETIAPINE	targetBased	4	Completed	01/12/2008	https://clinicaltrials.gov/study/NCT02132286	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	major depressive disorder	QUETIAPINE	targetBased	4	Completed	01/12/2008	https://clinicaltrials.gov/study/NCT02132286	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar II disorder	QUETIAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45c4c3a4-3acc-413e-9746-4816d513fac6	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	bipolar II disorder	QUETIAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03517f29-f270-4350-a57a-fbe1967b0096	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	bipolar II disorder	QUETIAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03517f29-f270-4350-a57a-fbe1967b0096	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar II disorder	QUETIAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03517f29-f270-4350-a57a-fbe1967b0096	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar II disorder	QUETIAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03517f29-f270-4350-a57a-fbe1967b0096	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar II disorder	QUETIAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03517f29-f270-4350-a57a-fbe1967b0096	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar II disorder	QUETIAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03517f29-f270-4350-a57a-fbe1967b0096	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	post-traumatic stress disorder	QUETIAPINE	targetBased	4	Completed	01/01/2006	https://clinicaltrials.gov/study/NCT00292370	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	post-traumatic stress disorder	QUETIAPINE	targetBased	4	Completed	01/08/2003	https://clinicaltrials.gov/study/NCT00237393	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	post-traumatic stress disorder	QUETIAPINE	targetBased	4	Completed	01/08/2003	https://clinicaltrials.gov/study/NCT00237393	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	post-traumatic stress disorder	QUETIAPINE	targetBased	4	Completed	01/08/2003	https://clinicaltrials.gov/study/NCT00237393	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	post-traumatic stress disorder	QUETIAPINE	targetBased	4	Completed	01/08/2003	https://clinicaltrials.gov/study/NCT00237393	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	post-traumatic stress disorder	QUETIAPINE	targetBased	4	Completed	01/08/2003	https://clinicaltrials.gov/study/NCT00237393	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	post-traumatic stress disorder	QUETIAPINE	targetBased	4	Completed	01/08/2003	https://clinicaltrials.gov/study/NCT00237393	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	depressive disorder	QUETIAPINE	targetBased	4	Terminated	01/07/2009	https://clinicaltrials.gov/study/NCT01305707	1	LoF	protect	Difficulties in recruiting
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	depressive disorder	QUETIAPINE	targetBased	4	Unknown status	01/11/2016	https://clinicaltrials.gov/study/NCT03004521	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	depressive disorder	QUETIAPINE	targetBased	4	Unknown status	01/11/2016	https://clinicaltrials.gov/study/NCT03004521	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	depressive disorder	QUETIAPINE	targetBased	4	Unknown status	01/11/2016	https://clinicaltrials.gov/study/NCT03004521	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	depressive disorder	QUETIAPINE	targetBased	4	Unknown status	01/11/2016	https://clinicaltrials.gov/study/NCT03004521	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	depressive disorder	QUETIAPINE	targetBased	4	Unknown status	01/11/2016	https://clinicaltrials.gov/study/NCT03004521	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	depressive disorder	QUETIAPINE	targetBased	4	Unknown status	01/11/2016	https://clinicaltrials.gov/study/NCT03004521	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	alcohol abuse	QUETIAPINE	targetBased	4	Completed	01/03/2004	https://clinicaltrials.gov/study/NCT00156715	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	unipolar depression	QUETIAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=473a3ac4-67f4-4782-baa9-7f9bdd8761f4	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	unipolar depression	QUETIAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7e37e999-f225-4d0a-b16d-37ac14ff29da	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	unipolar depression	QUETIAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7e37e999-f225-4d0a-b16d-37ac14ff29da	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	unipolar depression	QUETIAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7e37e999-f225-4d0a-b16d-37ac14ff29da	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	unipolar depression	QUETIAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7e37e999-f225-4d0a-b16d-37ac14ff29da	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	unipolar depression	QUETIAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7e37e999-f225-4d0a-b16d-37ac14ff29da	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	unipolar depression	QUETIAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7e37e999-f225-4d0a-b16d-37ac14ff29da	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	anxiety	QUETIAPINE	targetBased	4	Completed	01/02/2004	https://clinicaltrials.gov/study/NCT00113295	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	anxiety	QUETIAPINE	targetBased	4	Completed	01/02/2004	https://clinicaltrials.gov/study/NCT00113295	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	anxiety	QUETIAPINE	targetBased	4	Completed	01/02/2004	https://clinicaltrials.gov/study/NCT00113295	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	anxiety	QUETIAPINE	targetBased	4	Completed	01/02/2004	https://clinicaltrials.gov/study/NCT00113295	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	anxiety	QUETIAPINE	targetBased	4	Completed	01/02/2004	https://clinicaltrials.gov/study/NCT00113295	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	anxiety	QUETIAPINE	targetBased	4	Completed	01/02/2004	https://clinicaltrials.gov/study/NCT00113295	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	anxiety	QUETIAPINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	cocaine dependence	QUETIAPINE	targetBased	4	Completed	01/10/2003	https://clinicaltrials.gov/study/NCT00232336	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	panic disorder	QUETIAPINE	targetBased	4	Completed	01/02/2008	https://clinicaltrials.gov/study/NCT00619892	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Agitation	QUETIAPINE	targetBased	4	Completed	01/11/2013	https://clinicaltrials.gov/study/NCT02612948	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Agitation	QUETIAPINE	targetBased	4	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00457366	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Agitation	QUETIAPINE	targetBased	4	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00457366	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Agitation	QUETIAPINE	targetBased	4	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00457366	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Agitation	QUETIAPINE	targetBased	4	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00457366	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Agitation	QUETIAPINE	targetBased	4	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00457366	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Agitation	QUETIAPINE	targetBased	4	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00457366	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizoaffective disorder	QUETIAPINE	targetBased	4	Completed	01/09/2001	https://clinicaltrials.gov/study/NCT00515723	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizoaffective disorder	QUETIAPINE	targetBased	4	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00208143	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizoaffective disorder	QUETIAPINE	targetBased	4	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00208143	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizoaffective disorder	QUETIAPINE	targetBased	4	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00208143	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizoaffective disorder	QUETIAPINE	targetBased	4	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00208143	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizoaffective disorder	QUETIAPINE	targetBased	4	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00208143	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizoaffective disorder	QUETIAPINE	targetBased	4	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00208143	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	panic disorder	QUETIAPINE	targetBased	4	Completed	01/02/2008	https://clinicaltrials.gov/study/NCT00619892	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	panic disorder	QUETIAPINE	targetBased	4	Completed	01/02/2008	https://clinicaltrials.gov/study/NCT00619892	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	panic disorder	QUETIAPINE	targetBased	4	Completed	01/02/2008	https://clinicaltrials.gov/study/NCT00619892	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	panic disorder	QUETIAPINE	targetBased	4	Completed	01/02/2008	https://clinicaltrials.gov/study/NCT00619892	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	panic disorder	QUETIAPINE	targetBased	4	Completed	01/02/2008	https://clinicaltrials.gov/study/NCT00619892	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	panic disorder	QUETIAPINE	targetBased	4	Completed	01/02/2008	https://clinicaltrials.gov/study/NCT00619892	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar I disorder	QUETIAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2a74e8a0-b2fd-4d7f-8bf8-72148b1d3ae7	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar I disorder	QUETIAPINE	targetBased	3	Terminated	01/04/2009	https://clinicaltrials.gov/study/NCT00857818	0.7	LoF	protect	Slow Accrual
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar I disorder	QUETIAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03517f29-f270-4350-a57a-fbe1967b0096	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar I disorder	QUETIAPINE	targetBased	3	Completed	01/10/2005	https://clinicaltrials.gov/study/NCT00232414	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar I disorder	QUETIAPINE	targetBased	3	Completed	01/04/2004	https://clinicaltrials.gov/study/NCT00107731	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar I disorder	QUETIAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45c4c3a4-3acc-413e-9746-4816d513fac6	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar I disorder	QUETIAPINE	targetBased	4	Completed	01/06/2011	https://clinicaltrials.gov/study/NCT01588457	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar I disorder	QUETIAPINE	targetBased	3	Completed	01/08/2004	https://clinicaltrials.gov/study/NCT00227305	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	QUETIAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=56eaafad-52a5-4295-85fc-b59d63819ca3	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	QUETIAPINE	targetBased	4	Terminated	01/06/2010	https://clinicaltrials.gov/study/NCT01128114	1	LoF	protect	Poor recruitment
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	QUETIAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6173e1ce-0a85-40b0-99f0-1a6d78e67198	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	QUETIAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=904f80af-44b6-d964-1680-ac9e6b61327b	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	QUETIAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9737dd88-4700-457d-b596-8f56330232ed	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	QUETIAPINE	targetBased	4	Completed	01/08/2002	https://clinicaltrials.gov/study/NCT00048802	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	QUETIAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3e482854-45ac-4de9-88a3-e5f70dbdc57b	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	QUETIAPINE	targetBased	4	Completed	01/02/2003	https://clinicaltrials.gov/study/NCT00932529	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	QUETIAPINE	targetBased	4	Completed	01/10/2005	https://clinicaltrials.gov/study/NCT02305823	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	QUETIAPINE	targetBased	4	Completed	01/10/2005	https://clinicaltrials.gov/study/NCT02305823	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	mental or behavioural disorder	QUETIAPINE	targetBased	4	Completed	01/10/2005	https://clinicaltrials.gov/study/NCT02305823	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	mental or behavioural disorder	QUETIAPINE	targetBased	4	Completed	01/10/2005	https://clinicaltrials.gov/study/NCT02305823	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	QUETIAPINE	targetBased	4	Completed	01/10/2005	https://clinicaltrials.gov/study/NCT02305823	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	QUETIAPINE	targetBased	4	Completed	01/10/2005	https://clinicaltrials.gov/study/NCT02305823	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	substance dependence	QUETIAPINE	targetBased	4	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00208143	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	substance dependence	QUETIAPINE	targetBased	4	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00208143	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	substance dependence	QUETIAPINE	targetBased	4	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00208143	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	substance dependence	QUETIAPINE	targetBased	4	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00208143	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	substance dependence	QUETIAPINE	targetBased	4	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00208143	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	substance dependence	QUETIAPINE	targetBased	4	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00208143	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	generalized anxiety disorder	QUETIAPINE	targetBased	3	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00322595	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	generalized anxiety disorder	QUETIAPINE	targetBased	3	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00322595	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	generalized anxiety disorder	QUETIAPINE	targetBased	3	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00322595	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	generalized anxiety disorder	QUETIAPINE	targetBased	3	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00322595	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	generalized anxiety disorder	QUETIAPINE	targetBased	3	Completed	01/04/2006	https://clinicaltrials.gov/study/NCT00329446	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	generalized anxiety disorder	QUETIAPINE	targetBased	3	Completed	01/04/2006	https://clinicaltrials.gov/study/NCT00329446	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	generalized anxiety disorder	QUETIAPINE	targetBased	3	Completed	01/04/2006	https://clinicaltrials.gov/study/NCT00329446	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	generalized anxiety disorder	QUETIAPINE	targetBased	3	Completed	01/04/2006	https://clinicaltrials.gov/study/NCT00329446	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	generalized anxiety disorder	QUETIAPINE	targetBased	3	Completed	01/04/2006	https://clinicaltrials.gov/study/NCT00329446	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	generalized anxiety disorder	QUETIAPINE	targetBased	3	Completed	01/04/2006	https://clinicaltrials.gov/study/NCT00329446	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	psychosis	QUETIAPINE	targetBased	4	Unknown status	01/05/2010	https://clinicaltrials.gov/study/NCT01119014	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	psychosis	QUETIAPINE	targetBased	3	Completed	01/07/2003	https://clinicaltrials.gov/study/NCT00449397	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	psychosis	QUETIAPINE	targetBased	4	Terminated	01/07/2013	https://clinicaltrials.gov/study/NCT01844700	0.5	LoF	protect	very slow recruitment, no sufficient results
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	psychosis	QUETIAPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AH04	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	substance abuse	QUETIAPINE	targetBased	4	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00208143	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	substance abuse	QUETIAPINE	targetBased	4	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00208143	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	substance abuse	QUETIAPINE	targetBased	4	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00208143	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	substance abuse	QUETIAPINE	targetBased	4	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00208143	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	substance abuse	QUETIAPINE	targetBased	4	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00208143	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	substance abuse	QUETIAPINE	targetBased	4	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00208143	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	neurotic disorder	QUETIAPINE	targetBased	3	Completed	01/08/2007	https://clinicaltrials.gov/study/NCT00534599	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizoaffective disorder	QUETIAPINE	targetBased	4	Completed	01/01/2007	https://clinicaltrials.gov/study/NCT00423878	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizoaffective disorder	QUETIAPINE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizoaffective disorder	QUETIAPINE	targetBased	4	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00208143	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizoaffective disorder	QUETIAPINE	targetBased	4	Completed	01/07/2004	https://clinicaltrials.gov/study/NCT00090012	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizoaffective disorder	QUETIAPINE	targetBased	4	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00330863	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizoaffective disorder	QUETIAPINE	targetBased	4	Completed	21/05/2018	https://clinicaltrials.gov/study/NCT03568500	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizoaffective disorder	QUETIAPINE	targetBased	4	Completed	01/10/2004	https://clinicaltrials.gov/study/NCT00246259	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	substance dependence	QUETIAPINE	targetBased	4	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00208143	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	depressive disorder	QUETIAPINE	targetBased	4	Completed	01/04/2007	https://clinicaltrials.gov/study/NCT00675896	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	depressive disorder	QUETIAPINE	targetBased	4	Completed	01/04/2008	https://clinicaltrials.gov/study/NCT00253266	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	depressive disorder	QUETIAPINE	targetBased	4	Completed	01/09/2008	https://clinicaltrials.gov/study/NCT01200901	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	depressive disorder	QUETIAPINE	targetBased	4	Terminated	01/07/2009	https://clinicaltrials.gov/study/NCT01305707	1	LoF	protect	Difficulties in recruiting
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	depressive disorder	QUETIAPINE	targetBased	4	Unknown status	01/11/2016	https://clinicaltrials.gov/study/NCT03004521	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	depressive disorder	QUETIAPINE	targetBased	4	Completed	01/08/2010	https://clinicaltrials.gov/study/NCT01133821	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	depressive disorder	QUETIAPINE	targetBased	4	Completed	01/03/2009	https://clinicaltrials.gov/study/NCT00982345	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	QUETIAPINE	targetBased	4	Unknown status	01/05/2010	https://clinicaltrials.gov/study/NCT01119014	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	psychosis	QUETIAPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AH04	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	psychosis	QUETIAPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AH04	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	psychosis	QUETIAPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AH04	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	psychosis	QUETIAPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AH04	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	QUETIAPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AH04	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	QUETIAPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AH04	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	anxiety	QUETIAPINE	targetBased	3	Completed	01/09/2006	https://clinicaltrials.gov/study/NCT00389064	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	anxiety	QUETIAPINE	targetBased	3	Completed	01/03/2006	https://clinicaltrials.gov/study/NCT00314210	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	anxiety	QUETIAPINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	anxiety	QUETIAPINE	targetBased	3	Completed	01/08/2007	https://clinicaltrials.gov/study/NCT00534599	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	anxiety	QUETIAPINE	targetBased	4	Completed	01/02/2004	https://clinicaltrials.gov/study/NCT00113295	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	substance abuse	QUETIAPINE	targetBased	4	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00208143	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	mood disorder	QUETIAPINE	targetBased	3	Completed	01/04/2006	https://clinicaltrials.gov/study/NCT00309699	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	mood disorder	QUETIAPINE	targetBased	3	Completed	01/06/2003	https://clinicaltrials.gov/study/NCT00221468	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	cocaine dependence	QUETIAPINE	targetBased	4	Completed	01/10/2003	https://clinicaltrials.gov/study/NCT00232336	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	cocaine dependence	QUETIAPINE	targetBased	4	Completed	01/10/2003	https://clinicaltrials.gov/study/NCT00232336	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	cocaine dependence	QUETIAPINE	targetBased	4	Completed	01/10/2003	https://clinicaltrials.gov/study/NCT00232336	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	cocaine dependence	QUETIAPINE	targetBased	4	Completed	01/10/2003	https://clinicaltrials.gov/study/NCT00232336	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	cocaine dependence	QUETIAPINE	targetBased	4	Completed	01/10/2003	https://clinicaltrials.gov/study/NCT00232336	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	cocaine dependence	QUETIAPINE	targetBased	4	Completed	01/10/2003	https://clinicaltrials.gov/study/NCT00232336	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Dementia	QUETIAPINE	targetBased	3	Terminated	01/05/2006	https://clinicaltrials.gov/study/NCT00315900	0.7	LoF	protect	Investigator closed study and left VAMC.
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Dementia	QUETIAPINE	targetBased	3	Terminated	01/05/2006	https://clinicaltrials.gov/study/NCT00315900	0.7	LoF	protect	Investigator closed study and left VAMC.
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Dementia	QUETIAPINE	targetBased	3	Terminated	01/05/2006	https://clinicaltrials.gov/study/NCT00315900	0.7	LoF	protect	Investigator closed study and left VAMC.
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Dementia	QUETIAPINE	targetBased	3	Terminated	01/05/2006	https://clinicaltrials.gov/study/NCT00315900	0.7	LoF	protect	Investigator closed study and left VAMC.
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Dementia	QUETIAPINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Dementia	QUETIAPINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Dementia	QUETIAPINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Dementia	QUETIAPINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Dementia	QUETIAPINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Dementia	QUETIAPINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	mood disorder	QUETIAPINE	targetBased	3	Completed	01/04/2006	https://clinicaltrials.gov/study/NCT00309699	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	mood disorder	QUETIAPINE	targetBased	3	Completed	01/04/2006	https://clinicaltrials.gov/study/NCT00309699	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	mood disorder	QUETIAPINE	targetBased	3	Completed	01/04/2006	https://clinicaltrials.gov/study/NCT00309699	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	mood disorder	QUETIAPINE	targetBased	3	Completed	01/04/2006	https://clinicaltrials.gov/study/NCT00309699	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	mood disorder	QUETIAPINE	targetBased	3	Completed	01/06/2003	https://clinicaltrials.gov/study/NCT00221468	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	mood disorder	QUETIAPINE	targetBased	3	Completed	01/06/2003	https://clinicaltrials.gov/study/NCT00221468	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	mood disorder	QUETIAPINE	targetBased	3	Completed	01/06/2003	https://clinicaltrials.gov/study/NCT00221468	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	mood disorder	QUETIAPINE	targetBased	3	Completed	01/06/2003	https://clinicaltrials.gov/study/NCT00221468	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	mood disorder	QUETIAPINE	targetBased	3	Completed	01/06/2003	https://clinicaltrials.gov/study/NCT00221468	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	mood disorder	QUETIAPINE	targetBased	3	Completed	01/06/2003	https://clinicaltrials.gov/study/NCT00221468	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar I disorder	QUETIAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2a74e8a0-b2fd-4d7f-8bf8-72148b1d3ae7	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	bipolar I disorder	QUETIAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45c4c3a4-3acc-413e-9746-4816d513fac6	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	bipolar I disorder	QUETIAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45c4c3a4-3acc-413e-9746-4816d513fac6	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar I disorder	QUETIAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45c4c3a4-3acc-413e-9746-4816d513fac6	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar I disorder	QUETIAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45c4c3a4-3acc-413e-9746-4816d513fac6	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar I disorder	QUETIAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45c4c3a4-3acc-413e-9746-4816d513fac6	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar I disorder	QUETIAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45c4c3a4-3acc-413e-9746-4816d513fac6	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	alcohol dependence	QUETIAPINE	targetBased	3	Completed	01/03/2003	https://clinicaltrials.gov/study/NCT00124059	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	alcohol dependence	QUETIAPINE	targetBased	3	Completed	01/03/2003	https://clinicaltrials.gov/study/NCT00124059	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	alcohol dependence	QUETIAPINE	targetBased	3	Completed	01/03/2003	https://clinicaltrials.gov/study/NCT00124059	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	alcohol dependence	QUETIAPINE	targetBased	3	Completed	01/03/2003	https://clinicaltrials.gov/study/NCT00124059	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	alcohol dependence	QUETIAPINE	targetBased	3	Completed	01/01/2006	https://clinicaltrials.gov/study/NCT00114686	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	alcohol dependence	QUETIAPINE	targetBased	3	Completed	01/01/2006	https://clinicaltrials.gov/study/NCT00114686	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	alcohol dependence	QUETIAPINE	targetBased	3	Completed	01/01/2006	https://clinicaltrials.gov/study/NCT00114686	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	alcohol dependence	QUETIAPINE	targetBased	3	Completed	01/01/2006	https://clinicaltrials.gov/study/NCT00114686	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	alcohol dependence	QUETIAPINE	targetBased	3	Completed	01/01/2006	https://clinicaltrials.gov/study/NCT00114686	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	alcohol dependence	QUETIAPINE	targetBased	3	Completed	01/01/2006	https://clinicaltrials.gov/study/NCT00114686	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	alcohol abuse	QUETIAPINE	targetBased	4	Completed	01/03/2004	https://clinicaltrials.gov/study/NCT00156715	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	alcohol abuse	QUETIAPINE	targetBased	4	Completed	01/03/2004	https://clinicaltrials.gov/study/NCT00156715	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	alcohol abuse	QUETIAPINE	targetBased	4	Completed	01/03/2004	https://clinicaltrials.gov/study/NCT00156715	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	alcohol abuse	QUETIAPINE	targetBased	4	Completed	01/03/2004	https://clinicaltrials.gov/study/NCT00156715	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	alcohol abuse	QUETIAPINE	targetBased	4	Completed	01/03/2004	https://clinicaltrials.gov/study/NCT00156715	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	alcohol abuse	QUETIAPINE	targetBased	4	Completed	01/03/2004	https://clinicaltrials.gov/study/NCT00156715	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Agitation	QUETIAPINE	targetBased	3	Completed	01/09/2002	https://clinicaltrials.gov/study/NCT00621647	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Agitation	QUETIAPINE	targetBased	3	Terminated	01/05/2006	https://clinicaltrials.gov/study/NCT00315900	0.7	LoF	protect	Investigator closed study and left VAMC.
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Agitation	QUETIAPINE	targetBased	4	Completed	01/11/2013	https://clinicaltrials.gov/study/NCT02612948	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Agitation	QUETIAPINE	targetBased	4	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00457366	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	QUETIAPINE	targetBased	4	Completed	01/09/2009	https://clinicaltrials.gov/study/NCT00954122	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	QUETIAPINE	targetBased	4	Completed	01/12/2000	https://clinicaltrials.gov/study/NCT00014001	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	QUETIAPINE	targetBased	4	Completed	01/12/2000	https://clinicaltrials.gov/study/NCT00014001	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	QUETIAPINE	targetBased	4	Completed	01/12/2000	https://clinicaltrials.gov/study/NCT00014001	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	QUETIAPINE	targetBased	4	Completed	01/12/2000	https://clinicaltrials.gov/study/NCT00014001	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	QUETIAPINE	targetBased	4	Completed	01/12/2000	https://clinicaltrials.gov/study/NCT00014001	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	QUETIAPINE	targetBased	4	Completed	01/12/2000	https://clinicaltrials.gov/study/NCT00014001	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	social anxiety disorder	QUETIAPINE	targetBased	4	Completed	01/12/2006	https://clinicaltrials.gov/study/NCT00407199	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	social anxiety disorder	QUETIAPINE	targetBased	4	Completed	01/03/2006	https://clinicaltrials.gov/study/NCT01224067	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	social anxiety disorder	QUETIAPINE	targetBased	4	Completed	01/03/2006	https://clinicaltrials.gov/study/NCT01224067	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	social anxiety disorder	QUETIAPINE	targetBased	4	Completed	01/03/2006	https://clinicaltrials.gov/study/NCT01224067	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	social anxiety disorder	QUETIAPINE	targetBased	4	Completed	01/03/2006	https://clinicaltrials.gov/study/NCT01224067	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	social anxiety disorder	QUETIAPINE	targetBased	4	Completed	01/03/2006	https://clinicaltrials.gov/study/NCT01224067	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	social anxiety disorder	QUETIAPINE	targetBased	4	Completed	01/03/2006	https://clinicaltrials.gov/study/NCT01224067	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	treatment resistant depression	QUETIAPINE	targetBased	4	Recruiting	07/08/2021	https://clinicaltrials.gov/study/NCT04936126	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	treatment resistant depression	QUETIAPINE	targetBased	4	Recruiting	07/08/2021	https://clinicaltrials.gov/study/NCT04936126	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	treatment resistant depression	QUETIAPINE	targetBased	4	Recruiting	07/08/2021	https://clinicaltrials.gov/study/NCT04936126	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	treatment resistant depression	QUETIAPINE	targetBased	4	Recruiting	07/08/2021	https://clinicaltrials.gov/study/NCT04936126	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	treatment resistant depression	QUETIAPINE	targetBased	4	Recruiting	07/08/2021	https://clinicaltrials.gov/study/NCT04936126	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	treatment resistant depression	QUETIAPINE	targetBased	4	Recruiting	07/08/2021	https://clinicaltrials.gov/study/NCT04936126	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	treatment resistant depression	QUETIAPINE	targetBased	3	Completed	01/11/2008	https://clinicaltrials.gov/study/NCT00789854	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Borderline personality disorder	QUETIAPINE	targetBased	3	Completed	01/05/2005	https://clinicaltrials.gov/study/NCT00122070	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Borderline personality disorder	QUETIAPINE	targetBased	3	Completed	01/05/2005	https://clinicaltrials.gov/study/NCT00122070	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Borderline personality disorder	QUETIAPINE	targetBased	3	Completed	01/05/2005	https://clinicaltrials.gov/study/NCT00122070	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Borderline personality disorder	QUETIAPINE	targetBased	3	Completed	01/05/2005	https://clinicaltrials.gov/study/NCT00122070	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Borderline personality disorder	QUETIAPINE	targetBased	3	Completed	01/06/2008	https://clinicaltrials.gov/study/NCT00880919	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Borderline personality disorder	QUETIAPINE	targetBased	3	Completed	01/06/2008	https://clinicaltrials.gov/study/NCT00880919	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Borderline personality disorder	QUETIAPINE	targetBased	3	Completed	01/06/2008	https://clinicaltrials.gov/study/NCT00880919	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Borderline personality disorder	QUETIAPINE	targetBased	3	Completed	01/06/2008	https://clinicaltrials.gov/study/NCT00880919	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Borderline personality disorder	QUETIAPINE	targetBased	3	Completed	01/06/2008	https://clinicaltrials.gov/study/NCT00880919	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Borderline personality disorder	QUETIAPINE	targetBased	3	Completed	01/06/2008	https://clinicaltrials.gov/study/NCT00880919	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	social anxiety disorder	QUETIAPINE	targetBased	3	Terminated	01/06/2006	https://clinicaltrials.gov/study/NCT00302770	0.7	LoF	protect	This study was terminated due to poor enrollment
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	social anxiety disorder	QUETIAPINE	targetBased	4	Completed	01/12/2006	https://clinicaltrials.gov/study/NCT00407199	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	social anxiety disorder	QUETIAPINE	targetBased	4	Completed	01/03/2006	https://clinicaltrials.gov/study/NCT01224067	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	social anxiety disorder	QUETIAPINE	targetBased	3	Completed	01/10/2008	https://clinicaltrials.gov/study/NCT00773162	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	depressive disorder	BROMPERIDOL	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	depressive disorder	BROMPERIDOL	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	depressive disorder	BROMPERIDOL	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	depressive disorder	BROMPERIDOL	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	depressive disorder	BROMPERIDOL	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	depressive disorder	BROMPERIDOL	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	anxiety	BROMPERIDOL	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	anxiety	BROMPERIDOL	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	anxiety	BROMPERIDOL	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	anxiety	BROMPERIDOL	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	anxiety	BROMPERIDOL	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	anxiety	BROMPERIDOL	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizoaffective disorder	BROMPERIDOL	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizoaffective disorder	BROMPERIDOL	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizoaffective disorder	BROMPERIDOL	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizoaffective disorder	BROMPERIDOL	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizoaffective disorder	BROMPERIDOL	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizoaffective disorder	BROMPERIDOL	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	psychosis	BROMPERIDOL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AD06	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	psychosis	BROMPERIDOL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AD06	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	psychosis	BROMPERIDOL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AD06	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	psychosis	BROMPERIDOL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AD06	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	BROMPERIDOL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AD06	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	BROMPERIDOL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AD06	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Dementia	BROMPERIDOL	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Dementia	BROMPERIDOL	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Dementia	BROMPERIDOL	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Dementia	BROMPERIDOL	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Dementia	BROMPERIDOL	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Dementia	BROMPERIDOL	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	BROMPERIDOL	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	BROMPERIDOL	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	BROMPERIDOL	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	BROMPERIDOL	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	BROMPERIDOL	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	BROMPERIDOL	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	BROMPERIDOL	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	FLUPHENAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=50c7e742-1165-4c45-bbf6-172cf70a387a	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	FLUPHENAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=50c7e742-1165-4c45-bbf6-172cf70a387a	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	mental or behavioural disorder	FLUPHENAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=50c7e742-1165-4c45-bbf6-172cf70a387a	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	mental or behavioural disorder	FLUPHENAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=50c7e742-1165-4c45-bbf6-172cf70a387a	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	FLUPHENAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=50c7e742-1165-4c45-bbf6-172cf70a387a	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	FLUPHENAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=50c7e742-1165-4c45-bbf6-172cf70a387a	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	psychosis	FLUPHENAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AB02	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	psychosis	FLUPHENAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AB02	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	psychosis	FLUPHENAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AB02	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	psychosis	FLUPHENAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AB02	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	FLUPHENAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AB02	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	FLUPHENAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AB02	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	FLUPHENAZINE	targetBased	3	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00161018	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	FLUPHENAZINE	targetBased	3	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00161018	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	FLUPHENAZINE	targetBased	3	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00161018	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	FLUPHENAZINE	targetBased	3	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00161018	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	FLUPHENAZINE	targetBased	3	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00161018	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	FLUPHENAZINE	targetBased	3	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00161018	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	psychosis	PROCHLORPERAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AB04	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	psychosis	PROCHLORPERAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AB04	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	psychosis	PROCHLORPERAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AB04	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	psychosis	PROCHLORPERAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AB04	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	PROCHLORPERAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AB04	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	PROCHLORPERAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AB04	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	PROCHLORPERAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4924c2cf-ffe0-7398-e054-00144ff88e88	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	PROCHLORPERAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=016b4aa0-ec8f-4bbc-aa07-58e3da801c3b	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	PROCHLORPERAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=016b4aa0-ec8f-4bbc-aa07-58e3da801c3b	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	PROCHLORPERAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=016b4aa0-ec8f-4bbc-aa07-58e3da801c3b	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	PROCHLORPERAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=016b4aa0-ec8f-4bbc-aa07-58e3da801c3b	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	PROCHLORPERAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=016b4aa0-ec8f-4bbc-aa07-58e3da801c3b	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	PROCHLORPERAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=016b4aa0-ec8f-4bbc-aa07-58e3da801c3b	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	anxiety disorder	PROCHLORPERAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4924c2cf-ffe0-7398-e054-00144ff88e88	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	anxiety disorder	PROCHLORPERAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4924c2cf-ffe0-7398-e054-00144ff88e88	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	anxiety disorder	PROCHLORPERAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4924c2cf-ffe0-7398-e054-00144ff88e88	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	anxiety disorder	PROCHLORPERAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4924c2cf-ffe0-7398-e054-00144ff88e88	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	anxiety disorder	PROCHLORPERAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4924c2cf-ffe0-7398-e054-00144ff88e88	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	anxiety disorder	PROCHLORPERAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4924c2cf-ffe0-7398-e054-00144ff88e88	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		sleep apnea	KETAMINE	targetBased	4	Recruiting	23/07/2020	https://clinicaltrials.gov/study/NCT04452383	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		delirium	KETAMINE	targetBased	4	Recruiting	25/08/2023	https://clinicaltrials.gov/study/NCT06010927	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		delirium	KETAMINE	targetBased	4	Not yet recruiting	15/05/2023	https://clinicaltrials.gov/study/NCT05821972	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		delirium	KETAMINE	targetBased	4	Completed	01/07/2013	https://clinicaltrials.gov/study/NCT02433041	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		delirium	KETAMINE	targetBased	3	Completed	01/02/2014	https://clinicaltrials.gov/study/NCT01690988	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		acute stress reaction	KETAMINE	targetBased	4	Active, not recruiting	15/04/2020	https://clinicaltrials.gov/study/NCT04769297	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		bipolar I disorder	KETAMINE	targetBased	4	Completed	01/06/2017	https://clinicaltrials.gov/study/NCT03156504	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		schizophrenia	KETAMINE	targetBased	4	Completed	01/06/2010	https://clinicaltrials.gov/study/NCT01140620	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		schizophrenia	KETAMINE	targetBased	4	Not yet recruiting	24/05/2019	https://clinicaltrials.gov/study/NCT03829124	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		opioid dependence	KETAMINE	targetBased	4	Completed	01/02/2003	https://clinicaltrials.gov/study/NCT00300794	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		opioid dependence	KETAMINE	targetBased	3	Active, not recruiting	25/11/2017	https://clinicaltrials.gov/study/NCT03345173	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		alcohol dependence	KETAMINE	targetBased	3	Suspended	01/04/2006	https://clinicaltrials.gov/study/NCT00329394	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		depressive disorder	KETAMINE	targetBased	4	Recruiting	22/07/2022	https://clinicaltrials.gov/study/NCT05487885	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		depressive disorder	KETAMINE	targetBased	4	Unknown status	01/07/2014	https://clinicaltrials.gov/study/NCT02267980	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		depressive disorder	KETAMINE	targetBased	4	Enrolling by invitation	01/10/2023	https://clinicaltrials.gov/study/NCT06034821	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		depressive disorder	KETAMINE	targetBased	4	Completed	14/09/2017	https://clinicaltrials.gov/study/NCT03149991	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		depressive disorder	KETAMINE	targetBased	4	Unknown status	01/09/2016	https://clinicaltrials.gov/study/NCT02924090	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		depressive disorder	KETAMINE	targetBased	4	Completed	01/09/2021	https://clinicaltrials.gov/study/NCT05026203	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		depressive disorder	KETAMINE	targetBased	4	Withdrawn	01/09/2022	https://clinicaltrials.gov/study/NCT04220125	1	LoF	protect	No enrollment
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		pain agnosia	KETAMINE	targetBased	4	Not yet recruiting	01/12/2024	https://clinicaltrials.gov/study/NCT06408974	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		unipolar depression	KETAMINE	targetBased	4	Completed	01/06/2010	https://clinicaltrials.gov/study/NCT01881763	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		unipolar depression	KETAMINE	targetBased	4	Completed	01/06/2017	https://clinicaltrials.gov/study/NCT03156504	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		bipolar disorder	KETAMINE	targetBased	3	Suspended	29/10/2018	https://clinicaltrials.gov/study/NCT03674671	0.7	LoF	protect	insufficient funding
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		bipolar disorder	KETAMINE	targetBased	4	Completed	01/06/2017	https://clinicaltrials.gov/study/NCT03156504	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		bipolar disorder	KETAMINE	targetBased	4	Completed	01/06/2010	https://clinicaltrials.gov/study/NCT01881763	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		bipolar disorder	KETAMINE	targetBased	4	Completed	01/03/2013	https://clinicaltrials.gov/study/NCT01833897	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		bipolar disorder	KETAMINE	targetBased	4	Terminated	01/07/2009	https://clinicaltrials.gov/study/NCT00947791	1	LoF	protect	Change in available resources for study procedures
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		treatment resistant depression	KETAMINE	targetBased	4	Completed	22/10/2020	https://clinicaltrials.gov/study/NCT04504175	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		treatment resistant depression	KETAMINE	targetBased	4	Recruiting	03/06/2024	https://clinicaltrials.gov/study/NCT06278779	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		treatment resistant depression	KETAMINE	targetBased	4	Withdrawn	01/03/2008	https://clinicaltrials.gov/study/NCT00646087	1	LoF	protect	Pilot study determined that this study would not be feasible.
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		treatment resistant depression	KETAMINE	targetBased	4	Unknown status	01/06/2016	https://clinicaltrials.gov/study/NCT02772211	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		treatment resistant depression	KETAMINE	targetBased	4	Completed	01/09/2013	https://clinicaltrials.gov/study/NCT01935115	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		treatment resistant depression	KETAMINE	targetBased	4	Recruiting	01/09/2017	https://clinicaltrials.gov/study/NCT03272698	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		mental or behavioural disorder	KETAMINE	targetBased	4	Completed	15/06/2019	https://clinicaltrials.gov/study/NCT05320991	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		mental or behavioural disorder	KETAMINE	targetBased	4	Completed	01/02/2003	https://clinicaltrials.gov/study/NCT00205712	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		postpartum depression	KETAMINE	targetBased	4	Completed	23/11/2017	https://clinicaltrials.gov/study/NCT03336541	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		postpartum depression	KETAMINE	targetBased	4	Not yet recruiting	01/12/2019	https://clinicaltrials.gov/study/NCT03927378	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		postpartum depression	KETAMINE	targetBased	3	Completed	12/11/2020	https://clinicaltrials.gov/study/NCT04227704	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		obstructive sleep apnea	KETAMINE	targetBased	4	Completed	01/12/2014	https://clinicaltrials.gov/study/NCT02425202	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		major depressive episode	KETAMINE	targetBased	4	Completed	01/04/2008	https://clinicaltrials.gov/study/NCT00680433	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		major depressive disorder	KETAMINE	targetBased	4	Completed	22/08/2019	https://clinicaltrials.gov/study/NCT03861988	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		major depressive disorder	KETAMINE	targetBased	4	Recruiting	13/10/2022	https://clinicaltrials.gov/study/NCT05450432	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		major depressive disorder	KETAMINE	targetBased	4	Completed	01/03/2016	https://clinicaltrials.gov/study/NCT02544607	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		major depressive disorder	KETAMINE	targetBased	4	Completed	09/10/2020	https://clinicaltrials.gov/study/NCT04091971	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		major depressive disorder	KETAMINE	targetBased	4	Recruiting	31/01/2024	https://clinicaltrials.gov/study/NCT06213324	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		major depressive disorder	KETAMINE	targetBased	4	Completed	01/10/2015	https://clinicaltrials.gov/study/NCT02579928	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		major depressive disorder	KETAMINE	targetBased	4	Terminated	01/11/2010	https://clinicaltrials.gov/study/NCT01260649	1	LoF	protect	lack of funding to cover staff salary (clinician and research coordinator)
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		alcohol withdrawal	KETAMINE	targetBased	4	Withdrawn	01/02/2018	https://clinicaltrials.gov/study/NCT02823977	1	LoF	protect	Funding not obtained
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		alcohol withdrawal	KETAMINE	targetBased	4	Withdrawn	12/04/2019	https://clinicaltrials.gov/study/NCT03788889	1	LoF	protect	internal practice and policy limitations including time commitment / workflow issues
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Agitation	KETAMINE	targetBased	4	Completed	01/07/2016	https://clinicaltrials.gov/study/NCT02909465	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Agitation	KETAMINE	targetBased	4	Withdrawn	01/04/2014	https://clinicaltrials.gov/study/NCT02103881	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Agitation	KETAMINE	targetBased	4	Completed	01/02/2012	https://clinicaltrials.gov/study/NCT02022488	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	BUTORPHANOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9822ca3f-aee2-46e5-8a96-495400e65d10	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	BUTORPHANOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9822ca3f-aee2-46e5-8a96-495400e65d10	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	BUTORPHANOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b8e48063-0b40-ee43-85c1-4ef2de80c404	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	BUTORPHANOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b8e48063-0b40-ee43-85c1-4ef2de80c404	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	drug dependence	BUTORPHANOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9822ca3f-aee2-46e5-8a96-495400e65d10	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	drug dependence	BUTORPHANOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b8e48063-0b40-ee43-85c1-4ef2de80c404	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	bipolar disorder	TAMOXIFEN CITRATE	targetBased	3	Completed	01/04/2003	https://clinicaltrials.gov/study/NCT00411203	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	bipolar disorder	TAMOXIFEN CITRATE	targetBased	3	Completed	01/04/2003	https://clinicaltrials.gov/study/NCT00411203	0.7		protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	post-traumatic stress disorder	METHYLPHENIDATE	targetBased	4	Recruiting	05/02/2024	https://clinicaltrials.gov/study/NCT05776056	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	Williams syndrome	METHYLPHENIDATE	targetBased	4	Recruiting	01/05/2001	https://clinicaltrials.gov/study/NCT00768820	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	obsessive-compulsive disorder	METHYLPHENIDATE	targetBased	4	Completed	01/10/2013	https://clinicaltrials.gov/study/NCT02194075	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	Dementia	METHYLPHENIDATE	targetBased	4	Terminated	01/11/2012	https://clinicaltrials.gov/study/NCT01825577	1	LoF	protect	Administrative Reasons
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	Dementia	METHYLPHENIDATE	targetBased	3	Unknown status	01/05/2012	https://clinicaltrials.gov/study/NCT01599975	0.7	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	depressive disorder	METHYLPHENIDATE	targetBased	4	Completed	01/02/2008	https://clinicaltrials.gov/study/NCT00602290	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	depressive disorder	METHYLPHENIDATE	targetBased	3	Terminated	01/04/2002	https://clinicaltrials.gov/study/NCT00031798	0.7	LoF	protect	low accrual; loss of funding
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	depressive disorder	METHYLPHENIDATE	targetBased	3	Unknown status	01/03/2011	https://clinicaltrials.gov/study/NCT01497548	0.7	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	nicotine dependence	METHYLPHENIDATE	targetBased	3	Completed	01/11/2005	https://clinicaltrials.gov/study/NCT00253747	0.7	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	major depressive disorder	METHYLPHENIDATE	targetBased	3	Completed	01/06/2005	https://clinicaltrials.gov/study/NCT00246233	0.7	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	narcolepsy-cataplexy syndrome	METHYLPHENIDATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ec8a8896-077d-4dee-9e10-97172512c5ed	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	narcolepsy-cataplexy syndrome	METHYLPHENIDATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cd83fc91-47a3-4be4-9727-caf9ec0371e8	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	narcolepsy-cataplexy syndrome	METHYLPHENIDATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0bf0835-6a2f-4067-a158-8b86c4b0668a	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	narcolepsy-cataplexy syndrome	METHYLPHENIDATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9e3c22d9-71d9-46a7-b315-8021c94c4bec	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	delirium	METHYLPHENIDATE	targetBased	3	Terminated	01/02/2008	https://clinicaltrials.gov/study/NCT00599287	0.7	LoF	protect	Inclusion rate too low due to a lack of eligible patients and difficulties obtaining informed consent.
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	anxiety	METHYLPHENIDATE	targetBased	4	Completed	16/06/2014	https://clinicaltrials.gov/study/NCT02153944	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	bipolar disorder	METHYLPHENIDATE	targetBased	3	Completed	01/03/2012	https://clinicaltrials.gov/study/NCT01541605	0.7	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	METHYLPHENIDATE	targetBased	4	Completed	17/04/2012	https://clinicaltrials.gov/study/NCT01552915	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	METHYLPHENIDATE	targetBased	4	Recruiting	27/07/2021	https://clinicaltrials.gov/study/NCT04781972	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	METHYLPHENIDATE	targetBased	4	Unknown status	01/09/2016	https://clinicaltrials.gov/study/NCT02677519	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	METHYLPHENIDATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f63155b9-ea71-4a30-be32-37173f87bcbf	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	METHYLPHENIDATE	targetBased	4	Terminated	03/08/2021	https://clinicaltrials.gov/study/NCT04987762	1	LoF	protect	due to administrative reasons not related to efficacy or safety.
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	METHYLPHENIDATE	targetBased	4	Completed	01/11/2008	https://clinicaltrials.gov/study/NCT00778310	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	METHYLPHENIDATE	targetBased	4	Completed	01/09/2015	https://clinicaltrials.gov/study/NCT02473185	1	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	major depressive disorder	GEPIRONE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021164s000lbl.pdf	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	major depressive disorder	GEPIRONE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021164s000lbl.pdf	1	GoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		delirium	MEMANTINE	targetBased	4	Terminated	01/03/2006	https://clinicaltrials.gov/study/NCT00303433	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		eating disorder	MEMANTINE	targetBased	4	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00330655	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		attention deficit hyperactivity disorder	MEMANTINE	targetBased	4	Completed	01/03/2007	https://clinicaltrials.gov/study/NCT00586573	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		post-traumatic stress disorder	MEMANTINE	targetBased	4	Completed	01/07/2005	https://clinicaltrials.gov/study/NCT02258828	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Dementia	MEMANTINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1fa2b7bc-94e5-4566-a7c5-419f8fd393a7	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Dementia	MEMANTINE	targetBased	4	Completed	01/09/2007	https://clinicaltrials.gov/study/NCT00371059	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Dementia	MEMANTINE	targetBased	4	Completed	01/11/2004	https://clinicaltrials.gov/study/NCT00768261	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Dementia	MEMANTINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b9f27baf-aa2a-443a-9ef5-e002d23407ba	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Dementia	MEMANTINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c8f5c20b-4573-44c5-89fc-4da11b2e1fe1	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Dementia	MEMANTINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=81496236-0a90-4265-8244-cba6a6b4f3ac	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Dementia	MEMANTINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N06DX01	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		schizophrenia	MEMANTINE	targetBased	3	Unknown status	01/01/2014	https://clinicaltrials.gov/study/NCT02001103	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		schizophrenia	MEMANTINE	targetBased	3	Terminated	01/04/2004	https://clinicaltrials.gov/study/NCT00148616	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		schizophrenia	MEMANTINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		schizophrenia	MEMANTINE	targetBased	3	Terminated	01/11/2005	https://clinicaltrials.gov/study/NCT00148590	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		schizophrenia	MEMANTINE	targetBased	4	Completed	01/01/2006	https://clinicaltrials.gov/study/NCT00757978	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		anxiety	MEMANTINE	targetBased	3	Completed	01/12/2006	https://clinicaltrials.gov/study/NCT00411398	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		anxiety	MEMANTINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		depressive disorder	MEMANTINE	targetBased	4	Completed	01/10/2013	https://clinicaltrials.gov/study/NCT01902004	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		depressive disorder	MEMANTINE	targetBased	3	Completed	01/06/2002	https://clinicaltrials.gov/study/NCT00040261	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		depressive disorder	MEMANTINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		depressive disorder	MEMANTINE	targetBased	4	Completed	01/08/2005	https://clinicaltrials.gov/study/NCT00183729	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		depressive disorder	MEMANTINE	targetBased	4	Completed	01/06/2006	https://clinicaltrials.gov/study/NCT00344682	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Pick disease	MEMANTINE	targetBased	4	Completed	01/05/2004	https://clinicaltrials.gov/study/NCT00187525	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		bipolar disorder	MEMANTINE	targetBased	4	Completed	01/08/2005	https://clinicaltrials.gov/study/NCT00305578	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		bipolar disorder	MEMANTINE	targetBased	3	Unknown status	01/01/2013	https://clinicaltrials.gov/study/NCT03039842	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		bipolar disorder	MEMANTINE	targetBased	4	Completed	01/11/2005	https://clinicaltrials.gov/study/NCT00586066	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		learning disability	MEMANTINE	targetBased	3	Recruiting	13/11/2018	https://clinicaltrials.gov/study/NCT03553875	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		autism spectrum disorder	MEMANTINE	targetBased	4	Completed	01/01/2010	https://clinicaltrials.gov/study/NCT01333865	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		autism spectrum disorder	MEMANTINE	targetBased	3	Recruiting	13/11/2018	https://clinicaltrials.gov/study/NCT03553875	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		autism spectrum disorder	MEMANTINE	targetBased	3	Completed	17/02/2015	https://clinicaltrials.gov/study/NCT01972074	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		autism	MEMANTINE	targetBased	3	Recruiting	13/11/2018	https://clinicaltrials.gov/study/NCT03553875	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		obsessive-compulsive disorder	MEMANTINE	targetBased	3	Not yet recruiting	01/09/2021	https://clinicaltrials.gov/study/NCT05015595	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		substance abuse	MEMANTINE	targetBased	3	Completed	01/03/2009	https://clinicaltrials.gov/study/NCT01189214	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	unipolar depression	ZIMELDINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N06AB02	1	LoF	protect
Primary Cell Based High Throughput Screening Assay for Agonists of the 5-Hydroxytryptamine Receptor Subtype 1E (5HT1E)	HTR1E	HTR1E	5-hydroxytryptamine receptor 1E	unipolar depression	ZIMELDINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N06AB02	1	LoF	protect
Primary Cell Based High Throughput Screening Assay for Antagonists of the 5-Hydroxytryptamine Receptor Subtype 1E (5HT1E)	HTR1E	HTR1E	5-hydroxytryptamine receptor 1E	unipolar depression	ZIMELDINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N06AB02	1	LoF	protect
Counterscreen for agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A)	HTR5A	HTR5A	5-hydroxytryptamine receptor 5A	unipolar depression	ZIMELDINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N06AB02	1	LoF	protect
Counterscreen for inverse agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify inverse agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A)	HTR5A	HTR5A	5-hydroxytryptamine receptor 5A	unipolar depression	ZIMELDINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N06AB02	1	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	unipolar depression	ZIMELDINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N06AB02	1	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	unipolar depression	ZIMELDINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N06AB02	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	DEXMETHYLPHENIDATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7c552f11-e24a-4d9b-bb8d-be10c928eca8	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	DEXMETHYLPHENIDATE	targetBased	4	Recruiting	24/05/2023	https://clinicaltrials.gov/study/NCT05721235	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	DEXMETHYLPHENIDATE	targetBased	4	Completed	01/10/2008	https://clinicaltrials.gov/study/NCT00776009	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	DEXMETHYLPHENIDATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d334e2f1-7497-4131-a5c0-7ac30d4741cb	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	DEXMETHYLPHENIDATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cad21255-f17f-4744-b20d-76d138ca5df2	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	DEXMETHYLPHENIDATE	targetBased	4	Active, not recruiting	22/03/2023	https://clinicaltrials.gov/study/NCT05685732	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	DEXMETHYLPHENIDATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dd659d39-41f5-4612-8f17-bad602b4784d	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	delirium	LOXAPINE	targetBased	3	Terminated	09/04/2023	https://clinicaltrials.gov/study/NCT05324852	0.7	LoF	protect	Sponsor decision:
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	bipolar disorder	LOXAPINE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/adasuve	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	bipolar disorder	LOXAPINE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/adasuve	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	bipolar disorder	LOXAPINE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/adasuve	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	delirium	LOXAPINE	targetBased	3	Terminated	09/04/2023	https://clinicaltrials.gov/study/NCT05324852	0.7	LoF	protect	Sponsor decision:
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	delirium	LOXAPINE	targetBased	3	Terminated	09/04/2023	https://clinicaltrials.gov/study/NCT05324852	0.7	LoF	protect	Sponsor decision:
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	delirium	LOXAPINE	targetBased	3	Terminated	09/04/2023	https://clinicaltrials.gov/study/NCT05324852	0.7	LoF	protect	Sponsor decision:
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	delirium	LOXAPINE	targetBased	3	Terminated	09/04/2023	https://clinicaltrials.gov/study/NCT05324852	0.7	LoF	protect	Sponsor decision:
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	delirium	LOXAPINE	targetBased	3	Terminated	09/04/2023	https://clinicaltrials.gov/study/NCT05324852	0.7	LoF	protect	Sponsor decision:
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	delirium	LOXAPINE	targetBased	3	Terminated	09/04/2023	https://clinicaltrials.gov/study/NCT05324852	0.7	LoF	protect	Sponsor decision:
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	LOXAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=613a6459-0e61-4bed-9138-2836ff49f40b	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	LOXAPINE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/adasuve	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	LOXAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=257148b5-869e-4a06-89ca-8b8686e8e528	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	LOXAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dee2537b-1bd8-42f6-990f-62359e646822	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	bipolar disorder	LOXAPINE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/adasuve	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	bipolar disorder	LOXAPINE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/adasuve	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar disorder	LOXAPINE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/adasuve	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar disorder	LOXAPINE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/adasuve	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar disorder	LOXAPINE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/adasuve	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar disorder	LOXAPINE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/adasuve	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	delirium	LOXAPINE	targetBased	3	Terminated	09/04/2023	https://clinicaltrials.gov/study/NCT05324852	0.7	LoF	protect	Sponsor decision:
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	delirium	LOXAPINE	targetBased	3	Terminated	09/04/2023	https://clinicaltrials.gov/study/NCT05324852	0.7	LoF	protect	Sponsor decision:
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	delirium	LOXAPINE	targetBased	3	Terminated	09/04/2023	https://clinicaltrials.gov/study/NCT05324852	0.7	LoF	protect	Sponsor decision:
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	psychosis	LOXAPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AH01	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	psychosis	LOXAPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AH01	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	psychosis	LOXAPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AH01	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	anxiety	LOXAPINE	targetBased	3	Terminated	01/12/2005	https://clinicaltrials.gov/study/NCT00290082	0.35	LoF	protect	2 complications with midazolam
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	anxiety	LOXAPINE	targetBased	3	Terminated	01/12/2005	https://clinicaltrials.gov/study/NCT00290082	0.35	LoF	protect	2 complications with midazolam
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	anxiety	LOXAPINE	targetBased	3	Terminated	01/12/2005	https://clinicaltrials.gov/study/NCT00290082	0.35	LoF	protect	2 complications with midazolam
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	anxiety	LOXAPINE	targetBased	3	Terminated	01/12/2005	https://clinicaltrials.gov/study/NCT00290082	0.35	LoF	protect	2 complications with midazolam
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	anxiety	LOXAPINE	targetBased	3	Terminated	01/12/2005	https://clinicaltrials.gov/study/NCT00290082	0.35	LoF	protect	2 complications with midazolam
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	anxiety	LOXAPINE	targetBased	3	Terminated	01/12/2005	https://clinicaltrials.gov/study/NCT00290082	0.35	LoF	protect	2 complications with midazolam
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Agitation	LOXAPINE	targetBased	4	Terminated	30/09/2017	https://clinicaltrials.gov/study/NCT03110900	1	LoF	protect	Sponsor Withdrawal
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Agitation	LOXAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=257148b5-869e-4a06-89ca-8b8686e8e528	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Agitation	LOXAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=257148b5-869e-4a06-89ca-8b8686e8e528	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Agitation	LOXAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=257148b5-869e-4a06-89ca-8b8686e8e528	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Agitation	LOXAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=257148b5-869e-4a06-89ca-8b8686e8e528	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Agitation	LOXAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=257148b5-869e-4a06-89ca-8b8686e8e528	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Agitation	LOXAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=257148b5-869e-4a06-89ca-8b8686e8e528	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar I disorder	LOXAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=257148b5-869e-4a06-89ca-8b8686e8e528	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar I disorder	LOXAPINE	targetBased	3	Completed	01/07/2008	https://clinicaltrials.gov/study/NCT00721955	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	LOXAPINE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/adasuve	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	psychosis	LOXAPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AH01	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Agitation	LOXAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=257148b5-869e-4a06-89ca-8b8686e8e528	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Agitation	LOXAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b074f950-246a-41f0-aedf-32f38998a4b1	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Agitation	LOXAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b074f950-246a-41f0-aedf-32f38998a4b1	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Agitation	LOXAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b074f950-246a-41f0-aedf-32f38998a4b1	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Agitation	LOXAPINE	targetBased	4	Terminated	30/09/2017	https://clinicaltrials.gov/study/NCT03110900	1	LoF	protect	Sponsor Withdrawal
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Agitation	LOXAPINE	targetBased	4	Terminated	30/09/2017	https://clinicaltrials.gov/study/NCT03110900	1	LoF	protect	Sponsor Withdrawal
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Agitation	LOXAPINE	targetBased	4	Terminated	30/09/2017	https://clinicaltrials.gov/study/NCT03110900	1	LoF	protect	Sponsor Withdrawal
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	schizophrenia	LOXAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dee2537b-1bd8-42f6-990f-62359e646822	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	schizophrenia	LOXAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=613a6459-0e61-4bed-9138-2836ff49f40b	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	schizophrenia	LOXAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=613a6459-0e61-4bed-9138-2836ff49f40b	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	schizophrenia	LOXAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=613a6459-0e61-4bed-9138-2836ff49f40b	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	schizophrenia	LOXAPINE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/adasuve	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	schizophrenia	LOXAPINE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/adasuve	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	schizophrenia	LOXAPINE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/adasuve	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	psychosis	LOXAPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AH01	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	psychosis	LOXAPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AH01	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	psychosis	LOXAPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AH01	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	psychosis	LOXAPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AH01	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	LOXAPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AH01	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	LOXAPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AH01	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	anxiety	LOXAPINE	targetBased	3	Terminated	01/12/2005	https://clinicaltrials.gov/study/NCT00290082	0.35	LoF	protect	2 complications with midazolam
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	bipolar I disorder	LOXAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=257148b5-869e-4a06-89ca-8b8686e8e528	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	bipolar I disorder	LOXAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=257148b5-869e-4a06-89ca-8b8686e8e528	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	bipolar I disorder	LOXAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=257148b5-869e-4a06-89ca-8b8686e8e528	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	bipolar I disorder	LOXAPINE	targetBased	3	Completed	01/07/2008	https://clinicaltrials.gov/study/NCT00721955	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	bipolar I disorder	LOXAPINE	targetBased	3	Completed	01/07/2008	https://clinicaltrials.gov/study/NCT00721955	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	bipolar I disorder	LOXAPINE	targetBased	3	Completed	01/07/2008	https://clinicaltrials.gov/study/NCT00721955	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar I disorder	LOXAPINE	targetBased	3	Completed	01/07/2008	https://clinicaltrials.gov/study/NCT00721955	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	bipolar I disorder	LOXAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=257148b5-869e-4a06-89ca-8b8686e8e528	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	bipolar I disorder	LOXAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=257148b5-869e-4a06-89ca-8b8686e8e528	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar I disorder	LOXAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=257148b5-869e-4a06-89ca-8b8686e8e528	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar I disorder	LOXAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=257148b5-869e-4a06-89ca-8b8686e8e528	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar I disorder	LOXAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=257148b5-869e-4a06-89ca-8b8686e8e528	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar I disorder	LOXAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=257148b5-869e-4a06-89ca-8b8686e8e528	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Agitation	LOXAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b074f950-246a-41f0-aedf-32f38998a4b1	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Agitation	LOXAPINE	targetBased	4	Terminated	30/09/2017	https://clinicaltrials.gov/study/NCT03110900	1	LoF	protect	Sponsor Withdrawal
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Agitation	LOXAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=257148b5-869e-4a06-89ca-8b8686e8e528	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	LOXAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=257148b5-869e-4a06-89ca-8b8686e8e528	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	LOXAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=613a6459-0e61-4bed-9138-2836ff49f40b	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	LOXAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=613a6459-0e61-4bed-9138-2836ff49f40b	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	LOXAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=613a6459-0e61-4bed-9138-2836ff49f40b	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	LOXAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=613a6459-0e61-4bed-9138-2836ff49f40b	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	LOXAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=613a6459-0e61-4bed-9138-2836ff49f40b	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	LOXAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=613a6459-0e61-4bed-9138-2836ff49f40b	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	anxiety	LOXAPINE	targetBased	3	Terminated	01/12/2005	https://clinicaltrials.gov/study/NCT00290082	0.35	LoF	protect	2 complications with midazolam
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	anxiety	LOXAPINE	targetBased	3	Terminated	01/12/2005	https://clinicaltrials.gov/study/NCT00290082	0.35	LoF	protect	2 complications with midazolam
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	anxiety	LOXAPINE	targetBased	3	Terminated	01/12/2005	https://clinicaltrials.gov/study/NCT00290082	0.35	LoF	protect	2 complications with midazolam
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	LOPERAMIDE	targetBased	4	Completed	01/01/2014	https://clinicaltrials.gov/study/NCT03017430	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	LOPERAMIDE	targetBased	4	Completed	01/01/2014	https://clinicaltrials.gov/study/NCT03017430	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	depressive disorder	BENPERIDOL	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	depressive disorder	BENPERIDOL	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	depressive disorder	BENPERIDOL	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	depressive disorder	BENPERIDOL	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	depressive disorder	BENPERIDOL	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	depressive disorder	BENPERIDOL	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	anxiety	BENPERIDOL	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	anxiety	BENPERIDOL	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	anxiety	BENPERIDOL	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	anxiety	BENPERIDOL	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	anxiety	BENPERIDOL	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	anxiety	BENPERIDOL	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizoaffective disorder	BENPERIDOL	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizoaffective disorder	BENPERIDOL	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizoaffective disorder	BENPERIDOL	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizoaffective disorder	BENPERIDOL	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizoaffective disorder	BENPERIDOL	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizoaffective disorder	BENPERIDOL	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	psychosis	BENPERIDOL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AD07	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	psychosis	BENPERIDOL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AD07	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	psychosis	BENPERIDOL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AD07	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	psychosis	BENPERIDOL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AD07	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	BENPERIDOL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AD07	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	BENPERIDOL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AD07	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Dementia	BENPERIDOL	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Dementia	BENPERIDOL	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Dementia	BENPERIDOL	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Dementia	BENPERIDOL	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Dementia	BENPERIDOL	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Dementia	BENPERIDOL	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	BENPERIDOL	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	BENPERIDOL	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	BENPERIDOL	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	BENPERIDOL	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	BENPERIDOL	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	BENPERIDOL	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	BENPERIDOL	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	depressive disorder	FLUSPIRILENE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	depressive disorder	FLUSPIRILENE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	depressive disorder	FLUSPIRILENE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	depressive disorder	FLUSPIRILENE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	depressive disorder	FLUSPIRILENE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	depressive disorder	FLUSPIRILENE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	anxiety	FLUSPIRILENE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	anxiety	FLUSPIRILENE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	anxiety	FLUSPIRILENE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	anxiety	FLUSPIRILENE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	anxiety	FLUSPIRILENE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	anxiety	FLUSPIRILENE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizoaffective disorder	FLUSPIRILENE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizoaffective disorder	FLUSPIRILENE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizoaffective disorder	FLUSPIRILENE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizoaffective disorder	FLUSPIRILENE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizoaffective disorder	FLUSPIRILENE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizoaffective disorder	FLUSPIRILENE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	psychosis	FLUSPIRILENE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AG01	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	psychosis	FLUSPIRILENE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AG01	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	psychosis	FLUSPIRILENE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AG01	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	psychosis	FLUSPIRILENE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AG01	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	FLUSPIRILENE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AG01	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	FLUSPIRILENE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AG01	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Dementia	FLUSPIRILENE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Dementia	FLUSPIRILENE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Dementia	FLUSPIRILENE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Dementia	FLUSPIRILENE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Dementia	FLUSPIRILENE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Dementia	FLUSPIRILENE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	FLUSPIRILENE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	FLUSPIRILENE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	FLUSPIRILENE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	FLUSPIRILENE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	FLUSPIRILENE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	FLUSPIRILENE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	FLUSPIRILENE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	methamphetamine-induced psychosis	CINNARIZINE	targetBased	4	Completed	01/03/2010	https://clinicaltrials.gov/study/NCT01939093	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	BUTORPHANOL TARTRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9822ca3f-aee2-46e5-8a96-495400e65d10	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	BUTORPHANOL TARTRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9822ca3f-aee2-46e5-8a96-495400e65d10	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	BUTORPHANOL TARTRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b8e48063-0b40-ee43-85c1-4ef2de80c404	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	BUTORPHANOL TARTRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b8e48063-0b40-ee43-85c1-4ef2de80c404	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	drug dependence	BUTORPHANOL TARTRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b8e48063-0b40-ee43-85c1-4ef2de80c404	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	drug dependence	BUTORPHANOL TARTRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9822ca3f-aee2-46e5-8a96-495400e65d10	1	GoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	treatment resistant depression	BUPROPION	targetBased	4	Completed	24/02/2017	https://clinicaltrials.gov/study/NCT02960763	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	treatment resistant depression	BUPROPION	targetBased	3	Completed	08/07/2019	https://clinicaltrials.gov/study/NCT04039022	0.7	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	schizoaffective disorder	BUPROPION	targetBased	4	Completed	01/07/2001	https://clinicaltrials.gov/study/NCT00320723	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	smoking behavior	BUPROPION	targetBased	3	Completed	01/02/2002	https://clinicaltrials.gov/study/NCT00033592	0.7	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	Dementia	BUPROPION	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	bipolar I disorder	BUPROPION	targetBased	3	Completed	01/11/2010	https://clinicaltrials.gov/study/NCT00958633	0.7	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	depressive disorder	BUPROPION	targetBased	4	Unknown status	01/06/2004	https://clinicaltrials.gov/study/NCT00106197	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	depressive disorder	BUPROPION	targetBased	4	Terminated	01/01/2005	https://clinicaltrials.gov/study/NCT00181896	1	LoF	protect	Study was terminated due to lack of recruitment
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	depressive disorder	BUPROPION	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fddb7191-c4f9-4e82-bd7d-259c3767710a	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	depressive disorder	BUPROPION	targetBased	4	Terminated	23/07/2019	https://clinicaltrials.gov/study/NCT03993457	1	LoF	protect	terminated during COVID due to inability to see participants in person.
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	depressive disorder	BUPROPION	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=06d4d890-11ed-4f31-8778-c73432e3ea69	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	depressive disorder	BUPROPION	targetBased	4	Completed	01/01/2007	https://clinicaltrials.gov/study/NCT03927950	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	depressive disorder	BUPROPION	targetBased	4	Completed	01/10/2002	https://clinicaltrials.gov/study/NCT00178828	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	methamphetamine dependence	BUPROPION	targetBased	3	Completed	05/05/2017	https://clinicaltrials.gov/study/NCT03078075	0.7	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	nicotine dependence	BUPROPION	targetBased	4	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT01621009	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	nicotine dependence	BUPROPION	targetBased	4	Completed	01/07/2005	https://clinicaltrials.gov/study/NCT00484692	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	nicotine dependence	BUPROPION	targetBased	4	Completed	01/09/2004	https://clinicaltrials.gov/study/NCT00332644	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	nicotine dependence	BUPROPION	targetBased	4	Completed	01/10/2014	https://clinicaltrials.gov/study/NCT02245308	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	nicotine dependence	BUPROPION	targetBased	4	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT01621022	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	nicotine dependence	BUPROPION	targetBased	4	Completed	01/07/2009	https://clinicaltrials.gov/study/NCT00991081	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	nicotine dependence	BUPROPION	targetBased	4	Terminated	01/03/2005	https://clinicaltrials.gov/study/NCT00119210	1	LoF	protect	We were unable to recruit sufficient numbers of patients and decided that the study protocol was not feasible to implement
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	schizophrenia	BUPROPION	targetBased	4	Completed	01/07/2001	https://clinicaltrials.gov/study/NCT00320723	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	schizophrenia	BUPROPION	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	major depressive disorder	BUPROPION	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fddb7191-c4f9-4e82-bd7d-259c3767710a	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	major depressive disorder	BUPROPION	targetBased	4	Recruiting	27/12/2023	https://clinicaltrials.gov/study/NCT06223880	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	major depressive disorder	BUPROPION	targetBased	4	Not yet recruiting	01/06/2023	https://clinicaltrials.gov/study/NCT02129751	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	major depressive disorder	BUPROPION	targetBased	4	Recruiting	30/09/2022	https://clinicaltrials.gov/study/NCT05537584	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	major depressive disorder	BUPROPION	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=02500709-7f2c-4251-bd8c-94ab6cdadd4c	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	major depressive disorder	BUPROPION	targetBased	4	Withdrawn	15/10/2020	https://clinicaltrials.gov/study/NCT04388189	1	LoF	protect	No participants enrolled
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	major depressive disorder	BUPROPION	targetBased	4	Completed	01/09/2004	https://clinicaltrials.gov/study/NCT00316160	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	dysthymic disorder	BUPROPION	targetBased	4	Completed	01/12/2004	https://clinicaltrials.gov/study/NCT00296777	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	dysthymic disorder	BUPROPION	targetBased	4	Withdrawn	01/08/2013	https://clinicaltrials.gov/study/NCT01942187	1	LoF	protect	No participants enrolled.
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	dysthymic disorder	BUPROPION	targetBased	4	Completed	01/11/2004	https://clinicaltrials.gov/study/NCT00225251	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	dysthymic disorder	BUPROPION	targetBased	4	Completed	01/02/2005	https://clinicaltrials.gov/study/NCT00296712	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	dysthymic disorder	BUPROPION	targetBased	4	Completed	01/07/2006	https://clinicaltrials.gov/study/NCT00404755	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	mood disorder	BUPROPION	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=06d4d890-11ed-4f31-8778-c73432e3ea69	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	anxiety	BUPROPION	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	bipolar disorder	BUPROPION	targetBased	4	Unknown status	01/04/2014	https://clinicaltrials.gov/study/NCT01583023	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	bipolar disorder	BUPROPION	targetBased	4	Completed	01/07/2001	https://clinicaltrials.gov/study/NCT00177567	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	bipolar disorder	BUPROPION	targetBased	4	Terminated	01/01/2005	https://clinicaltrials.gov/study/NCT00181896	1	LoF	protect	Study was terminated due to lack of recruitment
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	substance dependence	BUPROPION	targetBased	4	Completed	01/07/2005	https://clinicaltrials.gov/study/NCT00484692	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	unipolar depression	BUPROPION	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10a64abf-9704-4abb-98fb-bca228cab93a	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	unipolar depression	BUPROPION	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=82f5292b-b113-4f10-9469-04386fa8e9d4	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	unipolar depression	BUPROPION	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5d229da8-aa9b-4760-90e1-bf10b849e054	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	unipolar depression	BUPROPION	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dee3f124-bc24-4a37-b2eb-501a66fef064	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	unipolar depression	BUPROPION	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=332403a7-3138-4f58-a33b-37fd3d573177	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	unipolar depression	BUPROPION	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N06AX12	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	unipolar depression	BUPROPION	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0a7eb657-e991-4243-8165-58e506180a9e	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	BUPROPION	targetBased	3	Completed	01/10/2002	https://clinicaltrials.gov/study/NCT00048360	0.7	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	substance abuse	BUPROPION	targetBased	4	Completed	01/07/2005	https://clinicaltrials.gov/study/NCT00484692	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Agitation	NALBUPHINE	targetBased	4	Recruiting	01/03/2022	https://clinicaltrials.gov/study/NCT05273671	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Agitation	NALBUPHINE	targetBased	4	Recruiting	01/03/2022	https://clinicaltrials.gov/study/NCT05273671	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Agitation	NALBUPHINE	targetBased	4	Recruiting	01/05/2023	https://clinicaltrials.gov/study/NCT05769530	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Agitation	NALBUPHINE	targetBased	4	Recruiting	01/05/2023	https://clinicaltrials.gov/study/NCT05769530	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	delirium	NALBUPHINE	targetBased	3	Not yet recruiting	02/04/2024	https://clinicaltrials.gov/study/NCT06306040	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	delirium	NALBUPHINE	targetBased	3	Not yet recruiting	02/04/2024	https://clinicaltrials.gov/study/NCT06306040	0.7	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Agitation	NALBUPHINE	targetBased	4	Recruiting	01/05/2023	https://clinicaltrials.gov/study/NCT05769530	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Agitation	NALBUPHINE	targetBased	4	Recruiting	01/03/2022	https://clinicaltrials.gov/study/NCT05273671	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	delirium	NALBUPHINE	targetBased	3	Not yet recruiting	02/04/2024	https://clinicaltrials.gov/study/NCT06306040	0.7	GoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	DEXMETHYLPHENIDATE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=77342716-6dd7-488d-bfa4-9637feb4b5f0	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	DEXMETHYLPHENIDATE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dd659d39-41f5-4612-8f17-bad602b4784d	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	DEXMETHYLPHENIDATE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c7beed0d-a4cb-4c4d-933a-c17c4bab6ef1	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	DEXMETHYLPHENIDATE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cad21255-f17f-4744-b20d-76d138ca5df2	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	DEXMETHYLPHENIDATE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1ebab71b-5b74-4705-ba05-4734f1c4561f	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	DEXMETHYLPHENIDATE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d334e2f1-7497-4131-a5c0-7ac30d4741cb	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	DEXMETHYLPHENIDATE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=694ebbf3-966b-4c0d-8d3c-ed95ee0dc8cb	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	CHLORPROTHIXENE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Dementia	CHLORPROTHIXENE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Dementia	CHLORPROTHIXENE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Dementia	CHLORPROTHIXENE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Dementia	CHLORPROTHIXENE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	psychosis	CHLORPROTHIXENE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AF03	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	psychosis	CHLORPROTHIXENE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AF03	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	psychosis	CHLORPROTHIXENE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AF03	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	depressive disorder	CHLORPROTHIXENE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	depressive disorder	CHLORPROTHIXENE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	depressive disorder	CHLORPROTHIXENE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	depressive disorder	CHLORPROTHIXENE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	depressive disorder	CHLORPROTHIXENE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	depressive disorder	CHLORPROTHIXENE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	anxiety	CHLORPROTHIXENE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	anxiety	CHLORPROTHIXENE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	anxiety	CHLORPROTHIXENE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	anxiety	CHLORPROTHIXENE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	anxiety	CHLORPROTHIXENE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	anxiety	CHLORPROTHIXENE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	psychosis	CHLORPROTHIXENE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AF03	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	schizophrenia	CHLORPROTHIXENE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	schizophrenia	CHLORPROTHIXENE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	schizophrenia	CHLORPROTHIXENE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	depressive disorder	CHLORPROTHIXENE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	depressive disorder	CHLORPROTHIXENE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	depressive disorder	CHLORPROTHIXENE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	depressive disorder	CHLORPROTHIXENE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	psychosis	CHLORPROTHIXENE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AF03	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	psychosis	CHLORPROTHIXENE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AF03	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	psychosis	CHLORPROTHIXENE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AF03	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	psychosis	CHLORPROTHIXENE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AF03	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	CHLORPROTHIXENE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AF03	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	CHLORPROTHIXENE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AF03	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	anxiety	CHLORPROTHIXENE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Dementia	CHLORPROTHIXENE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Dementia	CHLORPROTHIXENE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Dementia	CHLORPROTHIXENE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Dementia	CHLORPROTHIXENE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Dementia	CHLORPROTHIXENE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Dementia	CHLORPROTHIXENE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	CHLORPROTHIXENE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	CHLORPROTHIXENE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	CHLORPROTHIXENE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	CHLORPROTHIXENE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	CHLORPROTHIXENE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	CHLORPROTHIXENE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	anxiety	CHLORPROTHIXENE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	anxiety	CHLORPROTHIXENE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	anxiety	CHLORPROTHIXENE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS	D1_activators	DRD1	Dopaminereceptor1	Tourette syndrome	ECOPIPAM	targetBased	3	Recruiting	16/08/2023	https://clinicaltrials.gov/study/NCT06021522	0.7	LoF	protect
Allosteric Modulators of D1 Receptors: Primary Screen	D1	DRD1	Dopamine receptor D1	Tourette syndrome	ECOPIPAM	targetBased	3	Recruiting	16/08/2023	https://clinicaltrials.gov/study/NCT06021522	0.7	LoF	protect
Antagonist of Human D 1 Dopamine Receptor: qHTS	D1_inhibitors	DRD1	Dopaminereceptor1	Tourette syndrome	ECOPIPAM	targetBased	3	Recruiting	16/08/2023	https://clinicaltrials.gov/study/NCT06021522	0.7	LoF	protect
Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS	D1_activators	DRD1	Dopaminereceptor1	Tourette syndrome	ECOPIPAM	targetBased	3	Recruiting	31/01/2023	https://clinicaltrials.gov/study/NCT05615220	0.7	LoF	protect
Allosteric Modulators of D1 Receptors: Primary Screen	D1	DRD1	Dopamine receptor D1	Tourette syndrome	ECOPIPAM	targetBased	3	Recruiting	31/01/2023	https://clinicaltrials.gov/study/NCT05615220	0.7	LoF	protect
Antagonist of Human D 1 Dopamine Receptor: qHTS	D1_inhibitors	DRD1	Dopaminereceptor1	Tourette syndrome	ECOPIPAM	targetBased	3	Recruiting	31/01/2023	https://clinicaltrials.gov/study/NCT05615220	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	bipolar disorder	PRAMIPEXOLE	targetBased	4	Completed	01/10/2014	https://clinicaltrials.gov/study/NCT02397837	1	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	bipolar disorder	PRAMIPEXOLE	targetBased	4	Completed	01/10/2014	https://clinicaltrials.gov/study/NCT02397837	1	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	bipolar disorder	PRAMIPEXOLE	targetBased	4	Completed	01/10/2014	https://clinicaltrials.gov/study/NCT02397837	1	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	bipolar disorder	PRAMIPEXOLE	targetBased	4	Completed	01/10/2005	https://clinicaltrials.gov/study/NCT00597896	1	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	bipolar disorder	PRAMIPEXOLE	targetBased	4	Completed	01/10/2005	https://clinicaltrials.gov/study/NCT00597896	1	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	bipolar disorder	PRAMIPEXOLE	targetBased	4	Completed	01/10/2005	https://clinicaltrials.gov/study/NCT00597896	1	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	eating disorder	PRAMIPEXOLE	targetBased	3	Withdrawn	01/04/2010	https://clinicaltrials.gov/study/NCT01106053	0.7	GoF	protect	No participants were recruited and study has been closed.
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	eating disorder	PRAMIPEXOLE	targetBased	3	Withdrawn	01/04/2010	https://clinicaltrials.gov/study/NCT01106053	0.7	GoF	protect	No participants were recruited and study has been closed.
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	eating disorder	PRAMIPEXOLE	targetBased	3	Withdrawn	01/04/2010	https://clinicaltrials.gov/study/NCT01106053	0.7	GoF	protect	No participants were recruited and study has been closed.
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	treatment resistant depression	PRAMIPEXOLE	targetBased	4	Recruiting	07/08/2021	https://clinicaltrials.gov/study/NCT04936126	1	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	treatment resistant depression	PRAMIPEXOLE	targetBased	4	Recruiting	07/08/2021	https://clinicaltrials.gov/study/NCT04936126	1	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	treatment resistant depression	PRAMIPEXOLE	targetBased	4	Recruiting	07/08/2021	https://clinicaltrials.gov/study/NCT04936126	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar disorder	PRAMIPEXOLE	targetBased	4	Completed	01/10/2005	https://clinicaltrials.gov/study/NCT00597896	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	bipolar disorder	PRAMIPEXOLE	targetBased	4	Completed	01/10/2014	https://clinicaltrials.gov/study/NCT02397837	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	bipolar disorder	PRAMIPEXOLE	targetBased	4	Completed	01/10/2014	https://clinicaltrials.gov/study/NCT02397837	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar disorder	PRAMIPEXOLE	targetBased	4	Completed	01/10/2014	https://clinicaltrials.gov/study/NCT02397837	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar disorder	PRAMIPEXOLE	targetBased	4	Completed	01/10/2014	https://clinicaltrials.gov/study/NCT02397837	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar disorder	PRAMIPEXOLE	targetBased	4	Completed	01/10/2014	https://clinicaltrials.gov/study/NCT02397837	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar disorder	PRAMIPEXOLE	targetBased	4	Completed	01/10/2014	https://clinicaltrials.gov/study/NCT02397837	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Tourette syndrome	PRAMIPEXOLE	targetBased	3	Terminated	01/05/2008	https://clinicaltrials.gov/study/NCT00681863	0.7	GoF	protect	Terminated for slow enrollment.
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Tourette syndrome	PRAMIPEXOLE	targetBased	3	Terminated	01/05/2008	https://clinicaltrials.gov/study/NCT00681863	0.7	GoF	protect	Terminated for slow enrollment.
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Tourette syndrome	PRAMIPEXOLE	targetBased	3	Terminated	01/05/2008	https://clinicaltrials.gov/study/NCT00681863	0.7	GoF	protect	Terminated for slow enrollment.
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Tourette syndrome	PRAMIPEXOLE	targetBased	3	Terminated	01/05/2008	https://clinicaltrials.gov/study/NCT00681863	0.7	GoF	protect	Terminated for slow enrollment.
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Tourette syndrome	PRAMIPEXOLE	targetBased	3	Terminated	01/05/2008	https://clinicaltrials.gov/study/NCT00681863	0.7	GoF	protect	Terminated for slow enrollment.
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Tourette syndrome	PRAMIPEXOLE	targetBased	3	Terminated	01/05/2008	https://clinicaltrials.gov/study/NCT00681863	0.7	GoF	protect	Terminated for slow enrollment.
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	post-traumatic stress disorder	PRAMIPEXOLE	targetBased	3	Terminated	19/02/2019	https://clinicaltrials.gov/study/NCT03765138	0.7	GoF	protect	Patient recruitment difficulties
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	post-traumatic stress disorder	PRAMIPEXOLE	targetBased	3	Terminated	19/02/2019	https://clinicaltrials.gov/study/NCT03765138	0.7	GoF	protect	Patient recruitment difficulties
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	post-traumatic stress disorder	PRAMIPEXOLE	targetBased	3	Terminated	19/02/2019	https://clinicaltrials.gov/study/NCT03765138	0.7	GoF	protect	Patient recruitment difficulties
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	major depressive disorder	PRAMIPEXOLE	targetBased	4	Completed	01/02/2014	https://clinicaltrials.gov/study/NCT02033369	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	major depressive disorder	PRAMIPEXOLE	targetBased	4	Completed	01/02/2014	https://clinicaltrials.gov/study/NCT02033369	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	major depressive disorder	PRAMIPEXOLE	targetBased	4	Completed	01/02/2014	https://clinicaltrials.gov/study/NCT02033369	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	major depressive disorder	PRAMIPEXOLE	targetBased	4	Completed	01/02/2014	https://clinicaltrials.gov/study/NCT02033369	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	major depressive disorder	PRAMIPEXOLE	targetBased	4	Completed	01/02/2014	https://clinicaltrials.gov/study/NCT02033369	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	major depressive disorder	PRAMIPEXOLE	targetBased	4	Completed	01/02/2014	https://clinicaltrials.gov/study/NCT02033369	1	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	major depressive disorder	PRAMIPEXOLE	targetBased	4	Completed	01/02/2014	https://clinicaltrials.gov/study/NCT02033369	1	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	major depressive disorder	PRAMIPEXOLE	targetBased	4	Completed	01/02/2014	https://clinicaltrials.gov/study/NCT02033369	1	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	major depressive disorder	PRAMIPEXOLE	targetBased	4	Completed	01/02/2014	https://clinicaltrials.gov/study/NCT02033369	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	post-traumatic stress disorder	PRAMIPEXOLE	targetBased	3	Terminated	19/02/2019	https://clinicaltrials.gov/study/NCT03765138	0.7	GoF	protect	Patient recruitment difficulties
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	post-traumatic stress disorder	PRAMIPEXOLE	targetBased	3	Terminated	19/02/2019	https://clinicaltrials.gov/study/NCT03765138	0.7	GoF	protect	Patient recruitment difficulties
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	post-traumatic stress disorder	PRAMIPEXOLE	targetBased	3	Terminated	19/02/2019	https://clinicaltrials.gov/study/NCT03765138	0.7	GoF	protect	Patient recruitment difficulties
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	post-traumatic stress disorder	PRAMIPEXOLE	targetBased	3	Terminated	19/02/2019	https://clinicaltrials.gov/study/NCT03765138	0.7	GoF	protect	Patient recruitment difficulties
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	post-traumatic stress disorder	PRAMIPEXOLE	targetBased	3	Terminated	19/02/2019	https://clinicaltrials.gov/study/NCT03765138	0.7	GoF	protect	Patient recruitment difficulties
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	post-traumatic stress disorder	PRAMIPEXOLE	targetBased	3	Terminated	19/02/2019	https://clinicaltrials.gov/study/NCT03765138	0.7	GoF	protect	Patient recruitment difficulties
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	depressive disorder	PRAMIPEXOLE	targetBased	4	Completed	01/09/2003	https://clinicaltrials.gov/study/NCT00231959	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	depressive disorder	PRAMIPEXOLE	targetBased	4	Terminated	01/02/2010	https://clinicaltrials.gov/study/NCT01066897	1	GoF	protect	Lack of funding prevented further recruitment
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	depressive disorder	PRAMIPEXOLE	targetBased	4	Terminated	01/02/2010	https://clinicaltrials.gov/study/NCT01066897	1	GoF	protect	Lack of funding prevented further recruitment
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	depressive disorder	PRAMIPEXOLE	targetBased	4	Terminated	01/02/2010	https://clinicaltrials.gov/study/NCT01066897	1	GoF	protect	Lack of funding prevented further recruitment
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	depressive disorder	PRAMIPEXOLE	targetBased	4	Terminated	01/02/2010	https://clinicaltrials.gov/study/NCT01066897	1	GoF	protect	Lack of funding prevented further recruitment
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	depressive disorder	PRAMIPEXOLE	targetBased	4	Terminated	01/02/2010	https://clinicaltrials.gov/study/NCT01066897	1	GoF	protect	Lack of funding prevented further recruitment
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	depressive disorder	PRAMIPEXOLE	targetBased	4	Terminated	01/02/2010	https://clinicaltrials.gov/study/NCT01066897	1	GoF	protect	Lack of funding prevented further recruitment
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizoaffective disorder	PRAMIPEXOLE	targetBased	3	Unknown status	01/03/2011	https://clinicaltrials.gov/study/NCT01320982	0.7	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizoaffective disorder	PRAMIPEXOLE	targetBased	3	Unknown status	01/03/2011	https://clinicaltrials.gov/study/NCT01320982	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizoaffective disorder	PRAMIPEXOLE	targetBased	3	Unknown status	01/03/2011	https://clinicaltrials.gov/study/NCT01320982	0.7	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizoaffective disorder	PRAMIPEXOLE	targetBased	3	Unknown status	01/03/2011	https://clinicaltrials.gov/study/NCT01320982	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizoaffective disorder	PRAMIPEXOLE	targetBased	3	Unknown status	01/03/2011	https://clinicaltrials.gov/study/NCT01320982	0.7	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizoaffective disorder	PRAMIPEXOLE	targetBased	3	Unknown status	01/03/2011	https://clinicaltrials.gov/study/NCT01320982	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	eating disorder	PRAMIPEXOLE	targetBased	3	Withdrawn	01/04/2010	https://clinicaltrials.gov/study/NCT01106053	0.7	GoF	protect	No participants were recruited and study has been closed.
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	eating disorder	PRAMIPEXOLE	targetBased	3	Withdrawn	01/04/2010	https://clinicaltrials.gov/study/NCT01106053	0.7	GoF	protect	No participants were recruited and study has been closed.
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	eating disorder	PRAMIPEXOLE	targetBased	3	Withdrawn	01/04/2010	https://clinicaltrials.gov/study/NCT01106053	0.7	GoF	protect	No participants were recruited and study has been closed.
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	eating disorder	PRAMIPEXOLE	targetBased	3	Withdrawn	01/04/2010	https://clinicaltrials.gov/study/NCT01106053	0.7	GoF	protect	No participants were recruited and study has been closed.
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	eating disorder	PRAMIPEXOLE	targetBased	3	Withdrawn	01/04/2010	https://clinicaltrials.gov/study/NCT01106053	0.7	GoF	protect	No participants were recruited and study has been closed.
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	eating disorder	PRAMIPEXOLE	targetBased	3	Withdrawn	01/04/2010	https://clinicaltrials.gov/study/NCT01106053	0.7	GoF	protect	No participants were recruited and study has been closed.
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	schizophrenia	PRAMIPEXOLE	targetBased	3	Unknown status	01/03/2011	https://clinicaltrials.gov/study/NCT01320982	0.7	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	schizophrenia	PRAMIPEXOLE	targetBased	3	Unknown status	01/03/2011	https://clinicaltrials.gov/study/NCT01320982	0.7	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	schizophrenia	PRAMIPEXOLE	targetBased	3	Unknown status	01/03/2011	https://clinicaltrials.gov/study/NCT01320982	0.7	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	depressive disorder	PRAMIPEXOLE	targetBased	4	Terminated	01/02/2010	https://clinicaltrials.gov/study/NCT01066897	1	GoF	protect	Lack of funding prevented further recruitment
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	depressive disorder	PRAMIPEXOLE	targetBased	4	Terminated	01/02/2010	https://clinicaltrials.gov/study/NCT01066897	1	GoF	protect	Lack of funding prevented further recruitment
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	depressive disorder	PRAMIPEXOLE	targetBased	4	Terminated	01/02/2010	https://clinicaltrials.gov/study/NCT01066897	1	GoF	protect	Lack of funding prevented further recruitment
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	depressive disorder	PRAMIPEXOLE	targetBased	3	Recruiting	21/04/2023	https://clinicaltrials.gov/study/NCT05825235	0.7	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	depressive disorder	PRAMIPEXOLE	targetBased	4	Completed	01/09/2003	https://clinicaltrials.gov/study/NCT00231959	1	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	depressive disorder	PRAMIPEXOLE	targetBased	4	Completed	01/09/2003	https://clinicaltrials.gov/study/NCT00231959	1	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	depressive disorder	PRAMIPEXOLE	targetBased	4	Completed	01/09/2003	https://clinicaltrials.gov/study/NCT00231959	1	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Tourette syndrome	PRAMIPEXOLE	targetBased	3	Terminated	01/05/2008	https://clinicaltrials.gov/study/NCT00681863	0.7	GoF	protect	Terminated for slow enrollment.
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Tourette syndrome	PRAMIPEXOLE	targetBased	3	Terminated	01/05/2008	https://clinicaltrials.gov/study/NCT00681863	0.7	GoF	protect	Terminated for slow enrollment.
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Tourette syndrome	PRAMIPEXOLE	targetBased	3	Terminated	01/05/2008	https://clinicaltrials.gov/study/NCT00681863	0.7	GoF	protect	Terminated for slow enrollment.
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	PRAMIPEXOLE	targetBased	3	Unknown status	01/03/2011	https://clinicaltrials.gov/study/NCT01320982	0.7	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	PRAMIPEXOLE	targetBased	3	Unknown status	01/03/2011	https://clinicaltrials.gov/study/NCT01320982	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	PRAMIPEXOLE	targetBased	3	Unknown status	01/03/2011	https://clinicaltrials.gov/study/NCT01320982	0.7	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	PRAMIPEXOLE	targetBased	3	Unknown status	01/03/2011	https://clinicaltrials.gov/study/NCT01320982	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	PRAMIPEXOLE	targetBased	3	Unknown status	01/03/2011	https://clinicaltrials.gov/study/NCT01320982	0.7	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	PRAMIPEXOLE	targetBased	3	Unknown status	01/03/2011	https://clinicaltrials.gov/study/NCT01320982	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	treatment resistant depression	PRAMIPEXOLE	targetBased	4	Recruiting	07/08/2021	https://clinicaltrials.gov/study/NCT04936126	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	treatment resistant depression	PRAMIPEXOLE	targetBased	4	Recruiting	07/08/2021	https://clinicaltrials.gov/study/NCT04936126	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	treatment resistant depression	PRAMIPEXOLE	targetBased	4	Recruiting	07/08/2021	https://clinicaltrials.gov/study/NCT04936126	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	treatment resistant depression	PRAMIPEXOLE	targetBased	4	Recruiting	07/08/2021	https://clinicaltrials.gov/study/NCT04936126	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	treatment resistant depression	PRAMIPEXOLE	targetBased	4	Recruiting	07/08/2021	https://clinicaltrials.gov/study/NCT04936126	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	treatment resistant depression	PRAMIPEXOLE	targetBased	4	Recruiting	07/08/2021	https://clinicaltrials.gov/study/NCT04936126	1	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	schizoaffective disorder	PRAMIPEXOLE	targetBased	3	Unknown status	01/03/2011	https://clinicaltrials.gov/study/NCT01320982	0.7	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	schizoaffective disorder	PRAMIPEXOLE	targetBased	3	Unknown status	01/03/2011	https://clinicaltrials.gov/study/NCT01320982	0.7	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	schizoaffective disorder	PRAMIPEXOLE	targetBased	3	Unknown status	01/03/2011	https://clinicaltrials.gov/study/NCT01320982	0.7	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	opioid dependence	OXYMORPHONE	targetBased	4	Terminated	14/09/2016	https://clinicaltrials.gov/study/NCT02741076	1	GoF	protect	Inability to recruit sufficient no. of subjects over an acceptable time period
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	OXYMORPHONE	targetBased	4	Terminated	14/09/2016	https://clinicaltrials.gov/study/NCT02741076	1	GoF	protect	Inability to recruit sufficient no. of subjects over an acceptable time period
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	OXYMORPHONE	targetBased	4	Terminated	14/09/2016	https://clinicaltrials.gov/study/NCT02741076	1	GoF	protect	Inability to recruit sufficient no. of subjects over an acceptable time period
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	opioid dependence	NALMEFENE	targetBased	4	Withdrawn	01/06/2023	https://clinicaltrials.gov/study/NCT05808881	1	GoF	protect	Due to changes in research objectives and methodological approach.
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	NALMEFENE	targetBased	3	Recruiting	31/03/2023	https://clinicaltrials.gov/study/NCT05540288	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	NALMEFENE	targetBased	3	Recruiting	31/03/2023	https://clinicaltrials.gov/study/NCT05540288	0.7	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	drug dependence	NALMEFENE	targetBased	3	Recruiting	31/03/2023	https://clinicaltrials.gov/study/NCT05540288	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	NALMEFENE	targetBased	4	Withdrawn	01/06/2023	https://clinicaltrials.gov/study/NCT05808881	1	LoF	protect	Due to changes in research objectives and methodological approach.
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	NALMEFENE	targetBased	4	Withdrawn	01/06/2023	https://clinicaltrials.gov/study/NCT05808881	1	LoF	protect	Due to changes in research objectives and methodological approach.
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	alcohol dependence	NALMEFENE	targetBased	4	Terminated	01/08/2014	https://clinicaltrials.gov/study/NCT02195817	1	LoF	protect	The study was terminated due to enrolment challenges
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	alcohol dependence	NALMEFENE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N07BB05	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	alcohol dependence	NALMEFENE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N07BB05	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	alcohol dependence	NALMEFENE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/selincro	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	alcohol dependence	NALMEFENE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/selincro	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	alcohol dependence	NALMEFENE	targetBased	4	Completed	01/09/2014	https://clinicaltrials.gov/study/NCT02197598	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	alcohol dependence	NALMEFENE	targetBased	4	Completed	01/09/2014	https://clinicaltrials.gov/study/NCT02197598	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	alcohol dependence	NALMEFENE	targetBased	3	Completed	01/12/2008	https://clinicaltrials.gov/study/NCT00811720	0.7	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	alcohol dependence	NALMEFENE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N07BB05	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	alcohol dependence	NALMEFENE	targetBased	3	Completed	13/07/2015	https://clinicaltrials.gov/study/NCT02382276	0.7	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	alcohol dependence	NALMEFENE	targetBased	3	Completed	01/03/2009	https://clinicaltrials.gov/study/NCT00811941	0.7	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	alcohol dependence	NALMEFENE	targetBased	4	Terminated	01/08/2014	https://clinicaltrials.gov/study/NCT02195817	1	GoF	protect	The study was terminated due to enrolment challenges
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	alcohol dependence	NALMEFENE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/selincro	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	alcohol dependence	NALMEFENE	targetBased	3	Completed	01/03/2009	https://clinicaltrials.gov/study/NCT00812461	0.7	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	alcohol dependence	NALMEFENE	targetBased	4	Completed	01/09/2014	https://clinicaltrials.gov/study/NCT02197598	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	psychosis	CLOTHIAPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AH06	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain agnosia	REMIFENTANIL	targetBased	4	Not yet recruiting	01/06/2024	https://clinicaltrials.gov/study/NCT06454292	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain agnosia	REMIFENTANIL	targetBased	4	Not yet recruiting	01/06/2024	https://clinicaltrials.gov/study/NCT06454292	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain agnosia	REMIFENTANIL	targetBased	4	Not yet recruiting	01/06/2024	https://clinicaltrials.gov/study/NCT06444997	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain agnosia	REMIFENTANIL	targetBased	4	Not yet recruiting	01/06/2024	https://clinicaltrials.gov/study/NCT06444997	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	REMIFENTANIL	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02334046	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	REMIFENTANIL	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02334046	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	REMIFENTANIL	targetBased	4	Completed	16/11/2017	https://clinicaltrials.gov/study/NCT03330782	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	REMIFENTANIL	targetBased	4	Completed	16/11/2017	https://clinicaltrials.gov/study/NCT03330782	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	REMIFENTANIL	targetBased	4	Completed	01/10/2013	https://clinicaltrials.gov/study/NCT01931683	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	REMIFENTANIL	targetBased	4	Completed	01/10/2013	https://clinicaltrials.gov/study/NCT01931683	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Agitation	REMIFENTANIL	targetBased	4	Completed	01/05/2015	https://clinicaltrials.gov/study/NCT02428283	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Agitation	REMIFENTANIL	targetBased	4	Completed	01/05/2015	https://clinicaltrials.gov/study/NCT02428283	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Agitation	REMIFENTANIL	targetBased	4	Unknown status	01/04/2014	https://clinicaltrials.gov/study/NCT02104297	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Agitation	REMIFENTANIL	targetBased	4	Unknown status	01/04/2014	https://clinicaltrials.gov/study/NCT02104297	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Agitation	REMIFENTANIL	targetBased	4	Not yet recruiting	15/11/2022	https://clinicaltrials.gov/study/NCT05624424	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Agitation	REMIFENTANIL	targetBased	4	Not yet recruiting	15/11/2022	https://clinicaltrials.gov/study/NCT05624424	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	delirium	REMIFENTANIL	targetBased	4	Unknown status	01/07/2014	https://clinicaltrials.gov/study/NCT02078583	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	delirium	REMIFENTANIL	targetBased	4	Unknown status	01/07/2014	https://clinicaltrials.gov/study/NCT02078583	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	obstructive sleep apnea	REMIFENTANIL	targetBased	4	Completed	01/07/2012	https://clinicaltrials.gov/study/NCT01895348	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	obstructive sleep apnea	REMIFENTANIL	targetBased	4	Completed	01/07/2012	https://clinicaltrials.gov/study/NCT01895348	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	REMIFENTANIL	targetBased	4	Completed	01/01/2012	https://clinicaltrials.gov/study/NCT01495377	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	REMIFENTANIL	targetBased	4	Completed	01/01/2012	https://clinicaltrials.gov/study/NCT01495377	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	REMIFENTANIL	targetBased	3	Terminated	29/11/2017	https://clinicaltrials.gov/study/NCT03316339	0.7	GoF	protect	Sponsor's decision
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	REMIFENTANIL	targetBased	4	Unknown status	11/01/2019	https://clinicaltrials.gov/study/NCT03812003	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	REMIFENTANIL	targetBased	4	Unknown status	11/01/2019	https://clinicaltrials.gov/study/NCT03812003	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	REMIFENTANIL	targetBased	4	Completed	01/10/2010	https://clinicaltrials.gov/study/NCT01191645	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	REMIFENTANIL	targetBased	4	Completed	01/10/2010	https://clinicaltrials.gov/study/NCT01191645	1	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	dysthymic disorder	LEVODOPA	targetBased	4	Terminated	09/01/2019	https://clinicaltrials.gov/study/NCT03761030	1	GoF	protect	The project end date was reached prior to the full sample enrollment
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	dysthymic disorder	LEVODOPA	targetBased	4	Terminated	09/01/2019	https://clinicaltrials.gov/study/NCT03761030	1	GoF	protect	The project end date was reached prior to the full sample enrollment
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	dysthymic disorder	LEVODOPA	targetBased	4	Terminated	09/01/2019	https://clinicaltrials.gov/study/NCT03761030	1	GoF	protect	The project end date was reached prior to the full sample enrollment
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	impulse control disorder	LEVODOPA	targetBased	4	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01683253	1	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	impulse control disorder	LEVODOPA	targetBased	4	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01683253	1	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	impulse control disorder	LEVODOPA	targetBased	4	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01683253	1	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	post-traumatic stress disorder	LEVODOPA	targetBased	4	Completed	01/03/2016	https://clinicaltrials.gov/study/NCT02560389	1	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	post-traumatic stress disorder	LEVODOPA	targetBased	4	Completed	01/03/2016	https://clinicaltrials.gov/study/NCT02560389	1	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	post-traumatic stress disorder	LEVODOPA	targetBased	4	Completed	01/03/2016	https://clinicaltrials.gov/study/NCT02560389	1	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	major depressive disorder	LEVODOPA	targetBased	4	Terminated	09/01/2019	https://clinicaltrials.gov/study/NCT03761030	1	GoF	protect	The project end date was reached prior to the full sample enrollment
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	major depressive disorder	LEVODOPA	targetBased	4	Terminated	09/01/2019	https://clinicaltrials.gov/study/NCT03761030	1	GoF	protect	The project end date was reached prior to the full sample enrollment
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	major depressive disorder	LEVODOPA	targetBased	4	Terminated	09/01/2019	https://clinicaltrials.gov/study/NCT03761030	1	GoF	protect	The project end date was reached prior to the full sample enrollment
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	depressive disorder	LEVODOPA	targetBased	4	Recruiting	21/11/2023	https://clinicaltrials.gov/study/NCT06075771	1	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	depressive disorder	LEVODOPA	targetBased	4	Terminated	07/10/2021	https://clinicaltrials.gov/study/NCT04650217	1	GoF	protect	Study terminated by sponsor (NIMH)
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	depressive disorder	LEVODOPA	targetBased	4	Terminated	07/10/2021	https://clinicaltrials.gov/study/NCT04650217	1	GoF	protect	Study terminated by sponsor (NIMH)
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	depressive disorder	LEVODOPA	targetBased	4	Terminated	07/10/2021	https://clinicaltrials.gov/study/NCT04650217	1	GoF	protect	Study terminated by sponsor (NIMH)
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	depressive disorder	LEVODOPA	targetBased	4	Completed	09/10/2015	https://clinicaltrials.gov/study/NCT02513485	1	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	depressive disorder	LEVODOPA	targetBased	4	Completed	09/10/2015	https://clinicaltrials.gov/study/NCT02513485	1	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	depressive disorder	LEVODOPA	targetBased	4	Completed	09/10/2015	https://clinicaltrials.gov/study/NCT02513485	1	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	dyslexia	LEVODOPA	targetBased	4	Unknown status	01/01/2005	https://clinicaltrials.gov/study/NCT00111371	1	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	dyslexia	LEVODOPA	targetBased	4	Unknown status	01/01/2005	https://clinicaltrials.gov/study/NCT00111371	1	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	dyslexia	LEVODOPA	targetBased	4	Unknown status	01/01/2005	https://clinicaltrials.gov/study/NCT00111371	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Sleep Disorder	VOLINANSERIN	targetBased	3	Terminated	01/04/2007	https://clinicaltrials.gov/study/NCT00464061	0.35	LoF	protect	Sponsor's decision due to absence of demonstration of efficacy of volinanserin in primary insomnia with predominant sleep maintenance problems
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Sleep Disorder	VOLINANSERIN	targetBased	3	Completed	01/06/2007	https://clinicaltrials.gov/study/NCT00495885	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Sleep Disorder	VOLINANSERIN	targetBased	3	Terminated	01/11/2008	https://clinicaltrials.gov/study/NCT00788515	0.35	LoF	protect	Sponsor's decision due to absence of demonstration of efficacy of volinanserin in primary insomnia with predominant sleep maintenance problems
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Sleep Disorder	VOLINANSERIN	targetBased	3	Completed	01/04/2007	https://clinicaltrials.gov/study/NCT00464243	0.7	LoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	depressive disorder	CHOLECALCIFEROL	targetBased	4	Unknown status	01/03/2011	https://clinicaltrials.gov/study/NCT01390662	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	schizoaffective disorder	CHOLECALCIFEROL	targetBased	4	Completed	01/01/2010	https://clinicaltrials.gov/study/NCT01169142	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	drug dependence	CHOLECALCIFEROL	targetBased	4	Recruiting	11/01/2022	https://clinicaltrials.gov/study/NCT05161351	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	schizophrenia	CHOLECALCIFEROL	targetBased	4	Completed	01/01/2010	https://clinicaltrials.gov/study/NCT01169142	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	schizophrenia	CHOLECALCIFEROL	targetBased	3	Not yet recruiting	15/04/2020	https://clinicaltrials.gov/study/NCT03284294	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	chronic tic disorder	TIAPRIDE	targetBased	3	Completed	01/01/2008	https://clinicaltrials.gov/study/NCT01501695	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	chronic tic disorder	TIAPRIDE	targetBased	3	Completed	01/01/2008	https://clinicaltrials.gov/study/NCT01501695	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	chronic tic disorder	TIAPRIDE	targetBased	3	Completed	01/01/2008	https://clinicaltrials.gov/study/NCT01501695	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	chronic tic disorder	TIAPRIDE	targetBased	3	Completed	01/01/2008	https://clinicaltrials.gov/study/NCT01501695	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	chronic tic disorder	TIAPRIDE	targetBased	3	Completed	01/01/2008	https://clinicaltrials.gov/study/NCT01501695	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	chronic tic disorder	TIAPRIDE	targetBased	3	Completed	01/01/2008	https://clinicaltrials.gov/study/NCT01501695	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	chronic tic disorder	TIAPRIDE	targetBased	3	Completed	01/01/2008	https://clinicaltrials.gov/study/NCT01501695	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	chronic tic disorder	TIAPRIDE	targetBased	3	Completed	01/01/2008	https://clinicaltrials.gov/study/NCT01501695	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	chronic tic disorder	TIAPRIDE	targetBased	3	Completed	01/01/2008	https://clinicaltrials.gov/study/NCT01501695	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Tourette syndrome	TIAPRIDE	targetBased	3	Completed	01/01/2008	https://clinicaltrials.gov/study/NCT01501695	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Tourette syndrome	TIAPRIDE	targetBased	3	Completed	01/01/2008	https://clinicaltrials.gov/study/NCT01501695	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Tourette syndrome	TIAPRIDE	targetBased	3	Completed	01/01/2008	https://clinicaltrials.gov/study/NCT01501695	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Tourette syndrome	TIAPRIDE	targetBased	3	Completed	01/01/2008	https://clinicaltrials.gov/study/NCT01501695	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Tourette syndrome	TIAPRIDE	targetBased	3	Completed	01/01/2008	https://clinicaltrials.gov/study/NCT01501695	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Tourette syndrome	TIAPRIDE	targetBased	3	Completed	01/01/2008	https://clinicaltrials.gov/study/NCT01501695	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Dementia	TIAPRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Dementia	TIAPRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Dementia	TIAPRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	psychosis	TIAPRIDE	targetBased	3			https://www.whocc.no/atc_ddd_index/?code=N05AL03	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	psychosis	TIAPRIDE	targetBased	3			https://www.whocc.no/atc_ddd_index/?code=N05AL03	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	psychosis	TIAPRIDE	targetBased	3			https://www.whocc.no/atc_ddd_index/?code=N05AL03	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	depressive disorder	TIAPRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	depressive disorder	TIAPRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	depressive disorder	TIAPRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	depressive disorder	TIAPRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	depressive disorder	TIAPRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	depressive disorder	TIAPRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	anxiety	TIAPRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	anxiety	TIAPRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	anxiety	TIAPRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	anxiety	TIAPRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	anxiety	TIAPRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	anxiety	TIAPRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	schizophrenia	TIAPRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	schizophrenia	TIAPRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	schizophrenia	TIAPRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	depressive disorder	TIAPRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	depressive disorder	TIAPRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	depressive disorder	TIAPRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	psychosis	TIAPRIDE	targetBased	3			https://www.whocc.no/atc_ddd_index/?code=N05AL03	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	psychosis	TIAPRIDE	targetBased	3			https://www.whocc.no/atc_ddd_index/?code=N05AL03	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	psychosis	TIAPRIDE	targetBased	3			https://www.whocc.no/atc_ddd_index/?code=N05AL03	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	psychosis	TIAPRIDE	targetBased	3			https://www.whocc.no/atc_ddd_index/?code=N05AL03	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	TIAPRIDE	targetBased	3			https://www.whocc.no/atc_ddd_index/?code=N05AL03	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	TIAPRIDE	targetBased	3			https://www.whocc.no/atc_ddd_index/?code=N05AL03	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Tourette syndrome	TIAPRIDE	targetBased	3	Completed	01/01/2008	https://clinicaltrials.gov/study/NCT01501695	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Tourette syndrome	TIAPRIDE	targetBased	3	Completed	01/01/2008	https://clinicaltrials.gov/study/NCT01501695	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Tourette syndrome	TIAPRIDE	targetBased	3	Completed	01/01/2008	https://clinicaltrials.gov/study/NCT01501695	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Dementia	TIAPRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Dementia	TIAPRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Dementia	TIAPRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Dementia	TIAPRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Dementia	TIAPRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Dementia	TIAPRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	TIAPRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	TIAPRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	TIAPRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	TIAPRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	TIAPRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	TIAPRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	anxiety	TIAPRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	anxiety	TIAPRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	anxiety	TIAPRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	psychosis	ACETOPHENAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AB07	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	psychosis	ACETOPHENAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AB07	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	psychosis	ACETOPHENAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AB07	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	psychosis	ACETOPHENAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AB07	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	ACETOPHENAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AB07	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	ACETOPHENAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AB07	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	psychosis	MESORIDAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AC03	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	psychosis	MESORIDAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AC03	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	psychosis	MESORIDAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AC03	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	psychosis	MESORIDAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AC03	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	psychosis	MESORIDAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AC03	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	MESORIDAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AC03	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	MESORIDAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AC03	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	cocaine dependence	BIPERIDEN	targetBased	4	Unknown status	01/01/2009	https://clinicaltrials.gov/study/NCT00495183	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	cocaine dependence	BIPERIDEN	targetBased	4	Unknown status	01/01/2009	https://clinicaltrials.gov/study/NCT00495183	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	cocaine dependence	BIPERIDEN	targetBased	4	Unknown status	01/01/2009	https://clinicaltrials.gov/study/NCT00495183	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	cocaine dependence	BIPERIDEN	targetBased	4	Unknown status	01/01/2009	https://clinicaltrials.gov/study/NCT00495183	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	cocaine dependence	BIPERIDEN	targetBased	4	Unknown status	01/01/2009	https://clinicaltrials.gov/study/NCT00495183	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	cocaine dependence	BIPERIDEN	targetBased	3	Completed	01/05/2011	https://clinicaltrials.gov/study/NCT01251393	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	cocaine dependence	BIPERIDEN	targetBased	3	Completed	01/05/2011	https://clinicaltrials.gov/study/NCT01251393	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	cocaine dependence	BIPERIDEN	targetBased	3	Completed	01/05/2011	https://clinicaltrials.gov/study/NCT01251393	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	anxiety	BIPERIDEN	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	anxiety	BIPERIDEN	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	anxiety	BIPERIDEN	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	anxiety	BIPERIDEN	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	anxiety	BIPERIDEN	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	depressive disorder	BIPERIDEN	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	depressive disorder	BIPERIDEN	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	depressive disorder	BIPERIDEN	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	depressive disorder	BIPERIDEN	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	depressive disorder	BIPERIDEN	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	schizophrenia	BIPERIDEN	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	schizophrenia	BIPERIDEN	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	schizophrenia	BIPERIDEN	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	schizophrenia	BIPERIDEN	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	schizophrenia	BIPERIDEN	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Dementia	BIPERIDEN	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Dementia	BIPERIDEN	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Dementia	BIPERIDEN	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Dementia	BIPERIDEN	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Dementia	BIPERIDEN	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	psychosis	DROPERIDOL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AD08	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	psychosis	DROPERIDOL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AD08	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	psychosis	DROPERIDOL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AD08	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	psychosis	DROPERIDOL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AD08	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	psychosis	DROPERIDOL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AD08	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	psychosis	DROPERIDOL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AD08	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	psychosis	DROPERIDOL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AD08	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	psychosis	DROPERIDOL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AD08	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	DROPERIDOL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AD08	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	DROPERIDOL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AD08	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	chronic tic disorder	ARIPIPRAZOLE	targetBased	3	Completed	01/10/2008	https://clinicaltrials.gov/study/NCT00706589	0.7	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	chronic tic disorder	ARIPIPRAZOLE	targetBased	3	Completed	01/10/2008	https://clinicaltrials.gov/study/NCT00706589	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	chronic tic disorder	ARIPIPRAZOLE	targetBased	3	Completed	01/10/2008	https://clinicaltrials.gov/study/NCT00706589	0.7	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	chronic tic disorder	ARIPIPRAZOLE	targetBased	3	Completed	01/10/2008	https://clinicaltrials.gov/study/NCT00706589	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	chronic tic disorder	ARIPIPRAZOLE	targetBased	3	Completed	01/10/2008	https://clinicaltrials.gov/study/NCT00706589	0.7	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	chronic tic disorder	ARIPIPRAZOLE	targetBased	3	Completed	01/10/2008	https://clinicaltrials.gov/study/NCT00706589	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	treatment resistant depression	ARIPIPRAZOLE	targetBased	4	Completed	24/02/2017	https://clinicaltrials.gov/study/NCT02960763	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	treatment resistant depression	ARIPIPRAZOLE	targetBased	4	Completed	24/02/2017	https://clinicaltrials.gov/study/NCT02960763	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	major depressive disorder	ARIPIPRAZOLE	targetBased	4	Terminated	01/05/2009	https://clinicaltrials.gov/study/NCT00926835	1	LoF	protect	due to patient recruitment difficulties
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	major depressive disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/09/2011	https://clinicaltrials.gov/study/NCT01429831	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	major depressive disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/10/2005	https://clinicaltrials.gov/study/NCT00608543	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	major depressive disorder	ARIPIPRAZOLE	targetBased	4	Completed	10/02/2012	https://clinicaltrials.gov/study/NCT01696617	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	major depressive disorder	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=16710a27-aa76-4dd7-92e8-7d3c7efe3e42	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	major depressive disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/03/2005	https://clinicaltrials.gov/study/NCT00220636	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	major depressive disorder	ARIPIPRAZOLE	targetBased	4	Completed	24/02/2017	https://clinicaltrials.gov/study/NCT02960763	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	conduct disorder	ARIPIPRAZOLE	targetBased	4	Completed	17/11/2004	https://clinicaltrials.gov/study/NCT00250705	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	conduct disorder	ARIPIPRAZOLE	targetBased	4	Completed	17/11/2004	https://clinicaltrials.gov/study/NCT00250705	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	conduct disorder	ARIPIPRAZOLE	targetBased	4	Completed	17/11/2004	https://clinicaltrials.gov/study/NCT00250705	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	conduct disorder	ARIPIPRAZOLE	targetBased	4	Completed	17/11/2004	https://clinicaltrials.gov/study/NCT00250705	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	conduct disorder	ARIPIPRAZOLE	targetBased	4	Completed	17/11/2004	https://clinicaltrials.gov/study/NCT00250705	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	conduct disorder	ARIPIPRAZOLE	targetBased	4	Completed	17/11/2004	https://clinicaltrials.gov/study/NCT00250705	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	aggressive behavior	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ffb6ef30-2619-4652-864c-4d5e94526a15	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	aggressive behavior	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ffb6ef30-2619-4652-864c-4d5e94526a15	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	post-traumatic stress disorder	ARIPIPRAZOLE	targetBased	3	Completed	01/01/2004	https://clinicaltrials.gov/study/NCT00440713	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	aggressive behavior	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ffb6ef30-2619-4652-864c-4d5e94526a15	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	aggressive behavior	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ffb6ef30-2619-4652-864c-4d5e94526a15	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	aggressive behavior	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ffb6ef30-2619-4652-864c-4d5e94526a15	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	aggressive behavior	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ffb6ef30-2619-4652-864c-4d5e94526a15	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	aggressive behavior	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ffb6ef30-2619-4652-864c-4d5e94526a15	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	aggressive behavior	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ffb6ef30-2619-4652-864c-4d5e94526a15	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	mental or behavioural disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/10/2005	https://clinicaltrials.gov/study/NCT02305823	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	mental or behavioural disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/10/2005	https://clinicaltrials.gov/study/NCT02305823	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	mental or behavioural disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT00806234	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	mental or behavioural disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT00806234	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	mental or behavioural disorder	ARIPIPRAZOLE	targetBased	3	Completed	01/03/2004	https://clinicaltrials.gov/study/NCT00095524	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	mental or behavioural disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/10/2008	https://clinicaltrials.gov/study/NCT02526030	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	mental or behavioural disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/10/2008	https://clinicaltrials.gov/study/NCT02526030	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	autism spectrum disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/08/2009	https://clinicaltrials.gov/study/NCT01028820	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	autism spectrum disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/08/2009	https://clinicaltrials.gov/study/NCT01028820	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	unipolar depression	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6875b848-8b13-45f8-ada5-69ef8aece6b6	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	unipolar depression	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=217e52b5-3a7b-4bbe-af3c-b18de7d426c3	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	unipolar depression	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=440012b2-4fab-4e2e-ba7f-6ca5558d1e23	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	unipolar depression	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1be1bea7-71d5-406a-bcf3-e1d58f406389	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	unipolar depression	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0424faf3-202f-438a-b65e-2a228790b8f9	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	unipolar depression	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d8275c2d-f42d-4f32-aa9f-03a202c8e99f	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	unipolar depression	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=231e2433-31fe-4612-80f0-ba00dee3b26a	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	chronic tic disorder	ARIPIPRAZOLE	targetBased	3	Completed	01/10/2008	https://clinicaltrials.gov/study/NCT00706589	0.7	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	bipolar disorder	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c040bd1d-45b7-49f2-93ea-aed7220b30ac	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	bipolar disorder	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cbbd3dc0-6a39-48f7-91b9-a95c6c12ee0c	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	bipolar disorder	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cbbd3dc0-6a39-48f7-91b9-a95c6c12ee0c	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	bipolar disorder	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=16710a27-aa76-4dd7-92e8-7d3c7efe3e42	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	bipolar disorder	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=16710a27-aa76-4dd7-92e8-7d3c7efe3e42	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	bipolar disorder	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b6243233-8846-4ea8-a2fa-a563e48fdc29	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	bipolar disorder	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b6243233-8846-4ea8-a2fa-a563e48fdc29	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=16710a27-aa76-4dd7-92e8-7d3c7efe3e42	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	ARIPIPRAZOLE	targetBased	4	Completed	01/10/2011	https://clinicaltrials.gov/study/NCT01446328	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	ARIPIPRAZOLE	targetBased	4	Completed	01/04/2004	https://clinicaltrials.gov/study/NCT00634348	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	ARIPIPRAZOLE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02146547	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	ARIPIPRAZOLE	targetBased	4	Unknown status	01/09/2006	https://clinicaltrials.gov/study/NCT00395915	1	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	depressive disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/08/2009	https://clinicaltrials.gov/study/NCT00892047	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	depressive disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/08/2009	https://clinicaltrials.gov/study/NCT00892047	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	depressive disorder	ARIPIPRAZOLE	targetBased	3	Withdrawn	01/06/2005	https://clinicaltrials.gov/study/NCT00276978	0.7	GoF	protect	Initiation of study was stopped due to administrative reasons before first subject was enrolled.
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	depressive disorder	ARIPIPRAZOLE	targetBased	4	Terminated	01/07/2009	https://clinicaltrials.gov/study/NCT01305707	1	GoF	protect	Difficulties in recruiting
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	depressive disorder	ARIPIPRAZOLE	targetBased	4	Terminated	01/07/2009	https://clinicaltrials.gov/study/NCT01305707	1	GoF	protect	Difficulties in recruiting
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	depressive disorder	ARIPIPRAZOLE	targetBased	4	Unknown status	01/06/2017	https://clinicaltrials.gov/study/NCT03148509	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	depressive disorder	ARIPIPRAZOLE	targetBased	4	Unknown status	01/06/2017	https://clinicaltrials.gov/study/NCT03148509	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	ARIPIPRAZOLE	targetBased	4	Unknown status	01/12/2014	https://clinicaltrials.gov/study/NCT02282085	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	ARIPIPRAZOLE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/21436s04021713s03121729s02321866s025lbl.pdf	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar disorder	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6875b848-8b13-45f8-ada5-69ef8aece6b6	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	bipolar disorder	ARIPIPRAZOLE	targetBased	4	Terminated	01/12/2007	https://clinicaltrials.gov/study/NCT00592683	1	GoF	protect	Supply Omega-3 Fatty Acids expired and supplier no longer made same composition.
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	bipolar disorder	ARIPIPRAZOLE	targetBased	4	Terminated	01/12/2007	https://clinicaltrials.gov/study/NCT00592683	1	GoF	protect	Supply Omega-3 Fatty Acids expired and supplier no longer made same composition.
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar disorder	ARIPIPRAZOLE	targetBased	4	Terminated	01/12/2007	https://clinicaltrials.gov/study/NCT00592683	1	GoF	protect	Supply Omega-3 Fatty Acids expired and supplier no longer made same composition.
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar disorder	ARIPIPRAZOLE	targetBased	4	Terminated	01/12/2007	https://clinicaltrials.gov/study/NCT00592683	1	GoF	protect	Supply Omega-3 Fatty Acids expired and supplier no longer made same composition.
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar disorder	ARIPIPRAZOLE	targetBased	4	Terminated	01/12/2007	https://clinicaltrials.gov/study/NCT00592683	1	GoF	protect	Supply Omega-3 Fatty Acids expired and supplier no longer made same composition.
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar disorder	ARIPIPRAZOLE	targetBased	4	Terminated	01/12/2007	https://clinicaltrials.gov/study/NCT00592683	1	GoF	protect	Supply Omega-3 Fatty Acids expired and supplier no longer made same composition.
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	eating disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00685334	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	eating disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00685334	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	treatment refractory schizophrenia	ARIPIPRAZOLE	targetBased	4	Not yet recruiting	20/08/2023	https://clinicaltrials.gov/study/NCT05766540	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	treatment refractory schizophrenia	ARIPIPRAZOLE	targetBased	4	Not yet recruiting	20/08/2023	https://clinicaltrials.gov/study/NCT05766540	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	chronic tic disorder	ARIPIPRAZOLE	targetBased	3	Completed	01/10/2008	https://clinicaltrials.gov/study/NCT00706589	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	chronic tic disorder	ARIPIPRAZOLE	targetBased	3	Completed	01/10/2008	https://clinicaltrials.gov/study/NCT00706589	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	alcohol dependence	ARIPIPRAZOLE	targetBased	3	Completed	01/02/2011	https://clinicaltrials.gov/study/NCT01292057	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	alcohol dependence	ARIPIPRAZOLE	targetBased	4	Completed	01/04/2004	https://clinicaltrials.gov/study/NCT00082199	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	methamphetamine dependence	ARIPIPRAZOLE	targetBased	4	Withdrawn	01/08/2009	https://clinicaltrials.gov/study/NCT00728312	1	LoF	protect	PI left the VA.
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	methamphetamine dependence	ARIPIPRAZOLE	targetBased	4	Terminated	01/09/2012	https://clinicaltrials.gov/study/NCT01813656	0.5	LoF	protect	Aripiprazole arm had obvious adverse reactions,especially akathisia.
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	methamphetamine dependence	ARIPIPRAZOLE	targetBased	4	Terminated	01/07/2012	https://clinicaltrials.gov/study/NCT01813643	0.5	LoF	protect	Effects of aripiprazole was not obvious and showed adverse reaction obviously
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Agitation	ARIPIPRAZOLE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202971s008lbl.pdf	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Agitation	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=231e2433-31fe-4612-80f0-ba00dee3b26a	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Agitation	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=231e2433-31fe-4612-80f0-ba00dee3b26a	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Agitation	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=16710a27-aa76-4dd7-92e8-7d3c7efe3e42	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Agitation	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=16710a27-aa76-4dd7-92e8-7d3c7efe3e42	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Agitation	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e8fe516e-25fc-45f6-9a88-542deaa1c3e8	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Agitation	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e8fe516e-25fc-45f6-9a88-542deaa1c3e8	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Tourette syndrome	ARIPIPRAZOLE	targetBased	4	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00241176	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Tourette syndrome	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0f24ce78-525a-4bb1-a23d-03f152558575	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Tourette syndrome	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0f24ce78-525a-4bb1-a23d-03f152558575	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Tourette syndrome	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0f24ce78-525a-4bb1-a23d-03f152558575	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Tourette syndrome	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0f24ce78-525a-4bb1-a23d-03f152558575	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Tourette syndrome	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0f24ce78-525a-4bb1-a23d-03f152558575	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Tourette syndrome	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0f24ce78-525a-4bb1-a23d-03f152558575	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	autism	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d0640208-44e9-4052-a56f-9a4cd9a5aaab	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	autism	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=12c08d3d-7556-444d-8d01-7737e1507d32	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	autism	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=12c08d3d-7556-444d-8d01-7737e1507d32	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	autism	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=634b6431-48ca-480c-a4d8-0ba022bbf0f4	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	autism	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=634b6431-48ca-480c-a4d8-0ba022bbf0f4	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	autism	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e8fe516e-25fc-45f6-9a88-542deaa1c3e8	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	autism	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e8fe516e-25fc-45f6-9a88-542deaa1c3e8	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	dysthymic disorder	ARIPIPRAZOLE	targetBased	4	Withdrawn	01/08/2013	https://clinicaltrials.gov/study/NCT01942187	1	LoF	protect	No participants enrolled.
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	dysthymic disorder	ARIPIPRAZOLE	targetBased	4	Withdrawn	01/08/2013	https://clinicaltrials.gov/study/NCT01942187	1	GoF	protect	No participants enrolled.
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	dysthymic disorder	ARIPIPRAZOLE	targetBased	4	Withdrawn	01/08/2013	https://clinicaltrials.gov/study/NCT01942187	1	GoF	protect	No participants enrolled.
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	dysthymic disorder	ARIPIPRAZOLE	targetBased	4	Withdrawn	01/08/2013	https://clinicaltrials.gov/study/NCT01942187	1	GoF	protect	No participants enrolled.
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	dysthymic disorder	ARIPIPRAZOLE	targetBased	4	Withdrawn	01/08/2013	https://clinicaltrials.gov/study/NCT01942187	1	GoF	protect	No participants enrolled.
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	dysthymic disorder	ARIPIPRAZOLE	targetBased	4	Withdrawn	01/08/2013	https://clinicaltrials.gov/study/NCT01942187	1	GoF	protect	No participants enrolled.
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	dysthymic disorder	ARIPIPRAZOLE	targetBased	4	Withdrawn	01/08/2013	https://clinicaltrials.gov/study/NCT01942187	1	GoF	protect	No participants enrolled.
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	mental or behavioural disorder	ARIPIPRAZOLE	targetBased	3	Completed	01/03/2004	https://clinicaltrials.gov/study/NCT00095524	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	mental or behavioural disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/10/2005	https://clinicaltrials.gov/study/NCT02305823	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	mental or behavioural disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT00806234	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	mental or behavioural disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/10/2008	https://clinicaltrials.gov/study/NCT02526030	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	conduct disorder	ARIPIPRAZOLE	targetBased	4	Completed	17/11/2004	https://clinicaltrials.gov/study/NCT00250705	1	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	post-traumatic stress disorder	ARIPIPRAZOLE	targetBased	3	Completed	01/01/2004	https://clinicaltrials.gov/study/NCT00440713	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	post-traumatic stress disorder	ARIPIPRAZOLE	targetBased	3	Completed	01/01/2004	https://clinicaltrials.gov/study/NCT00440713	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	treatment resistant depression	ARIPIPRAZOLE	targetBased	4	Completed	24/02/2017	https://clinicaltrials.gov/study/NCT02960763	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Dementia	ARIPIPRAZOLE	targetBased	3	Completed	01/12/2003	https://clinicaltrials.gov/study/NCT00095719	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Dementia	ARIPIPRAZOLE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	major depressive disorder	ARIPIPRAZOLE	targetBased	4	Terminated	01/05/2009	https://clinicaltrials.gov/study/NCT00926835	1	GoF	protect	due to patient recruitment difficulties
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	major depressive disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/09/2011	https://clinicaltrials.gov/study/NCT01429831	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	major depressive disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/09/2011	https://clinicaltrials.gov/study/NCT01429831	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	major depressive disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/09/2011	https://clinicaltrials.gov/study/NCT01429831	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	major depressive disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/09/2011	https://clinicaltrials.gov/study/NCT01429831	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	major depressive disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/09/2011	https://clinicaltrials.gov/study/NCT01429831	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	major depressive disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/09/2011	https://clinicaltrials.gov/study/NCT01429831	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	social anxiety disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/03/2004	https://clinicaltrials.gov/study/NCT00177008	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	social anxiety disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/03/2004	https://clinicaltrials.gov/study/NCT00177008	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	postpartum depression	ARIPIPRAZOLE	targetBased	3	Completed	01/06/2011	https://clinicaltrials.gov/study/NCT01386086	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Tourette syndrome	ARIPIPRAZOLE	targetBased	4	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00241176	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Tourette syndrome	ARIPIPRAZOLE	targetBased	3	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01727700	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Tourette syndrome	ARIPIPRAZOLE	targetBased	3	Completed	02/05/2018	https://clinicaltrials.gov/study/NCT03487783	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Tourette syndrome	ARIPIPRAZOLE	targetBased	3	Completed	19/10/2011	https://clinicaltrials.gov/study/NCT01416441	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Tourette syndrome	ARIPIPRAZOLE	targetBased	4	Terminated	13/10/2018	https://clinicaltrials.gov/study/NCT03661983	1	LoF	protect	Lack of feasibility for completion of the trial within a reasonable time frame.
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Tourette syndrome	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0f24ce78-525a-4bb1-a23d-03f152558575	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Tourette syndrome	ARIPIPRAZOLE	targetBased	3	Completed	01/01/2013	https://clinicaltrials.gov/study/NCT01727713	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Tourette syndrome	ARIPIPRAZOLE	targetBased	3	Completed	27/07/2011	https://clinicaltrials.gov/study/NCT01418339	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Tourette syndrome	ARIPIPRAZOLE	targetBased	3	Completed	02/08/2011	https://clinicaltrials.gov/study/NCT01418352	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	post-traumatic stress disorder	ARIPIPRAZOLE	targetBased	3	Completed	01/01/2004	https://clinicaltrials.gov/study/NCT00440713	0.7	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	post-traumatic stress disorder	ARIPIPRAZOLE	targetBased	3	Completed	01/01/2004	https://clinicaltrials.gov/study/NCT00440713	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	post-traumatic stress disorder	ARIPIPRAZOLE	targetBased	3	Completed	01/01/2004	https://clinicaltrials.gov/study/NCT00440713	0.7	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	post-traumatic stress disorder	ARIPIPRAZOLE	targetBased	3	Completed	01/01/2004	https://clinicaltrials.gov/study/NCT00440713	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	post-traumatic stress disorder	ARIPIPRAZOLE	targetBased	3	Completed	01/01/2004	https://clinicaltrials.gov/study/NCT00440713	0.7	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	post-traumatic stress disorder	ARIPIPRAZOLE	targetBased	3	Completed	01/01/2004	https://clinicaltrials.gov/study/NCT00440713	0.7	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	depressive disorder	ARIPIPRAZOLE	targetBased	4	Terminated	01/07/2009	https://clinicaltrials.gov/study/NCT01305707	1	GoF	protect	Difficulties in recruiting
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	depressive disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/08/2009	https://clinicaltrials.gov/study/NCT00892047	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	depressive disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/08/2009	https://clinicaltrials.gov/study/NCT00892047	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	depressive disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/08/2009	https://clinicaltrials.gov/study/NCT00892047	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	depressive disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/08/2009	https://clinicaltrials.gov/study/NCT00892047	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	depressive disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/08/2009	https://clinicaltrials.gov/study/NCT00892047	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	depressive disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/08/2009	https://clinicaltrials.gov/study/NCT00892047	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	major depressive disorder	ARIPIPRAZOLE	targetBased	4	Completed	24/02/2017	https://clinicaltrials.gov/study/NCT02960763	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	major depressive disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/09/2011	https://clinicaltrials.gov/study/NCT01429831	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	major depressive disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/09/2011	https://clinicaltrials.gov/study/NCT01429831	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	major depressive disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/05/2017	https://clinicaltrials.gov/study/NCT02977299	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	major depressive disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/05/2017	https://clinicaltrials.gov/study/NCT02977299	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	major depressive disorder	ARIPIPRAZOLE	targetBased	4	Terminated	01/05/2009	https://clinicaltrials.gov/study/NCT00926835	1	GoF	protect	due to patient recruitment difficulties
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	major depressive disorder	ARIPIPRAZOLE	targetBased	4	Terminated	01/05/2009	https://clinicaltrials.gov/study/NCT00926835	1	GoF	protect	due to patient recruitment difficulties
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	eating disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00685334	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	unipolar depression	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=217e52b5-3a7b-4bbe-af3c-b18de7d426c3	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	unipolar depression	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c040bd1d-45b7-49f2-93ea-aed7220b30ac	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	unipolar depression	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c040bd1d-45b7-49f2-93ea-aed7220b30ac	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	unipolar depression	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c040bd1d-45b7-49f2-93ea-aed7220b30ac	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	unipolar depression	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c040bd1d-45b7-49f2-93ea-aed7220b30ac	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	unipolar depression	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c040bd1d-45b7-49f2-93ea-aed7220b30ac	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	unipolar depression	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c040bd1d-45b7-49f2-93ea-aed7220b30ac	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	treatment refractory schizophrenia	ARIPIPRAZOLE	targetBased	4	Not yet recruiting	20/08/2023	https://clinicaltrials.gov/study/NCT05766540	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	anxiety	ARIPIPRAZOLE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	anxiety	ARIPIPRAZOLE	targetBased	4	Completed	01/03/2005	https://clinicaltrials.gov/study/NCT00208169	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	anxiety	ARIPIPRAZOLE	targetBased	4	Completed	01/03/2005	https://clinicaltrials.gov/study/NCT00208169	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	anxiety	ARIPIPRAZOLE	targetBased	4	Completed	01/03/2005	https://clinicaltrials.gov/study/NCT00208169	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	anxiety	ARIPIPRAZOLE	targetBased	4	Completed	01/03/2005	https://clinicaltrials.gov/study/NCT00208169	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	anxiety	ARIPIPRAZOLE	targetBased	4	Completed	01/03/2005	https://clinicaltrials.gov/study/NCT00208169	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	anxiety	ARIPIPRAZOLE	targetBased	4	Completed	01/03/2005	https://clinicaltrials.gov/study/NCT00208169	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	methamphetamine dependence	ARIPIPRAZOLE	targetBased	4	Terminated	01/07/2012	https://clinicaltrials.gov/study/NCT01813643	0.5	GoF	protect	Effects of aripiprazole was not obvious and showed adverse reaction obviously
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	methamphetamine dependence	ARIPIPRAZOLE	targetBased	4	Terminated	01/07/2012	https://clinicaltrials.gov/study/NCT01813643	0.5	GoF	protect	Effects of aripiprazole was not obvious and showed adverse reaction obviously
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	methamphetamine dependence	ARIPIPRAZOLE	targetBased	4	Withdrawn	01/08/2009	https://clinicaltrials.gov/study/NCT00728312	1	GoF	protect	PI left the VA.
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	methamphetamine dependence	ARIPIPRAZOLE	targetBased	4	Withdrawn	01/08/2009	https://clinicaltrials.gov/study/NCT00728312	1	GoF	protect	PI left the VA.
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	methamphetamine dependence	ARIPIPRAZOLE	targetBased	4	Terminated	01/09/2012	https://clinicaltrials.gov/study/NCT01813656	0.5	GoF	protect	Aripiprazole arm had obvious adverse reactions,especially akathisia.
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	methamphetamine dependence	ARIPIPRAZOLE	targetBased	4	Terminated	01/09/2012	https://clinicaltrials.gov/study/NCT01813656	0.5	GoF	protect	Aripiprazole arm had obvious adverse reactions,especially akathisia.
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Agitation	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d9fc9628-40da-4eaa-ba7e-412c90abe35c	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Agitation	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d8275c2d-f42d-4f32-aa9f-03a202c8e99f	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Agitation	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d8275c2d-f42d-4f32-aa9f-03a202c8e99f	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Agitation	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d8275c2d-f42d-4f32-aa9f-03a202c8e99f	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Agitation	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d8275c2d-f42d-4f32-aa9f-03a202c8e99f	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Agitation	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d8275c2d-f42d-4f32-aa9f-03a202c8e99f	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Agitation	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d8275c2d-f42d-4f32-aa9f-03a202c8e99f	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizoaffective disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/03/2005	https://clinicaltrials.gov/study/NCT00208169	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizoaffective disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/03/2004	https://clinicaltrials.gov/study/NCT00224822	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizoaffective disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/03/2004	https://clinicaltrials.gov/study/NCT00224822	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizoaffective disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/03/2004	https://clinicaltrials.gov/study/NCT00224822	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizoaffective disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/03/2004	https://clinicaltrials.gov/study/NCT00224822	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizoaffective disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/03/2004	https://clinicaltrials.gov/study/NCT00224822	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizoaffective disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/03/2004	https://clinicaltrials.gov/study/NCT00224822	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	aggressive behavior	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ffb6ef30-2619-4652-864c-4d5e94526a15	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	eating disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00685334	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	eating disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00685334	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	eating disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00685334	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	eating disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00685334	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	eating disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00685334	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	eating disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00685334	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar I disorder	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0f24ce78-525a-4bb1-a23d-03f152558575	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar I disorder	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar I disorder	ARIPIPRAZOLE	targetBased	4	Unknown status	01/06/2012	https://clinicaltrials.gov/study/NCT01710163	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar I disorder	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=06dda03f-8481-46d6-af02-4f51e1a3a065	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar I disorder	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e8787c3f-5e41-42d1-8091-44b56346620f	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar I disorder	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=16710a27-aa76-4dd7-92e8-7d3c7efe3e42	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar I disorder	ARIPIPRAZOLE	targetBased	3	Completed	01/08/2012	https://clinicaltrials.gov/study/NCT01567527	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d8275c2d-f42d-4f32-aa9f-03a202c8e99f	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c005ffe2-ed95-4254-9cfe-4073a09cd718	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=12c08d3d-7556-444d-8d01-7737e1507d32	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6875b848-8b13-45f8-ada5-69ef8aece6b6	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	ARIPIPRAZOLE	targetBased	4	Terminated	01/12/2007	https://clinicaltrials.gov/study/NCT00592683	1	LoF	protect	Supply Omega-3 Fatty Acids expired and supplier no longer made same composition.
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=440012b2-4fab-4e2e-ba7f-6ca5558d1e23	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=16710a27-aa76-4dd7-92e8-7d3c7efe3e42	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT00806234	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/10/2005	https://clinicaltrials.gov/study/NCT02305823	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/10/2005	https://clinicaltrials.gov/study/NCT02305823	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	mental or behavioural disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/10/2005	https://clinicaltrials.gov/study/NCT02305823	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	mental or behavioural disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/10/2005	https://clinicaltrials.gov/study/NCT02305823	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/10/2005	https://clinicaltrials.gov/study/NCT02305823	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/10/2005	https://clinicaltrials.gov/study/NCT02305823	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	schizoaffective disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/03/2005	https://clinicaltrials.gov/study/NCT00208169	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	schizoaffective disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/03/2004	https://clinicaltrials.gov/study/NCT00224822	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	schizoaffective disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/03/2004	https://clinicaltrials.gov/study/NCT00224822	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	schizoaffective disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/08/2006	https://clinicaltrials.gov/study/NCT00520650	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	schizoaffective disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/08/2006	https://clinicaltrials.gov/study/NCT00520650	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	schizoaffective disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/03/2004	https://clinicaltrials.gov/study/NCT00177008	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	schizoaffective disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/03/2004	https://clinicaltrials.gov/study/NCT00177008	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	autism spectrum disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/08/2009	https://clinicaltrials.gov/study/NCT01028820	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	treatment refractory schizophrenia	ARIPIPRAZOLE	targetBased	4	Not yet recruiting	20/08/2023	https://clinicaltrials.gov/study/NCT05766540	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	treatment refractory schizophrenia	ARIPIPRAZOLE	targetBased	4	Not yet recruiting	20/08/2023	https://clinicaltrials.gov/study/NCT05766540	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	treatment refractory schizophrenia	ARIPIPRAZOLE	targetBased	4	Not yet recruiting	20/08/2023	https://clinicaltrials.gov/study/NCT05766540	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	treatment refractory schizophrenia	ARIPIPRAZOLE	targetBased	4	Not yet recruiting	20/08/2023	https://clinicaltrials.gov/study/NCT05766540	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	treatment refractory schizophrenia	ARIPIPRAZOLE	targetBased	4	Not yet recruiting	20/08/2023	https://clinicaltrials.gov/study/NCT05766540	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	treatment refractory schizophrenia	ARIPIPRAZOLE	targetBased	4	Not yet recruiting	20/08/2023	https://clinicaltrials.gov/study/NCT05766540	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	psychosis	ARIPIPRAZOLE	targetBased	4	Terminated	01/07/2014	https://clinicaltrials.gov/study/NCT02357849	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	psychosis	ARIPIPRAZOLE	targetBased	4	Terminated	01/07/2013	https://clinicaltrials.gov/study/NCT01844700	0.5	LoF	protect	very slow recruitment, no sufficient results
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	psychosis	ARIPIPRAZOLE	targetBased	4	Completed	01/10/2009	https://clinicaltrials.gov/study/NCT01026584	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	psychosis	ARIPIPRAZOLE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AX12	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	psychosis	ARIPIPRAZOLE	targetBased	4	Completed	01/08/2010	https://clinicaltrials.gov/study/NCT01161277	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	psychosis	ARIPIPRAZOLE	targetBased	4	Unknown status	01/05/2010	https://clinicaltrials.gov/study/NCT01119014	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	substance abuse	ARIPIPRAZOLE	targetBased	4	Completed	01/03/2005	https://clinicaltrials.gov/study/NCT00208169	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	substance abuse	ARIPIPRAZOLE	targetBased	4	Completed	01/03/2005	https://clinicaltrials.gov/study/NCT00208169	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	substance abuse	ARIPIPRAZOLE	targetBased	4	Completed	01/03/2005	https://clinicaltrials.gov/study/NCT00208169	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	substance abuse	ARIPIPRAZOLE	targetBased	4	Completed	01/03/2005	https://clinicaltrials.gov/study/NCT00208169	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	substance abuse	ARIPIPRAZOLE	targetBased	4	Completed	01/03/2005	https://clinicaltrials.gov/study/NCT00208169	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	substance abuse	ARIPIPRAZOLE	targetBased	4	Completed	01/03/2005	https://clinicaltrials.gov/study/NCT00208169	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizoaffective disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/01/2007	https://clinicaltrials.gov/study/NCT00423878	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizoaffective disorder	ARIPIPRAZOLE	targetBased	4	Completed	21/05/2018	https://clinicaltrials.gov/study/NCT03568500	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizoaffective disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/03/2004	https://clinicaltrials.gov/study/NCT00177008	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizoaffective disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/07/2006	https://clinicaltrials.gov/study/NCT00325689	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizoaffective disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/07/2004	https://clinicaltrials.gov/study/NCT00304655	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizoaffective disorder	ARIPIPRAZOLE	targetBased	4	Terminated	01/04/2013	https://clinicaltrials.gov/study/NCT01913327	1	LoF	protect	Insufficient Funds and Inadequate Subject Recruitment
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizoaffective disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/08/2006	https://clinicaltrials.gov/study/NCT00520650	1	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	dysthymic disorder	ARIPIPRAZOLE	targetBased	4	Withdrawn	01/08/2013	https://clinicaltrials.gov/study/NCT01942187	1	GoF	protect	No participants enrolled.
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	dysthymic disorder	ARIPIPRAZOLE	targetBased	4	Withdrawn	01/08/2013	https://clinicaltrials.gov/study/NCT01942187	1	GoF	protect	No participants enrolled.
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	unipolar depression	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bbc2b53b-b712-49eb-b2ce-766bcc448616	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	unipolar depression	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b6243233-8846-4ea8-a2fa-a563e48fdc29	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	unipolar depression	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b6243233-8846-4ea8-a2fa-a563e48fdc29	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	unipolar depression	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=634b6431-48ca-480c-a4d8-0ba022bbf0f4	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	unipolar depression	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=634b6431-48ca-480c-a4d8-0ba022bbf0f4	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	unipolar depression	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e8fe516e-25fc-45f6-9a88-542deaa1c3e8	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	unipolar depression	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e8fe516e-25fc-45f6-9a88-542deaa1c3e8	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	substance abuse	ARIPIPRAZOLE	targetBased	4	Completed	01/03/2005	https://clinicaltrials.gov/study/NCT00208169	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	substance abuse	ARIPIPRAZOLE	targetBased	4	Completed	01/03/2005	https://clinicaltrials.gov/study/NCT00208169	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	depressive disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/08/2009	https://clinicaltrials.gov/study/NCT00892047	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	depressive disorder	ARIPIPRAZOLE	targetBased	3	Withdrawn	01/06/2005	https://clinicaltrials.gov/study/NCT00276978	0.7	LoF	protect	Initiation of study was stopped due to administrative reasons before first subject was enrolled.
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	depressive disorder	ARIPIPRAZOLE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	depressive disorder	ARIPIPRAZOLE	targetBased	4	Terminated	01/07/2009	https://clinicaltrials.gov/study/NCT01305707	1	LoF	protect	Difficulties in recruiting
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	depressive disorder	ARIPIPRAZOLE	targetBased	4	Unknown status	01/06/2017	https://clinicaltrials.gov/study/NCT03148509	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	depressive disorder	ARIPIPRAZOLE	targetBased	3	Completed	01/06/2003	https://clinicaltrials.gov/study/NCT00556140	0.7	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Tourette syndrome	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0f24ce78-525a-4bb1-a23d-03f152558575	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Tourette syndrome	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0f24ce78-525a-4bb1-a23d-03f152558575	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Tourette syndrome	ARIPIPRAZOLE	targetBased	4	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00241176	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Tourette syndrome	ARIPIPRAZOLE	targetBased	4	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00241176	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Tourette syndrome	ARIPIPRAZOLE	targetBased	4	Terminated	13/10/2018	https://clinicaltrials.gov/study/NCT03661983	1	GoF	protect	Lack of feasibility for completion of the trial within a reasonable time frame.
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Tourette syndrome	ARIPIPRAZOLE	targetBased	4	Terminated	13/10/2018	https://clinicaltrials.gov/study/NCT03661983	1	GoF	protect	Lack of feasibility for completion of the trial within a reasonable time frame.
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Tourette syndrome	ARIPIPRAZOLE	targetBased	3	Completed	19/10/2011	https://clinicaltrials.gov/study/NCT01416441	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	psychosis	ARIPIPRAZOLE	targetBased	4	Unknown status	01/05/2010	https://clinicaltrials.gov/study/NCT01119014	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	psychosis	ARIPIPRAZOLE	targetBased	4	Terminated	01/07/2014	https://clinicaltrials.gov/study/NCT02357849	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	psychosis	ARIPIPRAZOLE	targetBased	4	Terminated	01/07/2014	https://clinicaltrials.gov/study/NCT02357849	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	psychosis	ARIPIPRAZOLE	targetBased	4	Completed	01/10/2009	https://clinicaltrials.gov/study/NCT01026584	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	psychosis	ARIPIPRAZOLE	targetBased	4	Completed	01/10/2009	https://clinicaltrials.gov/study/NCT01026584	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	psychosis	ARIPIPRAZOLE	targetBased	4	Completed	01/08/2010	https://clinicaltrials.gov/study/NCT01161277	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	psychosis	ARIPIPRAZOLE	targetBased	4	Completed	01/08/2010	https://clinicaltrials.gov/study/NCT01161277	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	ARIPIPRAZOLE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AX12	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	psychosis	ARIPIPRAZOLE	targetBased	4	Completed	01/08/2010	https://clinicaltrials.gov/study/NCT01161277	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	psychosis	ARIPIPRAZOLE	targetBased	4	Completed	01/08/2010	https://clinicaltrials.gov/study/NCT01161277	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	psychosis	ARIPIPRAZOLE	targetBased	4	Completed	01/08/2010	https://clinicaltrials.gov/study/NCT01161277	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	psychosis	ARIPIPRAZOLE	targetBased	4	Completed	01/08/2010	https://clinicaltrials.gov/study/NCT01161277	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	ARIPIPRAZOLE	targetBased	4	Completed	01/08/2010	https://clinicaltrials.gov/study/NCT01161277	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	ARIPIPRAZOLE	targetBased	4	Completed	01/08/2010	https://clinicaltrials.gov/study/NCT01161277	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	alcohol dependence	ARIPIPRAZOLE	targetBased	3	Completed	01/02/2011	https://clinicaltrials.gov/study/NCT01292057	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	alcohol dependence	ARIPIPRAZOLE	targetBased	3	Completed	01/02/2011	https://clinicaltrials.gov/study/NCT01292057	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	alcohol dependence	ARIPIPRAZOLE	targetBased	4	Completed	01/04/2004	https://clinicaltrials.gov/study/NCT00082199	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	alcohol dependence	ARIPIPRAZOLE	targetBased	4	Completed	01/04/2004	https://clinicaltrials.gov/study/NCT00082199	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	anxiety	ARIPIPRAZOLE	targetBased	4	Completed	01/03/2005	https://clinicaltrials.gov/study/NCT00208169	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	anxiety	ARIPIPRAZOLE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	substance abuse	ARIPIPRAZOLE	targetBased	4	Completed	01/03/2005	https://clinicaltrials.gov/study/NCT00208169	1	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	schizophrenia	ARIPIPRAZOLE	targetBased	4	Completed	01/03/2004	https://clinicaltrials.gov/study/NCT00224822	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	schizophrenia	ARIPIPRAZOLE	targetBased	4	Completed	04/01/2017	https://clinicaltrials.gov/study/NCT02697045	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	schizophrenia	ARIPIPRAZOLE	targetBased	4	Completed	04/01/2017	https://clinicaltrials.gov/study/NCT02697045	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	schizophrenia	ARIPIPRAZOLE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/aripiprazole-mylan-pharma	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	schizophrenia	ARIPIPRAZOLE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/aripiprazole-mylan-pharma	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	schizophrenia	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1be1bea7-71d5-406a-bcf3-e1d58f406389	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	schizophrenia	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1be1bea7-71d5-406a-bcf3-e1d58f406389	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	attention deficit hyperactivity disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/04/2005	https://clinicaltrials.gov/study/NCT00221962	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	attention deficit hyperactivity disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/08/2005	https://clinicaltrials.gov/study/NCT00305370	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	autism	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e8fe516e-25fc-45f6-9a88-542deaa1c3e8	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	autism	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cbbd3dc0-6a39-48f7-91b9-a95c6c12ee0c	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	autism	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b6243233-8846-4ea8-a2fa-a563e48fdc29	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	autism	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6875b848-8b13-45f8-ada5-69ef8aece6b6	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	autism	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0424faf3-202f-438a-b65e-2a228790b8f9	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	autism	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f9648990-0627-4c66-aae1-d3eef398b5b4	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	autism	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0f24ce78-525a-4bb1-a23d-03f152558575	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	pervasive developmental disorder	ARIPIPRAZOLE	targetBased	3	Completed	01/02/2009	https://clinicaltrials.gov/study/NCT00870727	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	tic disorder	ARIPIPRAZOLE	targetBased	4	Suspended	01/06/2024	https://clinicaltrials.gov/study/NCT05361993	1	GoF	protect	External factor: trial equipment problems
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	tic disorder	ARIPIPRAZOLE	targetBased	4	Suspended	01/06/2024	https://clinicaltrials.gov/study/NCT05361993	1	GoF	protect	External factor: trial equipment problems
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	tic disorder	ARIPIPRAZOLE	targetBased	4	Suspended	01/06/2024	https://clinicaltrials.gov/study/NCT05361993	1	GoF	protect	External factor: trial equipment problems
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	tic disorder	ARIPIPRAZOLE	targetBased	4	Suspended	01/06/2024	https://clinicaltrials.gov/study/NCT05361993	1	GoF	protect	External factor: trial equipment problems
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	tic disorder	ARIPIPRAZOLE	targetBased	4	Suspended	01/06/2024	https://clinicaltrials.gov/study/NCT05361993	1	GoF	protect	External factor: trial equipment problems
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	tic disorder	ARIPIPRAZOLE	targetBased	4	Suspended	01/06/2024	https://clinicaltrials.gov/study/NCT05361993	1	GoF	protect	External factor: trial equipment problems
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	tic disorder	ARIPIPRAZOLE	targetBased	3	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01727700	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	methamphetamine dependence	ARIPIPRAZOLE	targetBased	4	Withdrawn	01/08/2009	https://clinicaltrials.gov/study/NCT00728312	1	GoF	protect	PI left the VA.
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	methamphetamine dependence	ARIPIPRAZOLE	targetBased	4	Withdrawn	01/08/2009	https://clinicaltrials.gov/study/NCT00728312	1	GoF	protect	PI left the VA.
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	methamphetamine dependence	ARIPIPRAZOLE	targetBased	4	Withdrawn	01/08/2009	https://clinicaltrials.gov/study/NCT00728312	1	GoF	protect	PI left the VA.
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	methamphetamine dependence	ARIPIPRAZOLE	targetBased	4	Withdrawn	01/08/2009	https://clinicaltrials.gov/study/NCT00728312	1	GoF	protect	PI left the VA.
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	methamphetamine dependence	ARIPIPRAZOLE	targetBased	4	Withdrawn	01/08/2009	https://clinicaltrials.gov/study/NCT00728312	1	GoF	protect	PI left the VA.
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	methamphetamine dependence	ARIPIPRAZOLE	targetBased	4	Withdrawn	01/08/2009	https://clinicaltrials.gov/study/NCT00728312	1	GoF	protect	PI left the VA.
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	methamphetamine dependence	ARIPIPRAZOLE	targetBased	4	Terminated	01/09/2012	https://clinicaltrials.gov/study/NCT01813656	0.5	GoF	protect	Aripiprazole arm had obvious adverse reactions,especially akathisia.
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	methamphetamine dependence	ARIPIPRAZOLE	targetBased	4	Terminated	01/09/2012	https://clinicaltrials.gov/study/NCT01813656	0.5	GoF	protect	Aripiprazole arm had obvious adverse reactions,especially akathisia.
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	tic disorder	ARIPIPRAZOLE	targetBased	3	Completed	01/01/2013	https://clinicaltrials.gov/study/NCT01727713	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	tic disorder	ARIPIPRAZOLE	targetBased	3	Completed	01/01/2013	https://clinicaltrials.gov/study/NCT01727713	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	tic disorder	ARIPIPRAZOLE	targetBased	4	Suspended	01/06/2024	https://clinicaltrials.gov/study/NCT05361993	1	GoF	protect	External factor: trial equipment problems
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	tic disorder	ARIPIPRAZOLE	targetBased	4	Suspended	01/06/2024	https://clinicaltrials.gov/study/NCT05361993	1	GoF	protect	External factor: trial equipment problems
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	tic disorder	ARIPIPRAZOLE	targetBased	3	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01727700	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	tic disorder	ARIPIPRAZOLE	targetBased	3	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01727700	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Dementia	ARIPIPRAZOLE	targetBased	3	Completed	01/12/2003	https://clinicaltrials.gov/study/NCT00095719	0.7	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Dementia	ARIPIPRAZOLE	targetBased	3	Completed	01/12/2003	https://clinicaltrials.gov/study/NCT00095719	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Dementia	ARIPIPRAZOLE	targetBased	3	Completed	01/12/2003	https://clinicaltrials.gov/study/NCT00095719	0.7	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Dementia	ARIPIPRAZOLE	targetBased	3	Completed	01/12/2003	https://clinicaltrials.gov/study/NCT00095719	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Dementia	ARIPIPRAZOLE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Dementia	ARIPIPRAZOLE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Dementia	ARIPIPRAZOLE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Dementia	ARIPIPRAZOLE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Dementia	ARIPIPRAZOLE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Dementia	ARIPIPRAZOLE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	pervasive developmental disorder	ARIPIPRAZOLE	targetBased	3	Completed	01/02/2009	https://clinicaltrials.gov/study/NCT00870727	0.7	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	pervasive developmental disorder	ARIPIPRAZOLE	targetBased	3	Completed	01/02/2009	https://clinicaltrials.gov/study/NCT00870727	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	pervasive developmental disorder	ARIPIPRAZOLE	targetBased	3	Completed	01/02/2009	https://clinicaltrials.gov/study/NCT00870727	0.7	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	pervasive developmental disorder	ARIPIPRAZOLE	targetBased	3	Completed	01/02/2009	https://clinicaltrials.gov/study/NCT00870727	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	pervasive developmental disorder	ARIPIPRAZOLE	targetBased	3	Completed	01/02/2009	https://clinicaltrials.gov/study/NCT00870727	0.7	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	pervasive developmental disorder	ARIPIPRAZOLE	targetBased	3	Completed	01/02/2009	https://clinicaltrials.gov/study/NCT00870727	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	postpartum depression	ARIPIPRAZOLE	targetBased	3	Completed	01/06/2011	https://clinicaltrials.gov/study/NCT01386086	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	postpartum depression	ARIPIPRAZOLE	targetBased	3	Completed	01/06/2011	https://clinicaltrials.gov/study/NCT01386086	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	autism spectrum disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/08/2009	https://clinicaltrials.gov/study/NCT01028820	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	autism spectrum disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/08/2009	https://clinicaltrials.gov/study/NCT01028820	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	autism spectrum disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/08/2009	https://clinicaltrials.gov/study/NCT01028820	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	autism spectrum disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/08/2009	https://clinicaltrials.gov/study/NCT01028820	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	autism spectrum disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/08/2009	https://clinicaltrials.gov/study/NCT01028820	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	autism spectrum disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/08/2009	https://clinicaltrials.gov/study/NCT01028820	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	attention deficit hyperactivity disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/04/2005	https://clinicaltrials.gov/study/NCT00221962	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	attention deficit hyperactivity disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/04/2005	https://clinicaltrials.gov/study/NCT00221962	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	attention deficit hyperactivity disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/08/2005	https://clinicaltrials.gov/study/NCT00305370	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	attention deficit hyperactivity disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/08/2005	https://clinicaltrials.gov/study/NCT00305370	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	tic disorder	ARIPIPRAZOLE	targetBased	4	Suspended	01/06/2024	https://clinicaltrials.gov/study/NCT05361993	1	LoF	protect	External factor: trial equipment problems
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	tic disorder	ARIPIPRAZOLE	targetBased	3	Completed	01/01/2013	https://clinicaltrials.gov/study/NCT01727713	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	tic disorder	ARIPIPRAZOLE	targetBased	3	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01727700	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar I disorder	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	bipolar I disorder	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=16710a27-aa76-4dd7-92e8-7d3c7efe3e42	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	bipolar I disorder	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=16710a27-aa76-4dd7-92e8-7d3c7efe3e42	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar I disorder	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=16710a27-aa76-4dd7-92e8-7d3c7efe3e42	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar I disorder	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=16710a27-aa76-4dd7-92e8-7d3c7efe3e42	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar I disorder	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=16710a27-aa76-4dd7-92e8-7d3c7efe3e42	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar I disorder	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=16710a27-aa76-4dd7-92e8-7d3c7efe3e42	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	pervasive developmental disorder	ARIPIPRAZOLE	targetBased	3	Completed	01/02/2009	https://clinicaltrials.gov/study/NCT00870727	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	pervasive developmental disorder	ARIPIPRAZOLE	targetBased	3	Completed	01/02/2009	https://clinicaltrials.gov/study/NCT00870727	0.7	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	alcohol dependence	ARIPIPRAZOLE	targetBased	3	Completed	01/02/2011	https://clinicaltrials.gov/study/NCT01292057	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	alcohol dependence	ARIPIPRAZOLE	targetBased	4	Completed	01/04/2004	https://clinicaltrials.gov/study/NCT00082199	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	alcohol dependence	ARIPIPRAZOLE	targetBased	4	Completed	01/04/2004	https://clinicaltrials.gov/study/NCT00082199	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	alcohol dependence	ARIPIPRAZOLE	targetBased	4	Completed	01/04/2004	https://clinicaltrials.gov/study/NCT00082199	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	alcohol dependence	ARIPIPRAZOLE	targetBased	4	Completed	01/04/2004	https://clinicaltrials.gov/study/NCT00082199	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	alcohol dependence	ARIPIPRAZOLE	targetBased	4	Completed	01/04/2004	https://clinicaltrials.gov/study/NCT00082199	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	alcohol dependence	ARIPIPRAZOLE	targetBased	4	Completed	01/04/2004	https://clinicaltrials.gov/study/NCT00082199	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	postpartum depression	ARIPIPRAZOLE	targetBased	3	Completed	01/06/2011	https://clinicaltrials.gov/study/NCT01386086	0.7	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	postpartum depression	ARIPIPRAZOLE	targetBased	3	Completed	01/06/2011	https://clinicaltrials.gov/study/NCT01386086	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	postpartum depression	ARIPIPRAZOLE	targetBased	3	Completed	01/06/2011	https://clinicaltrials.gov/study/NCT01386086	0.7	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	postpartum depression	ARIPIPRAZOLE	targetBased	3	Completed	01/06/2011	https://clinicaltrials.gov/study/NCT01386086	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	postpartum depression	ARIPIPRAZOLE	targetBased	3	Completed	01/06/2011	https://clinicaltrials.gov/study/NCT01386086	0.7	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	postpartum depression	ARIPIPRAZOLE	targetBased	3	Completed	01/06/2011	https://clinicaltrials.gov/study/NCT01386086	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Agitation	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=16710a27-aa76-4dd7-92e8-7d3c7efe3e42	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Agitation	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b40bfd2b-9ff1-45bf-a40f-e9812f1df228	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Agitation	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b6243233-8846-4ea8-a2fa-a563e48fdc29	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Agitation	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ffb6ef30-2619-4652-864c-4d5e94526a15	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Agitation	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0424faf3-202f-438a-b65e-2a228790b8f9	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Agitation	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e8fe516e-25fc-45f6-9a88-542deaa1c3e8	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Agitation	ARIPIPRAZOLE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202971s008lbl.pdf	1	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	conduct disorder	ARIPIPRAZOLE	targetBased	4	Completed	17/11/2004	https://clinicaltrials.gov/study/NCT00250705	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	conduct disorder	ARIPIPRAZOLE	targetBased	4	Completed	17/11/2004	https://clinicaltrials.gov/study/NCT00250705	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	ARIPIPRAZOLE	targetBased	4	Completed	01/03/2005	https://clinicaltrials.gov/study/NCT00208169	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1be1bea7-71d5-406a-bcf3-e1d58f406389	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1be1bea7-71d5-406a-bcf3-e1d58f406389	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1be1bea7-71d5-406a-bcf3-e1d58f406389	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1be1bea7-71d5-406a-bcf3-e1d58f406389	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1be1bea7-71d5-406a-bcf3-e1d58f406389	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1be1bea7-71d5-406a-bcf3-e1d58f406389	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	attention deficit hyperactivity disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/08/2005	https://clinicaltrials.gov/study/NCT00305370	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	attention deficit hyperactivity disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/04/2005	https://clinicaltrials.gov/study/NCT00221962	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	attention deficit hyperactivity disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/04/2005	https://clinicaltrials.gov/study/NCT00221962	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	attention deficit hyperactivity disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/04/2005	https://clinicaltrials.gov/study/NCT00221962	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	attention deficit hyperactivity disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/04/2005	https://clinicaltrials.gov/study/NCT00221962	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	attention deficit hyperactivity disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/04/2005	https://clinicaltrials.gov/study/NCT00221962	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	attention deficit hyperactivity disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/04/2005	https://clinicaltrials.gov/study/NCT00221962	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	anxiety	ARIPIPRAZOLE	targetBased	4	Completed	01/03/2005	https://clinicaltrials.gov/study/NCT00208169	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	anxiety	ARIPIPRAZOLE	targetBased	4	Completed	01/03/2005	https://clinicaltrials.gov/study/NCT00208169	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	anxiety	ARIPIPRAZOLE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	anxiety	ARIPIPRAZOLE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	bipolar I disorder	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=16710a27-aa76-4dd7-92e8-7d3c7efe3e42	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	bipolar I disorder	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=06dda03f-8481-46d6-af02-4f51e1a3a065	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	bipolar I disorder	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=06dda03f-8481-46d6-af02-4f51e1a3a065	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	bipolar I disorder	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0f24ce78-525a-4bb1-a23d-03f152558575	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	bipolar I disorder	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0f24ce78-525a-4bb1-a23d-03f152558575	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	bipolar I disorder	ARIPIPRAZOLE	targetBased	4	Unknown status	01/06/2012	https://clinicaltrials.gov/study/NCT01710163	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	bipolar I disorder	ARIPIPRAZOLE	targetBased	4	Unknown status	01/06/2012	https://clinicaltrials.gov/study/NCT01710163	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	social anxiety disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/03/2004	https://clinicaltrials.gov/study/NCT00177008	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	social anxiety disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/03/2004	https://clinicaltrials.gov/study/NCT00177008	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	social anxiety disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/03/2004	https://clinicaltrials.gov/study/NCT00177008	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	social anxiety disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/03/2004	https://clinicaltrials.gov/study/NCT00177008	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	social anxiety disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/03/2004	https://clinicaltrials.gov/study/NCT00177008	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	social anxiety disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/03/2004	https://clinicaltrials.gov/study/NCT00177008	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	autism	ARIPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0f24ce78-525a-4bb1-a23d-03f152558575	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	autism	ARIPIPRAZOLE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202971s008lbl.pdf	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	autism	ARIPIPRAZOLE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202971s008lbl.pdf	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	autism	ARIPIPRAZOLE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202971s008lbl.pdf	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	autism	ARIPIPRAZOLE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202971s008lbl.pdf	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	autism	ARIPIPRAZOLE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202971s008lbl.pdf	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	autism	ARIPIPRAZOLE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202971s008lbl.pdf	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	treatment resistant depression	ARIPIPRAZOLE	targetBased	4	Completed	24/02/2017	https://clinicaltrials.gov/study/NCT02960763	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	treatment resistant depression	ARIPIPRAZOLE	targetBased	4	Completed	24/02/2017	https://clinicaltrials.gov/study/NCT02960763	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	treatment resistant depression	ARIPIPRAZOLE	targetBased	4	Completed	24/02/2017	https://clinicaltrials.gov/study/NCT02960763	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	treatment resistant depression	ARIPIPRAZOLE	targetBased	4	Completed	24/02/2017	https://clinicaltrials.gov/study/NCT02960763	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	treatment resistant depression	ARIPIPRAZOLE	targetBased	4	Completed	24/02/2017	https://clinicaltrials.gov/study/NCT02960763	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	treatment resistant depression	ARIPIPRAZOLE	targetBased	4	Completed	24/02/2017	https://clinicaltrials.gov/study/NCT02960763	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Dementia	ARIPIPRAZOLE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Dementia	ARIPIPRAZOLE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Dementia	ARIPIPRAZOLE	targetBased	3	Completed	01/12/2003	https://clinicaltrials.gov/study/NCT00095719	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Dementia	ARIPIPRAZOLE	targetBased	3	Completed	01/12/2003	https://clinicaltrials.gov/study/NCT00095719	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	social anxiety disorder	ARIPIPRAZOLE	targetBased	4	Completed	01/03/2004	https://clinicaltrials.gov/study/NCT00177008	1	LoF	protect
Antagonist of Human D 1 Dopamine Receptor: qHTS	D1_inhibitors	DRD1	Dopaminereceptor1	unipolar depression	AMOXAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a16297df-3158-48db-85e5-5cd506885556	1	LoF	protect
Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS	D1_activators	DRD1	Dopaminereceptor1	unipolar depression	AMOXAPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N06AA17	1	LoF	protect
Allosteric Modulators of D1 Receptors: Primary Screen	D1	DRD1	Dopamine receptor D1	unipolar depression	AMOXAPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N06AA17	1	LoF	protect
Antagonist of Human D 1 Dopamine Receptor: qHTS	D1_inhibitors	DRD1	Dopaminereceptor1	unipolar depression	AMOXAPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N06AA17	1	LoF	protect
Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS	D1_activators	DRD1	Dopaminereceptor1	unipolar depression	AMOXAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=261006c8-3fd0-491b-b322-42beff6f9880	1	LoF	protect
Allosteric Modulators of D1 Receptors: Primary Screen	D1	DRD1	Dopamine receptor D1	unipolar depression	AMOXAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=261006c8-3fd0-491b-b322-42beff6f9880	1	LoF	protect
Antagonist of Human D 1 Dopamine Receptor: qHTS	D1_inhibitors	DRD1	Dopaminereceptor1	unipolar depression	AMOXAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=261006c8-3fd0-491b-b322-42beff6f9880	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	unipolar depression	AMOXAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=261006c8-3fd0-491b-b322-42beff6f9880	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	unipolar depression	AMOXAPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N06AA17	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	unipolar depression	AMOXAPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N06AA17	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	unipolar depression	AMOXAPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N06AA17	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	unipolar depression	AMOXAPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N06AA17	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	unipolar depression	AMOXAPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N06AA17	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	unipolar depression	AMOXAPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N06AA17	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	unipolar depression	AMOXAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=261006c8-3fd0-491b-b322-42beff6f9880	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	unipolar depression	AMOXAPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N06AA17	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	unipolar depression	AMOXAPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N06AA17	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	unipolar depression	AMOXAPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N06AA17	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	unipolar depression	AMOXAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a16297df-3158-48db-85e5-5cd506885556	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	unipolar depression	AMOXAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a16297df-3158-48db-85e5-5cd506885556	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	unipolar depression	AMOXAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a16297df-3158-48db-85e5-5cd506885556	1	LoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	schizophrenia	RALOXIFENE HYDROCHLORIDE	targetBased	4	Completed	01/08/2006	https://clinicaltrials.gov/study/NCT00361543	1		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	schizophrenia	RALOXIFENE HYDROCHLORIDE	targetBased	4	Completed	01/01/2012	https://clinicaltrials.gov/study/NCT01481883	1		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	schizophrenia	RALOXIFENE HYDROCHLORIDE	targetBased	4	Completed	17/07/2018	https://clinicaltrials.gov/study/NCT03418831	1		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	schizophrenia	RALOXIFENE HYDROCHLORIDE	targetBased	4	Completed	01/04/2011	https://clinicaltrials.gov/study/NCT02354001	1		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	schizoaffective disorder	RALOXIFENE HYDROCHLORIDE	targetBased	4	Completed	01/04/2011	https://clinicaltrials.gov/study/NCT02354001	1		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	schizoaffective disorder	RALOXIFENE HYDROCHLORIDE	targetBased	4	Completed	01/08/2006	https://clinicaltrials.gov/study/NCT00361543	1		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	schizoaffective disorder	RALOXIFENE HYDROCHLORIDE	targetBased	4	Completed	01/01/2012	https://clinicaltrials.gov/study/NCT01481883	1		protect
Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS	D1_activators	DRD1	Dopaminereceptor1	unipolar depression	AMINEPTINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N06AA19	1	LoF	protect
Allosteric Modulators of D1 Receptors: Primary Screen	D1	DRD1	Dopamine receptor D1	unipolar depression	AMINEPTINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N06AA19	1	LoF	protect
Antagonist of Human D 1 Dopamine Receptor: qHTS	D1_inhibitors	DRD1	Dopaminereceptor1	unipolar depression	AMINEPTINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N06AA19	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	unipolar depression	AMINEPTINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N06AA19	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	unipolar depression	AMINEPTINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N06AA19	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	unipolar depression	AMINEPTINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N06AA19	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	unipolar depression	AMINEPTINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N06AA19	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	unipolar depression	AMINEPTINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N06AA19	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	unipolar depression	AMINEPTINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N06AA19	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	THIOTHIXENE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=17dbfc4c-d62e-4efa-930d-29df7de69fa3	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	psychosis	THIOTHIXENE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AF04	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	psychosis	THIOTHIXENE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AF04	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	psychosis	THIOTHIXENE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AF04	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	psychosis	THIOTHIXENE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AF04	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	psychosis	THIOTHIXENE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AF04	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	THIOTHIXENE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AF04	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	THIOTHIXENE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AF04	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	THIOTHIXENE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=17dbfc4c-d62e-4efa-930d-29df7de69fa3	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	THIOTHIXENE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=17dbfc4c-d62e-4efa-930d-29df7de69fa3	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	THIOTHIXENE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=17dbfc4c-d62e-4efa-930d-29df7de69fa3	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	THIOTHIXENE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=17dbfc4c-d62e-4efa-930d-29df7de69fa3	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	THIOTHIXENE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=17dbfc4c-d62e-4efa-930d-29df7de69fa3	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	THIOTHIXENE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=17dbfc4c-d62e-4efa-930d-29df7de69fa3	1	LoF	protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	delirium	ISOFLURANE	targetBased	4	Terminated	01/01/2014	https://clinicaltrials.gov/study/NCT02111447	1		protect	Not enough participants
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	delirium	ISOFLURANE	targetBased	4	Terminated	01/01/2014	https://clinicaltrials.gov/study/NCT02111447	1		protect	Not enough participants
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	depressive disorder	LEVETIRACETAM	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	alcohol dependence	LEVETIRACETAM	targetBased	3	Completed	01/05/2007	https://clinicaltrials.gov/study/NCT00758277	0.7	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	alcohol dependence	LEVETIRACETAM	targetBased	4	Completed	01/01/2006	https://clinicaltrials.gov/study/NCT00325182	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Tourette syndrome	LEVETIRACETAM	targetBased	4	Completed	01/02/2007	https://clinicaltrials.gov/study/NCT00370838	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	panic disorder	LEVETIRACETAM	targetBased	3	Completed	01/01/2006	https://clinicaltrials.gov/study/NCT00279617	0.7	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	schizophrenia	LEVETIRACETAM	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	alcohol withdrawal	LEVETIRACETAM	targetBased	3	Completed	01/01/2006	https://clinicaltrials.gov/study/NCT00146471	0.7	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	Dementia	LEVETIRACETAM	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	anxiety	LEVETIRACETAM	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	BLONANSERIN	targetBased	3	Completed	01/02/2012	https://clinicaltrials.gov/study/NCT01516424	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	BLONANSERIN	targetBased	4	Terminated	22/01/2019	https://clinicaltrials.gov/study/NCT03784222	1	LoF	protect	Company's business decision
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	schizophrenia	BLONANSERIN	targetBased	3	Completed	01/02/2012	https://clinicaltrials.gov/study/NCT01516424	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	schizophrenia	BLONANSERIN	targetBased	3	Completed	01/02/2012	https://clinicaltrials.gov/study/NCT01516424	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	schizophrenia	BLONANSERIN	targetBased	3	Completed	01/02/2012	https://clinicaltrials.gov/study/NCT01516424	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	schizophrenia	BLONANSERIN	targetBased	4	Terminated	22/01/2019	https://clinicaltrials.gov/study/NCT03784222	1	LoF	protect	Company's business decision
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	schizophrenia	BLONANSERIN	targetBased	4	Terminated	22/01/2019	https://clinicaltrials.gov/study/NCT03784222	1	LoF	protect	Company's business decision
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	schizophrenia	BLONANSERIN	targetBased	4	Terminated	22/01/2019	https://clinicaltrials.gov/study/NCT03784222	1	LoF	protect	Company's business decision
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	BLONANSERIN	targetBased	4	Terminated	22/01/2019	https://clinicaltrials.gov/study/NCT03784222	1	LoF	protect	Company's business decision
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	BLONANSERIN	targetBased	4	Terminated	22/01/2019	https://clinicaltrials.gov/study/NCT03784222	1	LoF	protect	Company's business decision
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	BLONANSERIN	targetBased	4	Terminated	22/01/2019	https://clinicaltrials.gov/study/NCT03784222	1	LoF	protect	Company's business decision
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	BLONANSERIN	targetBased	4	Terminated	22/01/2019	https://clinicaltrials.gov/study/NCT03784222	1	LoF	protect	Company's business decision
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	BLONANSERIN	targetBased	4	Terminated	22/01/2019	https://clinicaltrials.gov/study/NCT03784222	1	LoF	protect	Company's business decision
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	BLONANSERIN	targetBased	4	Terminated	22/01/2019	https://clinicaltrials.gov/study/NCT03784222	1	LoF	protect	Company's business decision
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	BLONANSERIN	targetBased	3	Completed	01/02/2012	https://clinicaltrials.gov/study/NCT01516424	0.7	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	separation anxiety disorder	VILAZODONE	targetBased	4	Completed	01/12/2013	https://clinicaltrials.gov/study/NCT01999920	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	separation anxiety disorder	VILAZODONE	targetBased	4	Completed	01/12/2013	https://clinicaltrials.gov/study/NCT01999920	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	depressive disorder	VILAZODONE	targetBased	4	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT01715519	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	depressive disorder	VILAZODONE	targetBased	4	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT01715519	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	post-traumatic stress disorder	VILAZODONE	targetBased	4	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT01715519	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	post-traumatic stress disorder	VILAZODONE	targetBased	4	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT01715519	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	major depressive disorder	VILAZODONE	targetBased	4	Completed	01/12/2011	https://clinicaltrials.gov/study/NCT01473381	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	major depressive disorder	VILAZODONE	targetBased	4	Completed	01/12/2011	https://clinicaltrials.gov/study/NCT01473394	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	major depressive disorder	VILAZODONE	targetBased	4	Completed	01/12/2011	https://clinicaltrials.gov/study/NCT01473394	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	major depressive disorder	VILAZODONE	targetBased	4	Completed	01/04/2012	https://clinicaltrials.gov/study/NCT01573598	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	major depressive disorder	VILAZODONE	targetBased	4	Completed	01/04/2012	https://clinicaltrials.gov/study/NCT01573598	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	major depressive disorder	VILAZODONE	targetBased	4	Completed	01/07/2012	https://clinicaltrials.gov/study/NCT01608295	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	major depressive disorder	VILAZODONE	targetBased	4	Completed	01/07/2012	https://clinicaltrials.gov/study/NCT01608295	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	unipolar depression	VILAZODONE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N06AX24	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	unipolar depression	VILAZODONE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N06AX24	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	unipolar depression	VILAZODONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4c55ccfb-c4cf-11df-851a-0800200c9a66	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	unipolar depression	VILAZODONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4c55ccfb-c4cf-11df-851a-0800200c9a66	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	unipolar depression	VILAZODONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bfef9e19-d0f5-40fa-954c-b73c812eb242	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	unipolar depression	VILAZODONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bfef9e19-d0f5-40fa-954c-b73c812eb242	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	generalized anxiety disorder	VILAZODONE	targetBased	3	Completed	30/06/2012	https://clinicaltrials.gov/study/NCT01629966	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	generalized anxiety disorder	VILAZODONE	targetBased	3	Completed	30/06/2012	https://clinicaltrials.gov/study/NCT01629966	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	generalized anxiety disorder	VILAZODONE	targetBased	3	Completed	30/04/2013	https://clinicaltrials.gov/study/NCT01844115	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	generalized anxiety disorder	VILAZODONE	targetBased	3	Completed	30/04/2013	https://clinicaltrials.gov/study/NCT01844115	0.7	GoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	schizoaffective disorder	MODAFINIL	targetBased	4	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00423943	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	schizoaffective disorder	MODAFINIL	targetBased	4	Terminated	01/04/2013	https://clinicaltrials.gov/study/NCT01913327	1	LoF	protect	Insufficient Funds and Inadequate Subject Recruitment
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	depressive disorder	MODAFINIL	targetBased	4	Completed	01/02/2003	https://clinicaltrials.gov/study/NCT00208715	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	methamphetamine dependence	MODAFINIL	targetBased	4	Completed	01/02/2009	https://clinicaltrials.gov/study/NCT00751023	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	obstructive sleep apnea	MODAFINIL	targetBased	4	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00086281	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	obstructive sleep apnea	MODAFINIL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01f6690c-1410-42ad-8eb3-e7df32eab3ba	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	obstructive sleep apnea	MODAFINIL	targetBased	4	Terminated	01/02/2016	https://clinicaltrials.gov/study/NCT02494102	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	obstructive sleep apnea	MODAFINIL	targetBased	3	Completed	01/10/2004	https://clinicaltrials.gov/study/NCT00107809	0.7	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	obstructive sleep apnea	MODAFINIL	targetBased	3	Completed	01/10/2004	https://clinicaltrials.gov/study/NCT00107848	0.7	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	schizophrenia	MODAFINIL	targetBased	4	Completed	01/05/2008	https://clinicaltrials.gov/study/NCT00711464	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	schizophrenia	MODAFINIL	targetBased	4	Terminated	01/04/2013	https://clinicaltrials.gov/study/NCT01913327	1	LoF	protect	Insufficient Funds and Inadequate Subject Recruitment
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	schizophrenia	MODAFINIL	targetBased	4	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00423943	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	schizophrenia	MODAFINIL	targetBased	4	Completed	01/09/2003	https://clinicaltrials.gov/study/NCT00573417	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	major depressive disorder	MODAFINIL	targetBased	3	Withdrawn	01/12/2018	https://clinicaltrials.gov/study/NCT04317001	0.7	LoF	protect	Researcher leading the study moved institutions study not feasible
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	Sleep Disorder	MODAFINIL	targetBased	3	Completed	01/08/2005	https://clinicaltrials.gov/study/NCT00236080	0.7	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	narcolepsy-cataplexy syndrome	MODAFINIL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01f6690c-1410-42ad-8eb3-e7df32eab3ba	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	cocaine dependence	MODAFINIL	targetBased	3	Completed	01/04/2009	https://clinicaltrials.gov/study/NCT00701532	0.7	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	bipolar disorder	MODAFINIL	targetBased	4	Completed	01/01/2014	https://clinicaltrials.gov/study/NCT01965925	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	narcolepsy	MODAFINIL	targetBased	3	Completed	01/04/2003	https://clinicaltrials.gov/study/NCT00066170	0.7	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	narcolepsy	MODAFINIL	targetBased	3	Completed	01/10/2004	https://clinicaltrials.gov/study/NCT00107848	0.7	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	narcolepsy	MODAFINIL	targetBased	3	Completed	01/01/2005	https://clinicaltrials.gov/study/NCT00214968	0.7	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	narcolepsy	MODAFINIL	targetBased	3	Completed	01/10/2004	https://clinicaltrials.gov/study/NCT00107796	0.7	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	insomnia	MODAFINIL	targetBased	4	Completed	01/01/2005	https://clinicaltrials.gov/study/NCT00124384	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	MODAFINIL	targetBased	3	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00228540	0.7	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	MODAFINIL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N06BA07	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	MODAFINIL	targetBased	3	Completed	01/09/2003	https://clinicaltrials.gov/study/NCT00214981	0.7	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	MODAFINIL	targetBased	3	Completed	01/06/2006	https://clinicaltrials.gov/study/NCT00343811	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	schizophrenia	SAMIDORPHAN	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213378s000lbl.pdf	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	schizophrenia	SAMIDORPHAN	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213378s000lbl.pdf	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	bipolar I disorder	SAMIDORPHAN	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213378s000lbl.pdf	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	bipolar I disorder	SAMIDORPHAN	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213378s000lbl.pdf	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	bipolar I disorder	SAMIDORPHAN	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213378s000lbl.pdf	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	schizophrenia	SAMIDORPHAN	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213378s000lbl.pdf	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	major depressive disorder	PSILOCYBINE	targetBased	3	Not yet recruiting	01/04/2024	https://clinicaltrials.gov/study/NCT06247839	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	unipolar depression	PSILOCYBINE	targetBased	3	Recruiting	05/03/2024	https://clinicaltrials.gov/study/NCT06308653	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	treatment resistant depression	PSILOCYBINE	targetBased	3	Recruiting	19/01/2023	https://clinicaltrials.gov/study/NCT05624268	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	treatment resistant depression	PSILOCYBINE	targetBased	3	Recruiting	14/02/2023	https://clinicaltrials.gov/study/NCT05711940	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	treatment resistant depression	PSILOCYBINE	targetBased	3	Recruiting	19/04/2024	https://clinicaltrials.gov/study/NCT06303739	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	depressive disorder	PSILOCYBINE	targetBased	3	Recruiting	19/04/2024	https://clinicaltrials.gov/study/NCT06303739	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	anxiety	NALUZOTAN	targetBased	3	Completed	01/08/2005	https://clinicaltrials.gov/study/NCT00248183	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	anxiety	NALUZOTAN	targetBased	3	Completed	01/08/2005	https://clinicaltrials.gov/study/NCT00248183	0.7	GoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	mental or behavioural disorder	SIBUTRAMINE	targetBased	4	Completed	01/04/2001	https://clinicaltrials.gov/study/NCT00044187	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	schizophrenia	SIBUTRAMINE	targetBased	4	Completed	01/04/2001	https://clinicaltrials.gov/study/NCT00044187	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	bipolar disorder	SIBUTRAMINE	targetBased	4	Completed	01/04/2001	https://clinicaltrials.gov/study/NCT00044187	1	LoF	protect
Antagonist of Human D 1 Dopamine Receptor: qHTS	D1_inhibitors	DRD1	Dopaminereceptor1	schizophrenia	PIMOZIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS	D1_activators	DRD1	Dopaminereceptor1	schizophrenia	PIMOZIDE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
Allosteric Modulators of D1 Receptors: Primary Screen	D1	DRD1	Dopamine receptor D1	schizophrenia	PIMOZIDE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
Antagonist of Human D 1 Dopamine Receptor: qHTS	D1_inhibitors	DRD1	Dopaminereceptor1	schizophrenia	PIMOZIDE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS	D1_activators	DRD1	Dopaminereceptor1	schizophrenia	PIMOZIDE	targetBased	4	Completed	01/10/2004	https://clinicaltrials.gov/study/NCT00158223	1	LoF	protect
Allosteric Modulators of D1 Receptors: Primary Screen	D1	DRD1	Dopamine receptor D1	schizophrenia	PIMOZIDE	targetBased	4	Completed	01/10/2004	https://clinicaltrials.gov/study/NCT00158223	1	LoF	protect
Antagonist of Human D 1 Dopamine Receptor: qHTS	D1_inhibitors	DRD1	Dopaminereceptor1	schizophrenia	PIMOZIDE	targetBased	4	Completed	01/10/2004	https://clinicaltrials.gov/study/NCT00158223	1	LoF	protect
Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS	D1_activators	DRD1	Dopaminereceptor1	schizoaffective disorder	PIMOZIDE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
Allosteric Modulators of D1 Receptors: Primary Screen	D1	DRD1	Dopamine receptor D1	schizoaffective disorder	PIMOZIDE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
Antagonist of Human D 1 Dopamine Receptor: qHTS	D1_inhibitors	DRD1	Dopaminereceptor1	schizoaffective disorder	PIMOZIDE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	PIMOZIDE	targetBased	4	Completed	01/10/2004	https://clinicaltrials.gov/study/NCT00158223	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	PIMOZIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	PIMOZIDE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Tourette syndrome	PIMOZIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70b079e2-a1f7-4a93-8685-d60a4d7c1280	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Tourette syndrome	PIMOZIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70b079e2-a1f7-4a93-8685-d60a4d7c1280	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Tourette syndrome	PIMOZIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70b079e2-a1f7-4a93-8685-d60a4d7c1280	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Tourette syndrome	PIMOZIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70b079e2-a1f7-4a93-8685-d60a4d7c1280	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Tourette syndrome	PIMOZIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70b079e2-a1f7-4a93-8685-d60a4d7c1280	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Tourette syndrome	PIMOZIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70b079e2-a1f7-4a93-8685-d60a4d7c1280	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Dementia	PIMOZIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Dementia	PIMOZIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Dementia	PIMOZIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Dementia	PIMOZIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Tourette syndrome	PIMOZIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70b079e2-a1f7-4a93-8685-d60a4d7c1280	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	psychosis	PIMOZIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AG02	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	psychosis	PIMOZIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AG02	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	psychosis	PIMOZIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AG02	1	LoF	protect
Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS	D1_activators	DRD1	Dopaminereceptor1	psychosis	PIMOZIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AG02	1	LoF	protect
Allosteric Modulators of D1 Receptors: Primary Screen	D1	DRD1	Dopamine receptor D1	psychosis	PIMOZIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AG02	1	LoF	protect
Antagonist of Human D 1 Dopamine Receptor: qHTS	D1_inhibitors	DRD1	Dopaminereceptor1	psychosis	PIMOZIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AG02	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	depressive disorder	PIMOZIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	depressive disorder	PIMOZIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	depressive disorder	PIMOZIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	depressive disorder	PIMOZIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	depressive disorder	PIMOZIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	depressive disorder	PIMOZIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS	D1_activators	DRD1	Dopaminereceptor1	Dementia	PIMOZIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Allosteric Modulators of D1 Receptors: Primary Screen	D1	DRD1	Dopamine receptor D1	Dementia	PIMOZIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Antagonist of Human D 1 Dopamine Receptor: qHTS	D1_inhibitors	DRD1	Dopaminereceptor1	Dementia	PIMOZIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	anxiety	PIMOZIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	anxiety	PIMOZIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	anxiety	PIMOZIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	anxiety	PIMOZIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	anxiety	PIMOZIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	anxiety	PIMOZIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizoaffective disorder	PIMOZIDE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizoaffective disorder	PIMOZIDE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizoaffective disorder	PIMOZIDE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizoaffective disorder	PIMOZIDE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizoaffective disorder	PIMOZIDE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizoaffective disorder	PIMOZIDE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	psychosis	PIMOZIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AG02	1	LoF	protect
Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS	D1_activators	DRD1	Dopaminereceptor1	depressive disorder	PIMOZIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Allosteric Modulators of D1 Receptors: Primary Screen	D1	DRD1	Dopamine receptor D1	depressive disorder	PIMOZIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Antagonist of Human D 1 Dopamine Receptor: qHTS	D1_inhibitors	DRD1	Dopaminereceptor1	depressive disorder	PIMOZIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizoaffective disorder	PIMOZIDE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	schizophrenia	PIMOZIDE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	schizophrenia	PIMOZIDE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	schizophrenia	PIMOZIDE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	schizophrenia	PIMOZIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	schizophrenia	PIMOZIDE	targetBased	4	Completed	01/10/2004	https://clinicaltrials.gov/study/NCT00158223	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	schizophrenia	PIMOZIDE	targetBased	4	Completed	01/10/2004	https://clinicaltrials.gov/study/NCT00158223	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	schizophrenia	PIMOZIDE	targetBased	4	Completed	01/10/2004	https://clinicaltrials.gov/study/NCT00158223	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	depressive disorder	PIMOZIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	depressive disorder	PIMOZIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	depressive disorder	PIMOZIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	depressive disorder	PIMOZIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	psychosis	PIMOZIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AG02	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	psychosis	PIMOZIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AG02	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	psychosis	PIMOZIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AG02	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	psychosis	PIMOZIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AG02	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	PIMOZIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AG02	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	PIMOZIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AG02	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	anxiety	PIMOZIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Tourette syndrome	PIMOZIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70b079e2-a1f7-4a93-8685-d60a4d7c1280	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Tourette syndrome	PIMOZIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70b079e2-a1f7-4a93-8685-d60a4d7c1280	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Tourette syndrome	PIMOZIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70b079e2-a1f7-4a93-8685-d60a4d7c1280	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Dementia	PIMOZIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Dementia	PIMOZIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Dementia	PIMOZIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Dementia	PIMOZIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Dementia	PIMOZIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Dementia	PIMOZIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS	D1_activators	DRD1	Dopaminereceptor1	Tourette syndrome	PIMOZIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70b079e2-a1f7-4a93-8685-d60a4d7c1280	1	LoF	protect
Allosteric Modulators of D1 Receptors: Primary Screen	D1	DRD1	Dopamine receptor D1	Tourette syndrome	PIMOZIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70b079e2-a1f7-4a93-8685-d60a4d7c1280	1	LoF	protect
Antagonist of Human D 1 Dopamine Receptor: qHTS	D1_inhibitors	DRD1	Dopaminereceptor1	Tourette syndrome	PIMOZIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70b079e2-a1f7-4a93-8685-d60a4d7c1280	1	LoF	protect
Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS	D1_activators	DRD1	Dopaminereceptor1	anxiety	PIMOZIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Allosteric Modulators of D1 Receptors: Primary Screen	D1	DRD1	Dopamine receptor D1	anxiety	PIMOZIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Antagonist of Human D 1 Dopamine Receptor: qHTS	D1_inhibitors	DRD1	Dopaminereceptor1	anxiety	PIMOZIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	PIMOZIDE	targetBased	4	Completed	01/10/2004	https://clinicaltrials.gov/study/NCT00158223	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	PIMOZIDE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	PIMOZIDE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	PIMOZIDE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	PIMOZIDE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	PIMOZIDE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	PIMOZIDE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	anxiety	PIMOZIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	anxiety	PIMOZIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	anxiety	PIMOZIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	schizoaffective disorder	PIMOZIDE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	schizoaffective disorder	PIMOZIDE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	schizoaffective disorder	PIMOZIDE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Dementia	NIMODIPINE	targetBased	4	Completed	01/06/2008	https://clinicaltrials.gov/study/NCT00814658	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	depressive disorder	NIMODIPINE	targetBased	4	Terminated	01/08/2008	https://clinicaltrials.gov/study/NCT00781326	1	LoF	protect	Final cost of study medication was significantly greater than initial estimate,
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	enuresis	DESMOPRESSIN	targetBased	4	Completed	01/10/2017	https://clinicaltrials.gov/study/NCT03389412	1	GoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	enuresis	DESMOPRESSIN	targetBased	4	Unknown status	01/04/2012	https://clinicaltrials.gov/study/NCT01582542	1	GoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	enuresis	DESMOPRESSIN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8ca799f1-7029-4527-9ab4-7512504bb8e2	1	GoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	enuresis	DESMOPRESSIN	targetBased	4	Completed	01/12/2004	https://clinicaltrials.gov/study/NCT00209261	1	GoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	enuresis	DESMOPRESSIN	targetBased	4	Recruiting	15/03/2020	https://clinicaltrials.gov/study/NCT04545931	1	GoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	enuresis	DESMOPRESSIN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6d55baa9-2b62-469c-93ae-3909ab249332	1	GoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	enuresis	DESMOPRESSIN	targetBased	4	Completed	01/04/2011	https://clinicaltrials.gov/study/NCT01645475	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	bipolar disorder	BIFEPRUNOX	targetBased	3	Completed	01/06/2005	https://clinicaltrials.gov/study/NCT00134459	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	bipolar disorder	BIFEPRUNOX	targetBased	3	Completed	01/06/2005	https://clinicaltrials.gov/study/NCT00134459	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	depressive disorder	BIFEPRUNOX	targetBased	3	Completed	01/06/2005	https://clinicaltrials.gov/study/NCT00245973	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	depressive disorder	BIFEPRUNOX	targetBased	3	Completed	01/06/2005	https://clinicaltrials.gov/study/NCT00245973	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	bipolar disorder	BIFEPRUNOX	targetBased	3	Completed	01/06/2005	https://clinicaltrials.gov/study/NCT00134459	0.7	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	bipolar disorder	BIFEPRUNOX	targetBased	3	Completed	01/06/2005	https://clinicaltrials.gov/study/NCT00134459	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar disorder	BIFEPRUNOX	targetBased	3	Completed	01/06/2005	https://clinicaltrials.gov/study/NCT00134459	0.7	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar disorder	BIFEPRUNOX	targetBased	3	Completed	01/06/2005	https://clinicaltrials.gov/study/NCT00134459	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar disorder	BIFEPRUNOX	targetBased	3	Completed	01/06/2005	https://clinicaltrials.gov/study/NCT00134459	0.7	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar disorder	BIFEPRUNOX	targetBased	3	Completed	01/06/2005	https://clinicaltrials.gov/study/NCT00134459	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	depressive disorder	BIFEPRUNOX	targetBased	3	Completed	01/06/2005	https://clinicaltrials.gov/study/NCT00245973	0.7	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	depressive disorder	BIFEPRUNOX	targetBased	3	Completed	01/06/2005	https://clinicaltrials.gov/study/NCT00245973	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	depressive disorder	BIFEPRUNOX	targetBased	3	Completed	01/06/2005	https://clinicaltrials.gov/study/NCT00245973	0.7	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	depressive disorder	BIFEPRUNOX	targetBased	3	Completed	01/06/2005	https://clinicaltrials.gov/study/NCT00245973	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	depressive disorder	BIFEPRUNOX	targetBased	3	Completed	01/06/2005	https://clinicaltrials.gov/study/NCT00245973	0.7	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	depressive disorder	BIFEPRUNOX	targetBased	3	Completed	01/06/2005	https://clinicaltrials.gov/study/NCT00245973	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	schizophrenia	BIFEPRUNOX	targetBased	3	Completed	01/05/2005	https://clinicaltrials.gov/study/NCT00230828	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	schizophrenia	BIFEPRUNOX	targetBased	3	Completed	01/05/2005	https://clinicaltrials.gov/study/NCT00230828	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	schizophrenia	BIFEPRUNOX	targetBased	3	Terminated	01/11/2006	https://clinicaltrials.gov/study/NCT00366704	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	schizophrenia	BIFEPRUNOX	targetBased	3	Terminated	01/11/2006	https://clinicaltrials.gov/study/NCT00366704	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	schizophrenia	BIFEPRUNOX	targetBased	3	Completed	01/05/2005	https://clinicaltrials.gov/study/NCT00193713	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	schizophrenia	BIFEPRUNOX	targetBased	3	Completed	01/05/2005	https://clinicaltrials.gov/study/NCT00193713	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	schizophrenia	BIFEPRUNOX	targetBased	3	Terminated	01/04/2007	https://clinicaltrials.gov/study/NCT00396214	0.7	GoF	protect	This trial discontinued on 2 May 2008 due to lack of enrolment
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	schizophrenia	BIFEPRUNOX	targetBased	3	Terminated	01/04/2007	https://clinicaltrials.gov/study/NCT00396214	0.7	GoF	protect	This trial discontinued on 2 May 2008 due to lack of enrolment
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	schizophrenia	BIFEPRUNOX	targetBased	3	Completed	01/07/2006	https://clinicaltrials.gov/study/NCT00380224	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	schizophrenia	BIFEPRUNOX	targetBased	3	Completed	01/07/2006	https://clinicaltrials.gov/study/NCT00380224	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	BIFEPRUNOX	targetBased	3	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00193687	0.7	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	BIFEPRUNOX	targetBased	3	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00193687	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	BIFEPRUNOX	targetBased	3	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00193687	0.7	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	BIFEPRUNOX	targetBased	3	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00193687	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	BIFEPRUNOX	targetBased	3	Completed	01/11/2006	https://clinicaltrials.gov/study/NCT00366171	0.7	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	BIFEPRUNOX	targetBased	3	Completed	01/11/2006	https://clinicaltrials.gov/study/NCT00366171	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	BIFEPRUNOX	targetBased	3	Completed	01/11/2006	https://clinicaltrials.gov/study/NCT00366171	0.7	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	BIFEPRUNOX	targetBased	3	Completed	01/11/2006	https://clinicaltrials.gov/study/NCT00366171	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	BIFEPRUNOX	targetBased	3	Completed	01/11/2006	https://clinicaltrials.gov/study/NCT00366171	0.7	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	BIFEPRUNOX	targetBased	3	Completed	01/11/2006	https://clinicaltrials.gov/study/NCT00366171	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	attention deficit hyperactivity disorder	NOREPINEPHRINE	targetBased	4	Completed	01/10/2005	https://clinicaltrials.gov/study/NCT00757029	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	post-traumatic stress disorder	NOREPINEPHRINE	targetBased	4	Active, not recruiting	01/06/2020	https://clinicaltrials.gov/study/NCT04597190	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	opioid dependence	HYDROCODONE	targetBased	4	Completed	30/01/2018	https://clinicaltrials.gov/study/NCT03457116	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	HYDROCODONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6ccfbd98-7750-4955-a654-ec104fb666f9	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	HYDROCODONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=016b3c9e-b7e4-455b-9482-61714aea2b14	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	HYDROCODONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=016b3c9e-b7e4-455b-9482-61714aea2b14	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	HYDROCODONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=901d4115-f71a-4681-bd0e-c9b691151b78	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	HYDROCODONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=901d4115-f71a-4681-bd0e-c9b691151b78	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	HYDROCODONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=470df63a-5c0f-42df-9023-a330a901153e	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	HYDROCODONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=470df63a-5c0f-42df-9023-a330a901153e	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	drug dependence	HYDROCODONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6ccfbd98-7750-4955-a654-ec104fb666f9	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	drug dependence	HYDROCODONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=901d4115-f71a-4681-bd0e-c9b691151b78	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	drug dependence	HYDROCODONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=470df63a-5c0f-42df-9023-a330a901153e	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	drug dependence	HYDROCODONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9e5daeac-8573-48e9-877f-c08701255c5b	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	drug dependence	HYDROCODONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=016b3c9e-b7e4-455b-9482-61714aea2b14	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	drug dependence	HYDROCODONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=25f400d9-1d6e-4d38-8f0d-98d471eba73b	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	HYDROCODONE	targetBased	4	Completed	30/01/2018	https://clinicaltrials.gov/study/NCT03457116	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	HYDROCODONE	targetBased	4	Completed	30/01/2018	https://clinicaltrials.gov/study/NCT03457116	1	GoF	protect
Primary Cell Based High Throughput Screening Assay for Agonists of the 5-Hydroxytryptamine Receptor Subtype 1E (5HT1E)	HTR1E	HTR1E	5-hydroxytryptamine receptor 1E	mental or behavioural disorder	AMISULPRIDE	targetBased	4	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT00204061	1	LoF	protect
Primary Cell Based High Throughput Screening Assay for Antagonists of the 5-Hydroxytryptamine Receptor Subtype 1E (5HT1E)	HTR1E	HTR1E	5-hydroxytryptamine receptor 1E	mental or behavioural disorder	AMISULPRIDE	targetBased	4	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT00204061	1	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	mental or behavioural disorder	AMISULPRIDE	targetBased	4	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT00204061	1	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	mental or behavioural disorder	AMISULPRIDE	targetBased	4	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT00204061	1	LoF	protect
Primary Cell Based High Throughput Screening Assay for Agonists of the 5-Hydroxytryptamine Receptor Subtype 1E (5HT1E)	HTR1E	HTR1E	5-hydroxytryptamine receptor 1E	schizoaffective disorder	AMISULPRIDE	targetBased	4	Completed	01/05/2011	https://clinicaltrials.gov/study/NCT01248195	1	LoF	protect
Primary Cell Based High Throughput Screening Assay for Antagonists of the 5-Hydroxytryptamine Receptor Subtype 1E (5HT1E)	HTR1E	HTR1E	5-hydroxytryptamine receptor 1E	schizoaffective disorder	AMISULPRIDE	targetBased	4	Completed	01/05/2011	https://clinicaltrials.gov/study/NCT01248195	1	LoF	protect
Primary Cell Based High Throughput Screening Assay for Agonists of the 5-Hydroxytryptamine Receptor Subtype 1E (5HT1E)	HTR1E	HTR1E	5-hydroxytryptamine receptor 1E	schizoaffective disorder	AMISULPRIDE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
Primary Cell Based High Throughput Screening Assay for Antagonists of the 5-Hydroxytryptamine Receptor Subtype 1E (5HT1E)	HTR1E	HTR1E	5-hydroxytryptamine receptor 1E	schizoaffective disorder	AMISULPRIDE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
Primary Cell Based High Throughput Screening Assay for Agonists of the 5-Hydroxytryptamine Receptor Subtype 1E (5HT1E)	HTR1E	HTR1E	5-hydroxytryptamine receptor 1E	schizoaffective disorder	AMISULPRIDE	targetBased	4	Completed	01/06/2012	https://clinicaltrials.gov/study/NCT01609153	1	LoF	protect
Primary Cell Based High Throughput Screening Assay for Antagonists of the 5-Hydroxytryptamine Receptor Subtype 1E (5HT1E)	HTR1E	HTR1E	5-hydroxytryptamine receptor 1E	schizoaffective disorder	AMISULPRIDE	targetBased	4	Completed	01/06/2012	https://clinicaltrials.gov/study/NCT01609153	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	mental or behavioural disorder	AMISULPRIDE	targetBased	4	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT00204061	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	mental or behavioural disorder	AMISULPRIDE	targetBased	4	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT00204061	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	mental or behavioural disorder	AMISULPRIDE	targetBased	4	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT00204061	1	LoF	protect
Counterscreen for agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A)	HTR5A	HTR5A	5-hydroxytryptamine receptor 5A	Dementia	AMISULPRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Counterscreen for inverse agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify inverse agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A)	HTR5A	HTR5A	5-hydroxytryptamine receptor 5A	Dementia	AMISULPRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Counterscreen for inverse agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify inverse agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A)	HTR5A	HTR5A	5-hydroxytryptamine receptor 5A	schizophrenia	AMISULPRIDE	targetBased	4	Completed	01/06/2005	https://clinicaltrials.gov/study/NCT00245674	1	LoF	protect
Counterscreen for agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A)	HTR5A	HTR5A	5-hydroxytryptamine receptor 5A	schizophrenia	AMISULPRIDE	targetBased	4	Not yet recruiting	01/10/2018	https://clinicaltrials.gov/study/NCT03510325	1	LoF	protect
Counterscreen for inverse agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify inverse agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A)	HTR5A	HTR5A	5-hydroxytryptamine receptor 5A	schizophrenia	AMISULPRIDE	targetBased	4	Not yet recruiting	01/10/2018	https://clinicaltrials.gov/study/NCT03510325	1	LoF	protect
Counterscreen for agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A)	HTR5A	HTR5A	5-hydroxytryptamine receptor 5A	schizophrenia	AMISULPRIDE	targetBased	4	Completed	01/02/2004	https://clinicaltrials.gov/study/NCT00331981	1	LoF	protect
Counterscreen for inverse agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify inverse agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A)	HTR5A	HTR5A	5-hydroxytryptamine receptor 5A	schizophrenia	AMISULPRIDE	targetBased	4	Completed	01/02/2004	https://clinicaltrials.gov/study/NCT00331981	1	LoF	protect
Counterscreen for agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A)	HTR5A	HTR5A	5-hydroxytryptamine receptor 5A	schizophrenia	AMISULPRIDE	targetBased	4	Completed	01/05/2005	https://clinicaltrials.gov/study/NCT00436371	1	LoF	protect
Counterscreen for inverse agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify inverse agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A)	HTR5A	HTR5A	5-hydroxytryptamine receptor 5A	schizophrenia	AMISULPRIDE	targetBased	4	Completed	01/05/2005	https://clinicaltrials.gov/study/NCT00436371	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	AMISULPRIDE	targetBased	4	Not yet recruiting	01/10/2018	https://clinicaltrials.gov/study/NCT03510325	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	AMISULPRIDE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	AMISULPRIDE	targetBased	4	Not yet recruiting	01/05/2021	https://clinicaltrials.gov/study/NCT04446234	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	AMISULPRIDE	targetBased	4	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT01105481	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	AMISULPRIDE	targetBased	4	Completed	01/06/2005	https://clinicaltrials.gov/study/NCT00245674	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	AMISULPRIDE	targetBased	4	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT00204061	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	AMISULPRIDE	targetBased	4	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01795183	1	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	depressive disorder	AMISULPRIDE	targetBased	4	Recruiting	04/05/2021	https://clinicaltrials.gov/study/NCT04876521	1	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	depressive disorder	AMISULPRIDE	targetBased	4	Recruiting	04/05/2021	https://clinicaltrials.gov/study/NCT04876521	1	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	depressive disorder	AMISULPRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	depressive disorder	AMISULPRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Primary Cell Based High Throughput Screening Assay for Agonists of the 5-Hydroxytryptamine Receptor Subtype 1E (5HT1E)	HTR1E	HTR1E	5-hydroxytryptamine receptor 1E	Dementia	AMISULPRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Primary Cell Based High Throughput Screening Assay for Antagonists of the 5-Hydroxytryptamine Receptor Subtype 1E (5HT1E)	HTR1E	HTR1E	5-hydroxytryptamine receptor 1E	Dementia	AMISULPRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Primary Cell Based High Throughput Screening Assay for Antagonists of the 5-Hydroxytryptamine Receptor Subtype 1E (5HT1E)	HTR1E	HTR1E	5-hydroxytryptamine receptor 1E	schizophrenia	AMISULPRIDE	targetBased	4	Completed	01/02/2004	https://clinicaltrials.gov/study/NCT00331981	1	LoF	protect
Primary Cell Based High Throughput Screening Assay for Agonists of the 5-Hydroxytryptamine Receptor Subtype 1E (5HT1E)	HTR1E	HTR1E	5-hydroxytryptamine receptor 1E	schizophrenia	AMISULPRIDE	targetBased	4	Completed	01/06/2012	https://clinicaltrials.gov/study/NCT01609153	1	LoF	protect
Primary Cell Based High Throughput Screening Assay for Antagonists of the 5-Hydroxytryptamine Receptor Subtype 1E (5HT1E)	HTR1E	HTR1E	5-hydroxytryptamine receptor 1E	schizophrenia	AMISULPRIDE	targetBased	4	Completed	01/06/2012	https://clinicaltrials.gov/study/NCT01609153	1	LoF	protect
Primary Cell Based High Throughput Screening Assay for Agonists of the 5-Hydroxytryptamine Receptor Subtype 1E (5HT1E)	HTR1E	HTR1E	5-hydroxytryptamine receptor 1E	schizophrenia	AMISULPRIDE	targetBased	4	Completed	01/10/2011	https://clinicaltrials.gov/study/NCT01446328	1	LoF	protect
Primary Cell Based High Throughput Screening Assay for Antagonists of the 5-Hydroxytryptamine Receptor Subtype 1E (5HT1E)	HTR1E	HTR1E	5-hydroxytryptamine receptor 1E	schizophrenia	AMISULPRIDE	targetBased	4	Completed	01/10/2011	https://clinicaltrials.gov/study/NCT01446328	1	LoF	protect
Primary Cell Based High Throughput Screening Assay for Agonists of the 5-Hydroxytryptamine Receptor Subtype 1E (5HT1E)	HTR1E	HTR1E	5-hydroxytryptamine receptor 1E	schizophrenia	AMISULPRIDE	targetBased	4	Unknown status	01/10/2017	https://clinicaltrials.gov/study/NCT03802838	1	LoF	protect
Primary Cell Based High Throughput Screening Assay for Antagonists of the 5-Hydroxytryptamine Receptor Subtype 1E (5HT1E)	HTR1E	HTR1E	5-hydroxytryptamine receptor 1E	schizophrenia	AMISULPRIDE	targetBased	4	Unknown status	01/10/2017	https://clinicaltrials.gov/study/NCT03802838	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Dementia	AMISULPRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Dementia	AMISULPRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Dementia	AMISULPRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Counterscreen for agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A)	HTR5A	HTR5A	5-hydroxytryptamine receptor 5A	depressive disorder	AMISULPRIDE	targetBased	4	Recruiting	04/05/2021	https://clinicaltrials.gov/study/NCT04876521	1	LoF	protect
Counterscreen for inverse agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify inverse agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A)	HTR5A	HTR5A	5-hydroxytryptamine receptor 5A	depressive disorder	AMISULPRIDE	targetBased	4	Recruiting	04/05/2021	https://clinicaltrials.gov/study/NCT04876521	1	LoF	protect
Counterscreen for agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A)	HTR5A	HTR5A	5-hydroxytryptamine receptor 5A	depressive disorder	AMISULPRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Counterscreen for inverse agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify inverse agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A)	HTR5A	HTR5A	5-hydroxytryptamine receptor 5A	depressive disorder	AMISULPRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	mental or behavioural disorder	AMISULPRIDE	targetBased	4	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT00204061	1	LoF	protect
Counterscreen for agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A)	HTR5A	HTR5A	5-hydroxytryptamine receptor 5A	psychosis	AMISULPRIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AL05	1	LoF	protect
Counterscreen for inverse agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify inverse agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A)	HTR5A	HTR5A	5-hydroxytryptamine receptor 5A	psychosis	AMISULPRIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AL05	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Dementia	AMISULPRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	psychosis	AMISULPRIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AL05	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	psychosis	AMISULPRIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AL05	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	psychosis	AMISULPRIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AL05	1	LoF	protect
Primary Cell Based High Throughput Screening Assay for Agonists of the 5-Hydroxytryptamine Receptor Subtype 1E (5HT1E)	HTR1E	HTR1E	5-hydroxytryptamine receptor 1E	depressive disorder	AMISULPRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Primary Cell Based High Throughput Screening Assay for Antagonists of the 5-Hydroxytryptamine Receptor Subtype 1E (5HT1E)	HTR1E	HTR1E	5-hydroxytryptamine receptor 1E	depressive disorder	AMISULPRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Primary Cell Based High Throughput Screening Assay for Agonists of the 5-Hydroxytryptamine Receptor Subtype 1E (5HT1E)	HTR1E	HTR1E	5-hydroxytryptamine receptor 1E	depressive disorder	AMISULPRIDE	targetBased	4	Recruiting	04/05/2021	https://clinicaltrials.gov/study/NCT04876521	1	LoF	protect
Primary Cell Based High Throughput Screening Assay for Antagonists of the 5-Hydroxytryptamine Receptor Subtype 1E (5HT1E)	HTR1E	HTR1E	5-hydroxytryptamine receptor 1E	depressive disorder	AMISULPRIDE	targetBased	4	Recruiting	04/05/2021	https://clinicaltrials.gov/study/NCT04876521	1	LoF	protect
Counterscreen for agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A)	HTR5A	HTR5A	5-hydroxytryptamine receptor 5A	schizoaffective disorder	AMISULPRIDE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
Counterscreen for inverse agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify inverse agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A)	HTR5A	HTR5A	5-hydroxytryptamine receptor 5A	schizoaffective disorder	AMISULPRIDE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
Counterscreen for agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A)	HTR5A	HTR5A	5-hydroxytryptamine receptor 5A	schizoaffective disorder	AMISULPRIDE	targetBased	4	Completed	01/06/2012	https://clinicaltrials.gov/study/NCT01609153	1	LoF	protect
Counterscreen for inverse agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify inverse agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A)	HTR5A	HTR5A	5-hydroxytryptamine receptor 5A	schizoaffective disorder	AMISULPRIDE	targetBased	4	Completed	01/06/2012	https://clinicaltrials.gov/study/NCT01609153	1	LoF	protect
Counterscreen for agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A)	HTR5A	HTR5A	5-hydroxytryptamine receptor 5A	schizoaffective disorder	AMISULPRIDE	targetBased	4	Completed	01/05/2011	https://clinicaltrials.gov/study/NCT01248195	1	LoF	protect
Counterscreen for inverse agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify inverse agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A)	HTR5A	HTR5A	5-hydroxytryptamine receptor 5A	schizoaffective disorder	AMISULPRIDE	targetBased	4	Completed	01/05/2011	https://clinicaltrials.gov/study/NCT01248195	1	LoF	protect
Primary Cell Based High Throughput Screening Assay for Agonists of the 5-Hydroxytryptamine Receptor Subtype 1E (5HT1E)	HTR1E	HTR1E	5-hydroxytryptamine receptor 1E	anxiety	AMISULPRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Primary Cell Based High Throughput Screening Assay for Antagonists of the 5-Hydroxytryptamine Receptor Subtype 1E (5HT1E)	HTR1E	HTR1E	5-hydroxytryptamine receptor 1E	anxiety	AMISULPRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	depressive disorder	AMISULPRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	depressive disorder	AMISULPRIDE	targetBased	4	Recruiting	04/05/2021	https://clinicaltrials.gov/study/NCT04876521	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	depressive disorder	AMISULPRIDE	targetBased	4	Recruiting	04/05/2021	https://clinicaltrials.gov/study/NCT04876521	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	depressive disorder	AMISULPRIDE	targetBased	4	Recruiting	04/05/2021	https://clinicaltrials.gov/study/NCT04876521	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	depressive disorder	AMISULPRIDE	targetBased	4	Recruiting	04/05/2021	https://clinicaltrials.gov/study/NCT04876521	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	depressive disorder	AMISULPRIDE	targetBased	4	Recruiting	04/05/2021	https://clinicaltrials.gov/study/NCT04876521	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	depressive disorder	AMISULPRIDE	targetBased	4	Recruiting	04/05/2021	https://clinicaltrials.gov/study/NCT04876521	1	LoF	protect
Counterscreen for agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A)	HTR5A	HTR5A	5-hydroxytryptamine receptor 5A	mental or behavioural disorder	AMISULPRIDE	targetBased	4	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT00204061	1	LoF	protect
Counterscreen for inverse agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify inverse agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A)	HTR5A	HTR5A	5-hydroxytryptamine receptor 5A	mental or behavioural disorder	AMISULPRIDE	targetBased	4	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT00204061	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	anxiety	AMISULPRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	anxiety	AMISULPRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	anxiety	AMISULPRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	anxiety	AMISULPRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	anxiety	AMISULPRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	anxiety	AMISULPRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizoaffective disorder	AMISULPRIDE	targetBased	4	Completed	01/05/2011	https://clinicaltrials.gov/study/NCT01248195	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizoaffective disorder	AMISULPRIDE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizoaffective disorder	AMISULPRIDE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizoaffective disorder	AMISULPRIDE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizoaffective disorder	AMISULPRIDE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizoaffective disorder	AMISULPRIDE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizoaffective disorder	AMISULPRIDE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	AMISULPRIDE	targetBased	4	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT00204061	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	AMISULPRIDE	targetBased	4	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT00204061	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	mental or behavioural disorder	AMISULPRIDE	targetBased	4	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT00204061	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	mental or behavioural disorder	AMISULPRIDE	targetBased	4	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT00204061	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	AMISULPRIDE	targetBased	4	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT00204061	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	AMISULPRIDE	targetBased	4	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT00204061	1	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	schizoaffective disorder	AMISULPRIDE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	schizoaffective disorder	AMISULPRIDE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	schizoaffective disorder	AMISULPRIDE	targetBased	4	Completed	01/05/2011	https://clinicaltrials.gov/study/NCT01248195	1	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	schizoaffective disorder	AMISULPRIDE	targetBased	4	Completed	01/05/2011	https://clinicaltrials.gov/study/NCT01248195	1	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	schizoaffective disorder	AMISULPRIDE	targetBased	4	Completed	01/06/2012	https://clinicaltrials.gov/study/NCT01609153	1	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	schizoaffective disorder	AMISULPRIDE	targetBased	4	Completed	01/06/2012	https://clinicaltrials.gov/study/NCT01609153	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	psychosis	AMISULPRIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AL05	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizoaffective disorder	AMISULPRIDE	targetBased	4	Completed	01/05/2011	https://clinicaltrials.gov/study/NCT01248195	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizoaffective disorder	AMISULPRIDE	targetBased	4	Completed	01/06/2012	https://clinicaltrials.gov/study/NCT01609153	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizoaffective disorder	AMISULPRIDE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	schizophrenia	AMISULPRIDE	targetBased	4	Terminated	01/01/2008	https://clinicaltrials.gov/study/NCT01615185	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	schizophrenia	AMISULPRIDE	targetBased	4	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT00204061	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	schizophrenia	AMISULPRIDE	targetBased	4	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT00204061	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	schizophrenia	AMISULPRIDE	targetBased	4	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT00204061	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	schizophrenia	AMISULPRIDE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	schizophrenia	AMISULPRIDE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	schizophrenia	AMISULPRIDE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	depressive disorder	AMISULPRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	depressive disorder	AMISULPRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	depressive disorder	AMISULPRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	depressive disorder	AMISULPRIDE	targetBased	4	Recruiting	04/05/2021	https://clinicaltrials.gov/study/NCT04876521	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	depressive disorder	AMISULPRIDE	targetBased	4	Recruiting	04/05/2021	https://clinicaltrials.gov/study/NCT04876521	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	depressive disorder	AMISULPRIDE	targetBased	4	Recruiting	04/05/2021	https://clinicaltrials.gov/study/NCT04876521	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	depressive disorder	AMISULPRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	depressive disorder	AMISULPRIDE	targetBased	4	Recruiting	04/05/2021	https://clinicaltrials.gov/study/NCT04876521	1	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	psychosis	AMISULPRIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AL05	1	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	psychosis	AMISULPRIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AL05	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	psychosis	AMISULPRIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AL05	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	psychosis	AMISULPRIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AL05	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	psychosis	AMISULPRIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AL05	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	psychosis	AMISULPRIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AL05	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	AMISULPRIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AL05	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	AMISULPRIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AL05	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	anxiety	AMISULPRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	schizophrenia	AMISULPRIDE	targetBased	4	Not yet recruiting	01/05/2021	https://clinicaltrials.gov/study/NCT04446234	1	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	schizophrenia	AMISULPRIDE	targetBased	4	Completed	01/09/2008	https://clinicaltrials.gov/study/NCT00761670	1	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	schizophrenia	AMISULPRIDE	targetBased	4	Completed	01/09/2008	https://clinicaltrials.gov/study/NCT00761670	1	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	schizophrenia	AMISULPRIDE	targetBased	4	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT00204061	1	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	schizophrenia	AMISULPRIDE	targetBased	4	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT00204061	1	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	schizophrenia	AMISULPRIDE	targetBased	4	Completed	01/09/2011	https://clinicaltrials.gov/study/NCT01246232	1	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	schizophrenia	AMISULPRIDE	targetBased	4	Completed	01/09/2011	https://clinicaltrials.gov/study/NCT01246232	1	LoF	protect
Counterscreen for agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A)	HTR5A	HTR5A	5-hydroxytryptamine receptor 5A	anxiety	AMISULPRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Counterscreen for inverse agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify inverse agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A)	HTR5A	HTR5A	5-hydroxytryptamine receptor 5A	anxiety	AMISULPRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Primary Cell Based High Throughput Screening Assay for Agonists of the 5-Hydroxytryptamine Receptor Subtype 1E (5HT1E)	HTR1E	HTR1E	5-hydroxytryptamine receptor 1E	psychosis	AMISULPRIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AL05	1	LoF	protect
Primary Cell Based High Throughput Screening Assay for Antagonists of the 5-Hydroxytryptamine Receptor Subtype 1E (5HT1E)	HTR1E	HTR1E	5-hydroxytryptamine receptor 1E	psychosis	AMISULPRIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AL05	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Dementia	AMISULPRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Dementia	AMISULPRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Dementia	AMISULPRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Dementia	AMISULPRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Dementia	AMISULPRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Dementia	AMISULPRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	AMISULPRIDE	targetBased	4	Not yet recruiting	01/05/2021	https://clinicaltrials.gov/study/NCT04446234	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	AMISULPRIDE	targetBased	4	Not yet recruiting	01/10/2018	https://clinicaltrials.gov/study/NCT03510325	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	AMISULPRIDE	targetBased	4	Not yet recruiting	01/10/2018	https://clinicaltrials.gov/study/NCT03510325	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	AMISULPRIDE	targetBased	4	Not yet recruiting	01/10/2018	https://clinicaltrials.gov/study/NCT03510325	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	AMISULPRIDE	targetBased	4	Not yet recruiting	01/10/2018	https://clinicaltrials.gov/study/NCT03510325	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	AMISULPRIDE	targetBased	4	Not yet recruiting	01/10/2018	https://clinicaltrials.gov/study/NCT03510325	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	AMISULPRIDE	targetBased	4	Not yet recruiting	01/10/2018	https://clinicaltrials.gov/study/NCT03510325	1	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	anxiety	AMISULPRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	anxiety	AMISULPRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	anxiety	AMISULPRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	anxiety	AMISULPRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	anxiety	AMISULPRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	schizoaffective disorder	AMISULPRIDE	targetBased	4	Completed	01/06/2012	https://clinicaltrials.gov/study/NCT01609153	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	schizoaffective disorder	AMISULPRIDE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	schizoaffective disorder	AMISULPRIDE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	schizoaffective disorder	AMISULPRIDE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	schizoaffective disorder	AMISULPRIDE	targetBased	4	Completed	01/05/2011	https://clinicaltrials.gov/study/NCT01248195	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	schizoaffective disorder	AMISULPRIDE	targetBased	4	Completed	01/05/2011	https://clinicaltrials.gov/study/NCT01248195	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	schizoaffective disorder	AMISULPRIDE	targetBased	4	Completed	01/05/2011	https://clinicaltrials.gov/study/NCT01248195	1	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Dementia	AMISULPRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Dementia	AMISULPRIDE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		anxiety	ESKETAMINE	targetBased	4	Recruiting	30/06/2023	https://clinicaltrials.gov/study/NCT05925283	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		depressive disorder	ESKETAMINE	targetBased	4	Completed	04/11/2020	https://clinicaltrials.gov/study/NCT04599855	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		depressive disorder	ESKETAMINE	targetBased	4	Recruiting	08/10/2021	https://clinicaltrials.gov/study/NCT04303325	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		depressive disorder	ESKETAMINE	targetBased	3	Completed	01/10/2015	https://clinicaltrials.gov/study/NCT02493868	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		depressive disorder	ESKETAMINE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/spravato	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		depressive disorder	ESKETAMINE	targetBased	3	Completed	10/08/2015	https://clinicaltrials.gov/study/NCT02417064	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		depressive disorder	ESKETAMINE	targetBased	3	Completed	20/08/2015	https://clinicaltrials.gov/study/NCT02422186	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		depressive disorder	ESKETAMINE	targetBased	3	Completed	07/08/2015	https://clinicaltrials.gov/study/NCT02418585	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		depressive disorder	ESKETAMINE	targetBased	3	Withdrawn	01/12/2019	https://clinicaltrials.gov/study/NCT03852160	0.7	LoF	protect	New design was developed to better fit company strategy, a new study has replaced 5413541TRD3011 study
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		depressive disorder	ESKETAMINE	targetBased	3	Completed	08/09/2020	https://clinicaltrials.gov/study/NCT04476446	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		pain agnosia	ESKETAMINE	targetBased	4	Recruiting	08/02/2022	https://clinicaltrials.gov/study/NCT04964219	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		pain agnosia	ESKETAMINE	targetBased	4	Recruiting	11/08/2022	https://clinicaltrials.gov/study/NCT05466708	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		unipolar depression	ESKETAMINE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211243lbl.pdf	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		unipolar depression	ESKETAMINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N06AX27	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		unipolar depression	ESKETAMINE	targetBased	4	Active, not recruiting	26/04/2021	https://clinicaltrials.gov/study/NCT04829318	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		treatment resistant depression	ESKETAMINE	targetBased	4	Recruiting	03/06/2024	https://clinicaltrials.gov/study/NCT06278779	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		postpartum depression	ESKETAMINE	targetBased	4	Active, not recruiting	19/06/2020	https://clinicaltrials.gov/study/NCT05698394	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		postpartum depression	ESKETAMINE	targetBased	4	Recruiting	01/05/2023	https://clinicaltrials.gov/study/NCT05826327	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		postpartum depression	ESKETAMINE	targetBased	4	Not yet recruiting	20/02/2022	https://clinicaltrials.gov/study/NCT05229913	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		major depressive disorder	ESKETAMINE	targetBased	4	Recruiting	13/10/2022	https://clinicaltrials.gov/study/NCT05450432	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		major depressive disorder	ESKETAMINE	targetBased	3	Completed	21/08/2020	https://clinicaltrials.gov/study/NCT04338321	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		major depressive disorder	ESKETAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d81a6a79-a74a-44b7-822c-0dfa3036eaed	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		major depressive disorder	ESKETAMINE	targetBased	4	Withdrawn	27/10/2023	https://clinicaltrials.gov/study/NCT05554627	1	LoF	protect	Study funding was withdrawn by study sponsor (CSR\&D) prior to enrollment due to budget constraints.
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		major depressive disorder	ESKETAMINE	targetBased	3	Completed	09/06/2017	https://clinicaltrials.gov/study/NCT03039192	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		major depressive disorder	ESKETAMINE	targetBased	3	Completed	15/06/2017	https://clinicaltrials.gov/study/NCT03097133	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		major depressive disorder	ESKETAMINE	targetBased	4	Recruiting	31/10/2023	https://clinicaltrials.gov/study/NCT06103760	1	LoF	protect
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	schizophrenia	EXENATIDE	targetBased	4	Completed	01/09/2014	https://clinicaltrials.gov/study/NCT02417142	1	GoF	protect
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	schizophrenia	EXENATIDE	targetBased	4	Completed	01/09/2014	https://clinicaltrials.gov/study/NCT02417142	1	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	schizophrenia	EXENATIDE	targetBased	4	Completed	01/09/2014	https://clinicaltrials.gov/study/NCT02417142	1	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	schizoaffective disorder	EXENATIDE	targetBased	4	Completed	01/09/2014	https://clinicaltrials.gov/study/NCT02417142	1	GoF	protect
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	schizoaffective disorder	EXENATIDE	targetBased	4	Completed	01/09/2014	https://clinicaltrials.gov/study/NCT02417142	1	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	schizoaffective disorder	EXENATIDE	targetBased	4	Completed	01/09/2014	https://clinicaltrials.gov/study/NCT02417142	1	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	autism spectrum disorder	OXYTOCIN	targetBased	3	Completed	26/07/2018	https://clinicaltrials.gov/study/NCT03640156	0.7	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	autism spectrum disorder	OXYTOCIN	targetBased	3	Completed	09/10/2017	https://clinicaltrials.gov/study/NCT02985749	0.7	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	autism spectrum disorder	OXYTOCIN	targetBased	4	Completed	01/04/2015	https://clinicaltrials.gov/study/NCT02940574	1	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	post-traumatic stress disorder	OXYTOCIN	targetBased	4	Completed	01/08/2011	https://clinicaltrials.gov/study/NCT01325168	1	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	alcohol dependence	OXYTOCIN	targetBased	3	Completed	01/10/2016	https://clinicaltrials.gov/study/NCT02903251	0.7	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	alcohol dependence	OXYTOCIN	targetBased	4	Completed	01/05/2013	https://clinicaltrials.gov/study/NCT01829516	1	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	alcohol dependence	OXYTOCIN	targetBased	3	Completed	01/11/2017	https://clinicaltrials.gov/study/NCT03339024	0.7	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	nicotine dependence	OXYTOCIN	targetBased	4	Completed	01/07/2016	https://clinicaltrials.gov/study/NCT02595749	1	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	schizophrenia	OXYTOCIN	targetBased	4	Completed	01/06/2012	https://clinicaltrials.gov/study/NCT01614093	1	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	schizophrenia	OXYTOCIN	targetBased	4	Active, not recruiting	04/01/2018	https://clinicaltrials.gov/study/NCT03245437	1	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	schizophrenia	OXYTOCIN	targetBased	3	Recruiting	01/03/2012	https://clinicaltrials.gov/study/NCT01987050	0.7	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	drug dependence	OXYTOCIN	targetBased	4	Terminated	01/11/2008	https://clinicaltrials.gov/study/NCT00975416	1	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	anxiety	OXYTOCIN	targetBased	4	Completed	01/12/2008	https://clinicaltrials.gov/study/NCT01081249	1	GoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	depressive disorder	AMLODIPINE	targetBased	3	Unknown status	01/04/2012	https://clinicaltrials.gov/study/NCT01557153	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	heroin dependence	HYDROMORPHONE	targetBased	3	Completed	01/12/2011	https://clinicaltrials.gov/study/NCT01447212	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	heroin dependence	HYDROMORPHONE	targetBased	3	Completed	01/12/2011	https://clinicaltrials.gov/study/NCT01447212	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	HYDROMORPHONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=22e635cb-98c0-e4f9-6a71-62d7487a0a6c	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	HYDROMORPHONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=22e635cb-98c0-e4f9-6a71-62d7487a0a6c	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	HYDROMORPHONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3832ede8-d3fc-455d-ecab-3b77be5869f5	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	HYDROMORPHONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3832ede8-d3fc-455d-ecab-3b77be5869f5	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	HYDROMORPHONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b95bfd6c-cee5-f57d-e053-2995a90a5ce1	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	HYDROMORPHONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b95bfd6c-cee5-f57d-e053-2995a90a5ce1	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	HYDROMORPHONE	targetBased	4	Completed	20/05/2020	https://clinicaltrials.gov/study/NCT04396587	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	HYDROMORPHONE	targetBased	4	Completed	20/05/2020	https://clinicaltrials.gov/study/NCT04396587	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	LEVOMETHADYL ACETATE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N07BC03	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	LEVOMETHADYL ACETATE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N07BC03	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	LEVOMETHADYL ACETATE	targetBased	4	Completed	01/03/1995	https://clinicaltrials.gov/study/NCT00000300	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	LEVOMETHADYL ACETATE	targetBased	4	Completed	01/03/1995	https://clinicaltrials.gov/study/NCT00000300	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	LEVOMETHADYL ACETATE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/orlaam	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	LEVOMETHADYL ACETATE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/orlaam	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	attention deficit hyperactivity disorder	ERGOCALCIFEROL	targetBased	4	Recruiting	25/02/2021	https://clinicaltrials.gov/study/NCT04284059	1	GoF	protect
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	THRB	Thyroid hormone receptor beta	bipolar disorder	LIOTHYRONINE	targetBased	3	Completed	01/07/2008	https://clinicaltrials.gov/study/NCT00790738	0.7	GoF	protect
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	THRB	Thyroid hormone receptor beta	bipolar disorder	LIOTHYRONINE	targetBased	3	Completed	01/10/2002	https://clinicaltrials.gov/study/NCT00158990	0.7	GoF	protect
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	THRB	Thyroid hormone receptor beta	depressive disorder	LIOTHYRONINE	targetBased	4	Completed	01/04/2003	https://clinicaltrials.gov/study/NCT00531713	1	GoF	protect
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	THRB	Thyroid hormone receptor beta	depressive disorder	LIOTHYRONINE	targetBased	4	Terminated	01/09/2001	https://clinicaltrials.gov/study/NCT00296686	1	GoF	protect	Study is no longer funded.
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	THRB	Thyroid hormone receptor beta	depressive disorder	LIOTHYRONINE	targetBased	3	Completed	01/10/2002	https://clinicaltrials.gov/study/NCT00158990	0.7	GoF	protect
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	THRB	Thyroid hormone receptor beta	depressive disorder	LIOTHYRONINE	targetBased	4	Completed	01/09/1996	https://clinicaltrials.gov/study/NCT00208702	1	GoF	protect
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	THRB	Thyroid hormone receptor beta	depressive disorder	LIOTHYRONINE	targetBased	4	Completed	01/07/2001	https://clinicaltrials.gov/study/NCT00021528	1	GoF	protect
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	THRB	Thyroid hormone receptor beta	depressive disorder	LIOTHYRONINE	targetBased	3	Completed	01/07/2008	https://clinicaltrials.gov/study/NCT00790738	0.7	GoF	protect
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	THRB	Thyroid hormone receptor beta	unipolar depression	LIOTHYRONINE	targetBased	3	Completed	01/10/2002	https://clinicaltrials.gov/study/NCT00158990	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Sleep Disorder	EPLIVANSERIN	targetBased	3	Completed	01/04/2008	https://clinicaltrials.gov/study/NCT00679900	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Sleep Disorder	EPLIVANSERIN	targetBased	3	Completed	01/11/2005	https://clinicaltrials.gov/study/NCT00253968	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	insomnia	EPLIVANSERIN	targetBased	3	Completed	01/02/2006	https://clinicaltrials.gov/study/NCT00308503	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	insomnia	EPLIVANSERIN	targetBased	3	Completed	01/11/2005	https://clinicaltrials.gov/study/NCT00253968	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	insomnia	EPLIVANSERIN	targetBased	3	Completed	01/12/2008	https://clinicaltrials.gov/study/NCT00805350	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	insomnia	EPLIVANSERIN	targetBased	3	Completed	01/11/2005	https://clinicaltrials.gov/study/NCT00253903	0.7	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	major depressive disorder	BUPRENORPHINE	targetBased	3	Completed	01/09/2011	https://clinicaltrials.gov/study/NCT01407575	0.7	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	major depressive disorder	BUPRENORPHINE	targetBased	3	Recruiting	01/08/2020	https://clinicaltrials.gov/study/NCT04116528	0.7	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	major depressive disorder	BUPRENORPHINE	targetBased	4	Recruiting	19/10/2020	https://clinicaltrials.gov/study/NCT04276259	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	cocaine dependence	BUPRENORPHINE	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00000216	0.7	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	cocaine dependence	BUPRENORPHINE	targetBased	3	Completed	01/02/1995	https://clinicaltrials.gov/study/NCT00000311	0.7	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	opioid dependence	BUPRENORPHINE	targetBased	4	Completed	01/08/1999	https://clinicaltrials.gov/study/NCT00007527	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	opioid dependence	BUPRENORPHINE	targetBased	4	Completed	22/02/2008	https://clinicaltrials.gov/study/NCT00604188	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	opioid dependence	BUPRENORPHINE	targetBased	4	Completed	01/08/1999	https://clinicaltrials.gov/study/NCT00015340	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	opioid dependence	BUPRENORPHINE	targetBased	4	Completed	01/03/2013	https://clinicaltrials.gov/study/NCT03174067	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	opioid dependence	BUPRENORPHINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc2755a5-3292-4b49-872d-e22c386a4e44	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	opioid dependence	BUPRENORPHINE	targetBased	4	Completed	24/06/2019	https://clinicaltrials.gov/study/NCT03604159	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	opioid dependence	BUPRENORPHINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=033f2324-09d4-ce5c-ff60-e3b03d0538c1	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	heroin dependence	BUPRENORPHINE	targetBased	4	Completed	01/08/2005	https://clinicaltrials.gov/study/NCT00310934	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	heroin dependence	BUPRENORPHINE	targetBased	4	Completed	01/08/2005	https://clinicaltrials.gov/study/NCT00310934	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	heroin dependence	BUPRENORPHINE	targetBased	4	Unknown status	01/08/2008	https://clinicaltrials.gov/study/NCT00750217	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	heroin dependence	BUPRENORPHINE	targetBased	4	Unknown status	01/08/2008	https://clinicaltrials.gov/study/NCT00750217	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	heroin dependence	BUPRENORPHINE	targetBased	3	Terminated	01/11/2018	https://clinicaltrials.gov/study/NCT03711318	0.7	GoF	protect	continuing study was no longer feasible
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	heroin dependence	BUPRENORPHINE	targetBased	3	Terminated	01/11/2018	https://clinicaltrials.gov/study/NCT03711318	0.7	GoF	protect	continuing study was no longer feasible
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	heroin dependence	BUPRENORPHINE	targetBased	3	Completed	01/02/2001	https://clinicaltrials.gov/study/NCT00032955	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	heroin dependence	BUPRENORPHINE	targetBased	3	Completed	01/02/2001	https://clinicaltrials.gov/study/NCT00032955	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	BUPRENORPHINE	targetBased	4	Completed	01/02/2003	https://clinicaltrials.gov/study/NCT00367874	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	BUPRENORPHINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N07BC01	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	BUPRENORPHINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N07BC01	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	BUPRENORPHINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=36338030-20e2-4ddb-bc06-6c43be4f50a0	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	BUPRENORPHINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=36338030-20e2-4ddb-bc06-6c43be4f50a0	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	BUPRENORPHINE	targetBased	4	Completed	01/08/1999	https://clinicaltrials.gov/study/NCT00015340	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	BUPRENORPHINE	targetBased	4	Completed	01/08/1999	https://clinicaltrials.gov/study/NCT00015340	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	opioid use disorder	BUPRENORPHINE	targetBased	4	Recruiting	20/06/2024	https://clinicaltrials.gov/study/NCT05450718	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	opioid use disorder	BUPRENORPHINE	targetBased	4	Recruiting	01/12/2023	https://clinicaltrials.gov/study/NCT05944952	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	opioid use disorder	BUPRENORPHINE	targetBased	4	Completed	01/03/2023	https://clinicaltrials.gov/study/NCT05704543	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	opioid use disorder	BUPRENORPHINE	targetBased	4	Recruiting	04/06/2024	https://clinicaltrials.gov/study/NCT06323824	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	opioid use disorder	BUPRENORPHINE	targetBased	4	Recruiting	03/11/2020	https://clinicaltrials.gov/study/NCT04375033	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	opioid use disorder	BUPRENORPHINE	targetBased	4	Enrolling by invitation	01/04/2018	https://clinicaltrials.gov/study/NCT03396276	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	opioid use disorder	BUPRENORPHINE	targetBased	4	Withdrawn	30/11/2018	https://clinicaltrials.gov/study/NCT03740243	1	GoF	protect	No enrollment
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	major depressive disorder	BUPRENORPHINE	targetBased	4	Recruiting	19/10/2020	https://clinicaltrials.gov/study/NCT04276259	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	major depressive disorder	BUPRENORPHINE	targetBased	4	Recruiting	19/10/2020	https://clinicaltrials.gov/study/NCT04276259	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	major depressive disorder	BUPRENORPHINE	targetBased	3	Recruiting	01/08/2020	https://clinicaltrials.gov/study/NCT04116528	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	major depressive disorder	BUPRENORPHINE	targetBased	3	Recruiting	01/08/2020	https://clinicaltrials.gov/study/NCT04116528	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	major depressive disorder	BUPRENORPHINE	targetBased	3	Completed	01/09/2011	https://clinicaltrials.gov/study/NCT01407575	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	major depressive disorder	BUPRENORPHINE	targetBased	3	Completed	01/09/2011	https://clinicaltrials.gov/study/NCT01407575	0.7	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	drug dependence	BUPRENORPHINE	targetBased	4	Completed	01/06/2013	https://clinicaltrials.gov/study/NCT01843023	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	drug dependence	BUPRENORPHINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N07BC51	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	drug dependence	BUPRENORPHINE	targetBased	4	Completed	01/02/2003	https://clinicaltrials.gov/study/NCT00367874	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	drug dependence	BUPRENORPHINE	targetBased	4	Completed	01/08/1999	https://clinicaltrials.gov/study/NCT00015340	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	drug dependence	BUPRENORPHINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b086772e-d15a-4d13-b1a2-38bfbde1f18c	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	drug dependence	BUPRENORPHINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=36338030-20e2-4ddb-bc06-6c43be4f50a0	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	drug dependence	BUPRENORPHINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=593b95a7-b716-cdf4-e053-2a91aa0a35ee	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	heroin dependence	BUPRENORPHINE	targetBased	4	Unknown status	01/08/2008	https://clinicaltrials.gov/study/NCT00750217	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	heroin dependence	BUPRENORPHINE	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00000302	0.7	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	heroin dependence	BUPRENORPHINE	targetBased	3	Completed	01/04/1996	https://clinicaltrials.gov/study/NCT00015171	0.7	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	heroin dependence	BUPRENORPHINE	targetBased	4	Completed	01/08/2005	https://clinicaltrials.gov/study/NCT00310934	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	heroin dependence	BUPRENORPHINE	targetBased	3	Completed	01/02/2001	https://clinicaltrials.gov/study/NCT00032955	0.7	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	heroin dependence	BUPRENORPHINE	targetBased	3	Completed	01/09/2008	https://clinicaltrials.gov/study/NCT00574067	0.7	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	heroin dependence	BUPRENORPHINE	targetBased	3	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT00032968	0.7	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	heroin dependence	BUPRENORPHINE	targetBased	3	Terminated	01/11/2018	https://clinicaltrials.gov/study/NCT03711318	0.7	GoF	protect	continuing study was no longer feasible
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	depressive disorder	BUPRENORPHINE	targetBased	3	Completed	01/09/2011	https://clinicaltrials.gov/study/NCT01407575	0.7	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	depressive disorder	BUPRENORPHINE	targetBased	4	Recruiting	19/10/2020	https://clinicaltrials.gov/study/NCT04276259	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	overdose	BUPRENORPHINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=36338030-20e2-4ddb-bc06-6c43be4f50a0	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	morphine dependence	BUPRENORPHINE	targetBased	3	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT00032968	0.7	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	morphine dependence	BUPRENORPHINE	targetBased	3	Completed	01/02/2001	https://clinicaltrials.gov/study/NCT00032955	0.7	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	substance withdrawal syndrome	BUPRENORPHINE	targetBased	3	Completed	01/02/2001	https://clinicaltrials.gov/study/NCT00032955	0.7	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	substance withdrawal syndrome	BUPRENORPHINE	targetBased	4	Completed	01/02/2003	https://clinicaltrials.gov/study/NCT00367874	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	substance withdrawal syndrome	BUPRENORPHINE	targetBased	3	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT00032968	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	BUPRENORPHINE	targetBased	4	Completed	01/03/2013	https://clinicaltrials.gov/study/NCT03174067	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	BUPRENORPHINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc2755a5-3292-4b49-872d-e22c386a4e44	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	BUPRENORPHINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fc2755a5-3292-4b49-872d-e22c386a4e44	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	BUPRENORPHINE	targetBased	4	Completed	01/03/2008	https://clinicaltrials.gov/study/NCT00605033	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	BUPRENORPHINE	targetBased	4	Completed	01/03/2008	https://clinicaltrials.gov/study/NCT00605033	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	BUPRENORPHINE	targetBased	4	Completed	24/06/2019	https://clinicaltrials.gov/study/NCT03604159	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	BUPRENORPHINE	targetBased	4	Completed	24/06/2019	https://clinicaltrials.gov/study/NCT03604159	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	depressive disorder	BUPRENORPHINE	targetBased	3	Completed	01/09/2011	https://clinicaltrials.gov/study/NCT01407575	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	depressive disorder	BUPRENORPHINE	targetBased	3	Completed	01/09/2011	https://clinicaltrials.gov/study/NCT01407575	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	depressive disorder	BUPRENORPHINE	targetBased	4	Recruiting	19/10/2020	https://clinicaltrials.gov/study/NCT04276259	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	depressive disorder	BUPRENORPHINE	targetBased	4	Recruiting	19/10/2020	https://clinicaltrials.gov/study/NCT04276259	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	overdose	BUPRENORPHINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=36338030-20e2-4ddb-bc06-6c43be4f50a0	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	overdose	BUPRENORPHINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=36338030-20e2-4ddb-bc06-6c43be4f50a0	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	neonatal abstinence syndrome	BUPRENORPHINE	targetBased	3	Completed	01/11/2011	https://clinicaltrials.gov/study/NCT01452789	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	neonatal abstinence syndrome	BUPRENORPHINE	targetBased	3	Completed	01/11/2011	https://clinicaltrials.gov/study/NCT01452789	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	neonatal abstinence syndrome	BUPRENORPHINE	targetBased	3	Completed	01/11/2011	https://clinicaltrials.gov/study/NCT01452789	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid use disorder	BUPRENORPHINE	targetBased	4	Enrolling by invitation	01/04/2018	https://clinicaltrials.gov/study/NCT03396276	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid use disorder	BUPRENORPHINE	targetBased	4	Recruiting	07/01/2021	https://clinicaltrials.gov/study/NCT04219540	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid use disorder	BUPRENORPHINE	targetBased	4	Recruiting	07/01/2021	https://clinicaltrials.gov/study/NCT04219540	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid use disorder	BUPRENORPHINE	targetBased	4	Completed	29/08/2019	https://clinicaltrials.gov/study/NCT03993392	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid use disorder	BUPRENORPHINE	targetBased	4	Completed	29/08/2019	https://clinicaltrials.gov/study/NCT03993392	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid use disorder	BUPRENORPHINE	targetBased	4	Completed	01/11/2020	https://clinicaltrials.gov/study/NCT04283500	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid use disorder	BUPRENORPHINE	targetBased	4	Completed	01/11/2020	https://clinicaltrials.gov/study/NCT04283500	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cocaine dependence	BUPRENORPHINE	targetBased	3	Completed	01/02/1995	https://clinicaltrials.gov/study/NCT00000311	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cocaine dependence	BUPRENORPHINE	targetBased	3	Completed	01/02/1995	https://clinicaltrials.gov/study/NCT00000311	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cocaine dependence	BUPRENORPHINE	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00000216	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	cocaine dependence	BUPRENORPHINE	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00000216	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	substance withdrawal syndrome	BUPRENORPHINE	targetBased	3	Completed	01/02/2001	https://clinicaltrials.gov/study/NCT00032955	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	substance withdrawal syndrome	BUPRENORPHINE	targetBased	3	Completed	01/02/2001	https://clinicaltrials.gov/study/NCT00032955	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	substance withdrawal syndrome	BUPRENORPHINE	targetBased	4	Completed	01/02/2003	https://clinicaltrials.gov/study/NCT00367874	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	substance withdrawal syndrome	BUPRENORPHINE	targetBased	4	Completed	01/02/2003	https://clinicaltrials.gov/study/NCT00367874	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	substance withdrawal syndrome	BUPRENORPHINE	targetBased	3	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT00032968	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	substance withdrawal syndrome	BUPRENORPHINE	targetBased	3	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT00032968	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	morphine dependence	BUPRENORPHINE	targetBased	3	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT00032968	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	morphine dependence	BUPRENORPHINE	targetBased	3	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT00032968	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	morphine dependence	BUPRENORPHINE	targetBased	3	Completed	01/02/2001	https://clinicaltrials.gov/study/NCT00032955	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	morphine dependence	BUPRENORPHINE	targetBased	3	Completed	01/02/2001	https://clinicaltrials.gov/study/NCT00032955	0.7	GoF	protect
FRET-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1)	HCRTR1	HCRTR1	Orexin/Hypocretin receptor type 1	insomnia	ALMOREXANT	targetBased	3	Completed	01/03/2008	https://clinicaltrials.gov/study/NCT00608985	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1)	HCRTR1	HCRTR1	Orexin/Hypocretin receptor type 1	insomnia	ALMOREXANT	targetBased	3	Completed	01/03/2008	https://clinicaltrials.gov/study/NCT00608985	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	post-traumatic stress disorder	PALIPERIDONE	targetBased	4	Withdrawn	01/09/2008	https://clinicaltrials.gov/study/NCT00766064	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	PALIPERIDONE	targetBased	4	Completed	01/04/2008	https://clinicaltrials.gov/study/NCT00761579	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	PALIPERIDONE	targetBased	4	Completed	01/08/2011	https://clinicaltrials.gov/study/NCT01399450	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	PALIPERIDONE	targetBased	4	Completed	01/11/2008	https://clinicaltrials.gov/study/NCT00827840	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	PALIPERIDONE	targetBased	4	Unknown status	01/07/2009	https://clinicaltrials.gov/study/NCT00937261	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	PALIPERIDONE	targetBased	4	Recruiting	16/08/2023	https://clinicaltrials.gov/study/NCT05741502	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	PALIPERIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7b8e5b26-b9e4-4704-921b-3c3c0d159916	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	PALIPERIDONE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	bipolar disorder	PALIPERIDONE	targetBased	4	Terminated	01/11/2007	https://clinicaltrials.gov/study/NCT00592358	1	LoF	protect	Slow enrollment.
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	bipolar disorder	PALIPERIDONE	targetBased	4	Terminated	01/11/2007	https://clinicaltrials.gov/study/NCT00592358	1	LoF	protect	Slow enrollment.
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar disorder	PALIPERIDONE	targetBased	4	Terminated	01/11/2007	https://clinicaltrials.gov/study/NCT00592358	1	LoF	protect	Slow enrollment.
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar disorder	PALIPERIDONE	targetBased	4	Terminated	01/11/2007	https://clinicaltrials.gov/study/NCT00592358	1	LoF	protect	Slow enrollment.
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar disorder	PALIPERIDONE	targetBased	4	Terminated	01/11/2007	https://clinicaltrials.gov/study/NCT00592358	1	LoF	protect	Slow enrollment.
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar disorder	PALIPERIDONE	targetBased	4	Terminated	01/11/2007	https://clinicaltrials.gov/study/NCT00592358	1	LoF	protect	Slow enrollment.
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar disorder	PALIPERIDONE	targetBased	3	Completed	01/02/2006	https://clinicaltrials.gov/study/NCT00299715	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	methamphetamine dependence	PALIPERIDONE	targetBased	4	Completed	01/02/2013	https://clinicaltrials.gov/study/NCT01825928	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	methamphetamine dependence	PALIPERIDONE	targetBased	4	Completed	01/02/2013	https://clinicaltrials.gov/study/NCT01822730	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	mental or behavioural disorder	PALIPERIDONE	targetBased	4	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT00806234	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	mental or behavioural disorder	PALIPERIDONE	targetBased	3	Completed	01/12/2006	https://clinicaltrials.gov/study/NCT00412373	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	mental or behavioural disorder	PALIPERIDONE	targetBased	4	Completed	01/10/2007	https://clinicaltrials.gov/study/NCT00535145	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Dementia	PALIPERIDONE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	post-traumatic stress disorder	PALIPERIDONE	targetBased	4	Withdrawn	01/09/2008	https://clinicaltrials.gov/study/NCT00766064	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	post-traumatic stress disorder	PALIPERIDONE	targetBased	4	Withdrawn	01/09/2008	https://clinicaltrials.gov/study/NCT00766064	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	post-traumatic stress disorder	PALIPERIDONE	targetBased	4	Withdrawn	01/09/2008	https://clinicaltrials.gov/study/NCT00766064	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	post-traumatic stress disorder	PALIPERIDONE	targetBased	4	Withdrawn	01/09/2008	https://clinicaltrials.gov/study/NCT00766064	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	post-traumatic stress disorder	PALIPERIDONE	targetBased	4	Withdrawn	01/09/2008	https://clinicaltrials.gov/study/NCT00766064	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	post-traumatic stress disorder	PALIPERIDONE	targetBased	4	Withdrawn	01/09/2008	https://clinicaltrials.gov/study/NCT00766064	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	depressive disorder	PALIPERIDONE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	depressive disorder	PALIPERIDONE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	depressive disorder	PALIPERIDONE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	depressive disorder	PALIPERIDONE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	depressive disorder	PALIPERIDONE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	depressive disorder	PALIPERIDONE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	anxiety	PALIPERIDONE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	anxiety	PALIPERIDONE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	anxiety	PALIPERIDONE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	anxiety	PALIPERIDONE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	anxiety	PALIPERIDONE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	anxiety	PALIPERIDONE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizoaffective disorder	PALIPERIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7b8e5b26-b9e4-4704-921b-3c3c0d159916	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizoaffective disorder	PALIPERIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=87d7eb59-2177-431d-bf6b-e14509c0c829	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizoaffective disorder	PALIPERIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=87d7eb59-2177-431d-bf6b-e14509c0c829	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizoaffective disorder	PALIPERIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=87d7eb59-2177-431d-bf6b-e14509c0c829	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizoaffective disorder	PALIPERIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=87d7eb59-2177-431d-bf6b-e14509c0c829	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizoaffective disorder	PALIPERIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=87d7eb59-2177-431d-bf6b-e14509c0c829	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizoaffective disorder	PALIPERIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=87d7eb59-2177-431d-bf6b-e14509c0c829	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	PALIPERIDONE	targetBased	4	Terminated	01/11/2007	https://clinicaltrials.gov/study/NCT00592358	1	LoF	protect	Slow enrollment.
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	PALIPERIDONE	targetBased	3	Completed	01/04/2006	https://clinicaltrials.gov/study/NCT00309699	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	PALIPERIDONE	targetBased	3	Completed	01/02/2006	https://clinicaltrials.gov/study/NCT00299715	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	PALIPERIDONE	targetBased	3	Completed	01/04/2006	https://clinicaltrials.gov/study/NCT00309686	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	PALIPERIDONE	targetBased	3	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00490971	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	PALIPERIDONE	targetBased	4	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT00806234	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	PALIPERIDONE	targetBased	4	Completed	01/10/2007	https://clinicaltrials.gov/study/NCT00535145	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	PALIPERIDONE	targetBased	4	Completed	01/10/2007	https://clinicaltrials.gov/study/NCT00535145	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	mental or behavioural disorder	PALIPERIDONE	targetBased	4	Completed	01/10/2007	https://clinicaltrials.gov/study/NCT00535145	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	mental or behavioural disorder	PALIPERIDONE	targetBased	4	Completed	01/10/2007	https://clinicaltrials.gov/study/NCT00535145	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	PALIPERIDONE	targetBased	4	Completed	01/10/2007	https://clinicaltrials.gov/study/NCT00535145	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	PALIPERIDONE	targetBased	4	Completed	01/10/2007	https://clinicaltrials.gov/study/NCT00535145	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	psychosis	PALIPERIDONE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AX13	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	psychosis	PALIPERIDONE	targetBased	4	Completed	01/02/2010	https://clinicaltrials.gov/study/NCT01157585	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizoaffective disorder	PALIPERIDONE	targetBased	4	Completed	01/07/2009	https://clinicaltrials.gov/study/NCT02075528	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizoaffective disorder	PALIPERIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=87d7eb59-2177-431d-bf6b-e14509c0c829	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizoaffective disorder	PALIPERIDONE	targetBased	4	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00330863	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizoaffective disorder	PALIPERIDONE	targetBased	4	Completed	01/10/2007	https://clinicaltrials.gov/study/NCT00535145	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizoaffective disorder	PALIPERIDONE	targetBased	4	Unknown status	01/04/2015	https://clinicaltrials.gov/study/NCT02433717	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizoaffective disorder	PALIPERIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8de6a6eb-9ed8-4e05-9a4c-d657b5634f76	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizoaffective disorder	PALIPERIDONE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	depressive disorder	PALIPERIDONE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	PALIPERIDONE	targetBased	4	Completed	01/02/2010	https://clinicaltrials.gov/study/NCT01157585	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	psychosis	PALIPERIDONE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AX13	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	psychosis	PALIPERIDONE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AX13	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	psychosis	PALIPERIDONE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AX13	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	psychosis	PALIPERIDONE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AX13	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	PALIPERIDONE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AX13	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	PALIPERIDONE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AX13	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	anxiety	PALIPERIDONE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	autism	PALIPERIDONE	targetBased	3	Completed	01/11/2007	https://clinicaltrials.gov/study/NCT00549562	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	methamphetamine dependence	PALIPERIDONE	targetBased	4	Completed	01/02/2013	https://clinicaltrials.gov/study/NCT01825928	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	methamphetamine dependence	PALIPERIDONE	targetBased	4	Completed	01/02/2013	https://clinicaltrials.gov/study/NCT01822730	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	methamphetamine dependence	PALIPERIDONE	targetBased	4	Completed	01/02/2013	https://clinicaltrials.gov/study/NCT01822730	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	methamphetamine dependence	PALIPERIDONE	targetBased	4	Completed	01/02/2013	https://clinicaltrials.gov/study/NCT01822730	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	methamphetamine dependence	PALIPERIDONE	targetBased	4	Completed	01/02/2013	https://clinicaltrials.gov/study/NCT01822730	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	methamphetamine dependence	PALIPERIDONE	targetBased	4	Completed	01/02/2013	https://clinicaltrials.gov/study/NCT01822730	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	methamphetamine dependence	PALIPERIDONE	targetBased	4	Completed	01/02/2013	https://clinicaltrials.gov/study/NCT01822730	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	mood disorder	PALIPERIDONE	targetBased	3	Completed	01/04/2006	https://clinicaltrials.gov/study/NCT00309699	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Dementia	PALIPERIDONE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Dementia	PALIPERIDONE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Dementia	PALIPERIDONE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Dementia	PALIPERIDONE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Dementia	PALIPERIDONE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Dementia	PALIPERIDONE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	mood disorder	PALIPERIDONE	targetBased	3	Completed	01/04/2006	https://clinicaltrials.gov/study/NCT00309699	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	mood disorder	PALIPERIDONE	targetBased	3	Completed	01/04/2006	https://clinicaltrials.gov/study/NCT00309699	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	mood disorder	PALIPERIDONE	targetBased	3	Completed	01/04/2006	https://clinicaltrials.gov/study/NCT00309699	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	mood disorder	PALIPERIDONE	targetBased	3	Completed	01/04/2006	https://clinicaltrials.gov/study/NCT00309699	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	mood disorder	PALIPERIDONE	targetBased	3	Completed	01/04/2006	https://clinicaltrials.gov/study/NCT00309699	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	mood disorder	PALIPERIDONE	targetBased	3	Completed	01/04/2006	https://clinicaltrials.gov/study/NCT00309699	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	PALIPERIDONE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	PALIPERIDONE	targetBased	4	Completed	01/04/2008	https://clinicaltrials.gov/study/NCT00784238	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	PALIPERIDONE	targetBased	4	Completed	01/04/2008	https://clinicaltrials.gov/study/NCT00784238	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	PALIPERIDONE	targetBased	4	Completed	01/04/2008	https://clinicaltrials.gov/study/NCT00784238	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	PALIPERIDONE	targetBased	4	Completed	01/04/2008	https://clinicaltrials.gov/study/NCT00784238	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	PALIPERIDONE	targetBased	4	Completed	01/04/2008	https://clinicaltrials.gov/study/NCT00784238	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	PALIPERIDONE	targetBased	4	Completed	01/04/2008	https://clinicaltrials.gov/study/NCT00784238	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	autism	PALIPERIDONE	targetBased	3	Completed	01/11/2007	https://clinicaltrials.gov/study/NCT00549562	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	autism	PALIPERIDONE	targetBased	3	Completed	01/11/2007	https://clinicaltrials.gov/study/NCT00549562	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	autism	PALIPERIDONE	targetBased	3	Completed	01/11/2007	https://clinicaltrials.gov/study/NCT00549562	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	autism	PALIPERIDONE	targetBased	3	Completed	01/11/2007	https://clinicaltrials.gov/study/NCT00549562	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	autism	PALIPERIDONE	targetBased	3	Completed	01/11/2007	https://clinicaltrials.gov/study/NCT00549562	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	autism	PALIPERIDONE	targetBased	3	Completed	01/11/2007	https://clinicaltrials.gov/study/NCT00549562	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	heroin dependence	DIACETYLMORPHINE	targetBased	3	Completed	01/12/2011	https://clinicaltrials.gov/study/NCT01447212	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	heroin dependence	DIACETYLMORPHINE	targetBased	3	Completed	01/12/2011	https://clinicaltrials.gov/study/NCT01447212	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	DIACETYLMORPHINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N07BC06	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	DIACETYLMORPHINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N07BC06	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	DIACETYLMORPHINE	targetBased	3	Completed	01/03/2002	https://clinicaltrials.gov/study/NCT00268814	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	DIACETYLMORPHINE	targetBased	3	Completed	01/03/2002	https://clinicaltrials.gov/study/NCT00268814	0.7	GoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	smoking behavior	BUPROPION HYDROCHLORIDE	targetBased	3	Completed	01/02/2002	https://clinicaltrials.gov/study/NCT00033592	0.7	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	bipolar I disorder	BUPROPION HYDROCHLORIDE	targetBased	3	Completed	01/11/2010	https://clinicaltrials.gov/study/NCT00958633	0.7	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	depressive disorder	BUPROPION HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7d6bdc28-f334-47f3-8336-c3bebbf57461	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	depressive disorder	BUPROPION HYDROCHLORIDE	targetBased	3	Completed	19/01/2006	https://clinicaltrials.gov/study/NCT00296517	0.7	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	depressive disorder	BUPROPION HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fddb7191-c4f9-4e82-bd7d-259c3767710a	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	depressive disorder	BUPROPION HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=06d4d890-11ed-4f31-8778-c73432e3ea69	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	nicotine dependence	BUPROPION HYDROCHLORIDE	targetBased	4	Completed	01/07/2005	https://clinicaltrials.gov/study/NCT00484692	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	nicotine dependence	BUPROPION HYDROCHLORIDE	targetBased	3	Completed	01/09/2001	https://clinicaltrials.gov/study/NCT00086385	0.7	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	nicotine dependence	BUPROPION HYDROCHLORIDE	targetBased	4	Completed	01/07/2009	https://clinicaltrials.gov/study/NCT00991081	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	major depressive disorder	BUPROPION HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ef0bb8f2-7710-4236-8b47-57b74c8bca3e	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	major depressive disorder	BUPROPION HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fddb7191-c4f9-4e82-bd7d-259c3767710a	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	major depressive disorder	BUPROPION HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=06d4d890-11ed-4f31-8778-c73432e3ea69	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	major depressive disorder	BUPROPION HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=00f9395d-2fe4-4b0c-890a-6873f56fb10a	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	major depressive disorder	BUPROPION HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a6f7f0e4-87ea-4508-b899-91c8ba819ab7	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	major depressive disorder	BUPROPION HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=02500709-7f2c-4251-bd8c-94ab6cdadd4c	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	major depressive disorder	BUPROPION HYDROCHLORIDE	targetBased	4	Completed	01/03/2008	https://clinicaltrials.gov/study/NCT00590863	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	mood disorder	BUPROPION HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=06d4d890-11ed-4f31-8778-c73432e3ea69	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	substance dependence	BUPROPION HYDROCHLORIDE	targetBased	4	Completed	01/07/2005	https://clinicaltrials.gov/study/NCT00484692	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	unipolar depression	BUPROPION HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=82f5292b-b113-4f10-9469-04386fa8e9d4	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	unipolar depression	BUPROPION HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e9cef726-267e-4e4f-ac12-d92a8664bf20	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	unipolar depression	BUPROPION HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b5d286ce-e23f-4dde-b400-cb4832172ece	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	unipolar depression	BUPROPION HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ace9755b-e938-4464-beb4-01d6a22eab20	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	unipolar depression	BUPROPION HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a93a7bfb-1159-4aa4-8982-9f5347d52ec5	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	unipolar depression	BUPROPION HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1de23b24-eb8c-4d16-a929-297132bf00d2	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	unipolar depression	BUPROPION HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3b41a8f8-34f4-4a38-9013-9cefafd6009c	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	substance abuse	BUPROPION HYDROCHLORIDE	targetBased	4	Completed	01/07/2005	https://clinicaltrials.gov/study/NCT00484692	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		delirium	MEMANTINE HYDROCHLORIDE	targetBased	4	Terminated	01/03/2006	https://clinicaltrials.gov/study/NCT00303433	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		attention deficit hyperactivity disorder	MEMANTINE HYDROCHLORIDE	targetBased	4	Completed	01/03/2007	https://clinicaltrials.gov/study/NCT00586573	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Dementia	MEMANTINE HYDROCHLORIDE	targetBased	4	Completed	01/11/2004	https://clinicaltrials.gov/study/NCT00768261	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Dementia	MEMANTINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=81496236-0a90-4265-8244-cba6a6b4f3ac	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Dementia	MEMANTINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c65fe60f-8daa-4c77-b072-b3d8540baf38	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Dementia	MEMANTINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b9f27baf-aa2a-443a-9ef5-e002d23407ba	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Dementia	MEMANTINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2335950c-be3b-4248-ad04-e9763aee47d2	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Dementia	MEMANTINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1fa2b7bc-94e5-4566-a7c5-419f8fd393a7	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Dementia	MEMANTINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c8f5c20b-4573-44c5-89fc-4da11b2e1fe1	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		learning disability	MEMANTINE HYDROCHLORIDE	targetBased	3	Recruiting	13/11/2018	https://clinicaltrials.gov/study/NCT03553875	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		autism spectrum disorder	MEMANTINE HYDROCHLORIDE	targetBased	3	Recruiting	13/11/2018	https://clinicaltrials.gov/study/NCT03553875	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		autism spectrum disorder	MEMANTINE HYDROCHLORIDE	targetBased	3	Completed	17/02/2015	https://clinicaltrials.gov/study/NCT01972074	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		autism spectrum disorder	MEMANTINE HYDROCHLORIDE	targetBased	4	Completed	01/01/2010	https://clinicaltrials.gov/study/NCT01333865	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		autism	MEMANTINE HYDROCHLORIDE	targetBased	3	Recruiting	13/11/2018	https://clinicaltrials.gov/study/NCT03553875	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	MEPERIDINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fae5cc34-5917-4445-9516-25f97ffca8db	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	MEPERIDINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fae5cc34-5917-4445-9516-25f97ffca8db	1	GoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		bipolar I disorder	KETAMINE HYDROCHLORIDE	targetBased	4	Completed	01/06/2017	https://clinicaltrials.gov/study/NCT03156504	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		opioid dependence	KETAMINE HYDROCHLORIDE	targetBased	3	Active, not recruiting	25/11/2017	https://clinicaltrials.gov/study/NCT03345173	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		depressive disorder	KETAMINE HYDROCHLORIDE	targetBased	4	Unknown status	01/12/2018	https://clinicaltrials.gov/study/NCT03666494	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		depressive disorder	KETAMINE HYDROCHLORIDE	targetBased	4	Completed	01/09/2021	https://clinicaltrials.gov/study/NCT05026203	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		depressive disorder	KETAMINE HYDROCHLORIDE	targetBased	4	Completed	02/05/2017	https://clinicaltrials.gov/study/NCT03194594	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		unipolar depression	KETAMINE HYDROCHLORIDE	targetBased	4	Completed	01/06/2017	https://clinicaltrials.gov/study/NCT03156504	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		bipolar disorder	KETAMINE HYDROCHLORIDE	targetBased	4	Completed	01/06/2017	https://clinicaltrials.gov/study/NCT03156504	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		major depressive disorder	KETAMINE HYDROCHLORIDE	targetBased	3	Withdrawn	01/08/2019	https://clinicaltrials.gov/study/NCT03051945	0.7	LoF	protect	Unable to perform brain imaging
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		major depressive disorder	KETAMINE HYDROCHLORIDE	targetBased	4	Not yet recruiting	01/01/2023	https://clinicaltrials.gov/study/NCT05506462	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	opioid dependence	NALOXONE HYDROCHLORIDE	targetBased	4	Completed	01/11/2013	https://clinicaltrials.gov/study/NCT02038790	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	opioid dependence	NALOXONE HYDROCHLORIDE	targetBased	4	Withdrawn	01/06/2023	https://clinicaltrials.gov/study/NCT05808881	1	LoF	protect	Due to changes in research objectives and methodological approach.
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	unipolar depression	NALOXONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=236349ef-2cb5-47ca-a3a5-99534c3a4996	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	unipolar depression	NALOXONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=236349ef-2cb5-47ca-a3a5-99534c3a4996	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	unipolar depression	NALOXONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9be31bdf-e220-2978-e053-2a95a90a03c6	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	unipolar depression	NALOXONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9be31bdf-e220-2978-e053-2a95a90a03c6	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	unipolar depression	NALOXONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=784a0e98-c2d6-f845-e053-2991aa0ac4b4	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	unipolar depression	NALOXONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=784a0e98-c2d6-f845-e053-2991aa0ac4b4	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	NALOXONE HYDROCHLORIDE	targetBased	4	Completed	01/11/2013	https://clinicaltrials.gov/study/NCT02038790	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	NALOXONE HYDROCHLORIDE	targetBased	4	Completed	01/11/2013	https://clinicaltrials.gov/study/NCT02038790	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	NALOXONE HYDROCHLORIDE	targetBased	4	Withdrawn	01/06/2023	https://clinicaltrials.gov/study/NCT05808881	1	LoF	protect	Due to changes in research objectives and methodological approach.
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	NALOXONE HYDROCHLORIDE	targetBased	4	Withdrawn	01/06/2023	https://clinicaltrials.gov/study/NCT05808881	1	LoF	protect	Due to changes in research objectives and methodological approach.
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	unipolar depression	NALOXONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9be31bdf-e220-2978-e053-2a95a90a03c6	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	unipolar depression	NALOXONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=784a0e98-c2d6-f845-e053-2991aa0ac4b4	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	unipolar depression	NALOXONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=236349ef-2cb5-47ca-a3a5-99534c3a4996	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	obsessive-compulsive disorder	METHYLPHENIDATE HYDROCHLORIDE	targetBased	4	Completed	01/10/2013	https://clinicaltrials.gov/study/NCT02194075	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	depressive disorder	METHYLPHENIDATE HYDROCHLORIDE	targetBased	3	Terminated	01/04/2002	https://clinicaltrials.gov/study/NCT00031798	0.7	LoF	protect	low accrual; loss of funding
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	nicotine dependence	METHYLPHENIDATE HYDROCHLORIDE	targetBased	3	Completed	01/11/2005	https://clinicaltrials.gov/study/NCT00253747	0.7	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	METHYLPHENIDATE HYDROCHLORIDE	targetBased	4	Completed	19/09/2019	https://clinicaltrials.gov/study/NCT04152629	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	METHYLPHENIDATE HYDROCHLORIDE	targetBased	4	Completed	01/04/2008	https://clinicaltrials.gov/study/NCT01065259	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	METHYLPHENIDATE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2bfb390f-ba99-4d21-8a9e-50fa8ec217c0	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	METHYLPHENIDATE HYDROCHLORIDE	targetBased	4	Withdrawn	31/10/2018	https://clinicaltrials.gov/study/NCT03580005	1	LoF	protect	The study was cancelled prior to the enrollment of any participants.
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	METHYLPHENIDATE HYDROCHLORIDE	targetBased	4	Completed	01/10/2007	https://clinicaltrials.gov/study/NCT00564954	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	METHYLPHENIDATE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=effd952d-ac94-47bb-b107-589a4934dcca	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	METHYLPHENIDATE HYDROCHLORIDE	targetBased	4	Completed	30/07/2016	https://clinicaltrials.gov/study/NCT02470234	1	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	Dementia	DABIGATRAN ETEXILATE	targetBased	4	Completed	03/04/2017	https://clinicaltrials.gov/study/NCT03061006	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	major depressive disorder	SCOPOLAMINE	targetBased	4	Completed	15/03/2017	https://clinicaltrials.gov/study/NCT03131050	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	major depressive disorder	SCOPOLAMINE	targetBased	4	Completed	15/03/2017	https://clinicaltrials.gov/study/NCT03131050	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	major depressive disorder	SCOPOLAMINE	targetBased	4	Completed	15/03/2017	https://clinicaltrials.gov/study/NCT03131050	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	major depressive disorder	SCOPOLAMINE	targetBased	4	Completed	15/03/2017	https://clinicaltrials.gov/study/NCT03131050	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	major depressive disorder	SCOPOLAMINE	targetBased	4	Completed	15/03/2017	https://clinicaltrials.gov/study/NCT03131050	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	depressive disorder	SCOPOLAMINE	targetBased	4	Completed	01/01/2018	https://clinicaltrials.gov/study/NCT03386448	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	depressive disorder	SCOPOLAMINE	targetBased	4	Completed	01/01/2018	https://clinicaltrials.gov/study/NCT03386448	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	depressive disorder	SCOPOLAMINE	targetBased	4	Completed	01/01/2018	https://clinicaltrials.gov/study/NCT03386448	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	depressive disorder	SCOPOLAMINE	targetBased	4	Completed	01/01/2018	https://clinicaltrials.gov/study/NCT03386448	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	depressive disorder	SCOPOLAMINE	targetBased	4	Completed	01/01/2018	https://clinicaltrials.gov/study/NCT03386448	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Dementia	LEVOMEPROMAZINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Dementia	LEVOMEPROMAZINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Dementia	LEVOMEPROMAZINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	psychosis	LEVOMEPROMAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AA02	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	psychosis	LEVOMEPROMAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AA02	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	psychosis	LEVOMEPROMAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AA02	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	depressive disorder	LEVOMEPROMAZINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	depressive disorder	LEVOMEPROMAZINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	depressive disorder	LEVOMEPROMAZINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	depressive disorder	LEVOMEPROMAZINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	depressive disorder	LEVOMEPROMAZINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	depressive disorder	LEVOMEPROMAZINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	anxiety	LEVOMEPROMAZINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	anxiety	LEVOMEPROMAZINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	anxiety	LEVOMEPROMAZINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	anxiety	LEVOMEPROMAZINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	anxiety	LEVOMEPROMAZINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	anxiety	LEVOMEPROMAZINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	schizophrenia	LEVOMEPROMAZINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	schizophrenia	LEVOMEPROMAZINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	schizophrenia	LEVOMEPROMAZINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	depressive disorder	LEVOMEPROMAZINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	depressive disorder	LEVOMEPROMAZINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	depressive disorder	LEVOMEPROMAZINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	psychosis	LEVOMEPROMAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AA02	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	psychosis	LEVOMEPROMAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AA02	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	psychosis	LEVOMEPROMAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AA02	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	psychosis	LEVOMEPROMAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AA02	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	LEVOMEPROMAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AA02	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	LEVOMEPROMAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AA02	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Dementia	LEVOMEPROMAZINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Dementia	LEVOMEPROMAZINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Dementia	LEVOMEPROMAZINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Dementia	LEVOMEPROMAZINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Dementia	LEVOMEPROMAZINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Dementia	LEVOMEPROMAZINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	LEVOMEPROMAZINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	LEVOMEPROMAZINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	LEVOMEPROMAZINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	LEVOMEPROMAZINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	LEVOMEPROMAZINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	LEVOMEPROMAZINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	anxiety	LEVOMEPROMAZINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	anxiety	LEVOMEPROMAZINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	anxiety	LEVOMEPROMAZINE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1)	HCRTR1	HCRTR1	Orexin/Hypocretin receptor type 1	insomnia	SUVOREXANT	targetBased	4	Recruiting	18/04/2019	https://clinicaltrials.gov/study/NCT03768713	1	LoF	protect
FRET-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1)	HCRTR1	HCRTR1	Orexin/Hypocretin receptor type 1	insomnia	SUVOREXANT	targetBased	4	Completed	25/05/2017	https://clinicaltrials.gov/study/NCT03034018	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1)	HCRTR1	HCRTR1	Orexin/Hypocretin receptor type 1	insomnia	SUVOREXANT	targetBased	4	Completed	25/05/2017	https://clinicaltrials.gov/study/NCT03034018	1	LoF	protect
FRET-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1)	HCRTR1	HCRTR1	Orexin/Hypocretin receptor type 1	insomnia	SUVOREXANT	targetBased	4	Completed	15/04/2018	https://clinicaltrials.gov/study/NCT03312517	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1)	HCRTR1	HCRTR1	Orexin/Hypocretin receptor type 1	insomnia	SUVOREXANT	targetBased	4	Completed	15/04/2018	https://clinicaltrials.gov/study/NCT03312517	1	LoF	protect
FRET-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1)	HCRTR1	HCRTR1	Orexin/Hypocretin receptor type 1	insomnia	SUVOREXANT	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e5b72731-1acb-45b7-9c13-290ad12d3951	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1)	HCRTR1	HCRTR1	Orexin/Hypocretin receptor type 1	insomnia	SUVOREXANT	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e5b72731-1acb-45b7-9c13-290ad12d3951	1	LoF	protect
FRET-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1)	HCRTR1	HCRTR1	Orexin/Hypocretin receptor type 1	panic disorder	SUVOREXANT	targetBased	4	Completed	01/05/2016	https://clinicaltrials.gov/study/NCT02593682	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1)	HCRTR1	HCRTR1	Orexin/Hypocretin receptor type 1	panic disorder	SUVOREXANT	targetBased	4	Completed	01/05/2016	https://clinicaltrials.gov/study/NCT02593682	1	LoF	protect
FRET-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1)	HCRTR1	HCRTR1	Orexin/Hypocretin receptor type 1	post-traumatic stress disorder	SUVOREXANT	targetBased	4	Completed	03/01/2017	https://clinicaltrials.gov/study/NCT02849548	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1)	HCRTR1	HCRTR1	Orexin/Hypocretin receptor type 1	post-traumatic stress disorder	SUVOREXANT	targetBased	4	Completed	03/01/2017	https://clinicaltrials.gov/study/NCT02849548	1	LoF	protect
FRET-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1)	HCRTR1	HCRTR1	Orexin/Hypocretin receptor type 1	Sleep Disorder	SUVOREXANT	targetBased	4	Completed	01/02/2016	https://clinicaltrials.gov/study/NCT02491788	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1)	HCRTR1	HCRTR1	Orexin/Hypocretin receptor type 1	Sleep Disorder	SUVOREXANT	targetBased	4	Completed	01/02/2016	https://clinicaltrials.gov/study/NCT02491788	1	LoF	protect
FRET-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1)	HCRTR1	HCRTR1	Orexin/Hypocretin receptor type 1	delirium	SUVOREXANT	targetBased	3	Completed	22/10/2020	https://clinicaltrials.gov/study/NCT04571944	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1)	HCRTR1	HCRTR1	Orexin/Hypocretin receptor type 1	delirium	SUVOREXANT	targetBased	3	Completed	22/10/2020	https://clinicaltrials.gov/study/NCT04571944	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	METHYLNALTREXONE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/relistor	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	METHYLNALTREXONE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/relistor	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	AMPHETAMINE ASPARTATE	targetBased	3	Completed	25/04/2005	https://clinicaltrials.gov/study/NCT00152022	0.7		protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	AMPHETAMINE ASPARTATE	targetBased	3	Completed	10/03/2005	https://clinicaltrials.gov/study/NCT00152035	0.7		protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	AMPHETAMINE ASPARTATE	targetBased	3	Completed	27/01/2005	https://clinicaltrials.gov/study/NCT00150579	0.7		protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Agitation	BENZTROPINE MESYLATE	targetBased	4	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00457366	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Agitation	BENZTROPINE MESYLATE	targetBased	4	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00457366	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Agitation	BENZTROPINE MESYLATE	targetBased	4	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00457366	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Agitation	BENZTROPINE MESYLATE	targetBased	4	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00457366	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Agitation	BENZTROPINE MESYLATE	targetBased	4	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00457366	1	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	depressive disorder	BUSPIRONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=19a92a99-f73a-42f5-b048-28ba0b4df9e6	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	depressive disorder	BUSPIRONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=19a92a99-f73a-42f5-b048-28ba0b4df9e6	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	anxiety disorder	BUSPIRONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d0fea556-a015-45c9-98ef-a8b17da4c889	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	anxiety disorder	BUSPIRONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aca8b358-d172-43d6-95bb-8064b8ed680c	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	anxiety disorder	BUSPIRONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aca8b358-d172-43d6-95bb-8064b8ed680c	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	anxiety disorder	BUSPIRONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ed60a885-6b02-48c8-979f-27d371e91d6e	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	anxiety disorder	BUSPIRONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ed60a885-6b02-48c8-979f-27d371e91d6e	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	anxiety disorder	BUSPIRONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=547d2a83-fa9e-44e9-9538-fe7f9be92ebb	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	anxiety disorder	BUSPIRONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=547d2a83-fa9e-44e9-9538-fe7f9be92ebb	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	schizoaffective disorder	BUSPIRONE HYDROCHLORIDE	targetBased	3	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT00178971	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	schizoaffective disorder	BUSPIRONE HYDROCHLORIDE	targetBased	3	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT00178971	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	schizophrenia	BUSPIRONE HYDROCHLORIDE	targetBased	3	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT00178971	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	schizophrenia	BUSPIRONE HYDROCHLORIDE	targetBased	3	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT00178971	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	generalized anxiety disorder	BUSPIRONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=19a92a99-f73a-42f5-b048-28ba0b4df9e6	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	generalized anxiety disorder	BUSPIRONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=19a92a99-f73a-42f5-b048-28ba0b4df9e6	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	MOLINDONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1275e92f-9573-4d0c-8e77-1c9ac47696d2	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	MOLINDONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1275e92f-9573-4d0c-8e77-1c9ac47696d2	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	MOLINDONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1275e92f-9573-4d0c-8e77-1c9ac47696d2	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	MOLINDONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1275e92f-9573-4d0c-8e77-1c9ac47696d2	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	MOLINDONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1275e92f-9573-4d0c-8e77-1c9ac47696d2	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	MOLINDONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1275e92f-9573-4d0c-8e77-1c9ac47696d2	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	MOLINDONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1275e92f-9573-4d0c-8e77-1c9ac47696d2	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	major depressive disorder	NEFAZODONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0bd4c34a-4f43-4c84-8b98-1d074cba97d5	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	unipolar depression	NEFAZODONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0bd4c34a-4f43-4c84-8b98-1d074cba97d5	1	LoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	enuresis	DESMOPRESSIN ACETATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6d55baa9-2b62-469c-93ae-3909ab249332	1	GoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	enuresis	DESMOPRESSIN ACETATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d9d8442a-4722-4b41-9faa-1ee853a4cc3b	1	GoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	enuresis	DESMOPRESSIN ACETATE	targetBased	4	Completed	01/12/2004	https://clinicaltrials.gov/study/NCT00209261	1	GoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	enuresis	DESMOPRESSIN ACETATE	targetBased	3	Completed	01/07/2013	https://clinicaltrials.gov/study/NCT02538302	0.7	GoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	enuresis	DESMOPRESSIN ACETATE	targetBased	4	Recruiting	15/03/2020	https://clinicaltrials.gov/study/NCT04545931	1	GoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	enuresis	DESMOPRESSIN ACETATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8ca799f1-7029-4527-9ab4-7512504bb8e2	1	GoF	protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	drug dependence	SEVOFLURANE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02334046	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	delirium	SEVOFLURANE	targetBased	4	Withdrawn	01/09/2017	https://clinicaltrials.gov/study/NCT02394418	1		protect	for technical reasons
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	delirium	SEVOFLURANE	targetBased	4	Recruiting	21/03/2022	https://clinicaltrials.gov/study/NCT05158998	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	delirium	SEVOFLURANE	targetBased	4	Not yet recruiting	01/02/2024	https://clinicaltrials.gov/study/NCT06214117	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	delirium	SEVOFLURANE	targetBased	4	Completed	01/05/2022	https://clinicaltrials.gov/study/NCT05331027	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	delirium	SEVOFLURANE	targetBased	4	Terminated	01/01/2014	https://clinicaltrials.gov/study/NCT02111447	1		protect	Not enough participants
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	depressive disorder	SEVOFLURANE	targetBased	4	Unknown status	01/07/2014	https://clinicaltrials.gov/study/NCT02267980	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	depressive disorder	SEVOFLURANE	targetBased	4	Completed	01/02/2012	https://clinicaltrials.gov/study/NCT01870219	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	depressive disorder	SEVOFLURANE	targetBased	4	Completed	01/02/2012	https://clinicaltrials.gov/study/NCT01870219	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	depressive disorder	SEVOFLURANE	targetBased	4	Unknown status	01/07/2014	https://clinicaltrials.gov/study/NCT02267980	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	delirium	SEVOFLURANE	targetBased	4	Withdrawn	01/09/2017	https://clinicaltrials.gov/study/NCT02394418	1		protect	for technical reasons
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	delirium	SEVOFLURANE	targetBased	4	Not yet recruiting	01/02/2024	https://clinicaltrials.gov/study/NCT06214117	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	delirium	SEVOFLURANE	targetBased	4	Terminated	01/01/2014	https://clinicaltrials.gov/study/NCT02111447	1		protect	Not enough participants
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	delirium	SEVOFLURANE	targetBased	4	Completed	01/05/2022	https://clinicaltrials.gov/study/NCT05331027	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	delirium	SEVOFLURANE	targetBased	4	Recruiting	21/03/2022	https://clinicaltrials.gov/study/NCT05158998	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	Agitation	SEVOFLURANE	targetBased	4	Not yet recruiting	15/11/2022	https://clinicaltrials.gov/study/NCT05624424	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	Agitation	SEVOFLURANE	targetBased	4	Completed	30/01/2022	https://clinicaltrials.gov/study/NCT05223010	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	Agitation	SEVOFLURANE	targetBased	4	Unknown status	01/05/2014	https://clinicaltrials.gov/study/NCT02169843	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	Agitation	SEVOFLURANE	targetBased	4	Completed	01/05/2015	https://clinicaltrials.gov/study/NCT02428283	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	Agitation	SEVOFLURANE	targetBased	4	Completed	01/04/2013	https://clinicaltrials.gov/study/NCT01878656	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	drug dependence	SEVOFLURANE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02334046	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	Agitation	SEVOFLURANE	targetBased	4	Completed	30/01/2022	https://clinicaltrials.gov/study/NCT05223010	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	Agitation	SEVOFLURANE	targetBased	4	Not yet recruiting	15/11/2022	https://clinicaltrials.gov/study/NCT05624424	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	Agitation	SEVOFLURANE	targetBased	4	Unknown status	01/05/2014	https://clinicaltrials.gov/study/NCT02169843	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	Agitation	SEVOFLURANE	targetBased	4	Completed	01/05/2015	https://clinicaltrials.gov/study/NCT02428283	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	Agitation	SEVOFLURANE	targetBased	4	Completed	01/04/2013	https://clinicaltrials.gov/study/NCT01878656	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	delirium	DESFLURANE	targetBased	4	Completed	01/05/2022	https://clinicaltrials.gov/study/NCT05331027	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	delirium	DESFLURANE	targetBased	4	Completed	01/05/2022	https://clinicaltrials.gov/study/NCT05331027	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	Agitation	DESFLURANE	targetBased	4	Completed	01/04/2013	https://clinicaltrials.gov/study/NCT01878656	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	Agitation	DESFLURANE	targetBased	4	Completed	01/04/2013	https://clinicaltrials.gov/study/NCT01878656	1		protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	major depressive disorder	TRAZODONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=17b3356e-458d-47f6-89a5-80828ab48d4c	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	major depressive disorder	TRAZODONE HYDROCHLORIDE	targetBased	3	Completed	01/06/2007	https://clinicaltrials.gov/study/NCT00775203	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	major depressive disorder	TRAZODONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=66da652a-72b4-c17f-e053-2a91aa0a8d69	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	major depressive disorder	TRAZODONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10a30879-f6e2-4030-95b8-0979c18c418a	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	unipolar depression	TRAZODONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=49196e9e-aeef-4663-8be9-6b523ae7fb7a	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	METHADONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4a44bde6-c348-4316-b0e0-c24b407cb823	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	METHADONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4a44bde6-c348-4316-b0e0-c24b407cb823	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	METHADONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4c796a39-d87f-4358-9d4b-26e27464b642	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	METHADONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4c796a39-d87f-4358-9d4b-26e27464b642	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	METHADONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=06cc3fba-68f9-4188-a239-fbd37a9f563a	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	METHADONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=06cc3fba-68f9-4188-a239-fbd37a9f563a	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	METHADONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4c796a39-d87f-4358-9d4b-26e27464b642	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	METHADONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4c796a39-d87f-4358-9d4b-26e27464b642	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	METHADONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5e70e915-b946-4a80-bcc6-3f49bc30f2f5	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	METHADONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5e70e915-b946-4a80-bcc6-3f49bc30f2f5	1	GoF	protect
qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium	IMPA1	IMPA1	Inositol monophosphatase 1	anxiety	LITHIUM CARBONATE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium	IMPA1	IMPA1	Inositol monophosphatase 1	alcohol dependence	LITHIUM CARBONATE	targetBased	3	Completed	01/01/2006	https://clinicaltrials.gov/study/NCT00114686	0.7	LoF	protect
Luminescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha	GSK3A	GSK3A	Glycogen synthase kinase-3 alpha	insomnia	LITHIUM CARBONATE	targetBased	4	Completed	06/11/2020	https://clinicaltrials.gov/study/NCT04479566	1	LoF	protect
Luminescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha	GSK3A	GSK3A	Glycogen synthase kinase-3 alpha	conduct disorder	LITHIUM CARBONATE	targetBased	3	Completed	01/09/1997	https://clinicaltrials.gov/study/NCT00000385	0.7	LoF	protect
qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium	IMPA1	IMPA1	Inositol monophosphatase 1	schizophrenia	LITHIUM CARBONATE	targetBased	3	Completed	01/02/2005	https://clinicaltrials.gov/study/NCT00183443	0.7	LoF	protect
qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium	IMPA1	IMPA1	Inositol monophosphatase 1	schizophrenia	LITHIUM CARBONATE	targetBased	4	Completed	01/11/2001	https://clinicaltrials.gov/study/NCT00202306	1	LoF	protect
qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium	IMPA1	IMPA1	Inositol monophosphatase 1	schizophrenia	LITHIUM CARBONATE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Luminescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha	GSK3A	GSK3A	Glycogen synthase kinase-3 alpha	bipolar I disorder	LITHIUM CARBONATE	targetBased	4	Completed	01/06/2011	https://clinicaltrials.gov/study/NCT01588457	1	LoF	protect
Luminescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha	GSK3A	GSK3A	Glycogen synthase kinase-3 alpha	bipolar I disorder	LITHIUM CARBONATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7dc9c6d2-6d9a-49e4-a8ab-437b0ed5f84e	1	LoF	protect
Luminescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha	GSK3A	GSK3A	Glycogen synthase kinase-3 alpha	bipolar I disorder	LITHIUM CARBONATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=04518b80-7563-4544-bf05-04f286223faa	1	LoF	protect
Luminescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha	GSK3A	GSK3A	Glycogen synthase kinase-3 alpha	bipolar I disorder	LITHIUM CARBONATE	targetBased	4	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT00976794	1	LoF	protect
Luminescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha	GSK3A	GSK3A	Glycogen synthase kinase-3 alpha	bipolar I disorder	LITHIUM CARBONATE	targetBased	4	Unknown status	01/06/2012	https://clinicaltrials.gov/study/NCT01710163	1	LoF	protect
Luminescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha	GSK3A	GSK3A	Glycogen synthase kinase-3 alpha	bipolar I disorder	LITHIUM CARBONATE	targetBased	4	Withdrawn	01/09/2011	https://clinicaltrials.gov/study/NCT01495156	1	LoF	protect
Luminescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha	GSK3A	GSK3A	Glycogen synthase kinase-3 alpha	bipolar I disorder	LITHIUM CARBONATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=05312159-3d8a-45e0-99cb-b83a7b200cd3	1	LoF	protect
qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium	IMPA1	IMPA1	Inositol monophosphatase 1	aggressive behavior	LITHIUM CARBONATE	targetBased	3	Completed	01/09/1997	https://clinicaltrials.gov/study/NCT00000385	0.7	LoF	protect
Luminescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha	GSK3A	GSK3A	Glycogen synthase kinase-3 alpha	schizophrenia	LITHIUM CARBONATE	targetBased	4	Completed	01/11/2001	https://clinicaltrials.gov/study/NCT00202306	1	LoF	protect
Luminescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha	GSK3A	GSK3A	Glycogen synthase kinase-3 alpha	schizophrenia	LITHIUM CARBONATE	targetBased	3	Completed	01/02/2005	https://clinicaltrials.gov/study/NCT00183443	0.7	LoF	protect
Luminescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha	GSK3A	GSK3A	Glycogen synthase kinase-3 alpha	schizophrenia	LITHIUM CARBONATE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Luminescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha	GSK3A	GSK3A	Glycogen synthase kinase-3 alpha	depressive disorder	LITHIUM CARBONATE	targetBased	4	Unknown status	01/06/2009	https://clinicaltrials.gov/study/NCT00927550	1	LoF	protect
Luminescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha	GSK3A	GSK3A	Glycogen synthase kinase-3 alpha	depressive disorder	LITHIUM CARBONATE	targetBased	4	Completed	01/07/2001	https://clinicaltrials.gov/study/NCT00021528	1	LoF	protect
Luminescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha	GSK3A	GSK3A	Glycogen synthase kinase-3 alpha	depressive disorder	LITHIUM CARBONATE	targetBased	4	Terminated	01/07/2009	https://clinicaltrials.gov/study/NCT01305707	1	LoF	protect	Difficulties in recruiting
Luminescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha	GSK3A	GSK3A	Glycogen synthase kinase-3 alpha	depressive disorder	LITHIUM CARBONATE	targetBased	4	Completed	01/09/2009	https://clinicaltrials.gov/study/NCT00974155	1	LoF	protect
Luminescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha	GSK3A	GSK3A	Glycogen synthase kinase-3 alpha	depressive disorder	LITHIUM CARBONATE	targetBased	4	Unknown status	01/08/2017	https://clinicaltrials.gov/study/NCT03219008	1	LoF	protect
Luminescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha	GSK3A	GSK3A	Glycogen synthase kinase-3 alpha	depressive disorder	LITHIUM CARBONATE	targetBased	4	Completed	01/01/2010	https://clinicaltrials.gov/study/NCT01028508	1	LoF	protect
Luminescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha	GSK3A	GSK3A	Glycogen synthase kinase-3 alpha	depressive disorder	LITHIUM CARBONATE	targetBased	4	Completed	01/12/2007	https://clinicaltrials.gov/study/NCT00602537	1	LoF	protect
Luminescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha	GSK3A	GSK3A	Glycogen synthase kinase-3 alpha	anxiety	LITHIUM CARBONATE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Luminescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha	GSK3A	GSK3A	Glycogen synthase kinase-3 alpha	treatment resistant depression	LITHIUM CARBONATE	targetBased	3	Completed	01/11/2008	https://clinicaltrials.gov/study/NCT00789854	0.7	LoF	protect
Luminescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha	GSK3A	GSK3A	Glycogen synthase kinase-3 alpha	unipolar depression	LITHIUM CARBONATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=42bed965-4b8f-4471-bcc9-091f87238653	1	LoF	protect
Luminescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha	GSK3A	GSK3A	Glycogen synthase kinase-3 alpha	major depressive disorder	LITHIUM CARBONATE	targetBased	3	Terminated	01/06/2007	https://clinicaltrials.gov/study/NCT00400088	0.7	LoF	protect	Recruitment difficulties
Luminescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha	GSK3A	GSK3A	Glycogen synthase kinase-3 alpha	major depressive disorder	LITHIUM CARBONATE	targetBased	3	Completed	01/11/2008	https://clinicaltrials.gov/study/NCT00789854	0.7	LoF	protect
Luminescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha	GSK3A	GSK3A	Glycogen synthase kinase-3 alpha	major depressive disorder	LITHIUM CARBONATE	targetBased	4	Completed	01/01/2008	https://clinicaltrials.gov/study/NCT00627887	1	LoF	protect
Luminescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha	GSK3A	GSK3A	Glycogen synthase kinase-3 alpha	major depressive disorder	LITHIUM CARBONATE	targetBased	4	Completed	01/09/2011	https://clinicaltrials.gov/study/NCT01416220	1	LoF	protect
Luminescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha	GSK3A	GSK3A	Glycogen synthase kinase-3 alpha	major depressive disorder	LITHIUM CARBONATE	targetBased	4	Terminated	01/05/2009	https://clinicaltrials.gov/study/NCT00926835	1	LoF	protect	due to patient recruitment difficulties
qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium	IMPA1	IMPA1	Inositol monophosphatase 1	depressive disorder	LITHIUM CARBONATE	targetBased	4	Completed	01/05/2010	https://clinicaltrials.gov/study/NCT02901249	1	LoF	protect
qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium	IMPA1	IMPA1	Inositol monophosphatase 1	depressive disorder	LITHIUM CARBONATE	targetBased	4	Unknown status	01/11/2016	https://clinicaltrials.gov/study/NCT03004521	1	LoF	protect
qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium	IMPA1	IMPA1	Inositol monophosphatase 1	depressive disorder	LITHIUM CARBONATE	targetBased	4	Completed	01/02/2001	https://clinicaltrials.gov/study/NCT00044616	1	LoF	protect
qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium	IMPA1	IMPA1	Inositol monophosphatase 1	depressive disorder	LITHIUM CARBONATE	targetBased	4	Terminated	01/07/2009	https://clinicaltrials.gov/study/NCT01305707	1	LoF	protect	Difficulties in recruiting
qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium	IMPA1	IMPA1	Inositol monophosphatase 1	depressive disorder	LITHIUM CARBONATE	targetBased	4	Completed	01/07/2001	https://clinicaltrials.gov/study/NCT00021528	1	LoF	protect
qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium	IMPA1	IMPA1	Inositol monophosphatase 1	depressive disorder	LITHIUM CARBONATE	targetBased	4	Unknown status	01/08/2017	https://clinicaltrials.gov/study/NCT03219008	1	LoF	protect
qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium	IMPA1	IMPA1	Inositol monophosphatase 1	depressive disorder	LITHIUM CARBONATE	targetBased	4	Completed	01/09/2009	https://clinicaltrials.gov/study/NCT00974155	1	LoF	protect
qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium	IMPA1	IMPA1	Inositol monophosphatase 1	autism spectrum disorder	LITHIUM CARBONATE	targetBased	3	Active, not recruiting	21/02/2022	https://clinicaltrials.gov/study/NCT04623398	0.7	LoF	protect
Luminescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha	GSK3A	GSK3A	Glycogen synthase kinase-3 alpha	alcohol dependence	LITHIUM CARBONATE	targetBased	3	Completed	01/01/2006	https://clinicaltrials.gov/study/NCT00114686	0.7	LoF	protect
Luminescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha	GSK3A	GSK3A	Glycogen synthase kinase-3 alpha	bipolar disorder	LITHIUM CARBONATE	targetBased	4	Completed	01/11/2001	https://clinicaltrials.gov/study/NCT00202306	1	LoF	protect
Luminescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha	GSK3A	GSK3A	Glycogen synthase kinase-3 alpha	bipolar disorder	LITHIUM CARBONATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7f3aa4f5-908a-44e7-8113-b64f91dc86e7	1	LoF	protect
Luminescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha	GSK3A	GSK3A	Glycogen synthase kinase-3 alpha	bipolar disorder	LITHIUM CARBONATE	targetBased	4	Withdrawn	01/12/2006	https://clinicaltrials.gov/study/NCT01075126	1	LoF	protect	key investigator relocated.
Luminescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha	GSK3A	GSK3A	Glycogen synthase kinase-3 alpha	bipolar disorder	LITHIUM CARBONATE	targetBased	4	Unknown status	01/06/2012	https://clinicaltrials.gov/study/NCT01938859	1	LoF	protect
Luminescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha	GSK3A	GSK3A	Glycogen synthase kinase-3 alpha	bipolar disorder	LITHIUM CARBONATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e038fdbc-6d80-4840-afb6-032bf006913f	1	LoF	protect
Luminescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha	GSK3A	GSK3A	Glycogen synthase kinase-3 alpha	bipolar disorder	LITHIUM CARBONATE	targetBased	4	Completed	01/06/2011	https://clinicaltrials.gov/study/NCT01588457	1	LoF	protect
Luminescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha	GSK3A	GSK3A	Glycogen synthase kinase-3 alpha	bipolar disorder	LITHIUM CARBONATE	targetBased	4	Completed	01/03/1996	https://clinicaltrials.gov/study/NCT00870311	1	LoF	protect
Luminescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha	GSK3A	GSK3A	Glycogen synthase kinase-3 alpha	aggressive behavior	LITHIUM CARBONATE	targetBased	3	Completed	01/09/1997	https://clinicaltrials.gov/study/NCT00000385	0.7	LoF	protect
qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium	IMPA1	IMPA1	Inositol monophosphatase 1	insomnia	LITHIUM CARBONATE	targetBased	4	Completed	06/11/2020	https://clinicaltrials.gov/study/NCT04479566	1	LoF	protect
qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium	IMPA1	IMPA1	Inositol monophosphatase 1	major depressive disorder	LITHIUM CARBONATE	targetBased	4	Completed	01/09/2011	https://clinicaltrials.gov/study/NCT01416220	1	LoF	protect
qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium	IMPA1	IMPA1	Inositol monophosphatase 1	major depressive disorder	LITHIUM CARBONATE	targetBased	4	Terminated	01/05/2009	https://clinicaltrials.gov/study/NCT00926835	1	LoF	protect	due to patient recruitment difficulties
qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium	IMPA1	IMPA1	Inositol monophosphatase 1	major depressive disorder	LITHIUM CARBONATE	targetBased	3	Terminated	01/06/2007	https://clinicaltrials.gov/study/NCT00400088	0.7	LoF	protect	Recruitment difficulties
qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium	IMPA1	IMPA1	Inositol monophosphatase 1	major depressive disorder	LITHIUM CARBONATE	targetBased	4	Completed	01/01/2008	https://clinicaltrials.gov/study/NCT00627887	1	LoF	protect
qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium	IMPA1	IMPA1	Inositol monophosphatase 1	major depressive disorder	LITHIUM CARBONATE	targetBased	3	Completed	01/11/2008	https://clinicaltrials.gov/study/NCT00789854	0.7	LoF	protect
Luminescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha	GSK3A	GSK3A	Glycogen synthase kinase-3 alpha	Dementia	LITHIUM CARBONATE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium	IMPA1	IMPA1	Inositol monophosphatase 1	unipolar depression	LITHIUM CARBONATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=42bed965-4b8f-4471-bcc9-091f87238653	1	LoF	protect
qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium	IMPA1	IMPA1	Inositol monophosphatase 1	treatment resistant depression	LITHIUM CARBONATE	targetBased	3	Completed	01/11/2008	https://clinicaltrials.gov/study/NCT00789854	0.7	LoF	protect
Luminescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha	GSK3A	GSK3A	Glycogen synthase kinase-3 alpha	autism spectrum disorder	LITHIUM CARBONATE	targetBased	3	Active, not recruiting	21/02/2022	https://clinicaltrials.gov/study/NCT04623398	0.7	LoF	protect
qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium	IMPA1	IMPA1	Inositol monophosphatase 1	Dementia	LITHIUM CARBONATE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium	IMPA1	IMPA1	Inositol monophosphatase 1	bipolar I disorder	LITHIUM CARBONATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=05312159-3d8a-45e0-99cb-b83a7b200cd3	1	LoF	protect
qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium	IMPA1	IMPA1	Inositol monophosphatase 1	bipolar I disorder	LITHIUM CARBONATE	targetBased	4	Unknown status	01/04/2007	https://clinicaltrials.gov/study/NCT00608075	1	LoF	protect
qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium	IMPA1	IMPA1	Inositol monophosphatase 1	bipolar I disorder	LITHIUM CARBONATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7dc9c6d2-6d9a-49e4-a8ab-437b0ed5f84e	1	LoF	protect
qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium	IMPA1	IMPA1	Inositol monophosphatase 1	bipolar I disorder	LITHIUM CARBONATE	targetBased	4	Withdrawn	01/09/2011	https://clinicaltrials.gov/study/NCT01495156	1	LoF	protect
qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium	IMPA1	IMPA1	Inositol monophosphatase 1	bipolar I disorder	LITHIUM CARBONATE	targetBased	4	Completed	01/06/2011	https://clinicaltrials.gov/study/NCT01588457	1	LoF	protect
qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium	IMPA1	IMPA1	Inositol monophosphatase 1	bipolar I disorder	LITHIUM CARBONATE	targetBased	4	Unknown status	01/06/2012	https://clinicaltrials.gov/study/NCT01710163	1	LoF	protect
qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium	IMPA1	IMPA1	Inositol monophosphatase 1	bipolar I disorder	LITHIUM CARBONATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=04518b80-7563-4544-bf05-04f286223faa	1	LoF	protect
qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium	IMPA1	IMPA1	Inositol monophosphatase 1	bipolar disorder	LITHIUM CARBONATE	targetBased	4	Terminated	28/03/2017	https://clinicaltrials.gov/study/NCT03210480	1	LoF	protect	Sponsor's decision due to slow enrollment rate.
qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium	IMPA1	IMPA1	Inositol monophosphatase 1	bipolar disorder	LITHIUM CARBONATE	targetBased	4	Terminated	01/01/2012	https://clinicaltrials.gov/study/NCT01526148	1	LoF	protect	Ran out of funding
qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium	IMPA1	IMPA1	Inositol monophosphatase 1	bipolar disorder	LITHIUM CARBONATE	targetBased	4	Completed	01/07/2001	https://clinicaltrials.gov/study/NCT00177567	1	LoF	protect
qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium	IMPA1	IMPA1	Inositol monophosphatase 1	bipolar disorder	LITHIUM CARBONATE	targetBased	4	Unknown status	01/09/2013	https://clinicaltrials.gov/study/NCT01893229	1	LoF	protect
qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium	IMPA1	IMPA1	Inositol monophosphatase 1	bipolar disorder	LITHIUM CARBONATE	targetBased	4	Unknown status	01/06/2017	https://clinicaltrials.gov/study/NCT03148535	1	LoF	protect
qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium	IMPA1	IMPA1	Inositol monophosphatase 1	bipolar disorder	LITHIUM CARBONATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03685ed5-d626-472a-b268-fcb8259f5b41	1	LoF	protect
qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium	IMPA1	IMPA1	Inositol monophosphatase 1	bipolar disorder	LITHIUM CARBONATE	targetBased	4	Completed	01/02/2001	https://clinicaltrials.gov/study/NCT00044616	1	LoF	protect
qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium	IMPA1	IMPA1	Inositol monophosphatase 1	conduct disorder	LITHIUM CARBONATE	targetBased	3	Completed	01/09/1997	https://clinicaltrials.gov/study/NCT00000385	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	FLUPHENAZINE DECANOATE	targetBased	4	Completed	01/12/2000	https://clinicaltrials.gov/study/NCT00014001	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	FLUPHENAZINE DECANOATE	targetBased	4	Completed	01/12/2000	https://clinicaltrials.gov/study/NCT00014001	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	FLUPHENAZINE DECANOATE	targetBased	4	Completed	01/12/2000	https://clinicaltrials.gov/study/NCT00014001	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	FLUPHENAZINE DECANOATE	targetBased	4	Completed	01/12/2000	https://clinicaltrials.gov/study/NCT00014001	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	FLUPHENAZINE DECANOATE	targetBased	4	Completed	01/12/2000	https://clinicaltrials.gov/study/NCT00014001	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	FLUPHENAZINE DECANOATE	targetBased	4	Completed	01/12/2000	https://clinicaltrials.gov/study/NCT00014001	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain agnosia	OXYCODONE HYDROCHLORIDE	targetBased	4	Not yet recruiting	01/06/2024	https://clinicaltrials.gov/study/NCT06444997	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain agnosia	OXYCODONE HYDROCHLORIDE	targetBased	4	Not yet recruiting	01/06/2024	https://clinicaltrials.gov/study/NCT06444997	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	OXYCODONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03c9ff0d-46e8-448c-944a-7ad59d1afd6d	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	OXYCODONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03c9ff0d-46e8-448c-944a-7ad59d1afd6d	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	OXYCODONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=504aa63a-4772-2e03-e054-00144ff88e88	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	OXYCODONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=504aa63a-4772-2e03-e054-00144ff88e88	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	OXYCODONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3848642e-cc9e-4150-8199-281b294c18bc	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	OXYCODONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3848642e-cc9e-4150-8199-281b294c18bc	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	opioid dependence	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4	Terminated	17/05/2021	https://clinicaltrials.gov/study/NCT04766996	1	LoF	protect	Loss of surgery team member deemed the study procedures impossible to achieve, and no replacement could be found in a timely manner to complete trial as initially planned.
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	opioid dependence	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4	Terminated	17/05/2021	https://clinicaltrials.gov/study/NCT04766996	1	LoF	protect	Loss of surgery team member deemed the study procedures impossible to achieve, and no replacement could be found in a timely manner to complete trial as initially planned.
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	opioid dependence	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4	Terminated	17/05/2021	https://clinicaltrials.gov/study/NCT04766996	1	LoF	protect	Loss of surgery team member deemed the study procedures impossible to achieve, and no replacement could be found in a timely manner to complete trial as initially planned.
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	opioid dependence	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4	Terminated	17/05/2021	https://clinicaltrials.gov/study/NCT04766996	1	LoF	protect	Loss of surgery team member deemed the study procedures impossible to achieve, and no replacement could be found in a timely manner to complete trial as initially planned.
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	opioid dependence	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4	Terminated	17/05/2021	https://clinicaltrials.gov/study/NCT04766996	1	LoF	protect	Loss of surgery team member deemed the study procedures impossible to achieve, and no replacement could be found in a timely manner to complete trial as initially planned.
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	opioid dependence	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4	Terminated	17/05/2021	https://clinicaltrials.gov/study/NCT04766996	1	LoF	protect	Loss of surgery team member deemed the study procedures impossible to achieve, and no replacement could be found in a timely manner to complete trial as initially planned.
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Anorexia	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=80fb18a3-824a-4360-947e-63f0a167245b	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Anorexia	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=80fb18a3-824a-4360-947e-63f0a167245b	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Anorexia	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=80fb18a3-824a-4360-947e-63f0a167245b	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Anorexia	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=80fb18a3-824a-4360-947e-63f0a167245b	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Anorexia	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=80fb18a3-824a-4360-947e-63f0a167245b	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Anorexia	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=80fb18a3-824a-4360-947e-63f0a167245b	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	depressive disorder	FLUPHENAZINE ENANTHATE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	depressive disorder	FLUPHENAZINE ENANTHATE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	depressive disorder	FLUPHENAZINE ENANTHATE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	depressive disorder	FLUPHENAZINE ENANTHATE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	depressive disorder	FLUPHENAZINE ENANTHATE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	depressive disorder	FLUPHENAZINE ENANTHATE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	anxiety	FLUPHENAZINE ENANTHATE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	anxiety	FLUPHENAZINE ENANTHATE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	anxiety	FLUPHENAZINE ENANTHATE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	anxiety	FLUPHENAZINE ENANTHATE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	anxiety	FLUPHENAZINE ENANTHATE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	anxiety	FLUPHENAZINE ENANTHATE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizoaffective disorder	FLUPHENAZINE ENANTHATE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizoaffective disorder	FLUPHENAZINE ENANTHATE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizoaffective disorder	FLUPHENAZINE ENANTHATE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizoaffective disorder	FLUPHENAZINE ENANTHATE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizoaffective disorder	FLUPHENAZINE ENANTHATE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizoaffective disorder	FLUPHENAZINE ENANTHATE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Dementia	FLUPHENAZINE ENANTHATE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Dementia	FLUPHENAZINE ENANTHATE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Dementia	FLUPHENAZINE ENANTHATE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Dementia	FLUPHENAZINE ENANTHATE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Dementia	FLUPHENAZINE ENANTHATE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Dementia	FLUPHENAZINE ENANTHATE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	FLUPHENAZINE ENANTHATE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	FLUPHENAZINE ENANTHATE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	FLUPHENAZINE ENANTHATE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	FLUPHENAZINE ENANTHATE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	FLUPHENAZINE ENANTHATE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	FLUPHENAZINE ENANTHATE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02307396	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	FLUPHENAZINE ENANTHATE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	methamphetamine dependence	METHAMPHETAMINE HYDROCHLORIDE	targetBased	4	Completed	16/08/2019	https://clinicaltrials.gov/study/NCT03973489	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	METHAMPHETAMINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f03a68d5-ed00-8a2d-af68-28be909ea85f	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	delirium	HALOPERIDOL DECANOATE	targetBased	4	Completed	01/09/2010	https://clinicaltrials.gov/study/NCT01174290	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	delirium	HALOPERIDOL DECANOATE	targetBased	4	Completed	01/09/2010	https://clinicaltrials.gov/study/NCT01174290	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	delirium	HALOPERIDOL DECANOATE	targetBased	4	Completed	01/09/2010	https://clinicaltrials.gov/study/NCT01174290	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	delirium	HALOPERIDOL DECANOATE	targetBased	4	Completed	01/09/2010	https://clinicaltrials.gov/study/NCT01174290	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	delirium	HALOPERIDOL DECANOATE	targetBased	4	Completed	01/09/2010	https://clinicaltrials.gov/study/NCT01174290	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	delirium	HALOPERIDOL DECANOATE	targetBased	4	Completed	01/09/2010	https://clinicaltrials.gov/study/NCT01174290	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	delirium	HALOPERIDOL DECANOATE	targetBased	4	Completed	01/09/2010	https://clinicaltrials.gov/study/NCT01174290	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	HALOPERIDOL DECANOATE	targetBased	4	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01136772	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	HALOPERIDOL DECANOATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=af0159a8-dff5-449a-aa2b-a0c430081e21	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	HALOPERIDOL DECANOATE	targetBased	4	Terminated	01/01/2005	https://clinicaltrials.gov/study/NCT00947375	1	LoF	protect	All of the mentioned aim and objectives were achieved before the February 2007
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	HALOPERIDOL DECANOATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1a0e38cb-fd9f-4962-9f81-5c0023ca6b4c	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	HALOPERIDOL DECANOATE	targetBased	3	Completed	05/11/2019	https://clinicaltrials.gov/study/NCT04327843	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	delirium	HALOPERIDOL DECANOATE	targetBased	4	Completed	01/09/2010	https://clinicaltrials.gov/study/NCT01174290	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	delirium	HALOPERIDOL DECANOATE	targetBased	4	Completed	01/09/2010	https://clinicaltrials.gov/study/NCT01174290	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	delirium	HALOPERIDOL DECANOATE	targetBased	4	Completed	01/09/2010	https://clinicaltrials.gov/study/NCT01174290	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizoaffective disorder	HALOPERIDOL DECANOATE	targetBased	4	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01136772	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizoaffective disorder	HALOPERIDOL DECANOATE	targetBased	4	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01136772	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizoaffective disorder	HALOPERIDOL DECANOATE	targetBased	4	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01136772	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizoaffective disorder	HALOPERIDOL DECANOATE	targetBased	4	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01136772	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizoaffective disorder	HALOPERIDOL DECANOATE	targetBased	4	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01136772	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizoaffective disorder	HALOPERIDOL DECANOATE	targetBased	4	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01136772	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizoaffective disorder	HALOPERIDOL DECANOATE	targetBased	4	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01136772	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	schizophrenia	HALOPERIDOL DECANOATE	targetBased	4	Terminated	01/01/2005	https://clinicaltrials.gov/study/NCT00947375	1	LoF	protect	All of the mentioned aim and objectives were achieved before the February 2007
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	schizophrenia	HALOPERIDOL DECANOATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1a0e38cb-fd9f-4962-9f81-5c0023ca6b4c	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	schizophrenia	HALOPERIDOL DECANOATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1a0e38cb-fd9f-4962-9f81-5c0023ca6b4c	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	schizophrenia	HALOPERIDOL DECANOATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1a0e38cb-fd9f-4962-9f81-5c0023ca6b4c	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	schizophrenia	HALOPERIDOL DECANOATE	targetBased	4	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01136772	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	schizophrenia	HALOPERIDOL DECANOATE	targetBased	4	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01136772	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	schizophrenia	HALOPERIDOL DECANOATE	targetBased	4	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01136772	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	HALOPERIDOL DECANOATE	targetBased	4	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01136772	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	HALOPERIDOL DECANOATE	targetBased	4	Terminated	01/01/2005	https://clinicaltrials.gov/study/NCT00947375	1	LoF	protect	All of the mentioned aim and objectives were achieved before the February 2007
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	HALOPERIDOL DECANOATE	targetBased	4	Terminated	01/01/2005	https://clinicaltrials.gov/study/NCT00947375	1	LoF	protect	All of the mentioned aim and objectives were achieved before the February 2007
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	HALOPERIDOL DECANOATE	targetBased	4	Terminated	01/01/2005	https://clinicaltrials.gov/study/NCT00947375	1	LoF	protect	All of the mentioned aim and objectives were achieved before the February 2007
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	HALOPERIDOL DECANOATE	targetBased	4	Terminated	01/01/2005	https://clinicaltrials.gov/study/NCT00947375	1	LoF	protect	All of the mentioned aim and objectives were achieved before the February 2007
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	HALOPERIDOL DECANOATE	targetBased	4	Terminated	01/01/2005	https://clinicaltrials.gov/study/NCT00947375	1	LoF	protect	All of the mentioned aim and objectives were achieved before the February 2007
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	HALOPERIDOL DECANOATE	targetBased	4	Terminated	01/01/2005	https://clinicaltrials.gov/study/NCT00947375	1	LoF	protect	All of the mentioned aim and objectives were achieved before the February 2007
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	schizoaffective disorder	HALOPERIDOL DECANOATE	targetBased	4	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01136772	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	schizoaffective disorder	HALOPERIDOL DECANOATE	targetBased	4	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01136772	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	schizoaffective disorder	HALOPERIDOL DECANOATE	targetBased	4	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01136772	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	CODEINE PHOSPHATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=df9801fc-03fe-41da-a6b3-0f76788217c9	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	CODEINE PHOSPHATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=73828e5b-6a29-21d9-e053-2991aa0acac4	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	CODEINE PHOSPHATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=73828e5b-6a29-21d9-e053-2991aa0acac4	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	CODEINE PHOSPHATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=48a7e42b-934f-4ec6-e054-00144ff88e88	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	CODEINE PHOSPHATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=48a7e42b-934f-4ec6-e054-00144ff88e88	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	CODEINE PHOSPHATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=44aeca03-3ac2-4d5b-91c2-9d0442086468	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	CODEINE PHOSPHATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=44aeca03-3ac2-4d5b-91c2-9d0442086468	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	drug dependence	CODEINE PHOSPHATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=df9801fc-03fe-41da-a6b3-0f76788217c9	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	drug dependence	CODEINE PHOSPHATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=44aeca03-3ac2-4d5b-91c2-9d0442086468	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	drug dependence	CODEINE PHOSPHATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1cab3106-1064-4b42-892b-39f405d9e02f	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	drug dependence	CODEINE PHOSPHATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=73828e5b-6a29-21d9-e053-2991aa0acac4	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	drug dependence	CODEINE PHOSPHATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=160cd55a-a8ed-43f2-baf7-046d3c3b317f	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	drug dependence	CODEINE PHOSPHATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=48a7e42b-934f-4ec6-e054-00144ff88e88	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Agitation	NALBUPHINE HYDROCHLORIDE	targetBased	4	Recruiting	01/03/2022	https://clinicaltrials.gov/study/NCT05273671	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Agitation	NALBUPHINE HYDROCHLORIDE	targetBased	4	Recruiting	01/03/2022	https://clinicaltrials.gov/study/NCT05273671	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	delirium	NALBUPHINE HYDROCHLORIDE	targetBased	3	Not yet recruiting	02/04/2024	https://clinicaltrials.gov/study/NCT06306040	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	delirium	NALBUPHINE HYDROCHLORIDE	targetBased	3	Not yet recruiting	02/04/2024	https://clinicaltrials.gov/study/NCT06306040	0.7	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Agitation	NALBUPHINE HYDROCHLORIDE	targetBased	4	Recruiting	01/03/2022	https://clinicaltrials.gov/study/NCT05273671	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	delirium	NALBUPHINE HYDROCHLORIDE	targetBased	3	Not yet recruiting	02/04/2024	https://clinicaltrials.gov/study/NCT06306040	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Self-injurious behavior	NALTREXONE HYDROCHLORIDE	targetBased	3	Unknown status	01/07/1997	https://clinicaltrials.gov/study/NCT00065936	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Self-injurious behavior	NALTREXONE HYDROCHLORIDE	targetBased	3	Unknown status	01/07/1997	https://clinicaltrials.gov/study/NCT00065936	0.7	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Self-injurious behavior	NALTREXONE HYDROCHLORIDE	targetBased	3	Unknown status	01/07/1997	https://clinicaltrials.gov/study/NCT00065936	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	LOXAPINE SUCCINATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dee2537b-1bd8-42f6-990f-62359e646822	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	schizophrenia	LOXAPINE SUCCINATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dee2537b-1bd8-42f6-990f-62359e646822	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	schizophrenia	LOXAPINE SUCCINATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dee2537b-1bd8-42f6-990f-62359e646822	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	schizophrenia	LOXAPINE SUCCINATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dee2537b-1bd8-42f6-990f-62359e646822	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	LOXAPINE SUCCINATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dee2537b-1bd8-42f6-990f-62359e646822	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	LOXAPINE SUCCINATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dee2537b-1bd8-42f6-990f-62359e646822	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	LOXAPINE SUCCINATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dee2537b-1bd8-42f6-990f-62359e646822	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	LOXAPINE SUCCINATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dee2537b-1bd8-42f6-990f-62359e646822	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	LOXAPINE SUCCINATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dee2537b-1bd8-42f6-990f-62359e646822	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	LOXAPINE SUCCINATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dee2537b-1bd8-42f6-990f-62359e646822	1	LoF	protect
Luminescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha	GSK3A	GSK3A	Glycogen synthase kinase-3 alpha	bipolar I disorder	LITHIUM CITRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1a04cc23-61fa-455b-9718-2cdcf54036e0	1	LoF	protect
qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium	IMPA1	IMPA1	Inositol monophosphatase 1	bipolar I disorder	LITHIUM CITRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1a04cc23-61fa-455b-9718-2cdcf54036e0	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	binge eating	LISDEXAMFETAMINE DIMESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=704e4378-ca83-445c-8b45-3cfa51c1ecad	1		protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	depressive disorder	LISDEXAMFETAMINE DIMESYLATE	targetBased	4	Completed	01/04/2013	https://clinicaltrials.gov/study/NCT01863459	1		protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	schizophrenia	LISDEXAMFETAMINE DIMESYLATE	targetBased	3	Terminated	01/11/2012	https://clinicaltrials.gov/study/NCT01738698	0.7		protect	Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized.
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	schizophrenia	LISDEXAMFETAMINE DIMESYLATE	targetBased	3	Terminated	01/02/2013	https://clinicaltrials.gov/study/NCT01760889	0.7		protect	Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	schizophrenia	LISDEXAMFETAMINE DIMESYLATE	targetBased	3	Terminated	01/02/2013	https://clinicaltrials.gov/study/NCT01760993	0.7		protect	Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized.
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	schizophrenia	LISDEXAMFETAMINE DIMESYLATE	targetBased	3	Withdrawn	27/01/2012	https://clinicaltrials.gov/study/NCT01234298	0.7		protect	Study was discontinued due to non-safety related business prioritization decisions
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	major depressive disorder	LISDEXAMFETAMINE DIMESYLATE	targetBased	3	Completed	27/10/2011	https://clinicaltrials.gov/study/NCT01436149	0.7		protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	major depressive disorder	LISDEXAMFETAMINE DIMESYLATE	targetBased	3	Terminated	27/02/2012	https://clinicaltrials.gov/study/NCT01436175	0.35		protect	SPD489 failed to demonstrate a benefit as adjunctive treatment to antidepressants. Termination was not related to any new safety findings.
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	major depressive disorder	LISDEXAMFETAMINE DIMESYLATE	targetBased	4	Completed	01/09/2010	https://clinicaltrials.gov/study/NCT01148979	1		protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	major depressive disorder	LISDEXAMFETAMINE DIMESYLATE	targetBased	3	Completed	19/10/2011	https://clinicaltrials.gov/study/NCT01436162	0.7		protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	eating disorder	LISDEXAMFETAMINE DIMESYLATE	targetBased	3	Completed	26/11/2012	https://clinicaltrials.gov/study/NCT01718509	0.7		protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	eating disorder	LISDEXAMFETAMINE DIMESYLATE	targetBased	3	Completed	27/01/2014	https://clinicaltrials.gov/study/NCT02009163	0.7		protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	eating disorder	LISDEXAMFETAMINE DIMESYLATE	targetBased	3	Completed	26/11/2012	https://clinicaltrials.gov/study/NCT01718483	0.7		protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	eating disorder	LISDEXAMFETAMINE DIMESYLATE	targetBased	3	Completed	21/08/2012	https://clinicaltrials.gov/study/NCT01657019	0.7		protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	drug dependence	LISDEXAMFETAMINE DIMESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a310fc51-2743-4755-8398-fed5402283f6	1		protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	LISDEXAMFETAMINE DIMESYLATE	targetBased	4	Completed	01/07/2008	https://clinicaltrials.gov/study/NCT00733356	1		protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	LISDEXAMFETAMINE DIMESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a310fc51-2743-4755-8398-fed5402283f6	1		protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	LISDEXAMFETAMINE DIMESYLATE	targetBased	4	Not yet recruiting	01/08/2011	https://clinicaltrials.gov/study/NCT01413165	1		protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	LISDEXAMFETAMINE DIMESYLATE	targetBased	4	Completed	03/04/2012	https://clinicaltrials.gov/study/NCT01552902	1		protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	LISDEXAMFETAMINE DIMESYLATE	targetBased	4	Completed	07/07/2011	https://clinicaltrials.gov/study/NCT01328756	1		protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	LISDEXAMFETAMINE DIMESYLATE	targetBased	4	Completed	17/04/2012	https://clinicaltrials.gov/study/NCT01552915	1		protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	LISDEXAMFETAMINE DIMESYLATE	targetBased	4	Completed	30/04/2009	https://clinicaltrials.gov/study/NCT00877487	1		protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	sleep apnea	ARMODAFINIL	targetBased	3	Completed	01/01/2004	https://clinicaltrials.gov/study/NCT00078312	0.7	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	schizoaffective disorder	ARMODAFINIL	targetBased	4	Completed	01/08/2006	https://clinicaltrials.gov/study/NCT00373672	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	hypersomnia	ARMODAFINIL	targetBased	3	Completed	01/09/2008	https://clinicaltrials.gov/study/NCT00758498	0.7	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	hypersomnia	ARMODAFINIL	targetBased	3	Completed	01/03/2004	https://clinicaltrials.gov/study/NCT00080288	0.7	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	hypersomnia	ARMODAFINIL	targetBased	4	Completed	01/09/2008	https://clinicaltrials.gov/study/NCT00711516	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	hypersomnia	ARMODAFINIL	targetBased	4	Completed	01/03/2010	https://clinicaltrials.gov/study/NCT01080807	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	Dementia	ARMODAFINIL	targetBased	4	Completed	01/11/2009	https://clinicaltrials.gov/study/NCT01023672	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	depressive disorder	ARMODAFINIL	targetBased	3	Terminated	30/04/2010	https://clinicaltrials.gov/study/NCT01121536	0.7	LoF	protect	Business decision related to efficacy rather than tolerability limitations, not stopped for any safety reasons.
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	depressive disorder	ARMODAFINIL	targetBased	3	Completed	01/03/2010	https://clinicaltrials.gov/study/NCT01072630	0.7	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	depressive disorder	ARMODAFINIL	targetBased	3	Completed	01/01/2010	https://clinicaltrials.gov/study/NCT01072929	0.7	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	depressive disorder	ARMODAFINIL	targetBased	3	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01305408	0.7	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	obstructive sleep apnea	ARMODAFINIL	targetBased	3	Completed	01/02/2004	https://clinicaltrials.gov/study/NCT00078325	0.7	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	obstructive sleep apnea	ARMODAFINIL	targetBased	3	Completed	01/05/2004	https://clinicaltrials.gov/study/NCT00228553	0.7	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	obstructive sleep apnea	ARMODAFINIL	targetBased	3	Completed	01/10/2005	https://clinicaltrials.gov/study/NCT00228566	0.7	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	obstructive sleep apnea	ARMODAFINIL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10f918f7-4782-470e-a50e-35c7c66bfd79	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	obstructive sleep apnea	ARMODAFINIL	targetBased	3	Completed	01/03/2004	https://clinicaltrials.gov/study/NCT00079677	0.7	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	obstructive sleep apnea	ARMODAFINIL	targetBased	3	Completed	01/01/2004	https://clinicaltrials.gov/study/NCT00078312	0.7	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	schizophrenia	ARMODAFINIL	targetBased	4	Completed	01/08/2006	https://clinicaltrials.gov/study/NCT00373672	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	Sleep Disorder	ARMODAFINIL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2c824d4c-2309-4e2a-bc74-aa8d80a5c454	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	Sleep Disorder	ARMODAFINIL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0310a062-51fd-4e74-8a5f-7f21a16f52c9	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	Sleep Disorder	ARMODAFINIL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10f918f7-4782-470e-a50e-35c7c66bfd79	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	Sleep Disorder	ARMODAFINIL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a2b3b762-7984-409c-82e4-8d216055df72	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	Sleep Disorder	ARMODAFINIL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e7bfb636-4b0a-440c-a4d3-d26393a14ac5	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	Sleep Disorder	ARMODAFINIL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=795a7ba3-c60b-4637-aa99-06c1e10af8a7	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	Sleep Disorder	ARMODAFINIL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d878aed0-ddbf-8fa1-abf7-d3e480260845	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	narcolepsy-cataplexy syndrome	ARMODAFINIL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2c824d4c-2309-4e2a-bc74-aa8d80a5c454	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	narcolepsy-cataplexy syndrome	ARMODAFINIL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0310a062-51fd-4e74-8a5f-7f21a16f52c9	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	narcolepsy-cataplexy syndrome	ARMODAFINIL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a2b3b762-7984-409c-82e4-8d216055df72	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	narcolepsy-cataplexy syndrome	ARMODAFINIL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=795a7ba3-c60b-4637-aa99-06c1e10af8a7	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	narcolepsy-cataplexy syndrome	ARMODAFINIL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e7bfb636-4b0a-440c-a4d3-d26393a14ac5	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	narcolepsy-cataplexy syndrome	ARMODAFINIL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d878aed0-ddbf-8fa1-abf7-d3e480260845	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	narcolepsy-cataplexy syndrome	ARMODAFINIL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10f918f7-4782-470e-a50e-35c7c66bfd79	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	narcolepsy	ARMODAFINIL	targetBased	3	Completed	01/01/2004	https://clinicaltrials.gov/study/NCT00078312	0.7	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	narcolepsy	ARMODAFINIL	targetBased	3	Completed	01/03/2004	https://clinicaltrials.gov/study/NCT00078377	0.7	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	narcolepsy	ARMODAFINIL	targetBased	3	Completed	01/05/2004	https://clinicaltrials.gov/study/NCT00228553	0.7	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	narcolepsy	ARMODAFINIL	targetBased	3	Completed	01/10/2005	https://clinicaltrials.gov/study/NCT00228566	0.7	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	ARMODAFINIL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N06BA13	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	methamphetamine dependence	METHAMPHETAMINE	targetBased	4	Completed	16/08/2019	https://clinicaltrials.gov/study/NCT03973489	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	METHAMPHETAMINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N06BA03	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	METHAMPHETAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f03a68d5-ed00-8a2d-af68-28be909ea85f	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Agitation	BENZTROPINE	targetBased	4	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00457366	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Agitation	BENZTROPINE	targetBased	4	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00457366	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Agitation	BENZTROPINE	targetBased	4	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00457366	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Agitation	BENZTROPINE	targetBased	4	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00457366	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Agitation	BENZTROPINE	targetBased	4	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00457366	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	schizophrenia	BENZTROPINE	targetBased	4	Completed	01/12/2008	https://clinicaltrials.gov/study/NCT00802100	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	schizophrenia	BENZTROPINE	targetBased	4	Completed	01/12/2008	https://clinicaltrials.gov/study/NCT00802100	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	schizophrenia	BENZTROPINE	targetBased	4	Completed	01/12/2008	https://clinicaltrials.gov/study/NCT00802100	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	schizophrenia	BENZTROPINE	targetBased	4	Completed	01/12/2008	https://clinicaltrials.gov/study/NCT00802100	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	schizophrenia	BENZTROPINE	targetBased	4	Completed	01/12/2008	https://clinicaltrials.gov/study/NCT00802100	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	binge eating	LISDEXAMFETAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=704e4378-ca83-445c-8b45-3cfa51c1ecad	1		protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	depressive disorder	LISDEXAMFETAMINE	targetBased	3	Terminated	01/01/2010	https://clinicaltrials.gov/study/NCT01131559	0.7		protect	Sponsor halted study.
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	depressive disorder	LISDEXAMFETAMINE	targetBased	4	Completed	01/04/2013	https://clinicaltrials.gov/study/NCT01863459	1		protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	schizophrenia	LISDEXAMFETAMINE	targetBased	3	Withdrawn	27/01/2012	https://clinicaltrials.gov/study/NCT01234298	0.7		protect	Study was discontinued due to non-safety related business prioritization decisions
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	schizophrenia	LISDEXAMFETAMINE	targetBased	3	Terminated	01/02/2013	https://clinicaltrials.gov/study/NCT01760889	0.7		protect	Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	schizophrenia	LISDEXAMFETAMINE	targetBased	3	Terminated	01/11/2012	https://clinicaltrials.gov/study/NCT01738698	0.7		protect	Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized.
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	schizophrenia	LISDEXAMFETAMINE	targetBased	3	Terminated	01/02/2013	https://clinicaltrials.gov/study/NCT01760993	0.7		protect	Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized.
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	major depressive disorder	LISDEXAMFETAMINE	targetBased	4	Completed	01/09/2010	https://clinicaltrials.gov/study/NCT01148979	1		protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	major depressive disorder	LISDEXAMFETAMINE	targetBased	3	Completed	27/10/2011	https://clinicaltrials.gov/study/NCT01436149	0.7		protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	major depressive disorder	LISDEXAMFETAMINE	targetBased	3	Terminated	27/02/2012	https://clinicaltrials.gov/study/NCT01436175	0.35		protect	SPD489 failed to demonstrate a benefit as adjunctive treatment to antidepressants. Termination was not related to any new safety findings.
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	major depressive disorder	LISDEXAMFETAMINE	targetBased	3	Completed	19/10/2011	https://clinicaltrials.gov/study/NCT01436162	0.7		protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	eating disorder	LISDEXAMFETAMINE	targetBased	3	Completed	21/08/2012	https://clinicaltrials.gov/study/NCT01657019	0.7		protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	eating disorder	LISDEXAMFETAMINE	targetBased	3	Completed	26/11/2012	https://clinicaltrials.gov/study/NCT01718483	0.7		protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	eating disorder	LISDEXAMFETAMINE	targetBased	3	Completed	27/01/2014	https://clinicaltrials.gov/study/NCT02009163	0.7		protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	eating disorder	LISDEXAMFETAMINE	targetBased	3	Completed	26/11/2012	https://clinicaltrials.gov/study/NCT01718509	0.7		protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	eating disorder	LISDEXAMFETAMINE	targetBased	3	Completed	01/01/2010	https://clinicaltrials.gov/study/NCT01090713	0.7		protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	drug dependence	LISDEXAMFETAMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a310fc51-2743-4755-8398-fed5402283f6	1		protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	bipolar disorder	LISDEXAMFETAMINE	targetBased	3	Terminated	01/01/2010	https://clinicaltrials.gov/study/NCT01093963	0.7		protect	Enrollment goals not met
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	bipolar disorder	LISDEXAMFETAMINE	targetBased	4	Terminated	01/02/2010	https://clinicaltrials.gov/study/NCT01051440	1		protect	Slow enrollment
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	LISDEXAMFETAMINE	targetBased	4	Completed	03/04/2012	https://clinicaltrials.gov/study/NCT01552902	1		protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	LISDEXAMFETAMINE	targetBased	4	Completed	19/05/2010	https://clinicaltrials.gov/study/NCT01101022	1		protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	LISDEXAMFETAMINE	targetBased	4	Completed	01/04/2008	https://clinicaltrials.gov/study/NCT00753012	1		protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	LISDEXAMFETAMINE	targetBased	4	Completed	30/04/2009	https://clinicaltrials.gov/study/NCT00877487	1		protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	LISDEXAMFETAMINE	targetBased	4	Completed	17/04/2012	https://clinicaltrials.gov/study/NCT01552915	1		protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	LISDEXAMFETAMINE	targetBased	4	Completed	01/07/2008	https://clinicaltrials.gov/study/NCT00733356	1		protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	LISDEXAMFETAMINE	targetBased	4	Completed	01/04/2013	https://clinicaltrials.gov/study/NCT01863459	1		protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		alcohol abuse	ACAMPROSATE	targetBased	4	Completed	01/03/2007	https://clinicaltrials.gov/study/NCT00452543	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		social anxiety disorder	ACAMPROSATE	targetBased	4	Completed	01/04/2006	https://clinicaltrials.gov/study/NCT00330174	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		generalized anxiety disorder	ACAMPROSATE	targetBased	4	Completed	01/04/2006	https://clinicaltrials.gov/study/NCT00330174	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Dementia	ACAMPROSATE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		schizophrenia	ACAMPROSATE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		schizophrenia	ACAMPROSATE	targetBased	4	Completed	01/06/2008	https://clinicaltrials.gov/study/NCT00688324	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		anxiety	ACAMPROSATE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		alcohol dependence	ACAMPROSATE	targetBased	4	Completed	01/04/2006	https://clinicaltrials.gov/study/NCT00330174	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		alcohol dependence	ACAMPROSATE	targetBased	4	Completed	01/11/2009	https://clinicaltrials.gov/study/NCT00855699	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		alcohol dependence	ACAMPROSATE	targetBased	4	Unknown status	01/03/2003	https://clinicaltrials.gov/study/NCT00120601	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		alcohol dependence	ACAMPROSATE	targetBased	4	Completed	01/04/2007	https://clinicaltrials.gov/study/NCT00466661	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		alcohol dependence	ACAMPROSATE	targetBased	4	Completed	01/09/2000	https://clinicaltrials.gov/study/NCT00435435	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		alcohol dependence	ACAMPROSATE	targetBased	4	Completed	01/03/2007	https://clinicaltrials.gov/study/NCT00452543	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		alcohol dependence	ACAMPROSATE	targetBased	4	Completed	01/11/2002	https://clinicaltrials.gov/study/NCT00317031	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		depressive disorder	ACAMPROSATE	targetBased	4	Completed	01/04/2006	https://clinicaltrials.gov/study/NCT00330174	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		depressive disorder	ACAMPROSATE	targetBased	3	Terminated	01/01/2015	https://clinicaltrials.gov/study/NCT02374567	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		bipolar disorder	ACAMPROSATE	targetBased	4	Completed	01/04/2007	https://clinicaltrials.gov/study/NCT00466661	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		schizoaffective disorder	ACAMPROSATE	targetBased	4	Completed	01/06/2008	https://clinicaltrials.gov/study/NCT00688324	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		major depressive disorder	ACAMPROSATE	targetBased	4	Completed	01/03/2007	https://clinicaltrials.gov/study/NCT00452543	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		gambling behaviour	ACAMPROSATE	targetBased	4	Completed	01/10/2007	https://clinicaltrials.gov/study/NCT00571103	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	delirium	GLYCOPYRRONIUM	targetBased	4	Completed	01/03/2017	https://clinicaltrials.gov/study/NCT03229486	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	delirium	GLYCOPYRRONIUM	targetBased	4	Completed	01/03/2017	https://clinicaltrials.gov/study/NCT03229486	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	delirium	GLYCOPYRRONIUM	targetBased	4	Completed	01/03/2017	https://clinicaltrials.gov/study/NCT03229486	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	delirium	GLYCOPYRRONIUM	targetBased	4	Completed	01/03/2017	https://clinicaltrials.gov/study/NCT03229486	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	delirium	GLYCOPYRRONIUM	targetBased	4	Completed	01/03/2017	https://clinicaltrials.gov/study/NCT03229486	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	delirium	GLYCOPYRRONIUM	targetBased	4	Completed	01/03/2017	https://clinicaltrials.gov/study/NCT03229486	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	delirium	GLYCOPYRRONIUM	targetBased	4	Completed	01/03/2017	https://clinicaltrials.gov/study/NCT03229486	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	delirium	GLYCOPYRRONIUM	targetBased	4	Completed	01/03/2017	https://clinicaltrials.gov/study/NCT03229486	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	delirium	GLYCOPYRRONIUM	targetBased	4	Completed	01/03/2017	https://clinicaltrials.gov/study/NCT03229486	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	delirium	GLYCOPYRRONIUM	targetBased	4	Completed	01/03/2017	https://clinicaltrials.gov/study/NCT03229486	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	delirium	GLYCOPYRRONIUM	targetBased	4	Completed	01/03/2017	https://clinicaltrials.gov/study/NCT03229486	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	nicotine dependence	BUPROPION HYDROBROMIDE	targetBased	4	Completed	01/07/2009	https://clinicaltrials.gov/study/NCT00991081	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	major depressive disorder	BUPROPION HYDROBROMIDE	targetBased	4	Not yet recruiting	01/06/2023	https://clinicaltrials.gov/study/NCT02129751	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	unipolar depression	BUPROPION HYDROBROMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2315d6e5-144d-4163-9711-f855c759cf8e	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	unipolar depression	BUPROPION HYDROBROMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6494d2d9-0ce4-4126-b1c7-49684395942b	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	unipolar depression	BUPROPION HYDROBROMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5cb7fd36-ae36-409b-af79-9c432e1cf5d9	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	METHYLNALTREXONE BROMIDE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/relistor	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	METHYLNALTREXONE BROMIDE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/relistor	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	major depressive disorder	LURASIDONE	targetBased	3	Withdrawn	01/01/2012	https://clinicaltrials.gov/study/NCT01423240	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	major depressive disorder	LURASIDONE	targetBased	3	Completed	01/09/2011	https://clinicaltrials.gov/study/NCT01421134	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	major depressive disorder	LURASIDONE	targetBased	3	Completed	01/09/2011	https://clinicaltrials.gov/study/NCT01423253	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	LURASIDONE	targetBased	4	Completed	01/02/2013	https://clinicaltrials.gov/study/NCT02199743	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	LURASIDONE	targetBased	4	Terminated	30/12/2021	https://clinicaltrials.gov/study/NCT05213143	1	LoF	protect	Company's business decision
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	LURASIDONE	targetBased	4	Completed	16/08/2021	https://clinicaltrials.gov/study/NCT05011669	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	LURASIDONE	targetBased	4	Completed	01/10/2011	https://clinicaltrials.gov/study/NCT01569659	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	LURASIDONE	targetBased	4	Unknown status	01/12/2014	https://clinicaltrials.gov/study/NCT02282085	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	LURASIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=afad3051-9df2-4c54-9684-e8262a133af8	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	LURASIDONE	targetBased	4	Recruiting	16/08/2023	https://clinicaltrials.gov/study/NCT05741502	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar disorder	LURASIDONE	targetBased	4	Completed	07/02/2019	https://clinicaltrials.gov/study/NCT03902613	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	bipolar disorder	LURASIDONE	targetBased	4	Withdrawn	01/01/2017	https://clinicaltrials.gov/study/NCT01932541	1	LoF	protect	On hold due to competing departmental studies
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	bipolar disorder	LURASIDONE	targetBased	4	Withdrawn	01/01/2017	https://clinicaltrials.gov/study/NCT01932541	1	LoF	protect	On hold due to competing departmental studies
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar disorder	LURASIDONE	targetBased	4	Withdrawn	01/01/2017	https://clinicaltrials.gov/study/NCT01932541	1	LoF	protect	On hold due to competing departmental studies
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar disorder	LURASIDONE	targetBased	4	Withdrawn	01/01/2017	https://clinicaltrials.gov/study/NCT01932541	1	LoF	protect	On hold due to competing departmental studies
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar disorder	LURASIDONE	targetBased	4	Withdrawn	01/01/2017	https://clinicaltrials.gov/study/NCT01932541	1	LoF	protect	On hold due to competing departmental studies
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar disorder	LURASIDONE	targetBased	4	Withdrawn	01/01/2017	https://clinicaltrials.gov/study/NCT01932541	1	LoF	protect	On hold due to competing departmental studies
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	mental or behavioural disorder	LURASIDONE	targetBased	4	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT00806234	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	major depressive disorder	LURASIDONE	targetBased	3	Completed	01/09/2011	https://clinicaltrials.gov/study/NCT01423253	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	major depressive disorder	LURASIDONE	targetBased	3	Completed	01/09/2011	https://clinicaltrials.gov/study/NCT01423253	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	major depressive disorder	LURASIDONE	targetBased	3	Completed	01/09/2011	https://clinicaltrials.gov/study/NCT01423253	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	major depressive disorder	LURASIDONE	targetBased	3	Completed	01/09/2011	https://clinicaltrials.gov/study/NCT01423253	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	major depressive disorder	LURASIDONE	targetBased	3	Withdrawn	01/01/2012	https://clinicaltrials.gov/study/NCT01423240	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	major depressive disorder	LURASIDONE	targetBased	3	Withdrawn	01/01/2012	https://clinicaltrials.gov/study/NCT01423240	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	major depressive disorder	LURASIDONE	targetBased	3	Withdrawn	01/01/2012	https://clinicaltrials.gov/study/NCT01423240	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	major depressive disorder	LURASIDONE	targetBased	3	Withdrawn	01/01/2012	https://clinicaltrials.gov/study/NCT01423240	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	major depressive disorder	LURASIDONE	targetBased	3	Withdrawn	01/01/2012	https://clinicaltrials.gov/study/NCT01423240	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	major depressive disorder	LURASIDONE	targetBased	3	Withdrawn	01/01/2012	https://clinicaltrials.gov/study/NCT01423240	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	depressive disorder	LURASIDONE	targetBased	3	Completed	01/03/2014	https://clinicaltrials.gov/study/NCT02046369	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	depressive disorder	LURASIDONE	targetBased	3	Completed	01/03/2014	https://clinicaltrials.gov/study/NCT02046369	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	depressive disorder	LURASIDONE	targetBased	3	Completed	01/03/2014	https://clinicaltrials.gov/study/NCT02046369	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	depressive disorder	LURASIDONE	targetBased	3	Completed	01/03/2014	https://clinicaltrials.gov/study/NCT02046369	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	depressive disorder	LURASIDONE	targetBased	3	Terminated	11/12/2020	https://clinicaltrials.gov/study/NCT04383691	0.7	LoF	protect	Company's business decision
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	depressive disorder	LURASIDONE	targetBased	3	Terminated	11/12/2020	https://clinicaltrials.gov/study/NCT04383691	0.7	LoF	protect	Company's business decision
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	depressive disorder	LURASIDONE	targetBased	3	Terminated	11/12/2020	https://clinicaltrials.gov/study/NCT04383691	0.7	LoF	protect	Company's business decision
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	depressive disorder	LURASIDONE	targetBased	3	Terminated	11/12/2020	https://clinicaltrials.gov/study/NCT04383691	0.7	LoF	protect	Company's business decision
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	depressive disorder	LURASIDONE	targetBased	3	Terminated	11/12/2020	https://clinicaltrials.gov/study/NCT04383691	0.7	LoF	protect	Company's business decision
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	depressive disorder	LURASIDONE	targetBased	3	Terminated	11/12/2020	https://clinicaltrials.gov/study/NCT04383691	0.7	LoF	protect	Company's business decision
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizoaffective disorder	LURASIDONE	targetBased	4	Completed	01/02/2013	https://clinicaltrials.gov/study/NCT02199743	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizoaffective disorder	LURASIDONE	targetBased	4	Completed	01/02/2013	https://clinicaltrials.gov/study/NCT02199743	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizoaffective disorder	LURASIDONE	targetBased	4	Completed	01/02/2013	https://clinicaltrials.gov/study/NCT02199743	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizoaffective disorder	LURASIDONE	targetBased	4	Completed	01/02/2013	https://clinicaltrials.gov/study/NCT02199743	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizoaffective disorder	LURASIDONE	targetBased	4	Completed	01/02/2013	https://clinicaltrials.gov/study/NCT02199743	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizoaffective disorder	LURASIDONE	targetBased	4	Completed	01/02/2013	https://clinicaltrials.gov/study/NCT02199743	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizoaffective disorder	LURASIDONE	targetBased	3	Completed	01/06/2010	https://clinicaltrials.gov/study/NCT01143077	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar I disorder	LURASIDONE	targetBased	3	Completed	01/06/2012	https://clinicaltrials.gov/study/NCT01575561	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar I disorder	LURASIDONE	targetBased	3	Completed	01/05/2014	https://clinicaltrials.gov/study/NCT02147379	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar I disorder	LURASIDONE	targetBased	3	Completed	01/06/2011	https://clinicaltrials.gov/study/NCT01358357	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar I disorder	LURASIDONE	targetBased	3	Completed	29/01/2014	https://clinicaltrials.gov/study/NCT01986114	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	LURASIDONE	targetBased	4	Withdrawn	01/01/2017	https://clinicaltrials.gov/study/NCT01932541	1	LoF	protect	On hold due to competing departmental studies
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	LURASIDONE	targetBased	3	Completed	01/04/2009	https://clinicaltrials.gov/study/NCT00868452	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	LURASIDONE	targetBased	4	Completed	07/02/2019	https://clinicaltrials.gov/study/NCT03902613	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	LURASIDONE	targetBased	3	Completed	01/04/2009	https://clinicaltrials.gov/study/NCT00868959	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	LURASIDONE	targetBased	3	Completed	01/11/2010	https://clinicaltrials.gov/study/NCT01284517	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	LURASIDONE	targetBased	3	Recruiting	08/05/2017	https://clinicaltrials.gov/study/NCT02731612	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	LURASIDONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=afad3051-9df2-4c54-9684-e8262a133af8	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	LURASIDONE	targetBased	3	Completed	01/04/2009	https://clinicaltrials.gov/study/NCT00868699	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	LURASIDONE	targetBased	3	Completed	19/02/2014	https://clinicaltrials.gov/study/NCT01986101	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	LURASIDONE	targetBased	4	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT00806234	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	LURASIDONE	targetBased	4	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT00806234	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	mental or behavioural disorder	LURASIDONE	targetBased	4	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT00806234	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	mental or behavioural disorder	LURASIDONE	targetBased	4	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT00806234	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	LURASIDONE	targetBased	4	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT00806234	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	LURASIDONE	targetBased	4	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT00806234	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	psychosis	LURASIDONE	targetBased	3			https://www.whocc.no/atc_ddd_index/?code=N05AE05	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizoaffective disorder	LURASIDONE	targetBased	3	Completed	01/06/2010	https://clinicaltrials.gov/study/NCT01143077	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizoaffective disorder	LURASIDONE	targetBased	4	Completed	01/02/2013	https://clinicaltrials.gov/study/NCT02199743	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizoaffective disorder	LURASIDONE	targetBased	3	Completed	01/08/2010	https://clinicaltrials.gov/study/NCT01143090	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizoaffective disorder	LURASIDONE	targetBased	3	Completed	01/03/2008	https://clinicaltrials.gov/study/NCT00641745	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	depressive disorder	LURASIDONE	targetBased	3	Terminated	11/12/2020	https://clinicaltrials.gov/study/NCT04383691	0.7	LoF	protect	Company's business decision
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	depressive disorder	LURASIDONE	targetBased	3	Completed	01/03/2014	https://clinicaltrials.gov/study/NCT02046369	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	psychosis	LURASIDONE	targetBased	3			https://www.whocc.no/atc_ddd_index/?code=N05AE05	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	psychosis	LURASIDONE	targetBased	3			https://www.whocc.no/atc_ddd_index/?code=N05AE05	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	psychosis	LURASIDONE	targetBased	3			https://www.whocc.no/atc_ddd_index/?code=N05AE05	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	psychosis	LURASIDONE	targetBased	3			https://www.whocc.no/atc_ddd_index/?code=N05AE05	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	LURASIDONE	targetBased	3			https://www.whocc.no/atc_ddd_index/?code=N05AE05	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	LURASIDONE	targetBased	3			https://www.whocc.no/atc_ddd_index/?code=N05AE05	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	autism	LURASIDONE	targetBased	3	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT01911442	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar I disorder	LURASIDONE	targetBased	3	Completed	01/05/2014	https://clinicaltrials.gov/study/NCT02147379	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar I disorder	LURASIDONE	targetBased	3	Completed	01/05/2014	https://clinicaltrials.gov/study/NCT02147379	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar I disorder	LURASIDONE	targetBased	3	Completed	01/05/2014	https://clinicaltrials.gov/study/NCT02147379	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar I disorder	LURASIDONE	targetBased	3	Completed	01/05/2014	https://clinicaltrials.gov/study/NCT02147379	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	bipolar I disorder	LURASIDONE	targetBased	3	Completed	29/01/2014	https://clinicaltrials.gov/study/NCT01986114	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	bipolar I disorder	LURASIDONE	targetBased	3	Completed	29/01/2014	https://clinicaltrials.gov/study/NCT01986114	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar I disorder	LURASIDONE	targetBased	3	Completed	29/01/2014	https://clinicaltrials.gov/study/NCT01986114	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar I disorder	LURASIDONE	targetBased	3	Completed	29/01/2014	https://clinicaltrials.gov/study/NCT01986114	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar I disorder	LURASIDONE	targetBased	3	Completed	29/01/2014	https://clinicaltrials.gov/study/NCT01986114	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar I disorder	LURASIDONE	targetBased	3	Completed	29/01/2014	https://clinicaltrials.gov/study/NCT01986114	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	LURASIDONE	targetBased	4	Terminated	30/12/2021	https://clinicaltrials.gov/study/NCT05213143	1	LoF	protect	Company's business decision
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	LURASIDONE	targetBased	4	Completed	03/01/2018	https://clinicaltrials.gov/study/NCT03393026	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	LURASIDONE	targetBased	4	Completed	03/01/2018	https://clinicaltrials.gov/study/NCT03393026	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	LURASIDONE	targetBased	4	Completed	03/01/2018	https://clinicaltrials.gov/study/NCT03393026	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	LURASIDONE	targetBased	4	Completed	03/01/2018	https://clinicaltrials.gov/study/NCT03393026	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	LURASIDONE	targetBased	4	Completed	03/01/2018	https://clinicaltrials.gov/study/NCT03393026	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	LURASIDONE	targetBased	4	Completed	03/01/2018	https://clinicaltrials.gov/study/NCT03393026	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	autism	LURASIDONE	targetBased	3	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT01911442	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	autism	LURASIDONE	targetBased	3	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT01911442	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	autism	LURASIDONE	targetBased	3	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT01911442	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	autism	LURASIDONE	targetBased	3	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT01911442	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	autism	LURASIDONE	targetBased	3	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT01911442	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	autism	LURASIDONE	targetBased	3	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT01911442	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	TRAMADOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b3c702f7-0a8c-a52b-e053-2995a90a6df3	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	TRAMADOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b3c702f7-0a8c-a52b-e053-2995a90a6df3	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	TRAMADOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3da3815b-fa99-4b20-8564-96d32d84df28	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	TRAMADOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3da3815b-fa99-4b20-8564-96d32d84df28	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	post-traumatic stress disorder	TRAMADOL	targetBased	4	Completed	01/09/2011	https://clinicaltrials.gov/study/NCT01517711	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	post-traumatic stress disorder	TRAMADOL	targetBased	4	Completed	01/09/2011	https://clinicaltrials.gov/study/NCT01517711	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	TRAMADOL	targetBased	4	Terminated	17/05/2021	https://clinicaltrials.gov/study/NCT04766996	1	GoF	protect	Loss of surgery team member deemed the study procedures impossible to achieve, and no replacement could be found in a timely manner to complete trial as initially planned.
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	TRAMADOL	targetBased	4	Terminated	17/05/2021	https://clinicaltrials.gov/study/NCT04766996	1	GoF	protect	Loss of surgery team member deemed the study procedures impossible to achieve, and no replacement could be found in a timely manner to complete trial as initially planned.
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	TRAMADOL	targetBased	3	Withdrawn	15/11/2019	https://clinicaltrials.gov/study/NCT03678792	0.7	GoF	protect	Infeasible to conduct at this time.
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	TRAMADOL	targetBased	3	Withdrawn	15/11/2019	https://clinicaltrials.gov/study/NCT03678792	0.7	GoF	protect	Infeasible to conduct at this time.
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	sleep apnea	TRAMADOL	targetBased	4	Completed	01/03/2018	https://clinicaltrials.gov/study/NCT03454217	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	sleep apnea	TRAMADOL	targetBased	4	Completed	01/03/2018	https://clinicaltrials.gov/study/NCT03454217	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	HYDROMORPHONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3832ede8-d3fc-455d-ecab-3b77be5869f5	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	HYDROMORPHONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3832ede8-d3fc-455d-ecab-3b77be5869f5	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	HYDROMORPHONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=22e635cb-98c0-e4f9-6a71-62d7487a0a6c	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	HYDROMORPHONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=22e635cb-98c0-e4f9-6a71-62d7487a0a6c	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	HYDROMORPHONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b95bfd6c-cee5-f57d-e053-2995a90a5ce1	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	HYDROMORPHONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b95bfd6c-cee5-f57d-e053-2995a90a5ce1	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	TRAMADOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3da3815b-fa99-4b20-8564-96d32d84df28	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	TRAMADOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3da3815b-fa99-4b20-8564-96d32d84df28	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	TRAMADOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b3c702f7-0a8c-a52b-e053-2995a90a6df3	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	TRAMADOL HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b3c702f7-0a8c-a52b-e053-2995a90a6df3	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	nicotine dependence	FORMOTEROL	targetBased	3	Completed	01/05/2017	https://clinicaltrials.gov/study/NCT03104634	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	anxiety disorder	TRIFLUOPERAZINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=09dc7f6a-cc69-4de8-8e13-b837ce144b4a	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	mental or behavioural disorder	TRIFLUOPERAZINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=09dc7f6a-cc69-4de8-8e13-b837ce144b4a	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	mental or behavioural disorder	TRIFLUOPERAZINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=09dc7f6a-cc69-4de8-8e13-b837ce144b4a	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	mental or behavioural disorder	TRIFLUOPERAZINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=09dc7f6a-cc69-4de8-8e13-b837ce144b4a	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	TRIFLUOPERAZINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=09dc7f6a-cc69-4de8-8e13-b837ce144b4a	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	mental or behavioural disorder	TRIFLUOPERAZINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=09dc7f6a-cc69-4de8-8e13-b837ce144b4a	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	TRIFLUOPERAZINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=09dc7f6a-cc69-4de8-8e13-b837ce144b4a	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	TRIFLUOPERAZINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=09dc7f6a-cc69-4de8-8e13-b837ce144b4a	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	mental or behavioural disorder	TRIFLUOPERAZINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=09dc7f6a-cc69-4de8-8e13-b837ce144b4a	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	mental or behavioural disorder	TRIFLUOPERAZINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=09dc7f6a-cc69-4de8-8e13-b837ce144b4a	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	TRIFLUOPERAZINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=09dc7f6a-cc69-4de8-8e13-b837ce144b4a	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	TRIFLUOPERAZINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=09dc7f6a-cc69-4de8-8e13-b837ce144b4a	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	schizophrenia	TRIFLUOPERAZINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=09dc7f6a-cc69-4de8-8e13-b837ce144b4a	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	schizophrenia	TRIFLUOPERAZINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=09dc7f6a-cc69-4de8-8e13-b837ce144b4a	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	schizophrenia	TRIFLUOPERAZINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=09dc7f6a-cc69-4de8-8e13-b837ce144b4a	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	anxiety disorder	TRIFLUOPERAZINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=09dc7f6a-cc69-4de8-8e13-b837ce144b4a	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	anxiety disorder	TRIFLUOPERAZINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=09dc7f6a-cc69-4de8-8e13-b837ce144b4a	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	anxiety disorder	TRIFLUOPERAZINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=09dc7f6a-cc69-4de8-8e13-b837ce144b4a	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	TRIFLUOPERAZINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=09dc7f6a-cc69-4de8-8e13-b837ce144b4a	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	TRIFLUOPERAZINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=09dc7f6a-cc69-4de8-8e13-b837ce144b4a	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	TRIFLUOPERAZINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=09dc7f6a-cc69-4de8-8e13-b837ce144b4a	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	TRIFLUOPERAZINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=09dc7f6a-cc69-4de8-8e13-b837ce144b4a	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	TRIFLUOPERAZINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=09dc7f6a-cc69-4de8-8e13-b837ce144b4a	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	TRIFLUOPERAZINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=09dc7f6a-cc69-4de8-8e13-b837ce144b4a	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	anxiety disorder	TRIFLUOPERAZINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=09dc7f6a-cc69-4de8-8e13-b837ce144b4a	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	anxiety disorder	TRIFLUOPERAZINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=09dc7f6a-cc69-4de8-8e13-b837ce144b4a	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	anxiety disorder	TRIFLUOPERAZINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=09dc7f6a-cc69-4de8-8e13-b837ce144b4a	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	anxiety disorder	TRIFLUOPERAZINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=09dc7f6a-cc69-4de8-8e13-b837ce144b4a	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	anxiety disorder	TRIFLUOPERAZINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=09dc7f6a-cc69-4de8-8e13-b837ce144b4a	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	anxiety disorder	TRIFLUOPERAZINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=09dc7f6a-cc69-4de8-8e13-b837ce144b4a	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	insomnia	ESMIRTAZAPINE	targetBased	3	Completed	06/06/2007	https://clinicaltrials.gov/study/NCT00506389	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	insomnia	ESMIRTAZAPINE	targetBased	3	Completed	07/12/2006	https://clinicaltrials.gov/study/NCT00482612	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	insomnia	ESMIRTAZAPINE	targetBased	3	Completed	07/12/2006	https://clinicaltrials.gov/study/NCT00610675	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	ZIPRASIDONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=819997d8-e091-4081-85e1-bf50d39837ee	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	ZIPRASIDONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=61e3fa7b-61c2-4d5d-a6b3-2618c15a6bd9	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	ZIPRASIDONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4890cf77-8da3-46ae-b6f6-abea7aae6b4d	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar disorder	ZIPRASIDONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0f8ff266-c144-4843-9d05-d6276bde2f4d	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	bipolar disorder	ZIPRASIDONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=61e3fa7b-61c2-4d5d-a6b3-2618c15a6bd9	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	bipolar disorder	ZIPRASIDONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=61e3fa7b-61c2-4d5d-a6b3-2618c15a6bd9	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar disorder	ZIPRASIDONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=61e3fa7b-61c2-4d5d-a6b3-2618c15a6bd9	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar disorder	ZIPRASIDONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=61e3fa7b-61c2-4d5d-a6b3-2618c15a6bd9	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar disorder	ZIPRASIDONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=61e3fa7b-61c2-4d5d-a6b3-2618c15a6bd9	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar disorder	ZIPRASIDONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=61e3fa7b-61c2-4d5d-a6b3-2618c15a6bd9	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Agitation	ZIPRASIDONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=61e3fa7b-61c2-4d5d-a6b3-2618c15a6bd9	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Agitation	ZIPRASIDONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=819997d8-e091-4081-85e1-bf50d39837ee	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Agitation	ZIPRASIDONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=819997d8-e091-4081-85e1-bf50d39837ee	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Agitation	ZIPRASIDONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=819997d8-e091-4081-85e1-bf50d39837ee	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Agitation	ZIPRASIDONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=819997d8-e091-4081-85e1-bf50d39837ee	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Agitation	ZIPRASIDONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=819997d8-e091-4081-85e1-bf50d39837ee	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Agitation	ZIPRASIDONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=819997d8-e091-4081-85e1-bf50d39837ee	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar I disorder	ZIPRASIDONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=61e3fa7b-61c2-4d5d-a6b3-2618c15a6bd9	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar I disorder	ZIPRASIDONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=819997d8-e091-4081-85e1-bf50d39837ee	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	ZIPRASIDONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0090b65d-d663-4588-b0e6-e6fc903ca18c	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	ZIPRASIDONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=75e6a13c-39a7-4df0-b39a-b65b8bd7f618	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	ZIPRASIDONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=315e24c2-2f8c-47d9-b1b1-ce006646098a	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	ZIPRASIDONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4282fe5b-9e3c-49e5-8670-b2a2c1b7b207	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	ZIPRASIDONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=819997d8-e091-4081-85e1-bf50d39837ee	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	ZIPRASIDONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0f8ff266-c144-4843-9d05-d6276bde2f4d	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	ZIPRASIDONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8326928a-2cb6-4f7f-9712-03a425a14c37	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar I disorder	ZIPRASIDONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=61e3fa7b-61c2-4d5d-a6b3-2618c15a6bd9	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	bipolar I disorder	ZIPRASIDONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=819997d8-e091-4081-85e1-bf50d39837ee	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	bipolar I disorder	ZIPRASIDONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=819997d8-e091-4081-85e1-bf50d39837ee	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar I disorder	ZIPRASIDONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=819997d8-e091-4081-85e1-bf50d39837ee	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar I disorder	ZIPRASIDONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=819997d8-e091-4081-85e1-bf50d39837ee	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar I disorder	ZIPRASIDONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=819997d8-e091-4081-85e1-bf50d39837ee	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar I disorder	ZIPRASIDONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=819997d8-e091-4081-85e1-bf50d39837ee	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Agitation	ZIPRASIDONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=819997d8-e091-4081-85e1-bf50d39837ee	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Agitation	ZIPRASIDONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=61e3fa7b-61c2-4d5d-a6b3-2618c15a6bd9	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	ZIPRASIDONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=819997d8-e091-4081-85e1-bf50d39837ee	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	ZIPRASIDONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=61e3fa7b-61c2-4d5d-a6b3-2618c15a6bd9	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	ZIPRASIDONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=61e3fa7b-61c2-4d5d-a6b3-2618c15a6bd9	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	ZIPRASIDONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=61e3fa7b-61c2-4d5d-a6b3-2618c15a6bd9	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	ZIPRASIDONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=61e3fa7b-61c2-4d5d-a6b3-2618c15a6bd9	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	ZIPRASIDONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=61e3fa7b-61c2-4d5d-a6b3-2618c15a6bd9	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	ZIPRASIDONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=61e3fa7b-61c2-4d5d-a6b3-2618c15a6bd9	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	FLUPHENAZINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=50c7e742-1165-4c45-bbf6-172cf70a387a	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	FLUPHENAZINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=50c7e742-1165-4c45-bbf6-172cf70a387a	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	mental or behavioural disorder	FLUPHENAZINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=50c7e742-1165-4c45-bbf6-172cf70a387a	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	mental or behavioural disorder	FLUPHENAZINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=50c7e742-1165-4c45-bbf6-172cf70a387a	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	FLUPHENAZINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=50c7e742-1165-4c45-bbf6-172cf70a387a	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	FLUPHENAZINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=50c7e742-1165-4c45-bbf6-172cf70a387a	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	LURASIDONE HYDROCHLORIDE	targetBased	3	Completed	01/08/2012	https://clinicaltrials.gov/study/NCT01614912	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	LURASIDONE HYDROCHLORIDE	targetBased	3	Completed	02/07/2012	https://clinicaltrials.gov/study/NCT01614899	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	LURASIDONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=afad3051-9df2-4c54-9684-e8262a133af8	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	LURASIDONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=88a244d1-eddb-499c-bee2-e1f49056e78f	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	bipolar disorder	LURASIDONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=afad3051-9df2-4c54-9684-e8262a133af8	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	bipolar disorder	LURASIDONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=afad3051-9df2-4c54-9684-e8262a133af8	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar disorder	LURASIDONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=afad3051-9df2-4c54-9684-e8262a133af8	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar disorder	LURASIDONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=afad3051-9df2-4c54-9684-e8262a133af8	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar disorder	LURASIDONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=afad3051-9df2-4c54-9684-e8262a133af8	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar disorder	LURASIDONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=afad3051-9df2-4c54-9684-e8262a133af8	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar disorder	LURASIDONE HYDROCHLORIDE	targetBased	3	Completed	19/02/2014	https://clinicaltrials.gov/study/NCT01986101	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar I disorder	LURASIDONE HYDROCHLORIDE	targetBased	3	Completed	29/01/2014	https://clinicaltrials.gov/study/NCT01986114	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	LURASIDONE HYDROCHLORIDE	targetBased	3	Completed	19/02/2014	https://clinicaltrials.gov/study/NCT01986101	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	LURASIDONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=afad3051-9df2-4c54-9684-e8262a133af8	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	bipolar I disorder	LURASIDONE HYDROCHLORIDE	targetBased	3	Completed	29/01/2014	https://clinicaltrials.gov/study/NCT01986114	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	bipolar I disorder	LURASIDONE HYDROCHLORIDE	targetBased	3	Completed	29/01/2014	https://clinicaltrials.gov/study/NCT01986114	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar I disorder	LURASIDONE HYDROCHLORIDE	targetBased	3	Completed	29/01/2014	https://clinicaltrials.gov/study/NCT01986114	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar I disorder	LURASIDONE HYDROCHLORIDE	targetBased	3	Completed	29/01/2014	https://clinicaltrials.gov/study/NCT01986114	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar I disorder	LURASIDONE HYDROCHLORIDE	targetBased	3	Completed	29/01/2014	https://clinicaltrials.gov/study/NCT01986114	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar I disorder	LURASIDONE HYDROCHLORIDE	targetBased	3	Completed	29/01/2014	https://clinicaltrials.gov/study/NCT01986114	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	LURASIDONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=afad3051-9df2-4c54-9684-e8262a133af8	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	LURASIDONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=88a244d1-eddb-499c-bee2-e1f49056e78f	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	LURASIDONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=88a244d1-eddb-499c-bee2-e1f49056e78f	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	LURASIDONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=88a244d1-eddb-499c-bee2-e1f49056e78f	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	LURASIDONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=88a244d1-eddb-499c-bee2-e1f49056e78f	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	LURASIDONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=88a244d1-eddb-499c-bee2-e1f49056e78f	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	LURASIDONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=88a244d1-eddb-499c-bee2-e1f49056e78f	1	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	depressive disorder	VILAZODONE HYDROCHLORIDE	targetBased	4	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT01715519	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	depressive disorder	VILAZODONE HYDROCHLORIDE	targetBased	4	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT01715519	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	post-traumatic stress disorder	VILAZODONE HYDROCHLORIDE	targetBased	4	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT01715519	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	post-traumatic stress disorder	VILAZODONE HYDROCHLORIDE	targetBased	4	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT01715519	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	unipolar depression	VILAZODONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4c55ccfb-c4cf-11df-851a-0800200c9a66	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	unipolar depression	VILAZODONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4c55ccfb-c4cf-11df-851a-0800200c9a66	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	unipolar depression	VILAZODONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bfef9e19-d0f5-40fa-954c-b73c812eb242	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	unipolar depression	VILAZODONE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bfef9e19-d0f5-40fa-954c-b73c812eb242	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	unipolar depression	ATICAPRANT	targetBased	3	Recruiting	22/06/2022	https://clinicaltrials.gov/study/NCT05455684	0.7	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	unipolar depression	ATICAPRANT	targetBased	3	Recruiting	22/09/2022	https://clinicaltrials.gov/study/NCT05518149	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	bipolar disorder	CARIPRAZINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4b5f7c65-aa2d-452a-b3db-bc85c06ff12f	1		protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	bipolar disorder	CARIPRAZINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4b5f7c65-aa2d-452a-b3db-bc85c06ff12f	1		protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	bipolar disorder	CARIPRAZINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4b5f7c65-aa2d-452a-b3db-bc85c06ff12f	1		protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	bipolar disorder	CARIPRAZINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4b5f7c65-aa2d-452a-b3db-bc85c06ff12f	1		protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	bipolar disorder	CARIPRAZINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4b5f7c65-aa2d-452a-b3db-bc85c06ff12f	1		protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar disorder	CARIPRAZINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4b5f7c65-aa2d-452a-b3db-bc85c06ff12f	1		protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar disorder	CARIPRAZINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4b5f7c65-aa2d-452a-b3db-bc85c06ff12f	1		protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar disorder	CARIPRAZINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4b5f7c65-aa2d-452a-b3db-bc85c06ff12f	1		protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar disorder	CARIPRAZINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4b5f7c65-aa2d-452a-b3db-bc85c06ff12f	1		protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	schizophrenia	CARIPRAZINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3435ec73-86ed-46d1-bd1f-ee6c30209123	1		protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	schizophrenia	CARIPRAZINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4b5f7c65-aa2d-452a-b3db-bc85c06ff12f	1		protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	schizophrenia	CARIPRAZINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4b5f7c65-aa2d-452a-b3db-bc85c06ff12f	1		protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	schizophrenia	CARIPRAZINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4b5f7c65-aa2d-452a-b3db-bc85c06ff12f	1		protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	schizophrenia	CARIPRAZINE HYDROCHLORIDE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/reagila	1		protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	schizophrenia	CARIPRAZINE HYDROCHLORIDE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/reagila	1		protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	schizophrenia	CARIPRAZINE HYDROCHLORIDE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/reagila	1		protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	bipolar I disorder	CARIPRAZINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3435ec73-86ed-46d1-bd1f-ee6c30209123	1		protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	bipolar I disorder	CARIPRAZINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3435ec73-86ed-46d1-bd1f-ee6c30209123	1		protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	bipolar I disorder	CARIPRAZINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3435ec73-86ed-46d1-bd1f-ee6c30209123	1		protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	bipolar I disorder	CARIPRAZINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3435ec73-86ed-46d1-bd1f-ee6c30209123	1		protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	bipolar I disorder	CARIPRAZINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3435ec73-86ed-46d1-bd1f-ee6c30209123	1		protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar I disorder	CARIPRAZINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3435ec73-86ed-46d1-bd1f-ee6c30209123	1		protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar I disorder	CARIPRAZINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3435ec73-86ed-46d1-bd1f-ee6c30209123	1		protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar I disorder	CARIPRAZINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3435ec73-86ed-46d1-bd1f-ee6c30209123	1		protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar I disorder	CARIPRAZINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3435ec73-86ed-46d1-bd1f-ee6c30209123	1		protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	CARIPRAZINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4b5f7c65-aa2d-452a-b3db-bc85c06ff12f	1		protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	CARIPRAZINE HYDROCHLORIDE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/reagila	1		protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	CARIPRAZINE HYDROCHLORIDE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/reagila	1		protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	CARIPRAZINE HYDROCHLORIDE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/reagila	1		protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	CARIPRAZINE HYDROCHLORIDE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/reagila	1		protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	CARIPRAZINE HYDROCHLORIDE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/reagila	1		protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	CARIPRAZINE HYDROCHLORIDE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/reagila	1		protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	bipolar disorder	CARIPRAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4b5f7c65-aa2d-452a-b3db-bc85c06ff12f	1		protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	bipolar disorder	CARIPRAZINE	targetBased	4	Recruiting	13/12/2022	https://clinicaltrials.gov/study/NCT05913947	1		protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	bipolar disorder	CARIPRAZINE	targetBased	4	Recruiting	13/12/2022	https://clinicaltrials.gov/study/NCT05913947	1		protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	bipolar disorder	CARIPRAZINE	targetBased	4	Recruiting	13/12/2022	https://clinicaltrials.gov/study/NCT05913947	1		protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	bipolar disorder	CARIPRAZINE	targetBased	4	Not yet recruiting	31/03/2024	https://clinicaltrials.gov/study/NCT05060549	1		protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	bipolar disorder	CARIPRAZINE	targetBased	4	Not yet recruiting	31/03/2024	https://clinicaltrials.gov/study/NCT05060549	1		protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	bipolar disorder	CARIPRAZINE	targetBased	4	Not yet recruiting	31/03/2024	https://clinicaltrials.gov/study/NCT05060549	1		protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar disorder	CARIPRAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4b5f7c65-aa2d-452a-b3db-bc85c06ff12f	1		protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	bipolar disorder	CARIPRAZINE	targetBased	4	Not yet recruiting	31/03/2024	https://clinicaltrials.gov/study/NCT05060549	1		protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	bipolar disorder	CARIPRAZINE	targetBased	4	Not yet recruiting	31/03/2024	https://clinicaltrials.gov/study/NCT05060549	1		protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar disorder	CARIPRAZINE	targetBased	4	Not yet recruiting	31/03/2024	https://clinicaltrials.gov/study/NCT05060549	1		protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar disorder	CARIPRAZINE	targetBased	4	Not yet recruiting	31/03/2024	https://clinicaltrials.gov/study/NCT05060549	1		protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar disorder	CARIPRAZINE	targetBased	4	Not yet recruiting	31/03/2024	https://clinicaltrials.gov/study/NCT05060549	1		protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar disorder	CARIPRAZINE	targetBased	4	Not yet recruiting	31/03/2024	https://clinicaltrials.gov/study/NCT05060549	1		protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	major depressive disorder	CARIPRAZINE	targetBased	4	Not yet recruiting	01/08/2024	https://clinicaltrials.gov/study/NCT05933538	1		protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	major depressive disorder	CARIPRAZINE	targetBased	4	Not yet recruiting	01/08/2024	https://clinicaltrials.gov/study/NCT05933538	1		protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	major depressive disorder	CARIPRAZINE	targetBased	4	Not yet recruiting	01/08/2024	https://clinicaltrials.gov/study/NCT05933538	1		protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	major depressive disorder	CARIPRAZINE	targetBased	4	Not yet recruiting	01/08/2024	https://clinicaltrials.gov/study/NCT05933538	1		protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	major depressive disorder	CARIPRAZINE	targetBased	4	Not yet recruiting	01/08/2024	https://clinicaltrials.gov/study/NCT05933538	1		protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	major depressive disorder	CARIPRAZINE	targetBased	4	Not yet recruiting	01/08/2024	https://clinicaltrials.gov/study/NCT05933538	1		protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	major depressive disorder	CARIPRAZINE	targetBased	3	Completed	29/04/2013	https://clinicaltrials.gov/study/NCT01838876	0.7		protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	psychosis	CARIPRAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AX15	1		protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	psychosis	CARIPRAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AX15	1		protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	psychosis	CARIPRAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AX15	1		protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	autism spectrum disorder	CARIPRAZINE	targetBased	3	Recruiting	07/07/2022	https://clinicaltrials.gov/study/NCT05439616	0.7		protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	autism spectrum disorder	CARIPRAZINE	targetBased	3	Recruiting	07/07/2022	https://clinicaltrials.gov/study/NCT05439616	0.7		protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	autism spectrum disorder	CARIPRAZINE	targetBased	3	Recruiting	07/07/2022	https://clinicaltrials.gov/study/NCT05439616	0.7		protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	major depressive disorder	CARIPRAZINE	targetBased	4	Not yet recruiting	01/08/2024	https://clinicaltrials.gov/study/NCT05933538	1		protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	major depressive disorder	CARIPRAZINE	targetBased	4	Not yet recruiting	01/08/2024	https://clinicaltrials.gov/study/NCT05933538	1		protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	major depressive disorder	CARIPRAZINE	targetBased	4	Not yet recruiting	01/08/2024	https://clinicaltrials.gov/study/NCT05933538	1		protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	major depressive disorder	CARIPRAZINE	targetBased	3	Completed	29/04/2013	https://clinicaltrials.gov/study/NCT01838876	0.7		protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	major depressive disorder	CARIPRAZINE	targetBased	3	Completed	29/04/2013	https://clinicaltrials.gov/study/NCT01838876	0.7		protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	major depressive disorder	CARIPRAZINE	targetBased	3	Completed	29/04/2013	https://clinicaltrials.gov/study/NCT01838876	0.7		protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	major depressive disorder	CARIPRAZINE	targetBased	3	Completed	15/11/2012	https://clinicaltrials.gov/study/NCT01715805	0.7		protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	major depressive disorder	CARIPRAZINE	targetBased	3	Completed	15/11/2012	https://clinicaltrials.gov/study/NCT01715805	0.7		protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	major depressive disorder	CARIPRAZINE	targetBased	3	Completed	15/11/2012	https://clinicaltrials.gov/study/NCT01715805	0.7		protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	depressive disorder	CARIPRAZINE	targetBased	3	Completed	15/06/2018	https://clinicaltrials.gov/study/NCT03573297	0.7		protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	depressive disorder	CARIPRAZINE	targetBased	3	Completed	15/06/2018	https://clinicaltrials.gov/study/NCT03573297	0.7		protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	depressive disorder	CARIPRAZINE	targetBased	3	Completed	15/06/2018	https://clinicaltrials.gov/study/NCT03573297	0.7		protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	depressive disorder	CARIPRAZINE	targetBased	3	Completed	15/06/2018	https://clinicaltrials.gov/study/NCT03573297	0.7		protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	depressive disorder	CARIPRAZINE	targetBased	3	Completed	17/03/2016	https://clinicaltrials.gov/study/NCT02670551	0.7		protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	depressive disorder	CARIPRAZINE	targetBased	3	Completed	17/03/2016	https://clinicaltrials.gov/study/NCT02670551	0.7		protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	depressive disorder	CARIPRAZINE	targetBased	3	Completed	17/03/2016	https://clinicaltrials.gov/study/NCT02670551	0.7		protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	depressive disorder	CARIPRAZINE	targetBased	3	Completed	17/03/2016	https://clinicaltrials.gov/study/NCT02670551	0.7		protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	depressive disorder	CARIPRAZINE	targetBased	3	Completed	17/03/2016	https://clinicaltrials.gov/study/NCT02670551	0.7		protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	depressive disorder	CARIPRAZINE	targetBased	3	Completed	17/03/2016	https://clinicaltrials.gov/study/NCT02670551	0.7		protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	schizophrenia	CARIPRAZINE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/reagila	1		protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	schizophrenia	CARIPRAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3435ec73-86ed-46d1-bd1f-ee6c30209123	1		protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	schizophrenia	CARIPRAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3435ec73-86ed-46d1-bd1f-ee6c30209123	1		protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	schizophrenia	CARIPRAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3435ec73-86ed-46d1-bd1f-ee6c30209123	1		protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	schizophrenia	CARIPRAZINE	targetBased	4	Recruiting	16/08/2023	https://clinicaltrials.gov/study/NCT05741502	1		protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	schizophrenia	CARIPRAZINE	targetBased	4	Recruiting	16/08/2023	https://clinicaltrials.gov/study/NCT05741502	1		protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	schizophrenia	CARIPRAZINE	targetBased	4	Recruiting	16/08/2023	https://clinicaltrials.gov/study/NCT05741502	1		protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	depressive disorder	CARIPRAZINE	targetBased	3	Completed	31/03/2016	https://clinicaltrials.gov/study/NCT02670538	0.7		protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	depressive disorder	CARIPRAZINE	targetBased	3	Completed	31/03/2016	https://clinicaltrials.gov/study/NCT02670538	0.7		protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	depressive disorder	CARIPRAZINE	targetBased	3	Completed	31/03/2016	https://clinicaltrials.gov/study/NCT02670538	0.7		protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	depressive disorder	CARIPRAZINE	targetBased	3	Completed	17/03/2016	https://clinicaltrials.gov/study/NCT02670551	0.7		protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	depressive disorder	CARIPRAZINE	targetBased	3	Completed	17/03/2016	https://clinicaltrials.gov/study/NCT02670551	0.7		protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	depressive disorder	CARIPRAZINE	targetBased	3	Completed	17/03/2016	https://clinicaltrials.gov/study/NCT02670551	0.7		protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	depressive disorder	CARIPRAZINE	targetBased	3	Completed	15/06/2018	https://clinicaltrials.gov/study/NCT03573297	0.7		protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	depressive disorder	CARIPRAZINE	targetBased	3	Completed	15/06/2018	https://clinicaltrials.gov/study/NCT03573297	0.7		protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	depressive disorder	CARIPRAZINE	targetBased	3	Completed	15/06/2018	https://clinicaltrials.gov/study/NCT03573297	0.7		protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	psychosis	CARIPRAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AX15	1		protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	psychosis	CARIPRAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AX15	1		protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	psychosis	CARIPRAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AX15	1		protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	psychosis	CARIPRAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AX15	1		protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	CARIPRAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AX15	1		protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	CARIPRAZINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AX15	1		protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	bipolar I disorder	CARIPRAZINE	targetBased	3	Completed	01/02/2010	https://clinicaltrials.gov/study/NCT01058668	0.7		protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	bipolar I disorder	CARIPRAZINE	targetBased	3	Completed	01/02/2010	https://clinicaltrials.gov/study/NCT01058668	0.7		protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	bipolar I disorder	CARIPRAZINE	targetBased	3	Completed	01/02/2010	https://clinicaltrials.gov/study/NCT01058668	0.7		protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	bipolar I disorder	CARIPRAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3435ec73-86ed-46d1-bd1f-ee6c30209123	1		protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	bipolar I disorder	CARIPRAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3435ec73-86ed-46d1-bd1f-ee6c30209123	1		protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	bipolar I disorder	CARIPRAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3435ec73-86ed-46d1-bd1f-ee6c30209123	1		protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	bipolar I disorder	CARIPRAZINE	targetBased	3	Completed	15/06/2018	https://clinicaltrials.gov/study/NCT03573297	0.7		protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	bipolar I disorder	CARIPRAZINE	targetBased	3	Completed	15/06/2018	https://clinicaltrials.gov/study/NCT03573297	0.7		protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	bipolar I disorder	CARIPRAZINE	targetBased	3	Completed	15/06/2018	https://clinicaltrials.gov/study/NCT03573297	0.7		protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	social anxiety disorder	CARIPRAZINE	targetBased	4	Not yet recruiting	15/07/2022	https://clinicaltrials.gov/study/NCT05384483	1		protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	social anxiety disorder	CARIPRAZINE	targetBased	4	Not yet recruiting	15/07/2022	https://clinicaltrials.gov/study/NCT05384483	1		protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	social anxiety disorder	CARIPRAZINE	targetBased	4	Not yet recruiting	15/07/2022	https://clinicaltrials.gov/study/NCT05384483	1		protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	autism spectrum disorder	CARIPRAZINE	targetBased	3	Recruiting	07/07/2022	https://clinicaltrials.gov/study/NCT05439616	0.7		protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	autism spectrum disorder	CARIPRAZINE	targetBased	3	Recruiting	07/07/2022	https://clinicaltrials.gov/study/NCT05439616	0.7		protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	autism spectrum disorder	CARIPRAZINE	targetBased	3	Recruiting	07/07/2022	https://clinicaltrials.gov/study/NCT05439616	0.7		protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	autism spectrum disorder	CARIPRAZINE	targetBased	3	Recruiting	07/07/2022	https://clinicaltrials.gov/study/NCT05439616	0.7		protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	autism spectrum disorder	CARIPRAZINE	targetBased	3	Recruiting	07/07/2022	https://clinicaltrials.gov/study/NCT05439616	0.7		protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	autism spectrum disorder	CARIPRAZINE	targetBased	3	Recruiting	07/07/2022	https://clinicaltrials.gov/study/NCT05439616	0.7		protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	bipolar I disorder	CARIPRAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3435ec73-86ed-46d1-bd1f-ee6c30209123	1		protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	bipolar I disorder	CARIPRAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3435ec73-86ed-46d1-bd1f-ee6c30209123	1		protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar I disorder	CARIPRAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3435ec73-86ed-46d1-bd1f-ee6c30209123	1		protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar I disorder	CARIPRAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3435ec73-86ed-46d1-bd1f-ee6c30209123	1		protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar I disorder	CARIPRAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3435ec73-86ed-46d1-bd1f-ee6c30209123	1		protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar I disorder	CARIPRAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3435ec73-86ed-46d1-bd1f-ee6c30209123	1		protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar I disorder	CARIPRAZINE	targetBased	3	Completed	15/06/2018	https://clinicaltrials.gov/study/NCT03573297	0.7		protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	CARIPRAZINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4b5f7c65-aa2d-452a-b3db-bc85c06ff12f	1		protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	CARIPRAZINE	targetBased	4	Recruiting	16/08/2023	https://clinicaltrials.gov/study/NCT05741502	1		protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	CARIPRAZINE	targetBased	4	Recruiting	16/08/2023	https://clinicaltrials.gov/study/NCT05741502	1		protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	CARIPRAZINE	targetBased	4	Recruiting	16/08/2023	https://clinicaltrials.gov/study/NCT05741502	1		protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	CARIPRAZINE	targetBased	4	Recruiting	16/08/2023	https://clinicaltrials.gov/study/NCT05741502	1		protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	CARIPRAZINE	targetBased	4	Recruiting	16/08/2023	https://clinicaltrials.gov/study/NCT05741502	1		protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	CARIPRAZINE	targetBased	4	Recruiting	16/08/2023	https://clinicaltrials.gov/study/NCT05741502	1		protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	attention deficit hyperactivity disorder	CARIPRAZINE	targetBased	4	Recruiting	01/12/2021	https://clinicaltrials.gov/study/NCT04843423	1		protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	attention deficit hyperactivity disorder	CARIPRAZINE	targetBased	4	Recruiting	01/12/2021	https://clinicaltrials.gov/study/NCT04843423	1		protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	attention deficit hyperactivity disorder	CARIPRAZINE	targetBased	4	Recruiting	01/12/2021	https://clinicaltrials.gov/study/NCT04843423	1		protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	attention deficit hyperactivity disorder	CARIPRAZINE	targetBased	4	Recruiting	01/12/2021	https://clinicaltrials.gov/study/NCT04843423	1		protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	attention deficit hyperactivity disorder	CARIPRAZINE	targetBased	4	Recruiting	01/12/2021	https://clinicaltrials.gov/study/NCT04843423	1		protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	attention deficit hyperactivity disorder	CARIPRAZINE	targetBased	4	Recruiting	01/12/2021	https://clinicaltrials.gov/study/NCT04843423	1		protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	attention deficit hyperactivity disorder	CARIPRAZINE	targetBased	4	Recruiting	01/12/2021	https://clinicaltrials.gov/study/NCT04843423	1		protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	attention deficit hyperactivity disorder	CARIPRAZINE	targetBased	4	Recruiting	01/12/2021	https://clinicaltrials.gov/study/NCT04843423	1		protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	attention deficit hyperactivity disorder	CARIPRAZINE	targetBased	4	Recruiting	01/12/2021	https://clinicaltrials.gov/study/NCT04843423	1		protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	social anxiety disorder	CARIPRAZINE	targetBased	4	Not yet recruiting	15/07/2022	https://clinicaltrials.gov/study/NCT05384483	1		protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	social anxiety disorder	CARIPRAZINE	targetBased	4	Not yet recruiting	15/07/2022	https://clinicaltrials.gov/study/NCT05384483	1		protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	social anxiety disorder	CARIPRAZINE	targetBased	4	Not yet recruiting	15/07/2022	https://clinicaltrials.gov/study/NCT05384483	1		protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	social anxiety disorder	CARIPRAZINE	targetBased	4	Not yet recruiting	15/07/2022	https://clinicaltrials.gov/study/NCT05384483	1		protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	social anxiety disorder	CARIPRAZINE	targetBased	4	Not yet recruiting	15/07/2022	https://clinicaltrials.gov/study/NCT05384483	1		protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	social anxiety disorder	CARIPRAZINE	targetBased	4	Not yet recruiting	15/07/2022	https://clinicaltrials.gov/study/NCT05384483	1		protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		alcohol dependence	ACAMPROSATE CALCIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fe6f754f-62b4-4c86-805d-221332409516	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		alcohol dependence	ACAMPROSATE CALCIUM	targetBased	3	Completed	05/08/2020	https://clinicaltrials.gov/study/NCT03634917	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		alcohol dependence	ACAMPROSATE CALCIUM	targetBased	4	Not yet recruiting	08/07/2024	https://clinicaltrials.gov/study/NCT06269627	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R	MC4R	MC4R	Melanocortin receptor 4	mental or behavioural disorder	BREMELANOTIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9146ae05-918b-483e-b86d-933485ce36eb	1	GoF	protect
TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R	MC4R	MC4R	Melanocortin receptor 4	mental or behavioural disorder	BREMELANOTIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9146ae05-918b-483e-b86d-933485ce36eb	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	MORPHINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=83497476-dea9-57ec-e053-2991aa0a08c1	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	MORPHINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=83497476-dea9-57ec-e053-2991aa0a08c1	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	MORPHINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=533034fd-c8e7-495b-8874-0db41bd1e65a	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	MORPHINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=533034fd-c8e7-495b-8874-0db41bd1e65a	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	obstructive sleep apnea	MORPHINE SULFATE	targetBased	3	Terminated	20/05/2016	https://clinicaltrials.gov/study/NCT03127800	0.7	GoF	protect	Difficulties with recruitment
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	obstructive sleep apnea	MORPHINE SULFATE	targetBased	3	Terminated	20/05/2016	https://clinicaltrials.gov/study/NCT03127800	0.7	GoF	protect	Difficulties with recruitment
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	MORPHINE SULFATE	targetBased	3	Terminated	06/12/2019	https://clinicaltrials.gov/study/NCT03948464	0.7	GoF	protect	Study unable to proceed per protocol due to COVID-19 precautions
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	MORPHINE SULFATE	targetBased	3	Terminated	06/12/2019	https://clinicaltrials.gov/study/NCT03948464	0.7	GoF	protect	Study unable to proceed per protocol due to COVID-19 precautions
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	MORPHINE SULFATE	targetBased	4	Terminated	14/09/2016	https://clinicaltrials.gov/study/NCT02741076	1	GoF	protect	Inability to recruit sufficient no. of subjects over an acceptable time period
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	MORPHINE SULFATE	targetBased	4	Terminated	14/09/2016	https://clinicaltrials.gov/study/NCT02741076	1	GoF	protect	Inability to recruit sufficient no. of subjects over an acceptable time period
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	overdose	MORPHINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=533034fd-c8e7-495b-8874-0db41bd1e65a	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	overdose	MORPHINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=533034fd-c8e7-495b-8874-0db41bd1e65a	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	neonatal abstinence syndrome	MORPHINE SULFATE	targetBased	4	Recruiting	21/02/2018	https://clinicaltrials.gov/study/NCT03092011	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	neonatal abstinence syndrome	MORPHINE SULFATE	targetBased	4	Recruiting	21/02/2018	https://clinicaltrials.gov/study/NCT03092011	1	GoF	protect
Modulation of AMPAR-stargazin complexes	AMPAStargazinComplexModulators	CACNG2	Voltage-dependent calcium channel gamma-2 subunit	generalized anxiety disorder	IMAGABALIN	targetBased	3	Terminated	01/05/2008	https://clinicaltrials.gov/study/NCT00658372	0.7		protect	Please see Detailed Description for termination reason.
Modulation of AMPAR-stargazin complexes	AMPAStargazinComplexModulators	CACNG2	Voltage-dependent calcium channel gamma-2 subunit	generalized anxiety disorder	IMAGABALIN	targetBased	3	Completed	01/10/2007	https://clinicaltrials.gov/study/NCT00542685	0.7		protect
Modulation of AMPAR-stargazin complexes	AMPAStargazinComplexModulators	CACNG2	Voltage-dependent calcium channel gamma-2 subunit	generalized anxiety disorder	IMAGABALIN	targetBased	3	Terminated	01/04/2008	https://clinicaltrials.gov/study/NCT00658008	0.7		protect	Please see Detailed Description for termination reason.
Modulation of AMPAR-stargazin complexes	AMPAStargazinComplexModulators	CACNG2	Voltage-dependent calcium channel gamma-2 subunit	generalized anxiety disorder	IMAGABALIN	targetBased	3	Terminated	01/10/2008	https://clinicaltrials.gov/study/NCT00735267	0.7		protect	Please see Detailed Description for termination reason.
Modulation of AMPAR-stargazin complexes	AMPAStargazinComplexModulators	CACNG2	Voltage-dependent calcium channel gamma-2 subunit	generalized anxiety disorder	IMAGABALIN	targetBased	3	Withdrawn	01/01/2009	https://clinicaltrials.gov/study/NCT00738738	0.7		protect	Please see Detailed Description for termination reason.
Modulation of AMPAR-stargazin complexes	AMPAStargazinComplexModulators	CACNG2	Voltage-dependent calcium channel gamma-2 subunit	generalized anxiety disorder	IMAGABALIN	targetBased	3	Terminated	01/05/2008	https://clinicaltrials.gov/study/NCT00658762	0.7		protect	Please see Detailed Description for termination reason.
Modulation of AMPAR-stargazin complexes	AMPAStargazinComplexModulators	CACNG2	Voltage-dependent calcium channel gamma-2 subunit	anxiety	IMAGABALIN	targetBased	3	Terminated	01/10/2008	https://clinicaltrials.gov/study/NCT00836069	0.7		protect	Pfizer has terminated the execution of this protocol
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	generalized anxiety disorder	IMAGABALIN	targetBased	3	Terminated	01/10/2008	https://clinicaltrials.gov/study/NCT00735267	0.7		protect	Please see Detailed Description for termination reason.
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	generalized anxiety disorder	IMAGABALIN	targetBased	3	Terminated	01/05/2008	https://clinicaltrials.gov/study/NCT00658762	0.7		protect	Please see Detailed Description for termination reason.
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	generalized anxiety disorder	IMAGABALIN	targetBased	3	Withdrawn	01/01/2009	https://clinicaltrials.gov/study/NCT00738738	0.7		protect	Please see Detailed Description for termination reason.
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	generalized anxiety disorder	IMAGABALIN	targetBased	3	Completed	01/10/2007	https://clinicaltrials.gov/study/NCT00542685	0.7		protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	generalized anxiety disorder	IMAGABALIN	targetBased	3	Terminated	01/05/2008	https://clinicaltrials.gov/study/NCT00658372	0.7		protect	Please see Detailed Description for termination reason.
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	generalized anxiety disorder	IMAGABALIN	targetBased	3	Terminated	01/04/2008	https://clinicaltrials.gov/study/NCT00658008	0.7		protect	Please see Detailed Description for termination reason.
Inhibitors of Cav3 T-type Calcium Channels: Primary Screen	CACNA1H_inhibitors	CACNA1H	Voltage-dependent T-type calcium channel subunit alpha-1H	anxiety	IMAGABALIN	targetBased	3	Terminated	01/10/2008	https://clinicaltrials.gov/study/NCT00836069	0.7		protect	Pfizer has terminated the execution of this protocol
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	anxiety	IMAGABALIN	targetBased	3	Terminated	01/10/2008	https://clinicaltrials.gov/study/NCT00836069	0.7		protect	Pfizer has terminated the execution of this protocol
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	anxiety	IMAGABALIN	targetBased	3	Terminated	01/10/2008	https://clinicaltrials.gov/study/NCT00836069	0.7		protect	Pfizer has terminated the execution of this protocol
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	generalized anxiety disorder	IMAGABALIN	targetBased	3	Terminated	01/04/2008	https://clinicaltrials.gov/study/NCT00658008	0.7		protect	Please see Detailed Description for termination reason.
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	generalized anxiety disorder	IMAGABALIN	targetBased	3	Withdrawn	01/01/2009	https://clinicaltrials.gov/study/NCT00738738	0.7		protect	Please see Detailed Description for termination reason.
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	generalized anxiety disorder	IMAGABALIN	targetBased	3	Terminated	01/05/2008	https://clinicaltrials.gov/study/NCT00658762	0.7		protect	Please see Detailed Description for termination reason.
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	generalized anxiety disorder	IMAGABALIN	targetBased	3	Terminated	01/10/2008	https://clinicaltrials.gov/study/NCT00735267	0.7		protect	Please see Detailed Description for termination reason.
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	generalized anxiety disorder	IMAGABALIN	targetBased	3	Completed	01/10/2007	https://clinicaltrials.gov/study/NCT00542685	0.7		protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	generalized anxiety disorder	IMAGABALIN	targetBased	3	Terminated	01/05/2008	https://clinicaltrials.gov/study/NCT00658372	0.7		protect	Please see Detailed Description for termination reason.
Inhibitors of Cav3 T-type Calcium Channels: Primary Screen	CACNA1H_inhibitors	CACNA1H	Voltage-dependent T-type calcium channel subunit alpha-1H	generalized anxiety disorder	IMAGABALIN	targetBased	3	Terminated	01/04/2008	https://clinicaltrials.gov/study/NCT00658008	0.7		protect	Please see Detailed Description for termination reason.
Inhibitors of Cav3 T-type Calcium Channels: Primary Screen	CACNA1H_inhibitors	CACNA1H	Voltage-dependent T-type calcium channel subunit alpha-1H	generalized anxiety disorder	IMAGABALIN	targetBased	3	Terminated	01/05/2008	https://clinicaltrials.gov/study/NCT00658762	0.7		protect	Please see Detailed Description for termination reason.
Inhibitors of Cav3 T-type Calcium Channels: Primary Screen	CACNA1H_inhibitors	CACNA1H	Voltage-dependent T-type calcium channel subunit alpha-1H	generalized anxiety disorder	IMAGABALIN	targetBased	3	Withdrawn	01/01/2009	https://clinicaltrials.gov/study/NCT00738738	0.7		protect	Please see Detailed Description for termination reason.
Inhibitors of Cav3 T-type Calcium Channels: Primary Screen	CACNA1H_inhibitors	CACNA1H	Voltage-dependent T-type calcium channel subunit alpha-1H	generalized anxiety disorder	IMAGABALIN	targetBased	3	Completed	01/10/2007	https://clinicaltrials.gov/study/NCT00542685	0.7		protect
Inhibitors of Cav3 T-type Calcium Channels: Primary Screen	CACNA1H_inhibitors	CACNA1H	Voltage-dependent T-type calcium channel subunit alpha-1H	generalized anxiety disorder	IMAGABALIN	targetBased	3	Terminated	01/10/2008	https://clinicaltrials.gov/study/NCT00735267	0.7		protect	Please see Detailed Description for termination reason.
Inhibitors of Cav3 T-type Calcium Channels: Primary Screen	CACNA1H_inhibitors	CACNA1H	Voltage-dependent T-type calcium channel subunit alpha-1H	generalized anxiety disorder	IMAGABALIN	targetBased	3	Terminated	01/05/2008	https://clinicaltrials.gov/study/NCT00658372	0.7		protect	Please see Detailed Description for termination reason.
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Mental deterioration	VORTIOXETINE	targetBased	4	Completed	31/08/2016	https://clinicaltrials.gov/study/NCT03272711	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Mental deterioration	VORTIOXETINE	targetBased	4	Completed	31/08/2016	https://clinicaltrials.gov/study/NCT03272711	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	bipolar disorder	VORTIOXETINE	targetBased	4	Completed	01/03/2022	https://clinicaltrials.gov/study/NCT05481957	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	bipolar disorder	VORTIOXETINE	targetBased	4	Completed	01/03/2022	https://clinicaltrials.gov/study/NCT05481957	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	depressive disorder	VORTIOXETINE	targetBased	3	Terminated	10/08/2021	https://clinicaltrials.gov/study/NCT05014919	0.7	GoF	protect	The study was terminated based on new efficacy data from another study.
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	depressive disorder	VORTIOXETINE	targetBased	3	Terminated	10/08/2021	https://clinicaltrials.gov/study/NCT05014919	0.7	GoF	protect	The study was terminated based on new efficacy data from another study.
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	depressive disorder	VORTIOXETINE	targetBased	4	Recruiting	20/11/2019	https://clinicaltrials.gov/study/NCT04301492	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	depressive disorder	VORTIOXETINE	targetBased	4	Recruiting	20/11/2019	https://clinicaltrials.gov/study/NCT04301492	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	depressive disorder	VORTIOXETINE	targetBased	3	Withdrawn	01/10/2016	https://clinicaltrials.gov/study/NCT02845349	0.7	GoF	protect	Funding withdrawn.
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	depressive disorder	VORTIOXETINE	targetBased	3	Withdrawn	01/10/2016	https://clinicaltrials.gov/study/NCT02845349	0.7	GoF	protect	Funding withdrawn.
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	post-traumatic stress disorder	VORTIOXETINE	targetBased	4	Completed	01/12/2016	https://clinicaltrials.gov/study/NCT02637895	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	post-traumatic stress disorder	VORTIOXETINE	targetBased	4	Completed	01/12/2016	https://clinicaltrials.gov/study/NCT02637895	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	major depressive disorder	VORTIOXETINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1a5b68e2-14d0-419d-9ec6-1ca97145e838	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	major depressive disorder	VORTIOXETINE	targetBased	4	Completed	01/12/2016	https://clinicaltrials.gov/study/NCT02749721	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	major depressive disorder	VORTIOXETINE	targetBased	4	Completed	01/12/2016	https://clinicaltrials.gov/study/NCT02749721	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	major depressive disorder	VORTIOXETINE	targetBased	4	Completed	10/02/2015	https://clinicaltrials.gov/study/NCT02371980	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	major depressive disorder	VORTIOXETINE	targetBased	4	Completed	10/02/2015	https://clinicaltrials.gov/study/NCT02371980	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	major depressive disorder	VORTIOXETINE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02332954	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	major depressive disorder	VORTIOXETINE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02332954	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	panic disorder	VORTIOXETINE	targetBased	4	Completed	01/05/2015	https://clinicaltrials.gov/study/NCT02395510	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	panic disorder	VORTIOXETINE	targetBased	4	Completed	01/05/2015	https://clinicaltrials.gov/study/NCT02395510	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	unipolar depression	VORTIOXETINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4b0700c9-b417-4c3a-b36f-de461e125bd3	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	unipolar depression	VORTIOXETINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4b0700c9-b417-4c3a-b36f-de461e125bd3	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	unipolar depression	VORTIOXETINE	targetBased	3			https://www.whocc.no/atc_ddd_index/?code=N06AX26	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	unipolar depression	VORTIOXETINE	targetBased	3			https://www.whocc.no/atc_ddd_index/?code=N06AX26	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	unipolar depression	VORTIOXETINE	targetBased	4	Terminated	24/08/2017	https://clinicaltrials.gov/study/NCT02969876	1	GoF	protect	Site was unable to reach Sponsor recruitment goals.
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	unipolar depression	VORTIOXETINE	targetBased	4	Terminated	24/08/2017	https://clinicaltrials.gov/study/NCT02969876	1	GoF	protect	Site was unable to reach Sponsor recruitment goals.
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	schizophrenia	VORTIOXETINE	targetBased	4	Active, not recruiting	01/02/2016	https://clinicaltrials.gov/study/NCT02357797	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	schizophrenia	VORTIOXETINE	targetBased	4	Active, not recruiting	01/02/2016	https://clinicaltrials.gov/study/NCT02357797	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	anxiety	VORTIOXETINE	targetBased	4	Completed	27/12/2019	https://clinicaltrials.gov/study/NCT04220996	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	anxiety	VORTIOXETINE	targetBased	4	Completed	27/12/2019	https://clinicaltrials.gov/study/NCT04220996	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	generalized anxiety disorder	VORTIOXETINE	targetBased	3	Completed	01/10/2008	https://clinicaltrials.gov/study/NCT00788034	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	generalized anxiety disorder	VORTIOXETINE	targetBased	3	Completed	01/10/2008	https://clinicaltrials.gov/study/NCT00788034	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	generalized anxiety disorder	VORTIOXETINE	targetBased	3	Completed	01/09/2008	https://clinicaltrials.gov/study/NCT00744627	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	generalized anxiety disorder	VORTIOXETINE	targetBased	3	Completed	01/09/2008	https://clinicaltrials.gov/study/NCT00744627	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	generalized anxiety disorder	VORTIOXETINE	targetBased	3	Completed	01/06/2008	https://clinicaltrials.gov/study/NCT00730691	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	generalized anxiety disorder	VORTIOXETINE	targetBased	3	Completed	01/06/2008	https://clinicaltrials.gov/study/NCT00730691	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	generalized anxiety disorder	VORTIOXETINE	targetBased	3	Completed	01/06/2008	https://clinicaltrials.gov/study/NCT00731120	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	generalized anxiety disorder	VORTIOXETINE	targetBased	3	Completed	01/06/2008	https://clinicaltrials.gov/study/NCT00731120	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	generalized anxiety disorder	VORTIOXETINE	targetBased	3	Completed	01/06/2008	https://clinicaltrials.gov/study/NCT00734071	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	generalized anxiety disorder	VORTIOXETINE	targetBased	3	Completed	01/06/2008	https://clinicaltrials.gov/study/NCT00734071	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	psychosis	VERALIPRIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AL06	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	psychosis	VERALIPRIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AL06	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	psychosis	VERALIPRIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AL06	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	psychosis	VERALIPRIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AL06	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	VERALIPRIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AL06	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	VERALIPRIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AL06	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	schizophrenia	SAMIDORPHAN L-MALATE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213378s000lbl.pdf	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	schizophrenia	SAMIDORPHAN L-MALATE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213378s000lbl.pdf	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	bipolar I disorder	SAMIDORPHAN L-MALATE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213378s000lbl.pdf	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	bipolar I disorder	SAMIDORPHAN L-MALATE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213378s000lbl.pdf	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	bipolar I disorder	SAMIDORPHAN L-MALATE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213378s000lbl.pdf	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	schizophrenia	SAMIDORPHAN L-MALATE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213378s000lbl.pdf	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Sleep Disorder	BREXPIPRAZOLE	targetBased	3	Completed	01/09/2013	https://clinicaltrials.gov/study/NCT01942733	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	major depressive disorder	BREXPIPRAZOLE	targetBased	4	Completed	01/04/2021	https://clinicaltrials.gov/study/NCT04830215	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	major depressive disorder	BREXPIPRAZOLE	targetBased	4	Recruiting	20/01/2023	https://clinicaltrials.gov/study/NCT05017311	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	major depressive disorder	BREXPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2d301358-6291-4ec1-bd87-37b4ad9bd850	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	major depressive disorder	BREXPIPRAZOLE	targetBased	3	Completed	04/10/2018	https://clinicaltrials.gov/study/NCT03737474	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	major depressive disorder	BREXPIPRAZOLE	targetBased	3	Completed	01/07/2014	https://clinicaltrials.gov/study/NCT02196506	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	major depressive disorder	BREXPIPRAZOLE	targetBased	3	Withdrawn	01/09/2014	https://clinicaltrials.gov/study/NCT02212613	0.7	LoF	protect	Low enrollment
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	major depressive disorder	BREXPIPRAZOLE	targetBased	4	Withdrawn	29/08/2022	https://clinicaltrials.gov/study/NCT05504486	1	LoF	protect	Sponsor strategic decision
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	major depressive disorder	BREXPIPRAZOLE	targetBased	3	Completed	13/07/2018	https://clinicaltrials.gov/study/NCT03538691	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	post-traumatic stress disorder	BREXPIPRAZOLE	targetBased	3	Terminated	01/12/2013	https://clinicaltrials.gov/study/NCT01987960	0.7	LoF	protect	The study was terminated due to challenges with patient eligibility; the decision to terminate was not based on any safety concerns
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	post-traumatic stress disorder	BREXPIPRAZOLE	targetBased	3	Completed	30/10/2019	https://clinicaltrials.gov/study/NCT04174170	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	post-traumatic stress disorder	BREXPIPRAZOLE	targetBased	3	Completed	17/10/2019	https://clinicaltrials.gov/study/NCT04124614	0.7	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	mental or behavioural disorder	BREXPIPRAZOLE	targetBased	3	Completed	01/07/2014	https://clinicaltrials.gov/study/NCT02196506	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	mental or behavioural disorder	BREXPIPRAZOLE	targetBased	3	Completed	01/07/2014	https://clinicaltrials.gov/study/NCT02196506	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	mental or behavioural disorder	BREXPIPRAZOLE	targetBased	3	Completed	01/06/2011	https://clinicaltrials.gov/study/NCT01360632	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	mental or behavioural disorder	BREXPIPRAZOLE	targetBased	3	Completed	01/06/2011	https://clinicaltrials.gov/study/NCT01360632	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	unipolar depression	BREXPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2d301358-6291-4ec1-bd87-37b4ad9bd850	1	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	bipolar disorder	BREXPIPRAZOLE	targetBased	3	Recruiting	10/05/2021	https://clinicaltrials.gov/study/NCT04569448	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	bipolar disorder	BREXPIPRAZOLE	targetBased	3	Recruiting	10/05/2021	https://clinicaltrials.gov/study/NCT04569448	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	bipolar disorder	BREXPIPRAZOLE	targetBased	4	Completed	01/03/2017	https://clinicaltrials.gov/study/NCT03427892	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	bipolar disorder	BREXPIPRAZOLE	targetBased	4	Completed	01/03/2017	https://clinicaltrials.gov/study/NCT03427892	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	BREXPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2d301358-6291-4ec1-bd87-37b4ad9bd850	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	BREXPIPRAZOLE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/rxulti	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	BREXPIPRAZOLE	targetBased	3	Active, not recruiting	23/08/2017	https://clinicaltrials.gov/study/NCT03238326	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	BREXPIPRAZOLE	targetBased	3	Withdrawn	01/06/2016	https://clinicaltrials.gov/study/NCT02758067	0.7	LoF	protect	This study was withdrawn for administrative reasons. There were no safety concerns.
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	BREXPIPRAZOLE	targetBased	3	Completed	01/07/2011	https://clinicaltrials.gov/study/NCT01396421	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	BREXPIPRAZOLE	targetBased	3	Recruiting	31/05/2022	https://clinicaltrials.gov/study/NCT05326347	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	BREXPIPRAZOLE	targetBased	3	Completed	30/06/2017	https://clinicaltrials.gov/study/NCT03198078	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	BREXPIPRAZOLE	targetBased	3	Completed	01/11/2013	https://clinicaltrials.gov/study/NCT02013622	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	BREXPIPRAZOLE	targetBased	3	Completed	01/02/2014	https://clinicaltrials.gov/study/NCT02054702	0.7	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	depressive disorder	BREXPIPRAZOLE	targetBased	3	Completed	01/03/2015	https://clinicaltrials.gov/study/NCT02400346	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	depressive disorder	BREXPIPRAZOLE	targetBased	3	Completed	01/03/2015	https://clinicaltrials.gov/study/NCT02400346	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	depressive disorder	BREXPIPRAZOLE	targetBased	3	Completed	01/07/2011	https://clinicaltrials.gov/study/NCT01360645	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	depressive disorder	BREXPIPRAZOLE	targetBased	3	Completed	01/07/2011	https://clinicaltrials.gov/study/NCT01360645	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	depressive disorder	BREXPIPRAZOLE	targetBased	4	Completed	14/09/2017	https://clinicaltrials.gov/study/NCT03149991	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	depressive disorder	BREXPIPRAZOLE	targetBased	4	Completed	14/09/2017	https://clinicaltrials.gov/study/NCT03149991	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	depressive disorder	BREXPIPRAZOLE	targetBased	3	Completed	04/10/2018	https://clinicaltrials.gov/study/NCT03737474	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	depressive disorder	BREXPIPRAZOLE	targetBased	3	Completed	04/10/2018	https://clinicaltrials.gov/study/NCT03737474	0.7	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar disorder	BREXPIPRAZOLE	targetBased	3	Recruiting	10/05/2021	https://clinicaltrials.gov/study/NCT04569448	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	bipolar disorder	BREXPIPRAZOLE	targetBased	4	Completed	01/03/2017	https://clinicaltrials.gov/study/NCT03427892	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	bipolar disorder	BREXPIPRAZOLE	targetBased	4	Completed	01/03/2017	https://clinicaltrials.gov/study/NCT03427892	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar disorder	BREXPIPRAZOLE	targetBased	4	Completed	01/03/2017	https://clinicaltrials.gov/study/NCT03427892	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar disorder	BREXPIPRAZOLE	targetBased	4	Completed	01/03/2017	https://clinicaltrials.gov/study/NCT03427892	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar disorder	BREXPIPRAZOLE	targetBased	4	Completed	01/03/2017	https://clinicaltrials.gov/study/NCT03427892	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar disorder	BREXPIPRAZOLE	targetBased	4	Completed	01/03/2017	https://clinicaltrials.gov/study/NCT03427892	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Agitation	BREXPIPRAZOLE	targetBased	3	Completed	16/05/2018	https://clinicaltrials.gov/study/NCT03548584	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Agitation	BREXPIPRAZOLE	targetBased	3	Completed	16/05/2018	https://clinicaltrials.gov/study/NCT03548584	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	mental or behavioural disorder	BREXPIPRAZOLE	targetBased	3	Completed	01/06/2011	https://clinicaltrials.gov/study/NCT01360632	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	mental or behavioural disorder	BREXPIPRAZOLE	targetBased	3	Completed	01/07/2014	https://clinicaltrials.gov/study/NCT02196506	0.7	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	post-traumatic stress disorder	BREXPIPRAZOLE	targetBased	3	Completed	30/10/2019	https://clinicaltrials.gov/study/NCT04174170	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	post-traumatic stress disorder	BREXPIPRAZOLE	targetBased	3	Completed	30/10/2019	https://clinicaltrials.gov/study/NCT04174170	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	post-traumatic stress disorder	BREXPIPRAZOLE	targetBased	3	Completed	17/10/2019	https://clinicaltrials.gov/study/NCT04124614	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	post-traumatic stress disorder	BREXPIPRAZOLE	targetBased	3	Completed	17/10/2019	https://clinicaltrials.gov/study/NCT04124614	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	post-traumatic stress disorder	BREXPIPRAZOLE	targetBased	3	Terminated	01/12/2013	https://clinicaltrials.gov/study/NCT01987960	0.7	GoF	protect	The study was terminated due to challenges with patient eligibility; the decision to terminate was not based on any safety concerns
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	post-traumatic stress disorder	BREXPIPRAZOLE	targetBased	3	Terminated	01/12/2013	https://clinicaltrials.gov/study/NCT01987960	0.7	GoF	protect	The study was terminated due to challenges with patient eligibility; the decision to terminate was not based on any safety concerns
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	major depressive disorder	BREXPIPRAZOLE	targetBased	4	Withdrawn	29/08/2022	https://clinicaltrials.gov/study/NCT05504486	1	GoF	protect	Sponsor strategic decision
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	major depressive disorder	BREXPIPRAZOLE	targetBased	4	Recruiting	20/01/2023	https://clinicaltrials.gov/study/NCT05017311	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	major depressive disorder	BREXPIPRAZOLE	targetBased	4	Recruiting	20/01/2023	https://clinicaltrials.gov/study/NCT05017311	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	major depressive disorder	BREXPIPRAZOLE	targetBased	4	Recruiting	20/01/2023	https://clinicaltrials.gov/study/NCT05017311	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	major depressive disorder	BREXPIPRAZOLE	targetBased	4	Recruiting	20/01/2023	https://clinicaltrials.gov/study/NCT05017311	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	major depressive disorder	BREXPIPRAZOLE	targetBased	4	Recruiting	20/01/2023	https://clinicaltrials.gov/study/NCT05017311	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	major depressive disorder	BREXPIPRAZOLE	targetBased	4	Recruiting	20/01/2023	https://clinicaltrials.gov/study/NCT05017311	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	post-traumatic stress disorder	BREXPIPRAZOLE	targetBased	3	Terminated	01/12/2013	https://clinicaltrials.gov/study/NCT01987960	0.7	GoF	protect	The study was terminated due to challenges with patient eligibility; the decision to terminate was not based on any safety concerns
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	post-traumatic stress disorder	BREXPIPRAZOLE	targetBased	3	Terminated	01/12/2013	https://clinicaltrials.gov/study/NCT01987960	0.7	GoF	protect	The study was terminated due to challenges with patient eligibility; the decision to terminate was not based on any safety concerns
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	post-traumatic stress disorder	BREXPIPRAZOLE	targetBased	3	Terminated	01/12/2013	https://clinicaltrials.gov/study/NCT01987960	0.7	GoF	protect	The study was terminated due to challenges with patient eligibility; the decision to terminate was not based on any safety concerns
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	post-traumatic stress disorder	BREXPIPRAZOLE	targetBased	3	Terminated	01/12/2013	https://clinicaltrials.gov/study/NCT01987960	0.7	GoF	protect	The study was terminated due to challenges with patient eligibility; the decision to terminate was not based on any safety concerns
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	post-traumatic stress disorder	BREXPIPRAZOLE	targetBased	3	Completed	30/10/2019	https://clinicaltrials.gov/study/NCT04174170	0.7	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	post-traumatic stress disorder	BREXPIPRAZOLE	targetBased	3	Completed	30/10/2019	https://clinicaltrials.gov/study/NCT04174170	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	post-traumatic stress disorder	BREXPIPRAZOLE	targetBased	3	Completed	30/10/2019	https://clinicaltrials.gov/study/NCT04174170	0.7	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	post-traumatic stress disorder	BREXPIPRAZOLE	targetBased	3	Completed	30/10/2019	https://clinicaltrials.gov/study/NCT04174170	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	post-traumatic stress disorder	BREXPIPRAZOLE	targetBased	3	Completed	30/10/2019	https://clinicaltrials.gov/study/NCT04174170	0.7	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	post-traumatic stress disorder	BREXPIPRAZOLE	targetBased	3	Completed	30/10/2019	https://clinicaltrials.gov/study/NCT04174170	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	depressive disorder	BREXPIPRAZOLE	targetBased	4	Completed	14/09/2017	https://clinicaltrials.gov/study/NCT03149991	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	depressive disorder	BREXPIPRAZOLE	targetBased	4	Completed	14/09/2017	https://clinicaltrials.gov/study/NCT03149991	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	depressive disorder	BREXPIPRAZOLE	targetBased	4	Completed	14/09/2017	https://clinicaltrials.gov/study/NCT03149991	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	depressive disorder	BREXPIPRAZOLE	targetBased	4	Completed	14/09/2017	https://clinicaltrials.gov/study/NCT03149991	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	depressive disorder	BREXPIPRAZOLE	targetBased	4	Completed	14/09/2017	https://clinicaltrials.gov/study/NCT03149991	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	depressive disorder	BREXPIPRAZOLE	targetBased	4	Completed	14/09/2017	https://clinicaltrials.gov/study/NCT03149991	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	depressive disorder	BREXPIPRAZOLE	targetBased	3	Completed	01/03/2015	https://clinicaltrials.gov/study/NCT02400346	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	major depressive disorder	BREXPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2d301358-6291-4ec1-bd87-37b4ad9bd850	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	major depressive disorder	BREXPIPRAZOLE	targetBased	4	Recruiting	20/01/2023	https://clinicaltrials.gov/study/NCT05017311	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	major depressive disorder	BREXPIPRAZOLE	targetBased	4	Recruiting	20/01/2023	https://clinicaltrials.gov/study/NCT05017311	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	major depressive disorder	BREXPIPRAZOLE	targetBased	4	Completed	01/04/2021	https://clinicaltrials.gov/study/NCT04830215	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	major depressive disorder	BREXPIPRAZOLE	targetBased	4	Completed	01/04/2021	https://clinicaltrials.gov/study/NCT04830215	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	major depressive disorder	BREXPIPRAZOLE	targetBased	4	Withdrawn	29/08/2022	https://clinicaltrials.gov/study/NCT05504486	1	GoF	protect	Sponsor strategic decision
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	major depressive disorder	BREXPIPRAZOLE	targetBased	4	Withdrawn	29/08/2022	https://clinicaltrials.gov/study/NCT05504486	1	GoF	protect	Sponsor strategic decision
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	unipolar depression	BREXPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2d301358-6291-4ec1-bd87-37b4ad9bd850	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	unipolar depression	BREXPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2d301358-6291-4ec1-bd87-37b4ad9bd850	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	unipolar depression	BREXPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2d301358-6291-4ec1-bd87-37b4ad9bd850	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	unipolar depression	BREXPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2d301358-6291-4ec1-bd87-37b4ad9bd850	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	unipolar depression	BREXPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2d301358-6291-4ec1-bd87-37b4ad9bd850	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	unipolar depression	BREXPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2d301358-6291-4ec1-bd87-37b4ad9bd850	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Sleep Disorder	BREXPIPRAZOLE	targetBased	3	Completed	01/09/2013	https://clinicaltrials.gov/study/NCT01942733	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Sleep Disorder	BREXPIPRAZOLE	targetBased	3	Completed	01/09/2013	https://clinicaltrials.gov/study/NCT01942733	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Agitation	BREXPIPRAZOLE	targetBased	3	Completed	16/05/2018	https://clinicaltrials.gov/study/NCT03548584	0.7	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Agitation	BREXPIPRAZOLE	targetBased	3	Completed	16/05/2018	https://clinicaltrials.gov/study/NCT03548584	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Agitation	BREXPIPRAZOLE	targetBased	3	Completed	16/05/2018	https://clinicaltrials.gov/study/NCT03548584	0.7	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Agitation	BREXPIPRAZOLE	targetBased	3	Completed	16/05/2018	https://clinicaltrials.gov/study/NCT03548584	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Agitation	BREXPIPRAZOLE	targetBased	3	Completed	16/05/2018	https://clinicaltrials.gov/study/NCT03548584	0.7	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Agitation	BREXPIPRAZOLE	targetBased	3	Completed	16/05/2018	https://clinicaltrials.gov/study/NCT03548584	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar I disorder	BREXPIPRAZOLE	targetBased	3	Completed	14/09/2017	https://clinicaltrials.gov/study/NCT03259555	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar I disorder	BREXPIPRAZOLE	targetBased	3	Completed	19/09/2017	https://clinicaltrials.gov/study/NCT03257865	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar I disorder	BREXPIPRAZOLE	targetBased	3	Completed	24/10/2017	https://clinicaltrials.gov/study/NCT03287869	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	BREXPIPRAZOLE	targetBased	3	Recruiting	10/05/2021	https://clinicaltrials.gov/study/NCT04569448	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	BREXPIPRAZOLE	targetBased	4	Completed	01/03/2017	https://clinicaltrials.gov/study/NCT03427892	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	mental or behavioural disorder	BREXPIPRAZOLE	targetBased	3	Completed	01/07/2014	https://clinicaltrials.gov/study/NCT02196506	0.7	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	mental or behavioural disorder	BREXPIPRAZOLE	targetBased	3	Completed	01/07/2014	https://clinicaltrials.gov/study/NCT02196506	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	BREXPIPRAZOLE	targetBased	3	Completed	01/07/2014	https://clinicaltrials.gov/study/NCT02196506	0.7	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	BREXPIPRAZOLE	targetBased	3	Completed	01/07/2014	https://clinicaltrials.gov/study/NCT02196506	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	BREXPIPRAZOLE	targetBased	3	Completed	01/06/2011	https://clinicaltrials.gov/study/NCT01360632	0.7	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	BREXPIPRAZOLE	targetBased	3	Completed	01/06/2011	https://clinicaltrials.gov/study/NCT01360632	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	mental or behavioural disorder	BREXPIPRAZOLE	targetBased	3	Completed	01/06/2011	https://clinicaltrials.gov/study/NCT01360632	0.7	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	mental or behavioural disorder	BREXPIPRAZOLE	targetBased	3	Completed	01/06/2011	https://clinicaltrials.gov/study/NCT01360632	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	BREXPIPRAZOLE	targetBased	3	Completed	01/06/2011	https://clinicaltrials.gov/study/NCT01360632	0.7	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	BREXPIPRAZOLE	targetBased	3	Completed	01/06/2011	https://clinicaltrials.gov/study/NCT01360632	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	psychosis	BREXPIPRAZOLE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AX16	1	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	unipolar depression	BREXPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2d301358-6291-4ec1-bd87-37b4ad9bd850	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	unipolar depression	BREXPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2d301358-6291-4ec1-bd87-37b4ad9bd850	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	depressive disorder	BREXPIPRAZOLE	targetBased	3	Completed	01/03/2015	https://clinicaltrials.gov/study/NCT02400346	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	depressive disorder	BREXPIPRAZOLE	targetBased	4	Completed	14/09/2017	https://clinicaltrials.gov/study/NCT03149991	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	depressive disorder	BREXPIPRAZOLE	targetBased	3	Completed	01/07/2011	https://clinicaltrials.gov/study/NCT01360645	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	depressive disorder	BREXPIPRAZOLE	targetBased	3	Completed	04/10/2018	https://clinicaltrials.gov/study/NCT03737474	0.7	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	psychosis	BREXPIPRAZOLE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AX16	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	psychosis	BREXPIPRAZOLE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AX16	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	psychosis	BREXPIPRAZOLE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AX16	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	psychosis	BREXPIPRAZOLE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AX16	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	psychosis	BREXPIPRAZOLE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AX16	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	psychosis	BREXPIPRAZOLE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AX16	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	BREXPIPRAZOLE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AX16	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	BREXPIPRAZOLE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AX16	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	schizophrenia	BREXPIPRAZOLE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/rxulti	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	schizophrenia	BREXPIPRAZOLE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/rxulti	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	schizophrenia	BREXPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2d301358-6291-4ec1-bd87-37b4ad9bd850	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	schizophrenia	BREXPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2d301358-6291-4ec1-bd87-37b4ad9bd850	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	schizophrenia	BREXPIPRAZOLE	targetBased	3	Completed	27/11/2019	https://clinicaltrials.gov/study/NCT03874494	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	schizophrenia	BREXPIPRAZOLE	targetBased	3	Completed	27/11/2019	https://clinicaltrials.gov/study/NCT03874494	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	schizophrenia	BREXPIPRAZOLE	targetBased	3	Completed	01/09/2011	https://clinicaltrials.gov/study/NCT01397786	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	schizophrenia	BREXPIPRAZOLE	targetBased	3	Completed	01/09/2011	https://clinicaltrials.gov/study/NCT01397786	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar I disorder	BREXPIPRAZOLE	targetBased	3	Completed	24/10/2017	https://clinicaltrials.gov/study/NCT03287869	0.7	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar I disorder	BREXPIPRAZOLE	targetBased	3	Completed	24/10/2017	https://clinicaltrials.gov/study/NCT03287869	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar I disorder	BREXPIPRAZOLE	targetBased	3	Completed	24/10/2017	https://clinicaltrials.gov/study/NCT03287869	0.7	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar I disorder	BREXPIPRAZOLE	targetBased	3	Completed	24/10/2017	https://clinicaltrials.gov/study/NCT03287869	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	bipolar I disorder	BREXPIPRAZOLE	targetBased	3	Completed	19/09/2017	https://clinicaltrials.gov/study/NCT03257865	0.7	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	bipolar I disorder	BREXPIPRAZOLE	targetBased	3	Completed	19/09/2017	https://clinicaltrials.gov/study/NCT03257865	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar I disorder	BREXPIPRAZOLE	targetBased	3	Completed	19/09/2017	https://clinicaltrials.gov/study/NCT03257865	0.7	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar I disorder	BREXPIPRAZOLE	targetBased	3	Completed	19/09/2017	https://clinicaltrials.gov/study/NCT03257865	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar I disorder	BREXPIPRAZOLE	targetBased	3	Completed	19/09/2017	https://clinicaltrials.gov/study/NCT03257865	0.7	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar I disorder	BREXPIPRAZOLE	targetBased	3	Completed	19/09/2017	https://clinicaltrials.gov/study/NCT03257865	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Agitation	BREXPIPRAZOLE	targetBased	3	Completed	16/05/2018	https://clinicaltrials.gov/study/NCT03548584	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	BREXPIPRAZOLE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2d301358-6291-4ec1-bd87-37b4ad9bd850	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	BREXPIPRAZOLE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/rxulti	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	BREXPIPRAZOLE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/rxulti	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	BREXPIPRAZOLE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/rxulti	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	BREXPIPRAZOLE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/rxulti	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	BREXPIPRAZOLE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/rxulti	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	BREXPIPRAZOLE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/rxulti	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Sleep Disorder	BREXPIPRAZOLE	targetBased	3	Completed	01/09/2013	https://clinicaltrials.gov/study/NCT01942733	0.7	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Sleep Disorder	BREXPIPRAZOLE	targetBased	3	Completed	01/09/2013	https://clinicaltrials.gov/study/NCT01942733	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Sleep Disorder	BREXPIPRAZOLE	targetBased	3	Completed	01/09/2013	https://clinicaltrials.gov/study/NCT01942733	0.7	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Sleep Disorder	BREXPIPRAZOLE	targetBased	3	Completed	01/09/2013	https://clinicaltrials.gov/study/NCT01942733	0.7	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Sleep Disorder	BREXPIPRAZOLE	targetBased	3	Completed	01/09/2013	https://clinicaltrials.gov/study/NCT01942733	0.7	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Sleep Disorder	BREXPIPRAZOLE	targetBased	3	Completed	01/09/2013	https://clinicaltrials.gov/study/NCT01942733	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	bipolar I disorder	BREXPIPRAZOLE	targetBased	3	Completed	14/09/2017	https://clinicaltrials.gov/study/NCT03259555	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	bipolar I disorder	BREXPIPRAZOLE	targetBased	3	Completed	14/09/2017	https://clinicaltrials.gov/study/NCT03259555	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	bipolar I disorder	BREXPIPRAZOLE	targetBased	3	Completed	19/09/2017	https://clinicaltrials.gov/study/NCT03257865	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	bipolar I disorder	BREXPIPRAZOLE	targetBased	3	Completed	19/09/2017	https://clinicaltrials.gov/study/NCT03257865	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	bipolar I disorder	BREXPIPRAZOLE	targetBased	3	Completed	24/10/2017	https://clinicaltrials.gov/study/NCT03287869	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	bipolar I disorder	BREXPIPRAZOLE	targetBased	3	Completed	24/10/2017	https://clinicaltrials.gov/study/NCT03287869	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	insomnia	ESMIRTAZAPINE MALEATE	targetBased	3	Completed	07/12/2006	https://clinicaltrials.gov/study/NCT00610675	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	PALIPERIDONE PALMITATE	targetBased	4	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02146547	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	PALIPERIDONE PALMITATE	targetBased	4	Completed	01/10/2011	https://clinicaltrials.gov/study/NCT01451736	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	PALIPERIDONE PALMITATE	targetBased	4	Not yet recruiting	01/08/2012	https://clinicaltrials.gov/study/NCT01458379	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	PALIPERIDONE PALMITATE	targetBased	4	Unknown status	01/04/2017	https://clinicaltrials.gov/study/NCT03080194	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	PALIPERIDONE PALMITATE	targetBased	4	Withdrawn	01/08/2010	https://clinicaltrials.gov/study/NCT01193166	1	LoF	protect	This study was stopped due to an internal reconsideration of priorities of the product portfolio.
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	PALIPERIDONE PALMITATE	targetBased	4	Completed	18/10/2018	https://clinicaltrials.gov/study/NCT03713658	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	PALIPERIDONE PALMITATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c39e65d7-fa44-4e4c-8b12-a654d3ed0eae	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	bipolar disorder	PALIPERIDONE PALMITATE	targetBased	4	Withdrawn	01/10/2010	https://clinicaltrials.gov/study/NCT01211704	1	LoF	protect	lack of funding
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	bipolar disorder	PALIPERIDONE PALMITATE	targetBased	4	Withdrawn	01/10/2010	https://clinicaltrials.gov/study/NCT01211704	1	LoF	protect	lack of funding
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar disorder	PALIPERIDONE PALMITATE	targetBased	4	Withdrawn	01/10/2010	https://clinicaltrials.gov/study/NCT01211704	1	LoF	protect	lack of funding
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar disorder	PALIPERIDONE PALMITATE	targetBased	4	Withdrawn	01/10/2010	https://clinicaltrials.gov/study/NCT01211704	1	LoF	protect	lack of funding
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar disorder	PALIPERIDONE PALMITATE	targetBased	4	Withdrawn	01/10/2010	https://clinicaltrials.gov/study/NCT01211704	1	LoF	protect	lack of funding
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar disorder	PALIPERIDONE PALMITATE	targetBased	4	Withdrawn	01/10/2010	https://clinicaltrials.gov/study/NCT01211704	1	LoF	protect	lack of funding
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizoaffective disorder	PALIPERIDONE PALMITATE	targetBased	4	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01136772	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizoaffective disorder	PALIPERIDONE PALMITATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1af14e42-951d-414d-8564-5d5fce138554	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizoaffective disorder	PALIPERIDONE PALMITATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1af14e42-951d-414d-8564-5d5fce138554	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizoaffective disorder	PALIPERIDONE PALMITATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1af14e42-951d-414d-8564-5d5fce138554	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizoaffective disorder	PALIPERIDONE PALMITATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1af14e42-951d-414d-8564-5d5fce138554	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizoaffective disorder	PALIPERIDONE PALMITATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1af14e42-951d-414d-8564-5d5fce138554	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizoaffective disorder	PALIPERIDONE PALMITATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1af14e42-951d-414d-8564-5d5fce138554	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	PALIPERIDONE PALMITATE	targetBased	4	Withdrawn	01/10/2010	https://clinicaltrials.gov/study/NCT01211704	1	LoF	protect	lack of funding
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizoaffective disorder	PALIPERIDONE PALMITATE	targetBased	3	Completed	01/09/2010	https://clinicaltrials.gov/study/NCT01193153	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizoaffective disorder	PALIPERIDONE PALMITATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1af14e42-951d-414d-8564-5d5fce138554	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizoaffective disorder	PALIPERIDONE PALMITATE	targetBased	4	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01136772	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	PALIPERIDONE PALMITATE	targetBased	4	Unknown status	01/04/2017	https://clinicaltrials.gov/study/NCT03080194	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	PALIPERIDONE PALMITATE	targetBased	4	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01685931	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	PALIPERIDONE PALMITATE	targetBased	4	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01685931	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	PALIPERIDONE PALMITATE	targetBased	4	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01685931	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	PALIPERIDONE PALMITATE	targetBased	4	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01685931	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	PALIPERIDONE PALMITATE	targetBased	4	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01685931	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	PALIPERIDONE PALMITATE	targetBased	4	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01685931	1	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	major depressive disorder	VORTIOXETINE HYDROBROMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1a5b68e2-14d0-419d-9ec6-1ca97145e838	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	major depressive disorder	VORTIOXETINE HYDROBROMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1a5b68e2-14d0-419d-9ec6-1ca97145e838	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	unipolar depression	VORTIOXETINE HYDROBROMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4b0700c9-b417-4c3a-b36f-de461e125bd3	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	unipolar depression	VORTIOXETINE HYDROBROMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4b0700c9-b417-4c3a-b36f-de461e125bd3	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	major depressive disorder	PIMAVANSERIN	targetBased	3	Terminated	06/06/2019	https://clinicaltrials.gov/study/NCT04000009	0.7	LoF	protect	The study was terminated for business reasons and not due to safety concerns.
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	major depressive disorder	PIMAVANSERIN	targetBased	3	Completed	25/04/2019	https://clinicaltrials.gov/study/NCT03968159	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	major depressive disorder	PIMAVANSERIN	targetBased	3	Completed	08/07/2019	https://clinicaltrials.gov/study/NCT03999918	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	PIMAVANSERIN	targetBased	3	Active, not recruiting	01/01/2017	https://clinicaltrials.gov/study/NCT03121586	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	PIMAVANSERIN	targetBased	3	Completed	26/10/2016	https://clinicaltrials.gov/study/NCT02970292	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	PIMAVANSERIN	targetBased	3	Active, not recruiting	05/08/2020	https://clinicaltrials.gov/study/NCT04531982	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Hallucinations	PIMAVANSERIN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1e6bea44-57d6-4bac-9328-46e1ee59f83b	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	psychosis	PIMAVANSERIN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1e6bea44-57d6-4bac-9328-46e1ee59f83b	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	psychosis	PIMAVANSERIN	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AX17	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	NALOXEGOL OXALATE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/moventig	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	NALOXEGOL OXALATE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/moventig	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	NALOXEGOL	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/moventig	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	NALOXEGOL	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/moventig	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	ARIPIPRAZOLE LAUROXIL	targetBased	3	Completed	15/11/2017	https://clinicaltrials.gov/study/NCT03345979	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	ARIPIPRAZOLE LAUROXIL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=17a8d11b-73b0-4833-a0b4-cf1ef85edefb	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	ARIPIPRAZOLE LAUROXIL	targetBased	3	Completed	01/06/2012	https://clinicaltrials.gov/study/NCT01626456	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	ARIPIPRAZOLE LAUROXIL	targetBased	4	Completed	01/12/2015	https://clinicaltrials.gov/study/NCT02634320	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	ARIPIPRAZOLE LAUROXIL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b18fdfd9-31cd-4a2f-9f1c-ebc70d7a9403	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	ARIPIPRAZOLE LAUROXIL	targetBased	3	Completed	01/12/2011	https://clinicaltrials.gov/study/NCT01469039	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	ARIPIPRAZOLE LAUROXIL	targetBased	4	Recruiting	23/01/2024	https://clinicaltrials.gov/study/NCT05662306	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	ARIPIPRAZOLE LAUROXIL	targetBased	3	Completed	01/07/2013	https://clinicaltrials.gov/study/NCT01895452	0.7	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	schizophrenia	ARIPIPRAZOLE LAUROXIL	targetBased	4	Completed	01/12/2015	https://clinicaltrials.gov/study/NCT02634320	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	schizophrenia	ARIPIPRAZOLE LAUROXIL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b18fdfd9-31cd-4a2f-9f1c-ebc70d7a9403	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	schizophrenia	ARIPIPRAZOLE LAUROXIL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b18fdfd9-31cd-4a2f-9f1c-ebc70d7a9403	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	schizophrenia	ARIPIPRAZOLE LAUROXIL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=17a8d11b-73b0-4833-a0b4-cf1ef85edefb	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	schizophrenia	ARIPIPRAZOLE LAUROXIL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=17a8d11b-73b0-4833-a0b4-cf1ef85edefb	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	schizophrenia	ARIPIPRAZOLE LAUROXIL	targetBased	4	Recruiting	23/01/2024	https://clinicaltrials.gov/study/NCT05662306	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	schizophrenia	ARIPIPRAZOLE LAUROXIL	targetBased	4	Recruiting	23/01/2024	https://clinicaltrials.gov/study/NCT05662306	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	ARIPIPRAZOLE LAUROXIL	targetBased	4	Recruiting	23/01/2024	https://clinicaltrials.gov/study/NCT05662306	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	ARIPIPRAZOLE LAUROXIL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b18fdfd9-31cd-4a2f-9f1c-ebc70d7a9403	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	ARIPIPRAZOLE LAUROXIL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b18fdfd9-31cd-4a2f-9f1c-ebc70d7a9403	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	ARIPIPRAZOLE LAUROXIL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b18fdfd9-31cd-4a2f-9f1c-ebc70d7a9403	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	ARIPIPRAZOLE LAUROXIL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b18fdfd9-31cd-4a2f-9f1c-ebc70d7a9403	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	ARIPIPRAZOLE LAUROXIL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b18fdfd9-31cd-4a2f-9f1c-ebc70d7a9403	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	ARIPIPRAZOLE LAUROXIL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b18fdfd9-31cd-4a2f-9f1c-ebc70d7a9403	1	GoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		depressive disorder	ESKETAMINE HYDROCHLORIDE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/spravato	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		unipolar depression	ESKETAMINE HYDROCHLORIDE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211243lbl.pdf	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		major depressive disorder	ESKETAMINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d81a6a79-a74a-44b7-822c-0dfa3036eaed	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	opioid dependence	BUPRENORPHINE HYDROCHLORIDE	targetBased	3	Completed	01/07/2014	https://clinicaltrials.gov/study/NCT02180659	0.7	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	opioid dependence	BUPRENORPHINE HYDROCHLORIDE	targetBased	4	Completed	22/02/2008	https://clinicaltrials.gov/study/NCT00604188	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	opioid dependence	BUPRENORPHINE HYDROCHLORIDE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/sixmo	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	opioid dependence	BUPRENORPHINE HYDROCHLORIDE	targetBased	4	Completed	01/03/2008	https://clinicaltrials.gov/study/NCT00605033	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	BUPRENORPHINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b086772e-d15a-4d13-b1a2-38bfbde1f18c	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	BUPRENORPHINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b086772e-d15a-4d13-b1a2-38bfbde1f18c	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	drug dependence	BUPRENORPHINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b086772e-d15a-4d13-b1a2-38bfbde1f18c	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	BUPRENORPHINE HYDROCHLORIDE	targetBased	4	Completed	01/03/2008	https://clinicaltrials.gov/study/NCT00605033	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	BUPRENORPHINE HYDROCHLORIDE	targetBased	4	Completed	01/03/2008	https://clinicaltrials.gov/study/NCT00605033	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	BUPRENORPHINE HYDROCHLORIDE	targetBased	3	Completed	01/07/2014	https://clinicaltrials.gov/study/NCT02180659	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	BUPRENORPHINE HYDROCHLORIDE	targetBased	4	Completed	22/02/2008	https://clinicaltrials.gov/study/NCT00604188	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	BUPRENORPHINE HYDROCHLORIDE	targetBased	4	Completed	22/02/2008	https://clinicaltrials.gov/study/NCT00604188	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	BUPRENORPHINE HYDROCHLORIDE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/sixmo	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	BUPRENORPHINE HYDROCHLORIDE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/sixmo	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain agnosia	OLICERIDINE	targetBased	4	Not yet recruiting	06/06/2024	https://clinicaltrials.gov/study/NCT06458400	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pain agnosia	OLICERIDINE	targetBased	4	Not yet recruiting	06/06/2024	https://clinicaltrials.gov/study/NCT06458400	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Hallucinations	PIMAVANSERIN TARTRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1e6bea44-57d6-4bac-9328-46e1ee59f83b	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	psychosis	PIMAVANSERIN TARTRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1e6bea44-57d6-4bac-9328-46e1ee59f83b	1	LoF	protect
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Dementia	ADUCANUMAB	pathwayBased	4			https://www.whocc.no/atc_ddd_index/?code=N06DX03	1		protect
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	APP	Amyloid-beta A4 protein, Amyloid-beta precursor protein	Dementia	ADUCANUMAB	pathwayBased	4			https://www.whocc.no/atc_ddd_index/?code=N06DX03	1		protect
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	APP	Amyloid-beta precursor protein	Dementia	ADUCANUMAB	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N06DX03	1		protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	major depressive disorder	ASENAPINE	targetBased	4	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT01670019	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	post-traumatic stress disorder	ASENAPINE	targetBased	4	Completed	01/06/2012	https://clinicaltrials.gov/study/NCT01587118	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	ASENAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5429f134-839f-4ffc-9944-55f51238def8	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	ASENAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03c696e9-0e6b-4e5c-be0a-41416f8019be	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	ASENAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=86a40942-8d6b-478c-995f-3c346b197463	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	ASENAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=685eaf44-5944-4f38-afba-0a4fc0b3462b	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	ASENAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=17209c32-56eb-4f84-954d-aed7b7a1b18d	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	ASENAPINE	targetBased	4	Unknown status	01/10/2013	https://clinicaltrials.gov/study/NCT01968161	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	ASENAPINE	targetBased	4	Completed	01/04/2012	https://clinicaltrials.gov/study/NCT01549041	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar disorder	ASENAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5429f134-839f-4ffc-9944-55f51238def8	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	bipolar disorder	ASENAPINE	targetBased	4	Completed	01/10/2011	https://clinicaltrials.gov/study/NCT01460290	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	bipolar disorder	ASENAPINE	targetBased	4	Completed	01/10/2011	https://clinicaltrials.gov/study/NCT01460290	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar disorder	ASENAPINE	targetBased	4	Completed	01/10/2011	https://clinicaltrials.gov/study/NCT01460290	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar disorder	ASENAPINE	targetBased	4	Completed	01/10/2011	https://clinicaltrials.gov/study/NCT01460290	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar disorder	ASENAPINE	targetBased	4	Completed	01/10/2011	https://clinicaltrials.gov/study/NCT01460290	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar disorder	ASENAPINE	targetBased	4	Completed	01/10/2011	https://clinicaltrials.gov/study/NCT01460290	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	mental or behavioural disorder	ASENAPINE	targetBased	4	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT00806234	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	major depressive disorder	ASENAPINE	targetBased	4	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT01670019	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	major depressive disorder	ASENAPINE	targetBased	4	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT01670019	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	major depressive disorder	ASENAPINE	targetBased	4	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT01670019	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	major depressive disorder	ASENAPINE	targetBased	4	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT01670019	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	major depressive disorder	ASENAPINE	targetBased	4	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT01670019	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	major depressive disorder	ASENAPINE	targetBased	4	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT01670019	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	post-traumatic stress disorder	ASENAPINE	targetBased	4	Completed	01/06/2012	https://clinicaltrials.gov/study/NCT01587118	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	post-traumatic stress disorder	ASENAPINE	targetBased	4	Completed	01/06/2012	https://clinicaltrials.gov/study/NCT01587118	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	post-traumatic stress disorder	ASENAPINE	targetBased	4	Completed	01/06/2012	https://clinicaltrials.gov/study/NCT01587118	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	post-traumatic stress disorder	ASENAPINE	targetBased	4	Completed	01/06/2012	https://clinicaltrials.gov/study/NCT01587118	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	post-traumatic stress disorder	ASENAPINE	targetBased	4	Completed	01/06/2012	https://clinicaltrials.gov/study/NCT01587118	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	post-traumatic stress disorder	ASENAPINE	targetBased	4	Completed	01/06/2012	https://clinicaltrials.gov/study/NCT01587118	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Agitation	ASENAPINE	targetBased	4	Completed	01/04/2012	https://clinicaltrials.gov/study/NCT01400113	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Agitation	ASENAPINE	targetBased	4	Completed	01/04/2012	https://clinicaltrials.gov/study/NCT01400113	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Agitation	ASENAPINE	targetBased	4	Completed	01/04/2012	https://clinicaltrials.gov/study/NCT01400113	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Agitation	ASENAPINE	targetBased	4	Completed	01/04/2012	https://clinicaltrials.gov/study/NCT01400113	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Agitation	ASENAPINE	targetBased	4	Completed	01/04/2012	https://clinicaltrials.gov/study/NCT01400113	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Agitation	ASENAPINE	targetBased	4	Completed	01/04/2012	https://clinicaltrials.gov/study/NCT01400113	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizoaffective disorder	ASENAPINE	targetBased	3	Completed	04/09/2003	https://clinicaltrials.gov/study/NCT00212784	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizoaffective disorder	ASENAPINE	targetBased	3	Completed	04/09/2003	https://clinicaltrials.gov/study/NCT00212784	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizoaffective disorder	ASENAPINE	targetBased	3	Completed	04/09/2003	https://clinicaltrials.gov/study/NCT00212784	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizoaffective disorder	ASENAPINE	targetBased	3	Completed	04/09/2003	https://clinicaltrials.gov/study/NCT00212784	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizoaffective disorder	ASENAPINE	targetBased	3	Completed	01/09/2004	https://clinicaltrials.gov/study/NCT00212771	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizoaffective disorder	ASENAPINE	targetBased	3	Completed	01/09/2004	https://clinicaltrials.gov/study/NCT00212771	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizoaffective disorder	ASENAPINE	targetBased	3	Completed	01/09/2004	https://clinicaltrials.gov/study/NCT00212771	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizoaffective disorder	ASENAPINE	targetBased	3	Completed	01/09/2004	https://clinicaltrials.gov/study/NCT00212771	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizoaffective disorder	ASENAPINE	targetBased	3	Completed	01/09/2004	https://clinicaltrials.gov/study/NCT00212771	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizoaffective disorder	ASENAPINE	targetBased	3	Completed	01/09/2004	https://clinicaltrials.gov/study/NCT00212771	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar I disorder	ASENAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=86a40942-8d6b-478c-995f-3c346b197463	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar I disorder	ASENAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5429f134-839f-4ffc-9944-55f51238def8	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar I disorder	ASENAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=16e1cc9f-7699-49ea-b179-acb65e162304	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar I disorder	ASENAPINE	targetBased	3	Completed	01/04/2012	https://clinicaltrials.gov/study/NCT01395992	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	ASENAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03c696e9-0e6b-4e5c-be0a-41416f8019be	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	ASENAPINE	targetBased	3	Completed	01/07/2005	https://clinicaltrials.gov/study/NCT00159783	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	ASENAPINE	targetBased	3	Completed	14/12/2004	https://clinicaltrials.gov/study/NCT00159796	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	ASENAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5429f134-839f-4ffc-9944-55f51238def8	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	ASENAPINE	targetBased	3	Completed	06/04/2012	https://clinicaltrials.gov/study/NCT00764478	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	ASENAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=17209c32-56eb-4f84-954d-aed7b7a1b18d	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	ASENAPINE	targetBased	4	Completed	01/10/2011	https://clinicaltrials.gov/study/NCT01460290	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	ASENAPINE	targetBased	3	Completed	16/06/2011	https://clinicaltrials.gov/study/NCT01244815	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	ASENAPINE	targetBased	4	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT00806234	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	ASENAPINE	targetBased	4	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT00806234	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	mental or behavioural disorder	ASENAPINE	targetBased	4	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT00806234	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	mental or behavioural disorder	ASENAPINE	targetBased	4	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT00806234	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	ASENAPINE	targetBased	4	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT00806234	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	ASENAPINE	targetBased	4	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT00806234	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	psychosis	ASENAPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AH05	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	psychosis	ASENAPINE	targetBased	3	Completed	01/02/2006	https://clinicaltrials.gov/study/NCT00281320	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizoaffective disorder	ASENAPINE	targetBased	3	Completed	04/09/2003	https://clinicaltrials.gov/study/NCT00212784	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizoaffective disorder	ASENAPINE	targetBased	3	Completed	01/09/2004	https://clinicaltrials.gov/study/NCT00212771	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	ASENAPINE	targetBased	3	Completed	01/02/2006	https://clinicaltrials.gov/study/NCT00281320	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	psychosis	ASENAPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AH05	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	psychosis	ASENAPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AH05	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	psychosis	ASENAPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AH05	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	psychosis	ASENAPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AH05	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	ASENAPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AH05	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	ASENAPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AH05	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar I disorder	ASENAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=86a40942-8d6b-478c-995f-3c346b197463	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	bipolar I disorder	ASENAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=16e1cc9f-7699-49ea-b179-acb65e162304	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	bipolar I disorder	ASENAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=16e1cc9f-7699-49ea-b179-acb65e162304	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar I disorder	ASENAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=16e1cc9f-7699-49ea-b179-acb65e162304	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar I disorder	ASENAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=16e1cc9f-7699-49ea-b179-acb65e162304	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar I disorder	ASENAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=16e1cc9f-7699-49ea-b179-acb65e162304	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar I disorder	ASENAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=16e1cc9f-7699-49ea-b179-acb65e162304	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Agitation	ASENAPINE	targetBased	4	Completed	01/04/2012	https://clinicaltrials.gov/study/NCT01400113	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	ASENAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=86a40942-8d6b-478c-995f-3c346b197463	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	ASENAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03c696e9-0e6b-4e5c-be0a-41416f8019be	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	ASENAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03c696e9-0e6b-4e5c-be0a-41416f8019be	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	ASENAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03c696e9-0e6b-4e5c-be0a-41416f8019be	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	ASENAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03c696e9-0e6b-4e5c-be0a-41416f8019be	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	ASENAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03c696e9-0e6b-4e5c-be0a-41416f8019be	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	ASENAPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03c696e9-0e6b-4e5c-be0a-41416f8019be	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	generalized anxiety disorder	QUETIAPINE FUMARATE	targetBased	3	Completed	01/05/2006	https://clinicaltrials.gov/study/NCT00322595	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	generalized anxiety disorder	QUETIAPINE FUMARATE	targetBased	3	Completed	01/04/2006	https://clinicaltrials.gov/study/NCT00329446	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	generalized anxiety disorder	QUETIAPINE FUMARATE	targetBased	3	Completed	01/04/2006	https://clinicaltrials.gov/study/NCT00329264	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	major depressive disorder	QUETIAPINE FUMARATE	targetBased	3	Completed	01/12/2012	https://clinicaltrials.gov/study/NCT01727726	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	major depressive disorder	QUETIAPINE FUMARATE	targetBased	3	Completed	01/04/2006	https://clinicaltrials.gov/study/NCT00320268	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	major depressive disorder	QUETIAPINE FUMARATE	targetBased	3	Completed	01/04/2006	https://clinicaltrials.gov/study/NCT00326144	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	major depressive disorder	QUETIAPINE FUMARATE	targetBased	4	Unknown status	01/05/2011	https://clinicaltrials.gov/study/NCT01357967	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	major depressive disorder	QUETIAPINE FUMARATE	targetBased	3	Completed	01/04/2006	https://clinicaltrials.gov/study/NCT00326105	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	major depressive disorder	QUETIAPINE FUMARATE	targetBased	4	Completed	01/04/2006	https://clinicaltrials.gov/study/NCT03207438	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	major depressive disorder	QUETIAPINE FUMARATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03517f29-f270-4350-a57a-fbe1967b0096	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	major depressive disorder	QUETIAPINE FUMARATE	targetBased	3	Completed	01/04/2006	https://clinicaltrials.gov/study/NCT00321490	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	major depressive disorder	QUETIAPINE FUMARATE	targetBased	3	Completed	01/12/2005	https://clinicaltrials.gov/study/NCT00278941	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	post-traumatic stress disorder	QUETIAPINE FUMARATE	targetBased	3	Completed	01/12/2004	https://clinicaltrials.gov/study/NCT00306540	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	unipolar depression	QUETIAPINE FUMARATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=51927f2e-3d56-4644-a6a8-40e0b9a5b579	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	unipolar depression	QUETIAPINE FUMARATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2a74e8a0-b2fd-4d7f-8bf8-72148b1d3ae7	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	unipolar depression	QUETIAPINE FUMARATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7e37e999-f225-4d0a-b16d-37ac14ff29da	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	unipolar depression	QUETIAPINE FUMARATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=473a3ac4-67f4-4782-baa9-7f9bdd8761f4	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	neurotic disorder	QUETIAPINE FUMARATE	targetBased	3	Completed	01/08/2007	https://clinicaltrials.gov/study/NCT00534599	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	neurotic disorder	QUETIAPINE FUMARATE	targetBased	3	Completed	01/08/2007	https://clinicaltrials.gov/study/NCT00534599	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	neurotic disorder	QUETIAPINE FUMARATE	targetBased	3	Completed	01/08/2007	https://clinicaltrials.gov/study/NCT00534599	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	neurotic disorder	QUETIAPINE FUMARATE	targetBased	3	Completed	01/08/2007	https://clinicaltrials.gov/study/NCT00534599	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	neurotic disorder	QUETIAPINE FUMARATE	targetBased	3	Completed	01/08/2007	https://clinicaltrials.gov/study/NCT00534599	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	neurotic disorder	QUETIAPINE FUMARATE	targetBased	3	Completed	01/08/2007	https://clinicaltrials.gov/study/NCT00534599	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	obsessive-compulsive disorder	QUETIAPINE FUMARATE	targetBased	3	Completed	01/04/2002	https://clinicaltrials.gov/study/NCT00254735	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Borderline personality disorder	QUETIAPINE FUMARATE	targetBased	3	Completed	01/05/2005	https://clinicaltrials.gov/study/NCT00122070	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	QUETIAPINE FUMARATE	targetBased	4	Completed	01/11/2010	https://clinicaltrials.gov/study/NCT01213836	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	QUETIAPINE FUMARATE	targetBased	4	Completed	01/04/2004	https://clinicaltrials.gov/study/NCT00214578	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	obsessive-compulsive disorder	QUETIAPINE FUMARATE	targetBased	3	Completed	01/04/2002	https://clinicaltrials.gov/study/NCT00254735	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	obsessive-compulsive disorder	QUETIAPINE FUMARATE	targetBased	3	Completed	01/04/2002	https://clinicaltrials.gov/study/NCT00254735	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	obsessive-compulsive disorder	QUETIAPINE FUMARATE	targetBased	3	Completed	01/04/2002	https://clinicaltrials.gov/study/NCT00254735	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	obsessive-compulsive disorder	QUETIAPINE FUMARATE	targetBased	3	Completed	01/04/2002	https://clinicaltrials.gov/study/NCT00254735	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	obsessive-compulsive disorder	QUETIAPINE FUMARATE	targetBased	3	Completed	01/04/2002	https://clinicaltrials.gov/study/NCT00254735	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	obsessive-compulsive disorder	QUETIAPINE FUMARATE	targetBased	3	Completed	01/04/2002	https://clinicaltrials.gov/study/NCT00254735	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	QUETIAPINE FUMARATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=289fdaa7-ba48-406e-b007-40f4a896f0d1	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	QUETIAPINE FUMARATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aaf50e8a-3c8e-4b19-b539-0384a9b1a707	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	QUETIAPINE FUMARATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f9d265a9-7491-48e1-a39e-0aaa67294cff	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	QUETIAPINE FUMARATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=636eeb46-f1e2-4e1b-bc6d-55eb09df9b49	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	QUETIAPINE FUMARATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9d2d5c5c-817d-4631-bd81-de66ab4ff81a	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar disorder	QUETIAPINE FUMARATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8048ac0a-5d4d-4d00-ab9c-7fcac27f0a60	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	bipolar disorder	QUETIAPINE FUMARATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6dd0822c-2d6d-4295-a6de-07756e1cbce7	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	bipolar disorder	QUETIAPINE FUMARATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6dd0822c-2d6d-4295-a6de-07756e1cbce7	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar disorder	QUETIAPINE FUMARATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6dd0822c-2d6d-4295-a6de-07756e1cbce7	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar disorder	QUETIAPINE FUMARATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6dd0822c-2d6d-4295-a6de-07756e1cbce7	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar disorder	QUETIAPINE FUMARATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6dd0822c-2d6d-4295-a6de-07756e1cbce7	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar disorder	QUETIAPINE FUMARATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6dd0822c-2d6d-4295-a6de-07756e1cbce7	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	alcohol dependence	QUETIAPINE FUMARATE	targetBased	3	Completed	01/03/2003	https://clinicaltrials.gov/study/NCT00124059	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	alcohol dependence	QUETIAPINE FUMARATE	targetBased	3	Completed	01/01/2006	https://clinicaltrials.gov/study/NCT00114686	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar II disorder	QUETIAPINE FUMARATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03517f29-f270-4350-a57a-fbe1967b0096	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar II disorder	QUETIAPINE FUMARATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45c4c3a4-3acc-413e-9746-4816d513fac6	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Dementia	QUETIAPINE FUMARATE	targetBased	3	Terminated	01/05/2006	https://clinicaltrials.gov/study/NCT00315900	0.7	LoF	protect	Investigator closed study and left VAMC.
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	major depressive disorder	QUETIAPINE FUMARATE	targetBased	4	Unknown status	01/05/2011	https://clinicaltrials.gov/study/NCT01357967	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	major depressive disorder	QUETIAPINE FUMARATE	targetBased	4	Completed	01/04/2006	https://clinicaltrials.gov/study/NCT03207438	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	major depressive disorder	QUETIAPINE FUMARATE	targetBased	4	Completed	01/04/2006	https://clinicaltrials.gov/study/NCT03207438	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	major depressive disorder	QUETIAPINE FUMARATE	targetBased	4	Completed	01/04/2006	https://clinicaltrials.gov/study/NCT03207438	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	major depressive disorder	QUETIAPINE FUMARATE	targetBased	4	Completed	01/04/2006	https://clinicaltrials.gov/study/NCT03207438	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	major depressive disorder	QUETIAPINE FUMARATE	targetBased	4	Completed	01/04/2006	https://clinicaltrials.gov/study/NCT03207438	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	major depressive disorder	QUETIAPINE FUMARATE	targetBased	4	Completed	01/04/2006	https://clinicaltrials.gov/study/NCT03207438	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar II disorder	QUETIAPINE FUMARATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03517f29-f270-4350-a57a-fbe1967b0096	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	bipolar II disorder	QUETIAPINE FUMARATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45c4c3a4-3acc-413e-9746-4816d513fac6	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	bipolar II disorder	QUETIAPINE FUMARATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45c4c3a4-3acc-413e-9746-4816d513fac6	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar II disorder	QUETIAPINE FUMARATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45c4c3a4-3acc-413e-9746-4816d513fac6	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar II disorder	QUETIAPINE FUMARATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45c4c3a4-3acc-413e-9746-4816d513fac6	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar II disorder	QUETIAPINE FUMARATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45c4c3a4-3acc-413e-9746-4816d513fac6	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar II disorder	QUETIAPINE FUMARATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45c4c3a4-3acc-413e-9746-4816d513fac6	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	post-traumatic stress disorder	QUETIAPINE FUMARATE	targetBased	3	Completed	01/12/2004	https://clinicaltrials.gov/study/NCT00306540	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	post-traumatic stress disorder	QUETIAPINE FUMARATE	targetBased	3	Completed	01/12/2004	https://clinicaltrials.gov/study/NCT00306540	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	post-traumatic stress disorder	QUETIAPINE FUMARATE	targetBased	3	Completed	01/12/2004	https://clinicaltrials.gov/study/NCT00306540	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	post-traumatic stress disorder	QUETIAPINE FUMARATE	targetBased	3	Completed	01/12/2004	https://clinicaltrials.gov/study/NCT00306540	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	post-traumatic stress disorder	QUETIAPINE FUMARATE	targetBased	3	Completed	01/12/2004	https://clinicaltrials.gov/study/NCT00306540	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	post-traumatic stress disorder	QUETIAPINE FUMARATE	targetBased	3	Completed	01/12/2004	https://clinicaltrials.gov/study/NCT00306540	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	depressive disorder	QUETIAPINE FUMARATE	targetBased	3	Completed	01/05/2005	https://clinicaltrials.gov/study/NCT00119652	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	depressive disorder	QUETIAPINE FUMARATE	targetBased	4	Completed	01/04/2007	https://clinicaltrials.gov/study/NCT00675896	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	depressive disorder	QUETIAPINE FUMARATE	targetBased	4	Completed	01/04/2007	https://clinicaltrials.gov/study/NCT00675896	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	depressive disorder	QUETIAPINE FUMARATE	targetBased	4	Completed	01/04/2007	https://clinicaltrials.gov/study/NCT00675896	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	depressive disorder	QUETIAPINE FUMARATE	targetBased	4	Completed	01/04/2007	https://clinicaltrials.gov/study/NCT00675896	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	depressive disorder	QUETIAPINE FUMARATE	targetBased	4	Completed	01/04/2007	https://clinicaltrials.gov/study/NCT00675896	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	depressive disorder	QUETIAPINE FUMARATE	targetBased	4	Completed	01/04/2007	https://clinicaltrials.gov/study/NCT00675896	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	unipolar depression	QUETIAPINE FUMARATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=51927f2e-3d56-4644-a6a8-40e0b9a5b579	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	unipolar depression	QUETIAPINE FUMARATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7e37e999-f225-4d0a-b16d-37ac14ff29da	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	unipolar depression	QUETIAPINE FUMARATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7e37e999-f225-4d0a-b16d-37ac14ff29da	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	unipolar depression	QUETIAPINE FUMARATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7e37e999-f225-4d0a-b16d-37ac14ff29da	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	unipolar depression	QUETIAPINE FUMARATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7e37e999-f225-4d0a-b16d-37ac14ff29da	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	unipolar depression	QUETIAPINE FUMARATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7e37e999-f225-4d0a-b16d-37ac14ff29da	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	unipolar depression	QUETIAPINE FUMARATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7e37e999-f225-4d0a-b16d-37ac14ff29da	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	anxiety	QUETIAPINE FUMARATE	targetBased	3	Completed	01/08/2007	https://clinicaltrials.gov/study/NCT00534599	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	anxiety	QUETIAPINE FUMARATE	targetBased	3	Completed	01/08/2007	https://clinicaltrials.gov/study/NCT00534599	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	anxiety	QUETIAPINE FUMARATE	targetBased	3	Completed	01/08/2007	https://clinicaltrials.gov/study/NCT00534599	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	anxiety	QUETIAPINE FUMARATE	targetBased	3	Completed	01/08/2007	https://clinicaltrials.gov/study/NCT00534599	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	anxiety	QUETIAPINE FUMARATE	targetBased	3	Completed	01/08/2007	https://clinicaltrials.gov/study/NCT00534599	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	anxiety	QUETIAPINE FUMARATE	targetBased	3	Completed	01/08/2007	https://clinicaltrials.gov/study/NCT00534599	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Agitation	QUETIAPINE FUMARATE	targetBased	3	Completed	01/09/2002	https://clinicaltrials.gov/study/NCT00621647	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Agitation	QUETIAPINE FUMARATE	targetBased	3	Completed	01/09/2002	https://clinicaltrials.gov/study/NCT00621647	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Agitation	QUETIAPINE FUMARATE	targetBased	3	Completed	01/09/2002	https://clinicaltrials.gov/study/NCT00621647	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Agitation	QUETIAPINE FUMARATE	targetBased	3	Completed	01/09/2002	https://clinicaltrials.gov/study/NCT00621647	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Agitation	QUETIAPINE FUMARATE	targetBased	3	Terminated	01/05/2006	https://clinicaltrials.gov/study/NCT00315900	0.7	LoF	protect	Investigator closed study and left VAMC.
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Agitation	QUETIAPINE FUMARATE	targetBased	3	Terminated	01/05/2006	https://clinicaltrials.gov/study/NCT00315900	0.7	LoF	protect	Investigator closed study and left VAMC.
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Agitation	QUETIAPINE FUMARATE	targetBased	3	Terminated	01/05/2006	https://clinicaltrials.gov/study/NCT00315900	0.7	LoF	protect	Investigator closed study and left VAMC.
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Agitation	QUETIAPINE FUMARATE	targetBased	3	Terminated	01/05/2006	https://clinicaltrials.gov/study/NCT00315900	0.7	LoF	protect	Investigator closed study and left VAMC.
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Agitation	QUETIAPINE FUMARATE	targetBased	3	Terminated	01/05/2006	https://clinicaltrials.gov/study/NCT00315900	0.7	LoF	protect	Investigator closed study and left VAMC.
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Agitation	QUETIAPINE FUMARATE	targetBased	3	Terminated	01/05/2006	https://clinicaltrials.gov/study/NCT00315900	0.7	LoF	protect	Investigator closed study and left VAMC.
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizoaffective disorder	QUETIAPINE FUMARATE	targetBased	4	Completed	01/07/2006	https://clinicaltrials.gov/study/NCT00325689	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizoaffective disorder	QUETIAPINE FUMARATE	targetBased	4	Completed	01/09/2003	https://clinicaltrials.gov/study/NCT00206102	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizoaffective disorder	QUETIAPINE FUMARATE	targetBased	4	Completed	01/09/2003	https://clinicaltrials.gov/study/NCT00206102	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizoaffective disorder	QUETIAPINE FUMARATE	targetBased	4	Completed	01/09/2003	https://clinicaltrials.gov/study/NCT00206102	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizoaffective disorder	QUETIAPINE FUMARATE	targetBased	4	Completed	01/09/2003	https://clinicaltrials.gov/study/NCT00206102	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizoaffective disorder	QUETIAPINE FUMARATE	targetBased	4	Completed	01/09/2003	https://clinicaltrials.gov/study/NCT00206102	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizoaffective disorder	QUETIAPINE FUMARATE	targetBased	4	Completed	01/09/2003	https://clinicaltrials.gov/study/NCT00206102	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar I disorder	QUETIAPINE FUMARATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2a74e8a0-b2fd-4d7f-8bf8-72148b1d3ae7	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar I disorder	QUETIAPINE FUMARATE	targetBased	3	Completed	01/08/2004	https://clinicaltrials.gov/study/NCT00227305	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar I disorder	QUETIAPINE FUMARATE	targetBased	3	Completed	01/04/2004	https://clinicaltrials.gov/study/NCT00107731	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar I disorder	QUETIAPINE FUMARATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45c4c3a4-3acc-413e-9746-4816d513fac6	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar I disorder	QUETIAPINE FUMARATE	targetBased	3	Completed	01/01/2006	https://clinicaltrials.gov/study/NCT00114686	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar I disorder	QUETIAPINE FUMARATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03517f29-f270-4350-a57a-fbe1967b0096	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar I disorder	QUETIAPINE FUMARATE	targetBased	3	Terminated	01/04/2009	https://clinicaltrials.gov/study/NCT00857818	0.7	LoF	protect	Slow Accrual
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	QUETIAPINE FUMARATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0f131f23-80dd-4a42-893a-b7d86cd0e037	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	QUETIAPINE FUMARATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=55c1bce9-9d05-4621-839d-a98b8d862692	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	QUETIAPINE FUMARATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9cde17b6-2452-4227-8a19-61acb57cff4f	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	QUETIAPINE FUMARATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e2d7800d-930a-49fe-9450-0e96833d44c2	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	QUETIAPINE FUMARATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94dfc588-1fd9-4435-93ec-c6dd4700aef5	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	QUETIAPINE FUMARATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8df82f5a-aa0e-4f8c-bae1-2f32ede3d7b6	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	QUETIAPINE FUMARATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=760c11f5-b3d2-4b24-94e9-d907a7448557	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	generalized anxiety disorder	QUETIAPINE FUMARATE	targetBased	3	Completed	01/04/2006	https://clinicaltrials.gov/study/NCT00329446	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	generalized anxiety disorder	QUETIAPINE FUMARATE	targetBased	3	Completed	01/04/2006	https://clinicaltrials.gov/study/NCT00329446	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	generalized anxiety disorder	QUETIAPINE FUMARATE	targetBased	3	Completed	01/04/2006	https://clinicaltrials.gov/study/NCT00329446	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	generalized anxiety disorder	QUETIAPINE FUMARATE	targetBased	3	Completed	01/04/2006	https://clinicaltrials.gov/study/NCT00329446	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	generalized anxiety disorder	QUETIAPINE FUMARATE	targetBased	3	Completed	01/04/2006	https://clinicaltrials.gov/study/NCT00329264	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	generalized anxiety disorder	QUETIAPINE FUMARATE	targetBased	3	Completed	01/04/2006	https://clinicaltrials.gov/study/NCT00329264	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	generalized anxiety disorder	QUETIAPINE FUMARATE	targetBased	3	Completed	01/04/2006	https://clinicaltrials.gov/study/NCT00329264	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	generalized anxiety disorder	QUETIAPINE FUMARATE	targetBased	3	Completed	01/04/2006	https://clinicaltrials.gov/study/NCT00329264	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	generalized anxiety disorder	QUETIAPINE FUMARATE	targetBased	3	Completed	01/04/2006	https://clinicaltrials.gov/study/NCT00329264	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	generalized anxiety disorder	QUETIAPINE FUMARATE	targetBased	3	Completed	01/04/2006	https://clinicaltrials.gov/study/NCT00329264	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	psychosis	QUETIAPINE FUMARATE	targetBased	3	Completed	01/07/2003	https://clinicaltrials.gov/study/NCT00449397	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	neurotic disorder	QUETIAPINE FUMARATE	targetBased	3	Completed	01/08/2007	https://clinicaltrials.gov/study/NCT00534599	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizoaffective disorder	QUETIAPINE FUMARATE	targetBased	4	Completed	01/09/2003	https://clinicaltrials.gov/study/NCT00206102	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizoaffective disorder	QUETIAPINE FUMARATE	targetBased	3	Terminated	01/04/2009	https://clinicaltrials.gov/study/NCT00857818	0.7	LoF	protect	Slow Accrual
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizoaffective disorder	QUETIAPINE FUMARATE	targetBased	4	Completed	01/07/2006	https://clinicaltrials.gov/study/NCT00325689	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	depressive disorder	QUETIAPINE FUMARATE	targetBased	3	Completed	01/08/2005	https://clinicaltrials.gov/study/NCT00206141	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	depressive disorder	QUETIAPINE FUMARATE	targetBased	3	Completed	01/05/2005	https://clinicaltrials.gov/study/NCT00119652	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	depressive disorder	QUETIAPINE FUMARATE	targetBased	4	Completed	01/04/2007	https://clinicaltrials.gov/study/NCT00675896	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	psychosis	QUETIAPINE FUMARATE	targetBased	3	Completed	01/07/2003	https://clinicaltrials.gov/study/NCT00449397	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	psychosis	QUETIAPINE FUMARATE	targetBased	3	Completed	01/07/2003	https://clinicaltrials.gov/study/NCT00449397	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	psychosis	QUETIAPINE FUMARATE	targetBased	3	Completed	01/07/2003	https://clinicaltrials.gov/study/NCT00449397	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	psychosis	QUETIAPINE FUMARATE	targetBased	3	Completed	01/07/2003	https://clinicaltrials.gov/study/NCT00449397	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	QUETIAPINE FUMARATE	targetBased	3	Completed	01/07/2003	https://clinicaltrials.gov/study/NCT00449397	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	QUETIAPINE FUMARATE	targetBased	3	Completed	01/07/2003	https://clinicaltrials.gov/study/NCT00449397	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	anxiety	QUETIAPINE FUMARATE	targetBased	3	Completed	01/08/2007	https://clinicaltrials.gov/study/NCT00534599	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Dementia	QUETIAPINE FUMARATE	targetBased	3	Terminated	01/05/2006	https://clinicaltrials.gov/study/NCT00315900	0.7	LoF	protect	Investigator closed study and left VAMC.
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Dementia	QUETIAPINE FUMARATE	targetBased	3	Terminated	01/05/2006	https://clinicaltrials.gov/study/NCT00315900	0.7	LoF	protect	Investigator closed study and left VAMC.
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Dementia	QUETIAPINE FUMARATE	targetBased	3	Terminated	01/05/2006	https://clinicaltrials.gov/study/NCT00315900	0.7	LoF	protect	Investigator closed study and left VAMC.
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Dementia	QUETIAPINE FUMARATE	targetBased	3	Terminated	01/05/2006	https://clinicaltrials.gov/study/NCT00315900	0.7	LoF	protect	Investigator closed study and left VAMC.
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Dementia	QUETIAPINE FUMARATE	targetBased	3	Terminated	01/05/2006	https://clinicaltrials.gov/study/NCT00315900	0.7	LoF	protect	Investigator closed study and left VAMC.
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Dementia	QUETIAPINE FUMARATE	targetBased	3	Terminated	01/05/2006	https://clinicaltrials.gov/study/NCT00315900	0.7	LoF	protect	Investigator closed study and left VAMC.
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar I disorder	QUETIAPINE FUMARATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03517f29-f270-4350-a57a-fbe1967b0096	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	bipolar I disorder	QUETIAPINE FUMARATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45c4c3a4-3acc-413e-9746-4816d513fac6	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	bipolar I disorder	QUETIAPINE FUMARATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45c4c3a4-3acc-413e-9746-4816d513fac6	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar I disorder	QUETIAPINE FUMARATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45c4c3a4-3acc-413e-9746-4816d513fac6	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar I disorder	QUETIAPINE FUMARATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45c4c3a4-3acc-413e-9746-4816d513fac6	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar I disorder	QUETIAPINE FUMARATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45c4c3a4-3acc-413e-9746-4816d513fac6	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar I disorder	QUETIAPINE FUMARATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45c4c3a4-3acc-413e-9746-4816d513fac6	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	alcohol dependence	QUETIAPINE FUMARATE	targetBased	3	Completed	01/03/2003	https://clinicaltrials.gov/study/NCT00124059	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	alcohol dependence	QUETIAPINE FUMARATE	targetBased	3	Completed	01/03/2003	https://clinicaltrials.gov/study/NCT00124059	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	alcohol dependence	QUETIAPINE FUMARATE	targetBased	3	Completed	01/03/2003	https://clinicaltrials.gov/study/NCT00124059	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	alcohol dependence	QUETIAPINE FUMARATE	targetBased	3	Completed	01/03/2003	https://clinicaltrials.gov/study/NCT00124059	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	alcohol dependence	QUETIAPINE FUMARATE	targetBased	3	Completed	01/01/2006	https://clinicaltrials.gov/study/NCT00114686	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	alcohol dependence	QUETIAPINE FUMARATE	targetBased	3	Completed	01/01/2006	https://clinicaltrials.gov/study/NCT00114686	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	alcohol dependence	QUETIAPINE FUMARATE	targetBased	3	Completed	01/01/2006	https://clinicaltrials.gov/study/NCT00114686	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	alcohol dependence	QUETIAPINE FUMARATE	targetBased	3	Completed	01/01/2006	https://clinicaltrials.gov/study/NCT00114686	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	alcohol dependence	QUETIAPINE FUMARATE	targetBased	3	Completed	01/01/2006	https://clinicaltrials.gov/study/NCT00114686	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	alcohol dependence	QUETIAPINE FUMARATE	targetBased	3	Completed	01/01/2006	https://clinicaltrials.gov/study/NCT00114686	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Agitation	QUETIAPINE FUMARATE	targetBased	3	Completed	01/09/2002	https://clinicaltrials.gov/study/NCT00621647	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Agitation	QUETIAPINE FUMARATE	targetBased	3	Terminated	01/05/2006	https://clinicaltrials.gov/study/NCT00315900	0.7	LoF	protect	Investigator closed study and left VAMC.
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	QUETIAPINE FUMARATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6173e1ce-0a85-40b0-99f0-1a6d78e67198	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	QUETIAPINE FUMARATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9fe6267a-c7b3-41e8-9006-a43014716acb	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	QUETIAPINE FUMARATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9fe6267a-c7b3-41e8-9006-a43014716acb	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	QUETIAPINE FUMARATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9fe6267a-c7b3-41e8-9006-a43014716acb	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	QUETIAPINE FUMARATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9fe6267a-c7b3-41e8-9006-a43014716acb	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	QUETIAPINE FUMARATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9fe6267a-c7b3-41e8-9006-a43014716acb	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	QUETIAPINE FUMARATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9fe6267a-c7b3-41e8-9006-a43014716acb	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	social anxiety disorder	QUETIAPINE FUMARATE	targetBased	3	Completed	01/10/2008	https://clinicaltrials.gov/study/NCT00773162	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	social anxiety disorder	QUETIAPINE FUMARATE	targetBased	3	Completed	01/10/2008	https://clinicaltrials.gov/study/NCT00773162	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	social anxiety disorder	QUETIAPINE FUMARATE	targetBased	3	Completed	01/10/2008	https://clinicaltrials.gov/study/NCT00773162	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	social anxiety disorder	QUETIAPINE FUMARATE	targetBased	3	Completed	01/10/2008	https://clinicaltrials.gov/study/NCT00773162	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	social anxiety disorder	QUETIAPINE FUMARATE	targetBased	3	Completed	01/10/2008	https://clinicaltrials.gov/study/NCT00773162	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	social anxiety disorder	QUETIAPINE FUMARATE	targetBased	3	Completed	01/10/2008	https://clinicaltrials.gov/study/NCT00773162	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Borderline personality disorder	QUETIAPINE FUMARATE	targetBased	3	Completed	01/05/2005	https://clinicaltrials.gov/study/NCT00122070	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Borderline personality disorder	QUETIAPINE FUMARATE	targetBased	3	Completed	01/05/2005	https://clinicaltrials.gov/study/NCT00122070	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Borderline personality disorder	QUETIAPINE FUMARATE	targetBased	3	Completed	01/05/2005	https://clinicaltrials.gov/study/NCT00122070	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Borderline personality disorder	QUETIAPINE FUMARATE	targetBased	3	Completed	01/05/2005	https://clinicaltrials.gov/study/NCT00122070	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Borderline personality disorder	QUETIAPINE FUMARATE	targetBased	3	Completed	01/05/2005	https://clinicaltrials.gov/study/NCT00122070	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Borderline personality disorder	QUETIAPINE FUMARATE	targetBased	3	Completed	01/05/2005	https://clinicaltrials.gov/study/NCT00122070	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	social anxiety disorder	QUETIAPINE FUMARATE	targetBased	3	Completed	01/10/2008	https://clinicaltrials.gov/study/NCT00773162	0.7	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	eating disorder	DASOTRALINE	targetBased	3	Completed	29/02/2016	https://clinicaltrials.gov/study/NCT02684279	0.7	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	eating disorder	DASOTRALINE	targetBased	3	Completed	31/03/2017	https://clinicaltrials.gov/study/NCT03107026	0.7	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	DASOTRALINE	targetBased	3	Completed	31/07/2017	https://clinicaltrials.gov/study/NCT03231800	0.7	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	DASOTRALINE	targetBased	3	Completed	01/06/2014	https://clinicaltrials.gov/study/NCT02160262	0.7	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	DASOTRALINE	targetBased	3	Completed	30/06/2015	https://clinicaltrials.gov/study/NCT02457819	0.7	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	DASOTRALINE	targetBased	3	Completed	30/04/2016	https://clinicaltrials.gov/study/NCT02734693	0.7	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	DASOTRALINE	targetBased	3	Completed	01/12/2014	https://clinicaltrials.gov/study/NCT02276209	0.7	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	CENTANAFADINE	targetBased	3	Completed	02/02/2022	https://clinicaltrials.gov/study/NCT05257265	0.7	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	CENTANAFADINE	targetBased	3	Recruiting	24/02/2022	https://clinicaltrials.gov/study/NCT05279313	0.7	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	CENTANAFADINE	targetBased	3	Completed	14/02/2019	https://clinicaltrials.gov/study/NCT03605849	0.7	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	CENTANAFADINE	targetBased	3	Completed	16/01/2019	https://clinicaltrials.gov/study/NCT03605680	0.7	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	CENTANAFADINE	targetBased	3	Completed	16/01/2019	https://clinicaltrials.gov/study/NCT03605836	0.7	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	CENTANAFADINE	targetBased	3	Recruiting	11/07/2022	https://clinicaltrials.gov/study/NCT05428033	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	major depressive disorder	LUMATEPERONE	targetBased	3	Recruiting	02/05/2023	https://clinicaltrials.gov/study/NCT05850689	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	major depressive disorder	LUMATEPERONE	targetBased	3	Completed	30/09/2021	https://clinicaltrials.gov/study/NCT05061706	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	major depressive disorder	LUMATEPERONE	targetBased	3	Completed	27/02/2020	https://clinicaltrials.gov/study/NCT04285515	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	major depressive disorder	LUMATEPERONE	targetBased	3	Completed	30/07/2021	https://clinicaltrials.gov/study/NCT04985942	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	major depressive disorder	LUMATEPERONE	targetBased	3	Enrolling by invitation	08/10/2021	https://clinicaltrials.gov/study/NCT05061719	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	LUMATEPERONE	targetBased	4	Recruiting	02/04/2024	https://clinicaltrials.gov/study/NCT06174116	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	LUMATEPERONE	targetBased	3	Completed	01/06/2015	https://clinicaltrials.gov/study/NCT02469155	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	LUMATEPERONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=db730b06-6351-47fd-8183-e61e61bbead5	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	LUMATEPERONE	targetBased	3	Active, not recruiting	08/07/2021	https://clinicaltrials.gov/study/NCT04959032	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	LUMATEPERONE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209500s000lbl.pdf	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	LUMATEPERONE	targetBased	3	Completed	01/11/2014	https://clinicaltrials.gov/study/NCT02282761	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar disorder	LUMATEPERONE	targetBased	3	Completed	15/12/2015	https://clinicaltrials.gov/study/NCT02600494	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar disorder	LUMATEPERONE	targetBased	3	Completed	15/12/2015	https://clinicaltrials.gov/study/NCT02600494	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar disorder	LUMATEPERONE	targetBased	3	Completed	15/12/2015	https://clinicaltrials.gov/study/NCT02600494	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar disorder	LUMATEPERONE	targetBased	3	Completed	15/12/2015	https://clinicaltrials.gov/study/NCT02600494	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	bipolar disorder	LUMATEPERONE	targetBased	3	Completed	27/02/2020	https://clinicaltrials.gov/study/NCT04285515	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	bipolar disorder	LUMATEPERONE	targetBased	3	Completed	27/02/2020	https://clinicaltrials.gov/study/NCT04285515	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar disorder	LUMATEPERONE	targetBased	3	Completed	27/02/2020	https://clinicaltrials.gov/study/NCT04285515	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar disorder	LUMATEPERONE	targetBased	3	Completed	27/02/2020	https://clinicaltrials.gov/study/NCT04285515	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar disorder	LUMATEPERONE	targetBased	3	Completed	27/02/2020	https://clinicaltrials.gov/study/NCT04285515	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar disorder	LUMATEPERONE	targetBased	3	Completed	27/02/2020	https://clinicaltrials.gov/study/NCT04285515	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	major depressive disorder	LUMATEPERONE	targetBased	3	Completed	30/09/2021	https://clinicaltrials.gov/study/NCT05061706	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	major depressive disorder	LUMATEPERONE	targetBased	3	Completed	30/09/2021	https://clinicaltrials.gov/study/NCT05061706	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	major depressive disorder	LUMATEPERONE	targetBased	3	Completed	30/09/2021	https://clinicaltrials.gov/study/NCT05061706	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	major depressive disorder	LUMATEPERONE	targetBased	3	Completed	30/09/2021	https://clinicaltrials.gov/study/NCT05061706	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	major depressive disorder	LUMATEPERONE	targetBased	3	Completed	27/02/2020	https://clinicaltrials.gov/study/NCT04285515	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	major depressive disorder	LUMATEPERONE	targetBased	3	Completed	27/02/2020	https://clinicaltrials.gov/study/NCT04285515	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	major depressive disorder	LUMATEPERONE	targetBased	3	Completed	27/02/2020	https://clinicaltrials.gov/study/NCT04285515	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	major depressive disorder	LUMATEPERONE	targetBased	3	Completed	27/02/2020	https://clinicaltrials.gov/study/NCT04285515	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	major depressive disorder	LUMATEPERONE	targetBased	3	Completed	27/02/2020	https://clinicaltrials.gov/study/NCT04285515	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	major depressive disorder	LUMATEPERONE	targetBased	3	Completed	27/02/2020	https://clinicaltrials.gov/study/NCT04285515	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizoaffective disorder	LUMATEPERONE	targetBased	4	Recruiting	02/04/2024	https://clinicaltrials.gov/study/NCT06174116	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizoaffective disorder	LUMATEPERONE	targetBased	4	Recruiting	02/04/2024	https://clinicaltrials.gov/study/NCT06174116	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizoaffective disorder	LUMATEPERONE	targetBased	4	Recruiting	02/04/2024	https://clinicaltrials.gov/study/NCT06174116	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizoaffective disorder	LUMATEPERONE	targetBased	4	Recruiting	02/04/2024	https://clinicaltrials.gov/study/NCT06174116	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizoaffective disorder	LUMATEPERONE	targetBased	4	Recruiting	02/04/2024	https://clinicaltrials.gov/study/NCT06174116	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizoaffective disorder	LUMATEPERONE	targetBased	4	Recruiting	02/04/2024	https://clinicaltrials.gov/study/NCT06174116	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	LUMATEPERONE	targetBased	3	Not yet recruiting	01/07/2024	https://clinicaltrials.gov/study/NCT06462612	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	LUMATEPERONE	targetBased	3	Completed	07/03/2016	https://clinicaltrials.gov/study/NCT02600507	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	LUMATEPERONE	targetBased	3	Completed	15/12/2015	https://clinicaltrials.gov/study/NCT02600494	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	LUMATEPERONE	targetBased	3	Completed	27/02/2020	https://clinicaltrials.gov/study/NCT04285515	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	LUMATEPERONE	targetBased	3	Recruiting	01/04/2024	https://clinicaltrials.gov/study/NCT06372964	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	LUMATEPERONE	targetBased	3	Completed	27/11/2017	https://clinicaltrials.gov/study/NCT03249376	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	LUMATEPERONE	targetBased	3	Recruiting	01/06/2024	https://clinicaltrials.gov/study/NCT06462586	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	psychosis	LUMATEPERONE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AD10	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	psychosis	LUMATEPERONE	targetBased	4	Terminated	11/05/2023	https://clinicaltrials.gov/study/NCT05890768	1	LoF	protect	PI was unable to meet 1 year recruitment goal
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizoaffective disorder	LUMATEPERONE	targetBased	4	Recruiting	02/04/2024	https://clinicaltrials.gov/study/NCT06174116	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	LUMATEPERONE	targetBased	4	Terminated	11/05/2023	https://clinicaltrials.gov/study/NCT05890768	1	LoF	protect	PI was unable to meet 1 year recruitment goal
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	psychosis	LUMATEPERONE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AD10	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	psychosis	LUMATEPERONE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AD10	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	psychosis	LUMATEPERONE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AD10	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	psychosis	LUMATEPERONE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AD10	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	LUMATEPERONE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AD10	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	LUMATEPERONE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=N05AD10	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	LUMATEPERONE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=db730b06-6351-47fd-8183-e61e61bbead5	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	LUMATEPERONE	targetBased	4	Recruiting	02/04/2024	https://clinicaltrials.gov/study/NCT06174116	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	LUMATEPERONE	targetBased	4	Recruiting	02/04/2024	https://clinicaltrials.gov/study/NCT06174116	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	LUMATEPERONE	targetBased	4	Recruiting	02/04/2024	https://clinicaltrials.gov/study/NCT06174116	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	LUMATEPERONE	targetBased	4	Recruiting	02/04/2024	https://clinicaltrials.gov/study/NCT06174116	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	LUMATEPERONE	targetBased	4	Recruiting	02/04/2024	https://clinicaltrials.gov/study/NCT06174116	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	LUMATEPERONE	targetBased	4	Recruiting	02/04/2024	https://clinicaltrials.gov/study/NCT06174116	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		major depressive disorder	RAPASTINEL	targetBased	3	Completed	02/11/2016	https://clinicaltrials.gov/study/NCT02943577	0.7	GoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		major depressive disorder	RAPASTINEL	targetBased	3	Completed	01/11/2016	https://clinicaltrials.gov/study/NCT02943564	0.7	GoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		major depressive disorder	RAPASTINEL	targetBased	3	Completed	13/11/2016	https://clinicaltrials.gov/study/NCT02951988	0.7	GoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		major depressive disorder	RAPASTINEL	targetBased	3	Terminated	30/10/2018	https://clinicaltrials.gov/study/NCT03675776	0.7	GoF	protect	Business decision to stop the program.
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		major depressive disorder	RAPASTINEL	targetBased	3	Terminated	02/08/2018	https://clinicaltrials.gov/study/NCT03614156	0.7	GoF	protect	Business decision to stop the program.
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		major depressive disorder	RAPASTINEL	targetBased	3	Withdrawn	01/07/2019	https://clinicaltrials.gov/study/NCT03855865	0.7	GoF	protect	Business decision to stop the program.
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		major depressive disorder	RAPASTINEL	targetBased	3	Terminated	15/06/2018	https://clinicaltrials.gov/study/NCT03560518	0.7	GoF	protect	Business decision to stop the program.
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		major depressive disorder	RAPASTINEL	targetBased	3	Completed	03/02/2017	https://clinicaltrials.gov/study/NCT03002077	0.7	GoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		major depressive disorder	RAPASTINEL	targetBased	3	Completed	15/10/2016	https://clinicaltrials.gov/study/NCT02932943	0.7	GoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		major depressive disorder	RAPASTINEL	targetBased	3	Terminated	23/08/2018	https://clinicaltrials.gov/study/NCT03668600	0.7	GoF	protect	Business decision to stop the program
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	narcolepsy-cataplexy syndrome	DEXTROAMPHETAMINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ffd56d70-d884-43be-a994-6e70a10e823e	1		protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	DEXTROAMPHETAMINE SULFATE	targetBased	3	Completed	10/03/2005	https://clinicaltrials.gov/study/NCT00152035	0.7		protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	DEXTROAMPHETAMINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ffd56d70-d884-43be-a994-6e70a10e823e	1		protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	DEXTROAMPHETAMINE SULFATE	targetBased	3	Completed	27/01/2005	https://clinicaltrials.gov/study/NCT00150579	0.7		protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	DEXTROAMPHETAMINE SULFATE	targetBased	3	Completed	25/04/2005	https://clinicaltrials.gov/study/NCT00152022	0.7		protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	major depressive disorder	ASENAPINE MALEATE	targetBased	4	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT01670019	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	post-traumatic stress disorder	ASENAPINE MALEATE	targetBased	4	Completed	01/06/2012	https://clinicaltrials.gov/study/NCT01587118	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	ASENAPINE MALEATE	targetBased	4	Unknown status	01/10/2013	https://clinicaltrials.gov/study/NCT01968161	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	ASENAPINE MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03c696e9-0e6b-4e5c-be0a-41416f8019be	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	ASENAPINE MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=86a40942-8d6b-478c-995f-3c346b197463	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	ASENAPINE MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=17209c32-56eb-4f84-954d-aed7b7a1b18d	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	ASENAPINE MALEATE	targetBased	4	Completed	01/04/2012	https://clinicaltrials.gov/study/NCT01549041	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	ASENAPINE MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5429f134-839f-4ffc-9944-55f51238def8	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	ASENAPINE MALEATE	targetBased	3	Completed	01/07/2005	https://clinicaltrials.gov/study/NCT00174265	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar disorder	ASENAPINE MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03c696e9-0e6b-4e5c-be0a-41416f8019be	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	bipolar disorder	ASENAPINE MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5429f134-839f-4ffc-9944-55f51238def8	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	bipolar disorder	ASENAPINE MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5429f134-839f-4ffc-9944-55f51238def8	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar disorder	ASENAPINE MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5429f134-839f-4ffc-9944-55f51238def8	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar disorder	ASENAPINE MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5429f134-839f-4ffc-9944-55f51238def8	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar disorder	ASENAPINE MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5429f134-839f-4ffc-9944-55f51238def8	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar disorder	ASENAPINE MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5429f134-839f-4ffc-9944-55f51238def8	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	mental or behavioural disorder	ASENAPINE MALEATE	targetBased	4	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT00806234	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	major depressive disorder	ASENAPINE MALEATE	targetBased	4	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT01670019	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	major depressive disorder	ASENAPINE MALEATE	targetBased	4	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT01670019	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	major depressive disorder	ASENAPINE MALEATE	targetBased	4	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT01670019	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	major depressive disorder	ASENAPINE MALEATE	targetBased	4	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT01670019	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	major depressive disorder	ASENAPINE MALEATE	targetBased	4	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT01670019	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	major depressive disorder	ASENAPINE MALEATE	targetBased	4	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT01670019	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	post-traumatic stress disorder	ASENAPINE MALEATE	targetBased	4	Completed	01/06/2012	https://clinicaltrials.gov/study/NCT01587118	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	post-traumatic stress disorder	ASENAPINE MALEATE	targetBased	4	Completed	01/06/2012	https://clinicaltrials.gov/study/NCT01587118	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	post-traumatic stress disorder	ASENAPINE MALEATE	targetBased	4	Completed	01/06/2012	https://clinicaltrials.gov/study/NCT01587118	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	post-traumatic stress disorder	ASENAPINE MALEATE	targetBased	4	Completed	01/06/2012	https://clinicaltrials.gov/study/NCT01587118	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	post-traumatic stress disorder	ASENAPINE MALEATE	targetBased	4	Completed	01/06/2012	https://clinicaltrials.gov/study/NCT01587118	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	post-traumatic stress disorder	ASENAPINE MALEATE	targetBased	4	Completed	01/06/2012	https://clinicaltrials.gov/study/NCT01587118	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Agitation	ASENAPINE MALEATE	targetBased	4	Completed	01/04/2012	https://clinicaltrials.gov/study/NCT01400113	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Agitation	ASENAPINE MALEATE	targetBased	4	Completed	01/04/2012	https://clinicaltrials.gov/study/NCT01400113	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Agitation	ASENAPINE MALEATE	targetBased	4	Completed	01/04/2012	https://clinicaltrials.gov/study/NCT01400113	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Agitation	ASENAPINE MALEATE	targetBased	4	Completed	01/04/2012	https://clinicaltrials.gov/study/NCT01400113	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Agitation	ASENAPINE MALEATE	targetBased	4	Completed	01/04/2012	https://clinicaltrials.gov/study/NCT01400113	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Agitation	ASENAPINE MALEATE	targetBased	4	Completed	01/04/2012	https://clinicaltrials.gov/study/NCT01400113	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizoaffective disorder	ASENAPINE MALEATE	targetBased	3	Completed	04/09/2003	https://clinicaltrials.gov/study/NCT00212784	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizoaffective disorder	ASENAPINE MALEATE	targetBased	3	Completed	04/09/2003	https://clinicaltrials.gov/study/NCT00212784	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizoaffective disorder	ASENAPINE MALEATE	targetBased	3	Completed	04/09/2003	https://clinicaltrials.gov/study/NCT00212784	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizoaffective disorder	ASENAPINE MALEATE	targetBased	3	Completed	04/09/2003	https://clinicaltrials.gov/study/NCT00212784	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizoaffective disorder	ASENAPINE MALEATE	targetBased	3	Completed	01/09/2004	https://clinicaltrials.gov/study/NCT00212771	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizoaffective disorder	ASENAPINE MALEATE	targetBased	3	Completed	01/09/2004	https://clinicaltrials.gov/study/NCT00212771	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizoaffective disorder	ASENAPINE MALEATE	targetBased	3	Completed	01/09/2004	https://clinicaltrials.gov/study/NCT00212771	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizoaffective disorder	ASENAPINE MALEATE	targetBased	3	Completed	01/09/2004	https://clinicaltrials.gov/study/NCT00212771	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizoaffective disorder	ASENAPINE MALEATE	targetBased	3	Completed	01/09/2004	https://clinicaltrials.gov/study/NCT00212771	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizoaffective disorder	ASENAPINE MALEATE	targetBased	3	Completed	01/09/2004	https://clinicaltrials.gov/study/NCT00212771	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar I disorder	ASENAPINE MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=86a40942-8d6b-478c-995f-3c346b197463	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar I disorder	ASENAPINE MALEATE	targetBased	3	Completed	01/04/2012	https://clinicaltrials.gov/study/NCT01395992	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar I disorder	ASENAPINE MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5429f134-839f-4ffc-9944-55f51238def8	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	ASENAPINE MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03c696e9-0e6b-4e5c-be0a-41416f8019be	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	ASENAPINE MALEATE	targetBased	4	Completed	01/10/2011	https://clinicaltrials.gov/study/NCT01460290	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	ASENAPINE MALEATE	targetBased	3	Completed	01/12/2011	https://clinicaltrials.gov/study/NCT01396291	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	ASENAPINE MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5429f134-839f-4ffc-9944-55f51238def8	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	ASENAPINE MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=17209c32-56eb-4f84-954d-aed7b7a1b18d	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	ASENAPINE MALEATE	targetBased	3	Completed	14/12/2004	https://clinicaltrials.gov/study/NCT00159796	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	ASENAPINE MALEATE	targetBased	3	Completed	01/07/2005	https://clinicaltrials.gov/study/NCT00159783	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	ASENAPINE MALEATE	targetBased	3	Completed	07/01/2005	https://clinicaltrials.gov/study/NCT00143182	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	ASENAPINE MALEATE	targetBased	4	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT00806234	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	ASENAPINE MALEATE	targetBased	4	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT00806234	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	mental or behavioural disorder	ASENAPINE MALEATE	targetBased	4	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT00806234	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	mental or behavioural disorder	ASENAPINE MALEATE	targetBased	4	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT00806234	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	ASENAPINE MALEATE	targetBased	4	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT00806234	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	mental or behavioural disorder	ASENAPINE MALEATE	targetBased	4	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT00806234	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	psychosis	ASENAPINE MALEATE	targetBased	3	Completed	01/02/2006	https://clinicaltrials.gov/study/NCT00281320	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizoaffective disorder	ASENAPINE MALEATE	targetBased	3	Completed	04/09/2003	https://clinicaltrials.gov/study/NCT00212784	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizoaffective disorder	ASENAPINE MALEATE	targetBased	3	Completed	01/09/2004	https://clinicaltrials.gov/study/NCT00212771	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	psychosis	ASENAPINE MALEATE	targetBased	3	Completed	01/02/2006	https://clinicaltrials.gov/study/NCT00281320	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	psychosis	ASENAPINE MALEATE	targetBased	3	Completed	01/02/2006	https://clinicaltrials.gov/study/NCT00281320	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	psychosis	ASENAPINE MALEATE	targetBased	3	Completed	01/02/2006	https://clinicaltrials.gov/study/NCT00281320	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	psychosis	ASENAPINE MALEATE	targetBased	3	Completed	01/02/2006	https://clinicaltrials.gov/study/NCT00281320	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	ASENAPINE MALEATE	targetBased	3	Completed	01/02/2006	https://clinicaltrials.gov/study/NCT00281320	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	psychosis	ASENAPINE MALEATE	targetBased	3	Completed	01/02/2006	https://clinicaltrials.gov/study/NCT00281320	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar I disorder	ASENAPINE MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5429f134-839f-4ffc-9944-55f51238def8	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	bipolar I disorder	ASENAPINE MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=86a40942-8d6b-478c-995f-3c346b197463	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	bipolar I disorder	ASENAPINE MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=86a40942-8d6b-478c-995f-3c346b197463	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar I disorder	ASENAPINE MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=86a40942-8d6b-478c-995f-3c346b197463	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar I disorder	ASENAPINE MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=86a40942-8d6b-478c-995f-3c346b197463	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar I disorder	ASENAPINE MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=86a40942-8d6b-478c-995f-3c346b197463	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar I disorder	ASENAPINE MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=86a40942-8d6b-478c-995f-3c346b197463	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Agitation	ASENAPINE MALEATE	targetBased	4	Completed	01/04/2012	https://clinicaltrials.gov/study/NCT01400113	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	ASENAPINE MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5429f134-839f-4ffc-9944-55f51238def8	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	ASENAPINE MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=17209c32-56eb-4f84-954d-aed7b7a1b18d	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	ASENAPINE MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=17209c32-56eb-4f84-954d-aed7b7a1b18d	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	ASENAPINE MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=17209c32-56eb-4f84-954d-aed7b7a1b18d	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	ASENAPINE MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=17209c32-56eb-4f84-954d-aed7b7a1b18d	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	ASENAPINE MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=17209c32-56eb-4f84-954d-aed7b7a1b18d	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	ASENAPINE MALEATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=17209c32-56eb-4f84-954d-aed7b7a1b18d	1	LoF	protect
FRET-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1)	HCRTR1	HCRTR1	Orexin/Hypocretin receptor type 1	insomnia	LEMBOREXANT	targetBased	4	Completed	24/03/2021	https://clinicaltrials.gov/study/NCT04742699	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1)	HCRTR1	HCRTR1	Orexin/Hypocretin receptor type 1	insomnia	LEMBOREXANT	targetBased	4	Completed	24/03/2021	https://clinicaltrials.gov/study/NCT04742699	1	LoF	protect
FRET-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1)	HCRTR1	HCRTR1	Orexin/Hypocretin receptor type 1	insomnia	LEMBOREXANT	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7074cb65-77b3-45d2-8e8d-da8dc0f70bfd	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1)	HCRTR1	HCRTR1	Orexin/Hypocretin receptor type 1	insomnia	LEMBOREXANT	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7074cb65-77b3-45d2-8e8d-da8dc0f70bfd	1	LoF	protect
FRET-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1)	HCRTR1	HCRTR1	Orexin/Hypocretin receptor type 1	insomnia	LEMBOREXANT	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212028s000lbl.pdf	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1)	HCRTR1	HCRTR1	Orexin/Hypocretin receptor type 1	insomnia	LEMBOREXANT	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212028s000lbl.pdf	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1)	HCRTR1	HCRTR1	Orexin/Hypocretin receptor type 1	insomnia	LEMBOREXANT	targetBased	3	Completed	31/05/2016	https://clinicaltrials.gov/study/NCT02783729	0.7	LoF	protect
FRET-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1)	HCRTR1	HCRTR1	Orexin/Hypocretin receptor type 1	alcohol dependence	LEMBOREXANT	targetBased	3	Completed	09/02/2023	https://clinicaltrials.gov/study/NCT05458609	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1)	HCRTR1	HCRTR1	Orexin/Hypocretin receptor type 1	alcohol dependence	LEMBOREXANT	targetBased	3	Completed	09/02/2023	https://clinicaltrials.gov/study/NCT05458609	0.7	LoF	protect
FRET-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1)	HCRTR1	HCRTR1	Orexin/Hypocretin receptor type 1	Sleep Disorder	LEMBOREXANT	targetBased	3	Completed	06/11/2020	https://clinicaltrials.gov/study/NCT04549168	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1)	HCRTR1	HCRTR1	Orexin/Hypocretin receptor type 1	Sleep Disorder	LEMBOREXANT	targetBased	3	Completed	06/11/2020	https://clinicaltrials.gov/study/NCT04549168	0.7	LoF	protect
FRET-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1)	HCRTR1	HCRTR1	Orexin/Hypocretin receptor type 1	Sleep Disorder	LEMBOREXANT	targetBased	4	Recruiting	10/03/2022	https://clinicaltrials.gov/study/NCT05344443	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1)	HCRTR1	HCRTR1	Orexin/Hypocretin receptor type 1	Sleep Disorder	LEMBOREXANT	targetBased	4	Recruiting	10/03/2022	https://clinicaltrials.gov/study/NCT05344443	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	opioid dependence	HYDROCODONE BITARTRATE	targetBased	4	Completed	30/01/2018	https://clinicaltrials.gov/study/NCT03457116	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	HYDROCODONE BITARTRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=901d4115-f71a-4681-bd0e-c9b691151b78	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	HYDROCODONE BITARTRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=016b3c9e-b7e4-455b-9482-61714aea2b14	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	HYDROCODONE BITARTRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=016b3c9e-b7e4-455b-9482-61714aea2b14	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	HYDROCODONE BITARTRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6ccfbd98-7750-4955-a654-ec104fb666f9	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	HYDROCODONE BITARTRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6ccfbd98-7750-4955-a654-ec104fb666f9	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	HYDROCODONE BITARTRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9e5daeac-8573-48e9-877f-c08701255c5b	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	HYDROCODONE BITARTRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9e5daeac-8573-48e9-877f-c08701255c5b	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	drug dependence	HYDROCODONE BITARTRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6ccfbd98-7750-4955-a654-ec104fb666f9	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	drug dependence	HYDROCODONE BITARTRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=901d4115-f71a-4681-bd0e-c9b691151b78	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	drug dependence	HYDROCODONE BITARTRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=016b3c9e-b7e4-455b-9482-61714aea2b14	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	drug dependence	HYDROCODONE BITARTRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=470df63a-5c0f-42df-9023-a330a901153e	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	drug dependence	HYDROCODONE BITARTRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9e5daeac-8573-48e9-877f-c08701255c5b	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	drug dependence	HYDROCODONE BITARTRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=25f400d9-1d6e-4d38-8f0d-98d471eba73b	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	HYDROCODONE BITARTRATE	targetBased	4	Completed	30/01/2018	https://clinicaltrials.gov/study/NCT03457116	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence	HYDROCODONE BITARTRATE	targetBased	4	Completed	30/01/2018	https://clinicaltrials.gov/study/NCT03457116	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	OLANZAPINE PAMOATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f9a73185-88de-4d7b-b3c0-bbf231483241	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	OLANZAPINE PAMOATE	targetBased	3	Completed	01/04/2006	https://clinicaltrials.gov/study/NCT00320489	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	schizophrenia	OLANZAPINE PAMOATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f9a73185-88de-4d7b-b3c0-bbf231483241	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	schizophrenia	OLANZAPINE PAMOATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f9a73185-88de-4d7b-b3c0-bbf231483241	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	schizophrenia	OLANZAPINE PAMOATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f9a73185-88de-4d7b-b3c0-bbf231483241	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	schizophrenia	OLANZAPINE PAMOATE	targetBased	3	Completed	01/04/2006	https://clinicaltrials.gov/study/NCT00320489	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	schizophrenia	OLANZAPINE PAMOATE	targetBased	3	Completed	01/04/2006	https://clinicaltrials.gov/study/NCT00320489	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	schizophrenia	OLANZAPINE PAMOATE	targetBased	3	Completed	01/04/2006	https://clinicaltrials.gov/study/NCT00320489	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	OLANZAPINE PAMOATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f9a73185-88de-4d7b-b3c0-bbf231483241	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	OLANZAPINE PAMOATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f9a73185-88de-4d7b-b3c0-bbf231483241	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	OLANZAPINE PAMOATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f9a73185-88de-4d7b-b3c0-bbf231483241	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	OLANZAPINE PAMOATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f9a73185-88de-4d7b-b3c0-bbf231483241	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	OLANZAPINE PAMOATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f9a73185-88de-4d7b-b3c0-bbf231483241	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	OLANZAPINE PAMOATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f9a73185-88de-4d7b-b3c0-bbf231483241	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	OLANZAPINE PAMOATE	targetBased	3	Completed	01/04/2006	https://clinicaltrials.gov/study/NCT00320489	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	nicotine dependence	FORMOTEROL FUMARATE	targetBased	3	Completed	01/05/2017	https://clinicaltrials.gov/study/NCT03104634	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	ZIPRASIDONE MESYLATE	targetBased	3	Completed	01/09/2008	https://clinicaltrials.gov/study/NCT00723606	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	bipolar disorder	ZIPRASIDONE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5c03ca62-5dd5-4cf5-abc7-b0c2873503dd	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	bipolar disorder	ZIPRASIDONE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5c03ca62-5dd5-4cf5-abc7-b0c2873503dd	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar disorder	ZIPRASIDONE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5c03ca62-5dd5-4cf5-abc7-b0c2873503dd	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	bipolar disorder	ZIPRASIDONE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5c03ca62-5dd5-4cf5-abc7-b0c2873503dd	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar disorder	ZIPRASIDONE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5c03ca62-5dd5-4cf5-abc7-b0c2873503dd	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	bipolar disorder	ZIPRASIDONE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5c03ca62-5dd5-4cf5-abc7-b0c2873503dd	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	bipolar disorder	ZIPRASIDONE MESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5c03ca62-5dd5-4cf5-abc7-b0c2873503dd	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	ZIPRASIDONE MESYLATE	targetBased	3	Completed	01/09/2008	https://clinicaltrials.gov/study/NCT00723606	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	ZIPRASIDONE MESYLATE	targetBased	3	Completed	01/09/2008	https://clinicaltrials.gov/study/NCT00723606	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	ZIPRASIDONE MESYLATE	targetBased	3	Completed	01/09/2008	https://clinicaltrials.gov/study/NCT00723606	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	ZIPRASIDONE MESYLATE	targetBased	3	Completed	01/09/2008	https://clinicaltrials.gov/study/NCT00723606	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	ZIPRASIDONE MESYLATE	targetBased	3	Completed	01/09/2008	https://clinicaltrials.gov/study/NCT00723606	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	ZIPRASIDONE MESYLATE	targetBased	3	Completed	01/09/2008	https://clinicaltrials.gov/study/NCT00723606	0.7	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	narcolepsy-cataplexy syndrome	DEXTROAMPHETAMINE SACCHARATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ffd56d70-d884-43be-a994-6e70a10e823e	1		protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	DEXTROAMPHETAMINE SACCHARATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ffd56d70-d884-43be-a994-6e70a10e823e	1		protect
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	delirium	LIRAGLUTIDE	targetBased	3	Not yet recruiting	30/04/2024	https://clinicaltrials.gov/study/NCT06361238	0.7	GoF	protect
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	delirium	LIRAGLUTIDE	targetBased	3	Not yet recruiting	30/04/2024	https://clinicaltrials.gov/study/NCT06361238	0.7	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	delirium	LIRAGLUTIDE	targetBased	3	Not yet recruiting	30/04/2024	https://clinicaltrials.gov/study/NCT06361238	0.7	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	major depressive disorder	LIRAGLUTIDE	targetBased	3	Completed	01/05/2015	https://clinicaltrials.gov/study/NCT02423824	0.7	GoF	protect
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	major depressive disorder	LIRAGLUTIDE	targetBased	3	Completed	01/05/2015	https://clinicaltrials.gov/study/NCT02423824	0.7	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	major depressive disorder	LIRAGLUTIDE	targetBased	3	Completed	01/05/2015	https://clinicaltrials.gov/study/NCT02423824	0.7	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	binge eating	LIRAGLUTIDE	targetBased	4	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01739049	1	GoF	protect
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	binge eating	LIRAGLUTIDE	targetBased	4	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01739049	1	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	binge eating	LIRAGLUTIDE	targetBased	4	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01739049	1	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	eating disorder	LIRAGLUTIDE	targetBased	3	Terminated	29/09/2017	https://clinicaltrials.gov/study/NCT03279731	0.7	GoF	protect	The study was not meeting recruitment goals.
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	eating disorder	LIRAGLUTIDE	targetBased	3	Terminated	29/09/2017	https://clinicaltrials.gov/study/NCT03279731	0.7	GoF	protect	The study was not meeting recruitment goals.
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	eating disorder	LIRAGLUTIDE	targetBased	3	Terminated	29/09/2017	https://clinicaltrials.gov/study/NCT03279731	0.7	GoF	protect	The study was not meeting recruitment goals.
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	bipolar disorder	LIRAGLUTIDE	targetBased	3	Completed	01/05/2015	https://clinicaltrials.gov/study/NCT02423824	0.7	GoF	protect
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	bipolar disorder	LIRAGLUTIDE	targetBased	3	Completed	01/05/2015	https://clinicaltrials.gov/study/NCT02423824	0.7	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	bipolar disorder	LIRAGLUTIDE	targetBased	3	Completed	01/05/2015	https://clinicaltrials.gov/study/NCT02423824	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	CODEINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=010905f9-3bcb-4b50-9fe8-a3ad0010f14c	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	drug dependence	CODEINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=010905f9-3bcb-4b50-9fe8-a3ad0010f14c	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	drug dependence	CODEINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=010905f9-3bcb-4b50-9fe8-a3ad0010f14c	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	HALOPERIDOL LACTATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e52d40f2-b658-4bc6-8a0c-74a340b762d8	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	HALOPERIDOL LACTATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e2eed126-cb82-42b1-9b48-9cbeb6873b50	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	HALOPERIDOL LACTATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=34893e69-ed5c-4929-bb15-fd8780d5034f	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	HALOPERIDOL LACTATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8397a841-f240-4767-9dcd-781e6d3f7c7f	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	HALOPERIDOL LACTATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7ce7f23c-f58b-4b8b-a31a-47bd4e792345	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	HALOPERIDOL LACTATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=153e747c-861d-44c4-aef6-6c49f53ca34a	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizophrenia	HALOPERIDOL LACTATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c72c2366-7b40-4cd9-845d-4b3983e6141a	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Agitation	HALOPERIDOL LACTATE	targetBased	3	Completed	01/07/2006	https://clinicaltrials.gov/study/NCT00797277	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Agitation	HALOPERIDOL LACTATE	targetBased	3	Completed	01/07/2006	https://clinicaltrials.gov/study/NCT00797277	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Agitation	HALOPERIDOL LACTATE	targetBased	3	Completed	01/07/2006	https://clinicaltrials.gov/study/NCT00797277	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Agitation	HALOPERIDOL LACTATE	targetBased	3	Completed	01/07/2006	https://clinicaltrials.gov/study/NCT00797277	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Agitation	HALOPERIDOL LACTATE	targetBased	3	Completed	01/07/2006	https://clinicaltrials.gov/study/NCT00797277	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Agitation	HALOPERIDOL LACTATE	targetBased	3	Completed	01/07/2006	https://clinicaltrials.gov/study/NCT00797277	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizoaffective disorder	HALOPERIDOL LACTATE	targetBased	3	Completed	01/07/2006	https://clinicaltrials.gov/study/NCT00797277	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizoaffective disorder	HALOPERIDOL LACTATE	targetBased	3	Completed	01/07/2006	https://clinicaltrials.gov/study/NCT00797277	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizoaffective disorder	HALOPERIDOL LACTATE	targetBased	3	Completed	01/07/2006	https://clinicaltrials.gov/study/NCT00797277	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizoaffective disorder	HALOPERIDOL LACTATE	targetBased	3	Completed	01/07/2006	https://clinicaltrials.gov/study/NCT00797277	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizoaffective disorder	HALOPERIDOL LACTATE	targetBased	3	Completed	01/07/2006	https://clinicaltrials.gov/study/NCT00797277	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizoaffective disorder	HALOPERIDOL LACTATE	targetBased	3	Completed	01/07/2006	https://clinicaltrials.gov/study/NCT00797277	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	schizoaffective disorder	HALOPERIDOL LACTATE	targetBased	3	Completed	01/07/2006	https://clinicaltrials.gov/study/NCT00797277	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Agitation	HALOPERIDOL LACTATE	targetBased	3	Completed	01/07/2006	https://clinicaltrials.gov/study/NCT00797277	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Agitation	HALOPERIDOL LACTATE	targetBased	3	Completed	01/07/2006	https://clinicaltrials.gov/study/NCT00797277	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Agitation	HALOPERIDOL LACTATE	targetBased	3	Completed	01/07/2006	https://clinicaltrials.gov/study/NCT00797277	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	schizophrenia	HALOPERIDOL LACTATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=89dc5e08-67c7-448a-95e7-56bb77e62cce	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	schizophrenia	HALOPERIDOL LACTATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8397a841-f240-4767-9dcd-781e6d3f7c7f	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	schizophrenia	HALOPERIDOL LACTATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8397a841-f240-4767-9dcd-781e6d3f7c7f	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	schizophrenia	HALOPERIDOL LACTATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8397a841-f240-4767-9dcd-781e6d3f7c7f	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	schizophrenia	HALOPERIDOL LACTATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=909259a3-7627-4d1e-91d3-3363b3493599	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	schizophrenia	HALOPERIDOL LACTATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=909259a3-7627-4d1e-91d3-3363b3493599	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	schizophrenia	HALOPERIDOL LACTATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=909259a3-7627-4d1e-91d3-3363b3493599	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Agitation	HALOPERIDOL LACTATE	targetBased	3	Completed	01/07/2006	https://clinicaltrials.gov/study/NCT00797277	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	HALOPERIDOL LACTATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c72c2366-7b40-4cd9-845d-4b3983e6141a	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	HALOPERIDOL LACTATE	targetBased	4	Completed	01/11/2000	https://clinicaltrials.gov/study/NCT00159081	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	schizophrenia	HALOPERIDOL LACTATE	targetBased	4	Completed	01/11/2000	https://clinicaltrials.gov/study/NCT00159081	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	HALOPERIDOL LACTATE	targetBased	4	Completed	01/11/2000	https://clinicaltrials.gov/study/NCT00159081	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	schizophrenia	HALOPERIDOL LACTATE	targetBased	4	Completed	01/11/2000	https://clinicaltrials.gov/study/NCT00159081	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	HALOPERIDOL LACTATE	targetBased	4	Completed	01/11/2000	https://clinicaltrials.gov/study/NCT00159081	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	schizophrenia	HALOPERIDOL LACTATE	targetBased	4	Completed	01/11/2000	https://clinicaltrials.gov/study/NCT00159081	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	schizoaffective disorder	HALOPERIDOL LACTATE	targetBased	3	Completed	01/07/2006	https://clinicaltrials.gov/study/NCT00797277	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	schizoaffective disorder	HALOPERIDOL LACTATE	targetBased	3	Completed	01/07/2006	https://clinicaltrials.gov/study/NCT00797277	0.7	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	schizoaffective disorder	HALOPERIDOL LACTATE	targetBased	3	Completed	01/07/2006	https://clinicaltrials.gov/study/NCT00797277	0.7	LoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	autism spectrum disorder	BALOVAPTAN	targetBased	3	Terminated	08/08/2018	https://clinicaltrials.gov/study/NCT03504917	0.35	LoF	protect	A futility analysis assessed that the study is highly unlikely to meet the pre-defined primary objective of the study. No new safety concerns were identified.
Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R	MC4R	MC4R	Melanocortin receptor 4	mental or behavioural disorder	BREMELANOTIDE ACETATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9146ae05-918b-483e-b86d-933485ce36eb	1	GoF	protect
TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R	MC4R	MC4R	Melanocortin receptor 4	mental or behavioural disorder	BREMELANOTIDE ACETATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9146ae05-918b-483e-b86d-933485ce36eb	1	GoF	protect
FRET-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1)	HCRTR1	HCRTR1	Orexin/Hypocretin receptor type 1	insomnia	DARIDOREXANT	targetBased	3	Recruiting	28/08/2023	https://clinicaltrials.gov/study/NCT06010693	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1)	HCRTR1	HCRTR1	Orexin/Hypocretin receptor type 1	insomnia	DARIDOREXANT	targetBased	3	Recruiting	28/08/2023	https://clinicaltrials.gov/study/NCT06010693	0.7	LoF	protect
FRET-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1)	HCRTR1	HCRTR1	Orexin/Hypocretin receptor type 1	insomnia	DARIDOREXANT	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214985s000lbl.pdf	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1)	HCRTR1	HCRTR1	Orexin/Hypocretin receptor type 1	insomnia	DARIDOREXANT	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214985s000lbl.pdf	1	LoF	protect
FRET-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1)	HCRTR1	HCRTR1	Orexin/Hypocretin receptor type 1	insomnia	DARIDOREXANT	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/quviviq	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1)	HCRTR1	HCRTR1	Orexin/Hypocretin receptor type 1	insomnia	DARIDOREXANT	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/quviviq	1	LoF	protect
FRET-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1)	HCRTR1	HCRTR1	Orexin/Hypocretin receptor type 1	insomnia	DARIDOREXANT	targetBased	3	Completed	29/05/2018	https://clinicaltrials.gov/study/NCT03575104	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1)	HCRTR1	HCRTR1	Orexin/Hypocretin receptor type 1	insomnia	DARIDOREXANT	targetBased	3	Completed	29/05/2018	https://clinicaltrials.gov/study/NCT03575104	0.7	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	SERDEXMETHYLPHENIDATE CHLORIDE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212994s000lbl.pdf	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	SERDEXMETHYLPHENIDATE	targetBased	4	Recruiting	14/09/2023	https://clinicaltrials.gov/study/NCT06000501	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	attention deficit hyperactivity disorder	SERDEXMETHYLPHENIDATE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/212994s000lbl.pdf	1	LoF	protect
FRET-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1)	HCRTR1	HCRTR1	Orexin/Hypocretin receptor type 1	insomnia	DARIDOREXANT HYDROCHLORIDE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214985s000lbl.pdf	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1)	HCRTR1	HCRTR1	Orexin/Hypocretin receptor type 1	insomnia	DARIDOREXANT HYDROCHLORIDE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214985s000lbl.pdf	1	LoF	protect
FRET-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1)	HCRTR1	HCRTR1	Orexin/Hypocretin receptor type 1	insomnia	DARIDOREXANT HYDROCHLORIDE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/quviviq	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1)	HCRTR1	HCRTR1	Orexin/Hypocretin receptor type 1	insomnia	DARIDOREXANT HYDROCHLORIDE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/quviviq	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human trace amine associated receptor 1 (TAAR1)	TAAR1	TAAR1	Trace amine-associated receptor 1	schizophrenia	ULOTARONT	targetBased	3	Enrolling by invitation	31/03/2023	https://clinicaltrials.gov/study/NCT05741528	0.7	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human trace amine associated receptor 1 (TAAR1)	TAAR1	TAAR1	Trace amine-associated receptor 1	schizophrenia	ULOTARONT	targetBased	3	Enrolling by invitation	31/03/2023	https://clinicaltrials.gov/study/NCT05741528	0.7	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human trace amine associated receptor 1 (TAAR1)	TAAR1	TAAR1	Trace amine-associated receptor 1	schizophrenia	ULOTARONT	targetBased	3	Terminated	16/05/2022	https://clinicaltrials.gov/study/NCT05359081	0.7	GoF	protect	Due to company business strategy
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human trace amine associated receptor 1 (TAAR1)	TAAR1	TAAR1	Trace amine-associated receptor 1	schizophrenia	ULOTARONT	targetBased	3	Terminated	16/05/2022	https://clinicaltrials.gov/study/NCT05359081	0.7	GoF	protect	Due to company business strategy
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human trace amine associated receptor 1 (TAAR1)	TAAR1	TAAR1	Trace amine-associated receptor 1	schizophrenia	ULOTARONT	targetBased	3	Completed	30/09/2019	https://clinicaltrials.gov/study/NCT04092686	0.7	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human trace amine associated receptor 1 (TAAR1)	TAAR1	TAAR1	Trace amine-associated receptor 1	schizophrenia	ULOTARONT	targetBased	3	Completed	30/09/2019	https://clinicaltrials.gov/study/NCT04092686	0.7	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human trace amine associated receptor 1 (TAAR1)	TAAR1	TAAR1	Trace amine-associated receptor 1	schizophrenia	ULOTARONT	targetBased	3	Terminated	04/10/2019	https://clinicaltrials.gov/study/NCT04109950	0.7	GoF	protect	Study terminated early, main goals achieved
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human trace amine associated receptor 1 (TAAR1)	TAAR1	TAAR1	Trace amine-associated receptor 1	schizophrenia	ULOTARONT	targetBased	3	Terminated	04/10/2019	https://clinicaltrials.gov/study/NCT04109950	0.7	GoF	protect	Study terminated early, main goals achieved
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human trace amine associated receptor 1 (TAAR1)	TAAR1	TAAR1	Trace amine-associated receptor 1	schizophrenia	ULOTARONT	targetBased	3	Completed	19/12/2022	https://clinicaltrials.gov/study/NCT05628103	0.7	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human trace amine associated receptor 1 (TAAR1)	TAAR1	TAAR1	Trace amine-associated receptor 1	schizophrenia	ULOTARONT	targetBased	3	Completed	19/12/2022	https://clinicaltrials.gov/study/NCT05628103	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	schizophrenia	ULOTARONT	targetBased	3	Terminated	16/05/2022	https://clinicaltrials.gov/study/NCT05359081	0.7	GoF	protect	Due to company business strategy
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	schizophrenia	ULOTARONT	targetBased	3	Terminated	16/05/2022	https://clinicaltrials.gov/study/NCT05359081	0.7	GoF	protect	Due to company business strategy
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	schizophrenia	ULOTARONT	targetBased	3	Terminated	04/10/2019	https://clinicaltrials.gov/study/NCT04109950	0.7	GoF	protect	Study terminated early, main goals achieved
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	schizophrenia	ULOTARONT	targetBased	3	Terminated	04/10/2019	https://clinicaltrials.gov/study/NCT04109950	0.7	GoF	protect	Study terminated early, main goals achieved
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	schizophrenia	ULOTARONT	targetBased	3	Enrolling by invitation	31/03/2023	https://clinicaltrials.gov/study/NCT05741528	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	schizophrenia	ULOTARONT	targetBased	3	Enrolling by invitation	31/03/2023	https://clinicaltrials.gov/study/NCT05741528	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	schizophrenia	ULOTARONT	targetBased	3	Completed	19/12/2022	https://clinicaltrials.gov/study/NCT05628103	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	schizophrenia	ULOTARONT	targetBased	3	Completed	19/12/2022	https://clinicaltrials.gov/study/NCT05628103	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	schizophrenia	ULOTARONT	targetBased	3	Completed	30/09/2019	https://clinicaltrials.gov/study/NCT04092686	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	schizophrenia	ULOTARONT	targetBased	3	Completed	30/09/2019	https://clinicaltrials.gov/study/NCT04092686	0.7	GoF	protect
FRET-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1)	HCRTR1	HCRTR1	Orexin/Hypocretin receptor type 1	insomnia	ORN-0829 HYDRATE	targetBased	3	Completed	30/08/2022	https://clinicaltrials.gov/study/NCT05453136	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1)	HCRTR1	HCRTR1	Orexin/Hypocretin receptor type 1	insomnia	ORN-0829 HYDRATE	targetBased	3	Completed	30/08/2022	https://clinicaltrials.gov/study/NCT05453136	0.7	LoF	protect
FRET-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1)	HCRTR1	HCRTR1	Orexin/Hypocretin receptor type 1	insomnia	ORN-0829 HYDRATE	targetBased	3	Completed	11/10/2022	https://clinicaltrials.gov/study/NCT05461352	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1)	HCRTR1	HCRTR1	Orexin/Hypocretin receptor type 1	insomnia	ORN-0829 HYDRATE	targetBased	3	Completed	11/10/2022	https://clinicaltrials.gov/study/NCT05461352	0.7	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	opioid dependence		targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/nyxoid	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence		targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/nyxoid	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	opioid dependence		targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/nyxoid	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	alcohol dependence		targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/selincro	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	alcohol dependence		targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/selincro	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	alcohol dependence		targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/selincro	1	GoF	protect

Partner with DrTarget for AI-Optimized Screening

We welcome collaborations with biotech companies, research institutions, and pharmaceutical partners looking to leverage AI for drug discovery. Get in touch to explore custom screening solutions and accelerate your research.